Awareness B-outcome ['Life-Impact']
about O
fertility O
and O
lifestyle-related B-outcome ['Life-Impact', 'Life-Impact']
factors I-outcome ['Life-Impact', 'Life-Impact']
were O
the O
main O
outcomes, O
measured O
through O
a O
questionnaire O
before O
the O
intervention O
and O
through O
a O
telephone O
survey O
after O
three O
months. O
[['Life-Impact'], ['Life-Impact', 'Life-Impact']]

A O
mindfulness-based O
intervention O
(MBI) O
represents O
a O
promising O
non-pharmacological O
framework O
for O
Alzheimer's O
disease O
prevention. O
[]

Title: O
Effect O
of O
the O
soft-tissue O
techniques O
in O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
patients O
with O
Crohn's O
disease: O
A O
randomized O
controlled O
trial. O
[['Life-Impact']]

Postoperative O
intravenous O
patient-controlled O
analgesia(PCA) O
was O
performed O
in O
all O
patients, O
with O
background O
doses O
of O
sufentanil O
0.04 O
mug. O
[]

The O
survey O
also O
collected O
data O
on O
these O
demographic O
variables: O
the O
name O
of O
the O
faculty O
member O
with O
whom O
the O
student O
met; O
student O
gender, O
age, O
and O
interest O
in O
EM; O
location O
prior O
to O
meeting; O
meeting-method O
preference; O
and O
number O
of O
EM O
shifts O
completed. O
[]

Title: O
Effect O
of O
Negative O
Pressure O
Wound O
Therapy O
on O
Wound B-outcome ['Physiological-Clinical']
Complications I-outcome ['Physiological-Clinical']
Post-Pancreatectomy. O
[['Physiological-Clinical']]

They O
had O
lost O
their O
ability O
to O
perform O
some O
basic O
living O
activities. O
[]

The O
secondary O
end O
points O
were O
also O
comparable O
between O
the O
two O
groups- O
Death B-outcome ['Mortality']
- O
1 O
of O
85(1.17%) O
vs. O
2 O
of O
98(2.04%), O
p O
= O
0.646, O
Stroke B-outcome ['Physiological-Clinical']
0 O
of O
85 O
vs. O
2 O
of O
98(2.04%), O
p O
= O
0.185 O
and O
acute B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
- O
2 O
of O
85(2.35%) O
vs. O
1 O
of O
98(1.02%), O
p O
= O
0.204. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Differences O
between O
two O
groups O
each O
time O
showed O
no O
statistical O
significance O
(p O
> O
0.05). O
[]

However, O
the O
higher O
number O
of O
premature O
withdrawals B-outcome ['Life-Impact']
in O
the O
TENS O
group O
may O
be O
due O
to O
early O
withdrawal B-outcome ['Life-Impact']
of O
patients O
who O
did O
not O
experience O
improvement O
of O
their O
symptoms. O
[['Life-Impact'], ['Life-Impact']]

In O
this O
study, O
for O
the O
first O
time, O
it O
was O
presented O
that O
pelvic B-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
(PFM) I-outcome ['Physiological-Clinical']
asymmetry I-outcome ['Physiological-Clinical']
visible O
in O
ultrasonography O
may O
be O
corrected O
by O
this O
specific O
exercise. O
[['Physiological-Clinical']]

SUBJECTS/METHODS: O
Samples O
from O
72 O
participants O
randomized O
to O
one O
of O
the O
following O
12-week O
intervention O
groups, O
FF O
(n O
= O
19), O
LF O
(n O
= O
19), O
CSO O
(n O
= O
17) O
or O
a O
control O
group O
(n O
= O
17), O
were O
available O
for O
the O
PBMC O
study. O
[]

A O
total O
of O
159 O
American O
Society O
of O
Anesthesiologists O
(ASA) O
physical O
status O
I O
to O
III O
patients O
scheduled O
for O
primary O
TKA O
were O
randomized O
to O
one O
of O
three O
study O
groups. O
[]

RESULTS: O
The O
mean O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
for O
the O
intercostal O
drainage O
group O
in O
the O
intensive O
care O
unit O
was O
1.5 O
day O
(1.0 O
to O
2.0 O
days) O
and O
2.0 O
days O
(25.1 O
to O
3.0 O
days) O
for O
the O
traditional O
chest O
drainage O
group O
(p=0.060). O
[['Resource-use']]

Title: O
Evaluation O
of O
the O
safety O
and O
efficacy O
of O
a O
new O
hemostatic O
powder O
using O
a O
quantitative O
surface B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
severity O
scale. O
[['Physiological-Clinical']]

Therefore, O
it O
can O
be O
used O
as O
an O
alternative O
method O
for O
patients O
who O
are O
willing O
to O
use O
this O
technique. O
[]

There O
was O
no O
difference O
for O
compression B-outcome ['Physiological-Clinical']
rate O
or O
recoil B-outcome ['Physiological-Clinical']
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

No O
other O
associations O
between O
changes O
in O
lifestyle B-outcome ['Life-Impact', 'Life-Impact']
or O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
during O
the O
first O
six O
months O
after O
randomization O
with O
cardiovascular B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
3(-)8 O
years O
later O
were O
observed. O
[['Life-Impact', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

For O
flexion B-outcome ['Physiological-Clinical']
and O
abduction B-outcome ['Physiological-Clinical']
activity, O
SuperPATH O
group O
at O
1 O
and O
3 O
days O
after O
operation O
were O
better O
than O
the O
control O
group O
( O
P<0.05), O
while O
no O
significant O
difference O
was O
found O
between O
2 O
groups O
at O
14 O
days, O
3 O
months, O
6 O
months, O
and O
1 O
year O
after O
operation O
( O
P>0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Amyotrophic O
Lateral O
Sclerosis O
(ALS) O
is O
a O
rapid O
progressive O
neurodegenerative O
disease, O
characterized O
by O
a O
selective O
loss O
of O
motor O
neurons, O
brain O
stem O
and O
spinal O
cord O
which O
leads O
to O
deterioration O
of O
motor O
abilities. O
[]

CONCLUSIONS: O
Training O
on O
wearing O
an O
N95 O
or O
higher O
respirator O
improved O
the O
protection B-outcome ['Life-Impact']
performance O
of O
respirators O
among O
healthcare O
providers O
working O
in O
the O
EMC. O
[['Life-Impact']]

There O
were O
no O
instances O
of O
urgent O
target O
lesion B-outcome ['Resource-use']
re-vascularisation I-outcome ['Resource-use']
or O
definite O
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
in O
either O
groups. O
[['Resource-use'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Preoperative O
celecoxib O
analgesia O
is O
more O
efficient O
and O
equally O
tolerated B-outcome ['Life-Impact']
compared O
to O
postoperative O
celecoxib O
analgesia O
in O
knee O
osteoarthritis O
patients O
undergoing O
total O
knee O
arthroplasty: O
A O
randomized, O
controlled O
study. O
[['Life-Impact']]

BACKGROUND: O
Complications O
related O
to O
concurrent O
chemoradiotherapy O
(CCRT) O
such O
as O
acute O
radiation-induced O
esophagitis O
(ARIE) O
may O
cause O
significant O
morbidity O
and O
unplanned O
treatment O
delays O
in O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
(NSCLC). O
[]

Results O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
index O
(SVRI) O
showed O
a O
decrease O
in O
Group O
SM O
but O
an O
increase O
in O
Group O
S O
(Ptime*group<0.0001) O
in O
the O
study O
period. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

A O
P O
value O
of O
less O
than O
.05 O
was O
considered O
statistically O
significant. O
[]

Patients O
were O
injected O
with O
BTX-A O
or O
normal O
saline O
in O
the O
medial O
part O
of O
the O
upper O
and O
lower O
eyelids. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Tobramycin/dexamethasone O
eye O
drops O
as O
a O
better O
choice O
for O
lacrimal O
duct O
probing O
in O
persistent O
congenital O
nasolacrimal O
duct O
obstruction: O
A O
consort O
study. O
[]

The O
tear O
levels O
of O
matrix B-outcome ['Physiological-Clinical']
metalloproteinase I-outcome ['Physiological-Clinical']
(MMP)-9 I-outcome ['Physiological-Clinical']
and O
serotonin B-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
at O
1 O
month O
after O
injection. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

Journal-Name:Indian O
heart O
journal O
[]

We O
describe O
an O
operations O
research O
(OR) O
Study O
and O
assessment O
of O
one O
form O
of O
community O
engagement, O
the O
development O
and O
implementation O
of O
a O
participatory O
community-based O
health O
information O
system O
(PCBHIS), O
in O
slum O
communities O
in O
Freetown, O
Sierra O
Leone. O
[]

Survival O
analyses O
were O
performed O
via O
the O
Kaplan-Meier O
method. O
[]

No O
statistically O
significant O
difference O
was O
found O
between O
the O
orthoses' O
effects O
on O
pain B-outcome ['Physiological-Clinical']
reduction O
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
(P O
> O
.05). O
[['Physiological-Clinical'], ['Life-Impact']]

No O
therapeutic O
intervention O
was O
applied O
to O
the O
CG. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
The O
RSB O
analgesia O
significantly O
enhanced O
the O
SFS24 O
scores O
in O
the O
study O
groups O
(p=0.001). O
[]

Funded O
by O
the O
Health O
Technology O
Assessment O
Programme O
of O
the O
National O
Institute O
for O
Health O
Research; O
SIFT O
Current O
Controlled O
Trials O
number, O
ISRCTN76463425.). O
[]

Although O
the O
reductions O
in O
weight B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
were O
comparable O
in O
IS O
and O
IR O
groups, O
only O
women O
with O
IR O
showed O
a O
significant O
increase O
in O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
concentration O
as O
a O
result O
of O
all O
interventions. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Crohn's O
disease O
(CD) O
is O
a O
highly O
prevalent O
inflammatory O
bowel O
disease O
(IBD), O
characterized O
by O
recurring O
flares O
altered O
by O
periods O
of O
inactive O
disease O
and O
remission, O
affecting O
physical O
and O
psychological O
aspects O
and O
quality O
of O
life O
(QoL). O
[]

We O
investigated O
whether O
oral O
antibiotic O
therapy O
is O
noninferior O
to O
intravenous O
antibiotic O
therapy O
for O
this O
indication. O
[]

For O
normal O
breathing, O
fit B-outcome ['Physiological-Clinical']
factors I-outcome ['Physiological-Clinical']
before O
and O
after O
training O
were O
121 O
(10-185) O
vs O
192 O
(161-200) O
for O
cup-type, O
200 O
(39-200) O
vs O
200 O
(200-200) O
for O
fold-type, O
and O
85 O
(18-157) O
vs O
173 O
(117-200) O
for O
valve-type. O
[['Physiological-Clinical']]

BACKGROUND O
AND O
PURPOSE: O
There O
is O
a O
need O
to O
investigate O
the O
effects O
of O
pilates O
exercises O
on O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
of O
patients O
with O
chronic O
kidney O
diseases O
(CKD). O
[['Life-Impact']]

BACKGROUND: O
Treatment O
of O
Plasmodium O
vivax O
malaria O
requires O
the O
clearing O
of O
asexual O
parasites, O
but O
relapse O
can O
be O
prevented O
only O
if O
dormant O
hypnozoites O
are O
cleared O
from O
the O
liver O
(a O
treatment O
termed O
"radical O
cure"). O
[]

Journal-Name:Zhongguo O
xiu O
fu O
chong O
jian O
wai O
ke O
za O
zhi O
= O
Zhongguo O
xiufu O
chongjian O
waike O
zazhi O
= O
Chinese O
journal O
of O
reparative O
and O
reconstructive O
surgery O
[]

Preoperative O
analgesia O
group O
also O
exhibited O
decreased O
patient's O
global B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
(PGA) O
score O
compared O
to O
postoperative O
analgesia O
group O
at O
2 O
hours, O
6 O
hours, O
12 O
hours, O
24 O
hours, O
and O
48 O
hours O
post O
operation. O
[['Physiological-Clinical']]

Publication O
date: O
2019/03/02 O
06:00 O
[medline] O
[]

Title: O
The O
Effects O
of O
Tai O
Chi O
on O
Heart B-outcome ['Physiological-Clinical']
Rate I-outcome ['Physiological-Clinical']
Variability I-outcome ['Physiological-Clinical']
in O
Older O
Chinese O
Individuals O
with O
Depression. O
[['Physiological-Clinical']]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
that O
emerged O
after O
treatment O
initiation O
were O
reported O
in O
41.1% O
of O
the O
patients O
in O
the O
omadacycline O
group O
and O
48.5% O
of O
the O
patients O
in O
the O
moxifloxacin O
group; O
the O
most O
frequent O
events O
were O
gastrointestinal B-outcome ['Physiological-Clinical']
(10.2% O
and O
18.0%, O
respectively), O
and O
the O
largest O
difference O
was O
for O
diarrhea B-outcome ['Physiological-Clinical']
(1.0% O
and O
8.0%). O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Yi O
xue O
ban O
= O
Journal O
of O
Central O
South O
University. O
[]

Operator-reported O
aspiration B-outcome ['Physiological-Clinical']
occurred O
during O
2.5% O
of O
intubations O
in O
the O
bag-mask O
ventilation O
group O
and O
during O
4.0% O
in O
the O
no-ventilation O
group O
(P O
= O
0.41). O
[['Physiological-Clinical']]

The O
BMI B-outcome ['Physiological-Clinical']
z-score O
of O
the O
overall O
completers O
decreased O
by O
about O
0.05 O
after O
the O
16-week O
intervention O
(p O
= O
0.02). O
[['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

The O
experimental O
group O
underwent O
the O
Brief O
Group O
Intervention, O
which O
had O
four O
group O
sessions, O
with O
weekly O
meetings. O
[]

But O
in O
practice, O
we O
found O
a O
lot O
of O
problems O
in O
using O
the O
ointment. O
[]

BACKGROUND: O
The O
aim O
of O
this O
analysis O
was O
to O
ascertain O
the O
type O
of O
relationship O
between O
fish O
and O
seafood O
consumption, O
omega-3 O
polyunsaturated O
fatty O
acids O
(omega-3 O
PUFA) O
intake, O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
prevalence. O
[['Physiological-Clinical', 'Life-Impact']]

Journal O
ID: O
8205248 O
[]

In O
addition, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
assessed O
during O
the O
period O
of O
this O
study. O
[['Adverse-effects']]

No O
major O
complications B-outcome ['Adverse-effects']
were O
noted. O
[['Adverse-effects']]

Under O
PCV O
mode, O
with O
the O
increase O
in O
oxygen O
atomization O
flow, O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
decreased O
gradually, O
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
increased O
gradually, O
with O
significant O
difference O
as O
compared O
with O
those O
before O
atomization O
when O
the O
atomized O
oxygen O
flow O
was O
9 O
L/min O
[ O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(mL): O
322.78+/-17.75 O
vs. O
518.17+/-8.97, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(mL): O
730.89+/-31.20 O
vs. O
519.00+/-9.06, O
both O
P O
< O
0.05]. O
There O
was O
no O
significant O
change O
in O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
no O
significant O
difference O
at O
9 O
L/min O
of O
atomized O
oxygen O
flow O
as O
compared O
with O
that O
before O
atomization O
(cmH2O: O
21.44+/-2.23 O
vs. O
21.39+/-2.55, O
P O
> O
0.05). O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
Sixteen O
non-heat O
acclimatized O
men O
heat O
acclimated O
during O
10-11 O
days O
of O
exercise O
in O
the O
heat O
(40 O
degrees O
C, O
40% O
RH). O
[]

CONCLUSION: O
The O
findings O
of O
this O
study O
showed O
that O
UGPRF O
may O
benefit O
for O
patients O
with O
FS O
after O
12 O
weeks O
treatment. O
[]

MAIN O
OUTCOME O
MEASURES: O
The O
primary O
outcome O
measure O
was O
a O
composite O
of O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
perinatal I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
: O
perinatal B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
Apgar B-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
<4, O
impaired B-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
, O
asphyxia B-outcome ['Physiological-Clinical']
, O
seizures B-outcome ['Physiological-Clinical']
, O
assisted B-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
, O
septicaemia B-outcome ['Physiological-Clinical']
, O
meningitis B-outcome ['Physiological-Clinical']
, O
bronchopulmonary B-outcome ['Physiological-Clinical']
dysplasia I-outcome ['Physiological-Clinical']
, O
intraventricular B-outcome ['Physiological-Clinical']
haemorrhage I-outcome ['Physiological-Clinical']
, O
periventricular B-outcome ['Physiological-Clinical']
leukomalacia I-outcome ['Physiological-Clinical']
, O
or O
necrotising B-outcome ['Physiological-Clinical']
enterocolitis I-outcome ['Physiological-Clinical']
. O
Secondary O
outcomes O
were O
two O
composite O
measures O
of O
severe B-outcome ['Physiological-Clinical']
maternal I-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
and O
spontaneous B-outcome ['Physiological-Clinical']
labour I-outcome ['Physiological-Clinical']
and O
birth O
. O
RESULTS: O
Between O
1 O
February O
2015 O
and O
29 O
February O
2016, O
60 O
midwifery O
practices O
enrolled O
13 O
520 O
women O
in O
mid-pregnancy O
(mean O
22.8 O
(SD O
2.4) O
weeks' O
gestation). O
[['Adverse-effects'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Maturitas O
[]

To O
objectify O
the O
treatment O
outcomes O
in O
both O
groups O
before O
and O
after O
the O
treatment, O
we O
measured O
myostatin O
concentration O
and O
performed O
the O
urinary B-outcome ['Physiological-Clinical']
incontinence I-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
assessment O
( O
The O
Revised O
Urinary B-outcome ['Physiological-Clinical']
Incontinence I-outcome ['Physiological-Clinical']
Scale]), O
perceived O
self-efficacy B-outcome ['Life-Impact']
assessment O
(General O
Self-Efficacy B-outcome ['Life-Impact']
Scale), O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
severity O
assessment O
( O
Beck O
Depression B-outcome ['Physiological-Clinical', 'Life-Impact']
Inventory]). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
immediate O
effectiveness O
of O
2 O
counterforce O
orthoses O
in O
improving O
the O
sensorimotor B-outcome ['Physiological-Clinical']
abilities O
of O
the O
hand O
in O
patients O
with O
lateral O
elbow O
tendinopathy. O
[['Physiological-Clinical']]

Cost B-outcome ['Resource-use']
per O
gained O
QALY O
was O
1704-7889 O
USD. O
[['Resource-use']]

Except O
for O
the O
number O
of O
infarctions, O
size O
and O
location O
should O
also O
be O
considered O
to O
stratify O
risk O
of O
stroke O
recurrence O
in O
minor O
stroke. O
[]

For O
the O
statistical O
analyses, O
the O
IBM O
SPSS O
Statistics O
22 O
(IBM O
SPSS, O
Turkey) O
program O
was O
used O
to O
assess O
the O
findings O
of O
the O
study. O
[]

Data O
was O
collected O
by O
semi-structured O
interviews O
between O
March O
and O
April O
2016. O
[]

Therefore, O
the O
purpose O
of O
this O
study O
was O
to O
use O
a O
combination O
of O
methods O
to O
elicit O
child O
and O
teacher O
perceptions O
regarding O
the O
feasibility B-outcome ['Life-Impact']
and O
acceptability B-outcome ['Life-Impact']
of O
the O
AS:Sk O
intervention, O
alongside O
systematic O
researcher O
observations. O
[['Life-Impact'], ['Life-Impact']]

Recovery O
of O
TOFr O
from O
0.25 O
to O
0.75 O
and O
from O
0.25 O
to O
0.9 O
was O
longer O
in O
patients O
treated O
with O
rocuronium O
than O
in O
those O
treated O
with O
cisatracurium O
(both O
P O
<.001). O
[]

Journal O
ID: O
2985248R O
[]

The O
secondary O
outcomes O
consisted O
of O
shoulder B-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
, O
measured O
by O
the O
score O
of O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
index O
(SPADI)]; O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
assessed O
by O
the O
Short O
Form-36 O
questionnaire O
(SF-36)]; O
and O
any O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
(AEs) I-outcome ['Adverse-effects']
during O
the O
treatment O
period. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Adverse-effects']]

Recent O
studies O
have O
shown O
that O
antibiotic O
therapy O
is O
both O
safe O
and O
cost-effective O
for O
a O
CT-scan O
confirmed O
uncomplicated O
acute O
appendicitis. O
[]

This O
single-blind O
preliminary O
randomized-controlled O
study O
investigated O
the O
effects O
of O
a O
MBI O
on O
anxio-depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
and O
memory B-outcome ['Life-Impact']
, O
compared O
to O
a O
psychoeducation-based O
intervention O
in O
older O
adults O
with O
aMCI. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Life-Impact']]

There O
were O
no O
significant O
differences O
in O
generated O
power B-outcome ['Physiological-Clinical']
and O
velocity B-outcome ['Physiological-Clinical']
in O
the O
CON O
phase O
of O
the O
movement O
between O
the O
GCAF O
and O
GCON. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Handgrip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
increase O
was O
also O
observed O
after O
HIIT O
(p=.002), O
but O
no O
differences O
were O
observed O
with O
MIIT O
and O
CG. O
[['Life-Impact']]

Publication O
date: O
2019/03/08 O
06:00 O
[medline] O
[]

CONCLUSION: O
The O
strong O
efficacy O
and O
favorable O
benefit-risk O
profile O
of O
DMF O
extends O
to O
Japanese, O
and O
more O
broadly, O
East O
Asian O
patients O
with O
RRMS. O
[]

CONCLUSION: O
In O
low O
risk O
pregnancies, O
routine O
ultrasonography O
in O
the O
third O
trimester O
along O
with O
clinically O
indicated O
ultrasonography O
was O
associated O
with O
higher O
antenatal O
detection O
of O
small B-outcome ['Physiological-Clinical']
for O
gestational O
age O
fetuses O
but O
not O
with O
a O
reduced O
incidence O
of O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
perinatal I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
compared O
with O
usual O
care O
alone. O
[['Physiological-Clinical'], ['Adverse-effects']]

2) O
Simulated O
scuba O
results O
in O
vitro: O
under O
VCV O
mode, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
respirator O
and O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
scuba O
in O
different O
preset O
VT O
groups O
were O
continuously O
increased O
with O
the O
increase O
in O
oxygen O
atomization O
flow, O
while O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
was O
not O
significantly O
changed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
anti-HAV B-outcome ['Physiological-Clinical']
GMCs I-outcome ['Physiological-Clinical']
in O
the O
Avaxim, O
Epaxal, O
and O
Havrix O
groups O
were O
5868.4 O
(95% O
CI: O
4237.2-8126.6), O
1962.1 O
(95% O
CI: O
1298.0-2965.9), O
and O
2232.9 O
mIU/mL O
(95% O
CI: O
1428.4-3490.4), O
respectively, O
after O
administration O
of O
2 O
doses O
(P O
< O
.001). O
[['Physiological-Clinical']]

Journal-Name:BMC O
gastroenterology O
[]

RESULTS: O
The O
intention-to-treat O
population O
included O
386 O
patients O
in O
the O
omadacycline O
group O
and O
388 O
patients O
in O
the O
moxifloxacin O
group. O
[]

OBJECTIVE: O
To O
explore O
the O
effects O
of O
propofol O
sedation O
on O
psychological B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
in O
patients O
undergoing O
surgery O
under O
epidural O
anesthesia. O
[['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT02546765. O
[]

There O
were O
three O
non-serious O
exercise-related O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
two O
exercise O
participants O
experienced O
disease B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
during O
follow-up. O
[['Adverse-effects'], ['Physiological-Clinical']]

Journal O
ID: O
0255562 O
[]

The O
level O
of O
activity O
has O
been O
assessed O
on O
the O
basis O
of O
a O
questionnaire O
and O
body O
posture O
assessments O
were O
done O
using O
a O
plumb O
line, O
pediscoliometer, O
digital O
inclinometer. O
[]

The O
pattern O
of O
FEV1 B-outcome ['Physiological-Clinical']
changes O
around O
exacerbations O
was O
similar O
in O
the O
triple O
therapy O
and O
dual O
bronchodilator O
groups, O
and O
a O
similar O
pattern O
was O
seen O
in O
moderate O
and O
severe O
exacerbations O
when O
analysed O
separately. O
[['Physiological-Clinical']]

The O
7-year O
biochemical B-outcome ['Physiological-Clinical', 'Mortality']
failure-free I-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(BCFFS) I-outcome ['Physiological-Clinical', 'Mortality']
of O
the O
MHF O
and O
EHF O
groups O
were O
90.5 O
and O
57.1% O
in O
the O
low-risk O
group O
(p O
= O
0.154); O
83.5 O
and O
42.9% O
in O
the O
intermediate O
risk O
group O
(p O
= O
0.018); O
and O
41.7 O
and O
40.0% O
in O
the O
high O
risk O
group O
(p O
= O
0.786), O
respectively. O
[['Physiological-Clinical', 'Mortality']]

Journal-Name:JAMA O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

There O
were O
33 O
(45%) O
female O
patients O
in O
the O
study O
and O
the O
average O
BMI O
was O
27.6. O
[]

Exercise O
can O
produce O
an O
imbalance O
between O
ROS O
and O
antioxidants, O
leading O
to O
oxidative O
stress-related O
tissue O
damages. O
[]

It O
involves O
the O
use O
of O
a O
non-toxic O
dye, O
called O
photosensitizer O
(FS), O
and O
a O
light O
source O
of O
a O
specific O
wavelength O
in O
the O
presence O
of O
the O
environmental O
oxygen. O
[]

Publication O
date: O
2019/02/08 O
06:00 O
[entrez] O
[]

We O
evaluated O
the O
comparative O
effectiveness O
of O
high-fidelity O
simulation O
training O
vs. O
standard O
manikin O
training O
for O
teaching O
medical O
students O
the O
American O
Heart O
Association O
(AHA) O
guidelines O
for O
high-quality O
CPR. O
[]

Participants O
underwent O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
evaluation, O
as O
well O
as O
measurements O
of O
the O
intervals B-outcome ['Physiological-Clinical']
between O
consecutive O
heartbeats O
or O
RR B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
for O
the O
analysis O
of O
HRV B-outcome ['Physiological-Clinical']
at O
the O
first O
and O
the O
last O
weeks O
of O
hospitalization O
of O
their O
preterms. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSION: O
In O
second-line O
treatment O
for O
metastatic O
colorectal O
cancer, O
mFOLFOX6 O
or O
FOLFIRI O
with O
erlotinib O
in O
a O
sequence-dependent O
fashion O
is O
not O
feasible O
despite O
potential O
promising O
activity. O
[]

There O
were O
no O
incidences O
of O
bradycardia B-outcome ['Physiological-Clinical']
and O
hypoxemia B-outcome ['Physiological-Clinical']
in O
either O
of O
the O
groups O
during O
study O
observation. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Tafenoquine O
showed O
efficacy O
for O
the O
radical O
cure B-outcome ['Physiological-Clinical']
of O
P. O
vivax O
malaria, O
although O
tafenoquine O
was O
not O
shown O
to O
be O
noninferior O
to O
primaquine. O
( O
[['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Participants O
were O
randomly O
administered O
loading O
doses O
of O
prasugrel O
60 O
mg O
(group O
A, O
n O
= O
166) O
or O
30 O
mg O
(group O
B, O
n O
= O
166) O
before O
undergoing O
elective O
PCI O
in O
a O
1:1 O
manner. O
[]

Main O
Outcomes O
and O
Measures: O
The O
primary O
outcome O
was O
incidence O
of O
postoperative O
in-hospital O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
by O
the O
Confusion O
Assessment O
Method. O
[['Physiological-Clinical', 'Life-Impact']]

Journal O
ID: O
2984818R O
[]

Initial O
forward O
movement O
in O
the O
IA O
group O
was O
4 O
to O
5 O
mm O
and O
was O
followed O
by O
subsequent O
bimonthly O
advancements O
of O
2 O
mm. O
[]

We O
collected O
6484 O
questionnaires, O
including O
3583 O
in O
the O
intervention O
group O
[response O
rate: O
96% O
(3583/3726) O
and O
2901 O
in O
the O
control O
group O
[response O
rate: O
90% O
(2901/3224)]. O
We O
observed O
that O
hand B-outcome ['Life-Impact']
washing I-outcome ['Life-Impact']
habit I-outcome ['Life-Impact']
of O
children O
and O
parent, O
knowledge B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
hand I-outcome ['Life-Impact']
food I-outcome ['Life-Impact']
mouth I-outcome ['Life-Impact']
disease I-outcome ['Life-Impact']
of O
parents, O
children's O
daily O
cleaning B-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
scores O
improved O
in O
the O
intervention O
group O
and O
higher O
than O
that O
in O
the O
control O
group O
at O
both O
the O
end O
of O
year O
1 O
(April O
1-July O
31, O
2011)and O
year O
2 O
(April O
1-July O
31, O
2012). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

The O
smaller O
sample O
size O
for O
women O
may O
account O
for O
some O
observed O
discrepancies O
in O
treatment B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
Although O
there O
were O
gender O
differences O
in O
baseline O
characteristics, O
IND/GLY O
demonstrated O
similar O
trends O
for O
exacerbation B-outcome ['Physiological-Clinical']
prevention O
and O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improvement O
in O
men O
and O
women O
with O
moderate-to-very-severe O
COPD O
and O
a O
history O
of O
exacerbations O
compared O
with O
SFC. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Interobserver O
reliability O
showed O
excellent O
agreement O
based O
on O
the O
intraclass O
correlation O
coefficient, O
and O
moderate O
to O
almost O
perfect O
agreement O
by O
kappa O
statistics. O
[]

Limitations: O
This O
post O
hoc O
analysis O
was O
limited O
to O
patients O
with O
moderate-to-severe O
plaque O
psoriasis O
with O
IGA O
>/=3 O
and O
BSA O
involvement O
(3%-12%). O
[]

Vitamin O
D O
is O
involved O
in O
bone O
metabolism O
and O
in O
many O
various O
extra-skeletal O
diseases O
such O
as O
malabsorption O
syndromes, O
cardiovascular O
and O
metabolic O
diseases, O
cancer, O
and O
autoimmune O
and O
neurological O
diseases. O
[]

Journal O
ID: O
7501160 O
[]

Various O
pharmacological O
agents, O
with O
the O
exception O
of O
calcium O
channel O
blockers, O
have O
been O
investigated O
to O
improve O
ET O
outcomes O
by O
reducing O
UC. O
[]

Journal-Name:Respiratory O
research O
[]

Publication O
Type: O
Journal O
Article O
[]

4) O
Conclusion: O
The O
effects O
found O
in O
the O
present O
study O
agree O
with O
antihypertensive O
and O
antioxidant O
effects O
previously O
reported O
for O
Spirulina O
maxima. O
[]

The O
drug B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
in O
the O
AG O
(4,413.60+/-1,772.35) O
yen O
were O
significantly O
lower O
than O
that O
in O
the O
CG O
(6,490.35+/-3,367.66) O
yen O
(P=0.01). O
[['Resource-use']]

Journal O
ID: O
2985248R O
[]

Background O
Very O
little O
research O
has O
been O
done O
to O
simultaneously O
investigate O
the O
effects O
of O
Tai O
Chi O
(TC) O
on O
depression O
and O
heart O
rate O
variability O
(HRV). O
[]

METHODS: O
This O
prospective O
study O
included O
113 O
cirrhotic O
patients O
with O
actively O
bleeding O
esophageal O
varices. O
[]

RESULTS: O
At O
a O
median O
follow-up O
of O
7.5 O
years O
(range, O
1.3-9.6 O
years), O
7-year O
biochemical B-outcome ['Physiological-Clinical', 'Mortality']
failure-free I-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(BCFFS) I-outcome ['Physiological-Clinical', 'Mortality']
was O
76.2% O
for O
the O
MHF O
group O
and O
46.2% O
for O
the O
EHF O
group O
(p O
= O
0.005). O
[['Physiological-Clinical', 'Mortality']]

Journal O
ID: O
7501160 O
[]

Publication O
date: O
2019/03/01 O
06:00 O
[entrez] O
[]

The O
LBW O
protocol O
can O
avoid O
iodine O
overdosing B-outcome ['Life-Impact']
, O
especially O
in O
patients O
with O
a O
high O
BMI. O
[['Life-Impact']]

Curcumin O
can O
be O
used O
as O
an O
effective O
alternative O
local O
drug O
delivery O
agent. O
[]

Journal-Name:Zhongguo O
fei O
ai O
za O
zhi O
= O
Chinese O
journal O
of O
lung O
cancer O
[]

Complete-case, O
per-protocol, O
and O
sensitivity O
analyses O
supported O
this O
result. O
[]

Ten O
SAEs B-outcome ['Adverse-effects']
were O
observed O
within O
the O
treatment O
period, O
and O
4 O
deaths B-outcome ['Mortality']
unrelated O
to O
the O
study O
medication. O
[['Adverse-effects'], ['Mortality']]

CONCLUSIONS: O
Findings O
highlight O
the O
complexity O
of O
implementing O
a O
mhGAP-based O
training O
given O
its O
interaction O
with O
contextual O
factors O
to O
influence O
the O
attainment O
of O
expected O
outcomes. O
[]

Results: O
A O
total O
of O
240 O
of O
279 O
patients O
(129 O
females O
and O
111 O
male) O
aged O
18 O
- O
65 O
years O
were O
referred O
and O
integrated O
in O
this O
clinical O
trial, O
whereas O
29 O
were O
rejected O
as O
not O
completing O
the O
requirements O
needed. O
[]

Funded O
by O
Ablynx; O
HERCULES O
ClinicalTrials.gov O
number, O
NCT02553317 O
.). O
[]

Journal O
ID: O
2985248R O
[]

However, O
these O
do O
not O
consider O
changes O
in O
Body O
Surface O
Area O
(BSA)]. O
The O
IGAxBSA O
composite O
tool O
is O
a O
simple, O
effective, O
validated O
alternative O
for O
measuring O
improvement O
in O
psoriasis O
severity. O
[]

Methods: O
A O
child O
survival O
project O
was O
implemented O
in O
10 O
slum O
communities, O
which O
were O
then O
randomly O
allocated O
to O
intervention O
(PCBHIS) O
and O
comparison O
areas. O
[]

Journal-Name: O
Revista O
latino-americana O
de O
enfermagem O
[]

RESULTS: O
The O
success B-outcome ['Physiological-Clinical']
rates O
in O
the O
tobramycin/dexamethasone O
eye O
drops O
group O
in O
both O
2 O
age O
subgroups O
were O
significantly O
higher O
than O
that O
in O
the O
ointment O
group O
and O
NS O
group O
(P O
< O
.05). O
[['Physiological-Clinical']]

A O
heat B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
test O
(120min, O
45% O
V O
O2peak) O
before O
(Pre O
HA) O
and O
after O
HA O
(Post O
HA) O
in O
similar O
hot O
conditions O
assessed O
heat B-outcome ['Physiological-Clinical']
acclimation I-outcome ['Physiological-Clinical']
status. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
100968551 O
[]

T O
Kujala O
score O
increased O
from O
70.77 O
points O
preoperatively O
to O
94.32 O
postoperatively O
(P O
< O
.001). O
[]

Journal-Name:BMC O
psychology O
[]

BACKGROUND: O
Desmoid O
tumors O
(also O
referred O
to O
as O
aggressive O
fibromatosis) O
are O
connective O
tissue O
neoplasms O
that O
can O
arise O
in O
any O
anatomical O
location O
and O
infiltrate O
the O
mesentery, O
neurovascular O
structures, O
and O
visceral O
organs. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrials.gov O
NCT01277302 O
. O
[]

Publication O
date: O
['2019/10/10 O
06:00' O
[]

There O
was O
no O
significant O
change O
in O
Coenzyme B-outcome ['Physiological-Clinical']
Q10 I-outcome ['Physiological-Clinical']
(CoQ10) I-outcome ['Physiological-Clinical']
level O
of O
amla O
(p O
= O
0.2942) O
or O
placebo O
groups O
(p O
= O
0.6744). O
[['Physiological-Clinical']]

Title: O
Randomized O
Evaluation O
of O
Videoconference O
Meetings O
for O
Medical O
Students' O
Mid-clerkship O
Feedback O
Sessions. O
[]

Journal O
ID: O
2985248R O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/01/12 O
06:00 O
[entrez] O
[]

Title: O
Cardiometabolic B-outcome ['Physiological-Clinical']
Health I-outcome ['Physiological-Clinical']
in O
Relation O
to O
Lifestyle O
and O
Body O
Weight O
Changes O
3(-)8 O
Years O
Earlier. O
[['Physiological-Clinical']]

Methods: O
Between O
June O
2015 O
and O
January O
2017, O
53 O
patients O
with O
high O
risk O
of O
vertebral O
"shell" O
after O
thoracolumbar O
fracture O
surgery O
were O
enrolled O
in O
a O
prospective O
study O
according O
to O
the O
selection O
criteria. O
[]

The O
study O
was O
aimed O
to O
observe O
the O
curative O
effect O
of O
device-guided O
rehabilitation O
on O
respiratory O
functions O
in O
stable O
COPD O
patients. O
[]

Results O
of O
the O
Active O
Schools: O
Skelmersdale O
(AS:Sk) O
multi-component O
pilot O
intervention O
indicated O
no O
significant O
positive O
change O
to O
child O
PA O
levels. O
[]

Journal O
ID: O
0224131 O
[]

Journal O
ID: O
2985248R O
[]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT01656278. O
[]

Patients O
in O
group O
A O
were O
treated O
with O
dimethyldiguanide O
combined O
with O
clomifene O
citrate, O
while O
patients O
in O
group O
B O
were O
treated O
with O
clomifene O
citrate O
alone. O
[]

Perceived O
ability B-outcome ['Life-Impact']
to O
exercise B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(frequency, X ['Physiological-Clinical', 'Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
duration S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
) O
in O
relation O
to O
each O
dietary O
period O
was O
also O
rated O
using O
a O
visual O
analogue O
scale. O
[['Life-Impact'], ['Physiological-Clinical', 'Physiological-Clinical']]

Journal-Name:Oncology O
reports O
[]

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O
[]

Antimicrobial O
photodynamic O
therapy O
(aPDT) O
has O
been O
widely O
used O
with O
very O
satisfactory O
results O
in O
the O
health O
sciences. O
[]

Objective: O
To O
determine O
whether O
a O
therapeutic O
strategy O
involving O
low-dose O
intracoronary O
fibrinolytic O
therapy O
with O
alteplase O
infused O
early O
after O
coronary O
reperfusion O
will O
reduce O
microvascular B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
. O
Design, O
Setting, O
and O
Participants: O
Between O
March O
17, O
2016, O
and O
December O
21, O
2017, O
440 O
patients O
presenting O
at O
11 O
hospitals O
in O
the O
United O
Kingdom O
within O
6 O
hours O
of O
STEMI O
due O
to O
a O
proximal-mid-vessel O
occlusion O
of O
a O
major O
coronary O
artery O
were O
randomized O
in O
a O
1:1:1 O
dose-ranging O
trial O
design. O
[['Physiological-Clinical']]

BACKGROUND: O
To O
identify O
baseline O
patient O
characteristics O
associated O
with O
early O
clinically O
significant O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(VA) I-outcome ['Physiological-Clinical']
improvements O
within O
3 O
months O
of O
treatment O
initiation O
in O
ranibizumab-treated O
patients O
with O
retinal O
vein O
occlusion O
(RVO) O
in O
the O
SHORE O
study. O
[['Physiological-Clinical']]

Journal O
ID: O
0255562 O
[]

Several O
studies O
have O
linked O
increased O
intake O
of O
dietary O
fibre O
to O
improvement O
in O
the O
management O
of O
body O
weight. O
[]

At O
the O
test-of-cure O
visit, O
a O
higher O
percentage O
of O
patients O
in O
the O
plazomicin O
group O
than O
in O
the O
meropenem O
group O
were O
found O
to O
have O
microbiologic B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
, O
including O
eradication O
of O
Enterobacteriaceae O
that O
were O
not O
susceptible O
to O
aminoglycosides O
(78.8% O
vs. O
68.6%) O
and O
Enterobacteriaceae O
that O
produce O
extended-spectrum O
beta-lactamases O
(82.4% O
vs. O
75.0%). O
[['Physiological-Clinical']]

A O
nonsignificant O
elevation O
of O
serum O
norepinephrine B-outcome ['Physiological-Clinical']
and O
epinephrine B-outcome ['Physiological-Clinical']
levels O
was O
observed O
in O
the O
methohexital O
group, O
while O
serum O
arginine B-outcome ['Physiological-Clinical']
vasopressin I-outcome ['Physiological-Clinical']
and O
angiotensin B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
levels O
did O
not O
differ O
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Exposure O
to O
sponsorship O
for O
healthier O
foods O
produced O
similar O
sponsorship O
effects O
for O
healthier O
food O
sponsor O
brands, O
as O
well O
as O
prompting O
a O
significant O
increase O
in O
the O
proportion O
of O
young O
adults O
showing O
a O
preference B-outcome ['Life-Impact']
for O
these O
products. O
[['Life-Impact']]

Publication O
date: O
2018/12/12 O
00:00 O
[accepted] O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

The O
Taurisolo((R)) O
polyphenol O
content O
was O
evaluated O
by O
a O
High O
Performance O
Liquid O
Chromatography-diode-array O
detector O
(HPLC-DAD) O
method, O
and O
RSV O
was O
monitored O
as O
an O
indicative O
marker. O
[]

The O
difference O
between O
groups O
was O
significant O
(p=.045). O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

There O
was O
no O
significant O
difference O
in O
the O
similarity O
of O
the O
simulators O
to O
the O
porcine O
larynx O
(P O
= O
.81). O
[]

Title: O
Randomized O
controlled O
trial O
comparing O
the O
efficacy O
of O
daily O
and O
every O
other O
day O
atorvastatin O
therapy O
and O
its O
correlation O
with O
serum O
hydroxymethylglutaryl-CoA B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
levels O
in O
naive O
dyslipidemic O
patients. O
[['Physiological-Clinical']]

CONCLUSION: O
Health O
education O
of O
diabetic O
individuals O
via O
Wechat O
platform O
in O
conjunction O
with O
conventional O
diabetes O
treatment O
could O
improve O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
positively O
influence O
other O
aspects O
of O
diabetes O
self-care B-outcome ['Life-Impact']
skills. O
[['Physiological-Clinical'], ['Life-Impact']]

MACE B-outcome ['Physiological-Clinical', 'Mortality']
at O
1 O
year O
were O
comparable O
in O
both O
the O
groups O
3 O
of O
85(3.52%) O
in O
the O
polymer-free O
group O
and O
3 O
of O
98(3.06%) O
in O
the O
biodegradable O
polymer O
group, O
p O
= O
0.859. O
[['Physiological-Clinical', 'Mortality']]

Journal O
ID: O
9420934 O
[]

DFUs O
which O
failed O
to O
heal O
during O
the O
study O
period O
(20/28, O
71.4 O
%) O
were O
more O
likely O
to O
be O
persistently O
colonized O
with O
a O
heterogeneous O
community O
of O
micro-organisms O
including O
anaerobes O
and O
Enterobacteriaceae O
(log-likelihood O
ratio O
9.56, O
P=0.008). O
[]

Relocating O
away O
from O
family O
and O
country O
for O
treatment, O
adjusting O
to O
life O
with O
a O
chronic O
condition O
and O
time O
lost O
to O
dialysis O
cause O
grief O
and O
sadness O
which O
have O
immense O
impact O
on O
quality O
of O
life O
and O
challenges O
treatment O
adherence. O
[]

The O
treatment O
sessions O
lasted O
for O
15 O
minutes, O
and O
occurred O
three O
times O
a O
week, O
for O
4 O
weeks. O
[]

Other O
dentoalveolar B-outcome ['Physiological-Clinical']
changes O
in O
both O
groups O
were O
intrusion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
maxillary O
first O
molars O
, O
and O
extrusion B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
the Seperator ['Physiological-Clinical', 'Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
first I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
molars I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
maxillary I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
incisors S3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
The O
mentolabial B-outcome ['Physiological-Clinical']
sulcus I-outcome ['Physiological-Clinical']
was O
flattened, O
soft B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
convexity I-outcome ['Physiological-Clinical']
was O
reduced, O
and O
forward O
movement B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical']
soft I-outcome ['Physiological-Clinical']
tissues I-outcome ['Physiological-Clinical']
was O
seen O
after O
Herbst O
therapy. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Estimates O
from O
regression-adjusted O
treatment O
effects O
indicate O
that O
the O
average O
PTSD B-outcome ['Physiological-Clinical', 'Life-Impact']
severity I-outcome ['Physiological-Clinical', 'Life-Impact']
score O
was O
reduced O
by O
9.7 O
points O
(p O
= O
0.01), O
or O
14.3% O
from O
pre- O
to O
post-intervention. O
[['Physiological-Clinical', 'Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Exercise O
training O
as O
an O
adjunctive O
therapy O
to O
montelukast O
in O
children O
with O
mild O
asthma: O
A O
randomized O
controlled O
trial. O
[]

Title: O
The O
periprocedural O
myocardial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
prevention O
during O
elective O
percutaneous O
coronary O
intervention O
as O
a O
result O
of O
pharmacological O
preconditioning O
with O
an O
oral O
form O
of O
nicorandil O
in O
patients O
with O
stable O
coronary O
artery O
disease. O
[['Physiological-Clinical']]

BACKGROUND: O
To O
combat O
emerging O
drug O
resistance O
in O
the O
Greater O
Mekong O
Sub-region O
(GMS) O
the O
World O
Health O
Organization O
and O
GMS O
countries O
have O
committed O
to O
eliminating O
malaria O
in O
the O
region O
by O
2030. O
[]

Likely O
due O
to O
greater O
beverage O
osmolality O
(81 O
+/- O
1.4 O
vs. O
11 O
+/- O
0.7 O
mOsmol/kg), O
thirst B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
remained O
12% O
higher O
with O
MW O
(p O
< O
0.05). O
[['Physiological-Clinical']]

Primary O
outcome O
was O
current O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
(100-mm O
visual O
analog O
scale); O
secondary O
outcome O
measures O
included O
function B-outcome ['Life-Impact']
( O
Oswestry O
Disability B-outcome ['Life-Impact']
Index]), O
pain B-outcome ['Physiological-Clinical']
on O
movement O
( O
Pain B-outcome ['Physiological-Clinical']
on O
Movement O
Questionnaire), O
perceived B-outcome ['Life-Impact']
change O
in O
health O
status O
, O
pressure B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
threshold, O
mechanical B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
threshold, O
and O
vibration B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
threshold. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
ergogenic O
effect O
of O
betaA O
has O
also O
been O
demonstrated O
for O
2000-m O
rowing O
performance O
prompting O
interest O
in O
whether O
betaA O
may O
be O
beneficial O
for O
sustained O
aerobic O
exercise. O
[]

Title: O
The O
use O
of O
ETView O
endotracheal O
tube O
for O
surveillance O
after O
tube O
positioning O
in O
patients O
undergoing O
lobectomy, O
randomized O
trial. O
[]

All O
patients O
received O
cyclophosphamide O
750 O
mg/m(2) O
and O
doxorubicin O
50 O
mg/m(2) O
on O
day O
1 O
of O
each O
cycle O
intravenously O
and O
prednisone O
100 O
mg O
once O
daily O
on O
days O
1 O
to O
5 O
of O
each O
cycle O
orally, O
followed O
by O
either O
brentuximab O
vedotin O
1.8 O
mg/kg O
and O
a O
placebo O
form O
of O
vincristine O
intravenously O
(A+CHP O
group) O
or O
vincristine O
1.4 O
mg/m(2) O
and O
a O
placebo O
form O
of O
brentuximab O
vedotin O
intravenously O
(CHOP O
group) O
on O
day O
1 O
of O
each O
cycle. O
[]

MATERIAL O
AND O
METHODS: O
Three O
hundred O
thirty-two O
Indian O
patients O
undergoing O
elective O
percutaneous O
coronary O
intervention O
(PCI) O
were O
enrolled O
in O
the O
study. O
[]

Publication O
Type: O
Journal O
Article O
[]

ClinicalTrials.gov O
number: O
NCT01782326 O
. O
[]

Publication O
date: O
2019/02/05 O
06:00 O
[medline] O
[]

DHA B-outcome ['Physiological-Clinical']
intakes O
up O
to O
7 O
mg/kg O
did O
not O
improve O
neurological B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
in O
PKU O
children. O
[['Physiological-Clinical'], ['Life-Impact']]

CONCLUSIONS: O
The O
WHO O
ACE O
approach O
supported O
development O
and O
sustainment O
of O
a O
network O
of O
organizations O
linking O
health O
care O
and O
social O
services O
across O
East O
Baltimore. O
[]

OBJECTIVE: O
To O
explore O
the O
clinical O
and O
programmatic O
feasibility O
of O
using O
800 O
mug O
of O
sublingual O
misoprostol O
to O
prevent O
and O
treat O
postpartum B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
(PPH) I-outcome ['Physiological-Clinical']
during O
home O
delivery. O
[['Physiological-Clinical']]

Title: O
A O
randomized O
controlled O
trial O
of O
neuromuscular O
electrical O
stimulation O
for O
chronic O
urinary O
retention O
following O
traumatic O
brain O
injury. O
[]

Title: O
The O
analgesic O
efficacy O
of O
oblique O
subcostal O
transversus O
abdominis O
plane O
block O
after O
laparoscopic O
hysterectomy: O
A O
randomized, O
controlled, O
observer-blinded O
study. O
[]

Title: O
IQOS(TM) O
vs. O
e-Cigarette O
vs. O
Tobacco O
Cigarette: O
A O
Direct O
Comparison O
of O
Short-Term O
Effects O
after O
Overnight-Abstinence. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Revista O
de O
saude O
publica O
[]

The O
participants O
were O
randomized O
into O
intervention O
group O
(IG) O
and O
control O
group O
(CG). O
[]

Participants O
completed O
a O
laboratory O
30-min O
rowing O
time-trial, O
followed O
by O
3x30-seconds O
(s) O
maximal O
sprint O
efforts O
at O
days O
0, O
14 O
and O
28 O
(T1-T3). O
[]

This O
study O
was O
registered O
in O
the O
Australian O
New O
Zealand O
Clinical O
Trial O
Registry O
(ANZCTR) O
under O
protocol O
number: O
ACTRN12617000449336. O
[]

Also O
the O
frequency O
of O
the O
troponin B-outcome ['Physiological-Clinical']
increase O
above O
the O
UNL(upper O
normal O
level) O
in O
the O
nicorandal O
group, O
was O
significantly O
(p O
= O
0.03) O
lower O
(in O
62% O
of O
cases O
compared O
to O
85% O
of O
the O
control O
group). O
[['Physiological-Clinical']]

The O
intervention O
period O
was O
from O
April O
1 O
to O
July O
31, O
2011 O
and O
April O
1 O
to O
July O
31, O
2012. O
[]

All O
subjects O
(20-45 O
years O
old), O
who O
were O
frequently O
referred O
to O
the O
private O
obstetrics O
and O
gynecology O
clinics, O
were O
initially O
monitored O
for O
PMS O
and O
depression. O
[]

Four-hundred O
twenty-four O
patients O
with O
septic O
shock O
were O
included O
between O
March O
2017 O
and O
March O
2018. O
[]

Publication O
Type: O
Journal O
Article O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS: O
This O
randomized O
controlled O
study O
included O
409 O
subjects O
(496 O
eyes) O
older O
than O
1-year-old O
with O
persistent O
CNLDO O
in O
southwest O
China, O
and O
classified O
into O
3 O
groups: O
96 O
cases O
(123 O
eyes) O
were O
the O
tobramycin/dexamethasone O
eye O
drops O
group O
(drops O
group), O
88 O
cases O
(104 O
eyes) O
were O
the O
tobramycin/dexamethasone O
ointment O
group O
(ointment O
group), O
and O
225 O
cases O
(269 O
eyes) O
were O
control O
group O
which O
probing O
with O
normal O
saline O
(NS O
group). O
[]

A O
sociodemographic O
questionnaire O
and O
the O
Alcohol B-outcome ['Physiological-Clinical']
Use I-outcome ['Physiological-Clinical']
Disorders I-outcome ['Physiological-Clinical']
Identification O
Test O
(Audit) O
were O
applied. O
[['Physiological-Clinical']]

BACKGROUND: O
Endometriosis O
is O
the O
major O
cause O
of O
progressive O
pelvic O
pain O
and O
subfertility. O
[]

One O
eye O
needed O
repair B-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
. O
There O
was O
no O
statistical O
difference O
between O
the O
2 O
groups O
(P O
> O
.05). O
[['Resource-use']]

Journal-Name: O
BMJ O
(Clinical O
research O
ed.) O
[]

In O
this O
clinical O
trial, O
we O
evaluated O
the O
effectiveness O
of O
platelet-rich O
plasma O
(PRP) O
in O
the O
treatment O
of O
thin O
endometrium. O
[]

Following O
a O
16-week O
washout O
phase, O
they O
consumed O
the O
alternative O
supplement. O
[]

Journal O
ID: O
0414003 O
[]

Journal O
ID: O
100968551 O
[]

The O
selected O
subjects O
will O
be O
divided O
into O
3 O
groups: O
G1: O
aPDT; O
G2: O
scraper, O
and O
G3: O
aPDT O
and O
scraper. O
[]

Journal-Name:BMC O
gastroenterology O
[]

At O
6 O
months, O
only O
one O
of O
116 O
patients O
(1%) O
assigned O
to O
carvedilol O
had O
an O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
(LVEF) I-outcome ['Physiological-Clinical']
<50% O
compared O
to O
four O
of O
the O
38 O
assigned O
to O
placebo O
(11%), O
(p=0.013). O
[['Physiological-Clinical']]

Mean O
compression B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
was O
0.724 O
(95% O
CI O
[0.699-0.751]) O
for O
SIM O
group O
and O
0.679 O
(95% O
CI O
[0.655-0.702]) O
for O
STD, O
p=0.01. O
[['Physiological-Clinical']]

BACKGROUND: O
Given O
the O
documented O
decline O
in O
levels O
of O
physical O
activity O
in O
early O
adolescence, O
promoting O
physical O
activity O
in O
young O
people O
is O
a O
priority O
for O
health O
promotion. O
[]

The O
patients O
with O
exercise O
habit O
(n O
= O
31) O
showed O
lower O
incidence O
of O
pain B-outcome ['Physiological-Clinical']
than O
patients O
without O
exercise O
habit O
(n O
= O
26) O
(P O
= O
.002, O
P O
= O
.005, O
and O
P O
= O
.037 O
in O
overall, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
abdominal, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
shoulder B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
pain E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']]

Title: O
Efficacy O
of O
a O
New O
Crosslinked O
Hyaluronan O
Gel O
in O
the O
Prevention O
of O
Intrauterine B-outcome ['Physiological-Clinical']
Adhesions I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

Similarly, O
there O
were O
no O
significant O
differences O
between O
the O
groups O
with O
respect O
to O
resting B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
(P O
= O
.94 O
for O
back O
pain O
and O
P O
= O
.16 O
for O
leg O
pain) O
and O
movement B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
(P O
= O
.52 O
for O
back O
pain O
and O
P O
= O
.56 O
for O
leg O
pain). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

Publication O
date: O
2019/02/08 O
06:00 O
[medline] O
[]

RESULTS: O
HSS, O
KSS, O
NASS O
scores, O
and O
ROM O
were O
elevated O
after O
patients O
receiving O
TKA. O
[]

Patients O
were O
divided O
into O
2 O
groups. O
[]

Title: O
Low O
dose O
human O
chorionic O
gonadotropin O
administration O
at O
the O
time O
of O
gonadotropin O
releasing-hormone O
agonist O
trigger O
versus O
35 O
h O
later O
in O
women O
at O
high O
risk O
of O
developing O
ovarian O
hyperstimulation O
syndrome O
- O
a O
prospective O
randomized O
double-blind O
clinical O
trial. O
[]

m(-2) O
and O
0.42 O
+/- O
0.40 O
degrees O
C, O
respectively, O
before O
exercise. O
[]

Compared O
with O
the O
Sham O
group, O
OSTAP O
block O
reduced O
the O
VAS O
scores O
at O
all O
time O
points O
during O
movement. O
[]

Grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
was O
tested O
in O
all O
patients O
using O
an O
electronic O
device O
before O
anesthesia O
and O
when O
TOFr O
values O
of O
0.7, O
0.8, O
and O
0.9, O
and O
an O
hour O
later O
of O
TOFr O
value O
of O
0.25. O
[['Life-Impact']]

Enrollment O
was O
September O
2015 O
to O
April O
2018, O
with O
follow-up O
ending O
in O
April O
2019. O
[]

A O
single O
agent O
to O
reduce O
cholesterol O
as O
well O
as O
TG O
is O
rare. O
[]

Publication O
date: O
2019/02/20 O
06:00 O
[medline] O
[]

BACKGROUND: O
Multidetector O
computed O
tomography O
(MDCT) O
images O
for O
rhinosinusitis O
may O
have O
a O
risk O
of O
radiation O
hazards. O
[]

Patients O
treated O
with O
IV O
acetaminophen O
had O
a O
significant O
reduction O
in O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
(10% O
vs O
28% O
placebo; O
difference, O
-18% O
[95% O
CI, O
-32% O
to O
-5%]; O
P O
= O
.01; O
HR, O
2.8 O
[95% O
CI, O
1.1-7.8]). O
[['Physiological-Clinical', 'Life-Impact']]

Title: O
Repeated O
doses O
of O
Praziquantel O
in O
Schistosomiasis O
Treatment O
(RePST) O
- O
single O
versus O
multiple O
praziquantel O
treatments O
in O
school-aged O
children O
in O
Cote O
d'Ivoire: O
a O
study O
protocol O
for O
an O
open-label, O
randomised O
controlled O
trial. O
[]

PARTICIPANTS: O
180 O
patients O
with O
chronic O
low O
back O
pain, O
previous O
disc O
herniation, O
and O
type O
1 O
(n=118) O
or O
type O
2 O
(n=62) O
Modic O
changes O
enrolled O
from O
June O
2015 O
to O
September O
2017. O
[]

Journal-Name:The O
Tohoku O
journal O
of O
experimental O
medicine O
[]

RESULTS: O
The O
results O
revealed O
that O
there O
was O
a O
statistically O
significant O
reduction O
in O
plaque B-outcome ['Physiological-Clinical']
index O
(PI) O
and O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
in O
the O
test O
group O
when O
compared O
with O
the O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Except O
that O
the O
Oswestry O
disability B-outcome ['Life-Impact']
index O
(ODI) O
score O
of O
the O
control O
group O
was O
significantly O
higher O
than O
that O
of O
the O
treatment O
group O
at O
last O
follow-up O
( O
P<0.05), O
there O
was O
no O
significant O
difference O
in O
VAS O
score O
and O
Oswestry O
disability B-outcome ['Life-Impact']
index O
(ODI) O
score O
between O
the O
two O
groups O
at O
the O
other O
time O
points O
( O
P>0.05). O
[['Life-Impact'], ['Life-Impact']]

The O
main O
objective O
of O
the O
study O
was O
to O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
of O
the O
Borg O
rating O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
at O
grading O
functional B-outcome ['Physiological-Clinical', 'Life-Impact']
training I-outcome ['Physiological-Clinical', 'Life-Impact']
intensity I-outcome ['Physiological-Clinical', 'Life-Impact']
of O
the O
affected O
upper O
limb O
in O
older O
adults O
with O
a O
chronic O
stroke O
and O
secondarily O
to O
explore O
the O
clinical O
changes O
between O
FT O
and O
ST O
when O
the O
intensity O
is O
regulated O
with O
Borg O
rating O
of O
perceived O
exertion]. O
Patients O
and O
methods: O
Twelve O
participants O
were O
randomized O
into O
a O
FT O
or O
ST O
group O
and O
trained O
their O
affected O
upper O
limb O
(3 O
times/week O
for O
4 O
weeks) O
with O
the O
intensity O
standardized O
with O
Borg O
rating O
of O
perceived O
exertion]. O
Feasibility B-outcome ['Life-Impact']
was O
assessed O
by O
adherence B-outcome ['Life-Impact']
, O
occurrence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
comparison O
of O
Borg O
rating O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
ratings O
between O
groups. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical']]

BACKGROUND: O
Mothers O
of O
preterm O
infants O
often O
have O
symptoms O
of O
anxiety O
and O
depression, O
recognized O
as O
risk O
factors O
for O
the O
development O
of O
cardiovascular O
diseases O
and O
associated O
with O
low O
rates O
of O
heart O
rate O
variability O
(HRV). O
[]

Small O
differences O
in O
the O
effects O
seen O
between O
genders O
may O
be O
attributed O
to O
the O
different O
sizes O
of O
the O
two O
groups O
and O
need O
to O
be O
further O
evaluated O
in O
randomized O
trials O
that O
are O
appropriately O
powered O
for O
gender O
analysis. O
[]

Journal-Name:BMC O
public O
health O
[]

Implementation O
methods: O
how O
and O
when O
the O
components O
were O
implemented B-outcome ['Life-Impact']
in O
schools. O
[['Life-Impact']]

BACKGROUND: O
Precooling O
(PC) O
before O
exercise O
may O
help O
prevent O
severe O
hyperthermia O
and O
exertional O
heatstroke O
(EHS). O
[]

Otherwise, O
there O
were O
marginal O
benefits O
for O
keeping O
the O
indwelling O
catheter O
for O
48 O
hours O
in O
terms O
of O
reducing O
the O
number O
of O
patients O
with O
moderate O
pain B-outcome ['Physiological-Clinical']
and O
improving O
the O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
. O
However, O
all O
three O
groups O
had O
similar O
opioid B-outcome ['Resource-use']
usage I-outcome ['Resource-use']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
functional B-outcome ['Life-Impact']
outcomes. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Life-Impact']]

METHODS: O
Ten O
physically O
active O
males O
(25.1 O
+/- O
3.9 O
years; O
weight O
78.71 O
+/- O
9.53 O
kg; O
height O
177.2 O
+/- O
4.6 O
cm; O
body O
fat O
15.5 O
+/- O
3.13%) O
participated O
in O
this O
study. O
[]

The O
current O
study O
combined O
hedonic O
liking O
with O
non-hypothetical O
experimental O
auctions O
to O
measure O
consumer O
preferences B-outcome ['Life-Impact']
for O
bitter O
tasting O
food O
and O
identify O
individual O
socio-demographic O
and O
psychographic O
characteristics O
that O
influence O
bitter B-outcome ['Life-Impact']
aversion I-outcome ['Life-Impact']
. O
Furthermore, O
the O
research O
analyzed O
whether O
consumer O
preferences B-outcome ['Life-Impact']
for O
bitter O
food O
were O
influenced O
by O
sensory O
and O
health-related O
information. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

However, O
although O
it O
was O
not O
sufficient O
to O
enhance O
muscle O
recovery O
observed O
by O
testosterone B-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
responses, O
it O
was O
observed O
that O
serum O
25(OH)D B-outcome ['Physiological-Clinical']
levels O
could O
be O
a O
predictor O
of O
anabolic B-outcome ['Physiological-Clinical']
and O
catabolic B-outcome ['Physiological-Clinical']
hormones. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Impressions B-outcome ['Life-Impact']
from O
the O
counselling O
were O
also O
assessed O
at O
follow-up. O
[['Life-Impact']]

Electronic O
address: O
cedar@stanford.edu. O
[]

Objective: O
To O
investigate O
the O
effects O
of O
dexmedetomidine O
on O
perioperative O
stress B-outcome ['Physiological-Clinical']
and O
postoperative O
pain B-outcome ['Physiological-Clinical']
in O
patients O
with O
radical O
resection O
of O
esophageal O
cancer O
under O
combined O
thoracoscope O
and O
laparoscope. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

This O
study O
aimed O
to O
develop O
a O
multidisciplinary O
lifestyle O
intervention O
program O
targeted O
at O
children O
and O
adolescents O
with O
moderate O
to O
severe O
obesity, O
and O
assess O
the O
additional O
effects O
of O
exercise O
intervention O
when O
compared O
to O
usual O
care. O
[]

This O
is O
the O
first O
experimental O
evidence O
of O
beta-Eudesmol O
effect O
for O
mental O
stress O
in O
human. O
[]

Title: O
[ O
Feasibility B-outcome ['Life-Impact']
of O
supraglottic O
tracheal O
tube O
ventilation O
during O
painless O
fiberbronchoscopy]. O
[['Life-Impact']]

2.1% O
reported O
thinking O
they O
would O
be O
better O
off O
dead O
or O
of O
hurting O
themselves O
in O
some O
way O
in O
the O
past O
2 O
weeks. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

Registered O
1 O
May O
2017 O
- O
Retrospectively O
registered, O
http://www.clinicaltrial.gov O
/ O
NCT03134690. O
[]

FUNDING: O
National O
Institute O
for O
Health O
Research O
Efficacy O
and O
Mechanism O
Evaluation O
Programme. O
[]

In B-outcome ['Physiological-Clinical']
stent I-outcome ['Physiological-Clinical']
re-stenosis I-outcome ['Physiological-Clinical']
was O
found O
in O
7 O
of O
85(8.2%) O
in O
the O
polymer-free O
group O
vs. O
6 O
of O
98(6.12%) O
in O
the O
biodegradable O
polymer O
group. O
[['Physiological-Clinical']]

Publication O
date: O
2019/02/27 O
06:00 O
[medline] O
[]

Assuming O
null O
hypothesis, O
80% O
power O
and O
5% O
alpha O
error, O
to O
detect O
a O
10% O
difference, O
adjusting O
for O
10% O
loss O
of O
follow O
up, O
sample O
size O
was O
204. O
[]

The O
primary O
endpoints O
were O
low B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
(LBW) I-outcome ['Physiological-Clinical']
, O
peripheral, B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
placental B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
parasitaemia E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
while O
the O
secondary O
endpoints O
were O
maternal B-outcome ['Physiological-Clinical']
anaemia I-outcome ['Physiological-Clinical']
, O
pre-term B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
, O
clinical B-outcome ['Physiological-Clinical']
malaria I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of O
SP. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Title: O
Induction O
chronomodulated O
chemotherapy O
plus O
radiotherapy O
for O
nasopharyngeal O
carcinoma: O
A O
Phase O
II O
prospective O
randomized O
study. O
[]

Also, O
safety O
parameters O
were O
similar O
between O
the O
two O
groups. O
[]

A O
sample O
of O
210 O
pregnant O
women O
within O
gestational O
ages O
of O
16-24 O
wk O
were O
recruited O
at O
antenatal O
clinics O
and O
equally O
randomized O
to O
either O
a O
two-dose O
SP O
or O
three-dose O
SP O
group. O
[]

In O
this O
study, O
we O
showed O
that O
supplementation O
with O
a O
PMP O
significantly O
improved O
reactive B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
species I-outcome ['Physiological-Clinical']
(ROS) I-outcome ['Physiological-Clinical']
scavenging O
activity O
and O
prevented O
DNA B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
However, O
additional O
research O
is O
still O
needed O
to O
further O
identify O
mechanisms O
of O
actions O
and O
the O
role O
of O
circulating O
phytonutrient O
metabolites. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Key O
secondary O
outcomes O
included O
a O
composite O
of O
TTP-related B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
recurrence B-outcome ['Physiological-Clinical']
of O
TTP, O
or O
a O
thromboembolic B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
during O
the O
trial O
treatment O
period; O
recurrence B-outcome ['Physiological-Clinical']
of O
TTP O
at O
any O
time O
during O
the O
trial; O
refractory B-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
; O
and O
normalization B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
organ-damage I-outcome ['Physiological-Clinical']
markers. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

However, O
the O
effect O
of O
PICSI O
on O
livebirth O
rates O
is O
uncertain. O
[]

One O
hundred O
and O
thirty O
adult O
patients O
with O
T2DM O
who O
were O
discharged O
to O
the O
community O
were O
randomly O
assigned O
to O
either O
the O
intervention O
or O
the O
control O
group. O
[]

BACKGROUND: O
The O
aim O
of O
this O
study O
was O
to O
analyze O
the O
response O
of O
selected O
components O
of O
the O
immune O
system O
in O
rowers O
to O
maximal O
physical O
exercise, O
and O
to O
verify O
if O
this O
response O
could O
be O
modulated O
by O
supplementation O
with O
L-theanine. O
[]

Publication O
date: O
2018/10/31 O
00:00 O
[accepted] O
[]

BACKGROUND: O
Congenital O
nasolacrimal O
duct O
obstruction O
(CNLDO) O
is O
common O
and. O
[]

RESULTS: O
Totally, O
135 O
infants O
in O
three O
groups O
were O
studied O
and O
the O
results O
showed O
that O
minimum O
and O
maximum O
gastric B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
were O
in O
prone O
(6.49 O
+/- O
8.25 O
ML) O
and O
supine O
(12.59 O
+/- O
11.9 O
ML) O
positions, O
respectively. O
[['Physiological-Clinical']]

The O
two O
groups O
only O
differ O
by O
the O
Simvastatin O
or O
placebo O
administration O
regimen O
while O
following O
the O
same O
procedure, O
with O
identical O
surgical O
instruments, O
and O
medical O
and O
nursing O
skilled O
staff. O
[]

MPH-ER O
was O
well O
tolerated B-outcome ['Life-Impact']
. O
Conclusion: O
Fluvoxamine O
combined O
with O
MPH-ER O
is O
effective O
in O
the O
treatment O
of O
refractory O
obsessive-compulsive O
disorder. O
[['Life-Impact']]

DISCUSSION: O
This O
trial O
will O
assess O
the O
effect O
of O
selenium O
supplementation O
on O
pregnancy B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
and O
HIV B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
among O
HIV-infected O
pregnant O
women O
in O
Lagos. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSION: O
The O
poster O
was O
well-received B-outcome ['Life-Impact']
, O
and O
participants O
reported O
compliance B-outcome ['Life-Impact']
with O
the O
moments O
for O
hand O
hygiene O
(although O
the O
full O
body O
wipe O
of O
the O
baby O
has O
since O
been O
removed). O
[['Life-Impact'], ['Life-Impact']]

BACKGROUND: O
beta-alanine O
(betaA) O
supplementation O
has O
been O
shown O
to O
increase O
intramuscular O
carnosine O
content O
and O
subsequent O
high-intensity O
performance O
in O
events O
lasting O
< O
4 O
minutes O
(min), O
which O
may O
be O
dependent O
on O
total, O
as O
opposed O
to O
daily, O
dose. O
[]

Only O
one O
tooth O
of O
G1 O
was O
unsuccessful B-outcome ['Physiological-Clinical']
; O
hence, O
pulpectomy B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
in O
both O
groups O
was O
not O
influenced O
by O
the O
filling O
material, O
nor O
by O
any O
other O
analyzed O
variable. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Comparison O
Of O
Simultaneous O
Versus O
Delayed O
Ventriculoperitoneal O
Shunting O
In O
Patients O
Undergoing O
Meningocoele O
Repair O
In O
Terms O
Of O
Infection B-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

In O
this O
open-label, O
randomized, O
prospective, O
multicenter O
study, O
108 O
children O
were O
enrolled O
and O
randomized O
to O
receive O
a O
pediatric O
form O
of O
Avaxim, O
Epaxal, O
or O
Havrix. O
[]

Publication O
Type: O
Journal O
Article O
[]

METHODS: O
Sixty O
patients O
scheduled O
to O
undergo O
elective O
ileostomy O
closure O
under O
epidural O
anesthesia O
were O
randomized O
into O
propofol O
sedation O
group O
and O
control O
group O
(n=30). O
[]

METHODS: O
In O
a O
multicenter, O
randomized O
trial O
conducted O
in O
seven O
intensive O
care O
units O
in O
the O
United O
States, O
we O
randomly O
assigned O
adults O
undergoing O
tracheal O
intubation O
to O
receive O
either O
ventilation O
with O
a O
bag-mask O
device O
or O
no O
ventilation O
between O
induction O
and O
laryngoscopy. O
[]

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O
[]

Journal O
ID: O
101273480 O
[]

National O
and O
Kapodistrian O
University O
of O
Athens, O
Athens, O
Greece. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

HR's O
for O
levofloxacin O
and O
moxifloxacin, O
compared O
to O
beta-lactam O
monotherapy, O
on O
any O
cardiac B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
were O
0.40 O
(95% O
CI O
0.18;0.87)and O
0.56 O
(95% O
CI O
0.36;0.87), O
respectively. O
[['Physiological-Clinical']]

The O
area O
of O
images O
that O
give O
confidence O
for O
sinus O
surgery O
at O
one O
time O
was O
higher O
for O
standard-dose O
MDCT O
protocol O
technique O
than O
low-dose O
MDCT O
protocol O
method. O
[]

A O
total O
of O
2048 O
were O
approached O
for O
participation O
in O
the O
ICU, O
of O
which O
1458 O
provided O
informed O
consent. O
[]

Method O
A O
prospective, O
randomized, O
double O
blind, O
placebo O
control O
trial O
was O
carried O
out O
in O
community O
after O
obtaining O
the O
ethical O
clearance O
from O
the O
IRC. O
[]

Eligible O
adults O
from O
132 O
sites O
in O
17 O
countries O
with O
previously O
untreated O
CD30-positive O
peripheral O
T-cell O
lymphomas O
(targeting O
75% O
with O
systemic O
anaplastic O
large O
cell O
lymphoma) O
were O
randomly O
assigned O
1:1 O
to O
receive O
either O
A+CHP O
or O
CHOP O
for O
six O
or O
eight O
21-day O
cycles. O
[]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT02241655. O
[]

FUNDING: O
University O
of O
Texas O
MD O
Anderson O
Cancer O
Center O
and O
National O
Cancer O
Institute O
Specialized O
Programs O
of O
Research O
Excellence. O
[]

Preoperative O
administration O
of O
celecoxib O
exhibits O
better O
efficacy O
and O
equal O
safety O
profiles O
compared O
to O
postoperative O
administration O
of O
celecoxib O
in O
knee O
OA O
patients O
undergoing O
TKA. O
[]

METHODS: O
Prospective O
randomized O
clinical O
trial O
including O
21 O
mothers O
of O
preterms O
admitted O
to O
the O
Neonatal O
Intensive O
Care O
Unit O
of O
a O
tertiary O
hospital, O
recruited O
from O
August O
2015 O
to O
September O
2017, O
and O
divided O
into O
control O
group O
(CG; O
n O
= O
11) O
and O
music O
therapy O
group O
(MTG; O
n O
= O
10). O
[]

Journal O
ID: O
101153626 O
[]

Title: O
Efficacy O
of O
a O
nootropic O
spearmint O
extract O
on O
reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
: O
a O
randomized, O
double-blind, O
placebo-controlled, O
parallel O
trial. O
[['Life-Impact']]

KT O
could O
be O
incorporated O
into O
gait O
re-education O
programmes O
to O
facilitate O
muscle O
contraction O
in O
these O
children. O
[]

OBJECTIVE: O
Data O
regarding O
efficacy O
comparison O
of O
daily O
regimen O
(DR) O
versus O
every O
other O
day O
regimen O
(EODR) O
atorvastatin O
therapy O
is O
not O
validated O
by O
estimation O
of O
serum O
hydroxymethylglutaryl-CoA O
reductase O
(HMGCR) O
levels O
and O
HMGCR O
correlation O
with O
lipid O
indices. O
[]

The O
experimental O
group O
(G1) O
was O
indicated O
from O
the O
entrance O
a O
diet O
hyperproteic O
low O
in O
colecistokinetics O
diet, O
and O
to O
the O
control O
group O
(G2) O
nothing O
by O
mouth. O
[]

Prot. O
[]

Journal-Name:Indian O
heart O
journal O
[]

Title: O
[Effectiveness O
of O
a O
self-administered O
rehabilitation O
program O
for O
shoulder O
pain O
syndrome O
in O
primary O
health O
care]. O
[]

In O
addition, O
subjects O
were O
monitored O
for O
eligible O
and O
ineligible O
criteria. O
[]

Journal O
ID: O
2985248R O
[]

Publication O
date: O
2018/12/04 O
00:00 O
[accepted] O
[]

A O
primary O
school O
in O
Changsha O
city O
was O
selected O
by O
random O
cluster O
sampling. O
[]

RESULTS: O
After O
treatment, O
patients O
in O
both O
groups O
achieved O
promising O
effectiveness. O
[]

RESULTS: O
PC O
lowered O
body B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
storage I-outcome ['Physiological-Clinical']
and O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
by O
15.7 O
+/- O
15.0 O
W O
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
Both O
groups O
showed O
a O
significant O
increase O
in O
noggin B-outcome ['Physiological-Clinical']
serum O
levels O
(denosumab O
p O
< O
0.001; O
placebo O
p O
< O
0.0001). O
[['Physiological-Clinical']]

Title: O
Bag-Mask O
Ventilation O
during O
Tracheal O
Intubation O
of O
Critically O
Ill O
Adults. O
[]

There O
was O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
such O
as O
arrhythmia, O
large O
vein O
thrombosis O
or O
irreducible O
hypotension O
in O
both O
groups, O
and O
there O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
general O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
such O
as O
sinus B-outcome ['Physiological-Clinical']
bradycardia I-outcome ['Physiological-Clinical']
, O
scleredema B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
, O
or O
systemic B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
[16.7% O
(3/18) O
vs. O
11.1% O
(2/18), O
5.6% O
(1/18) O
vs. O
5.6% O
(1/18), O
22.2% O
(4/18) O
vs. O
11.1% O
(2/18), O
5.6% O
(1/18) O
vs. O
5.6% O
(1/18), O
all O
P O
> O
0.05]. O
CONCLUSIONS: O
SBH O
treatment O
could O
significantly O
increase O
the O
neonatal B-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
neurological I-outcome ['Life-Impact']
assessment O
score O
at O
28 O
days O
of O
birth O
and O
Bayley O
scales O
of O
infant B-outcome ['Life-Impact', 'Life-Impact']
development I-outcome ['Life-Impact', 'Life-Impact']
score O
at O
15 O
months O
of O
age, O
reduce O
the O
incidence O
of O
severe B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
in O
moderate O
and O
severe O
HIE O
children, O
but O
it O
was O
not O
be O
proved O
that O
SBH O
could O
reduce O
the O
mortality B-outcome ['Mortality']
. O
Compared O
with O
routine O
treatment, O
SBH O
treatment O
had O
no O
significant O
superiority O
on O
improving O
the O
levels O
of O
serum O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
and O
S100 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
suggesting O
that O
SBH O
could O
not O
protect O
the O
brain O
by O
inhibiting O
the O
apoptosis O
of O
nerve O
cells O
and O
promoting O
the O
repair O
of O
nerve O
cells. O
[['Adverse-effects'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

CONCLUSION: O
The O
findings O
demonstrated O
that O
both O
regimens O
of O
drugs O
can O
control O
the O
hemodynamic B-outcome ['Physiological-Clinical']
status O
of O
patients O
during O
laparoscopic O
cholecystectomy, O
which O
provides O
effective O
postoperative O
analgesia O
for O
pain B-outcome ['Physiological-Clinical']
management. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

A O
total O
of O
360 O
patients O
were O
required O
after O
considering O
ineligible O
cases. O
[]

The O
primary O
end O
point O
was O
investigator-assessed O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
; O
rates O
of O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
evaluated. O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Adverse-effects']]

A O
high O
Gleason O
score O
and O
the O
presence O
of O
extracapsular O
extension O
in O
the O
radical O
prostatectomy O
specimens O
were O
highly O
predictive O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
. O
(Funded O
by O
the O
Swedish O
Cancer O
Society O
and O
others.). O
[['Mortality']]

LEVEL O
OF O
EVIDENCE: O
III. O
[]

Clear O
recommendations O
regarding O
the O
dosage O
should O
be O
established. O
[]

Journal O
ID: O
100968562 O
[]

In O
addition, O
they O
also O
underwent O
verum O
or O
sham O
TENS O
30 O
min O
daily, O
3 O
times O
weekly O
for O
4 O
weeks. O
[]

According O
to O
the O
random O
number O
table O
method, O
the O
patients O
were O
randomly O
divided O
into O
non-invasive O
ventilator O
group, O
rhodiola O
rosea+non-invasive O
ventilator O
group O
and O
rhodiola O
rosea O
group, O
with O
30 O
cases O
in O
each O
group. O
[]

METHODS: O
This O
parallel, O
two-group, O
randomised O
trial O
included O
couples O
undergoing O
an O
ICSI O
procedure O
with O
fresh O
embryo O
transfer O
at O
16 O
assisted O
conception O
units O
in O
the O
UK. O
[]

RESULTS: O
Despite O
similar O
fluoroscopy O
times O
(20.4+/-9.4min O
with O
RADPAD O
vs. O
19.4+/-9.2min O
without O
RADPAD, O
P=0.871) O
and O
total O
radiation O
dose O
(3.4+/-4.3 O
Gy O
with O
RADPAD O
vs. O
2.3+/-1.4 O
Gy, O
P=0.198), O
the O
relative B-outcome ['Life-Impact']
operator I-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
was O
significantly O
less O
with O
RADPAD O
(1.39+/-0.95) O
as O
compared O
to O
no O
RADPAD O
group O
(2.27+/-1.4) O
(p=0.004) O
amounting O
to O
a O
39% O
reduction. O
[['Life-Impact']]

The O
differences O
between O
the O
preoperative O
and O
postoperative O
changes O
were O
found O
statistically O
significant, O
but O
not O
different O
between O
the O
2 O
techniques O
at O
any O
given O
time O
studied. O
[]

Publication O
Type: O
Journal O
Article O
[]

RESULTS: O
Spearman O
rank O
correlation O
analysis O
indicated O
that O
there O
was O
a O
significant O
correlation O
between O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
TOFr O
during O
patient O
recovery O
from O
general O
anesthesia O
(correlation O
coefficient O
for O
grip O
strength O
recovery O
[rs] O
= O
0.886). O
[['Life-Impact']]

Journal O
ID: O
100968555 O
[]

DHA O
supplementation O
increased O
plasma O
glycerophospholipid B-outcome ['Physiological-Clinical']
DHA I-outcome ['Physiological-Clinical']
proportional O
to O
dose O
by O
0.4% O
DHA O
per O
1 O
mg O
intake/kg O
bodyweight. O
[['Physiological-Clinical']]

Title: O
Caplacizumab O
Treatment O
for O
Acquired O
Thrombotic O
Thrombocytopenic O
Purpura. O
[]

Publication O
date: O
2019/02/20 O
06:00 O
[entrez] O
[]

However, O
its O
effectiveness O
is O
controversial. O
[]

Further O
investigation O
would O
be O
required O
to O
confirm O
this O
effect O
and O
its O
mechanism O
and O
the O
genotype O
prediction O
of O
effects O
on O
dosing. O
[]

Furthermore, O
no O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
related O
to O
NES O
treatment O
were O
detected. O
[['Adverse-effects']]

Title: O
Comparison O
of O
Corneal O
Epithelial O
Remodeling O
Over O
2 O
Years O
in O
LASIK O
Versus O
SMILE: O
A O
Contralateral O
Eye O
Study. O
[]

At O
baseline O
and O
12-month O
follow-up, O
ocular O
exams O
for O
trachoma B-outcome ['Physiological-Clinical']
, O
ocular O
swabs O
for O
detection O
of O
chlamydial B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
, O
and O
finger O
prick O
blood O
for O
analysis O
of O
anti-chlamydial B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
were O
taken. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
[Surgical O
treatment O
strategy O
for O
the O
"shell" O
phenomenon O
after O
thoracolumbar O
fracture]. O
[]

Publication O
Type: O
Journal O
Article O
[]

Plasma O
malondialdehyde B-outcome ['Physiological-Clinical']
did O
not O
change O
after O
exercise O
in O
placebo O
but O
was O
significantly O
decreased O
in O
AA O
(p O
< O
0.05). O
[['Physiological-Clinical']]

The O
corresponding O
rates O
between O
weeks O
44 O
and O
80 O
were O
0.10+/-0.25 O
and O
0.03+/-0.28 O
(difference, O
0.07; O
two-sided O
90% O
CI, O
0.03 O
to O
0.10); O
the O
difference O
in O
the O
rate O
of O
progression B-outcome ['Physiological-Clinical']
between O
weeks O
44 O
and O
80 O
did O
not O
meet O
the O
criterion O
for O
noninferiority O
of O
early O
receipt O
of O
levodopa O
to O
delayed O
receipt. O
[['Physiological-Clinical']]

The O
correlations O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
versus O
heart B-outcome ['Physiological-Clinical']
variables O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
versus O
heart B-outcome ['Physiological-Clinical']
variables O
were O
established O
using O
Spearman O
correlation O
test. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

When O
the O
patient O
left O
the O
postanesthesia O
care O
unit, O
all O
had O
sore B-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
and O
26/15/25 O
patients O
in O
VDT/VST/DT O
group O
had O
hoarseness B-outcome ['Physiological-Clinical']
. O
All O
had O
good O
outcomes B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the O
surgical O
operations O
.We O
found O
the O
ETView O
tube O
to O
be O
helpful B-outcome ['Life-Impact']
in O
the O
endotracheal O
intubation O
and O
continuous O
surveillance O
of O
tube O
position O
in O
patients O
with O
video-assisted O
thoracoscopic O
lobectomy. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

The O
objective O
of O
this O
study O
is O
to O
evaluate O
the O
effect O
of O
intervention O
of O
intensive O
education O
on O
hand O
hygiene O
on O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(HFMD) I-outcome ['Physiological-Clinical']
. O
We O
randomized O
64 O
villages O
into O
intervention O
and O
control O
groups O
in O
Handan, O
Hebei O
province, O
China. O
[['Physiological-Clinical']]

Publication O
date: O
2019/03/06 O
06:00 O
[medline] O
[]

TRIAL O
REGISTRATION: O
This O
trial O
was O
registered O
prior O
to O
enrollment O
at O
the O
Registry O
for O
International O
Impact O
Evaluations O
(RIDIE O
STUDY O
ID: O
582a2462ae2ab): O
http://ridie.3ieimpact.org/index.php?r=search/detailView&id=492 O
. O
[]

Median O
end-tidal O
volatile O
anesthetic B-outcome ['Life-Impact']
concentration O
was O
significantly O
lower O
in O
the O
guided O
group O
than O
the O
usual O
care O
group O
(0.69 O
vs O
0.80 O
minimum O
alveolar B-outcome ['Physiological-Clinical']
concentration; O
difference, O
-0.11 O
[95% O
CI, O
-0.13 O
to O
-0.10), O
and O
median O
cumulative O
time B-outcome ['Physiological-Clinical']
with O
EEG O
suppression O
was O
significantly O
less O
(7 O
vs O
13 O
minutes; O
difference, O
-6.0 O
[95% O
CI, O
-9.9 O
to O
-2.1]). O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Conical O
implant O
interfaces, O
but O
not O
flat-to-flat O
or O
platform-switched O
implant O
interfaces, O
were O
associated O
with O
no O
marginal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
level O
(MBL) O
changes O
over O
3 O
years. O
[['Physiological-Clinical']]

Title: O
The O
influence O
of O
orlistat, O
metformin O
and O
diet O
on O
serum O
levels O
of O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
in O
obeses O
women O
with O
and O
without O
insulin O
resistance. O
[['Physiological-Clinical']]

Journal O
ID: O
0255562 O
[]

Our O
aim O
is O
to O
assess O
the O
effectiveness O
of O
a O
multifactorial O
intervention O
to O
improve O
adherence O
to O
the O
MD, O
diet O
quality O
and O
biomedical O
parameters. O
[]

Title: O
Are O
(All) O
Consumers O
Averse B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
Bitter I-outcome ['Life-Impact']
Taste I-outcome ['Life-Impact']
? O
[['Life-Impact']]

In O
group O
A O
simultaneous O
MMC O
repair O
and O
VP O
shunting O
was O
performed O
while O
in O
group O
B O
MMC O
repair O
was O
done O
in O
first O
and O
VP O
shunting O
was O
done O
two O
weeks O
postoperatively.. O
RESULTS: O
In O
this O
study O
mean O
age O
in O
Group O
A O
was O
1 O
years O
with O
SD+/-2.77 O
while O
mean O
age O
in O
Group O
B O
was O
1 O
years O
with O
SD+/-3.12. O
[]

CONCLUSION: O
Training O
using O
a O
gelatin-based O
cervical O
spine O
phantom O
helps O
novices O
acquire O
the O
skills B-outcome ['Life-Impact']
necessary O
to O
perform O
ultrasound-guided O
cervical O
medial O
branch O
blocks. O
[['Life-Impact']]

The O
results O
were O
analyzed O
using O
descriptive O
and O
inferential O
statistical O
tests O
in O
SPSS O
software. O
[]

The O
average O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
operating I-outcome ['Life-Impact']
procedure I-outcome ['Life-Impact']
was O
1 O
hour O
and O
35 O
minutes. O
[['Life-Impact']]

In O
the O
present O
study, O
we O
evaluated O
the O
Trimethylamine B-outcome ['Physiological-Clinical']
N-oxide I-outcome ['Physiological-Clinical']
(TMAO) I-outcome ['Physiological-Clinical']
-reducing O
effect O
of O
a O
novel O
nutraceutical O
formulation O
containing O
grape O
pomace O
extract O
in O
humans O
(Taurisolo((R))). O
[['Physiological-Clinical']]

RESULTS: O
The O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
normalization I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
platelet O
count O
was O
shorter O
with O
caplacizumab O
than O
with O
placebo O
(2.69 O
days O
[95% O
confidence O
interval O
{CI}, O
1.89 O
to O
2.83 O
vs. O
2.88 O
days O
[95% O
CI, O
2.68 O
to O
3.56], O
P=0.01), O
and O
patients O
who O
received O
caplacizumab O
were O
1.55 O
times O
as O
likely O
to O
have O
a O
normalization B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
platelet O
count O
as O
those O
who O
received O
placebo. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE: O
To O
verify O
the O
effectiveness O
of O
brief O
group O
intervention, O
performed O
by O
nurses, O
in O
reducing O
the O
hazardous B-outcome ['Physiological-Clinical']
or O
harmful O
alcohol O
use O
in O
users O
of O
a O
primary O
health O
care O
service. O
[['Physiological-Clinical']]

However, O
randomized O
clinical O
trials O
on O
krill O
powder O
are O
scarce O
and O
systematic O
data O
of O
krill O
meal O
on O
human O
safety O
is O
limited. O
[]

Publication O
Type: O
Comparative O
Study O
[]

Journal-Name:Medicine O
[]

Two O
events O
in O
the O
lactoferrin O
group O
(one O
case O
of O
blood B-outcome ['Physiological-Clinical']
in O
stool O
and O
one O
death B-outcome ['Mortality']
after O
intestinal O
perforation) O
were O
assessed O
as O
being O
possibly O
related O
to O
the O
trial O
intervention. O
[['Physiological-Clinical'], ['Mortality']]

Publication O
date: O
2019/01/03 O
00:00 O
[accepted] O
[]

CONCLUSIONS: O
We O
conclude O
that O
weight B-outcome ['Physiological-Clinical']
loss O
of O
6-7% O
with O
diet O
or O
with O
exercise O
plus O
diet O
reduced O
both O
subcutaneous B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
intra-abdominal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
fat E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
Only O
subcutaneous B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
statistically O
significantly O
reduced O
to O
a O
larger O
extent O
when O
exercise O
is O
combined O
with O
a O
small O
caloric O
restriction. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

PMID: O
31597020 O
[]

It O
has O
proven O
properties O
like O
anti-inflammatory, O
antioxidant, O
antimicrobial, O
hepatoprotective, O
immunostimulant, O
antiseptic, O
antimutagenic, O
and O
it O
also O
accelerates O
wound O
healing. O
[]

These O
results O
indicate O
that O
EMDs O
contribute O
to O
the O
healing B-outcome ['Physiological-Clinical']
of O
soft O
tissue O
without O
scarring. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(MAP), O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
peripheral B-outcome ['Physiological-Clinical']
capillary I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
SpO(2) I-outcome ['Physiological-Clinical']
, O
partial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
exhaled I-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
dioxide I-outcome ['Physiological-Clinical']
P(ET)CO(2) I-outcome ['Physiological-Clinical']
and O
bispectral O
index O
(BIS) O
were O
recorded O
after O
entering O
the O
operating O
room(T(0)), O
after O
anesthesia O
induction(T(1)), O
immediately O
after O
inserting O
laryngeal O
mask O
airway O
or O
tracheal O
tube(T(2)), O
fiberbronchoscopy O
inserting(T(3)), O
at O
the O
end O
of O
the O
operation(T(4)), O
and O
at O
the O
recovery O
of O
patients' O
consciousness(T(5)). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSIONS: O
The O
results O
of O
this O
study O
showed O
that O
verum O
TENS O
may O
benefit O
patients O
with O
acute O
tinnitus O
after O
4 O
weeks O
of O
treatment. O
[]

All O
patients O
who O
were O
randomly O
assigned O
to O
groups O
and O
received O
the O
study O
drug O
or O
placebo O
were O
included O
in O
the O
primary O
analyses. O
[]

Publication O
date: O
2018/11/06 O
00:00 O
[accepted] O
[]

Intranasal O
DEX O
2 O
mug/kg O
is O
an O
effective O
and O
safe O
alternative O
for O
premedication O
in O
children. O
[]

INCLUSION O
CRITERIA: O
Patients O
with O
stable O
coronary O
artery O
disease O
or O
recent O
acute O
coronary O
syndrome O
( O
>1 O
week O
from O
the O
date O
of O
STEMI), O
being O
taken O
up O
for O
elective O
angioplasty. O
[]

After O
the O
operation, O
intravenous O
fentanyl O
infusion O
(25 O
mug/h) O
was O
begun O
with O
loading O
dose O
25 O
mug O
in O
the O
IV O
group O
and O
only O
normal O
saline O
in O
the O
TFP O
group. O
[]

Conclusions O
and O
Relevance: O
Among O
patients O
undergoing O
THA, O
paracetamol O
plus O
ibuprofen O
significantly O
reduced O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
compared O
with O
paracetamol O
alone O
in O
the O
first O
24 O
hours O
after O
surgery; O
there O
was O
no O
statistically O
significant O
increase O
in O
SAEs B-outcome ['Adverse-effects']
in O
the O
pooled O
groups O
receiving O
ibuprofen O
alone O
vs O
with O
paracetamol O
alone. O
[['Resource-use'], ['Adverse-effects']]

Title: O
Once-Daily O
Plazomicin O
for O
Complicated O
Urinary O
Tract O
Infections. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
diastolic B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
significantly O
after O
yoga O
intervention O
(P<0.029). O
[['Physiological-Clinical']]

In O
addition, O
patients O
were O
assigned O
to O
receive O
a O
single O
300-mg O
dose O
of O
tafenoquine O
on O
day O
1 O
or O
2 O
(260 O
patients), O
placebo O
(133 O
patients), O
or O
a O
15-mg O
dose O
of O
primaquine O
once O
daily O
for O
14 O
days O
(129 O
patients). O
[]

RESULTS: O
Two O
groups O
showed O
no O
difference O
in O
baseline O
characteristics. O
[]

Each O
quadrant O
was O
categorized O
into O
control O
group O
(SRP O
alone; O
two O
quadrants O
per O
patient), O
test O
group O
1 O
(SRP O
+ O
PDT), O
and O
test O
group O
2 O
(SRP O
+ O
LLLT. O
[]

Aerosp O
Med O
Hum O
Perform. O
[]

METHODS: O
Ninety-two O
patients O
scheduled O
for O
orthopedic O
lower O
extremity O
surgery O
under O
general O
anesthesia O
were O
randomly O
assigned O
into O
1 O
of O
2 O
groups. O
[]

Journal O
ID: O
100968562 O
[]

Title: O
The O
effectiveness O
of O
a O
multidisciplinary O
intervention O
strategy O
for O
the O
treatment O
of O
symptomatic O
joint O
hypermobility O
in O
childhood: O
a O
randomised, O
single O
Centre O
parallel O
group O
trial O
(The O
Bendy O
Study). O
[]

The O
incidence O
of O
treatment B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
with O
surgery O
(18 O
of O
27 O
patients, O
67%) O
was O
significantly O
superior O
to O
that O
with O
active O
medical O
treatment O
(7 O
of O
25 O
patients, O
28%; O
P O
= O
0.007) O
or O
control O
medical O
treatment O
(3 O
of O
26 O
patients, O
12%; O
P<0.001). O
[['Physiological-Clinical']]

Comparing O
MRI O
sequences O
reveals O
significantly O
reduced O
interobserver O
variability O
and O
significantly O
improved O
accuracy O
on O
T2*W O
compared O
to O
T2W O
MRI O
for O
DSC O
and O
Cohen's O
kappa. O
[]

Publication O
date: O
2019/03/12 O
06:00 O
[medline] O
[]

The O
data O
were O
analyzed O
using O
repeated O
measures O
MANOVA. O
[]

Eligible O
women O
were O
undergoing O
IVF O
(fresh-embryo O
or O
frozen-embryo O
transfer), O
with O
no O
recent O
exposure O
to O
disruptive O
intrauterine O
instrumentation O
(e.g., O
hysteroscopy). O
[]

Rate O
of O
main B-outcome ['Physiological-Clinical']
curve I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
considering O
patients' O
gender O
(P-value0.657). O
[['Physiological-Clinical']]

We O
aimed O
to O
determine O
if O
a O
program O
of O
aerobic O
and O
resistance O
exercise O
could O
safely O
achieve O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
changes O
in O
patients O
with O
Inflammatory O
Bowel O
Disease. O
[['Physiological-Clinical']]

OBJECTIVE: O
One O
of O
the O
important O
aspects O
involved O
in O
achieving O
optimal O
outcomes O
after O
assisted O
reproductive O
treatment O
(ART) O
is O
the O
endometrium. O
[]

The O
mean O
value O
of O
137 O
kcal/serving O
is O
16% O
lower O
(p O
< O
0.0001) O
than O
what O
is O
typically O
found O
on O
food O
labels. O
[]

A O
noninferiority O
margin O
of O
10 O
percentage O
points O
was O
used. O
[]

OBJECTIVE: O
Menstrual O
pain O
is O
a O
periodic O
pain O
which O
happens O
during O
the O
days O
of O
menses. O
[]

The O
Schirmer O
test O
results O
did O
not O
significantly O
change O
postoperatively. O
[]

METHODS: O
65 O
randomly O
selected O
patients O
undergoing O
elective O
complex O
percutaneous O
coronary O
intervention O
(PCI) O
procedures O
from O
January O
2017 O
to O
2017 O
were O
randomized O
in O
a O
1:1 O
pattern O
with O
or O
without O
the O
RADPAD. O
[]

Journal-Name:Medicine O
[]

Conclusion: O
Compared O
with O
the O
posterolateral O
approach, O
the O
SuperPATH O
approach O
can O
reduce O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
, O
relieve O
early O
pain B-outcome ['Physiological-Clinical']
, O
promote O
recovery B-outcome ['Physiological-Clinical']
, O
and O
obtain O
the O
similar O
short-term O
effectiveness. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Methods: O
Post O
hoc O
analysis O
of O
212 O
patients O
with O
moderate-to-severe O
plaque O
psoriasis O
randomized O
(2:2:2:1) O
to O
HP/TAZ O
lotion, O
HP, O
TAZ, O
or O
vehicle O
once-daily O
for O
8 O
weeks, O
with O
a O
4-week O
posttreatment O
follow-up. O
[]

Palo O
Alto, O
CA, O
USA. O
[]

TRIAL O
REGISTRATION: O
NCT, O
NCT03134690. O
[]

Journal O
ID: O
2985248R O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
101521595 O
[]

Journal-Name:Indian O
heart O
journal O
[]

RESULTS: O
Of O
the O
1218 O
open O
fracture O
patients O
with O
complete O
data O
available O
for O
analysis, O
813 O
(66.7%) O
reported O
moderate O
to O
extreme O
pain B-outcome ['Physiological-Clinical']
at O
1 O
yr. O
[['Physiological-Clinical']]

Researchers O
were O
masked O
to O
allocation, O
but O
participants O
were O
not. O
[]

OBJECTIVE: O
The O
aim O
of O
the O
study O
was O
to O
test O
the O
applicability B-outcome ['Life-Impact']
of O
low-dose O
MDCT O
protocols O
for O
decision-making O
of O
sinus O
surgeries O
of O
patients O
with O
uncontrolled O
chronic O
rhinosinusitis. O
[['Life-Impact']]

There O
was O
a O
linear O
association O
between O
high, O
moderate, O
and O
low O
adherence, O
and O
a O
lower O
risk O
of O
gestational B-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
(GDM) I-outcome ['Physiological-Clinical']
, O
emergency B-outcome ['Resource-use']
C-section I-outcome ['Resource-use']
, O
perineal B-outcome ['Physiological-Clinical']
trauma I-outcome ['Physiological-Clinical']
, O
pregnancy-induced B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
and O
preeclampsia B-outcome ['Physiological-Clinical']
, O
prematurity B-outcome ['Physiological-Clinical']
, O
large-for-gestational-age B-outcome ['Physiological-Clinical']
, O
and/or O
small-for-gestational-age B-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
(UTI) I-outcome ['Physiological-Clinical']
, O
prematurity B-outcome ['Physiological-Clinical']
, O
and O
small-for-gestational-age B-outcome ['Physiological-Clinical']
(SGA) I-outcome ['Physiological-Clinical']
newborns O
(all O
p O
< O
0.05). O
[['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
The O
study O
was O
registered O
at O
clinicaltrials.gov O
ID: O
NCT02472951. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

This O
study O
explores O
the O
effects O
of O
sponsorship O
of O
an O
elite O
sporting O
event O
by: O
(A) O
non-food O
brands O
(control), O
(B) O
unhealthy O
food O
brands, O
(C) O
healthier O
food O
brands, O
or O
(D) O
an O
obesity O
prevention O
public O
health O
campaign O
on O
young O
adults' O
brand B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
, O
attitudes B-outcome ['Life-Impact']
, O
image B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
, O
event-sponsor B-outcome ['Life-Impact']
fit I-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
, O
and O
preference B-outcome ['Life-Impact']
for O
food O
sponsors' O
products. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Journal-Name:Nigerian O
journal O
of O
clinical O
practice O
[]

The O
primary O
outcome O
was O
parasite B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
at O
day O
29, O
after O
the O
first O
round O
of O
treatment. O
[['Physiological-Clinical']]

The O
assessors O
were O
masked O
as O
to O
group O
allocation. O
[]

FINDINGS: O
Between O
July O
31, O
2014, O
and O
March O
14, O
2016, O
656 O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
receive O
ixazomib O
maintenance O
therapy O
(n=395) O
or O
placebo O
(n=261). O
[]

The O
accumulation O
of O
damaged B-outcome ['Physiological-Clinical']
mtDNA I-outcome ['Physiological-Clinical']
and O
fragmented B-outcome ['Physiological-Clinical']
mitochondria I-outcome ['Physiological-Clinical']
resulted O
in O
increased O
reactive B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
species I-outcome ['Physiological-Clinical']
(ROS) I-outcome ['Physiological-Clinical']
generation, O
activation O
of O
apoptosis B-outcome ['Physiological-Clinical']
and O
loss O
of O
mitochondrial B-outcome ['Physiological-Clinical']
membrane I-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(DeltaPsim) I-outcome ['Physiological-Clinical']
in O
tubules O
and O
PBMCs. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

This O
8-week O
trial O
includes O
four O
two-weekly O
standard O
doses O
of O
PZQ O
in O
the O
"intense O
treatment" O
intervention O
group O
and O
one O
standard O
dose O
of O
PZQ O
in O
the O
"standard O
treatment" O
control O
group. O
[]

Results: O
(1)Compared O
with O
the O
results O
at O
baseline, O
the O
total O
scores O
of O
Pittsburgh O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
index O
(PSQI)], O
Beck O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
index O
(BDI) O
, O
Beck O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
inventory O
(BAI) O
in O
both O
groups O
significantly O
decreased O
at O
the O
end O
of O
treatment: O
CBT-i O
group, O
PSQI O
(4.7+/-2.5) O
vs. O
(12.9+/-3.5); O
BDI O
(3.2+/-4.4) O
vs. O
(9.7+/-6.4); O
BAI O
(4.2+/-5.6) O
vs. O
(10.7+/-8.1); O
and O
combination O
group, O
PSQI O
(5.8+/-2.8) O
vs. O
(13.9+/-3.1); O
BDI O
(4.5+/-4.8) O
vs. O
(13.8+/-8.7); O
BAI O
(4.4+/-4.0) O
vs. O
(14.1+/-6.3) O
(all O
P<0.01). O
( O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Angle B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
was O
3.29+/-6.60 O
for O
kyphosis O
angle O
and O
0.59+/-7.76 O
for O
lordosis O
angle. O
[['Physiological-Clinical']]

METHODS: O
Baltimore O
CONNECT O
involved O
22 O
CBOs O
in O
East O
Baltimore O
randomized O
to O
a O
co-developed O
intervention O
bundle O
versus O
control. O
[]

BACKGROUND: O
Pre- O
and O
co-administration O
of O
remifentanil O
in O
target-controlled O
propofol O
and O
remifentanil O
anesthesia O
are O
the O
most O
common O
methods O
in O
clinical O
practice. O
[]

Objective: O
To O
further O
define O
the O
role O
of O
a O
fixed O
combination O
halobetasol O
propionate O
0.01% O
and O
tazarotene O
0.045% O
(HP/TAZ) O
lotion O
in O
moderate-to-severe O
plaque O
psoriasis O
using O
the O
IGAxBSA O
composite O
tool. O
[]

Journal-Name: O
BMJ O
(Clinical O
research O
ed.) O
[]

Trial O
Registration: O
isrctn.com O
Identifier: O
ISRCTN89898870. O
[]

The O
primary O
clinical O
outcome O
was O
the O
variation O
in O
thirst B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
, O
evaluated O
by O
the O
Numeral O
Verbal O
Scale], O
and O
the O
secondary, O
the O
variation O
of O
the O
discomfort B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
thirst I-outcome ['Physiological-Clinical']
, O
evaluated O
by O
the O
Perioperative O
Thirst B-outcome ['Physiological-Clinical']
Discomfort I-outcome ['Physiological-Clinical']
Scale]. O
Mann-Whitney O
test O
was O
used O
to O
compare O
measures O
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
median O
plasma O
Nitrotyrosine B-outcome ['Physiological-Clinical']
(NT) I-outcome ['Physiological-Clinical']
concentrations O
(pg/ml) O
following O
surgery O
(POP1) O
were O
significantly O
lower O
in O
patients O
with O
cancer O
versus O
patients O
with O
benign O
disease O
(5.3 O
vs. O
7.6, O
p=0.008). O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

6.9% O
reported O
feeling O
down, O
depressed O
or O
hopeless O
in O
the O
past O
2 O
weeks. O
[]

At O
the O
same O
time, O
both O
groups O
showed O
no O
difference O
in O
terms O
of O
the O
serologic O
and O
biochemical O
response B-outcome ['Physiological-Clinical']
. O
Of O
all O
patients, O
2 O
dropped O
out O
due O
to O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
5 O
experienced O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
. O
CONCLUSION: O
Both O
capsules O
(ETV O
or O
TDF) O
were O
equally O
effective O
in O
nucleos(t)ide-naive O
CHB O
patients O
with O
a O
comparable O
side-effect B-outcome ['Adverse-effects']
profile O
even O
in O
a O
long-term O
of O
144 O
weeks. O
[['Physiological-Clinical'], ['Adverse-effects'], ['Adverse-effects'], ['Adverse-effects']]

The O
data O
were O
collected O
using O
the O
revised O
Illness B-outcome ['Life-Impact']
Perception I-outcome ['Life-Impact']
Questionnaire O
(IPQ-R) O
and O
Depression B-outcome ['Physiological-Clinical', 'Life-Impact']
Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
Stress B-outcome ['Life-Impact']
Scales O
(DASS-21 O
scores) O
which O
were O
completed O
by O
the O
participants. O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact']]

Journal O
ID: O
0421110 O
[]

RESULTS: O
Comparison O
of O
the O
median O
iodine O
dose B-outcome ['Life-Impact']
in O
patients O
with O
a O
normal O
or O
high O
BMI O
showed O
that O
it O
was O
significantly O
lower O
under O
the O
LBW O
protocol O
than O
the O
TBW O
protocol O
(558.2 O
and O
507.0 O
mg O
iodine/kg, O
P O
< O
0.001, O
respectively). O
[['Life-Impact']]

No O
changes O
in O
insulin B-outcome ['Physiological-Clinical']
or O
triglycerides B-outcome ['Physiological-Clinical']
were O
observed O
during O
the O
ingestion O
period. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

SIM O
group O
learned O
the O
AHA O
guidelines O
for O
high-quality O
CPR O
via O
an O
hour O
session O
that O
included O
a O
PowerPoint O
lecture O
with O
training O
on O
a O
high-fidelity O
simulator. O
[]

MATERIALS O
AND O
METHODS: O
This O
study O
was O
a O
clinical O
trial O
in O
which O
80 O
patients O
suffering O
from O
cancer O
were O
randomly O
assigned O
to O
two O
groups O
of O
experimental O
and O
control. O
[]

Title: O
Intraduodenal O
Administration O
of O
L-Valine O
Has O
No O
Effect O
on O
Antropyloroduodenal B-outcome ['Physiological-Clinical']
Pressures I-outcome ['Physiological-Clinical']
, O
Plasma O
Cholecystokinin B-outcome ['Physiological-Clinical']
Concentrations O
or O
Energy B-outcome ['Life-Impact']
Intake I-outcome ['Life-Impact']
in O
Healthy, O
Lean O
Men. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Publication O
date: O
2019/01/01 O
06:00 O
[medline] O
[]

Journal O
ID: O
101266132 O
[]

Journal O
ID: O
101234168 O
[]

BACKGROUND: O
Postprandial O
non-esterified O
fatty O
acid O
(NEFA) O
and O
triglyceride O
(TG) O
responses O
are O
increased O
in O
subjects O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
may O
impair O
insulin O
action O
and O
increase O
risk O
of O
cardiovascular O
disease O
and O
death. O
[]

Therefore, O
28 O
patients O
were O
randomly O
selected O
from O
the O
diagnostic O
group. O
[]

Some O
participants O
used O
the O
information O
from O
the O
poster O
to O
encourage B-outcome ['Life-Impact']
other O
caregivers O
to O
use O
the O
ABHR O
("after O
explaining O
to O
them, O
they O
liked O
it"). O
[['Life-Impact']]

CONCLUSION: O
The O
results O
of O
the O
present O
study O
and O
other O
experimental O
and O
clinical O
trials O
confirmed O
that O
the O
administration O
of O
the O
scorpion O
antivenom O
by O
intravenous O
route O
has O
a O
lower O
incidence O
of O
systemic O
toxicity B-outcome ['Adverse-effects']
, O
a O
better O
outcome O
of O
fatal B-outcome ['Mortality']
complication O
resulted O
from O
envenomation O
especially O
cardiogenic B-outcome ['Physiological-Clinical']
shock I-outcome ['Physiological-Clinical']
, O
decreased O
need B-outcome ['Resource-use']
for O
ICU O
facilities O
and O
mechanical B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
, O
shorter O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
better O
overall O
outcome O
than O
the O
intramuscular O
route. O
[['Adverse-effects'], ['Mortality'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Resource-use']]

Patients O
received O
triple O
therapy O
(long-acting O
muscarinic O
antagonist O
and O
long-acting O
beta2-agonist/inhaled O
corticosteroid O
[ICS]) O
for O
6 O
weeks, O
and O
were O
randomized O
to O
continue O
triple O
therapy O
or O
stepwise O
withdrawal O
of O
the O
ICS O
(dual O
bronchodilator O
group). O
[]

Transcripts O
were O
inductively O
coded O
using O
ATLAS.ti(R) O
and O
qualitatively O
analysed O
using O
thematic O
content O
analysis. O
[]

Journal-Name:International O
journal O
of O
environmental O
research O
and O
public O
health O
[]

Publication O
date: O
2018/12/31 O
06:00 O
[entrez] O
[]

BACKGROUND: O
The O
prevalence O
of O
obesity O
has O
increased O
significantly O
worldwide O
within O
the O
last O
decade. O
[]

METHODS: O
In O
this O
randomized O
controlled O
trial, O
we O
compared O
the O
efficacy O
of O
DR O
versus O
EODR O
by O
measuring O
lipid B-outcome ['Physiological-Clinical']
indices O
and O
serum O
HMGCR B-outcome ['Physiological-Clinical']
levels O
at O
baseline O
and O
after O
12 O
weeks O
of O
10mg O
atorvastatin O
therapy. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101291488 O
[]

CONCLUSION: O
Significant O
differences O
in O
MBLs O
were O
observed O
at O
different O
implant O
interfaces. O
[]

No O
additional O
side B-outcome ['Adverse-effects']
effect I-outcome ['Adverse-effects']
was O
observed O
by O
adding O
spinal O
Dex. O
[['Adverse-effects']]

CONCLUSIONS: O
The O
main O
finding O
of O
the O
study O
is O
that O
CAF O
ingestion O
increases O
movement B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
of O
the O
bar O
in O
the O
eccentric O
phase O
of O
the O
movement, O
what O
results O
in O
shortening O
of O
the O
time B-outcome ['Physiological-Clinical']
under O
tension O
(TUT) O
needed O
for O
performing O
a O
specific O
number O
of O
repetitions, O
without O
decreasing O
power B-outcome ['Physiological-Clinical']
and O
velocity B-outcome ['Physiological-Clinical']
in O
the O
CON O
phase O
of O
the O
movement. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Change O
in O
serum O
hydroxymethylglutaryl-CoA B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
(HMGCR) I-outcome ['Physiological-Clinical']
levels O
correlated O
more O
with O
change O
in O
lipid B-outcome ['Physiological-Clinical']
indices O
of O
DR O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Objective: O
To O
investigate O
the O
efficacy O
of O
cognitive-behavioral O
therapy O
for O
insomnia O
(CBT-i) O
or O
combination O
with O
tapered O
hypnotic O
agents. O
[]

Publication O
Type: O
Journal O
Article O
[]

Serum O
levels O
of O
Ca B-outcome ['Physiological-Clinical']
, O
P B-outcome ['Physiological-Clinical']
, O
parathyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
(iPTH) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
23 I-outcome ['Physiological-Clinical']
(FGF23) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
(FGFRs) I-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
were O
detected O
before O
and O
after O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Importance: O
Intraoperative O
electroencephalogram O
(EEG) O
waveform O
suppression, O
often O
suggesting O
excessive O
general O
anesthesia, O
has O
been O
associated O
with O
postoperative O
delirium. O
[]

BACKGROUND: O
Among O
patients O
with O
metastatic O
pancreatic O
cancer, O
combination O
chemotherapy O
with O
fluorouracil, O
leucovorin, O
irinotecan, O
and O
oxaliplatin O
(FOLFIRINOX) O
leads O
to O
longer O
overall O
survival O
than O
gemcitabine O
therapy. O
[]

Title: O
Efficacy O
of O
an O
ocular O
bandage O
contact O
lens O
for O
the O
treatment O
of O
dry O
eye O
after O
phacoemulsification. O
[]

Journal-Name:Medicine O
[]

The O
aim O
of O
this O
study O
was O
to O
collect O
data O
on O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
krill O
powder O
in O
humans O
and O
simultaneously O
gain O
efficacy O
data O
by O
measuring O
the O
risk O
factors O
for O
cardiovascular O
disease. O
[['Life-Impact']]

Contours O
were O
analysed O
with O
Monaco O
ADMIRE O
(research O
v. O
2.0) O
to O
assess O
interobserver O
variability O
and O
accuracy O
by O
comparison O
with O
a O
gold O
standard O
clinician O
contour. O
[]

RESULTS: O
Following O
similar O
dehydration O
(~ O
2%DeltaBW), O
MW O
had O
no O
differential O
(p O
> O
0.05) O
impact O
on O
any O
measure O
of O
rehydration. O
[]

min(-1)). O
[]

Despite O
their O
growing O
demographics O
in O
the O
US, O
there O
are O
few O
studies O
evaluating O
acne O
treatment O
in O
this O
population. O
[]

Patients O
were O
randomly O
assigned O
to O
undergo O
transthoracic O
open O
esophagectomy O
(open O
procedure) O
or O
hybrid O
minimally O
invasive O
esophagectomy O
(hybrid O
procedure). O
[]

Observers O
recorded O
time O
taken O
for O
contouring O
and O
scored O
image O
quality O
and O
confidence O
in O
contouring. O
[]

All O
patients O
had O
intravenous O
patient-controlled O
analgesia O
(PCA) O
with O
10 O
mug/kg O
of O
fentanyl O
for O
48 O
hours. O
[]

PMID: O
31613346 O
[]

Journal O
ID: O
2985248R O
[]

Journal-Name:Journal O
of O
Ayub O
Medical O
College, O
Abbottabad O
: O
JAMC O
[]

Publication O
Type: O
Comparative O
Study O
[]

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

Results: O
The O
hysteroscopic O
findings O
were O
available O
for O
20 O
patients O
in O
group O
1 O
and O
28 O
patients O
in O
group O
2. O
[]

Mean O
daily O
FEV1 B-outcome ['Physiological-Clinical']
began O
to O
decline O
from O
approximately O
2 O
weeks O
before O
the O
onset O
of O
symptoms O
of O
an O
exacerbation, O
dropping O
from O
0.907 O
L O
(mean O
Days O
- O
56 O
to O
- O
36 O
before O
the O
exacerbation) O
to O
0.860 O
L O
on O
the O
first O
day O
of O
the O
exacerbation. O
[['Physiological-Clinical']]

The O
linear O
mixed O
model O
was O
used O
for O
data O
analysis, O
in O
which O
a O
5% O
significance O
level O
was O
adopted. O
[]

The O
reduction O
in O
6-month O
follow-up O
( O
DIAGNOdent O
pen O
values O
were O
statistically O
significant O
in O
both O
groups O
relative O
to O
baseline O
values. O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

Journal O
ID: O
9113221 O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

There O
was O
no O
significant O
difference O
in O
the O
success B-outcome ['Life-Impact']
rate O
or O
procedure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
between O
the O
2 O
groups O
(success O
rate: O
P O
= O
.24, O
procedure O
time: O
P O
= O
.34). O
[['Life-Impact'], ['Life-Impact']]

Comparison O
of O
percentage O
of O
respondents O
fitting O
into O
body O
posture O
norms O
clearly O
indicates O
higher O
value O
in O
the O
group O
classified O
as O
active. O
[]

D-group O
received O
a O
12-wk O
diet O
intervention O
within O
primary O
health O
care O
followed O
by O
monthly O
emails O
up O
to O
the O
1-y O
follow-up. O
[]

Title: O
Halobetasol O
and O
Tazarotene: O
Further O
Defining O
the O
Role O
of O
a O
Unique O
Fixed O
Combination O
Topical O
Lotion O
in O
Moderate-to-Severe O
Plaque O
Psoriasis O
[]

Journal O
ID: O
8900488 O
[]

All O
eye O
drops O
were O
placed O
in O
identical, O
unlabelled O
vials. O
[]

In O
this O
regard, O
proper O
positioning O
is O
one O
of O
the O
key O
measures O
that O
is O
done O
by O
nurses; O
still O
there O
is O
a O
paucity O
of O
studies O
in O
this O
field O
and O
the O
results O
of O
these O
few O
studies O
are O
an O
area O
of O
ongoing O
debates. O
[]

Finally, O
participants O
reported O
their O
self-efficacy B-outcome ['Life-Impact']
to O
drink O
less O
and O
their O
alcohol B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
. O
RESULTS: O
There O
was O
no O
clear O
evidence O
that O
enhancing O
self-affirmation O
influenced O
any O
outcome. O
[['Life-Impact'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

BACKGROUND: O
Liver O
transplantation O
is O
the O
best O
treatment O
for O
end-stage O
liver O
disease. O
[]

T O
test O
was O
performed O
to O
compare O
the O
differences O
between O
two O
groups, O
and O
the O
results O
were O
corrected O
using O
Bonferroni O
method. O
[]

Title: O
Increased O
self-care B-outcome ['Life-Impact']
activities O
and O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
rate O
in O
relation O
to O
health O
education O
via O
Wechat O
among O
diabetes O
patients: O
A O
randomized O
clinical O
trial. O
[['Life-Impact'], ['Physiological-Clinical']]

Significant O
correlations O
were O
found O
between O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
parasympathetic B-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
using O
linear O
(r O
= O
- O
0.687; O
p O
= O
0.028) O
and O
nonlinear O
analyses O
(r O
= O
- O
0.689; O
p O
= O
0.027) O
in O
MTG. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

Journal-Name:Journal O
of O
ovarian O
research O
[]

The O
subsequent O
dose O
of O
spinal O
bupivacaine O
was O
determined O
by O
the O
improved O
up-down O
allocation O
method. O
[]

The O
intervention O
was O
scheduled O
to O
occur O
early O
during O
the O
primary O
PCI O
procedure, O
after O
reperfusion O
of O
the O
infarct-related O
coronary O
artery O
and O
before O
stent O
implant. O
[]

RESULTS: O
Non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
net O
area O
under O
curve O
(AUC) O
was O
increased O
by O
97 O
+/- O
38 O
mumol/Lx270 O
min O
(p O
= O
0.024) O
after O
breakfast O
but O
reduced O
by O
141 O
+/- O
33 O
mumol/Lx180 O
min O
(p O
< O
0.001) O
after O
lunch O
on O
the O
CRHP O
compared O
with O
CD O
diet. O
[['Physiological-Clinical']]

CONCLUSION: O
On O
the O
basis O
of O
present O
results O
the O
delayed-start O
protocol O
in O
poor O
responders O
can O
improve O
the O
fertilization B-outcome ['Physiological-Clinical']
rate O
and O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
embryos I-outcome ['Physiological-Clinical']
and O
reduce O
the O
cycle B-outcome ['Life-Impact']
cancellation I-outcome ['Life-Impact']
but O
have O
no O
significant O
effect O
on O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate; O
however, O
larger O
randomized O
clinical O
trials O
are O
required O
to O
compare O
it O
with O
other O
protocols. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

No O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported. O
[['Adverse-effects']]

Journal-Name:Occupational O
therapy O
international O
[]

Title: O
A O
Phase O
II O
Study O
Alternating O
Erlotinib O
With O
Second-line O
mFOLFOX6 O
or O
FOLFIRI O
for O
Metastatic O
Colorectal O
Cancer. O
[]

METHODS: O
A O
total O
of O
72 O
children, O
ages O
4 O
to O
12 O
years O
with O
MA O
were O
randomly O
assigned O
to O
a O
treatment O
group O
or O
a O
control O
group O
at O
a O
ratio O
of O
1:1. O
[]

Two O
clinical O
trials O
have O
examined O
this O
strategy O
and O
reported O
controversial O
results. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
intake O
of O
CSO O
in O
the O
CSO O
group, O
but O
not O
the O
increase O
in O
plasma O
ALA O
proportions, O
correlated O
inversely O
with O
the O
IFNG O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
in O
PBMCs O
(P O
= O
0.08). O
[['Physiological-Clinical']]

Clinical O
assessments, O
including O
neurological O
examination O
and O
EDSS O
scoring, O
were O
conducted O
at O
baseline O
and O
at O
weeks O
12 O
and O
24. O
[]

DISCUSSION: O
The O
evidence O
for O
cost-effectiveness O
at O
12 O
months O
was O
inconclusive. O
[]

The O
total B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
and O
arousal B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
were O
obtained O
by O
bispectral O
index O
(BIS) O
monitoring O
from O
20: O
00 O
(the O
first O
day) O
to O
6: O
00 O
(the O
second O
day). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
decolonization O
group O
had O
lower O
likelihoods O
of O
clinically O
judged O
infection B-outcome ['Physiological-Clinical']
from O
any O
cause O
(hazard O
ratio, O
0.83; O
95% O
CI, O
0.70 O
to O
0.99) O
and O
infection-related B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
(hazard O
ratio, O
0.76; O
95% O
CI, O
0.62 O
to O
0.93); O
treatment O
effects O
for O
secondary O
outcomes O
should O
be O
interpreted O
with O
caution O
owing O
to O
a O
lack O
of O
prespecified O
adjustment O
for O
multiple O
comparisons. O
[['Physiological-Clinical'], ['Resource-use']]

Title: O
Chocolate O
Milk O
versus O
carbohydrate O
supplements O
in O
adolescent O
athletes: O
a O
field O
based O
study. O
[]

BACKGROUND: O
Endotracheal O
intubation O
for O
general O
anesthesia O
causes O
postoperative O
sore O
throat O
(POST). O
[]

Importance: O
A O
meta-analysis O
of O
outcomes O
during O
the O
6 O
months O
after O
intensive O
care O
unit O
(ICU) O
discharge O
indicate O
a O
prevalence O
for O
clinically O
important O
posttraumatic O
stress O
disorder O
(PTSD) O
symptoms O
of O
25%. O
[]

At O
baseline, O
the O
ultrasonographic O
evaluation O
of O
pelvic B-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
(PFM) I-outcome ['Physiological-Clinical']
performed O
during O
resting O
and O
during O
voluntary O
pelvic O
muscles O
contraction O
showed O
the O
right-left O
length O
asymmetry. O
[['Physiological-Clinical']]

We O
compared O
the O
efficacy O
and O
safety O
of O
these O
two O
schedules. O
[]

CONCLUSION: O
Under O
the O
conditions O
of O
the O
present O
study, O
the O
95% O
effective O
dose B-outcome ['Life-Impact']
of O
intrathecal O
hyperbaric O
ropivacaine O
for O
successful B-outcome ['Life-Impact']
spinal I-outcome ['Life-Impact']
anesthesia I-outcome ['Life-Impact']
for O
cesarean O
section O
in O
healthy O
parturient O
receiving O
prophylactic O
infusion O
of O
phenylephrine O
was O
15.2 O
mg. O
[['Life-Impact'], ['Life-Impact']]

Collectively, O
the O
present O
results O
suggested O
that O
hydrogen O
gas O
reverses O
imbalances O
toward O
PD1+ B-outcome ['Physiological-Clinical']
CD8+ I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
to O
provide O
an O
improved O
prognosis. O
[['Physiological-Clinical']]

The O
control O
group O
included O
102 O
healthy O
children O
at O
the O
similar O
age O
(x O
= O
10.64 O
+/- O
1.1). O
[]

RESULTS: O
After O
followed O
up O
for O
6 O
to O
20 O
months, O
a O
thinner O
appearance B-outcome ['Life-Impact']
was O
seen O
in O
3 O
eyes O
(2.2%) O
in O
the O
corneal O
graft O
group O
and O
7 O
eyes O
(5.5%) O
in O
the O
scleral O
group. O
[['Life-Impact']]

Journal-Name:JAMA O
[]

Publication O
Type: O
Journal O
Article O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

Lean B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
increased O
by O
a O
median O
of O
1.59 O
kg O
and O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
decreased O
by O
a O
median O
of O
1.52 O
kg O
in O
the O
exercising O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

In O
addition, O
no O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
related O
to O
the O
treatment O
were O
recorded O
in O
either O
group. O
[['Adverse-effects']]

An O
in O
vitro O
study O
also O
confirmed O
that O
polyphenol O
extracts O
significantly O
decreased O
oxidative O
stress O
in O
murine O
myoblast O
cell O
line O
C2C12-derived. O
[]

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O
[]

Pretreatment O
and O
day-of-debond O
digital O
photographic O
images O
were O
taken O
of O
the O
teeth O
and O
assessed O
by O
up O
to O
5 O
clinical O
and O
3 O
lay O
assessors O
for O
the O
presence O
or O
absence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
the O
esthetic B-outcome ['Life-Impact']
impact. O
[['Physiological-Clinical'], ['Life-Impact']]

Journal O
ID: O
0374675 O
[]

Patients O
were O
randomized O
to O
receive O
equi-anesthetic O
doses O
of O
either O
propofol O
or O
methohexital O
for O
anesthetic O
induction. O
[]

Using O
the O
Quality O
Adjusted O
Life O
Year O
outcome, O
the O
intervention O
was O
not O
cost O
effective O
from O
an O
NHS/PSS O
perspective. O
[]

RESULTS: O
The O
number O
of O
task B-outcome ['Life-Impact']
repetitions I-outcome ['Life-Impact']
required O
to O
reach O
the O
learning O
curve O
plateau O
was O
45, O
42, O
and O
37 O
repetitions O
in O
groups O
I, O
II, O
and O
III, O
which O
means O
that O
there O
was O
continuous O
improvement O
in O
performing B-outcome ['Life-Impact']
the O
task O
after O
40 O
repetitions O
only O
in O
groups O
I O
and O
II. O
[['Life-Impact'], ['Life-Impact']]

The O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
was O
monitored O
at O
0, O
2, O
4, O
and O
24 O
hours O
postoperatively. O
[['Physiological-Clinical']]

Title: O
Clinical O
efficacy O
and O
safety O
of O
apatinib O
in O
patients O
with O
advanced O
colorectal O
cancer O
as O
the O
late-line O
treatment. O
[]

Journal O
ID: O
101521595 O
[]

Study O
2 O
tested O
2-week O
smartphone-based O
Monitor O
+ O
Accept O
and O
Monitor O
Only O
interventions O
compared O
with O
an O
active O
control O
training. O
[]

Title: O
Optimising O
the O
antibiotic O
treatment O
of O
uncomplicated O
acute O
appendicitis: O
a O
protocol O
for O
a O
multicentre O
randomised O
clinical O
trial O
(APPAC O
II O
trial). O
[]

Methods: O
Between O
March O
2017 O
and O
May O
2017, O
24 O
patients O
who O
planned O
to O
have O
a O
unilateral O
THA O
were O
enrolled O
in O
the O
study O
and O
randomized O
into O
2 O
groups. O
[]

Journal O
ID: O
101215359 O
[]

A O
randomized, O
controlled O
trial O
has O
begun O
to O
compare O
neoadjuvant O
chemotherapy O
using O
gemcitabine O
and O
S-1 O
with O
upfront O
surgery O
for O
patients O
planned O
resection O
of O
pancreatic O
cancer. O
[]

The O
majority O
of O
AEs B-outcome ['Adverse-effects']
were O
mild O
and O
transient. O
[['Adverse-effects']]

INTERVENTIONS: O
Patients O
were O
randomised O
to O
three O
months O
of O
oral O
treatment O
with O
either O
750 O
mg O
amoxicillin O
or O
placebo O
three O
times O
daily. O
[]

Recruitment O
was O
stopped O
after O
inclusion O
of O
19 O
and O
39 O
patients O
in O
monotherapy O
and O
combination O
arms O
respectively, O
as O
per O
pre-specified O
stopping O
rules. O
[]

Publication O
date: O
2018/12/14 O
06:00 O
[entrez] O
[]

METHODS: O
We O
conducted O
a O
randomized O
controlled O
trial O
on O
46 O
patients O
scheduled O
to O
undergo O
THR. O
[]

Randomisation O
was O
stratified O
by O
histological O
subtype O
according O
to O
local O
pathology O
assessment O
and O
by O
international O
prognostic O
index O
score. O
[]

Journal O
ID: O
101273480 O
[]

CONCLUSION: O
This O
is O
the O
first O
prognostic O
factor O
analysis O
in O
NSCLC O
performed O
on O
data O
from O
a O
large O
prospective O
study. O
[]

After O
the O
exercise, O
improvement O
was O
noted O
in O
Ober O
test O
(P O
= O
.005; O
d O
= O
0.75 O
on O
the O
right O
side, O
P O
= O
.005; O
d O
= O
0.78 O
on O
the O
left O
side) O
and O
in O
the O
Thomas O
test O
(P O
= O
.005; O
d O
= O
0.66 O
on O
the O
right O
side, O
P O
= O
.005; O
d O
= O
0.67 O
on O
the O
left O
side). O
[]

Among O
patients O
who O
underwent O
lymphadenectomy, O
the O
median O
number O
of O
removed O
nodes B-outcome ['Physiological-Clinical']
was O
57 O
(35 O
pelvic O
and O
22 O
paraaortic O
nodes). O
[['Physiological-Clinical']]

Both O
groups O
during O
the O
hospital O
stay O
received O
the O
usual O
diabetes O
education. O
[]

NCT: O
03200197. O
[]

Title: O
Omadacycline O
for O
Community-Acquired O
Bacterial O
Pneumonia. O
[]

However, O
it O
was O
confirmed O
that O
they O
were O
not O
associated O
with O
the O
test O
product. O
[]

Title: O
Comparison O
of O
the O
effectiveness O
of O
two-dose O
versus O
three-dose O
sulphadoxine-pyrimethamine O
in O
preventing O
adverse B-outcome ['Adverse-effects']
pregnancy I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
in O
Nigeria. O
[['Adverse-effects']]

In O
experimental O
group O
one, O
a O
15-minute O
trial O
of O
pelvis O
reposition O
exercise O
was O
carried O
out. O
[ O
[]

Clinical O
safety O
assessment O
failed O
to O
show O
toxicity O
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
Therefore, O
herbal O
congee O
containing O
the O
combined O
extract O
of O
M. O
alba O
and O
P. O
odoratum O
leaves O
is O
the O
potential O
functional O
food O
that O
can O
decrease O
the O
risk O
of O
osteoporosis. O
[['Adverse-effects']]

Journal-Name:Revista O
de O
la O
Facultad O
de O
Ciencias O
Medicas O
(Cordoba, O
Argentina) O
[]

Funded O
by O
the O
University O
of O
Auckland O
and O
others; O
PIP O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
number, O
ACTRN12614000626662 O
.). O
[]

Methods: O
This O
was O
a O
prospective, O
randomized, O
parallel-arm O
study O
of O
70 O
fourth-year O
medical O
students O
to O
either O
simulation O
(SIM) O
or O
standard O
training O
(STD) O
over O
an O
eight-month O
period. O
[]

Results O
The O
mean O
age O
of O
the O
participants O
was O
85.2 O
years. O
[]

The O
tear O
serotonin B-outcome ['Physiological-Clinical']
level O
in O
group O
A O
was O
reduced O
from O
2.76 O
+/- O
0.34 O
to O
1.73 O
+/- O
0.14 O
ng/mL O
(p O
< O
0.001). O
[['Physiological-Clinical']]

The O
differences O
of O
morbidity B-outcome ['Physiological-Clinical']
, O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
were O
compared O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

IR O
premenopausal O
women O
show O
significant O
increase O
in O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
serum O
concentrations O
regardless O
the O
method O
of O
intervention. O
[['Physiological-Clinical']]

Total O
knee O
arthroplasty O
(TKA) O
is O
a O
common O
orthopedic O
surgery O
known O
to O
be O
very O
painful. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Grade O
3 O
systemic B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AE I-outcome ['Adverse-effects']
occurred O
in O
5.4% O
and O
2.9% O
of O
the O
participants O
in O
the O
Havrix O
group O
after O
the O
1st O
and O
2nd O
doses, O
respectively. O
[['Adverse-effects']]

Title: O
Treatment O
with O
a O
5-day O
versus O
a O
10-day O
schedule O
of O
decitabine O
in O
older O
patients O
with O
newly O
diagnosed O
acute O
myeloid O
leukaemia: O
a O
randomised O
phase O
2 O
trial. O
[]

Journal-Name:Journal O
of O
science O
and O
medicine O
in O
sport O
[]

Title: O
A O
Feasibility O
RCT O
Evaluating O
a O
Play-Informed, O
Caregiver-Implemented, O
Home-Based O
Intervention O
to O
Improve O
the O
Play B-outcome ['Life-Impact']
of O
Children O
Who O
Are O
HIV O
Positive. O
[['Life-Impact']]

RESULTS: O
Eleven O
out O
of O
fifty O
patients O
in O
the O
study O
group O
developed O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
(CIN) I-outcome ['Physiological-Clinical']
(22%) O
compared O
to O
eighteen O
out O
of O
the O
fifty O
control O
patients O
(36%) O
(p=0.123). O
[['Physiological-Clinical']]

EG O
patients O
completed O
ExMI O
therapy. O
[]

Information O
will O
be O
useful O
for O
educators, O
community O
stakeholders O
and O
policy O
makers O
interested O
in O
developing O
programs O
to O
promote O
students' O
out-of-school O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
TRIAL O
REGISTRATION: O
ISRCTN39374060 O
. O
[['Life-Impact']]

All O
primary O
and O
secondary O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
8-week O
treatment, O
and O
4-week O
follow-up. O
[]

But O
persistent O
CNLDO O
in O
older O
children O
makes O
the O
success O
rate O
rapidly O
decreased O
due O
to O
long-term O
chronic O
inflammation. O
[]

Journal-Name: O
The O
New O
England O
journal O
of O
medicine O
[]

Title: O
Baseline O
characteristics O
associated O
with O
early O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
gains O
after O
ranibizumab O
treatment O
for O
retinal O
vein O
occlusion. O
[['Physiological-Clinical']]

Repeated O
measures O
analysis O
of O
variance O
(RMANOVA) O
demonstrated O
significant O
differences O
between O
the O
two O
groups O
over O
time O
for O
the O
Schirmer O
I O
test O
(p O
= O
0.002), O
corneal B-outcome ['Physiological-Clinical']
fluorescein I-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
(p O
= O
0.025), O
ocular B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
index](p O
= O
0.020), O
and O
frequency O
of O
lubricants B-outcome ['Resource-use']
(p O
= O
0.029). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

BACKGROUND: O
This O
randomized O
controlled O
trial O
evaluated O
the O
effectiveness O
of O
nerve O
electrical O
stimulation O
(NES) O
for O
the O
treatment O
of O
chemotherapy-induced O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
(CINV) O
in O
patients O
with O
advanced O
gastric O
cancer O
(AGC). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSION: O
CART O
showed O
significant O
improvement O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
(HRV) I-outcome ['Physiological-Clinical']
parameters O
indicating O
vagal O
dominance O
in O
middle-aged O
hypertensive O
women. O
[['Physiological-Clinical']]

This O
aims O
to O
investigate O
the O
effect O
of O
combined O
use O
of O
radial O
extracorporeal O
shock O
wave O
therapy O
(rESWT) O
and O
conventional O
rehabilitation O
therapy O
on O
postoperative O
rehabilitation O
of O
children O
with O
spastic O
cerebral O
palsy. O
[]

The O
primary O
outcome O
was O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
normalization I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
platelet O
count O
, O
with O
discontinuation O
of O
daily O
plasma O
exchange O
within O
5 O
days O
thereafter. O
[['Physiological-Clinical']]

There O
was O
a O
significant O
interaction O
of O
composite O
strength B-outcome ['Life-Impact']
score O
between O
groups, O
(p O
= O
.04, O
engp2 O
= O
.08). O
[['Life-Impact']]

There O
was O
no O
significant O
difference O
between O
the O
IBU-alone O
group O
vs O
HS-PCM O
+ O
IBU O
(2 O
mg O
[99.6% O
CI, O
-10 O
to O
7]; O
P O
= O
.81). O
[]

However, O
there O
are O
few O
and O
limited O
clinical O
studies. O
( O
[]

Methods: O
In O
this O
prospective O
study, O
one O
hundred O
patients O
undergoing O
radical O
resection O
of O
esophageal O
cancer O
in O
Affiliated O
Cancer O
Hospital O
of O
Zhengzhou O
University O
from O
January O
2016 O
to O
October O
2017, O
were O
randomly O
divided O
into O
control O
group O
(group O
C) O
and O
dexmedetomidine O
group O
(group O
D), O
n=50. O
[]

Daily O
vitD(3) O
+ O
PBA O
for O
16 O
weeks O
was O
well-tolerated O
and O
effectively O
improved O
vitD(3) B-outcome ['Physiological-Clinical']
status O
but O
did O
not O
reduce O
viral B-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
, O
restore O
peripheral B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
or O
improve O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BMI) I-outcome ['Physiological-Clinical']
or O
middle-upper-arm B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
(MUAC) I-outcome ['Physiological-Clinical']
in O
HIV O
patients O
with O
slow O
progressive O
disease. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Several O
approved O
inactivated O
hepatitis O
A O
(HA) O
vaccines O
are O
available O
in O
Korea. O
[]

Furthermore, O
the O
100-mm O
VAS O
for O
radiating B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
Oswestry O
disability B-outcome ['Life-Impact']
index O
(ODI)], O
Roland-Morris O
disability B-outcome ['Life-Impact']
questionnaire O
(RMDQ)], O
EuroQol O
5 O
Dimensions O
5 O
Levels O
(EQ-5D-5L)], O
global B-outcome ['Physiological-Clinical']
perceived I-outcome ['Physiological-Clinical']
effect O
(GPE), O
and O
deficiency B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
kidney I-outcome ['Physiological-Clinical']
index O
(DSKI) O
will O
be O
used O
to O
evaluate O
secondary O
outcomes. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

Journal-Name:Lancet O
(London, O
England) O
[]

The O
MMP-9 B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
rate O
of O
group O
A O
(76.92%) O
was O
significantly O
higher O
than O
that O
of O
group O
B O
(38.46%, O
p O
= O
0.005). O
[['Physiological-Clinical']]

Palo O
Alto, O
CA, O
USA. O
[]

Title: O
Patient O
coping O
and O
expectations O
predict O
recovery B-outcome ['Physiological-Clinical']
after O
major O
orthopaedic O
trauma. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

Journal-Name:Health O
and O
quality O
of O
life O
outcomes O
[]

CONCLUSIONS: O
For O
high O
responder O
patients O
receiving O
GnRH-agonist O
trigger, O
low O
dose O
hCG O
supplementation O
allowed O
high O
pregnancy B-outcome ['Physiological-Clinical']
rates O
after O
fresh O
embryo O
transfer, O
regardless O
of O
whether O
it O
was O
given O
at O
the O
time O
of O
trigger O
or O
at O
oocyte O
retrieval. O
[['Physiological-Clinical']]

Registered O
1 O
February O
2013. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Future O
studies O
are O
still O
needed O
to O
warrant O
these O
results. O
[]

Publication O
date: O
2019/01/31 O
06:00 O
[medline] O
[]

Journal-Name:Medicine O
[]

BACKGROUND: O
Tafenoquine, O
a O
single-dose O
therapy O
for O
Plasmodium O
vivax O
malaria, O
has O
been O
associated O
with O
relapse O
prevention O
through O
the O
clearance O
of O
P. O
vivax O
parasitemia O
and O
hypnozoites, O
termed O
"radical O
cure." O
[]

PSE O
also O
significantly O
increased O
hits B-outcome ['Life-Impact']
(treatment O
effect, O
p O
= O
0.020) O
at O
Day O
30 O
(PSE O
vs. O
PLA: O
19.25 O
+/- O
1.84 O
vs. O
18.45 O
+/- O
1.48 O
hits; O
p O
= O
0.007) O
and O
Day O
90 O
(PSE O
vs. O
PLA: O
19.39 O
+/- O
1.90 O
vs. O
18.66 O
+/- O
1.64 O
hits; O
p O
= O
0.026) O
for O
the O
multi-directional O
test O
with O
footplates. O
[['Life-Impact']]

Outcomes O
were O
measured O
in O
3 O
randomized O
conditions O
(no O
brace, O
forearm O
band, O
or O
elbow O
sleeve). O
[]

Journal O
ID: O
2985248R O
[]

Publication O
date: O
2019/02/14 O
06:00 O
[entrez] O
[]

Although O
there O
is O
strong O
evidence O
that O
topical O
repellents O
protect O
against O
mosquito O
bites, O
evidence O
is O
not O
well O
established O
for O
the O
effectiveness O
of O
repellents O
distributed O
as O
part O
of O
malaria O
control O
activities O
in O
protecting O
against O
episodes O
of O
malaria. O
[]

Talbot O
Advisors, O
Anna O
Maria, O
FL. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
The O
number O
of O
school O
children O
reported O
from O
intervention O
group O
was O
significantly O
higher O
than O
in O
control O
due O
to O
suspected O
symptoms O
of O
acute B-outcome ['Physiological-Clinical']
pharyngitis I-outcome ['Physiological-Clinical']
and O
or O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RF/RHD) I-outcome ['Physiological-Clinical']
were O
65 O
(2.84/1000) O
and O
15 O
(0.60/1000), O
respectively O
(p<0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sensory I-outcome ['Life-Impact']
block I-outcome ['Life-Impact']
was O
120.5 O
+/- O
37.0 O
minutes O
in O
Dex O
group O
and O
70.5 O
+/- O
34.5 O
minutes O
in O
Control O
group, O
respectively O
(P O
< O
.05). O
[['Life-Impact']]

The O
primary O
endpoint O
of O
overall O
(0-120 O
h O
after O
chemotherapy O
administration) O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
(CR) I-outcome ['Physiological-Clinical']
rate O
(no O
emesis, O
no O
rescue O
medication) O
was O
64.2%, O
60.0% O
and O
54.9% O
in O
the O
30-, O
100- O
and O
300-mg O
arms, O
respectively, O
without O
statistical O
significance O
for O
dose-response. O
[['Physiological-Clinical']]

INTRODUCTION: O
In O
this O
study, O
we O
aimed O
to O
compare O
the O
incidence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
bond B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
between O
2 O
groups O
of O
participants O
wearing O
fixed O
orthodontic O
appliances O
bonded O
with O
either O
light-cured O
resin-modified O
glass O
ionomer O
cement O
or O
light-cured O
composite. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

These O
findings O
were O
true O
irrespective O
of O
the O
type O
of O
resection O
performed. O
[]

BACKGROUND: O
This O
pilot O
study O
aimed O
to O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
effectiveness O
and O
safety O
of O
transcutaneous O
electrical O
nerve O
stimulation O
(TENS) O
for O
patients O
with O
acute O
tinnitus. O
[['Life-Impact']]

The O
trial O
was O
registered O
retrospectively O
with O
ISRCTN O
( O
ISRCTN86573140 O
). O
[]

Title: O
Music O
therapy O
intervention O
in O
cardiac B-outcome ['Physiological-Clinical']
autonomic I-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
, O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
in O
mothers O
of O
preterms: O
randomized O
controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

RESULTS: O
menthol O
chewing O
gum O
significantly O
reduced O
the O
intensity O
(p O
<0.001), O
with O
Cohen's O
medium-effect O
d, O
and O
thirst B-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
(p O
<0.001), O
with O
a O
large-effect O
Cohen's O
d. O
CONCLUSION: O
menthol O
chewing O
gum O
was O
effective O
in O
reducing O
the O
intensity B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
discomfort B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
preoperative I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
thirst E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
The O
strategy O
proved O
to O
be O
an O
innovative, O
feasible B-outcome ['Life-Impact']
and O
safe O
option O
in O
the O
use O
for O
the O
surgical O
patient, O
in O
the O
management O
of O
the O
preoperative O
thirst, O
in O
elective O
surgeries. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Life-Impact']]

The O
arterial B-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
dioxide I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
PaCO(2) I-outcome ['Physiological-Clinical']
), O
the O
time B-outcome ['Life-Impact']
spent I-outcome ['Life-Impact']
in O
successful O
positioning O
of O
the O
tube O
, O
the O
endoscope B-outcome ['Life-Impact']
indwelling I-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
tube B-outcome ['Life-Impact']
drawing I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
patients' O
awakening B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
satisfaction B-outcome ['Life-Impact']
of O
operators, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
during O
anesthesia, O
the O
numbers O
of O
bucking B-outcome ['Physiological-Clinical']
or O
body B-outcome ['Physiological-Clinical']
moving I-outcome ['Physiological-Clinical']
were O
also O
recorded. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
The O
effect O
of O
enamel O
matrix O
derivatives O
on O
root B-outcome ['Physiological-Clinical']
coverage I-outcome ['Physiological-Clinical']
: O
a O
12-month O
follow-up O
of O
a O
randomized O
clinical O
trial. O
[['Physiological-Clinical']]

Additional O
research, O
including O
comparison O
of O
IV O
vs O
oral O
acetaminophen O
and O
other O
potentially O
opioid-sparing O
analgesics, O
on O
the O
incidence O
of O
postoperative O
delirium O
is O
warranted. O
[]

Twelve O
(9.5%) O
and O
10 O
(7.9%) O
subjects O
experienced O
>30% O
endothelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
loss O
(ECL) O
at O
12 O
and O
24 O
months, O
respectively. O
[['Physiological-Clinical']]

Further O
process O
evaluations O
of O
multi-component O
school-based O
PA O
interventions O
are O
warranted O
to O
develop O
the O
limited O
evidence O
base. O
[]

CONCLUSION: O
the O
early O
stimulation O
is O
a O
therapy O
with O
bidirectional O
effect, O
because O
it O
has O
favorable O
effects O
on O
the O
person O
who O
administers O
it; O
promotes O
health O
and O
prevents O
illness O
in O
the O
process O
of O
adaptation O
to O
birth; O
especially O
in O
contexts O
of O
vulnerability. O
[]

Biochemical O
parameters O
including O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
(FPG) I-outcome ['Physiological-Clinical']
, O
2-hour B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
(2hPG) I-outcome ['Physiological-Clinical']
, O
glycosylated B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
A1c I-outcome ['Physiological-Clinical']
(HbA1c) I-outcome ['Physiological-Clinical']
were O
measured O
among O
the O
2 O
groups O
at O
baseline O
6-month O
and O
12-month. O
[ O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Global B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status O
showed O
a O
more O
favourable O
time O
course O
in O
the O
ATLG O
group O
compared O
with O
the O
non-ATLG O
group O
(p=0.02; O
treatment O
by O
visit O
interaction). O
[['Physiological-Clinical']]

The O
view O
from O
the O
tip O
appears O
continuously O
on O
a O
portable O
monitor O
in O
the O
anesthesia O
area. O
[]

Full O
history, O
clinical O
examination, O
and O
routine O
baseline O
investigations O
were O
performed. O
[]

However, O
consistent O
with O
previous O
research, O
we O
present O
further O
evidence O
of O
a O
role O
for O
active B-outcome ['Physiological-Clinical']
B12 I-outcome ['Physiological-Clinical']
, O
HcY B-outcome ['Physiological-Clinical']
and O
folate B-outcome ['Physiological-Clinical']
in O
supporting O
cognitive B-outcome ['Life-Impact']
improvement O
in O
adults O
with O
low O
B O
vitamin O
status. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Two O
patients O
presented O
a O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
during O
the O
study O
(one O
in O
each O
group) O
but O
non-attributable O
to O
the O
treatment O
studied. O
[['Adverse-effects']]

Title: O
Effectiveness O
of O
part-time O
vs O
full-time O
wear O
protocols O
of O
Twin-block O
appliance O
on O
dental B-outcome ['Physiological-Clinical']
and O
skeletal B-outcome ['Physiological-Clinical']
changes: O
A O
randomized O
controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
The O
immediate O
sensorimotor B-outcome ['Physiological-Clinical']
effects O
of O
elbow O
orthoses O
in O
patients O
with O
lateral O
elbow O
tendinopathy: O
a O
prospective O
crossover O
study. O
[['Physiological-Clinical']]

Journal O
ID: O
0255562 O
[]

For O
the O
evaluation O
of O
the O
association O
of O
the O
categorical O
variables O
the O
Chi-square O
test O
and O
Fisher's O
Exact O
Test O
will O
be O
used. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

We O
investigated O
whether O
prophylactic O
use O
of O
carvedilol O
can O
prevent O
doxorubicin-induced O
cardiotoxicity B-outcome ['Physiological-Clinical']
and O
whether O
any O
observed O
effect O
is O
dose O
related. O
[['Physiological-Clinical']]

The O
effectiveness O
of O
Bosinji, O
one O
of O
the O
herbal O
medicines O
used O
for O
low O
back O
pain O
and O
radiating O
pain O
in O
patient O
with O
LHIVD, O
has O
been O
reported O
in O
several O
studies; O
however, O
little O
clinical O
evidence O
is O
available O
owing O
to O
the O
methodological O
limitations O
in O
previous O
studies. O
[]

All O
local B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
and O
unsolicited O
AEs O
were O
grade O
1 O
or O
2. O
[['Adverse-effects']]

Objective: O
To O
determine O
whether O
an O
MRI-guided O
treat-to-target O
strategy O
vs O
a O
conventional O
clinical O
treat-to-target O
strategy O
improves O
outcomes O
in O
patients O
with O
RA O
in O
clinical O
remission. O
[]

Results: O
P(ET)CO(2) B-outcome ['Physiological-Clinical']
in O
group O
A O
at O
T(0), O
T(1), O
T(2), O
T(3), O
T(4), O
T(5) O
were O
(36.9+/-4.1), O
(36.3+/-4.7), O
(38.1+/-5.6), O
(40.4+/-4.0), O
(48.8+/-7.7), O
(45.3+/-7.6) O
mmHg, O
P(ET)CO(2) B-outcome ['Physiological-Clinical']
in O
group O
B O
were O
(38.6+/-4.4), O
(37.8+/-5.6), O
(37.8+/-5.4), O
(37.4+/-6.7), O
(43.3+/-12.2), O
(43.5+/-8.0) O
mmHg, O
at O
the O
end O
of O
operation, O
the O
P(ET)CO(2) B-outcome ['Physiological-Clinical']
at O
T(4) O
and O
T(5) O
were O
significantly O
higher O
than O
at O
T(0) O
in O
group O
A O
and O
group O
B O
(F=14.582, O
12.651, O
all O
P<0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Application O
of O
intrapulmonary O
wire O
combined O
with O
intrapleural O
fibrin O
glue O
in O
preoperative O
localization O
of O
small O
pulmonary O
nodules. O
[]

The O
secondary O
outcomes O
were O
serum O
levels O
of O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
and O
S100 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
. O
The O
occurrences O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
two O
groups O
were O
recorded. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

The O
potential O
role O
of O
the O
clinical O
assessment O
of O
peripheral O
perfusion O
as O
a O
target O
during O
resuscitation O
in O
early O
septic O
shock O
has O
not O
been O
established. O
[]

The O
hypothesis O
was O
that O
PFM O
asymmetry O
may O
have O
a O
functional O
reason O
related O
to O
lumbopelvic O
complex O
misalignment. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/01/31 O
06:00 O
[medline] O
[]

Journal O
ID: O
2985248R O
[]

BACKGROUND: O
Transcutaneous O
electrical O
nerve O
stimulation O
(TENS) O
is O
often O
used O
for O
the O
treatment O
of O
low-back O
pain O
(LBP). O
[]

Title: O
A O
high-fidelity O
simulator O
for O
needle O
cricothyroidotomy O
training O
is O
not O
associated O
with O
increased O
proficiency B-outcome ['Life-Impact']
compared O
with O
conventional O
simulators: O
A O
randomized O
controlled O
study. O
[['Life-Impact']]

DISCUSSION: O
Our O
study O
suggests O
a O
beneficial O
effect O
of O
oral O
glutamine O
supplementation O
for O
the O
prevention O
from O
radiation-induced O
injury B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
loss O
in O
advanced O
NSCLC O
patients O
who O
receiving O
CCRT. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

One O
hundred O
eighty-five O
patients O
were O
enrolled O
in O
this O
single-center, O
prospective, O
randomized, O
open-label O
study. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

min(-1); O
CON O
= O
0.19 O
+/- O
0.05 O
degrees O
C O
. O
[]

RESULTS: O
In O
the O
intention-to-treat O
population, O
the O
percentage O
of O
patients O
who O
were O
free O
from O
recurrence B-outcome ['Physiological-Clinical']
at O
6 O
months O
was O
62.4% O
in O
the O
tafenoquine O
group O
(95% O
confidence O
interval O
[CI], O
54.9 O
to O
69.0), O
27.7% O
in O
the O
placebo O
group O
(95% O
CI, O
19.6 O
to O
36.6), O
and O
69.6% O
in O
the O
primaquine O
group O
(95% O
CI, O
60.2 O
to O
77.1). O
[['Physiological-Clinical']]

RESULTS: O
Significant O
difference O
of O
HbA1c B-outcome ['Physiological-Clinical']
concentration O
and O
Self-Efficacy B-outcome ['Life-Impact']
were O
found O
between O
intervention O
and O
control O
groups O
at O
6-month O
and O
12-month O
(P O
<.05). O
[['Physiological-Clinical'], ['Life-Impact']]

METHODS: O
The O
schools O
in O
district O
Shimla O
were O
randomly O
assigned O
to O
intervention O
and O
controlled O
arm O
(442 O
vs. O
441 O
schools). O
[]

Additionally O
the O
authors O
evaluated O
whether O
CAF O
has O
a O
significant O
effect O
on O
velocity B-outcome ['Physiological-Clinical']
of O
the O
bar O
in O
the O
eccentric O
(ECC) O
phase O
(VEMEAN) O
of O
the O
bench O
press O
movement. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

We O
aimed O
to O
compare O
the O
immunogenicity B-outcome ['Physiological-Clinical']
and O
safety O
of O
the O
most O
commonly O
used O
HA O
vaccines O
in O
ethnic O
Korean O
children O
aged O
12 O
to O
18 O
months. O
[['Physiological-Clinical']]

Title: O
Can O
autologous O
platelet O
rich O
plasma O
expand O
endometrial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
and O
improve O
pregnancy B-outcome ['Physiological-Clinical']
rate O
during O
frozen-thawed O
embryo O
transfer O
cycle? O
[['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
This O
study O
was O
part O
of O
an O
effectiveness O
and O
process O
evaluation O
including O
24 O
intervention O
and O
27 O
control O
classes. O
[]

The O
overall O
approach O
includes O
providing O
universal O
access O
to O
diagnosis O
and O
treatment O
of O
malaria, O
and O
sustainable O
preventive O
measures, O
including O
vector O
control. O
[]

The O
main O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
eight O
weeks O
of O
supplementation O
with O
3000 O
IU/day O
of O
vitamin O
D O
on O
the O
hematological B-outcome ['Physiological-Clinical']
and O
iron B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
profile, O
as O
well O
as O
on O
the O
analytical O
values O
of O
testosterone B-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
on O
elite O
male O
traditional O
rowers. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

To O
analyze O
if O
25(OH)D O
was O
a O
good O
predictor O
of O
testosterone B-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
testosterone/cortisol B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
a O
stepwise O
regression O
model O
was O
performed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Fifty-five O
women O
in O
5 O
village O
clusters O
received O
the O
ABHR O
and O
used O
it O
from O
birth O
to O
3 O
months O
postnatally, O
with O
use O
guided O
by O
the O
new O
poster. O
[]

RESULTS: O
Eight O
hundred O
and O
eighty-eight O
patients O
in O
the O
WISDOM O
study O
had O
a O
moderate/severe O
exacerbation B-outcome ['Physiological-Clinical']
after O
the O
complete O
ICS O
withdrawal O
visit; O
360 O
of O
them O
contributed O
at O
least O
one O
FEV1 B-outcome ['Physiological-Clinical']
measure O
per O
week O
for O
the O
8 O
weeks O
before O
and O
after O
the O
event O
and O
are O
included O
in O
this O
analysis. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
The O
proportion O
of O
patients O
reporting O
severe O
pain B-outcome ['Physiological-Clinical']
, O
defined O
as O
a O
pain O
score O
of O
between O
7 O
and O
10, O
on O
postoperative O
day O
number O
2 O
(POD O
2) O
were O
21% O
for O
the O
single-shot O
group, O
14% O
for O
the O
24-hour O
block O
group, O
and O
12% O
for O
the O
48-hour O
block O
group O
(p O
= O
0.05). O
[['Physiological-Clinical']]

INTRODUCTION: O
Noggin O
is O
an O
antagonist O
of O
bone O
morphogenetic O
proteins O
(BMPs) O
and O
has O
a O
strong O
effect O
on O
osteogenesis. O
[]

METHODS: O
This O
randomized O
controlled O
clinical O
trial O
was O
conducted O
from O
April O
to O
October O
2015 O
in O
Tabriz, O
Iran. O
[]

METHODS: O
We O
performed O
a O
phase O
3, O
prospective, O
double-blind, O
double-dummy, O
randomized, O
controlled O
trial O
to O
compare O
tafenoquine O
with O
primaquine O
in O
terms O
of O
safety O
and O
efficacy. O
[]

DESIGN: O
Randomized O
control O
trial. O
[]

INTRODUCTION: O
Deficient O
levels O
of O
25-hydroxyvitamin O
D O
(25(OH)D) O
(<30 O
ng/mL) O
may O
compromise O
health O
and O
athletic O
performance. O
[]

Publication O
date: O
2018/12/15 O
06:00 O
[pubmed] O
[]

2018;17(12):1290-1296. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

Journal-Name:Graefe's O
archive O
for O
clinical O
and O
experimental O
ophthalmology O
= O
Albrecht O
von O
Graefes O
Archiv O
fur O
klinische O
und O
experimentelle O
Ophthalmologie O
[]

Adult O
mothers O
of O
children O
born O
in O
participating O
maternity O
wards O
were O
recruited O
between O
March O
2014 O
and O
February O
2015. O
[]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

The O
relative O
risk O
of O
SAE B-outcome ['Adverse-effects']
was O
1.44 O
(97.5% O
CI, O
0.79 O
to O
2.64; O
P O
= O
.18). O
[['Adverse-effects']]

The O
LBW O
patients O
(n O
= O
278) O
were O
injected O
with O
679 O
mg O
iodine/kg O
(men) O
or O
762 O
mg O
iodine/kg O
(women). O
[]

RESULTS: O
The O
mean O
age O
of O
participants O
was O
21.83 O
+/- O
2.07 O
years. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/02/08 O
06:00 O
[entrez] O
[]

No O
significant O
effect O
over O
24 O
h O
or O
qualitative O
feelings O
of O
satiety B-outcome ['Physiological-Clinical']
were O
observed. O
[['Physiological-Clinical']]

Publication O
Type: O
Equivalence O
Trial O
[]

Conclusions: O
Resin O
infiltration O
and O
fluoride O
varnish O
are O
clinically O
feasible B-outcome ['Life-Impact']
and O
efficacious O
methods O
for O
the O
treatment O
of O
anterior O
white B-outcome ['Physiological-Clinical']
spot I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
The O
inhibition O
of O
caries O
progression O
by O
resin O
infiltration O
should O
now O
be O
considered O
an O
alternative O
to O
fluoride O
treatment. O
[['Life-Impact'], ['Physiological-Clinical']]

CONCLUSION: O
Pharmacotherapeutic O
education O
of O
patients O
with O
T2DM O
can O
significantly O
improve O
30-day O
post-discharge O
medication O
adherence B-outcome ['Life-Impact']
, O
without O
a O
significant O
reduction O
in O
adverse B-outcome ['Adverse-effects']
clinical I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
. O
ClinicalTrial.gov O
identification O
number: O
NCT03438162. O
[['Life-Impact'], ['Adverse-effects']]

Four O
infants O
had O
consent O
withdrawn O
or O
unconfirmed, O
leaving O
1098 O
infants O
in O
the O
lactoferrin O
group O
and O
1101 O
in O
the O
sucrose O
group. O
[]

Overall, O
the O
103 O
enrolled O
participants O
were O
>/=85th O
percentile O
of O
age O
and O
sex-specific O
body O
mass O
index O
(BMI). O
[]

Journal O
ID: O
8908809 O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
at O
1, O
5, O
and O
10 O
years O
were O
96.7%, O
53.3%, O
and O
43.3%, O
respectively, O
in O
the O
CC O
group, O
and O
96.7%, O
43.3%, O
and O
33.3%, O
respectively, O
in O
the O
RC O
group O
(P O
= O
0.346). O
[['Mortality']]

FUNDING: O
Seattle O
Genetics O
Inc, O
Millennium O
Pharmaceuticals O
Inc, O
a O
wholly O
owned O
subsidiary O
of O
Takeda O
Pharmacuetical O
Company O
Limited, O
and O
National O
Institutes O
of O
Health O
National O
Cancer O
Institute O
Cancer O
Center. O
[]

Journal-Name:Medicine O
[]

CONCLUSIONS: O
The O
aforementioned O
results O
demonstrate O
that O
TKA O
is O
an O
effective O
surgery, O
and O
IV O
plus O
IA O
TXA O
injection O
functions O
more O
effectively O
in O
reducing O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
fibrinolytic B-outcome ['Physiological-Clinical']
activity O
in O
patients, O
which O
is O
a O
clinical O
factor O
of O
occult O
hemorrhage. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

A O
randomized, O
placebo-controlled, O
cross-over O
trial O
was O
carried O
out O
to O
evaluate O
the O
Trimethylamine B-outcome ['Physiological-Clinical']
N-oxide I-outcome ['Physiological-Clinical']
(TMAO) I-outcome ['Physiological-Clinical']
-reducing O
effect O
of O
Taurisolo((R)). O
[['Physiological-Clinical']]

Publication O
date: O
2018/12/14 O
00:00 O
[accepted] O
[]

Introduction: O
Research O
from O
Philip O
Morris O
International's O
science O
division O
on O
its O
Heat-not-Burn O
product O
IQOS(TM) O
focused O
on O
its O
chemical, O
toxicological, O
clinical, O
and O
behavioral O
aspects. O
[]

Publication O
date: O
2018/11/26 O
00:00 O
[accepted] O
[]

Journal O
ID: O
101225531 O
[]

Title: O
Dark O
Chocolate O
Intake O
Positively O
Modulates O
Redox B-outcome ['Physiological-Clinical']
Status O
and O
Markers O
of O
Muscular B-outcome ['Physiological-Clinical']
Damage I-outcome ['Physiological-Clinical']
in O
Elite O
Football O
Athletes: O
A O
Randomized O
Controlled O
Study. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Serious O
postoperative O
complications B-outcome ['Adverse-effects']
occurred O
more O
frequently O
in O
the O
lymphadenectomy O
group O
(e.g., O
incidence O
of O
repeat O
laparotomy, O
12.4% O
vs. O
6.5% O
[P O
= O
0.01]; O
mortality B-outcome ['Mortality']
within O
60 O
days O
after O
surgery, O
3.1% O
vs. O
0.9% O
[P O
= O
0.049]). O
[['Adverse-effects'], ['Mortality']]

Background O
Knee O
pain O
is O
one O
of O
the O
common O
complaints O
patients O
present O
with O
in O
any O
community O
based O
health O
camps O
and O
Osteoarthritis O
of O
knee O
is O
a O
usual O
diagnosis. O
[]

Conclusions: O
Albuminemia B-outcome ['Physiological-Clinical']
levels O
decreased O
significantly O
in O
both O
groups, O
and O
this O
decrease O
was O
more O
marked O
in O
the O
EEN O
group. O
[['Physiological-Clinical']]

METHODS: O
We O
conducted O
a O
6-year, O
double-blind O
trial O
involving O
2000 O
women O
with O
osteopenia O
(defined O
by O
a O
T O
score O
of O
-1.0 O
to O
-2.5 O
at O
either O
the O
total O
hip O
or O
the O
femoral O
neck O
on O
either O
side) O
who O
were O
65 O
years O
of O
age O
or O
older. O
[]

A O
total O
of O
136 O
patients O
with O
FS O
were O
recruited O
and O
then O
were O
equally O
randomly O
allocated O
into O
a O
treatment O
group O
(n O
= O
68) O
and O
a O
sham O
group O
(n O
= O
68). O
[]

Feeling O
down, O
depressed O
or O
hopeless O
was O
independently O
associated O
with O
recent O
eve-teasing O
(AOR O
2.9 O
(1.6-5.4)), O
a O
harassing O
or O
abusive O
school O
environment O
(AOR O
3.9 O
(1.8-8.2)), O
being O
frequently O
absent O
(AOR O
2.8 O
(1.5-5.5)) O
or O
having O
dropped O
out O
of O
school O
(AOR O
2.1 O
(1.0-4.3)), O
and O
living O
in O
Vijayapura O
district O
(AOR O
2.5 O
(1.6-4.1)). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Biochemical B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
tended O
to O
be O
a O
late O
event O
with O
a O
median O
time O
to O
occurrence O
of O
5 O
years. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

The O
blood O
levels O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
, O
sVCAM-1 B-outcome ['Physiological-Clinical']
, O
endothelin-1 B-outcome ['Physiological-Clinical']
, O
and O
sE-selectin B-outcome ['Physiological-Clinical']
were O
quantified; O
the O
activities O
of O
catalase B-outcome ['Physiological-Clinical']
, O
superoxide B-outcome ['Physiological-Clinical']
dismutase I-outcome ['Physiological-Clinical']
, O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
, O
glutathione B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
and O
concentrations O
of O
reduced O
glutathione B-outcome ['Physiological-Clinical']
, O
oxidized B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
, O
and O
thiobarbituric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
reactive O
substances, O
were O
also O
quantified O
before O
and O
after O
the O
treatment O
period. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
24 O
participants O
in O
the O
Traditional O
group O
and O
27 O
in O
the O
App O
group O
completed O
the O
study. O
[]

The O
changes O
in O
respiratory B-outcome ['Physiological-Clinical']
mechanical I-outcome ['Physiological-Clinical']
indexes O
were O
observed O
under O
different O
ventilation O
patterns O
and O
ventilator O
parameters O
of O
0 O
(only O
connected O
with O
atomizing O
device), O
5, O
7, O
9 O
L/min O
atomizing O
oxygen O
flow. O
[['Physiological-Clinical']]

RESULTS: O
Seventy-one O
patients O
(45% O
PAH, O
55% O
CTEPH; O
53.5% O
female; O
60 O
+/- O
13 O
years, O
mean O
pulmonary O
arterial O
pressure O
46 O
+/- O
10 O
mmHg, O
mean O
PVR O
700 O
+/- O
282dynes.sec.cm-5) O
were O
included. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Complications B-outcome ['Adverse-effects']
regarding O
opioids O
were O
compared O
between O
groups. O
[['Adverse-effects']]

The O
scores O
for O
the O
HMCs O
improved O
less O
in O
the O
intervention O
area O
than O
in O
the O
comparison O
area O
for O
all O
six O
components, O
but O
none O
of O
these O
differences O
were O
statistically O
significant. O
[]

The O
patients O
in O
the O
experimental O
group O
and O
control O
group O
will O
take O
2.5 O
g O
of O
Bosinji O
granule O
(1.523 O
g O
of O
Bosinji O
extract) O
or O
Loxonin O
tablet O
(60 O
mg O
of O
loxoprofen) O
3 O
times O
a O
day O
for O
6 O
weeks. O
[]

They O
were O
divided O
into O
VCV O
group O
and O
PCV O
group O
according O
to O
ventilation O
mode. O
[]

Barriers: O
time O
within O
an O
intense O
curriculum, O
space, O
sustaining O
child O
interest, O
parental O
support, O
school O
policies. O
[]

Although O
there O
was O
a O
general O
trend O
of O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
(FBS) I-outcome ['Physiological-Clinical']
reduction, O
the O
numbers O
of O
participants O
who O
may O
be O
classified O
as O
pre-diabetes O
and O
diabetes O
groups O
( O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
(FBS) I-outcome ['Physiological-Clinical']
100 O
mg/dl) O
in O
the O
amla O
group O
were O
only O
8. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Riociguat O
is O
a O
soluble O
guanylate O
cyclase O
stimulator O
approved O
for O
pulmonary O
arterial O
hypertension O
(PAH) O
and O
chronic O
thromboembolic O
pulmonary O
hypertension O
(CTPEH). O
[]

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O
[]

Journal O
ID: O
9422756 O
[]

Title: O
Alcohol O
pictorial O
health O
warning O
labels: O
the O
impact O
of O
self-affirmation O
and O
health O
warning O
severity. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
Omadacycline, O
a O
new O
once-daily O
aminomethylcycline O
antibiotic O
agent O
that O
can O
be O
administered O
intravenously O
or O
orally, O
reaches O
high O
concentrations O
in O
pulmonary O
tissues O
and O
is O
active O
against O
common O
pathogens O
that O
cause O
community-acquired O
bacterial O
pneumonia. O
[]

Patient O
survival O
of O
SPC-prognosis O
was O
well O
stratified O
regardless O
of O
EBV O
status O
and O
in O
microsatellite O
stable O
(MSS) O
group, O
but O
not O
in O
MSI-high O
group. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Moderate O
intake O
of O
total O
LC O
omega-3 O
PUFA O
(approximately O
0.5(-)1 O
g/day) O
was O
significantly O
associated O
with O
a O
lower O
prevalence O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
CONCLUSION: O
In O
our O
study, O
moderate O
fish O
and O
LC O
omega-3 O
PUFA O
intake, O
but O
not O
high O
intake, O
was O
associated O
with O
lower O
odds O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
suggesting O
a O
U-shaped O
relationship. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Both O
PPI O
and O
H2 O
blocker O
could O
inhibit O
acid B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
. O
LPR O
was O
diagnosed O
with O
reflux O
finding O
score O
and O
reflux O
symptom O
index. O
[['Physiological-Clinical']]

Journal-Name:BMC O
gastroenterology O
[]

CONCLUSIONS: O
Amongst O
patients O
undergoing O
surgical O
repair O
of O
open O
extremity O
fractures, O
high O
SPOC O
questionnaire O
scores O
at O
6 O
weeks O
post-surgery O
were O
predictive O
of O
persistent B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
reduced O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
and O
pain B-outcome ['Physiological-Clinical']
interference I-outcome ['Physiological-Clinical']
at O
1 O
yr. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

In O
the O
treatment O
arm O
there O
was O
a O
significant O
reduction O
of O
ocular B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
12 O
months O
after O
treatment O
(p O
= O
0.004) O
but O
no O
change O
in O
the O
control O
arm. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Title: O
Intrathecal O
dexmedetomidine O
can O
decrease O
the O
95% O
effective O
dose O
of O
bupivacaine O
in O
spinal O
anesthesia O
for O
cesarean O
section: O
A O
prospective, O
double-blinded, O
randomized O
study. O
[]

CONCLUSION: O
The O
prevention O
of O
the O
complications O
during O
the O
percutaneous O
myocardial O
revascularization O
should O
be O
considered O
with O
the O
position O
of O
the O
most O
suitable O
pharmacological O
support. O
[]

PATIENTS O
AND O
METHODS: O
A O
phase O
II O
trial O
(planned O
n=58) O
using O
second-line O
therapy O
for O
metastatic O
colorectal O
cancer O
with O
either O
oxaliplatin-based O
(mFOLFOX6) O
or O
irinotecan-based O
(FOLFIRI) O
combination O
chemotherapy O
and O
100 O
mg O
erlotinib O
daily O
on O
days O
3-8 O
after O
each O
infusion O
(days O
1 O
and O
2) O
every O
14 O
days. O
[]

Final O
outcome O
for O
presence O
of O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RF/RHD) I-outcome ['Physiological-Clinical']
or O
other O
heart B-outcome ['Physiological-Clinical']
Diseases I-outcome ['Physiological-Clinical']
was O
recorded O
after O
examination O
at O
nearest O
primary O
health O
centers O
and/or O
at O
Indira O
Gandhi O
Medical O
College O
Hospital, O
Shimla. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

At O
6 O
min, O
hemostasis B-outcome ['Physiological-Clinical']
was O
achieved O
in O
93.0% O
(238/256) O
of O
the O
HP O
group O
compared O
to O
77.3% O
(102/132) O
of O
the O
G O
+ O
T O
group O
(non-inferiority O
P O
< O
0.0001, O
superiority O
P O
< O
0.0001). O
[['Physiological-Clinical']]

Journal O
ID: O
100968562 O
[]

RESULTS: O
Forty-four O
individuals O
under O
hazardous O
or O
harmful O
alcohol O
use O
completed O
all O
phases O
of O
the O
research. O
[]

High O
adherence O
was O
defined O
as O
complying O
with O
5(-)6 O
targets; O
moderate O
adherence O
2(-)4 O
targets; O
low O
adherence O
0(-)1 O
targets. O
[]

Journal O
ID: O
0374675 O
[]

The O
TFP O
group O
(n O
= O
30) O
received O
a O
single O
TFP O
25 O
mug/ O
h O
to O
the O
anterior O
chest O
wall O
14 O
h O
before O
operation. O
[]

METHODS: O
Postprandial O
non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
and O
triglyceride B-outcome ['Physiological-Clinical']
responses O
were O
assessed O
in O
subjects O
with O
T2DM O
by O
comparing O
a O
carbohydrate-reduced O
high-protein O
(CRHP) O
diet O
with O
a O
conventional O
diabetes O
(CD) O
diet O
in O
an O
open-label, O
randomized, O
cross-over O
study. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Further O
additional O
benefits O
are O
better O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QoL) I-outcome ['Life-Impact']
and O
shorter O
immunosuppressive B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
compared O
with O
standard O
GVHD O
prophylaxis O
without O
ATLG. O
[['Life-Impact'], ['Resource-use']]

Journal O
ID: O
101147696 O
[]

Publication O
date: O
2019/01/31 O
06:00 O
[medline] O
[]

TRIAL O
REGISTER: O
NCT01511276 O
(clinicaltrials.gov), O
prospectively O
registered. O
[]

Hyaluronan-selected O
sperm O
have O
reduced O
levels O
of O
DNA O
damage O
and O
aneuploidy. O
[]

CONCLUSIONS: O
Oral O
antibiotic O
therapy O
was O
noninferior O
to O
intravenous O
antibiotic O
therapy O
when O
used O
during O
the O
first O
6 O
weeks O
for O
complex O
orthopedic O
infection, O
as O
assessed O
by O
treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
at O
1 O
year. O
( O
[['Physiological-Clinical']]

The O
"shell" B-outcome ['Physiological-Clinical']
phenomenon I-outcome ['Physiological-Clinical']
and O
surgery O
complications B-outcome ['Adverse-effects']
were O
observed O
at O
the O
same O
time. O
[['Physiological-Clinical'], ['Adverse-effects']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
100968562 O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

The O
mean O
and O
standard O
deviation O
of O
variables O
were O
obtained O
and O
the O
normality O
of O
data O
was O
analyzed O
using O
the O
Kolmogorov-Smirnov O
test. O
[]

If O
endometrial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
failed O
to O
increase O
after O
48 O
h, O
PRP O
infusion O
was O
repeated O
in O
the O
same O
cycle. O
[['Physiological-Clinical']]

Journal-Name:JAMA O
[]

OBJECTIVE: O
Primary O
objective O
was O
to O
compare O
the O
effects O
of O
atorvastatin O
40mg O
vs O
80mg O
on O
LDL-C B-outcome ['Physiological-Clinical']
in O
Indian O
patients O
with O
atherosclerotic O
dyslipidemia. O
[['Physiological-Clinical']]

L-valine O
did O
not O
affect O
antral, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
pyloric B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
(mean X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
number; X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
control: X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
14 X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
+/- X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
5; X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
L-Val-0.15: X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
21 X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
+/- X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
9; X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
L-Val-0.45: X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
11 X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
+/- X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
4) X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
or Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
duodenal B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
pressures E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
, O
plasma O
cholecystokinin B-outcome ['Physiological-Clinical']
(mean O
concentration, O
pmol/L; O
control: O
3.1 O
+/- O
0.3; O
L-Val-0.15: O
3.2 O
+/- O
0.3; O
L-Val-0.45: O
3.0 O
+/- O
0.3), O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
appetite B-outcome ['Physiological-Clinical']
perceptions I-outcome ['Physiological-Clinical']
, O
symptoms B-outcome ['Physiological-Clinical']
or O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
(kcal; O
control: O
1040 O
+/- O
73; O
L-Val-0.15: O
1040 O
+/- O
81; O
L-Val-0.45: O
1056 O
+/- O
100), O
at O
either O
load O
(p O
> O
0.05 O
for O
all). O
[['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Journal-Name:Medicine O
[]

The O
children O
in O
both O
groups O
were O
treated O
for O
a O
total O
of O
6 O
weeks. O
[]

Title: O
Music-instruction O
intervention O
for O
treatment O
of O
post-traumatic O
stress O
disorder: O
a O
randomized O
pilot O
study. O
[]

Patients O
who O
received O
caplacizumab O
needed O
less O
plasma B-outcome ['Resource-use']
exchange I-outcome ['Resource-use']
and O
had O
a O
shorter O
hospitalization B-outcome ['Resource-use']
than O
those O
who O
received O
placebo. O
[['Resource-use'], ['Resource-use']]

In O
the O
OSTAP O
group, O
the O
patients O
received O
a O
bilateral O
OSTAP O
block O
with O
40 O
mL O
of O
0.375% O
bupivacaine O
and O
in O
the O
Sham O
group O
received O
an O
US-guided O
bilateral O
OSTAP O
with O
40 O
mL O
of O
0.9% O
saline. O
[]

OBJECTIVES: O
To O
investigate O
the O
effectiveness O
of O
routine O
ultrasonography O
in O
the O
third O
trimester O
in O
reducing O
adverse B-outcome ['Physiological-Clinical', 'Mortality']
perinatal I-outcome ['Physiological-Clinical', 'Mortality']
outcomes O
in O
low O
risk O
pregnancies O
compared O
with O
usual O
care O
and O
the O
effect O
of O
this O
policy O
on O
maternal B-outcome ['Physiological-Clinical']
outcomes O
and O
obstetric B-outcome ['Resource-use']
interventions I-outcome ['Resource-use']
. O
DESIGN: O
Pragmatic, O
multicentre, O
stepped O
wedge O
cluster O
randomised O
trial. O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Resource-use']]

METHODS: O
A O
prospective, O
randomized, O
double-blind O
study O
in O
patients O
treated O
with O
doxorubicin, O
comparing O
placebo O
(n=38) O
with O
different O
doses O
of O
carvedilol O
[6.25mg/day O
(n=41), O
12.5mg/day O
(n=38) O
or O
25mg/day O
(n=37)]. O
The O
primary O
endpoint O
was O
the O
measured O
change O
in O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
(LVEF) I-outcome ['Physiological-Clinical']
from O
baseline O
to O
6 O
months. O
[['Physiological-Clinical']]

Slightly O
over O
one-quarter O
were O
veterans O
of O
the O
OEF/OIF O
wars. O
[]

Objectives O
To O
determine O
the O
acceptability B-outcome ['Life-Impact']
and O
feasibility B-outcome ['Life-Impact']
of O
the O
use O
of O
a O
robotic O
walking O
aid O
to O
support O
the O
work O
of O
physiotherapists O
in O
reducing O
fear B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
falling I-outcome ['Life-Impact']
in O
the O
rehabilitation O
of O
elderly O
patients O
with O
'psychomotor O
disadaptation' O
(the O
most O
severe O
form O
of O
post-fall O
syndrome). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

METHODS: O
A O
sample O
of O
37 O
patients O
poststroke O
(29 O
males) O
was O
randomly O
allocated O
to O
either O
SPT O
control O
group O
(n O
= O
18) O
or O
SPT O
and O
SMV O
(SPT-SMV) O
experimental O
group O
(n O
= O
19). O
[]

METHODS: O
The O
study O
was O
conducted O
in O
96 O
sub-village O
units O
(balozis) O
in O
the O
Kongwa O
district O
of O
Tanzania O
which O
were O
predicted O
from O
prior O
prevalence O
surveys O
to O
have O
TF O
between O
5 O
and O
9.9%. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
preoperative O
celecoxib O
administration O
in O
alleviating O
postoperative O
pain B-outcome ['Physiological-Clinical']
in O
knee O
osteoarthritis O
(OA) O
patients O
undergoing O
total O
knee O
arthroplasty O
(TKA).A O
total O
of O
226 O
knee O
OA O
patients O
underwent O
TKA O
were O
consecutively O
recruited O
and O
randomized O
into O
preoperative O
analgesia O
group O
and O
postoperative O
analgesia O
group O
as O
1:1 O
ratio. O
[['Physiological-Clinical']]

METHODS: O
Ninety-three O
infertile O
women O
were O
recruited O
into O
1 O
of O
2 O
groups: O
placebo O
(n O
= O
47) O
or O
nifedipine O
20 O
mg O
(n O
= O
46). O
[]

METHODS: O
APPAC O
II O
trial O
is O
a O
multicentre, O
open-label, O
non-inferiority O
randomised O
controlled O
trial O
comparing O
per O
oral O
(p.o.) O
[]

After O
baseline O
competency O
assessment, O
parents O
received O
instruction O
according O
to O
their O
group. O
[]

Journal O
ID: O
0255562 O
[]

November O
27, O
2013. O
[]

As O
hydrogen O
gas O
was O
recently O
reported O
to O
activate O
PGC1alpha, O
the O
present O
study O
investigated O
whether O
it O
restores O
exhausted O
CD8+ B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
to O
improve O
prognosis O
in O
patients O
with O
stage O
IV O
colorectal O
cancer. O
[['Physiological-Clinical']]

RBR-3x7gz8 O
). O
[]

Daily O
drainage B-outcome ['Resource-use']
and O
all O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
after O
operation O
were O
also O
compared. O
[['Resource-use'], ['Adverse-effects']]

They O
were O
randomly O
allocated O
into O
two O
groups: O
PAR-G O
(BiPAP O
in O
PAR O
for O
one O
hour), O
and O
1PO-G O
(BIPAP O
for O
one O
hour O
on O
the O
1PO). O
[]

METHODS: O
Patients O
admitted O
from O
Weifang O
People's O
Hospital O
from O
January O
2015 O
to O
December O
2016 O
who O
received O
TKA O
were O
injected O
with O
20 O
mg/kg O
TXA O
by O
IV O
before O
TKA O
(n O
= O
50), O
3.0 O
g O
TXA O
by O
IA O
after O
TKA O
(n O
= O
50), O
or O
combination O
of O
20 O
mg/kg O
TXA O
by O
IV O
before O
TKA O
and O
3.0 O
g O
TXA O
by O
IA O
after O
TKA O
(n O
= O
50). O
[]

However, O
the O
benefit O
of O
thromboprophylaxis O
in O
these O
patients O
is O
uncertain. O
[]

Publication O
date: O
2019/02/05 O
06:00 O
[medline] O
[]

The O
main O
group O
consisted O
of O
90 O
children O
diagnosed O
with O
asthma O
and O
allergies O
symptoms O
age O
9 O
to O
12 O
years O
old O
(x O
= O
10.75 O
+/- O
1.08). O
[]

The O
iso-caloric O
CRHP/CD O
diets O
contained O
31/54 O
E% O
from O
carbohydrate, O
29/16 O
E% O
energy O
from O
protein O
and O
40/30 O
E% O
from O
fat, O
respectively. O
[]

Journal-Name:Zhonghua O
yi O
xue O
za O
zhi O
[]

Journal O
ID: O
100968562 O
[]

The O
relationship O
between O
serum O
25(OH)vitamin O
D3 O
concentration O
and O
waist B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
supports O
vitamin O
D O
having O
a O
protective O
role O
in O
the O
current O
setting, O
since O
waist O
size O
is O
directly O
associated O
with O
the O
risk O
of O
cardiovascular O
and O
metabolic O
diseases. O
[['Physiological-Clinical']]

METHODS: O
In O
this O
experimental O
human O
laboratory O
study, O
participants O
(n O
= O
128) O
were O
randomised O
to O
a O
self-affirmation O
or O
control O
group. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Caplacizumab, O
an O
anti-von O
Willebrand O
factor O
humanized, O
bivalent O
variable-domain-only O
immunoglobulin O
fragment, O
inhibits O
interaction O
between O
von O
Willebrand O
factor O
multimers O
and O
platelets. O
[]

Title: O
The O
effect O
of O
different O
sources O
of O
fish O
and O
camelina O
sativa O
oil O
on O
immune O
cell O
and O
adipose O
tissue O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
in O
subjects O
with O
abnormal O
fasting O
glucose O
metabolism: O
a O
randomized O
controlled O
trial. O
[['Physiological-Clinical']]

Journal O
ID: O
101234168 O
[]

BACKGROUND: O
A O
lumbar O
herniated O
intervertebral O
disc O
(LHIVD) O
is O
a O
common O
problem O
that O
usually O
causes O
low O
back O
pain O
and O
radiating O
pain. O
[]

RESULTS: O
The O
two O
groups O
of O
patients O
were O
comparable O
for O
preoperative O
SAI O
scores O
(P&gt;0.05); O
The O
patients O
in O
the O
sedation O
group O
appeared O
to O
have O
lower O
intraoprative O
SAI O
scores, O
but O
this O
difference O
was O
not O
statistically O
significant O
(P=0.05). O
[]

At O
the O
end O
of O
follow-up, O
patients O
showed O
normal O
levels O
of O
vitamin O
D, O
with O
increased O
calcium B-outcome ['Physiological-Clinical']
levels I-outcome ['Physiological-Clinical']
and O
decreased O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
. O
Waist B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
also O
decreased. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSIONS: O
Contrast B-outcome ['Life-Impact']
enhancement I-outcome ['Life-Impact']
was O
equivalent O
under O
both O
protocols. O
[['Life-Impact']]

The O
OR O
Study O
intervention O
was O
delayed O
because O
of O
interruptions O
in O
finalizing O
the O
national O
CHW O
policy, O
two O
separate O
cholera O
epidemics, O
and O
the O
Ebola O
epidemic O
lasting O
more O
than O
2 O
years. O
[]

Journal-Name:PLoS O
neglected O
tropical O
diseases O
[]

The O
haemoglobin B-outcome ['Physiological-Clinical']
and O
hematocrit B-outcome ['Physiological-Clinical']
were O
recorded; O
the O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
intraoperative O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
were O
calculated. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Contrary O
to O
the O
progress O
in O
the O
management O
of O
severe O
AP, O
the O
MAP O
has O
not O
presented O
significant O
changes O
in O
recent O
years. O
[]

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
either O
group. O
[['Adverse-effects']]

All O
patients O
were O
randomly O
divided O
into O
two O
groups O
according O
to O
the O
order O
of O
treatment, O
27 O
cases O
in O
the O
treatment O
group O
were O
treated O
with O
short-segment O
fixation O
combined O
with O
vertebral O
reconstruction, O
26 O
cases O
in O
the O
control O
group O
were O
treated O
with O
short-segment O
fixation. O
[]

BACKGROUND: O
Radical O
prostatectomy O
reduces O
mortality O
among O
men O
with O
clinically O
detected O
localized O
prostate O
cancer, O
but O
evidence O
from O
randomized O
trials O
with O
long-term O
follow-up O
is O
sparse. O
[]

OBJECTIVE:: O
With O
increasing O
incorporation O
of O
MRI O
in O
radiotherapy, O
we O
investigate O
two O
MRI O
sequences O
for O
prostate O
delineation O
in O
radiographer-led O
image O
guidance. O
[]

Title: O
Prevalence O
and O
correlates O
of O
psychological O
distress O
among O
13-14 O
year O
old O
adolescent O
girls O
in O
North O
Karnataka, O
South O
India: O
a O
cross-sectional O
study. O
[]

Publication O
date: O
2019/01/24 O
06:00 O
[entrez] O
[]

CONCLUSION: O
Supplementation O
with O
ascorbic O
acid O
prior O
exercise O
improves O
antioxidant B-outcome ['Physiological-Clinical']
power O
but O
does O
not O
prevent O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
incidence O
of O
new O
opacity B-outcome ['Physiological-Clinical']
on O
chest O
radiography O
in O
the O
48 O
hours O
after O
tracheal O
intubation O
was O
16.4% O
and O
14.8%, O
respectively O
(P O
= O
0.73). O
[['Physiological-Clinical']]

Publication O
date: O
2019/03/09 O
06:00 O
[medline] O
[]

Journal O
ID: O
101303164 O
[]

Conclusions O
and O
Relevance: O
Among O
critically O
ill O
patients O
in O
the O
ICU, O
a O
nurse-led O
preventive, O
complex O
psychological O
intervention O
did O
not O
significantly O
reduce O
patient-reported O
posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
stress I-outcome ['Physiological-Clinical', 'Life-Impact']
disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
severity I-outcome ['Physiological-Clinical', 'Life-Impact']
at O
6 O
months. O
[['Physiological-Clinical', 'Life-Impact']]

The O
IRSN O
dosemeter O
model O
was O
considered O
the O
most O
convenient B-outcome ['Life-Impact']
. O
[['Life-Impact']]

Journal-Name:Eye O
& O
contact O
lens O
[]

Journal O
ID: O
101234168 O
[]

Title: O
The O
Effect O
of O
Whey O
and O
Soy O
Protein O
Isolates O
on O
Cognitive B-outcome ['Life-Impact']
Function I-outcome ['Life-Impact']
in O
Older O
Australians O
with O
Low O
Vitamin O
B12: O
A O
Randomised O
Controlled O
Crossover O
Trial. O
[['Life-Impact']]

Journal-Name: O
Revista O
da O
Associacao O
Medica O
Brasileira O
(1992) O
[]

Title: O
Effect O
of O
hand O
washing O
and O
personal O
hygiene O
on O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
: O
A O
community O
intervention O
study. O
[['Physiological-Clinical']]

Differences O
between O
treatment O
arms, O
based O
on O
the O
intention-to-treat O
principle, O
were O
adjusted O
for O
covariates O
and O
missing O
data O
were O
handled O
using O
multiple O
imputation. O
[]

We O
hypothesize O
that O
school O
students O
receiving O
the O
teacher-delivered O
intervention O
to O
promote O
autonomous O
motivation O
toward O
physical O
activity O
will O
exhibit O
greater O
participation B-outcome ['Life-Impact']
in O
physical O
activities O
outside O
of O
school, O
relative O
to O
students O
receiving O
a O
control O
intervention. O
[['Life-Impact']]

The O
final O
date O
for O
follow-up O
of O
cognitive O
outcomes O
was O
July O
22, O
2018. O
[]

Publication O
date: O
2019/02/13 O
06:00 O
[medline] O
[]

Journal O
ID: O
101521595 O
[]

Medication O
adherence B-outcome ['Life-Impact']
and O
occurrence O
of O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
( O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
readmission B-outcome ['Resource-use']
, O
emergency B-outcome ['Resource-use']
department I-outcome ['Resource-use']
visits I-outcome ['Resource-use']
, O
and O
death B-outcome ['Mortality']
) O
were O
assessed O
at O
the O
follow-up O
visit, O
30 O
days O
after O
discharge. O
[['Life-Impact'], ['Adverse-effects'], ['Adverse-effects'], ['Resource-use'], ['Resource-use'], ['Mortality']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
levels O
of O
CD3(+) B-outcome ['Physiological-Clinical']
, O
CD4(+) B-outcome ['Physiological-Clinical']
, O
CD4(+)/CD8(+) B-outcome ['Physiological-Clinical']
in O
group O
A O
were O
significantly O
higher O
than O
those O
in O
group O
A O
after O
treatment O
(P<0.05), O
the O
levels O
of O
CD8+ B-outcome ['Physiological-Clinical']
was O
significant O
lower O
than O
in O
group O
B O
(P<0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Little O
is O
known O
regarding O
the O
optimal O
method O
of O
instruction O
for O
this O
critical O
skill. O
[]

Publication O
Type: O
Journal O
Article O
[]

Journal O
ID: O
101147696 O
[]

OBJECTIVE: O
To O
reduce O
the O
inappropriate O
identification O
of O
eye O
drops, O
through O
the O
use O
of O
different O
colors. O
[]

To O
study O
the O
effect O
of O
rural O
county O
hospital O
vision O
centers O
(VC) O
on O
self-reported O
glasses B-outcome ['Life-Impact']
ownership I-outcome ['Life-Impact']
and O
wearing B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
(primary O
outcome) O
among O
rural O
children O
in O
China, O
we O
conducted O
a O
cluster-randomized O
controlled O
trial O
at O
a O
VC O
in O
the O
government O
hospital O
of O
Qinan O
County, O
a O
nationally-designated O
poor O
county. O
[['Life-Impact'], ['Life-Impact']]

Late-onset O
sepsis B-outcome ['Physiological-Clinical']
occurred O
in O
414 O
of O
1389 O
infants O
(29.8%) O
in O
the O
faster-increment O
group O
and O
434 O
of O
1397 O
(31.1%) O
in O
the O
slower-increment O
group O
(adjusted O
risk O
ratio, O
0.96; O
95% O
CI, O
0.86 O
to O
1.07). O
[['Physiological-Clinical']]

CLINICAL O
SIGNIFICANCE: O
Curcumin O
gel O
as O
an O
adjunct O
to O
SRP O
showed O
a O
marked O
improvement O
in O
restoring O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
by O
an O
improvement O
in O
clinical O
parameters. O
[['Physiological-Clinical']]

Journal O
ID: O
8610224 O
[]

BACKGROUND: O
Ambulatory O
patients O
receiving O
systemic O
cancer O
therapy O
are O
at O
varying O
risk O
for O
venous O
thromboembolism. O
[]

CONCLUSIONS: O
Physical B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
psychological B-outcome ['Life-Impact']
statuses O
of O
elderly O
housebound O
were O
significantly O
improved O
by O
Baduanjin O
training O
combined O
with O
CBT. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact']]

Publication O
date: O
2019/02/15 O
06:00 O
[medline] O
[]

The O
primary O
and O
secondary O
endpoints, O
excluding O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QoL) I-outcome ['Life-Impact']
, O
have O
been O
published. O
[['Life-Impact']]

For O
the O
majority, O
the O
provision O
of O
education O
and O
positive O
interventions O
aimed O
at O
promoting O
healthy O
exercise O
and O
self-management O
was O
associated O
with O
significant O
benefit O
without O
the O
need O
for O
more O
complex O
interventions. O
[]

In O
the O
low-dose O
remifentanil O
(LR) O
group O
(n O
= O
46), O
remifentanil O
was O
infused O
at O
a O
rate O
of O
0.05 O
mug/kg/min. O
[]

2) O
Methods: O
a O
prospective, O
randomized, O
parallel O
pilot O
study O
of O
4.5 O
g O
administration O
of O
Spirulina O
maxima O
or O
placebo O
for O
12 O
weeks O
in O
16 O
patients O
with O
systemic O
arterial O
hypertension O
(SAH) O
undergoing O
treatment O
with O
angiotensin-converting O
enzyme O
(ACE) O
inhibitors O
was O
performed O
to O
assess O
the O
effects O
on O
endothelial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
and O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
indicators. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Funded O
by O
the O
National O
Institute O
for O
Health O
Research O
and O
Cancer O
Research O
UK; O
Current O
Controlled O
Trials O
number, O
ISRCTN60477608 O
.). O
[]

Title: O
Remote O
ischemic O
preconditioning O
for O
prevention O
of O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
-Insights O
from O
an O
Indian O
study. O
[['Physiological-Clinical']]

Journal-Name:Zhonghua O
wei O
zhong O
bing O
ji O
jiu O
yi O
xue O
[]

They O
were O
randomly O
treated O
by O
endoscopic O
sclerotherapy O
or O
cyanoacrylate O
injection O
as O
banding O
was O
not O
suitable O
for O
those O
patients O
due O
to O
profuse O
bleeding O
making O
unclear O
endoscopic O
visual O
field. O
[]

Journal O
ID: O
8611905 O
[]

Publication O
Type: O
Comparative O
Study O
[]

The O
SPT-SMV O
experimental O
group O
received O
SMV O
at O
the O
end O
of O
each O
SPT O
session. O
[]

METHODS: O
We O
enrolled O
adults O
who O
were O
being O
treated O
for O
bone O
or O
joint O
infection O
at O
26 O
U.K. O
centers. O
[]

The O
objective O
of O
this O
study O
was O
to O
evaluate O
role O
of O
0.2% O
bio-adhesive O
chlorhexidine O
gel O
in O
reducing O
incidence O
of O
alveolar B-outcome ['Physiological-Clinical']
osteitis I-outcome ['Physiological-Clinical']
after O
surgical O
removal O
of O
mandibular O
third O
molars O
which O
causes O
extra O
monetary O
burden O
on O
the O
patients O
in O
the O
form O
of O
several O
follow O
up O
visits.. O
METHODS: O
A O
randomized O
clinical O
trial O
was O
performed O
in O
the O
Dental O
Section, O
Ayub O
Medical O
College, O
Abbottabad. O
[['Physiological-Clinical']]

Journal-Name:Nigerian O
journal O
of O
clinical O
practice O
[]

Introduction: O
Most O
medical O
schools O
teach O
cardiopulmonary O
resuscitation O
(CPR) O
during O
the O
final O
year O
in O
course O
curriculum O
to O
prepare O
students O
to O
manage O
the O
first O
minutes O
of O
clinical O
emergencies. O
[]

CONCLUSIONS: O
We O
have O
developed O
an O
automated, O
accurate, O
and O
precise O
assay O
for O
the O
determination O
of O
belatacept O
serum O
concentrations. O
[]

Importance: O
Despite O
guideline O
recommendations, O
many O
patients O
discontinue O
P2Y12 O
inhibitor O
therapy O
earlier O
than O
the O
recommended O
1 O
year O
after O
myocardial O
infarction O
(MI), O
and O
higher-potency O
P2Y12 O
inhibitors O
are O
underutilized. O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

Journal-Name:Medicine O
[]

Journal O
ID: O
100968547 O
[]

Dipirona O
and O
tramadol O
doses O
did O
not O
differ O
between O
groups O
(p=0.201 O
and O
p=0.341). O
[]

Publication O
date: O
['2019/10/15 O
06:00' O
[]

In O
contrast, O
children O
reported O
that O
the O
activities O
outside O
of O
the O
classroom O
were O
preferred B-outcome ['Life-Impact']
. O
Future O
school-based O
PA O
interventions O
should O
aim O
to O
achieve O
a O
balance O
between O
routine O
PA O
at O
a O
set O
time O
and O
PA O
that O
is O
flexible O
and O
adaptable. O
[['Life-Impact']]

Journal-Name:Nutrients O
[]

Couples O
were O
randomly O
assigned O
(1:1) O
with O
an O
online O
system O
to O
receive O
either O
PICSI O
or O
a O
standard O
ICSI O
procedure. O
[]

Preoperative O
analgesia O
group O
received O
celecoxib O
before O
and O
post O
operation; O
postoperative O
analgesia O
group O
received O
celecoxib O
post O
operation, O
all O
patients O
received O
TKA O
and O
intravenous O
patient-controlled O
analgesia O
(PCA) O
post O
operation. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
number O
of O
women O
that O
would O
need O
to O
be O
treated O
to O
prevent O
the O
occurrence O
of O
a O
fracture O
in O
1 O
woman O
was O
15. O
[]

Journal O
ID: O
100968562 O
[]

BACKGROUND: O
Counterforce O
orthoses O
are O
used O
to O
manage O
lateral O
elbow O
tendinopathy, O
and O
their O
effectiveness O
in O
improving O
motor O
function O
has O
been O
documented. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

Some O
cycles O
are O
cancelled O
due O
to O
inadequate O
endometrial O
growth O
in O
ART. O
[]

RESULTS: O
Methohexital O
resulted O
in O
less O
hypotension B-outcome ['Physiological-Clinical']
compared O
with O
propofol O
(P O
= O
.01), O
although O
the O
degree O
of O
refractory B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
was O
similar O
(P O
= O
.37). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/03/06 O
06:00 O
[medline] O
[]

The O
plasma O
concentrations O
of O
netupitant B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
its X ['Physiological-Clinical', 'Physiological-Clinical']
metabolites S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
increased O
with O
the O
dose O
increase O
from O
30 O
mg O
to O
300 O
mg. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Publication O
date: O
2019/02/05 O
06:00 O
[medline] O
[]

We O
aimed O
to O
assess O
the O
effects O
of O
training O
with O
N95 O
or O
higher O
filter O
respirators O
on O
the O
protection B-outcome ['Life-Impact']
performance O
of O
respirators O
among O
healthcare O
providers O
in O
the O
emergency O
medical O
center O
(EMC). O
[['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS: O
Under O
the O
VCV O
mode, O
the O
oxygen O
flow O
outside O
the O
atomization O
could O
lead O
to O
the O
increase O
in O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
the O
patient O
side, O
while O
under O
the O
PCV O
mode, O
the O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
the O
patient O
side O
had O
no O
significant O
change. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101234168 O
[]

For O
the O
safety O
evaluation, O
laboratory O
examinations O
including O
complete B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
test, O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
test, O
blood B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
test, O
inflammation B-outcome ['Physiological-Clinical']
test, O
and O
urine B-outcome ['Physiological-Clinical']
analysis I-outcome ['Physiological-Clinical']
will O
be O
conducted O
before O
and O
after O
taking O
the O
medications. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
0374675 O
[]

The O
aortic O
and O
hepatic O
equivalence O
margins O
were O
100 O
and O
20 O
Hounsfield O
units, O
respectively. O
[]

FUNDING: O
UK O
National O
Institute O
for O
Health O
Research O
Health O
Technology O
Assessment O
programme O
(10/57/49). O
[]

Title: O
Rehabilitation O
treatment O
of O
spastic O
cerebral O
palsy O
with O
radial O
extracorporeal O
shock O
wave O
therapy O
and O
rehabilitation O
therapy. O
[]

Intervention O
ICUs O
(n O
= O
12; O
669 O
participants) O
delivered O
usual O
care O
during O
a O
baseline O
period O
followed O
by O
an O
intervention O
period. O
[]

However, O
ED95 O
is O
more O
meaningful O
to O
clinical O
practice O
than O
ED50. O
[]

METHODS: O
A O
total O
of O
60 O
patients O
were O
randomly O
assigned O
to O
1 O
of O
2 O
groups: O
Pre-administered O
with O
remifentanil O
before O
propofol O
infusion O
(Group O
R, O
n O
= O
30) O
and O
co-administered O
with O
remifentanil O
with O
propofol O
(Group O
N, O
n O
= O
30). O
[]

Nausea B-outcome ['Physiological-Clinical']
scores O
at O
the O
24th O
postoperative O
hour O
were O
significantly O
lower O
in O
the O
OSTAP O
group O
compared O
with O
the O
Sham O
group O
CONCLUSION:: O
We O
concluded O
that O
bilateral O
US-guided O
OSTAP O
blocks O
reduced O
24th O
hour O
tramadol B-outcome ['Resource-use']
requirements O
and O
VAS O
scores O
after O
laparoscopic O
hysterectomy. O
[['Physiological-Clinical'], ['Resource-use']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

MATERIALS O
AND O
METHODS: O
In O
this O
blinded O
randomized O
trial, O
70 O
patients O
were O
assigned O
to O
receive O
four O
500mg O
capsules O
of O
green O
tea O
or O
starch O
as O
placebo O
daily O
for O
three O
days O
along O
with O
trimethoprim-sulfamethoxazole. O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

Journal O
ID: O
101225531 O
[]

During O
the O
intervention O
period, O
rivaroxaban O
led O
to O
a O
substantially O
lower O
incidence O
of O
such O
events, O
with O
a O
low O
incidence O
of O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
(Funded O
by O
Janssen O
and O
others; O
CASSINI O
ClinicalTrials.gov O
number, O
NCT02555878.). O
[['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
This O
study O
was O
retrospectively O
registered O
in O
the O
Iranian O
website O
( O
www.irct.ir O
) O
for O
registration O
of O
clinical O
trials O
( O
IRCT20170513033941N37 O
). O
[]

Journal O
ID: O
2985248R O
[]

When O
the O
endometrium B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
reached O
>/=7 O
mm, O
embryo O
transfer O
was O
done. O
[['Physiological-Clinical']]

BACKGROUND: O
Krill O
powder O
is O
rich O
in O
bioactive O
ingredients O
such O
as O
eicosapentaenoic O
acid O
(EPA), O
docosahexaenoic O
acid O
(DHA), O
phospholipids, O
protein O
and O
astaxanthin. O
[]

Results: O
Participant O
retention O
was O
100% O
at O
6 O
months. O
[]

Title: O
Body O
posture O
and O
physical O
activity O
in O
children O
diagnosed O
with O
asthma O
and O
allergies O
symptoms: O
A O
report O
from O
randomized O
observational O
studies. O
[]

Secondary O
outcomes O
will O
include O
vaccine O
hesitation B-outcome ['Life-Impact']
and O
intention B-outcome ['Life-Impact']
scores, O
mother's O
knowledge B-outcome ['Life-Impact']
, O
attitudes B-outcome ['Life-Impact']
and O
beliefs B-outcome ['Life-Impact']
about O
immunization, O
and O
psychosocial B-outcome ['Life-Impact', 'Life-Impact']
determinants O
of O
intention O
to O
vaccinate. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact', 'Life-Impact']]

CONCLUSIONS: O
Endometrial O
scratching O
did O
not O
result O
in O
a O
higher O
rate O
of O
live B-outcome ['Mortality']
birth I-outcome ['Mortality']
than O
no O
intervention O
among O
women O
undergoing O
IVF. O
( O
[['Mortality']]

METHODS: O
A O
total O
of O
60 O
cases O
were O
recruited O
during O
August O
2016 O
and O
June O
2017 O
according O
to O
the O
inclusion O
and O
exclusion O
criteria. O
[]

The O
total O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
(TST) O
and O
daytime B-outcome ['Life-Impact']
dysfunction I-outcome ['Life-Impact']
(DF) I-outcome ['Life-Impact']
in O
PSQI O
significantly O
decreased O
at O
week O
8 O
(both O
P<0.05). O
( O
[['Physiological-Clinical'], ['Life-Impact']]

REGISTRATION: O
NCT02190630. O
[]

PMID: O
31618331 O
[]

Date O
of O
registration: O
September O
2009. O
[]

DISCUSSION: O
In O
the O
case O
results O
of O
this O
Provincial O
RCT O
be O
confirmed, O
serious O
consideration O
should O
then O
be O
given O
by O
Ministry O
of O
Health O
authorities O
to O
the O
possible O
implementation O
of O
MI-based O
strategies O
across O
provincial O
maternity O
wards. O
[]

METHODS: O
A O
group O
of O
34 O
healthy O
volunteers O
was O
presented O
to O
two O
groups O
of O
four O
eye O
drops O
each. O
[]

Conclusion: O
Compared O
with O
conventional O
chemotherapy, O
induction O
chrono-chemotherapy O
seemed O
to O
reduce O
chemotherapy-related O
toxicities B-outcome ['Adverse-effects']
and O
improve O
average O
local O
relapse O
time O
in O
patients O
treated O
with O
combined O
chemoradiotherapy O
for O
NPC. O
[['Adverse-effects']]

BACKGROUND: O
Overweight O
and O
metabolic O
problems O
now O
add O
to O
the O
burden O
of O
illness O
in O
patients O
with O
Inflammatory O
Bowel O
Disease. O
[]

RESULTS: O
The O
multivariate O
analysis O
showed O
that O
lower O
nodal O
stage, O
the O
presence O
of O
squamous O
cell O
carcinoma O
(SCC), O
a O
broader O
surgical O
resection O
in O
patients O
with O
SCC, O
and O
being O
female O
with O
non-SCC O
were O
significantly O
associated O
with O
longer O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(DFS) I-outcome ['Physiological-Clinical', 'Mortality']
. O
Lower O
nodal O
stage O
and O
smaller O
tumor O
size O
were O
significantly O
associated O
with O
an O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
. O
Compared O
to O
Other O
International, O
enrollment O
in O
East O
Asia O
was O
associated O
with O
an O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
in O
patients O
with O
non-SCC. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Mortality']]

A O
simple O
population O
pharmacokinetic O
model O
was O
developed O
to O
visualize O
measured O
and O
predicted O
belatacept O
serum O
concentrations. O
[]

Patients O
with O
clinical O
improvement O
but O
without O
parasite O
clearance O
at O
day O
29 O
received O
a O
second O
round O
of O
the O
allocated O
treatment. O
[]

Title: O
High-intensity O
interval O
training O
and O
moderate-intensity O
continuous O
training O
in O
adults O
with O
Crohn's O
disease: O
a O
pilot O
randomised O
controlled O
trial. O
[]

30 O
individuals O
with O
CD O
were O
divided O
into O
2 O
groups: O
16 O
in O
the O
experimental O
group O
(EG) O
and O
14 O
in O
the O
control O
group O
(CG). O
[]

The O
response B-outcome ['Physiological-Clinical']
rate O
was O
18%. O
[['Physiological-Clinical']]

Publication O
date: O
2019/03/12 O
06:00 O
[medline] O
[]

Quantitative O
fit O
tests O
(QNFTs) O
were O
performed O
before O
and O
after O
training O
using O
three O
types O
of O
N95 O
or O
higher O
filter O
respirators O
(cup-type, O
fold-type, O
valve-type). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS: O
The O
results O
seem O
to O
indicate O
that O
using O
krill O
powder O
as O
a O
source O
for O
EPA O
and O
DHA O
is O
safe O
in O
therapeutic O
dose O
and O
the O
risk O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
let O
alone O
serious O
ones, O
is O
low. O
[['Adverse-effects']]

Plasma O
fentanyl O
levels O
were O
measured O
at O
admission, O
1, O
6, O
12, O
24, O
and O
48 O
h O
postoperatively. O
[]

Publication O
date: O
2018/01/25 O
00:00 O
[accepted] O
[]

RESULTS: O
Women O
in O
the O
green O
tea O
group O
showed O
a O
statistically O
significant O
decrease O
in O
the O
prevalence O
of O
cystitis B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
a O
statistically O
significant O
improvement O
in O
the O
urinalysis B-outcome ['Physiological-Clinical']
results O
except O
for O
hematuria O
after O
3 O
days O
of O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
The O
trial O
was O
registered O
prospectively O
with O
the O
national O
database O
at O
the O
Clinical O
Research O
Network O
(UKCRN O
Portfolio O
9366). O
[]

CONCLUSIONS: O
Among O
patients O
with O
CAP O
hospitalized O
to O
non-ICU O
wards, O
erythromycin O
use O
was O
associated O
with O
a O
68% O
increased O
risk O
of O
hospital-acquired O
cardiac B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
mainly O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
. O
Levofloxacin B-outcome ['Life-Impact']
and O
moxifloxacin B-outcome ['Life-Impact']
were O
associated O
with O
a O
lower O
risk O
of O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
. O
Although O
our O
study O
does O
not O
fully O
exclude O
confounding O
bias, O
findings O
remained O
largely O
unchanged O
in O
crude, O
adjusted, O
and O
sensitivity O
analyses. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

In O
the O
control O
group, O
the O
patients O
received O
the O
routine O
care. O
[]

Pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
was O
measured O
by O
the O
visual O
scale O
before O
treatment, O
1 O
h O
after O
consuming O
the O
drug O
(for O
24 O
h) O
and O
48 O
h O
after O
the O
onset O
of O
drug. O
[['Physiological-Clinical']]

All O
the O
included O
patients O
were O
equally O
and O
randomly O
divided O
into O
a O
verum O
TENS O
group O
and O
a O
sham O
TENS O
group, O
each O
group O
23 O
participants. O
[]

Journal-Name:The O
British O
journal O
of O
radiology O
[]

METHODS: O
We O
conducted O
a O
phase O
1 O
trial O
of O
givosiran O
in O
patients O
with O
acute O
intermittent O
porphyria. O
[]

Studies O
have O
reported O
that O
uterine O
contractions O
(UC) O
at O
the O
time O
of O
embryo O
transfer O
(ET) O
were O
inversely O
related O
to O
implantation O
and O
pregnancy O
rate, O
hence O
reducing O
the O
success O
of O
IVF O
treatments. O
[]

3) O
Compared O
with O
combination O
group, O
improvement O
of O
sleep B-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
(SOL) I-outcome ['Physiological-Clinical']
and O
sleep B-outcome ['Physiological-Clinical']
efficiency I-outcome ['Physiological-Clinical']
(SE) I-outcome ['Physiological-Clinical']
in O
CBT-i O
group O
was O
superior O
(both O
P=0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Sperm O
selection O
strategies O
aimed O
at O
improving O
success O
rates O
of O
intracytoplasmic O
sperm O
injection O
(ICSI) O
include O
binding O
to O
hyaluronic O
acid O
(herein O
termed O
hyaluronan). O
[]

Conclusion: O
Supraglottic O
tracheal O
tube O
ventilation O
for O
painless O
fiberbronchoscopy O
is O
a O
safe O
and O
effective O
procedure. O
[]

The O
average O
available O
energy O
(calorie) O
content O
of O
a O
28 O
g O
serving O
of O
cashew O
nuts O
was O
137 O
kcal O
(+/-3.4 O
kcal O
SEM) O
and O
ranged O
from O
105 O
to O
151 O
kcal. O
[]

Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QoL) I-outcome ['Life-Impact']
, O
assessed O
using O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
QLQ-HDC29 O
questionnaires, O
was O
an O
unpublished O
secondary O
endpoint, O
which O
we O
now O
report O
here. O
[['Life-Impact']]

Title: O
Pre-administration O
of O
remifentanil O
in O
target-controlled O
propofol O
and O
remifentanil O
anesthesia O
prolongs O
anesthesia B-outcome ['Life-Impact']
induction I-outcome ['Life-Impact']
in O
neurosurgical O
patients: O
A O
double-blind O
randomized O
controlled O
trial. O
[['Life-Impact']]

Publication O
Type: O
Multicenter O
Study O
[]

Publication O
date: O
2018/12/22 O
06:00 O
[entrez] O
[]

The O
trained O
nodal O
teachers O
reported O
children O
with O
symptoms O
of O
acute O
pharyngitis O
and O
or O
RF/RHD O
in O
intervention O
arm O
and O
children O
taken O
to O
hospitals O
by O
parents O
for O
symptoms O
of O
acute O
pharyngitis O
and O
or O
RF/RHD O
under O
control O
arm O
through O
mobile O
phone O
to O
coordinating O
centre. O
[]

The O
success B-outcome ['Physiological-Clinical']
rate O
in O
the O
group O
of O
colored O
eye O
drops O
was O
88% O
and, O
in O
the O
group O
of O
transparent, O
24%. O
[['Physiological-Clinical']]

A O
total O
of O
74 O
patients O
who O
have O
low O
back O
pain O
and O
radiating O
pain O
due O
to O
LHIVD O
will O
be O
recruited O
and O
randomly O
allocated O
to O
the O
experimental O
group O
and O
control O
group. O
[]

Poor O
nutritional O
status O
is O
common O
among O
human O
immunodeficiency O
virus O
(HIV)-infected O
patients O
including O
vitamin O
D O
(vitD(3)) O
deficiency. O
[]

There O
is O
currently O
no O
standard O
therapeutic O
regimen O
available O
for O
patients O
with O
advanced O
colorectal O
cancer O
in O
whom O
the O
disease O
continues O
to O
progress O
after O
2 O
or O
more O
lines O
of O
chemotherapy. O
[]

Journal O
ID: O
101273946 O
[]

Methods: O
This O
was O
a O
prospective O
study. O
[]

Title: O
Does O
the O
"delayed O
start" O
protocol O
with O
gonadotropin-releasing O
hormone O
antagonist O
improve O
the O
pregnancy B-outcome ['Physiological-Clinical']
outcome O
in O
Bologna O
poor O
responders? O
[['Physiological-Clinical']]

MAIN O
OUTCOME O
MEASURE(S): O
We O
evaluated O
all O
groups O
for O
observable O
scapular B-outcome ['Physiological-Clinical']
dyskinesis I-outcome ['Physiological-Clinical']
using O
the O
scapular O
dyskinesis O
test, O
scapular B-outcome ['Physiological-Clinical']
upward I-outcome ['Physiological-Clinical']
rotation I-outcome ['Physiological-Clinical']
using O
a O
digital O
inclinometer, O
and O
pectoralis B-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
using O
the O
pectoralis O
minor O
index O
at O
baseline, O
immediately O
after O
taping, O
and O
at O
60 O
to O
72 O
hours O
after O
taping. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
100968562 O
[]

In O
the O
intention-to-treat O
analysis O
at O
10 O
years, O
there O
were O
315 O
deaths B-outcome ['Mortality']
(20.3% O
of O
the O
patients) O
in O
the O
bilateral-graft O
group O
and O
329 O
deaths O
(21.2%) O
in O
the O
single-graft O
group O
(hazard O
ratio, O
0.96; O
95% O
confidence O
interval O
[CI], O
0.82 O
to O
1.12; O
P=0.62). O
[['Mortality']]

BACKGROUND: O
We O
assessed O
the O
effect O
of O
equivalent O
weight O
loss O
with O
or O
without O
exercise O
on O
(intra-) O
abdominal B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
in O
the O
SHAPE-2 O
study. O
[['Physiological-Clinical']]

There O
are O
also O
no O
studies O
that O
establish O
a O
clear O
relationship O
between O
EEN O
in O
MAP O
and O
levels O
of O
albuminemia O
and O
CRP. O
[]

METHODS: O
Eighty-two O
patients O
with O
T1-3bN0M0 O
prostate O
cancer O
who O
had O
not O
received O
androgen-deprivation O
therapy O
were O
randomized O
to O
one O
of O
five O
arms: O
Arm O
1, O
60 O
cobalt O
gray O
equivalent O
(CGE)/20 O
fractions/5 O
weeks; O
Arm O
2, O
54 O
CGE/15 O
fractions/5 O
weeks; O
Arm O
3, O
47 O
CGE/10 O
fractions/5 O
weeks; O
Arm O
4, O
35 O
CGE/5 O
fractions/2.5 O
weeks; O
and O
Arm O
5, O
35 O
CGE/5 O
fractions/4 O
weeks. O
[]

CONCLUSIONS:: O
We O
suggest O
that O
after O
reposition O
exercises, O
the O
pelvis O
was O
more O
symmetrically O
aligned O
in O
relation O
to O
body O
axis; O
therefore, O
the O
muscles O
of O
the O
pelvic O
floor O
have O
functional O
length O
and O
did O
not O
shorten O
or O
lengthen O
due O
to O
pelvis O
rotation. O
[]

RESULTS: O
Significant O
time O
x O
group O
interactions O
and O
moderate O
to O
high O
effect O
sizes O
were O
found O
for O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
physical B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
bodily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
general B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
perception I-outcome ['Life-Impact']
, O
vitality B-outcome ['Physiological-Clinical']
, O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
disturbance I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Life-Impact']
image I-outcome ['Life-Impact']
, O
and O
upset B-outcome ['Life-Impact']
by O
hair O
loss, O
favoring O
the O
exercise O
group. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Women O
with O
premenstrual O
syndrome O
(PMS) O
often O
complain O
about O
depression O
when O
their O
menstrual O
cycle O
begins. O
[]

Patients O
were O
randomized O
into O
2 O
groups. O
[]

RESULTS: O
In O
the O
PAR-G O
and O
1PO-G, O
respectively O
there O
were O
significant O
reductions O
in O
slow B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(SVC) I-outcome ['Physiological-Clinical']
(p=0.0007 O
vs. O
p<0.0001), O
inspiratory B-outcome ['Physiological-Clinical']
reserve I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(IRV) I-outcome ['Physiological-Clinical']
(p=0.0016 O
vs. O
p=0.0026), O
and O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(FVC) I-outcome ['Physiological-Clinical']
(p=0.0013 O
vs. O
p<0.0001) O
and O
expiratory B-outcome ['Physiological-Clinical']
reserve I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(ERV) I-outcome ['Physiological-Clinical']
was O
maintained O
only O
for O
the O
PAR-G O
(p=0.4446 O
vs. O
p=0.0191). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Regarding O
the O
composite O
outcome O
of O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
stroke B-outcome ['Physiological-Clinical']
, O
there O
were O
385 O
patients O
(24.9%) O
with O
an O
event O
in O
the O
bilateral-graft O
group O
and O
425 O
patients O
(27.3%) O
with O
an O
event O
in O
the O
single-graft O
group O
(hazard O
ratio, O
0.90; O
95% O
CI, O
0.79 O
to O
1.03). O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical']]

We O
observed O
a O
trend O
toward O
decreased O
incisional B-outcome ['Physiological-Clinical']
hernia I-outcome ['Physiological-Clinical']
rates O
in O
patients O
treated O
with O
NPWT. O
[['Physiological-Clinical']]

Journal-Name:Shanghai O
kou O
qiang O
yi O
xue O
= O
Shanghai O
journal O
of O
stomatology O
[]

All O
men O
received O
standard O
care, O
and O
men O
in O
the O
intervention O
group O
(IG) O
also O
received O
oral O
and O
written O
RLP-based O
information O
about O
lifestyle O
and O
fertility. O
[]

The O
primary O
outcome O
was O
the O
between-group O
difference O
in O
the O
mean O
change O
from O
baseline O
to O
week O
80 O
in O
the O
total O
score O
on O
the O
Unified O
Parkinson's B-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Rating O
Scale O
(UPDRS; O
scores O
range O
from O
0 O
to O
176, O
with O
higher O
scores O
signifying O
more O
severe O
disease). O
[['Physiological-Clinical']]

Therefore, O
evidence O
is O
scarce O
on O
what O
conditions O
play O
a O
role O
in O
successful O
implementation O
and O
how O
they O
interact. O
[]

CONCLUSIONS: O
This O
study O
concluded O
that O
if O
targeting O
the O
increasing O
worldwide O
obesity O
problem O
through O
workplace O
initiated O
weight O
loss O
programs, O
the O
sales O
pitch O
to O
managements O
and O
employers O
have O
to O
be O
tailored O
in O
order O
to O
increase O
the O
participation O
and O
the O
motivation O
for O
the O
initiative. O
[]

Journal O
ID: O
101471610 O
[]

Title: O
Right O
ventricular O
size O
and O
function O
under O
riociguat O
in O
pulmonary O
arterial O
hypertension O
and O
chronic O
thromboembolic O
pulmonary O
hypertension O
(the O
RIVER O
study). O
[]

Publication O
date: O
2018/12/10 O
00:00 O
[accepted] O
[]

Title: O
Randomized O
Delayed-Start O
Trial O
of O
Levodopa O
in O
Parkinson's O
Disease. O
[]

BACKGROUND: O
Incidence O
of O
end O
stage O
kidney O
disease O
(ESKD) O
for O
Indigenous O
Australians O
is O
especially O
high O
in O
remote O
and O
very O
remote O
areas O
of O
Australia O
(18 O
and O
20 O
times O
the O
rate O
of O
comparable O
non-Indigenous O
people). O
[]

For O
creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
, O
SuperPATH O
group O
at O
1 O
and O
3 O
days O
were O
lower O
than O
control O
group O
( O
P<0.05), O
while O
no O
significant O
difference O
was O
found O
between O
2 O
groups O
before O
operation O
and O
at O
14 O
days O
after O
operation O
( O
P>0.05). O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Meanwhile, O
active B-outcome ['Physiological-Clinical']
flexional I-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
and O
passive B-outcome ['Physiological-Clinical']
flexional I-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
in O
preoperative O
analgesia O
group O
were O
larger O
than O
that O
in O
postoperative O
analgesia O
group O
at O
72 O
hours O
post O
operation. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Responding O
patients O
received O
decitabine O
as O
consolidation O
therapy O
on O
a O
5-day O
schedule O
for O
up O
to O
24 O
cycles. O
[]

METHODS: O
In O
this O
randomized, O
crossover, O
counterbalanced O
study, O
12 O
subjects O
(6 O
men, O
6 O
women; O
age O
= O
22 O
+/- O
2 O
yr; O
mass O
= O
73.5 O
+/- O
7.9 O
kg; O
height O
= O
171 O
+/- O
7 O
cm) O
underwent O
15 O
min O
of O
CWI O
(10.0 O
+/- O
0.03 O
degrees O
C) O
in O
an O
environmental O
chamber O
(38.6 O
+/- O
0.6 O
degrees O
C; O
36 O
+/- O
2% O
humidity). O
[]

The O
treatment O
lasted O
for O
2 O
weeks. O
[]

Title: O
Combined O
phacoemulsification O
and O
viscocanalostomy O
with O
Ologen O
implant O
versus O
combined O
phacoemulsification O
and O
viscocanalostomy. O
[]

CONCLUSIONS: O
Once-daily O
plazomicin O
was O
noninferior O
to O
meropenem O
for O
the O
treatment O
of O
complicated O
UTIs O
and O
acute O
pyelonephritis O
caused O
by O
Enterobacteriaceae, O
including O
multidrug-resistant O
strains. O
( O
[]

Publication O
date: O
2019/01/10 O
00:00 O
[accepted] O
[]

Journal-Name:Lancet O
(London, O
England) O
[]

J O
Strength O
Cond O
Res O
33(1): O
225-233, O
2019-Upper O
limb O
strength O
deficits O
are O
frequently O
observed O
following O
breast O
cancer O
(BC) O
and O
its O
treatments. O
[]

Compared O
with O
the O
control O
group, O
the O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
of O
the O
SuperPATH O
group O
was O
longer O
( O
t=4.470, O
P=0.000), O
and O
the O
incision B-outcome ['Life-Impact']
was O
shorter O
( O
t=-2.168, O
P=0.041). O
[['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

FINDINGS: O
Between O
May O
12, O
2015, O
and O
Aug O
4, O
2016, O
184 O
overweight O
or O
obese O
patients O
with O
non-alcoholic O
steatohepatitis O
were O
screened O
for O
study O
inclusion. O
[]

In O
the O
15th O
day O
after O
surgery, O
drainage O
by O
the O
incision O
was O
1.53 O
and O
the O
traditional O
chest O
drainage O
was O
2.11 O
(p=0.440), O
30th O
days O
after O
drainage O
by O
incision O
was O
0.71 O
and O
traditional O
chest O
drainage O
was O
0.84 O
(p=0.787). O
[]

Results: O
The O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
rate O
of O
intervention O
group O
for O
patients O
and O
people O
with O
impaired O
glucose O
tolerance O
(72.2% O
and O
71.4%) O
were O
higher O
than O
control O
group O
(43.6% O
and O
26.7%), O
but O
the O
unchanged B-outcome ['Physiological-Clinical']
rate O
of O
intervention O
group O
(13.9% O
and O
0.0%) O
were O
lower O
than O
control O
group O
(42.3% O
and O
73.3%). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

This O
study, O
therefore, O
attempted O
to O
explore O
the O
effects O
of O
TC O
on O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
(HRV) I-outcome ['Physiological-Clinical']
parameters. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

The O
Delta O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
Delta O
cardiac B-outcome ['Physiological-Clinical']
output O
values O
were O
lower O
in O
the O
Group O
R O
(P O
= O
.02 O
and O
P O
= O
.04, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Notably, O
10 O
g O
of O
either O
L-leucine O
or O
L-isoleucine, O
administered O
intragastrically O
before O
a O
mixed-nutrient O
drink, O
lowered O
postprandial O
blood O
glucose, O
and O
intraduodenal O
infusion O
of O
L-leucine O
(at O
a O
rate O
of O
0.45 O
kcal/min, O
total: O
9.9 O
g) O
lowered O
fasting O
blood O
glucose O
and O
reduced O
energy O
intake O
from O
a O
subsequent O
meal. O
[]

Group O
B O
(scleral O
group) O
included O
124 O
cases O
(127 O
eyes), O
using O
the O
sclera O
as O
allograft. O
[]

PATIENTS O
AND O
METHODS: O
A O
randomized, O
single-blind O
clinical O
trial O
(evaluators) O
with O
an O
experimental O
group O
(self-administered O
rehabilitation) O
and O
a O
control O
group O
(standard O
physical O
therapy) O
was O
carried O
out O
in O
271 O
adult O
patients O
aged O
18 O
or O
older O
with O
unilateral O
shoulder O
pain O
lasting O
more O
than O
six O
weeks O
and O
less O
than O
three O
months. O
[]

Title: O
ED50 O
and O
ED95 O
of O
intrathecal O
hyperbaric O
ropivacaine O
for O
parturients O
undergoing O
cesarean O
section O
with O
prophylactic O
infusion O
of O
phenylephrine: O
A O
Prospective O
dose-finding O
Study. O
[]

T O
Self-rating O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(SDS) O
and O
self-rating O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
SAS O
scores O
of O
patients O
in O
the O
rhodiola O
rosea+non-invasive O
ventilator O
group O
decreased O
after O
treatment O
P<0.05 O
compared O
with O
those O
in O
the O
non-invasive O
ventilator O
group. O
[ O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

PARTICIPANTS: O
Twenty-five O
children O
with O
DCD O
were O
randomly O
allocated O
to O
the O
KT O
group O
(mean O
age O
= O
7.97 O
years) O
and O
24 O
to O
the O
control O
group O
(mean O
age O
= O
8.04 O
years). O
[]

Mean O
of O
deformity B-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
rate O
was O
91.49+/-10.67% O
using O
CrCo-Ti O
rods O
versus O
81.86+/-9.88% O
using O
Ti-Ti O
rods O
(P-value=0.01). O
[['Physiological-Clinical']]

CONCLUSIONS: O
Omadacycline O
was O
noninferior O
to O
moxifloxacin O
for O
the O
treatment O
of O
community-acquired O
bacterial O
pneumonia O
in O
adults. O
( O
[]

After O
eight O
weeks, O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
wrist B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
, O
thigh B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
, O
calf B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
, O
mid-arm B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
, O
and O
triceps B-outcome ['Physiological-Clinical']
skinfolds I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
both O
the O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

This O
trial O
is O
registered O
with O
ClinicalTrials.gov, O
number O
NCT01786343. O
[]

TRIAL O
REGISTRATION: O
ISRCTN67852437 O
, O
registered O
02/03/2015. O
[]

Title: O
Cobalt O
chromium-Titanium O
rods O
versus O
Titanium-Titanium O
rods O
for O
treatment O
of O
adolescent O
idiopathic O
scoliosis; O
which O
type O
of O
rod O
has O
better O
postoperative O
outcomes? O
[]

In O
acute, O
the O
maximum O
levels O
of O
resveratrol B-outcome ['Physiological-Clinical']
(RSV) I-outcome ['Physiological-Clinical']
were O
detected O
both O
in O
serum O
and O
whole O
blood O
60 O
min O
after O
the O
administration O
of O
Taurisolo((R)); O
in O
chronic, O
a O
significant O
increase O
of O
resveratrol B-outcome ['Physiological-Clinical']
(RSV) I-outcome ['Physiological-Clinical']
was O
detected O
in O
serum O
after O
the O
4-week O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

TRIAL O
FUNDING: O
Medical O
Research O
Council/ O
Wellcome O
Trust/ O
DfID O
(Global O
Health O
Trials O
Scheme). O
[]

Result:There O
were O
no O
significant O
differences O
in O
SDS O
and O
SAS O
scores O
between O
the O
three O
groups O
P>0.05. O
[ O
[]

Journal O
ID: O
101604552 O
[]

This O
study O
suggests O
that O
epithelial O
remodeling O
may O
correlate O
with O
relative O
curvature O
changes O
resulting O
after O
both O
techniques, O
rather O
than O
the O
obvious O
difference O
of O
subepithelial O
corneal O
denervation O
changes. O
[]

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O
[]

Thus, O
a O
double-blinded O
randomized, O
placebo-controlled O
trial O
was O
conducted O
to O
determine O
whether O
nifedipine, O
a O
calcium O
channel O
blocker O
with O
potent O
smooth O
muscle O
relaxing O
activity O
and O
an O
excellent O
safety O
profile, O
can O
improve O
the O
outcome O
of O
patients O
undergoing O
ET O
treatments. O
[]

Title: O
Cluster O
randomized O
evaluation O
of O
the O
Nia O
Project: O
study O
protocol. O
[]

Journal O
ID: O
7501160 O
[]

METHODS: O
In O
2 O
similarly O
designed O
studies O
of O
patients O
with O
episodic O
migraine O
(6 O
months) O
and O
1 O
study O
of O
patients O
with O
chronic O
migraine O
(3 O
months), O
patients O
randomized O
in O
a O
1:1:2 O
ratio O
received O
a O
subcutaneous O
injection O
of O
galcanezumab O
120 O
mg/month O
(after O
an O
initial O
loading O
dose O
of O
240 O
mg) O
or O
240 O
mg/month O
or O
placebo. O
[]

A O
total O
of O
18 O
of O
102 O
patients O
(18%) O
in O
the O
hybrid-procedure O
group O
had O
a O
major O
pulmonary B-outcome ['Physiological-Clinical']
complication I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
31 O
of O
103 O
(30%) O
in O
the O
open-procedure O
group. O
[['Physiological-Clinical']]

Title: O
Denosumab O
effects O
on O
serum O
levels O
of O
the O
bone O
morphogenetic O
proteins O
antagonist O
noggin B-outcome ['Physiological-Clinical']
in O
patients O
with O
transfusion-dependent O
thalassemia O
and O
osteoporosis. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O
[]

Interim O
analysis O
of O
a O
randomized, O
double O
blinded, O
placebo-controlled O
trial. O
[]

The O
means O
and O
CVs O
of O
MEP B-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
in O
all O
limbs O
were O
significantly O
lower O
in O
group O
I. O
The O
mean O
train-of-four B-outcome ['Physiological-Clinical']
(TOF) I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
from O
30 O
to O
80 O
min O
of O
operation O
were O
significantly O
higher O
in O
group O
B. O
CONCLUSION: O
We O
conclude O
that O
the O
continuous O
infusion O
of O
rocuronium O
effectively O
inhibited O
the O
involuntary B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
and O
spontaneous B-outcome ['Physiological-Clinical']
respiration I-outcome ['Physiological-Clinical']
of O
the O
patient O
while O
enabling O
MEP O
monitoring. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusion O
PRAM O
provides O
meaningful O
and O
direct O
monitoring O
of O
hemodynamics O
and O
cardiac O
efficiency O
during O
the O
dynamic O
period O
of O
anesthetic O
induction O
in O
children O
undergoing O
cardiac O
surgery. O
[]

These O
contextual O
factors O
interacted O
with O
the O
implemented O
training O
to O
influence O
knowledge O
about O
pharmacological O
treatments O
and O
symptoms O
of O
mental O
illness, O
confidence O
in O
providing O
treatment, O
negative O
beliefs O
about O
certain O
mental O
health O
conditions, O
and O
the O
understanding O
of O
the O
role O
of O
PCPs O
in O
mental O
health O
care O
delivery. O
[]

RESULTS: O
Participants O
identified O
more O
barriers O
than O
facilitators O
when O
describing O
contextual O
factors O
influencing O
the O
mhGAP-based O
training's O
expected O
outcomes. O
[]

Barriers O
were O
regrouped O
into O
five O
categories: O
structural O
factors O
(e.g., O
policies, O
social O
context, O
local O
workforce O
development, O
and O
physical O
aspects O
of O
the O
environment), O
organizational O
factors O
(e.g., O
logistical O
issues O
for O
the O
provision O
of O
care O
and O
collaboration O
within O
and O
across O
healthcare O
organizations), O
provider O
factors O
(e.g., O
previous O
mental O
health O
experience O
and O
personal O
characteristics), O
patient O
factors O
(e.g., O
beliefs O
about O
the O
health O
system O
and O
healthcare O
professionals, O
and O
motivation O
to O
seek O
care), O
and O
innovation O
factors O
(e.g., O
training O
characteristics). O
[]

Journal-Name: O
The O
New O
England O
journal O
of O
medicine O
[]

Patients O
in O
the O
non-invasive O
ventilator O
group O
were O
treated O
with O
continuous O
positive O
airway O
pressure O
CPAP O
for O
3 O
months, O
and O
those O
in O
the O
rhodiola O
rosea+non-invasive O
ventilator O
group O
were O
treated O
with O
oral O
rhodiola O
capsules O
for O
3 O
months O
on O
the O
basis O
of O
CPAP, O
and O
those O
in O
the O
rhodiola O
rosea O
treatment O
group O
were O
treated O
with O
pure O
oral O
rhodiola O
capsules O
for O
3 O
months. O
[]

Analyses O
were O
done O
according O
to O
the O
intention-to-treat O
principle. O
[]

BACKGROUND: O
Various O
studies O
indicate O
the O
negative O
effects O
of O
menopausal O
symptoms O
and O
complications O
on O
the O
quality O
of O
life O
(QOL) O
of O
women. O
[]

Main O
parameters O
setting O
of O
respirator: O
the O
predetermined O
tidal O
volume O
(VT) O
was O
set O
at O
500 O
mL O
in O
the O
VCV O
group; O
the O
preset O
pressure O
was O
regulated, O
so O
that O
when O
the O
atomizer O
was O
connected O
to O
the O
atomization O
device, O
the O
VT O
was O
nearly O
equal O
to O
or O
slightly O
larger O
than O
500 O
mL O
in O
the O
PCV O
group. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Finally, O
endometrial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
chemical, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
clinical, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
ongoing B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
pregnancy E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
rates O
were O
compared O
between O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']]

On O
the O
first O
day O
before O
surgery, O
the O
patient's O
general O
data O
were O
collected O
and O
the O
Pittsburgh O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
index O
(PSQI) O
was O
used O
to O
assess O
the O
patient's O
sleep B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
the O
past O
month. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

RESULTS: O
119 O
children O
aged O
5 O
to O
16 O
years, O
with O
symptomatic O
hypermobility O
were O
randomised O
to O
receive O
an O
individualised O
multidisciplinary O
intervention O
(I) O
(n O
= O
59) O
or O
standard O
management O
(S) O
(n O
= O
60). O
[]

The O
results O
showed O
that O
the O
menopausal O
women O
in O
D2 O
group O
increased O
serum O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
osteocalcin B-outcome ['Physiological-Clinical']
, O
and O
total O
phenolic B-outcome ['Physiological-Clinical']
compounds O
content O
but O
decreased O
CTX B-outcome ['Physiological-Clinical']
level. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
100968562 O
[]

The O
interventions O
were O
conducted O
by O
means O
of O
home O
visits O
over O
6 O
months. O
[]

Results: O
There O
was O
no O
significant O
difference O
in O
general O
data O
and O
Pittsburgh O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
index O
scale O
scores O
between O
the O
two O
groups O
of O
patients O
(all O
P>0.05). O
[['Physiological-Clinical']]

CONCLUSION: O
This O
is O
the O
first O
study O
comparing O
the O
impact O
of O
CM O
and O
CHO O
on O
athletic O
outcomes O
in O
an O
adolescent O
population O
in O
a O
field-based O
environment. O
[]

Endometriosis O
is O
a O
classic O
indication O
for O
IVF. O
[]

The O
participants O
were O
randomly O
assigned O
to O
experimental O
(n=25) O
and O
control O
(n=25) O
groups. O
[]

Journal-Name:BMC O
public O
health O
[]

We O
found O
no O
significant O
differences O
in O
the O
overall O
experience, O
helpfulness O
of O
the O
meeting, O
or O
stress O
levels O
of O
the O
meeting O
between O
those O
who O
met O
via O
videoconference O
vs. O
in-person O
(p=0.9909; O
p=0.8420; O
p=0.2352, O
respectively). O
[]

The O
data O
collection O
tools O
were O
the O
Menopause-Specific O
Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
Questionnaire O
(MENQOL) O
and O
a O
demographic O
characteristics O
questionnaire. O
[['Life-Impact']]

The O
OSTAP O
block O
is O
a O
promising O
technique O
for O
producing O
effective O
and O
prolonged O
postoperative O
analgesia O
in O
patients O
undergoing O
laparoscopic O
hysterectomy O
surgeries. O
[]

The O
patients O
will O
be O
randomized O
into O
a O
deep O
NMB O
group O
or O
a O
moderate O
NMB O
group O
with O
a O
1:1 O
ratio. O
[]

Compared O
to O
controls, O
subcutaneous B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
intra-abdominal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
fat E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
reduced O
significantly O
with O
both O
diet O
(- O
12.5% O
and O
- O
12.0%) O
and O
exercise O
plus O
diet O
(- O
16.0% O
and O
- O
14.6%). O
[['Physiological-Clinical', 'Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

In O
a O
prespecified O
supportive O
analysis O
involving O
the O
same O
population, O
the O
same O
end O
point O
was O
assessed O
during O
the O
intervention O
period O
(first O
receipt O
of O
trial O
agent O
to O
last O
dose O
plus O
2 O
days). O
[]

Patients O
in O
both O
groups O
improved O
significantly O
after O
treatment O
in O
Barthel O
index O
(BI)], O
elbow B-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
(ROM) I-outcome ['Physiological-Clinical']
, O
and O
elbow B-outcome ['Life-Impact']
muscles I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
. O
However, O
muscle B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
in O
elbow O
joint O
of O
the O
hemiplegic O
upper O
extremity O
improved O
significantly O
after O
SMV O
only O
in O
the O
experimental O
group O
(SPT-SMV). O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

At O
the O
end O
of O
an O
8-week O
consumption O
period, O
all O
subjects O
were O
determined O
serum O
bone B-outcome ['Physiological-Clinical']
markers O
including O
calcium B-outcome ['Physiological-Clinical']
, O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
osteocalcin B-outcome ['Physiological-Clinical']
, O
and O
beta B-outcome ['Physiological-Clinical']
CTX I-outcome ['Physiological-Clinical']
. O
In O
addition, O
the O
hematological B-outcome ['Physiological-Clinical']
and O
blood O
clinical B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
changes, O
and O
total O
phenolic B-outcome ['Physiological-Clinical']
content O
in O
the O
serum O
were O
also O
determined. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Effect O
of O
a O
Nutritional O
and O
Behavioral O
Intervention O
on O
Energy-Reduced O
Mediterranean O
Diet O
Adherence B-outcome ['Life-Impact']
Among O
Patients O
With O
Metabolic O
Syndrome: O
Interim O
Analysis O
of O
the O
PREDIMED-Plus O
Randomized O
Clinical O
Trial. O
[['Life-Impact']]

Journal-Name:Medicine O
[]

METHODS: O
Forty-four O
children O
(27 O
girls O
and O
17 O
boys) O
between O
13 O
and O
17 O
years O
of O
age O
with O
unilateral O
recurrent O
patellar O
dislocation O
underwent O
medial O
patellofemoral O
ligament O
(MPFL) O
reconstruction. O
[]

Title: O
Brentuximab O
vedotin O
with O
chemotherapy O
for O
CD30-positive O
peripheral O
T-cell O
lymphoma O
(ECHELON-2): O
a O
global, O
double-blind, O
randomised, O
phase O
3 O
trial. O
[]

Here, O
we O
describe O
a O
simple O
method O
for O
creating O
a O
cervical O
spine O
phantom O
and O
investigate O
whether O
the O
use O
of O
a O
gelatin-based O
phantom O
is O
associated O
with O
improved O
proficiency B-outcome ['Life-Impact']
in O
performing O
ultrasound-guided O
cervical O
medial O
branch O
block. O
[['Life-Impact']]

The O
median O
intervention O
period O
was O
3.34 O
years. O
[]

Journal O
ID: O
9206499 O
[]

Registered O
on O
3rd O
September O
2018, O
https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3571. O
[]

METHODS: O
In O
this O
double-blind, O
controlled O
trial, O
we O
randomly O
assigned O
145 O
patients O
with O
TTP O
to O
receive O
caplacizumab O
(10-mg O
intravenous O
loading O
bolus, O
followed O
by O
10 O
mg O
daily O
subcutaneously) O
or O
placebo O
during O
plasma O
exchange O
and O
for O
30 O
days O
thereafter. O
[]

A O
number O
of O
preventive O
methods O
have O
been O
tried. O
[]

Thirty O
minutes O
before O
operation, O
control O
group O
received O
intranasal O
placebo O
(0.9% O
saline) O
0.02 O
mL/kg, O
and O
DEX O
group O
received O
intranasal O
DEX O
2 O
mug/kg. O
[]

Subjects O
completed O
the O
demographic O
and O
Beck O
Depression O
Inventory-II O
(BDI-II) O
questionnaires O
before O
and O
after O
intervention. O
[]

No O
difference O
of O
adverse B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
incidences O
between O
2 O
groups O
was O
observed. O
[['Adverse-effects']]

After O
simulation O
training, O
participants O
performed O
cricothyroidotomy O
using O
an O
ex O
vivo O
porcine O
larynx O
fitted O
with O
an O
endoscope O
to O
record O
the O
procedure. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

RESULTS: O
The O
mean O
performance B-outcome ['Life-Impact']
score O
in O
test-1 O
was O
62.5 O
+/- O
10.1 O
points O
in O
the O
training O
group O
and O
62.3 O
+/- O
4.1 O
points O
in O
the O
control O
group O
[95% O
confidence O
interval O
(95% O
CI) O
-5.5 O
to O
5.8; O
P O
= O
.954]. O
In O
test-2, O
the O
mean O
score O
was O
86.8 O
+/- O
6.5 O
points O
and O
59.9 O
+/- O
4.4 O
points O
in O
the O
training O
and O
control O
groups, O
respectively O
(95% O
CI O
21.9-31.8; O
P O
< O
.001). O
[['Life-Impact']]

Implementation O
of O
multi-component O
PA O
interventions O
within O
schools O
is O
advocated O
but O
research O
has O
showed O
that O
they O
may O
not O
always O
be O
effective O
at O
increasing O
child O
PA. O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

Interventions: O
Twenty O
four O
ICUs O
were O
randomized O
1:1 O
to O
the O
intervention O
or O
control O
group. O
[]

The O
effect O
of O
groups O
and O
health B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
times O
was O
found O
on O
reduced O
HbA1c B-outcome ['Physiological-Clinical']
concentration O
and O
increased O
the O
total O
score O
of O
Self-Efficacy B-outcome ['Life-Impact']
(P O
<.05). O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact']]

RESULTS: O
In O
the O
per-protocol O
population, O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
occurred O
in O
98 O
of O
1063 O
participants O
(9.2%) O
in O
the O
education O
group O
and O
in O
67 O
of O
1058 O
(6.3%) O
in O
the O
decolonization O
group; O
84.8% O
of O
the O
MRSA B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
led O
to O
hospitalization B-outcome ['Resource-use']
. O
Infection B-outcome ['Physiological-Clinical']
from O
any O
cause O
occurred O
in O
23.7% O
of O
the O
participants O
in O
the O
education O
group O
and O
19.6% O
of O
those O
in O
the O
decolonization O
group; O
85.8% O
of O
the O
infections B-outcome ['Physiological-Clinical']
led O
to O
hospitalization B-outcome ['Resource-use']
. O
The O
hazard O
of O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
decolonization O
group O
than O
in O
the O
education O
group O
(hazard O
ratio, O
0.70; O
95% O
confidence O
interval O
[CI], O
0.52 O
to O
0.96; O
P=0.03; O
number O
needed O
to O
treat O
to O
prevent O
one O
infection B-outcome ['Physiological-Clinical']
, O
30; O
95% O
CI, O
18 O
to O
230); O
this O
lower O
hazard O
led O
to O
a O
lower O
risk O
of O
hospitalization B-outcome ['Resource-use']
due I-outcome ['Resource-use']
to I-outcome ['Resource-use']
MRSA I-outcome ['Resource-use']
infection I-outcome ['Resource-use']
(hazard O
ratio, O
0.71; O
95% O
CI, O
0.51 O
to O
0.99). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

CONCLUSION: O
Despite O
the O
decrease O
in O
the O
number O
of O
some O
cytotoxic B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
(CTLs) I-outcome ['Physiological-Clinical']
and O
an O
increase O
in O
the O
proportion O
of O
T B-outcome ['Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
(Tregs) I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
cytotoxic I-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
(CTLs) I-outcome ['Physiological-Clinical']
, O
supplementation O
with O
LTE O
seems O
to O
exert O
a O
beneficial O
effect O
on O
a O
disrupted O
Th1/Th2 O
balance O
in O
elite O
athletes, O
as O
shown O
by O
the O
decrease O
in O
interleukin B-outcome ['Physiological-Clinical']
10 I-outcome ['Physiological-Clinical']
(IL-10) I-outcome ['Physiological-Clinical']
concentration. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Data O
collection O
instruments O
consisted O
of O
demographic O
information O
and O
Strategies O
Used O
by O
People O
to O
Promote O
Health O
questionnaires. O
[]

CONCLUSIONS: O
This O
retrospective O
analysis O
found O
that O
better O
BCVA, O
greater O
total O
macular O
volume, O
and O
presence O
of O
subretinal O
fluid O
at O
baseline O
were O
associated O
with O
more O
rapid O
vision B-outcome ['Physiological-Clinical']
gains. O
[['Physiological-Clinical']]

During O
the O
final O
week O
of O
each O
intervention O
phase, O
subjects O
collected O
all O
feces O
and O
urine O
produced, O
and O
these O
were O
also O
analyzed O
for O
nitrogen B-outcome ['Physiological-Clinical']
(feces O
and O
urine), O
energy B-outcome ['Physiological-Clinical']
(feces O
and O
urine), O
and O
fat B-outcome ['Physiological-Clinical']
(feces). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
toxicity B-outcome ['Adverse-effects']
was O
manageable. O
[['Adverse-effects']]

In O
the O
SHM O
group, O
it O
was O
22, O
3, O
and O
5 O
cases O
respectively. O
[]

OBJECTIVE: O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
vitamin O
D O
and O
probiotic O
co-administration O
on O
mental B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
hormonal B-outcome ['Physiological-Clinical']
, O
inflammatory B-outcome ['Physiological-Clinical']
and O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
parameters O
in O
women O
with O
polycystic O
ovary O
syndrome O
(PCOS). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
7501160 O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
patients O
in O
the O
NES O
group O
received O
NES O
intervention, O
while O
the O
subjects O
in O
the O
sham O
group O
underwent O
sham O
NES. O
[]

Publication O
date: O
2019/01/29 O
06:00 O
[medline] O
[]

BACKGROUND: O
Post-traumatic O
Stress O
Disorder O
(PTSD) O
is O
a O
common O
sequelae O
of O
severe O
combat-related O
emotional O
trauma O
that O
is O
often O
associated O
with O
significantly O
reduced O
quality O
of O
life O
in O
afflicted O
veterans. O
[]

After O
the O
12-week O
treatments, O
the O
patients O
were O
examined O
for O
changes O
of O
TCM O
syndromes. O
[]

Journal O
ID: O
100968547 O
[]

Further O
studies O
are O
still O
needed O
to O
warrant O
the O
results O
of O
this O
study. O
[]

METHODS: O
Clinical O
and O
randomized O
trial O
with O
follow-up O
of O
three O
months. O
[]

Main O
Outcomes O
and O
Measures: O
The O
primary O
outcome O
was O
incident O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
during O
postoperative O
days O
1 O
through O
5. O
[['Physiological-Clinical', 'Life-Impact']]

Journal O
ID: O
2985248R O
[]

RESULTS: O
Among O
the O
1054 O
participants O
(527 O
in O
each O
group), O
end-point O
data O
were O
available O
for O
1015 O
(96.3%). O
[]

Journal O
ID: O
101479826 O
[]

RESULTS: O
After O
treatment, O
the O
6-minute O
walk B-outcome ['Life-Impact']
test O
(6MWT)], O
chronic B-outcome ['Physiological-Clinical']
obstructive I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(COPD) I-outcome ['Physiological-Clinical']
assessment O
test O
(CAT)], O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
airflow B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
, O
dyspnea B-outcome ['Physiological-Clinical']
, O
and O
exercise B-outcome ['Physiological-Clinical', 'Life-Impact']
capacity I-outcome ['Physiological-Clinical', 'Life-Impact']
(BODE) O
index O
were O
significantly O
increased O
compared O
with O
pre-treatment O
in O
both O
groups O
(P O
< O
.01), O
but O
not O
FVC% O
and O
FEVl%. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact']]

RESULTS: O
For O
the O
upper O
50th O
percentile O
group, O
the O
post-supplementation O
adjusted O
mean O
percent O
decline O
in O
maximal B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
isometric I-outcome ['Physiological-Clinical']
contraction I-outcome ['Physiological-Clinical']
(MVIC) I-outcome ['Physiological-Clinical']
was O
significantly O
less O
for O
the O
high O
dose O
group O
(8.9 O
+/- O
2.3%) O
than O
the O
low O
dose O
(17.0 O
+/- O
2.4%; O
p O
= O
0.022) O
and O
placebo O
(16.0 O
+/- O
2.4%; O
p O
= O
0.044) O
groups. O
[['Physiological-Clinical']]

All O
rural O
primary O
schools O
(n O
= O
164) O
in O
the O
county O
were O
invited O
to O
participate. O
[]

PATIENT O
AND O
METHODS: O
We O
propose O
a O
prospective, O
double-blinded, O
randomized O
phase O
2 O
study O
of O
2 O
parallel O
groups O
of O
eligible O
adult O
patients. O
[]

Furthermore, O
we O
observed O
a O
strong O
correlation O
between O
noggin B-outcome ['Physiological-Clinical']
and O
wrist B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
(r O
= O
-0.641, O
p O
= O
0.002) O
only O
in O
the O
denosumab O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

All O
participants O
were O
randomly O
divided O
into O
three O
groups, O
each O
using O
a O
different O
device O
system O
(motion O
tracking, O
finger O
motion O
control O
or O
touchscreen) O
to O
perform O
three O
task O
phases O
( O
acquisition B-outcome ['Life-Impact']
, O
retention B-outcome ['Life-Impact']
and O
transfer B-outcome ['Life-Impact']
). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Journal-Name:Anticancer O
research O
[]

For O
that O
highly O
selected O
subgroup, O
surgery O
was O
superior O
to O
medical O
treatment. O
( O
[]

CONCLUSION: O
We O
propose O
that O
CSO O
intake O
may O
partly O
exert O
its O
benefits O
through O
immuno-inflammatory O
molecular O
regulation O
in O
PBMCs, O
while O
modulation O
of O
ICAM1 O
expression, O
an O
endothelial/vascular-related O
gene, O
may O
be O
more O
dependent O
on O
the O
type O
of O
fish O
consumed. O
[]

The O
aim O
of O
this O
study O
was O
to O
exploit O
the O
effect O
of O
cocoa O
polyphenols O
on O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
muscular B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
induced O
by O
intensive O
physical O
exercise O
in O
elite O
football O
players. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Participants O
were O
randomly O
assigned O
to O
receive O
four O
infusions O
of O
either O
zoledronate O
at O
a O
dose O
of O
5 O
mg O
(zoledronate O
group) O
or O
normal O
saline O
(placebo O
group) O
at O
18-month O
intervals. O
[]

We O
will O
compare O
3-month, O
6-month, O
and O
12-month O
graft B-outcome ['Physiological-Clinical']
survival I-outcome ['Physiological-Clinical']
after O
LT, O
in O
order O
to O
identify O
a O
significant O
relation O
between O
the O
two O
homogenous O
groups O
of O
LT O
patients. O
[['Physiological-Clinical']]

The O
primary O
outcome O
was O
daily O
stool B-outcome ['Physiological-Clinical']
frequency. O
[['Physiological-Clinical']]

SHORE O
data O
were O
retrospectively O
analyzed O
to O
identify O
baseline O
patient O
characteristics O
associated O
with O
early O
clinically O
significant O
improvements O
in O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(VA) I-outcome ['Physiological-Clinical']
, O
defined O
as O
improvement O
to O
a O
Snellen O
equivalent O
of O
20/40 O
or O
better O
vision B-outcome ['Physiological-Clinical']
(>/= O
69 O
Early O
Treatment O
Diabetic B-outcome ['Physiological-Clinical']
Retinopathy I-outcome ['Physiological-Clinical']
Study O
(ETDRS) O
letters) O
or O
an O
increase O
in O
best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(BCVA) I-outcome ['Physiological-Clinical']
of O
15 O
or O
more O
ETDRS O
letters O
from O
baseline O
within O
3 O
months O
of O
treatment O
initiation. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
7501160 O
[]

Journal O
ID: O
2985248R O
[]

Title: O
Efficacy O
of O
Curcumin O
as O
an O
Adjunct O
to O
Scaling O
and O
Root O
Planing O
in O
Chronic O
Periodontitis O
Patients: O
A O
Randomized O
Controlled O
Clinical O
Trial. O
[]

Title: O
Mindfulness O
mechanisms O
and O
psychological B-outcome ['Life-Impact']
effects O
for O
aMCI O
patients: O
A O
comparison O
with O
psychoeducation. O
[['Life-Impact']]

CM O
had O
a O
more O
positive O
effect O
on O
strength B-outcome ['Life-Impact']
development O
and O
should O
be O
considered O
an O
appropriate O
post-exercise O
recovery O
supplement O
for O
adolescents. O
[['Life-Impact']]

BACKGROUND/OBJECTIVES: O
Molecular O
mechanisms O
linking O
fish O
and O
vegetable O
oil O
intakes O
to O
their O
healthy O
metabolic O
effects O
may O
involve O
attenuation O
of O
inflammation. O
[]

All O
participants O
were O
tested O
(test-1) O
following O
an O
introductory O
course O
of O
basic O
ultrasonography. O
[]

RESULTS: O
After O
6-week O
treatment O
and O
2-week O
follow-up, O
although O
ET O
plus O
montelukast O
did O
not O
show O
better O
effectiveness O
in O
improving O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
as O
evaluated O
by O
the O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
(FEV1) O
(P O
> O
.05) O
and O
FEV1/FVC B-outcome ['Physiological-Clinical']
(P O
> O
.05) O
than O
montelukast O
alone, O
significant O
relief O
in O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
(P O
< O
.01), O
and O
improvement O
in O
Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
(P O
< O
.01) O
have O
achieved. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

METHODS: O
(1) O
Clinical O
research: O
the O
patients O
needed O
sedative O
undergoing O
mechanical O
ventilation O
admitted O
to O
intensive O
care O
unit O
(ICU) O
of O
Qingdao O
Municipal O
Hospital O
from O
January O
2016 O
to O
January O
2018 O
were O
enrolled. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Participants O
assigned O
to O
both O
conditions O
experienced O
similar O
benefits O
regarding O
anxio-depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
and O
aging-related O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
General O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and O
memory B-outcome ['Life-Impact']
remained O
unchanged. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS: O
We O
intraoperatively O
randomly O
assigned O
patients O
with O
newly O
diagnosed O
advanced O
ovarian O
cancer O
(International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stage O
IIB O
through O
IV) O
who O
had O
undergone O
macroscopically O
complete O
resection O
and O
had O
normal O
lymph O
nodes O
both O
before O
and O
during O
surgery O
to O
either O
undergo O
or O
not O
undergo O
lymphadenectomy. O
[]

Finally, O
18 O
children O
of O
each O
group O
were O
enrolled O
in O
the O
analysis. O
[]

Title: O
Therapeutic O
effects O
of O
dimethyldiguanide O
combined O
with O
clomifene O
citrate O
in O
the O
treatment O
of O
polycystic O
ovary O
syndrome. O
[]

Here, O
we O
present O
the O
impact O
of O
the O
diet O
intervention O
on O
cost-effectiveness O
and O
explore O
changes O
in O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
. O
METHODS: O
A O
total O
of O
110 O
postpartum O
women O
with O
overweight/obesity O
were O
randomly O
assigned O
to O
diet O
(D-group) O
or O
control O
(C-group). O
[['Life-Impact']]

The O
subjects O
were O
randomly O
assigned O
to O
the O
high O
dose, O
low O
dose, O
or O
placebo O
group O
(each O
group: O
n O
= O
21). O
[]

Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
was O
assessed O
by O
the O
questionnaires O
SF36, O
EORTC O
QLQ-C30, O
and O
EORTC O
QLQ-BR23 O
at O
baseline, O
and O
at O
three, O
six, O
and O
nine O
months. O
[['Life-Impact']]

Publication O
date: O
2019/02/20 O
06:00 O
[medline] O
[]

Publication O
date: O
['2019/10/17 O
06:00' O
[]

Including O
men O
in O
preconception O
health O
policy O
guidelines O
and O
identifying O
suitable O
actors O
for O
care O
provision O
would O
be O
important O
first O
steps. O
[]

Additionally, O
both O
groups O
will O
receive O
the O
same O
acupuncture O
treatment O
once O
a O
week O
for O
6 O
weeks O
as O
a O
concurrent O
treatment. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrial.gov O
: O
NCT01015716 O
, O
registration O
data O
14.12.2010 O
(Prospectively O
registered). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/01/05 O
06:00 O
[medline] O
[]

We O
evaluated O
the O
effectiveness O
and O
usefulness O
of O
the O
single/double O
ETView O
TVT O
in O
monitoring O
the O
tracheal O
tube O
position O
during O
general O
anesthesia O
undergoing O
video-assisted O
thoracoscopic O
lobectomy. O
[]

All O
patients O
received O
parenteral O
intramuscular O
therapy O
of O
1 O
ml O
Vitamin O
B12 O
weekly O
for O
a O
total O
of O
4 O
weeks. O
[]

Treatment O
included O
weekly O
behavioral O
support O
for O
at O
least O
4 O
weeks. O
[]

BACKGROUND: O
To O
evaluate O
the O
safety O
and O
efficacy O
of O
a O
bandage O
contact O
lens O
for O
alleviating O
dry B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
after O
phacoemulsification. O
[['Physiological-Clinical']]

This O
study O
was O
conducted O
to O
compare O
the O
simultaneous O
vs O
delayed O
ventriculoperitoneal O
shunting O
in O
children O
undergoing O
myelomeningocele O
in O
terms O
of O
infection B-outcome ['Physiological-Clinical']
. O
METHODS: O
This O
Randomized O
Control O
Trial O
was O
conducted O
at O
department O
of O
Neurosurgery, O
Ayub O
Medical O
College, O
Abbottabad O
from O
7th O
March O
to O
7th O
June O
2016. O
[['Physiological-Clinical']]

We O
designed O
a O
prospective O
randomized O
study O
to O
assess O
the O
impact O
of O
glutamine O
(GLN) O
supplementation O
in O
preventing O
CCRT-induced O
toxicities B-outcome ['Adverse-effects']
of O
advanced O
NSCLC O
patients. O
[['Adverse-effects']]

The O
secondary O
outcome O
was O
the O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
hypoxemia I-outcome ['Physiological-Clinical']
, O
defined O
as O
an O
oxygen O
saturation O
of O
less O
than O
80%. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2018/12/31 O
06:00 O
[entrez] O
[]

Title: O
How O
mindfulness O
training O
promotes O
positive B-outcome ['Life-Impact']
emotions I-outcome ['Life-Impact']
: O
Dismantling O
acceptance O
skills O
training O
in O
two O
randomized O
controlled O
trials. O
[['Life-Impact']]

The O
PaCO(2) B-outcome ['Physiological-Clinical']
in O
group O
A O
was O
(62.0+/-4.7) O
mmHg O
, O
which O
was O
significantly O
higher O
than O
group O
B O
at O
the O
end O
of O
operation[(51.9+/-4.2) O
mmHg, O
t=2.432, O
P<0.05]. O
The O
time B-outcome ['Life-Impact']
spent I-outcome ['Life-Impact']
successfully I-outcome ['Life-Impact']
positioning I-outcome ['Life-Impact']
the O
insertion O
in O
group O
A O
and O
group O
B O
were O
(17.6+/-7.5), O
(29.8+/-13.6)s, O
the O
endoscope B-outcome ['Life-Impact']
indwelling I-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
were(0.8+/-0.1), O
(1.4+/-0.3)min, O
and O
the O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
were(32.3+/-4.3), O
(46.8+/-4.8)min, O
there O
were O
significantly O
difference O
between O
group O
A O
and O
group O
B(t=2.670, O
2.214, O
2.166, O
all O
P<0.05). O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

The O
direct O
and O
video O
groups O
performed O
2 O
handling B-outcome ['Life-Impact']
activities O
significantly O
better O
than O
the O
written-pictorial O
group. O
[['Life-Impact']]

Intra-abdominal B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
loss O
was O
not O
significantly O
larger O
in O
the O
exercise O
plus O
diet O
group O
(- O
3.8 O
cm(2), O
95%CI O
-9.0; O
1.3). O
[['Physiological-Clinical']]

Title: O
Promoting O
vaccination O
in O
the O
province O
of O
Quebec: O
the O
PromoVaQ O
randomized O
controlled O
trial O
protocol. O
[]

Journal O
ID: O
9114501 O
[]

Publication O
date: O
2018/12/22 O
06:00 O
[entrez] O
[]

Vanderbilt O
University O
Medical O
Center, O
Nashville, O
TN. O
[]

The O
intervention O
group O
received O
additional O
individual O
pre-discharge O
pharmacotherapeutic O
education O
about O
the O
discharge O
prescriptions. O
[]

21 O
patients O
(10.29%), O
were O
lost O
to O
follow O
up. O
[]

METHODS: O
We O
studied O
40 O
morbidly O
obese O
individuals O
aged O
between O
25 O
and O
55 O
years O
who O
underwent O
pulmonary O
function O
test O
and O
chest O
X-ray O
preoperatively, O
and O
on O
the O
day O
of O
discharge O
(2nd O
day O
after O
surgery). O
[]

We O
developed O
a O
moderate-intensity O
intervention O
program O
that O
can O
be O
sustained O
in O
the O
real-world O
setting O
and O
is O
practically O
applicable O
to O
both O
moderate O
and O
severe O
obesity. O
[]

Self-reported O
life-time O
medical O
diagnosis O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
or O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
antidepressants I-outcome ['Resource-use']
was O
considered O
as O
outcome. O
[['Physiological-Clinical', 'Life-Impact'], ['Resource-use']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/01/11 O
06:00 O
[entrez] O
[]

METHODS: O
A O
total O
of O
98 O
dyslipidemic O
patients O
were O
enrolled O
and O
divided O
into O
amla O
and O
placebo O
groups. O
[]

BACKGROUND: O
Studies O
have O
reported O
that O
the O
ED50 O
of O
intrathecal O
ropivacaine O
was O
increased O
when O
using O
prophylactic O
infusion O
of O
phenylephrine O
to O
prevent O
spinal-induced O
hypotension. O
[]

TRIAL O
REGISTRATION: O
This O
trial O
is O
registered O
on O
ClinicalTrials.gov O
(identifier: O
NCT01838668 O
), O
April O
20, O
2013 O
(retrospectively O
registered). O
[]

Publication O
date: O
2018/12/26 O
06:00 O
[entrez] O
[]

In O
this O
study, O
we O
compared O
the O
effects O
of O
no O
NMBD O
and O
continuous O
rocuronium O
infusion O
on O
the O
incidence O
of O
patient O
involuntary B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
and O
motor B-outcome ['Physiological-Clinical']
evoked I-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(MEP) I-outcome ['Physiological-Clinical']
monitoring. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
odds O
ratios O
(95% O
CI) O
for O
gestational B-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
(GDM) I-outcome ['Physiological-Clinical']
and O
CMFCs O
in O
women O
with O
a O
high O
adherence O
were O
0.35((0.18(-)0.67), O
p O
= O
0.002) O
and O
0.23((0.11(-)0.48), O
p O
< O
0.001), O
respectively. O
[['Physiological-Clinical']]

Gastric B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
before O
and O
one O
hours O
after O
feeding O
was O
measured O
and O
recorded O
for O
three O
positions O
including O
right-lateral, O
left-lateral, O
and O
prone. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

However, O
it O
is O
unknown O
if O
these O
characteristics O
are O
evident O
in O
people O
with O
PF O
osteoarthritis O
(OA), O
compared O
to O
pain-free O
older O
adults. O
[]

Journal-Name:Medicine O
[]

The O
secondary O
outcomes O
included O
visual O
analog O
scale O
(VAS) O
scores O
during O
movement, O
the O
tramadol B-outcome ['Resource-use']
consumption O
at O
the O
1st, O
4th, O
and O
12th O
postoperative O
hours, O
and O
nausea B-outcome ['Physiological-Clinical']
scores O
at O
the O
24th O
hour O
postoperatively. O
[['Resource-use'], ['Physiological-Clinical']]

Methods: O
A O
random O
cluster O
sampling O
method O
has O
been O
used, O
including O
300 O
rural O
residents O
aged O
above O
18 O
years O
old O
from O
three O
villages O
(184 O
in O
control O
group, O
116 O
in O
intervention O
group), O
in O
order O
to O
proceed O
the O
physical O
check-up O
and O
health O
education O
programs. O
[]

The O
incidence O
of O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(2.1%) O
in O
intervention O
group O
was O
significantly O
lower O
than O
that O
in O
control O
group O
(4.2%) O
at O
year O
2 O
(chi O
= O
22.138, O
P O
<.001). O
[['Physiological-Clinical']]

During O
clinically O
apparent O
infection, O
a O
reduction O
in O
the O
diversity O
of O
micro-organisms O
in O
a O
DFU O
was O
often O
observed O
due O
to O
expansion O
of O
one O
or O
two O
taxa, O
with O
recovery O
in O
diversity O
at O
resolution. O
[]

BACKGROUND: O
To O
study O
the O
efficacy O
of O
the O
biodegradable O
collagen O
implant O
Ologen(R) O
as O
an O
adjuvant O
in O
phaco-viscocanalostomy O
in O
patients O
with O
coexisting O
cataract O
and O
primary O
open O
angle O
glaucoma. O
[]

Publication O
date: O
2018/12/29 O
00:00 O
[accepted] O
[]

CONCLUSIONS: O
Whilst O
daily O
betaA O
may O
confer O
individual O
benefits, O
these O
results O
demonstrate O
limited O
impact O
of O
betaA O
(irrespective O
of O
dosing O
strategy) O
on O
30-min O
rowing B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
or Seperator ['Physiological-Clinical', 'Physiological-Clinical']
subsequent X ['Physiological-Clinical', 'Physiological-Clinical']
sprint B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
performance E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
Further O
investigation O
of O
betaA O
dosage O
> O
2.4 O
g.d(- O
1) O
and/or O
chronic O
intervention O
periods O
(> O
4-8 O
weeks) O
may O
be O
warranted O
based O
on O
within-group O
observations. O
[['Physiological-Clinical', 'Physiological-Clinical']]

METHODS: O
A O
randomized, O
double-blind, O
placebo-controlled O
trial O
involving O
confirmed O
HIV-positive O
pregnant O
women O
at O
the O
Lagos O
University O
Teaching O
Hospital O
(LUTH) O
between O
September O
2018 O
and O
February O
2019. O
[]

CONCLUSIONS: O
Our O
findings O
suggest O
that O
the O
active, O
music-instruction O
program O
holds O
promise O
as O
a O
complementary O
means O
of O
ameliorating O
PTSD B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
among O
this O
population. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

The O
project O
manager O
and O
the O
manager O
of O
the O
home-care O
centre O
both O
reflected O
mainly O
on O
improvement O
of O
the O
healthcare O
workers O
health. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

In O
this O
study O
a O
total O
of O
98 O
patients O
with O
MMC O
and O
hydrocephalus O
were O
randomly O
divided O
into O
two O
equal O
groups. O
[]

In O
addition, O
gene O
expression O
analysis O
in O
PBMC O
showed O
subtle O
changes O
in O
superoxide B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
processes. O
[['Physiological-Clinical']]

The O
primary O
outcome O
was O
the O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
, O
measured O
by O
the O
visual O
analog O
scale O
(VAS). O
[['Physiological-Clinical']]

Then O
the O
3 O
groups O
were O
divided O
into O
2 O
subgroups O
by O
age, O
12 O
to O
24 O
months O
and O
25 O
to O
36 O
months. O
[]

PURPOSE: O
To O
study O
the O
effect O
of O
Kangfuxin O
liquid O
combined O
with O
Garlicin O
Capsules O
in O
treatment O
of O
children O
with O
recurrent O
oral O
ulcer O
(ROU) O
and O
on O
immunological B-outcome ['Physiological-Clinical']
regulation I-outcome ['Physiological-Clinical']
. O
METHODS: O
This O
randomized O
controlled O
clinical O
study O
prospectively O
enrolled O
204 O
patients O
with O
ROU O
who O
were O
randomly O
divided O
into O
2 O
groups. O
[['Physiological-Clinical']]

All O
analyses O
were O
performed O
with O
the O
use O
of O
proportional-hazards O
models O
in O
the O
per-protocol O
population O
(all O
participants O
who O
underwent O
randomization, O
met O
the O
inclusion O
criteria, O
and O
survived O
beyond O
the O
recruitment O
hospitalization) O
and O
as-treated O
population O
(participants O
stratified O
according O
to O
adherence). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
overarching O
study O
aim O
was O
to O
understand O
how O
schools O
implemented B-outcome ['Life-Impact']
the O
AS:Sk O
intervention, O
with O
a O
specific O
focus O
on O
the O
frequency O
of O
intervention B-outcome ['Life-Impact']
component I-outcome ['Life-Impact']
implementation I-outcome ['Life-Impact']
, O
and O
how O
the O
components O
were O
incorporated B-outcome ['Life-Impact']
into O
the O
school O
day. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:British O
journal O
of O
anaesthesia O
[]

Title: O
[Evaluation O
of O
peer O
support O
education O
mode O
for O
type B-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
rural O
residents]. O
[['Physiological-Clinical']]

Publication O
date: O
2017/11/15 O
00:00 O
[accepted] O
[]

A O
net O
cost B-outcome ['Resource-use']
analysis O
from O
an O
employer O
perspective O
demonstrated O
the O
intervention O
group O
was O
associated O
with O
a O
mean O
of O
2.97 O
h O
less O
absenteeism B-outcome ['Life-Impact']
over O
a O
4 O
week O
period O
(p O
= O
0.62), O
which O
could O
result O
in O
net O
savings O
ranging O
from O
pound66 O
to O
pound735 O
depending O
on O
the O
wage O
rate O
employed. O
[['Resource-use'], ['Life-Impact']]

CONCLUSION: O
Pre-administration O
of O
remifentanil O
in O
target-controlled O
propofol O
and O
remifentanil O
anesthesia O
prolongs O
total O
induction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
about O
35% O
compared O
to O
co-administration O
of O
remifentanil O
and O
propofol O
by O
decreased O
CO. O
[['Life-Impact']]

The O
dry O
needling O
was O
applied O
in O
active O
trigger O
points O
located O
in O
the O
musculature O
of O
the O
head O
and O
the O
neck. O
[]

Journal O
ID: O
100968547 O
[]

Journal-Name:Medicine O
[]

Teachers O
assigned O
to O
the O
waitlist O
control O
condition O
will O
receive O
an O
alternative O
training O
on O
how O
to O
monitor O
physical O
functional O
capacity O
in O
children O
with O
special O
needs. O
[]

We O
explored O
characteristics O
of O
NSCLC O
that O
could O
predict O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(DFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
using O
Cox O
regression O
models. O
[['Physiological-Clinical', 'Mortality'], ['Mortality']]

General O
fertility B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
increased O
from O
a O
mean O
score O
of O
4.6 O
to O
5.5 O
out O
of O
12 O
(P O
= O
0.004) O
in O
the O
IG. O
[['Life-Impact']]

It O
scavenges O
free O
radicals O
and O
reactive O
oxygen O
species O
(ROS), O
which O
are O
produced O
during O
metabolic O
pathways. O
[]

Publication O
date: O
2018/11/20 O
00:00 O
[accepted] O
[]

Decompression O
could O
be O
cost-effective O
in O
the O
longer-term, O
but O
results O
of O
this O
analysis O
are O
sensitive O
to O
the O
assumptions O
made O
about O
how O
costs O
and O
QALYs O
are O
extrapolated O
beyond O
the O
follow-up O
of O
the O
trial. O
[]

The O
registration O
can O
be O
found O
at O
the O
following O
URL: O
https://clinicaltrials.gov/ct2/show/NCT01838668. O
[]

BACKGROUND: O
Few O
studies O
have O
been O
conducted O
on O
the O
utility O
of O
cervical O
spine O
phantoms O
for O
practicing O
cervical O
procedures. O
[]

CONCLUSIONS/SIGNIFICANCE: O
The O
extended O
treatment O
strategy O
with O
the O
combination O
regimen O
showed O
the O
highest O
documented O
efficacy O
in O
HIV-VL O
patients; O
these O
results O
support O
a O
recommendation O
of O
this O
regimen O
as O
first-line O
treatment O
strategy O
for O
HIV-VL O
patients O
in O
eastern O
Africa. O
[]

Direct O
comparison O
between O
both O
interventions O
revealed O
that O
the O
reduction O
in O
subcutaneous B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
was O
statistically O
significantly O
larger O
in O
the O
group O
that O
combined O
exercise O
with O
diet: O
an O
additional O
10.6 O
cm(2) O
(95%CI O
-18.7; O
- O
2.4) O
was O
lost O
compared O
to O
the O
diet-only O
group. O
[['Physiological-Clinical']]

This O
trial O
is O
registered O
with O
NCT03288623. O
[]

The O
degree O
of O
injured O
vertebra B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
, O
visual O
analogue O
scale O
(VAS) O
score, O
and O
Oswestry O
disability B-outcome ['Life-Impact']
index O
(ODI) O
score O
at O
preoperation, O
immediate O
after O
operation, O
and O
last O
follow-up O
were O
calculated O
and O
compared O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Life-Impact']]

This O
paper's O
objective O
is O
to O
fill O
that O
lack. O
[]

The O
first O
40 O
patients O
were O
allocated O
equally O
to O
the O
two O
treatment O
groups O
by O
computer-generated O
block O
randomisation O
(block O
size O
40), O
after O
which O
a O
response-adaptive O
randomisation O
algorithm O
used O
all O
previous O
patients' O
treatment O
and O
response O
data O
to O
decide O
the O
allocation O
of O
each O
following O
patient O
favouring O
the O
group O
with O
superior O
response. O
[]

Methylphenidate B-outcome ['Life-Impact']
dosing I-outcome ['Life-Impact']
was O
significantly O
higher O
in O
individuals O
on O
L-methylfolate O
over O
time O
(chi O
= O
7.35, O
P O
= O
0.007). O
[['Life-Impact']]

Therefore, O
this O
study O
determined O
if O
PC O
affected O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
(Trec) I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
storage I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
ratings O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
(RPE), O
thermal B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
, O
sweat B-outcome ['Physiological-Clinical']
rate, O
and O
postexercise O
cold-water O
immersion O
(CWI) O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
cooling O
rates. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
intended O
sample O
size O
is O
552 O
patients. O
[]

We O
will O
also O
assess O
teachers' O
autonomy-supportive B-outcome ['Life-Impact', 'Life-Impact']
techniques I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
behaviours S1-outcome ['Life-Impact', 'Life-Impact']
by O
observation. O
[['Life-Impact', 'Life-Impact']]

Publication O
date: O
2018/11/30 O
00:00 O
[accepted] O
[]

Title: O
Comparison O
of O
the O
long-term O
efficacy O
of O
tenofovir O
and O
entecavir O
in O
nucleos(t)ide O
analogue-naive O
HBeAg-positive O
patients O
with O
chronic O
hepatitis O
B: O
A O
large, O
multicentre, O
randomized O
controlled O
trials. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

In O
addition, O
22 O
patients O
treated O
by O
monthly O
regimen O
were O
evaluated O
after O
18 O
months O
of O
treatment. O
[]

Amer.). O
[]

TRIAL O
REGISTRATION O
NUMBER: O
www.clinicaltrials.gov O
NCT02011958. O
[]

The O
clinical O
and O
radiographic O
twelve-month O
outcomes O
indicated O
successful B-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
, O
independently O
of O
the O
root O
filling O
material O
used. O
[['Physiological-Clinical']]

Publication O
date: O
2018/12/20 O
06:00 O
[entrez] O
[]

Logistic O
regression O
analyses O
were O
used O
for O
between O
treatment O
comparisons. O
[]

Publication O
date: O
2018/12/19 O
06:00 O
[entrez] O
[]

There O
were O
no O
significant O
differences O
in O
the O
proportions O
of O
participants O
reporting O
local B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
systemic B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
unsolicited B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
and O
SAEs B-outcome ['Adverse-effects']
among O
the O
3 O
vaccine O
groups O
after O
the O
1st O
and O
2nd O
doses. O
[['Adverse-effects'], ['Adverse-effects'], ['Adverse-effects'], ['Adverse-effects']]

In O
the O
Province O
of O
Quebec, O
vaccine O
coverage O
in O
young O
children O
are O
sub-optimal, O
mostly O
due O
to O
ambivalence O
toward O
vaccine O
safety O
and O
efficacy. O
[]

Title: O
A O
randomized, O
double O
blind, O
placebo O
controlled, O
multicenter O
clinical O
trial O
to O
assess O
the O
efficacy O
and O
safety O
of O
Emblica O
officinalis O
extract O
in O
patients O
with O
dyslipidemia. O
[]

Journal O
ID: O
2985248R O
[]

Objective: O
To O
evaluate O
the O
effect O
of O
intensive O
blood O
pressure O
control O
on O
risk O
of O
dementia B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Design, O
Setting, O
and O
Participants: O
Randomized O
clinical O
trial O
conducted O
at O
102 O
sites O
in O
the O
United O
States O
and O
Puerto O
Rico O
among O
adults O
aged O
50 O
years O
or O
older O
with O
hypertension O
but O
without O
diabetes O
or O
history O
of O
stroke. O
[['Physiological-Clinical', 'Life-Impact']]

Thus, O
PrimaVie(R) O
Shilajit O
supplementation O
at O
500 O
mg.d(- O
1) O
elicited O
favorable O
muscle B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
connective B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
tissue E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
adaptations. O
[['Physiological-Clinical', 'Physiological-Clinical']]

No O
patients O
reported O
intraoperative B-outcome ['Physiological-Clinical', 'Life-Impact']
awareness I-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Postoperative O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting O
was O
reported O
in O
48 O
patients O
(7.8%) O
in O
the O
guided O
and O
55 O
patients O
(8.9%) O
in O
the O
usual O
care O
group. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

These O
and O
other O
related O
markers O
(holotranscobalamin, O
methylmalonic O
acid O
and O
homocysteine) O
have O
been O
linked O
with O
cognitive O
health. O
[]

Compared O
with O
group O
C, O
serum O
norepinephrines B-outcome ['Physiological-Clinical']
in O
group O
D O
was O
significantly O
less O
(t=13.276, O
16.027, O
14.319, O
12.771, O
12.296, O
respectively; O
all O
P<0.05) O
at O
T(1), O
T(2), O
T(3), O
T(4), O
T(5).And O
there O
were O
no O
difference O
between O
these O
two O
groups O
at O
T(0), O
T(6), O
T(7), O
T(8)(all O
P>0.05). O
[['Physiological-Clinical']]

Publication O
date: O
2019/02/18 O
00:00 O
[accepted] O
[]

Publication O
date: O
2018/12/20 O
06:00 O
[entrez] O
[]

RESULTS: O
After O
10-week O
treatment, O
the O
patients O
received O
NMES O
therapy O
showed O
better O
efficacy O
in O
primary O
endpoints O
of O
urodynamic B-outcome ['Physiological-Clinical']
values O
(P O
<.01) O
and O
Overactive B-outcome ['Physiological-Clinical']
Bladder I-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
(P O
<.01), O
and O
secondary O
endpoints O
of O
International O
Consultation O
on O
Incontinence B-outcome ['Physiological-Clinical']
Questionnaire-Short O
Form O
(ICIQ-SF) O
(P O
<.01) O
and O
Barthel O
Index O
(BI) O
(P O
<.01), O
compared O
with O
patients O
who O
underwent O
sham O
NMES. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

A O
series O
of O
multivariable O
analyses O
will O
also O
be O
carried O
out O
to O
identify O
and O
control O
for O
several O
possible O
confounders O
of O
the O
major O
pregnancy B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
and O
HIV B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
Statistical O
significance O
will O
be O
defined O
as O
P O
< O
.05. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Fish O
and O
seafood O
consumption O
and O
omega-3 O
PUFA O
intake O
were O
assessed O
through O
a O
validated O
food-frequency O
questionnaire. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Randomization O
began O
on O
November O
8, O
2010. O
[]

Publication O
Type: O
Journal O
Article O
[]

However, O
no O
significant O
differences O
were O
found O
between O
groups. O
[]

In O
the O
analyses O
of O
the O
experimental O
differences O
in O
each O
group O
the O
Wilcoxon O
test O
will O
be O
used. O
[]

In O
CLA O
group, O
93 O
patients O
were O
treated O
with O
the O
same O
regimen O
except O
FZD O
was O
replaced O
by O
CLA. O
[]

Publication O
date: O
2019/01/22 O
06:00 O
[medline] O
[]

Metabolomics O
was O
employed O
to O
investigate O
cellular B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
RESULTS: O
DKD O
patients O
had O
decreased O
mtDNA B-outcome ['Physiological-Clinical']
copy I-outcome ['Physiological-Clinical']
numbers O
and O
increased O
mtDNA B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
compared O
to O
DCs. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Further O
analysis O
of O
the O
causes O
of O
this O
asymmetry O
may O
lead O
to O
more O
accurate O
treatment O
of O
PFM O
dysfunctions. O
[]

Method:Ninety O
patients O
with O
moderate O
and O
severe O
OSA O
patients O
with O
negative O
emotions O
diagnosed O
by O
PSG, O
self-rating O
depression O
scale O
(SDS) O
and O
self-rating O
anxiety O
scale O
SAS O
were O
selected O
from O
the O
respiratory O
department O
of O
our O
hospital O
from O
February O
2015 O
to O
February O
2018. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

Journal-Name:Brazilian O
oral O
research O
[]

METHODS: O
Single O
centre O
prospective O
open O
labeled O
randomised O
controlled O
clinical O
trial. O
[]

Regression O
analyses O
were O
conducted O
to O
test O
for O
differences O
by O
sponsorship O
condition O
on O
the O
respective O
outcome O
measures. O
[]

Both O
effects O
remained O
significant O
after O
controlling O
for O
preferred O
meeting O
method O
(p<0.0001 O
and O
p=0.0003, O
respectively) O
and O
among O
EM-bound O
students O
(p=.0423 O
and O
p<0.0110, O
respectively). O
[]

Hops, O
the O
immature O
inflorescences O
of O
the O
female O
hop O
plant O
(Humulus O
lupulus O
L.) O
are O
one O
of O
the O
main O
components O
of O
beer O
and O
provides O
flavor O
and O
bitterness. O
[]

Title: O
Clinical O
research O
on O
the O
efficacy O
and O
safety O
of O
Bosinji O
for O
low O
back O
pain O
with O
radiculopathy O
caused O
by O
herniated O
intervertebral O
disc O
of O
the O
lumbar O
spine: O
A O
protocol O
for O
a O
multicenter, O
randomized, O
controlled O
equivalence O
trial. O
[]

Participants O
were O
followed O
for O
1 O
year. O
[]

Primary O
efficacy O
end O
point O
was O
composite O
of O
in-hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
and O
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
at O
96 O
h, O
while O
safety O
end O
point O
was O
in-hospital B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
RESULTS: O
The O
two O
groups O
did O
not O
differ O
in O
their O
baseline O
characteristics. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
Registration O
name: O
Virtual O
Task O
in O
Amyotrophic O
Lateral O
Sclerosis; O
Registration O
number: O
NCT03113630 O
; O
retrospectively O
registered O
on O
04/13/2017. O
[]

Secondary O
endpoints O
were O
assessed O
by O
estimating O
serum O
aspartate B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
(AST) I-outcome ['Physiological-Clinical']
, O
alanine B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
(ALT) I-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
MM I-outcome ['Physiological-Clinical']
(CK-MM) I-outcome ['Physiological-Clinical']
levels O
and O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
(ADRs) I-outcome ['Adverse-effects']
. O
RESULTS: O
A O
total O
of O
61 O
patients O
were O
enrolled O
of O
which O
46 O
completed O
the O
study O
(24 O
in O
DR O
vs O
22 O
in O
EODR O
group). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Sixteen O
subjects O
with O
well-controlled O
T2DM O
(median O
HbA1c O
47 O
mmol/mol, O
(37-67 O
mmol/mol) O
and O
BMI O
30 O
+/- O
4.4 O
kg/m(2)) O
participated O
in O
the O
study. O
[]

RESULTS: O
(1) O
Clinical O
research O
results: O
all O
77 O
patients O
were O
enrolled O
in O
the O
final O
analysis, O
including O
20 O
patients O
with O
7 O
L/min O
of O
atomized O
oxygen O
flow O
under O
VCV O
mode, O
18 O
patients O
with O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
and O
21 O
patients O
with O
7 O
L/min O
of O
atomized O
oxygen O
flow O
under O
PCV O
mode O
and O
18 O
patients O
with O
9 O
L/min O
of O
atomized O
oxygen O
flow. O
[]

Publication O
date: O
2018/07/27 O
00:00 O
[accepted] O
[]

Conclusion: O
Perioperative O
application O
of O
dexmedetomidine O
can O
effectively O
decrease O
the O
perioperative O
stress B-outcome ['Physiological-Clinical']
response, O
obviously O
cut O
down O
the O
perioperative O
opioid B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
, O
and O
prevent O
the O
transition O
from O
postoperative O
acute B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
to O
chronic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
patients O
with O
radical O
resection O
of O
esophageal O
cancer O
under O
combined O
thoracoscope O
and O
laparoscope. O
[['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
patients O
were O
followed O
up O
for O
6 O
months. O
[]

Significant O
survival O
benefit O
from O
adjuvant O
chemotherapy O
was O
observed O
by O
SPC-Prediction O
in O
MSS O
and O
EBV-negative O
gastric O
cancer. O
[]

Journal-Name:Yonsei O
medical O
journal O
[]

The O
primary O
outcomes O
are O
implantation B-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rates. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/03/07 O
06:00 O
[medline] O
[]

OBJECTIVE: O
to O
measure O
the O
effect O
of O
an O
infant O
stimulation O
therapy O
(auditory, O
tactile, O
visual O
and O
vestibular) O
on O
the O
adaptation B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
postnatal I-outcome ['Physiological-Clinical']
life I-outcome ['Physiological-Clinical']
of O
the O
mother-child O
dyad. O
[['Physiological-Clinical']]

Publication O
date: O
2018/12/27 O
00:00 O
[accepted] O
[]

Journal O
ID: O
101521595 O
[]

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred. O
[['Adverse-effects']]

Publication O
Type: O
Multicenter O
Study O
[]

T O
Diabetes O
Management O
Self-Efficacy B-outcome ['Life-Impact']
Scale O
was O
completed O
at O
baseline O
6-month O
and O
12-month. O
[['Life-Impact']]

The O
children O
have O
good O
recovery B-outcome ['Physiological-Clinical', 'Life-Impact']
conditions I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
no O
obvious O
postoperative O
agitation B-outcome ['Life-Impact']
and O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
after O
DEX O
administration. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

In O
addition, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
recorded O
during O
the O
study O
period. O
[['Adverse-effects']]

There O
was O
no O
significant O
difference O
in O
gender, O
age, O
body O
mass O
index, O
the O
type O
of O
disease, O
complicating O
diseases, O
and O
American O
Society O
of O
Anesthesiologists O
grading O
between O
2 O
groups O
( O
P>0.05). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Objective: O
To O
assess O
whether O
EEG-guided O
anesthetic O
administration O
decreases O
the O
incidence O
of O
postoperative O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Design, O
Setting, O
and O
Participants: O
Randomized O
clinical O
trial O
of O
1232 O
adults O
aged O
60 O
years O
and O
older O
undergoing O
major O
surgery O
and O
receiving O
general O
anesthesia O
at O
Barnes-Jewish O
Hospital O
in O
St O
Louis. O
[['Physiological-Clinical', 'Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

After O
the O
self-affirmation O
manipulation O
was O
administered, O
we O
tracked O
participants' O
eye B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
while O
they O
viewed O
images O
of O
six O
moderately-severe O
and O
six O
highly-severe O
pictorial O
health O
warning O
labels O
presented O
on O
large O
beer O
cans. O
[['Physiological-Clinical']]

RESULTS: O
The O
3-year O
assessment O
included O
45 O
conical O
interface O
(CI), O
34 O
flat-to-flat O
interface O
(FI), O
and O
32 O
platform-switched O
interface O
(PS) O
implants O
in O
111 O
participants. O
[]

Findings O
may O
also O
be O
used O
by O
decision-makers O
interested O
in O
implementing O
the O
mhGAP-IG O
training O
in O
other O
LMICs. O
[]

CTs O
were O
performed O
due O
to O
caries O
lesions O
in O
70.4% O
of O
the O
cases O
and O
due O
to O
trauma O
in O
29.6%. O
[]

Protrusion B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
proclination B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
incisors E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
were O
greater O
in O
the O
IA O
group O
(95.90 O
degrees O
+/- O
5.34 O
degrees O
) O
compared O
with O
the O
MA O
group O
(92.04 O
degrees O
+/- O
7.92 O
degrees O
). O
[['Physiological-Clinical', 'Physiological-Clinical']]

The O
first O
lotion O
formulation O
of O
tretinoin O
was O
developed O
using O
novel O
polymerized O
emulsion O
technology O
to O
provide O
an O
important O
alternative O
option O
to O
treat O
these O
acne O
patients O
who O
may O
be O
sensitive O
to O
the O
irritant O
effects O
of O
other O
tretinoin O
formulations. O
[]

MATERIALS O
AND O
METHODS: O
For O
this O
randomized O
controlled O
clinical O
trial, O
we O
enrolled O
50 O
CKD O
patients. O
[]

ATLG O
was O
descriptively O
superior O
to O
non-ATLG O
at O
24 O
months O
for O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
(points O
estimate O
-14.8 O
[95% O
CI O
-26.4 O
to O
-3.1]; O
p=0.014) O
and O
social B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
(-19.1 O
[-38.0 O
to O
-0.2]; O
p=0.047), O
gastrointestinal B-outcome ['Physiological-Clinical']
side-effects I-outcome ['Physiological-Clinical']
(8.8 O
[2.5-15.1]; O
p=0.008) O
and O
effect O
on O
family O
(13.5 O
[1.2-25.8]; O
p=0.032). O
[['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

Patients O
with O
laryngopharyngeal O
reflux O
(LPR) O
were O
reported O
to O
suffer O
from O
hypogeusia O
that O
affects O
quality O
of O
life. O
[]

The O
44 O
patients O
were O
randomly O
assigned O
into O
a O
study O
group O
and O
a O
control O
group, O
with O
22 O
patiencs O
in O
each O
group. O
[]

MEASUREMENTS: O
Peak B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
(in O
percentage O
of O
maximal O
voluntary O
isometric O
contraction O
[%MVIC]) O
in O
the O
lower O
limbs O
during O
gait O
was O
measured O
by O
means O
of O
surface O
electromyography, O
electrogoniometry, O
and O
foot O
contact O
switches. O
[['Physiological-Clinical']]

Title: O
Preventive O
effects O
of O
galcanezumab O
in O
adult O
patients O
with O
episodic O
or O
chronic O
migraine O
are O
persistent: O
data O
from O
the O
phase O
3, O
randomized, O
double-blind, O
placebo-controlled O
EVOLVE-1, O
EVOLVE-2, O
and O
REGAIN O
studies. O
[]

Exclusion O
criteria O
were O
presence O
of O
a O
severe O
congenital O
anomaly, O
anticipated O
enteral O
fasting O
for O
longer O
than O
14 O
days, O
or O
no O
realistic O
prospect O
of O
survival. O
[]

Modelling O
of O
the O
predicted O
species O
interactions O
in O
a O
single O
DFU O
with O
high O
diversity O
indicated O
that O
networks O
of O
metabolic O
interactions O
may O
exist O
that O
contribute O
to O
the O
formation O
of O
stable O
communities. O
[]

METHODS: O
The O
prospective, O
randomized, O
single-center O
study O
was O
conducted O
at O
the O
Medical O
Department O
of O
University O
Hospital O
Dubrava, O
Zagreb, O
between O
April O
and O
June O
2018. O
[]

Journal-Name:Nutrients O
[]

Each O
diet O
was O
consumed O
on O
two O
consecutive O
days, O
separated O
by O
a O
wash-out O
period. O
[]

All O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
6-week, O
and O
12-week O
treatment. O
[]

TRIAL O
REGISTRATION: O
ISRCTN O
99322160 O
, O
01/10/2018. O
[]

Between O
weeks O
4 O
and O
40, O
the O
rate O
of O
progression B-outcome ['Physiological-Clinical']
of O
symptoms, O
as O
measured O
in O
Unified O
Parkinson's B-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Rating O
Scale O
(UPDRS) O
points O
per O
week, O
was O
0.04+/-0.23 O
in O
the O
early-start O
group O
and O
0.06+/-0.34 O
in O
the O
delayed-start O
group O
(difference, O
-0.02; O
95% O
CI, O
-0.07 O
to O
0.03). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/28 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Multicenter O
Study O
[]

There O
was O
no O
significant O
difference O
in O
the O
control O
group O
(p=0.3). O
[]

BACKGROUND: O
We O
previously O
showed O
that O
human O
anti-T-lymphocyte O
globulin O
(ATLG) O
plus O
ciclosporin O
and O
methotrexate O
given O
to O
patients O
with O
acute O
leukaemia O
in O
remission, O
having O
allogeneic O
haemopoietic O
stem-cell O
transplantation O
with O
peripheral O
blood O
stem O
cells O
from O
an O
HLA-identical O
sibling O
donor O
after O
myeloablative O
conditioning, O
significantly O
reduced O
2-year O
chronic B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
graft-versus-host I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
disease I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(cGVHD) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
incidence X ['Physiological-Clinical', 'Physiological-Clinical']
and X ['Physiological-Clinical', 'Physiological-Clinical']
severity S4-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
without O
increasing O
disease B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
and O
infections O
, O
and O
improves O
cGVHD-free O
and O
relapse-free O
survival O
(cGRFS) O
. O
The O
aim O
of O
an O
extended O
follow-up O
study O
was O
the O
assessment O
of O
long-term O
outcomes, O
which O
are, O
in O
this O
context, O
scarcely O
reported O
in O
the O
literature. O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Japanese O
journal O
of O
clinical O
oncology O
[]

Journal O
ID: O
8910750 O
[]

CONCLUSION: O
Findings O
suggest O
that O
restricting O
elite O
sport O
sponsorship O
to O
healthier O
food O
brands O
that O
meet O
set O
nutritional O
criteria O
could O
help O
promote O
healthier O
eating O
among O
young O
adults. O
[]

The O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
achieve I-outcome ['Life-Impact']
1-lung I-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
with O
the O
VDT O
was O
58.5 O
+/- O
21.5 O
(mean O
+/- O
SD) O
seconds, O
the O
VST O
was O
38.2 O
+/- O
10.1 O
(mean O
+/- O
SD) O
seconds, O
and O
the O
DT O
group O
was O
195.5 O
+/- O
40.3 O
(mean O
+/- O
SD) O
seconds. O
[['Life-Impact']]

Journal-Name:Nutrients O
[]

To O
date, O
no O
published O
study O
has O
examined O
the O
effect O
of O
an O
active, O
music-instruction O
intervention O
as O
a O
complementary O
strategy O
to O
improve O
the O
psychological O
well-being O
of O
veterans O
with O
PTSD. O
[]

These O
have O
been O
shown O
to O
be O
immunogenic O
and O
safe O
in O
European O
children; O
however, O
their O
immunogenicity O
and O
safety O
have O
not O
been O
investigated O
among O
Korean O
children. O
[]

Control O
ICUs O
(n O
= O
12; O
789 O
participants) O
delivered O
usual O
care O
in O
both O
baseline O
and O
intervention O
periods. O
[]

Total O
180 O
patients O
were O
randomly O
divided O
into O
Group O
A O
in O
which O
patients O
received O
0.2% O
bio-adhesive O
chlorhexidine O
gel O
and O
Group O
B O
where O
patients O
received O
placebo O
gel O
in O
the O
extraction O
socket O
after O
removal O
of O
mandibular O
third O
molar. O
[]

BACKGROUND: O
Schools O
have O
been O
identified O
as O
key O
environments O
to O
promote O
child O
physical O
activity O
(PA). O
[]

Selenium O
is O
a O
non-metallic O
chemical O
element O
of O
great O
importance O
to O
human O
health. O
[]

Major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
8 O
of O
405 O
patients O
(2.0%) O
in O
the O
rivaroxaban O
group O
and O
in O
4 O
of O
404 O
(1.0%) O
in O
the O
placebo O
group O
(hazard O
ratio, O
1.96; O
95% O
CI, O
0.59 O
to O
6.49). O
[['Physiological-Clinical']]

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O
[]

This O
assessment, O
part O
of O
the O
BabyGel O
Pilot O
study, O
evaluated O
the O
acceptability O
of O
the O
'Newborn O
Moments O
for O
Hand O
Hygiene O
in O
the O
Home' O
poster. O
[]

Regression-adjusted O
difference O
in O
means O
were O
used O
to O
examine O
the O
intervention's O
effectiveness O
with O
respect O
to O
PTSD B-outcome ['Physiological-Clinical', 'Life-Impact']
symptomatology I-outcome ['Physiological-Clinical', 'Life-Impact']
(primary O
outcome) O
as O
well O
as O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
perceptions B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
cognitive I-outcome ['Life-Impact']
failures I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
isolation B-outcome ['Life-Impact']
, O
and O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(secondary O
outcomes). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Approved O
by O
the O
Ethics O
Committee O
of O
Lower O
Austria O
(GS4-EK-4/107-2010). O
[]

Publication O
date: O
2018/12/22 O
06:00 O
[entrez] O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Vaccine B-outcome ['Life-Impact']
coverage O
will O
be O
analyzed O
using O
Chi-squared O
distribution O
testing O
and O
logistic O
regression O
to O
identify O
determinant O
factors. O
[['Life-Impact']]

The O
associations O
between O
any O
2 O
groups O
of O
continuous O
variables O
will O
be O
tested O
using O
the O
t O
test O
or O
the O
Mann-Whitney O
U O
test O
and O
that O
of O
2 O
groups O
of O
categorical O
variables O
with O
chi-square O
or O
Fishers O
exact O
test O
where O
appropriate. O
[]

Both O
groups O
were O
assessed O
by O
6-minute O
walk B-outcome ['Life-Impact']
test O
(6MWT)], O
chronic B-outcome ['Physiological-Clinical']
obstructive I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(COPD) I-outcome ['Physiological-Clinical']
assessment O
test O
(CAT)], O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
airflow B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
, O
dyspnea B-outcome ['Physiological-Clinical']
, O
and O
exercise B-outcome ['Physiological-Clinical', 'Life-Impact']
capacity I-outcome ['Physiological-Clinical', 'Life-Impact']
(BODE) O
index]. O
Besides, O
the O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
(FVC%, O
FEVl%) O
were O
measured O
at O
6 O
months O
before O
and O
after O
treatment. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

OBJECTIVE: O
To O
develop O
an O
intervention O
protocol O
for O
children's O
unintentional O
injury O
risk O
behaviors, O
and O
to O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
of O
the O
protocol. O
[['Life-Impact']]

Participants O
in O
the O
experimental O
group O
participated O
in O
a O
24-week O
TC O
training O
program O
(three O
60-min O
sessions O
per O
week), O
whereas O
individuals O
in O
the O
control O
group O
maintained O
their O
unaltered O
lifestyle. O
[]

Journal-Name:Medicine O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
HIIT O
and O
MICT O
groups O
were O
offered O
three O
exercise O
sessions O
per O
week O
for O
the O
first O
12 O
weeks. O
[]

There O
were O
30 O
statistically O
significant O
metabolite B-outcome ['Physiological-Clinical']
differences O
in O
the O
stool O
of O
participants O
that O
consumed O
navy O
bean O
at O
day O
28 O
compared O
to O
the O
participants' O
baseline O
(p O
</= O
0.05) O
and O
26 O
significantly O
different O
metabolites B-outcome ['Physiological-Clinical']
when O
compared O
to O
the O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
goal O
of O
the O
study O
was O
to O
evaluate O
the O
results O
of O
medial O
patellofemoral O
ligament O
reconstruction O
in O
children. O
[]

Secondary O
endpoints O
include O
symptomatic B-outcome ['Physiological-Clinical']
malaria I-outcome ['Physiological-Clinical']
, O
Polymerase O
Chain O
Reaction O
(PCR)-detectable O
Plasmodium B-outcome ['Physiological-Clinical']
spp I-outcome ['Physiological-Clinical']
Infections I-outcome ['Physiological-Clinical']
, O
molecular O
markers O
of O
drug B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and O
antibodies B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
for O
Plasmodium O
spp O
Parasites O
. O
DISCUSSION: O
This O
study O
has O
been O
approved O
by O
relevant O
institutional O
ethics O
committees O
in O
Myanmar O
and O
Australia. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Surgical O
quality O
assurance O
was O
implemented O
by O
the O
credentialing O
of O
surgeons, O
standardization O
of O
technique, O
and O
monitoring O
of O
performance. O
[]

GovNCT01996241 O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS: O
A O
total O
of O
60 O
T2DM O
patients O
were O
divided O
into O
2 O
groups O
according O
to O
the O
presence O
of O
MVC: O
T2DM O
+ O
MVC O
group O
(n=30) O
and O
T2DM O
group O
(n=30). O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Bispectral I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BIS) I-outcome ['Physiological-Clinical']
60 I-outcome ['Physiological-Clinical']
and O
rocuronium B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
were O
longer O
in O
the O
Group O
R O
(P O
< O
.01 O
and O
P O
< O
.01, O
respectively). O
[['Physiological-Clinical'], ['Life-Impact']]

BACKGROUND: O
Mothers O
in O
Motion O
(MIM), O
a O
community-based O
intervention O
program, O
was O
designed O
to O
help O
young, O
low-income O
women O
with O
overweight O
or O
obesity O
prevent O
further O
weight O
gain O
by O
promoting O
stress O
management, O
healthy O
eating, O
and O
physical O
activity. O
[]

Owing O
to O
the O
multifactorial O
nature O
of O
wound O
complications, O
it O
is O
yet O
to O
be O
determined O
which O
cohorts O
of O
pancreatectomy O
patients O
will O
benefit O
from O
NPWT. O
[]

Under O
VCV O
mode, O
the O
levels O
of O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
were O
increased O
with O
the O
increase O
in O
atomized O
oxygen O
flow, O
and O
there O
was O
significant O
difference O
at O
9 O
L/min O
as O
compared O
with O
those O
before O
atomization O
[ O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(cmH2O): O
29.44+/-4.58 O
vs. O
24.39+/-4.64, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(mL): O
896.26+/-24.91 O
vs. O
497.61+/-8.67, O
both O
P O
< O
0.05]. O
There O
was O
no O
significant O
change O
in O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
no O
significant O
difference O
at O
9 O
L/min O
of O
atomized O
oxygen O
flow O
as O
compared O
with O
that O
before O
atomization O
(mL: O
494.67+/-3.07 O
vs. O
492.61+/-6.05, O
P O
> O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Among O
the O
440 O
patients O
randomized O
(mean O
age, O
60.5 O
years; O
15% O
women), O
the O
primary O
end O
point O
was O
achieved O
in O
396 O
patients O
(90%), O
17 O
(3.9%) O
withdrew, O
and O
all O
others O
were O
followed O
up O
to O
3 O
months. O
[]

All O
participants O
received O
allotments O
of O
extra-virgin O
olive O
oil O
(1 O
L/mo) O
and O
nuts O
(125 O
g/mo) O
for O
free. O
[]

In O
our O
adjusted O
multivariable O
regression O
models, O
SPOC O
scores O
at O
6 O
weeks O
post-surgery O
accounted O
for O
10% O
of O
the O
variation O
in O
short O
form-12 O
physical B-outcome ['Life-Impact']
component O
summary O
scores O
and O
14% O
of O
short O
form-12 O
mental B-outcome ['Life-Impact']
component O
summary O
scores O
at O
1 O
yr. O
[['Life-Impact'], ['Life-Impact']]

CONCLUSION: O
Preoperative O
low-dose O
MDCT O
should O
be O
used O
for O
diagnosis O
of O
uncontrolled O
chronic O
rhinosinusitis O
for O
decision O
making O
of O
sinus O
surgeries. O
[]

Publication O
date: O
2019/02/09 O
06:00 O
[medline] O
[]

Delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
during O
postoperative O
days O
1 O
to O
5 O
occurred O
in O
157 O
of O
604 O
patients O
(26.0%) O
in O
the O
guided O
group O
and O
140 O
of O
609 O
patients O
(23.0%) O
in O
the O
usual O
care O
group O
(difference, O
3.0% O
[95% O
CI, O
-2.0% O
to O
8.0%]; O
P O
= O
.22). O
[['Physiological-Clinical', 'Life-Impact']]

In O
the O
AGS O
group, O
allogeneic B-outcome ['Resource-use']
blood I-outcome ['Resource-use']
was O
infused O
in O
1 O
case O
during O
operation, O
and O
no O
allogeneic B-outcome ['Resource-use']
blood I-outcome ['Resource-use']
was O
infused O
in O
the O
other O
patients. O
[['Resource-use'], ['Resource-use']]

CLINICAL O
TRIAL O
REGISTRATION: O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
(ANZCTR) O
registration O
number O
ACTRN12618000368235 O
. O
[]

Surgical O
site O
infection O
(SSI) O
and O
incisional O
hernia O
are O
common O
complications O
after O
major O
pancreatectomy. O
[]

Oxidant/antioxidant B-outcome ['Physiological-Clinical']
status O
and O
markers O
of O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
were O
evaluated O
in O
24 O
elite O
football O
players O
and O
15 O
controls. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

SUMMARY O
OF O
KEY O
POINTS: O
This O
is O
a O
case-series O
report O
using O
data O
previously O
collected O
for O
a O
discontinued O
randomized O
controlled O
trial, O
in O
which O
participants O
received O
hippotherapy O
or O
standard O
outpatient O
clinic O
PT O
for O
a O
12-week O
treatment O
period. O
[]

In O
the O
patient-level O
meta-analysis, O
the O
percentage O
of O
patients O
who O
were O
free O
from O
recurrence B-outcome ['Physiological-Clinical']
at O
6 O
months O
was O
67.0% O
(95% O
CI, O
61.0 O
to O
72.3) O
among O
the O
426 O
patients O
in O
the O
tafenoquine O
group O
and O
72.8% O
(95% O
CI, O
65.6 O
to O
78.8) O
among O
the O
214 O
patients O
in O
the O
primaquine O
group. O
[['Physiological-Clinical']]

Journal O
ID: O
101217089 O
[]

Journal-Name:Reproductive O
health O
[]

Our O
purpose O
was O
to O
investigate O
the O
effectiveness O
and O
cost-effectiveness O
of O
three O
intervention-arms O
(combined O
neuromuscular O
exercise O
and O
back O
care O
counselling O
or O
either O
alone) O
compared O
with O
non-treatment. O
[]

In O
total, O
27 O
participants, O
inexperienced O
in O
spinal O
ultrasonography, O
were O
enrolled O
and O
allocated O
to O
1 O
of O
2 O
groups O
(training O
group, O
n O
= O
18; O
control O
group, O
n O
= O
9). O
[]

Title: O
Study O
on O
the O
safety O
of O
Polygala O
tenuifolia O
Willdenow O
root O
extract O
powder O
(BT-11) O
in O
young O
person O
aged O
from O
9 O
to O
19 O
years O
old. O
[]

In O
addition, O
the O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(TBL), O
hidden B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(HBL) I-outcome ['Physiological-Clinical']
, O
maximum O
hemoglobin B-outcome ['Physiological-Clinical']
(Hb) I-outcome ['Physiological-Clinical']
drop, O
fibrinolytic B-outcome ['Physiological-Clinical']
activity, O
as O
well O
as O
incidence O
of O
thromboembolism B-outcome ['Physiological-Clinical']
were O
measured. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:BMC O
psychology O
[]

Exhausted O
cluster O
of O
differentiation O
(CD)8+ O
T O
cells O
lose O
immunological O
activity O
due O
to O
mitochondrial O
dysfunction O
caused O
by O
peroxisome O
proliferatoractivated O
receptor O
gamma O
coactivator O
1alpha O
(PGC1alpha) O
inactivation, O
resulting O
in O
a O
poor O
prognosis O
in O
patients O
with O
cancer. O
[]

Journal-Name:Respiratory O
research O
[]

Vital O
status O
was O
not O
known O
for O
2.3% O
of O
the O
patients O
at O
10 O
years. O
[]

The O
follow O
up O
period O
was O
6 O
months. O
[]

METHOD: O
A O
prospective O
randomised, O
single O
centre O
parallel O
group O
trial O
comparing O
an O
8-week O
individualised O
multidisciplinary O
intervention O
programme O
(bespoke O
physiotherapy O
and O
occupational O
therapy O
in O
the O
clinical, O
home O
and O
school O
environment) O
with O
current O
standard O
management O
(advice, O
information O
and O
therapy O
referral O
if O
deemed O
necessary). O
[]

PSE O
was O
well O
tolerated B-outcome ['Life-Impact']
as O
evidenced O
by O
no O
effects O
observed O
in O
the O
blood B-outcome ['Physiological-Clinical']
safety O
panels. O
[['Life-Impact'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
Australian O
and O
New O
Zealand O
Clinical O
Trials O
Registry O
( O
ACTRN12616001434482 O
). O
[]

BACKGROUND: O
This O
study O
aimed O
to O
evaluate O
the O
effectiveness O
of O
neuromuscular O
electrical O
stimulation O
(NMES) O
therapy O
for O
chronic O
urinary O
retention O
(CUR) O
following O
traumatic O
brain O
injury O
(TBI). O
[]

The O
change O
in O
Unified O
Parkinson's B-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Rating O
Scale O
(UPDRS) O
score O
from O
baseline O
to O
week O
80 O
was O
-1.0+/-13.1 O
points O
and O
-2.0+/-13.0 O
points, O
respectively O
(difference, O
1.0 O
point; O
95% O
confidence O
interval O
[CI], O
-1.5 O
to O
3.5; O
P=0.44); O
this O
finding O
of O
no O
significant O
between-group O
difference O
at O
week O
80 O
implies O
that O
levodopa O
had O
no O
disease-modifying O
effect. O
[['Physiological-Clinical']]

All O
patients O
were O
anaesthetized O
(induced O
and O
maintained) O
with O
intravenous O
target-controlled O
infusion(TCl) O
of O
propofol O
and O
remifentanil, O
and O
intermittent O
intravenous O
injection O
of O
cisatracuriumbesylate. O
[]

Publication O
date: O
2019/03/07 O
06:00 O
[medline] O
[]

In O
the O
control O
group, O
no O
changes O
were O
observed O
with O
the O
exception O
of O
an O
increase O
of O
sNox2-dp B-outcome ['Physiological-Clinical']
, O
H2O2 B-outcome ['Physiological-Clinical']
, O
and O
myoglobin B-outcome ['Physiological-Clinical']
. O
A O
simple O
linear O
regression O
analysis O
showed O
that O
sNox2-dp B-outcome ['Physiological-Clinical']
was O
associated O
with O
a O
significant O
increase O
in O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
biomarker O
release O
(p O
= O
0.001). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Journal O
of O
ethnopharmacology O
[]

RESULTS: O
Gastrocnemius B-outcome ['Physiological-Clinical']
medialis I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
during O
mid O
stance O
(23.46%MVIC, O
95% O
CI O
= O
-32.53, O
-14.39) O
and O
late O
stance O
phases O
(3.25%MVIC, O
95% O
CI O
= O
-5.67, O
-0.81) O
of O
gait O
increased O
after O
the O
application O
of O
KT O
in O
the O
KT O
group O
compared O
to O
baseline O
values. O
[['Physiological-Clinical']]

In O
intervention O
arm, O
one O
child O
had O
rheumatic B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RHD) I-outcome ['Physiological-Clinical']
while O
three O
had O
congenital B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
; O
in O
control O
arm, O
one O
child O
had O
congenital B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
and O
three O
had O
rheumatic B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RHD) I-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
School O
based O
surveillance O
had O
higher O
rate O
of O
suspecting O
children O
with O
acute B-outcome ['Physiological-Clinical']
pharyngitis I-outcome ['Physiological-Clinical']
and O
or O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RF/RHD) I-outcome ['Physiological-Clinical']
although O
with O
low O
specificity. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Pain B-outcome ['Physiological-Clinical']
VAS O
scores O
at O
rest O
and O
at O
flexion O
were O
both O
lower O
in O
preoperative O
analgesia O
group O
compared O
to O
postoperative O
analgesia O
group O
at O
2 O
hours, O
6 O
hours, O
12 O
hours, O
and O
24 O
hours O
post O
operation. O
[['Physiological-Clinical']]

MATERIAL O
AND O
METHODS: O
Thirty-six O
elite O
male O
rowers O
(27 O
+/- O
6 O
years) O
were O
assigned O
to O
one O
of O
the O
two O
groups O
randomly: O
1) O
Control O
group O
(CG, O
n O
= O
18, O
height: O
181.05 O
+/- O
3.39 O
cm O
and O
body O
mass: O
77.02 O
+/- O
7.55 O
kg), O
2) O
Group O
treated O
with O
3,000 O
IU O
of O
vitamin O
D3/day O
(VD3G, O
s O
= O
18, O
height: O
179.70 O
+/- O
9.07 O
cm O
and O
body O
mass: O
76.19 O
+/- O
10.07 O
kg). O
[]

The O
basic O
antianginal O
therapy O
was O
allowed O
to O
use O
in O
both O
groups: O
beta-blockers, O
calcium O
antagonists, O
ATE O
inhibitors O
/ O
angiotensin O
II O
receptor O
blockers, O
statins, O
acetylsalicylic O
acid, O
blockers O
of O
P2Y12 O
receptor O
platelets. O
[]

METHODS: O
The O
study O
was O
designed O
as O
a O
prospective, O
delayed-entry O
randomized O
pilot O
trial. O
[]

The O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
rate O
at O
3 O
years O
was O
39.7% O
in O
the O
modified-FOLFIRINOX O
group O
and O
21.4% O
in O
the O
gemcitabine O
group. O
[['Physiological-Clinical', 'Mortality']]

The O
drug O
Simvastatin O
may O
help O
to O
protect O
donor O
livers O
against O
this O
damage O
and O
improve O
outcomes O
for O
transplant O
recipients. O
[]

Publication O
date: O
2019/01/18 O
06:00 O
[entrez] O
[]

Title: O
Spirulina O
maxima O
Decreases O
Endothelial B-outcome ['Physiological-Clinical']
Damage I-outcome ['Physiological-Clinical']
and O
Oxidative B-outcome ['Physiological-Clinical']
Stress I-outcome ['Physiological-Clinical']
Indicators O
in O
Patients O
with O
Systemic O
Arterial O
Hypertension: O
Results O
from O
Exploratory O
Controlled O
Clinical O
Trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Revista O
da O
Associacao O
Medica O
Brasileira O
(1992) O
[]

Objective: O
To O
evaluate O
the O
effect O
of O
postoperative O
intravenous O
(IV) O
acetaminophen O
(paracetamol) O
vs O
placebo O
combined O
with O
IV O
propofol O
vs O
dexmedetomidine O
on O
postoperative O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
among O
older O
patients O
undergoing O
cardiac O
surgery. O
[['Physiological-Clinical', 'Life-Impact']]

Fifty O
patients O
(56%) O
in O
the O
amoxicillin O
group O
experienced O
at O
least O
one O
drug O
related O
adverse B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
compared O
with O
31 O
(34%) O
in O
the O
placebo O
group. O
[['Adverse-effects']]

Journal O
ID: O
0255562 O
[]

OBJECTIVE: O
We O
conducted O
this O
study O
to O
compare O
the O
efficacy O
and O
safety O
of O
entecavir O
and O
tenofovir O
in O
the O
treatment O
of O
treatment-naive O
HBV O
e O
antigen O
(HBeAg)-positive O
patients O
with O
chronic O
hepatitis O
B O
(CHB) O
for O
144 O
weeks. O
[]

The O
same O
evaluation O
was O
used O
18 O
to O
30 O
months O
postoperatively O
to O
estimate O
the O
results O
of O
our O
treatment. O
[]

Consumption O
of O
WPI O
significantly O
improved O
active B-outcome ['Physiological-Clinical']
B12 I-outcome ['Physiological-Clinical']
and O
folate B-outcome ['Physiological-Clinical']
status O
but O
did O
not O
result O
in O
direct O
improvements O
in O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
. O
However, O
there O
was O
evidence O
of O
improvement O
in O
reaction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
(p O
= O
0.02) O
and O
reasoning B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
(p O
= O
0.04) O
in O
the O
SPI O
condition O
for O
females. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Publication O
date: O
2019/02/19 O
06:00 O
[entrez] O
[]

There O
was O
no O
statistically O
significant O
difference O
between O
the O
bracket O
adhesives O
in O
the O
numbers O
with O
at O
least O
1 O
new O
demineralized B-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
(risk O
ratio,1.25; O
95% O
confidence O
interval, O
0.74-2.13; O
P O
= O
0.403) O
or O
first-time O
bracket O
failure O
(risk O
ratio,0.88; O
95% O
confidence O
interval, O
0.67-1.16; O
P O
= O
0.35). O
[['Physiological-Clinical']]

Recruitment O
was O
from O
January O
2015 O
to O
May O
2018, O
with O
follow-up O
until O
July O
2018. O
[]

There O
was O
no O
difference O
in O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
between O
those O
in O
the O
enhanced O
SOC O
and O
the O
SOC O
groups. O
[['Life-Impact']]

Publication O
date: O
2018/12/14 O
06:00 O
[pubmed] O
[]

INTERPRETATION: O
The O
addition O
of O
ATLG O
to O
standard O
GVHD O
prophylaxis O
improves O
the O
probability O
of O
surviving B-outcome ['Mortality']
without O
disease B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
and O
cGVHD B-outcome ['Physiological-Clinical']
after O
myeloablative O
peripheral O
blood O
stem-cell O
transplantation O
from O
an O
HLA-identical O
sibling O
donor O
for O
patients O
with O
acute O
leukaemia O
in O
remission. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/17 O
06:00 O
[entrez] O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

RESULTS: O
the O
adaptive B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
was O
measured O
in O
two O
modes. O
[['Physiological-Clinical']]

CONCLUSIONS: O
The O
results O
of O
this O
clinical O
trial O
suggest O
that O
trigger O
point O
dry O
needling O
in O
patients O
with O
chronic O
tension-type O
headache O
is O
effective O
and O
safe O
in O
reducing O
headache B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
, Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
frequency X ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
duration S1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
, O
and O
increasing O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
TRIAL O
REGISTRATION: O
Clinical O
Trials O
NCT03500861. O
[['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical'], ['Life-Impact']]

Compared O
to O
controls, O
elite O
football O
players O
showed O
lower O
antioxidant B-outcome ['Physiological-Clinical']
power I-outcome ['Physiological-Clinical']
and O
higher O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
paralleled O
by O
an O
increase O
in O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
markers. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

School O
physical O
education O
(PE) O
is O
an O
important O
existing O
network O
in O
which O
participation O
in O
physical O
activity O
beyond O
school O
can O
be O
promoted O
to O
the O
captive O
young O
people. O
[]

Title: O
Effectiveness O
of O
brief O
group O
intervention O
in O
the O
harmful O
alcohol O
use O
in O
primary O
health O
care. O
[]

BACKGROUND O
AND O
PURPOSE: O
Self-efficacy O
is O
considered O
as O
one O
of O
the O
influential O
parameters O
affecting O
the O
health O
of O
patients. O
[]

METHODS: O
Sixty-six O
female O
patients O
with O
American O
Society O
of O
Anesthesiologists O
I, O
II, O
or O
III, O
aged O
18 O
to O
65 O
years O
who O
were O
scheduled O
for O
laparoscopic O
hysterectomy O
for O
benign O
gynecologic O
pathologies O
were O
recruited O
in O
this O
randomized, O
controlled, O
observer-blinded O
trial. O
[]

METHODS: O
The O
research O
is O
a O
prospective O
comparative O
randomized O
study. O
[]

In O
Group O
A O
(12%) O
patients O
had O
infection B-outcome ['Physiological-Clinical']
and O
(88%) O
whereas O
in O
Group O
B O
(20%) O
patients O
had O
infection B-outcome ['Physiological-Clinical']
and O
(80%) O
patients O
did O
n't O
had O
infection B-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
Simultaneous O
VP O
shunting O
was O
more O
effective O
than O
delayed O
VP O
shunting O
in O
children O
undergoing O
myelomeningocele O
in O
terms O
of O
infection B-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

There O
is O
a O
paucity O
of O
research O
on O
the O
determinants O
of O
psychological O
distress, O
particularly O
among O
the O
poorest O
girls O
in O
the O
poorest O
communities. O
[]

Title: O
[Effects O
of O
rhodiola O
rosea O
on O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
negative B-outcome ['Physiological-Clinical']
emotional I-outcome ['Physiological-Clinical']
states I-outcome ['Physiological-Clinical']
in O
patients O
with O
obstructive O
sleep O
apnea]. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Music O
therapy O
is O
used O
as O
a O
nonpharmacologic O
intervention O
for O
pain O
management O
and O
to O
promote O
rehabilitation O
exercise O
adherence. O
[]

Journal-Name:Journal O
of O
music O
therapy O
[]

Journal O
ID: O
100968562 O
[]

Ethical O
approval O
for O
the O
study O
was O
obtained O
from O
the O
LUTH's O
Health O
Research O
and O
Ethics O
Committee O
(Approval O
number: O
ADM/DCST/HREC/APP/2438; O
30th O
August O
2018). O
[]

1-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
25% O
in O
both O
groups. O
[['Mortality']]

AIMS: O
Cementless O
primary O
total O
hip O
arthroplasty O
(THA) O
is O
associated O
with O
risks O
of O
bleeding O
and O
thromboembolism. O
[]

STD O
group O
learned O
identical O
content O
using O
a O
low-fidelity O
Resusci O
Anne(R) O
CPR O
manikin. O
[]

The O
disease B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
rate O
of O
the O
apatinib O
group O
was O
significantly O
better O
than O
that O
of O
the O
observation O
group O
(70.4% O
vs O
26.9%, O
P O
= O
.002). O
[['Physiological-Clinical']]

The O
addition O
of O
tazarotene O
affords O
sustained O
benefits O
posttreatment. O
[]

Unchanged B-outcome ['Physiological-Clinical']
rate, O
transfer B-outcome ['Physiological-Clinical']
rate O
of O
patients, O
rate O
of O
impaired B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
, O
turn B-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
rate O
and O
other O
biochemical O
indicators O
of O
patients O
and O
people O
with O
impaired O
glucose O
tolerance O
from O
control O
group O
and O
intervention O
group O
were O
analyzed, O
to O
evaluate O
the O
intervention O
effects O
of O
peer O
support O
education O
mode. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Material O
and O
methods: O
A O
randomized, O
longitudinal O
and O
prospective O
clinical O
study O
was O
conducted. O
[]

Title: O
Randomized O
phase O
II/III O
trial O
of O
neoadjuvant O
chemotherapy O
with O
gemcitabine O
and O
S-1 O
versus O
upfront O
surgery O
for O
resectable O
pancreatic O
cancer O
(Prep-02/JSAP05). O
[]

CONCLUSIONS: O
Our O
evidence O
showed O
that O
the O
brief O
group O
intervention O
performed O
by O
the O
nurse O
in O
the O
primary O
health O
care O
context O
was O
effective O
to O
reduce O
alcohol B-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
in O
individuals O
with O
patterns O
of O
hazardous O
or O
harmful O
use. O
[['Physiological-Clinical']]

Title: O
Citrus O
Aurantium O
and O
caffeine O
complex O
versus O
placebo O
on O
biomarkers O
of O
metabolism B-outcome ['Physiological-Clinical']
: O
a O
double O
blind O
crossover O
design. O
[['Physiological-Clinical']]

Publication O
date: O
['2019/10/17 O
06:00' O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

Preoperatively, O
all O
patients O
were O
evaluated O
clinically O
( O
Kujala O
score O
questionnaire]) O
and O
radiologically. O
[]

Methods: O
Chemotherapy-naive O
patients O
were O
randomized O
(1:1:1) O
to O
a O
single O
oral O
netupitant O
30-, O
100- O
or O
300-mg O
dose O
before O
chemotherapy O
initiation. O
[]

Hagstrom, O
AD, O
Shorter, O
KA, O
and O
Marshall, O
PWM. O
[]

METHODS: O
Patients O
who O
were O
referred O
to O
Veterans O
Affairs O
(VA) O
gastroenterology O
clinics O
for O
PPI-refractory O
heartburn O
received O
20 O
mg O
of O
omeprazole O
twice O
daily O
for O
2 O
weeks, O
and O
those O
with O
persistent O
heartburn O
underwent O
endoscopy, O
esophageal O
biopsy, O
esophageal O
manometry, O
and O
multichannel O
intraluminal O
impedance-pH O
monitoring. O
[]

Cost-effectiveness O
ratios O
of O
FZD O
and O
CLA O
groups O
were O
0.75 O
and O
1.02, O
and O
incremental O
cost-effectiveness O
ratio O
of O
FZD O
group O
over O
CLA O
group O
was O
-3.62. O
[]

Publication O
date: O
2018/12/04 O
00:00 O
[accepted] O
[]

The O
initial O
dose O
of O
bupivacaine O
in O
the O
2 O
groups O
was O
4 O
mg, O
and O
the O
subsequent O
dose O
for O
the O
following O
patient O
was O
depended O
on O
the O
probability O
of O
the O
current O
dose. O
[]

From O
weeks O
12 O
- O
24, O
the O
total O
number O
of O
new O
gadolinium-enhancing B-outcome ['Physiological-Clinical']
(Gd(+)) I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
was O
reduced O
by O
84% O
(p O
< O
0.0001) O
in O
DMF O
compared O
with O
placebo. O
[['Physiological-Clinical']]

After O
suitable O
training, O
patients O
performed O
daily O
spirometry O
at O
home O
using O
a O
portable, O
battery-operated O
spirometer. O
[]

The O
appointment O
of O
the O
oral O
form O
of O
nicorandil O
(Cordinic, O
PIQ-FHARMA O
LLC) O
for O
2 O
days O
and O
1 O
day O
before O
PCI O
30 O
mg/day, O
then O
20 O
mg O
2 O
hours O
before O
the O
PCI O
and O
10 O
mg O
after O
6 O
hours O
after O
the O
surgery O
reduces O
the O
risk O
of O
intraoperative O
myocardial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
The O
obtained O
data O
give O
an O
opportunity O
to O
extend O
the O
indications O
for O
nicorandil's O
appointment O
in O
the O
drug O
support O
during O
PCI O
in O
patients O
with O
stable O
coronary O
artery O
disease. O
[['Physiological-Clinical']]

RESULTS: O
Of O
the O
68 O
Veterans O
who O
were O
self- O
or O
provider-referred O
to O
the O
program, O
25 O
(36.7%) O
were O
ineligible O
due O
to O
(i) O
absence O
of O
a O
PTSD O
diagnosis O
(n O
= O
3); O
participation O
in O
ongoing O
intense O
psychotherapy O
(n O
= O
4) O
or O
inpatient O
substance O
abuse O
program O
(n O
= O
2); O
current O
resident O
of O
the O
Domiciliary O
(n O
= O
8) O
and O
inability O
to O
participate O
due O
to O
distance O
of O
residence O
from O
the O
VA O
(n O
= O
8). O
[]

Publication O
Type: O
Journal O
Article O
[]

Title: O
Decolonization O
to O
Reduce O
Postdischarge O
Infection B-outcome ['Physiological-Clinical']
Risk O
among O
MRSA O
Carriers. O
[['Physiological-Clinical']]

Results: O
Among O
6874 O
randomized O
participants O
(mean O
[SD] O
age, O
65.0 O
[4.9] O
years; O
3406 O
[52%] O
men), O
6583 O
(96%) O
completed O
the O
12-month O
follow-up O
and O
were O
included O
in O
the O
main O
analysis. O
[]

Journal O
ID: O
8216186 O
[]

RESULTS: O
A O
total O
of O
1773 O
adult O
patients O
with O
episodic O
migraine O
(n O
= O
444 O
for O
galcanezumab O
120 O
mg; O
n O
= O
435 O
for O
galcanezumab O
240 O
mg; O
n O
= O
894 O
for O
placebo O
for O
2 O
studies O
pooled) O
and O
1113 O
patients O
with O
chronic O
migraine O
(n O
= O
278 O
for O
galcanezumab O
120 O
mg; O
n O
= O
277 O
for O
galcanezumab O
240 O
mg; O
n O
= O
558 O
for O
placebo) O
were O
evaluated. O
[]

There O
were O
no O
statistically O
significant O
effects O
for O
pedaling O
adherence B-outcome ['Life-Impact']
. O
Conclusions O
show O
an O
important O
role O
for O
live O
music O
therapy O
intervention O
on O
observed O
pain B-outcome ['Physiological-Clinical']
while O
engaged O
in O
co-treatment O
during O
this O
lower O
extremity O
ROM O
exercise. O
[['Life-Impact'], ['Physiological-Clinical']]

Journal O
ID: O
101160020 O
[]

The O
menstrual O
disturbances O
as O
a O
health O
problem O
among O
young O
girls O
affect O
not O
only O
reproductive, O
but O
also O
psychical O
health O
and O
quality O
of O
life. O
[]

RESULTS: O
There O
were O
49 O
patients O
allocated O
to O
receive O
misoprostol O
and O
38 O
allocated O
to O
receive O
placebo; O
the O
incidence O
of O
a O
20 O
g/L O
decrease O
in O
hemoglobin B-outcome ['Physiological-Clinical']
was O
similar O
between O
the O
groups O
(20/43 O
[47%] O
vs O
19/33 O
[58%], O
respectively; O
P=0.335). O
[['Physiological-Clinical']]

There O
were O
no O
differences O
in O
the O
baseline O
characteristics O
and O
outcome O
of O
ovarian O
stimulation O
between O
the O
two O
groups. O
[]

We O
hypothesized O
that O
this O
high-fidelity O
cricothyroidotomy O
simulator O
results O
in O
increased O
proficiency B-outcome ['Life-Impact']
for O
needle O
cricothyroidotomy O
compared O
with O
conventional O
simulators. O
[['Life-Impact']]

The O
presence O
of O
acute O
uncomplicated O
cystitis O
symptoms O
was O
recorded O
and O
urinalysis O
was O
performed. O
[]

Publication O
date: O
2019/01/29 O
06:00 O
[medline] O
[]

A O
3-way O
repeated O
measures O
ANOVA O
was O
employed O
for O
main O
analyses, O
with O
Bonferonni O
post-hoc O
assessment O
(P O
</= O
0.05). O
[]

OBJECTIVE: O
To O
compare O
the O
chest O
tube O
drainage O
by O
the O
same O
thoracotomy O
intercostal O
space O
with O
the O
traditional O
approach O
in O
patients O
undergoing O
muscle-sparing O
thoracotomy. O
[]

RESULTS: O
We O
observed O
a O
significant O
effect O
of O
the O
treatment O
in O
both O
the O
physical B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
task X ['Life-Impact', 'Life-Impact']
subscales X ['Life-Impact', 'Life-Impact']
of X ['Life-Impact', 'Life-Impact']
the X ['Life-Impact', 'Life-Impact']
global B-outcome ['Life-Impact', 'Life-Impact']
quality I-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
life E3-outcome ['Life-Impact', 'Life-Impact']
(GQoL) O
(P O
= O
.01 O
and O
P O
= O
.04, O
respectively) O
and O
also O
in O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
specific O
for O
CD O
(P O
</=.0001) O
but O
not O
in O
pain B-outcome ['Physiological-Clinical']
score O
(P O
= O
.28). O
[['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS: O
Soft, O
non-manipulative O
osteopathic O
treatment O
is O
effective O
in O
improving O
overall B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
physical-related B-outcome ['Life-Impact', 'Life-Impact']
quality I-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
life E3-outcome ['Life-Impact', 'Life-Impact']
in O
CD O
patients, O
regardless O
of O
the O
phase O
of O
the O
disease. O
[['Life-Impact', 'Life-Impact']]

Moreover, O
results O
prove O
that O
participants O
positively O
respond B-outcome ['Life-Impact']
to O
health-related O
information, O
whereas O
information O
on O
bitterness-taste O
generates O
lower O
preferences B-outcome ['Life-Impact']
. O
[['Life-Impact'], ['Life-Impact']]

CONCLUSION: O
The O
RSB O
analgesia O
could O
significantly O
enhance O
patient O
satisfaction B-outcome ['Life-Impact']
following O
midline O
laparotomy. O
[['Life-Impact']]

Funded O
by O
the O
AHRQ O
Healthcare-Associated O
Infections O
Program O
and O
others; O
ClinicalTrials.gov O
number, O
NCT01209234 O
.). O
[]

Publication O
date: O
2018/12/18 O
00:00 O
[accepted] O
[]

Though O
much O
of O
this O
risk O
is O
mitigated O
with O
trigger O
using O
gonadotropin O
releasing-hormone O
(GnRH) O
agonist O
alone, O
it O
may O
result O
in O
lower O
birth O
rates. O
[]

Title: O
[Effects O
of O
early O
enteral O
nutrition O
in O
patients O
with O
mild O
acute O
pancreatitis. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Lifestyle B-outcome ['Life-Impact', 'Life-Impact']
was O
assessed O
using O
questionnaires O
and O
weight B-outcome ['Physiological-Clinical']
was O
measured O
at O
baseline, O
3 O
and O
6 O
months O
after O
randomization. O
[['Life-Impact', 'Life-Impact'], ['Physiological-Clinical']]

Objective: O
To O
assess O
the O
effect O
of O
a O
nutritional O
and O
physical O
activity O
education O
program O
on O
dietary B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
. O
Design, O
Setting, O
and O
Participants: O
Preliminary O
exploratory O
interim O
analysis O
of O
an O
ongoing O
randomized O
trial. O
[['Life-Impact']]

SETTING: O
60 O
midwifery O
practices O
in O
the O
Netherlands. O
[]

Journal O
ID: O
0313225 O
[]

DESIGN: O
Open O
randomized O
monocentric O
study. O
[]

Compliance B-outcome ['Life-Impact']
rates O
varied O
between O
intervention-arms. O
[['Life-Impact']]

T O
Lund-Mackay O
score], O
modified O
Lund-Mackay O
score], O
estimated B-outcome ['Life-Impact']
radiation I-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
, O
and O
surgical B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
were O
evaluated O
for O
each O
patient. O
[['Life-Impact'], ['Adverse-effects']]

Publication O
Type: O
Journal O
Article O
[]

Journal O
ID: O
9425194 O
[]

CONCLUSION: O
Oral O
supplementation O
with O
3000 O
IU/day O
of O
vitamin O
D3 O
during O
eight O
weeks O
showed O
to O
be O
sufficient O
to O
prevent O
a O
decline O
in O
hematological O
levels O
of O
haemoglobin B-outcome ['Physiological-Clinical']
and O
haematocrit B-outcome ['Physiological-Clinical']
, O
and O
improve O
transferrin B-outcome ['Physiological-Clinical']
of O
25(OH)D O
levels. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:BMC O
public O
health O
[]

BACKGROUND: O
Observational O
data O
have O
shown O
that O
slow O
advancement O
of O
enteral O
feeding O
volumes O
in O
preterm O
infants O
is O
associated O
with O
a O
reduced O
risk O
of O
necrotizing O
enterocolitis O
but O
an O
increased O
risk O
of O
late-onset O
sepsis. O
[]

Journal-Name:Medicine O
[]

RESULTS: O
After O
4-week O
treatment, O
the O
patients O
undergoing O
verum O
TENS O
showed O
statistically O
efficacy O
of O
symptoms B-outcome ['Physiological-Clinical']
relief, O
as O
measured O
by O
the O
scales O
of O
Tinnitus B-outcome ['Physiological-Clinical']
Severity I-outcome ['Physiological-Clinical']
Scale O
(TSS) O
(P O
< O
.01), O
Tinnitus B-outcome ['Physiological-Clinical']
Questionnaire O
(TQ) O
(P O
< O
.01), O
and O
Tinnitus B-outcome ['Physiological-Clinical']
Handicap I-outcome ['Physiological-Clinical']
Inventory O
(THI)], O
(P O
< O
.01), O
and O
improvement O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
as O
assessed O
by O
the O
SF-12 O
(P O
< O
.01), O
compared O
with O
patients O
receiving O
sham O
TENS. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

A O
single O
trained O
operator O
performed O
the O
CT O
in O
a O
single O
visit O
in O
cases O
without O
periapical O
or O
interradicular O
radiolucency O
(PIR) O
or O
in O
multiple O
visits O
in O
cases O
with O
PIR. O
[]

Main O
Outcomes O
and O
Measures: O
Two O
co-primary O
outcomes: O
24-hour O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
using O
patient-controlled O
analgesia O
in O
pairwise O
comparisons O
between O
the O
4 O
groups O
(multiplicity-adjusted O
thresholds O
for O
statistical O
significance, O
P O
< O
.0042; O
minimal O
clinically O
important O
difference, O
10 O
mg), O
and O
proportion O
of O
patients O
with O
1 O
or O
more O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
(SAEs) I-outcome ['Adverse-effects']
within O
90 O
days O
(multiplicity-adjusted O
thresholds O
for O
statistical O
significance, O
P O
< O
.025). O
[['Resource-use'], ['Adverse-effects']]

Eighty O
percent O
of O
CI O
implants, O
61% O
of O
FI O
implants, O
and O
84% O
of O
PS O
implants O
were O
observed O
to O
have O
a O
clinically O
stable O
peri-implant B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
zenith I-outcome ['Physiological-Clinical']
position I-outcome ['Physiological-Clinical']
with O
less O
than O
0.5 O
mm O
of O
measured O
recession. O
[['Physiological-Clinical']]

Title: O
Can O
Reproductive O
Life O
Plan-based O
counselling O
increase O
men's O
fertility B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
? O
[['Life-Impact']]

Publication O
date: O
2018/12/14 O
06:00 O
[entrez] O
[]

Journal-Name:The O
International O
journal O
of O
oral O
& O
maxillofacial O
implants O
[]

Purpose: O
Intensity O
of O
a O
training O
program O
is O
a O
critical O
variable O
in O
treatment O
gains O
poststroke, O
but O
there O
are O
no O
guidelines O
to O
adequately O
dose O
the O
intensity O
of O
functional O
training O
(FT); O
the O
recommended O
type O
of O
training O
to O
promote O
poststroke O
recovery. O
[]

Postprandial O
qualitative O
appetite B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Physiological-Clinical']
, O
and O
GLP-1 B-outcome ['Physiological-Clinical']
were O
measured O
every O
30 O
min O
for O
7 O
h. O
Energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
values O
from O
an O
ad O
libitum O
dinner O
and O
for O
a O
24-h O
period O
were O
assessed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Publication O
Type: O
Letter O
[]

Patients O
in O
group O
A O
received O
Garlicin O
Capsules O
1/time, O
3 O
times/d, O
combined O
with O
Kangfuxin O
liquid O
10 O
mL O
to O
gargle O
3 O
times/d; O
patients O
in O
group O
B O
only O
received O
Kangfuxin O
liquid O
10 O
mL O
gargle O
5 O
min, O
3/d. O
[]

Journal O
ID: O
101090220 O
[]

Haematology O
[]

Journal O
ID: O
101213819 O
[]

Fifty O
participants O
(male O
and O
female O
aged O
20 O
to O
50 O
years) O
were O
randomly O
assigned O
to O
two O
groups. O
[]

TRIAL O
REGISTRATION: O
The O
original O
trial O
was O
retrospectively O
registered O
under O
ClinicalTrials.gov O
Identifier O
NCT01660204 O
on O
August O
8th, O
2012. O
[]

RESULTS: O
Initial O
bleeding B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
cyanoacrylate O
versus O
sclerotherapy O
groups O
(98.25, O
83.93% O
respectively, O
P O
= O
0.007). O
[['Physiological-Clinical']]

The O
administration O
of O
NMES O
or O
sham O
NMES, O
as O
intervention, O
was O
performed O
for O
an O
8-week O
period O
treatment, O
and O
4-week O
period O
follow-up. O
[]

The O
nasopharyngeal O
temperature O
was O
maintained O
at O
33.0-34.5 O
centigrade O
and O
the O
rectal O
temperature O
was O
maintained O
at O
34.5-35.0 O
centigrade. O
[]

They O
were O
equally O
divided O
the O
NES O
group O
and O
the O
sham O
group. O
[]

It O
impacts O
physical, O
mental, O
and O
social O
functioning O
as O
well O
as O
the O
quality O
of O
life, O
often O
leading O
to O
depression. O
[]

The O
mean O
(SD) O
er-MedDiet O
score O
was O
8.5 O
(2.6) O
at O
baseline O
and O
13.2 O
(2.7) O
at O
12 O
months O
in O
the O
intervention O
group O
(increase, O
4.7 O
[95% O
CI, O
4.6-4.8]) O
and O
8.6 O
(2.7) O
at O
baseline O
and O
11.1 O
(2.8) O
at O
12 O
months O
in O
the O
control O
group O
(increase, O
2.5 O
[95% O
CI, O
2.3-2.6]) O
(between-group O
difference, O
2.2 O
[95% O
CI, O
2.1-2.4]; O
P O
< O
.001). O
[]

After O
each O
fitting O
and O
at O
1-week O
follow-up, O
high- O
and O
low-contrast O
visual B-outcome ['Physiological-Clinical']
acuities I-outcome ['Physiological-Clinical']
were O
measured. O
[['Physiological-Clinical']]

METHODS: O
We O
randomly O
assigned O
609 O
patients O
with O
complicated O
urinary O
tract O
infections O
(UTIs), O
including O
acute O
pyelonephritis, O
in O
a O
1:1 O
ratio O
to O
receive O
intravenous O
plazomicin O
(15 O
mg O
per O
kilogram O
of O
body O
weight O
once O
daily) O
or O
meropenem O
(1 O
g O
every O
8 O
hours), O
with O
optional O
oral O
step-down O
therapy O
after O
at O
least O
4 O
days O
of O
intravenous O
therapy, O
for O
a O
total O
of O
7 O
to O
10 O
days O
of O
therapy. O
[]

Employees O
aged O
18-65 O
years O
with O
no O
self-reported O
medical O
contraindications O
to O
physical O
activity O
were O
included. O
[]

METHODS: O
The O
trial O
will O
adopt O
a O
waitlist-control O
design O
with O
cluster-randomization O
by O
school. O
[]

Patients O
in O
the O
Sham O
group O
received O
an O
US-guided O
bilateral O
OSTAP O
with O
40 O
mL O
of O
0.9% O
saline. O
[]

In O
this O
randomized O
controlled O
trial, O
we O
assessed O
the O
effects O
of O
a O
WSP O
formula O
on O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
management O
in O
58 O
white-collar O
workers O
through O
MR O
to O
elucidate O
the O
effects O
of O
this O
WSP-MR O
on O
factors O
leading O
to O
overweight. O
[['Physiological-Clinical']]

Title: O
Role O
Of O
0.2% O
Bio-Adhesive O
Chlorhexidine O
Gel O
In O
Reducing O
Incidence O
Of O
Alveolar B-outcome ['Physiological-Clinical']
Osteitis I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

All O
biomarkers O
of O
metabolic B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
were O
equivalent O
when O
evaluating O
R1 O
v O
R2. O
[['Physiological-Clinical']]

Patients O
with O
diabetes O
or O
glucose O
intolerance O
in O
the O
education O
group O
improved O
significantly O
in O
waist-to-hip B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
uric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
total B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
< O
P O
0> O
HDL-C O
. O
Glycemic B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
level O
also O
improved O
significantly O
in O
diabetes O
patients O
of O
the O
education O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

Missing O
values O
were O
imputed O
by O
linear O
interpolation O
(intermittent), O
backfilling O
(beginning) O
or O
carry O
forward O
(end). O
[]

METHOD: O
The O
double-blind O
study O
included O
20 O
members O
of O
the O
Polish O
Rowing O
Team. O
[]

BACKGROUD: O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
trigger O
point O
injection O
(TPI) O
and O
eutectic O
mixture O
local O
anesthetics O
(EMLA) O
cream O
on O
the O
postoperative O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
total O
laparoscopic O
hysterectomy. O
[['Physiological-Clinical']]

Periods O
of O
unilateral O
strength O
training O
should O
be O
implemented O
into O
periodized O
RT O
programs O
in O
this O
cohort. O
[]

The O
primary O
endpoint O
was O
achieved O
in O
similar O
proportions O
of O
patients O
in O
the O
two O
treatment O
groups O
(12 O
[43%] O
of O
28 O
in O
the O
5-day O
schedule O
group, O
95% O
credible O
interval O
26-60, O
and O
17 O
[40%] O
of O
43 O
in O
the O
10-day O
schedule O
group, O
26-54, O
p=0.78; O
difference O
3%, O
-21 O
to O
27). O
[]

Single-arm O
studies O
have O
suggested O
that O
a O
10-day O
schedule O
of O
decitabine O
cycles O
leads O
to O
better O
outcomes O
than O
the O
usual O
5-day O
schedule. O
[]

One O
group O
underwent O
thoracic O
drainage O
by O
the O
same O
intercostal O
space O
of O
thoracotomy O
and O
the O
other O
by O
traditional O
chest O
drainage O
approach. O
[]

The O
ratio O
of O
Apo O
B O
to O
Apo O
A1 O
was O
reduced O
more O
(p O
= O
0.0866) O
in O
the O
amla O
group O
as O
compared O
to O
the O
placebo. O
[]

Journal O
ID: O
2985248R O
[]

Compared O
with O
women O
whose O
inability O
to O
procreate O
is O
caused O
by O
simple O
tubal O
infertility, O
women O
with O
endometriosis O
often O
have O
lower O
pregnancy O
rates O
following O
in O
vitro O
fertilization/intracytoplasmic O
sperm O
injection O
(IVF/ICSI). O
[]

They O
were O
randomly O
divided O
into O
group O
A O
and O
group O
B, O
30 O
cases O
in O
each O
group. O
[]

Stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
index O
(SVI) O
and O
cardiac B-outcome ['Physiological-Clinical']
cycle I-outcome ['Physiological-Clinical']
efficiency O
(CCE) O
showed O
an O
increase O
in O
Group O
SM O
but O
a O
decrease O
in O
Group O
S O
(Ptime*group<0.0001). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
7703942 O
[]

Publication O
date: O
2019/03/02 O
06:00 O
[medline] O
[]

The O
RADPAD O
is O
a O
lead-free O
sterile O
drape O
containing O
bismuth O
and O
barium O
that O
reduces O
scatter O
radiation O
during O
fluoroscopic O
procedures. O
[]

TRIAL O
REGISTRATION: O
German O
register O
of O
clinical O
studies: O
DRKS00000622 O
. O
[]

The O
primary O
end O
point O
was O
intraoperative O
or O
postoperative O
complication B-outcome ['Adverse-effects']
of O
grade O
II O
or O
higher O
according O
to O
the O
Clavien-Dindo O
classification O
(indicating O
major O
complication B-outcome ['Adverse-effects']
leading O
to O
intervention) O
within O
30 O
days. O
[['Adverse-effects'], ['Adverse-effects']]

Journal O
ID: O
2985248R O
[]

In O
logistic O
regression O
models, O
treatment O
group O
membership O
was O
significantly O
associated O
with O
spectacle B-outcome ['Life-Impact']
ownership I-outcome ['Life-Impact']
(Odds O
Ratio O
[OR] O
= O
11.9, O
p O
< O
0.001) O
and O
wearing B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
(OR O
= O
7.2, O
p O
< O
0.001). O
[['Life-Impact'], ['Life-Impact']]

Median O
24-hour O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
20 O
mg O
(99.6% O
CI, O
0-148) O
in O
the O
PCM O
+ O
IBU O
group, O
36 O
mg O
(99.6% O
CI, O
0-166) O
for O
PCM O
alone, O
26 O
mg O
(99.6% O
CI, O
2-139) O
for O
IBU O
alone, O
and O
28 O
mg O
(99.6% O
CI, O
2-145) O
for O
HS-PCM O
+ O
IBU. O
[['Resource-use']]

SETTING: O
University O
laboratory O
setting. O
[]

Dehydration O
impairs O
physiological O
function O
and O
physical O
performance, O
thus O
understanding O
effective O
rehydration O
strategies O
is O
paramount. O
[]

The O
main O
goal O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
caffeine O
supplementation O
on O
time B-outcome ['Physiological-Clinical']
under O
tension O
(TUT) O
and O
the O
number O
of O
performed O
repetitions B-outcome ['Physiological-Clinical']
(REP) I-outcome ['Physiological-Clinical']
. O
The O
second O
objective O
was O
to O
determine O
the O
effects O
of O
CAF O
supplementation O
on O
power B-outcome ['Physiological-Clinical']
(P) I-outcome ['Physiological-Clinical']
and O
movement B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
(V) I-outcome ['Physiological-Clinical']
during O
the O
bench O
press O
movement. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
The O
95% O
effective O
dose B-outcome ['Life-Impact']
of O
intrathecal O
ropivacaine O
with O
5 O
mug O
sufentanil O
for O
successful O
anesthesia O
was O
15.2 O
mg O
(95%CI, O
13.5-18.8 O
mg), O
when O
receiving O
prophylactic O
infusion O
of O
phenylephrine. O
[['Life-Impact']]

Outcomes O
after O
16 O
weeks O
are O
amount O
and O
distribution B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
abdominal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
fat E2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
measured O
by O
magnetic O
resonance O
imaging O
(MRI) O
with O
the O
use O
of O
the O
three-point O
IDEAL O
Dixon O
method. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

This O
follows O
a O
4-week O
baseline O
period O
where O
all O
villages O
do O
not O
receive O
repellent. O
[]

METHODS: O
Forty-two O
patients O
with O
skeletal O
Class O
II O
malocclusion O
were O
treated O
with O
cast-splint O
Herbst O
appliances. O
[]

Journal O
ID: O
0014162 O
[]

Following O
the O
study, O
5 O
focus O
group O
discussions O
(FGDs) O
were O
conducted O
consisting O
of O
6-8 O
purposively O
sampled O
participants O
from O
intervention O
villages. O
[]

A O
partial O
support O
of O
the O
MAT O
and O
of O
ruminations O
reduction O
to O
the O
MBI's O
efficacy O
was O
found. O
[]

Title: O
A O
randomized O
trial O
of O
AmBisome O
monotherapy O
and O
AmBisome O
and O
miltefosine O
combination O
to O
treat O
visceral O
leishmaniasis O
in O
HIV O
co-infected O
patients O
in O
Ethiopia. O
[]

Follow-on O
oral O
antibiotics O
were O
permitted O
in O
both O
groups. O
[]

To O
date, O
methohexital O
has O
not O
been O
compared O
with O
the O
most O
commonly O
used O
induction O
agent, O
propofol. O
[]

METHODS: O
Eligible O
patients O
were O
aged O
60 O
years O
or O
older O
with O
acute O
myeloid O
leukaemia O
but O
unsuitable O
for O
intensive O
chemotherapy O
(or O
<60 O
years O
if O
unsuitable O
for O
intensive O
chemotherapy O
with O
an O
anthracycline O
plus O
cytarabine). O
[]

Belatacept O
concentrations O
were O
determined O
in O
a O
total O
of O
203 O
serum O
samples O
collected O
during O
26 O
infusion O
intervals O
from O
5 O
renal O
transplant O
recipients. O
[]

Journal O
ID: O
100968562 O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Spearman O
rank O
correlation O
analysis O
was O
performed O
to O
determine O
correlations O
between O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
TOFr. O
[['Life-Impact']]

The O
World O
Health O
Organisation O
(WHO) O
'5 O
Moments O
for O
Hand O
Hygiene' O
poster O
has O
been O
used O
to O
reduce O
hospital-acquired O
infections, O
but O
there O
is O
no O
similar O
tool O
to O
prevent O
community-acquired O
newborn O
infections O
in O
low-resource O
settings. O
[]

Title: O
Effect O
of O
Electroencephalography-Guided O
Anesthetic O
Administration O
on O
Postoperative O
Delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
Among O
Older O
Adults O
Undergoing O
Major O
Surgery: O
The O
ENGAGES O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical', 'Life-Impact']]

Metabolic B-outcome ['Physiological-Clinical']
pathways O
involving O
lysine B-outcome ['Physiological-Clinical']
, O
and O
phytochemicals B-outcome ['Physiological-Clinical']
were O
also O
modulated O
by O
navy O
bean O
intake O
in O
CRC O
survivors. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
"We O
find O
what O
we O
look O
for, O
and O
we O
look O
for O
what O
we O
know": O
factors O
interacting O
with O
a O
mental O
health O
training O
program O
to O
influence O
its O
expected O
outcomes O
in O
Tunisia. O
[]

CONCLUSION: O
Longitudinal O
profiling O
is O
an O
essential O
tool O
for O
improving O
our O
understanding O
of O
the O
microbiology O
of O
chronic O
wounds, O
as O
community O
dynamics O
associated O
with O
clinical O
events O
can O
only O
be O
identified O
by O
examining O
changes O
over O
multiple O
time O
points. O
[]

This O
study O
was O
an O
eight-week, O
double-blind, O
randomized, O
parallel-arm, O
and O
placebo-controlled O
trial. O
[]

Journal-Name:Medicine O
[]

Sixty O
patients O
completed O
the O
study. O
[]

Title: O
Long-term O
results O
of O
a O
phase O
II O
study O
of O
hypofractionated O
proton O
therapy O
for O
prostate O
cancer: O
moderate O
versus O
extreme O
hypofractionation. O
[]

In O
recent O
years, O
enamel O
matrix O
derivatives O
(EMDs) O
have O
been O
used O
for O
their O
regenerative O
potential O
in O
periodontics. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS: O
Seventy O
non-dialysis O
CKD-MBD O
patients O
with O
kidney O
deficiency O
and O
dampness-heat O
syndrome O
were O
randomized O
into O
control O
group O
(n=35) O
and O
treatment O
group O
(n=35). O
[]

Journal O
ID: O
8102988 O
[]

METHODS: O
A O
hundred O
of O
healthy O
parturients O
undergoing O
elective O
cesarean O
section O
under O
combined O
spinal-epidural O
anesthesia O
(CSEA) O
were O
enrolled O
in O
this O
randomized, O
double-blinded, O
dose-ranging O
study. O
[]

The O
mean O
increase O
in O
peak B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
, O
relative O
to O
control, O
was O
greater O
following O
HIIT O
than O
MICT O
(2.4 O
vs. O
0.7 O
mL/kg/min). O
[['Physiological-Clinical']]

CONCLUSIONS: O
A O
self-administered O
rehabilitation O
program O
for O
painful O
shoulder O
was O
non-inferior O
than O
usual O
physical O
therapy. O
[]

Publication O
date: O
['2019/10/11 O
06:00' O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Saliva O
cortisol B-outcome ['Physiological-Clinical']
, O
a O
marker O
of O
the O
endocrine B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
system, O
was O
not O
significantly O
different O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Day O
1, O
8 O
mg O
orally O
Days O
2-4). O
[]

Because O
of O
the O
time O
spent O
at O
the O
workplace, O
workplaces O
can O
be O
optimal O
arenas O
for O
weight O
loss O
programs O
and O
these O
programs O
have O
been O
effective O
to O
decrease O
body O
weight. O
[]

This O
study O
aimed O
to O
investigate O
the O
effect O
of O
relaxation O
techniques O
on O
self-efficacy B-outcome ['Life-Impact']
of O
patients O
suffering O
from O
cancer. O
[['Life-Impact']]

In O
part O
C, O
patients O
who O
had O
recurrent O
attacks O
were O
randomly O
assigned O
to O
receive O
injections O
of O
one O
of O
two O
doses O
of O
givosiran O
(2.5 O
or O
5.0 O
mg O
per O
kilogram) O
or O
placebo O
once O
monthly O
(total O
of O
four O
injections) O
or O
once O
quarterly O
(total O
of O
two O
injections) O
during O
a O
12-week O
period, O
starting O
on O
day O
0. O
[]

Journal O
ID: O
8912748 O
[]

In O
addition, O
lavender O
essential O
oil O
has O
been O
shown O
to O
have O
positive O
effects O
on O
some O
symptoms O
associated O
with O
menopause. O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
8 O
weeks O
of O
Shilajit O
supplementation O
at O
250 O
mg.d(- O
1) O
(low O
dose) O
and O
500 O
mg.d(- O
1) O
(high O
dose) O
versus O
placebo O
on O
maximal B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
isometric I-outcome ['Physiological-Clinical']
contraction I-outcome ['Physiological-Clinical']
(MVIC) I-outcome ['Physiological-Clinical']
strength, O
concentric B-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
torque I-outcome ['Physiological-Clinical']
, O
fatigue-induced O
percent O
decline O
in O
strength B-outcome ['Life-Impact']
, O
and O
serum O
hydroxyproline B-outcome ['Physiological-Clinical']
(HYP) I-outcome ['Physiological-Clinical']
. O
METHODS: O
Sixty-three O
recreationally-active O
men O
([Formula: O
see O
text O
+/- O
SD: O
21.2 O
+/- O
2.4 O
yr.; O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

We O
hope O
to O
show O
the O
oncologic O
benefits O
of O
deep O
NMB O
compared O
with O
moderate O
NMB O
during O
subtotal O
gastrectomy. O
[]

Publication O
date: O
2018/11/08 O
00:00 O
[revised] O
[]

28 O
received O
decitabine O
for O
5 O
days O
and O
43 O
for O
10 O
days, O
and O
all O
were O
assessable O
for O
efficacy O
and O
safety. O
[]

In O
the O
secondary O
analysis, O
the O
difference O
in O
the O
mean O
Roland-Morris O
Disability B-outcome ['Life-Impact']
Questionnaire O
(RMDQ) O
score O
between O
the O
groups O
was O
-2.3 O
(-4.2 O
to-0.4, O
P=0.02) O
for O
patients O
with O
type O
1 O
Modic O
changes O
and O
-0.1 O
(-2.7 O
to O
2.6, O
P=0.95) O
for O
patients O
with O
type O
2 O
Modic O
changes. O
[['Life-Impact']]

The O
aim O
of O
this O
large O
randomised O
controlled O
trial O
was O
to O
collect O
data O
to O
enhance O
the O
validity O
and O
applicability O
of O
the O
evidence O
from O
previous O
trials O
to O
inform O
practice. O
[]

Omadacycline, O
an O
aminomethylcycline O
antibiotic O
that O
can O
be O
administered O
once O
daily O
either O
orally O
or O
intravenously, O
is O
active O
against O
pathogens O
that O
commonly O
cause O
such O
infections, O
including O
antibiotic-resistant O
strains. O
[]

RESULTS: O
Among O
all O
the O
250 O
patients O
examined O
156 O
women O
were O
eligible O
for O
study O
and O
finally O
120 O
patients O
were O
allocated O
to O
intervention O
(n O
= O
60) O
and O
control O
(n O
= O
60) O
groups. O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Outcomes O
were O
performed O
on O
a O
simulated O
cardiac O
arrest O
case O
adapted O
from O
the O
AHA O
Advanced O
Cardiac O
Life O
Support O
(ACLS) O
SimMan(R) O
Scenario O
manual. O
[]

Journal O
ID: O
101234168 O
[]

Decolonization O
involved O
chlorhexidine O
mouthwash, O
baths O
or O
showers O
with O
chlorhexidine, O
and O
nasal O
mupirocin O
for O
5 O
days O
twice O
per O
month O
for O
6 O
months. O
[]

METHODS: O
The O
BabyGel O
pilot O
was O
a O
cluster O
randomised O
trial O
that O
assessed O
the O
post-partum O
use O
of O
alcohol-based O
hand O
rub O
(ABHR) O
to O
prevent O
neonatal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
Mbale, O
Uganda. O
[['Physiological-Clinical']]

RESULTS: O
The O
number O
of O
adherent B-outcome ['Life-Impact']
patients O
was O
significantly O
higher O
in O
the O
intervention O
group O
(57/64 O
[89.9%] O
vs O
41/61 O
[67.2%]; O
chi2 O
test, O
P=0.003]. O
There O
was O
no O
significant O
difference O
between O
the O
groups O
in O
the O
number O
of O
patients O
who O
experienced O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
(31/64 O
[48.4%] O
vs O
36/61 O
[59.0%]; O
chi2 O
test, O
P=0.236). O
[['Life-Impact'], ['Adverse-effects']]

In O
the O
follow-up O
study, O
which O
started O
on O
Feb O
7, O
2017, O
and O
was O
completed O
on O
June O
30, O
2017, O
61 O
patients O
were O
included O
in O
the O
ATLG O
group O
and O
53 O
were O
included O
in O
the O
non-ATLG O
group. O
[]

SafeWalker(R) O
supports O
the O
body O
weight O
whilst O
securing O
postural O
stability O
without O
relying O
on O
upper O
body O
strength O
or O
high O
cognitive O
demand. O
[]

In O
the O
high-dose O
remifentanil O
(HR) O
group O
(n O
= O
46), O
remifentanil O
was O
infused O
at O
a O
rate O
of O
0.25 O
mug/kg/min O
and O
subsequently O
increased O
or O
decreased O
by O
0.05 O
mug/kg/min O
per O
clinical O
demand. O
[]

Publication O
date: O
2018/06/12 O
00:00 O
[accepted] O
[]

Subjects O
and O
Methods: O
Among O
the O
children O
referred O
to O
the O
our O
University, O
Faculty O
of O
Dentistry, O
Department O
of O
Pediatric O
Dentistry, O
23 O
aged O
between O
8-14 O
with O
81 O
anterior O
white B-outcome ['Physiological-Clinical']
spot I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
included O
in O
the O
study. O
[['Physiological-Clinical']]

RESULTS: O
With O
a O
median O
follow-up O
of O
27.2 O
months, O
the O
2-year O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
rate O
was O
81% O
(95% O
confidence O
interval O
[CI], O
69 O
to O
96) O
in O
the O
sorafenib O
group O
and O
36% O
(95% O
CI, O
22 O
to O
57) O
in O
the O
placebo O
group O
(hazard O
ratio O
for O
progression B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
, O
0.13; O
95% O
CI, O
0.05 O
to O
0.31; O
P<0.001). O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Mortality']]

DISCUSSION: O
The O
results O
of O
this O
trial O
will O
be O
used O
to O
establish O
clinical O
evidence O
regarding O
the O
use O
of O
Bosinji O
with O
acupuncture O
treatment O
in O
the O
treatment O
of O
patients O
with O
LHIVD. O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Journal O
ID: O
2985248R O
[]

Title: O
Effectiveness O
of O
A O
Multifactorial O
Intervention O
in O
Increasing O
Adherence B-outcome ['Life-Impact']
to O
the O
Mediterranean O
Diet O
among O
Patients O
with O
Diabetes O
Mellitus O
Type O
2: O
A O
Controlled O
and O
Randomized O
Study O
(EMID O
Study). O
[['Life-Impact']]

Small O
bowel O
capsule O
endoscopy O
was O
performed O
before O
and O
2 O
weeks O
after O
low-dose O
aspirin O
administration. O
[]

OBJECTIVES: O
To O
determine O
if O
intermittent O
exercise-heat O
exposures O
(IHE) O
every O
fifth O
day O
sustain O
heat B-outcome ['Physiological-Clinical']
acclimation I-outcome ['Physiological-Clinical']
(HA) I-outcome ['Physiological-Clinical']
adaptations O
25 O
days O
after O
initial O
HA. O
[['Physiological-Clinical']]

Journal O
ID: O
101521595 O
[]

MAIN O
OUTCOME O
MEASURES: O
EIFEL O
and O
Dallas O
Pain B-outcome ['Physiological-Clinical']
Questionnaire O
scores. O
[['Physiological-Clinical']]

As O
obesity O
is O
recognised O
as O
a O
contributing O
factor O
when O
developing O
various O
health O
threatening O
chronic O
diseases, O
prevention O
initiatives O
focusing O
on O
weight O
loss O
are O
becoming O
more O
important. O
[]

On O
day O
28, O
mean O
cry B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
fuss B-outcome ['Life-Impact', 'Life-Impact']
time E1-outcome ['Life-Impact', 'Life-Impact']
became O
statistically O
different: O
142 O
(89) O
vs. O
199 O
(72), O
respectively O
(p O
< O
0.05). O
[['Life-Impact', 'Life-Impact']]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Journal O
ID: O
101153627 O
[]

Journal O
ID: O
8910750 O
[]

Journal O
ID: O
100891112 O
[]

The O
addition O
of O
SPOC O
scores O
to O
an O
adjusted O
regression O
model O
to O
predict O
pain B-outcome ['Physiological-Clinical']
interference I-outcome ['Physiological-Clinical']
improved O
the O
concordance O
statistic O
from O
0.66 O
to O
0.75, O
and O
the O
greatest O
risk O
was O
associated O
with O
high O
SPOC O
scores O
(odds O
ratio: O
6.06; O
99% O
CI: O
3.97-9.25; O
absolute O
risk O
increase: O
18.3%; O
95% O
CI: O
11.7%, O
26.7%). O
[['Physiological-Clinical']]

METHODS: O
Sixty-two O
10- O
to O
14-year-old O
patients O
were O
randomly O
allocated O
to O
either O
full-time O
(FT, O
22 O
hours O
daily) O
or O
part-time O
(PT, O
12 O
hours O
daily) O
wear O
of O
a O
modified O
Twin-block O
appliance. O
[]

All O
patients O
in O
both O
groups O
were O
treated O
for O
a O
total O
of O
10 O
days. O
[]

Publication O
date: O
2019/02/07 O
06:00 O
[entrez] O
[]

METHODS: O
Post O
hoc O
analysis O
of O
baseline O
patient O
characteristics O
in O
the O
randomized, O
open-label, O
vision O
examiner-masked O
SHORE O
phase O
4 O
study O
that O
compared O
monthly O
versus O
pro O
re O
nata O
dosing O
of O
ranibizumab O
in O
patients O
with O
branch O
and O
central O
RVO. O
[]

The O
aim O
of O
his O
study O
is O
to O
test O
our O
hypothesis O
that O
5 O
mug O
Dex O
could O
enhance O
the O
efficiency O
of O
intrathecal O
bupivacaine O
and O
reduce O
the O
dose B-outcome ['Life-Impact']
requirement O
of O
spinal O
bupivacaine O
for O
patients O
undergoing O
cesarean O
section. O
[['Life-Impact']]

Publication O
date: O
2018/11/13 O
00:00 O
[accepted] O
[]

The O
significance O
level O
adopted O
was O
of O
0.05. O
[]

respectively O
(p O
= O
0.450). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

L(- O
1)). O
[]

RESULTS: O
Among O
42 O
HIE O
children, O
1 O
child O
of O
severe O
congenital O
malformation O
and O
1 O
child O
of O
platelet O
count O
(PLT) O
< O
50x10(9)/L O
were O
excluded, O
and O
40 O
children O
were O
enrolled O
in O
the O
study O
group. O
[]

Publication O
date: O
2019/02/14 O
06:00 O
[entrez] O
[]

RESULTS: O
All O
groups O
significantly O
improved O
handling B-outcome ['Life-Impact']
performance. O
[['Life-Impact']]

Results: O
Smoking O
a O
cigarette O
for O
five O
minutes O
resulted O
in O
a O
significant O
increase O
of O
exhaled B-outcome ['Physiological-Clinical']
CO I-outcome ['Physiological-Clinical']
, O
whereas O
using O
an O
IQOS(TM) O
resulted O
in O
a O
small O
but O
reliable O
increase O
(0.3 O
ppm). O
[['Physiological-Clinical']]

Journal O
ID: O
101604552 O
[]

To O
improve O
the O
success O
rate, O
probing O
combined O
with O
tobramycin/dexamethasone O
ointment O
is O
considered O
effective. O
[]

Publication O
date: O
2018/07/06 O
00:00 O
[accepted] O
[]

METHODS: O
We O
derived O
data O
from O
the O
imaging O
subgroup O
of O
the O
Clopidogrel O
in O
High-risk O
Patients O
with O
Acute O
Nondisabling O
Cerebrovascular O
Events O
(CHANCE) O
trial. O
[]

METHODS: O
A O
clinical O
trial O
cross-over O
study O
was O
carried O
out O
on O
premature O
infants O
in O
NICU. O
[]

Fluvoxamine O
and O
MPH-ER O
were O
given O
to O
the O
study O
group, O
while O
fluvoxamine O
and O
placebo O
were O
given O
to O
the O
control O
group, O
with O
8 O
weeks O
of O
the O
treatment O
course. O
[ O
[]

Appropriate O
interim O
analyses O
will O
be O
conducted O
by O
a O
data O
monitoring O
and O
ethics O
committee O
(DMEC), O
and O
the O
final O
test O
will O
be O
an O
intention-to-treat O
analysis. O
[]

Conclusion: O
High-fidelity O
simulation O
training O
is O
superior O
to O
low-fidelity O
CPR O
manikin O
training O
for O
teaching O
fourth-year O
medical O
students O
implementation O
of O
high-quality O
CPR O
for O
chest B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
and O
compression B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSIONS: O
Based O
on O
this O
single-center O
prospective O
study, O
both O
of O
these O
therapies O
appear O
to O
have O
relatively O
favorable O
outcomes, O
although O
cyanoacrylate O
injection O
may O
be O
superior O
to O
sclerotherapy O
for O
initial O
control O
of O
active B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
TRIAL O
REGISTRATION: O
[ClinicalTrials.gov O
Identifier: O
NCT03388125 O
]-Date O
of O
registration: O
January O
2, O
2018 O
"Retrospectively O
registered". O
[['Physiological-Clinical']]

Title: O
Effect O
of O
diet O
with O
or O
without O
exercise O
on O
abdominal O
fat O
</> O
in O
postmenopausal O
women O
- O
a O
randomised O
trial. O
[]

Despite O
growing O
interest O
in O
natural O
rehydrating O
beverages, O
no O
study O
has O
examined O
maple O
water O
(MW). O
[]

Publication O
date: O
2019/02/14 O
06:00 O
[medline] O
[]

CBT-i O
group O
is O
superior O
in O
improving O
sleep B-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
(SOL) I-outcome ['Physiological-Clinical']
and O
sleep B-outcome ['Physiological-Clinical']
efficiency I-outcome ['Physiological-Clinical']
(SE) I-outcome ['Physiological-Clinical']
. O
Combination O
regimen O
in O
our O
study O
can O
significantly O
reduce O
the O
doses B-outcome ['Resource-use']
of O
medication. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Linear O
regressions O
examined O
between-groups O
relationships O
for O
foot O
and O
ankle O
characteristics O
and O
the O
FPPA. O
[]

Advances O
in O
knowledge: O
Our O
work O
is O
relevant O
for O
MRI O
sequence O
choice O
and O
development O
of O
the O
roles O
of O
the O
interprofessional O
team O
in O
the O
advancement O
of O
MRI-guided O
radiotherapy. O
[]

Conclusion:Rhodiola O
may O
improve O
the O
negative B-outcome ['Life-Impact']
emotions I-outcome ['Life-Impact']
such O
as O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
by O
inhibiting O
oxygen B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
and O
lipid B-outcome ['Physiological-Clinical']
peroxidation I-outcome ['Physiological-Clinical']
in O
patients O
with O
OSA. O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
The O
self-administered O
rehabilitation O
program O
showed O
an O
adjusted O
effectiveness O
of O
51% O
at O
the O
end O
of O
treatment O
compared O
to O
54% O
of O
the O
standard O
physical O
therapy O
(p O
> O
0.05). O
[]

Publication O
date: O
2019/02/06 O
06:00 O
[entrez] O
[]

201404134736 O
N6 O
. O
[]

Design, O
Setting, O
and O
Participants: O
Two-year, O
randomized, O
multicenter O
trial O
conducted O
at O
9 O
hospitals O
in O
Denmark. O
[]

Objective: O
To O
determine O
the O
efficacy O
and O
safety O
of O
tretinoin O
0.05% O
lotion O
in O
treating O
moderate-to-severe O
acne O
in O
a O
Hispanic O
population. O
[]

Publication O
date: O
2019/03/01 O
06:00 O
[medline] O
[]

METHODS: O
In O
this O
double-blind, O
phase O
3 O
trial, O
we O
randomly O
assigned O
87 O
patients O
with O
progressive, O
symptomatic, O
or O
recurrent O
desmoid O
tumors O
to O
receive O
either O
sorafenib O
(400-mg O
tablet O
once O
daily) O
or O
matching O
placebo. O
[]

Publication O
Type: O
Journal O
Article O
[]

All O
subjects O
will O
be O
submitted O
to O
microbiological O
analysis O
and O
evaluation O
with O
Oral O
ChromaTM O
before, O
immediately O
after O
treatment, O
7, O
14, O
and O
30 O
days O
after O
treatment. O
[]

Within O
30 O
days O
of O
surgery, O
4 O
patients O
(0.65%) O
in O
the O
guided O
group O
and O
19 O
(3.07%) O
in O
the O
usual O
care O
group O
died. O
[]

There O
was O
no O
significant O
difference O
in O
the O
baseline O
data O
of O
gender, O
gestational O
age, O
birth O
weight, O
age, O
5-minure O
Apgar O
score O
or O
SNAPPE O
II O
score O
between O
the O
two O
groups, O
indicating O
that O
the O
baseline O
data O
of O
the O
two O
groups O
were O
balanced O
and O
comparable. O
[]

Title: O
Medial O
patellofemoral O
ligament O
reconstruction O
in O
children: O
A O
comparative O
randomized O
short-term O
study O
of O
fascia O
lata O
allograft O
and O
gracilis O
tendon O
autograft O
reconstruction. O
[]

Title: O
Performance O
of O
Litholyme O
compared O
with O
Sodasorb O
carbon O
dioxide O
absorbents O
in O
a O
standard O
clinical O
setting. O
[]

However, O
most O
studies O
assessing O
implementation O
success O
focus O
on O
only O
one O
condition, O
although O
more O
conditions O
influence O
this O
process. O
[]

Moderately O
vitamin O
B12-deficient O
participants O
aged O
between O
45 O
and O
75 O
years O
(n O
= O
56) O
were O
recruited O
into O
this O
randomised O
controlled O
crossover O
trial. O
[]

Title: O
Does O
L-Methylfolate O
Supplement O
Methylphenidate O
Pharmacotherapy O
in O
Attention-Deficit/Hyperactivity O
Disorder?: O
[]

No O
major O
safety O
concerns O
related O
to O
the O
study O
medication O
were O
identified. O
[]

Publication O
Type: O
Journal O
Article O
[]

The O
patients O
were O
divided O
into O
two O
groups O
by O
random O
allocation O
using O
Ti-Ti O
rods O
(n O
= O
29) O
and O
CrCo-Ti O
rods O
(n O
= O
30) O
and O
the O
alone O
difference O
among O
them O
in O
the O
surgical O
procedure O
was O
rod O
material O
(Ti-Ti O
or O
CrCo-Ti O
rods) O
and O
finally, O
radiological B-outcome ['Physiological-Clinical']
outcomes O
were O
compared O
preoperatively, O
postoperatively O
and O
at O
last O
follow-up O
for O
12 O
months. O
[['Physiological-Clinical']]

INTRODUCTION: O
Halitosis O
is O
the O
term O
used O
to O
describe O
any O
unpleasant O
odor O
relative O
to O
expired O
air O
regardless O
of O
its O
source. O
[]

It O
was O
observed O
in O
both O
groups O
that, O
as O
CRP B-outcome ['Physiological-Clinical']
levels O
increased, O
albumin B-outcome ['Physiological-Clinical']
levels O
decreased O
significantly O
(p O
<0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Brazilian O
oral O
research O
[]

However, O
few O
studies O
have O
explored O
the O
application O
of O
OPEP O
in O
surgery O
lung O
cancer O
patients O
underwent O
lobectomy. O
[]

RESULTS: O
Plasma O
albumin B-outcome ['Physiological-Clinical']
and O
total O
protein B-outcome ['Physiological-Clinical']
levels O
increased O
immediately O
after O
exercise O
in O
placebo O
alongside O
slight O
reductions O
in O
glucose B-outcome ['Physiological-Clinical']
(p O
= O
0.001). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Background O
and O
Objectives: O
The O
authors O
sought O
to O
assess O
the O
effect O
of O
the O
use O
of O
a O
new O
crosslinked O
hyaluronan O
(NCH) O
gel O
on O
the O
prevention O
of O
intrauterine B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
(IUAs) I-outcome ['Physiological-Clinical']
in O
women O
underwent O
curettage O
in O
the O
second O
trimester. O
[['Physiological-Clinical']]

Title: O
Sorafenib O
for O
Advanced O
and O
Refractory O
Desmoid O
Tumors. O
[]

Title: O
Suspension O
Training O
HIIT O
Improves O
Gait B-outcome ['Life-Impact']
Speed I-outcome ['Life-Impact']
, O
Strength B-outcome ['Life-Impact']
and O
Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
in O
Older O
Adults. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

The O
secondary O
aim O
was O
to O
assess O
the O
non-inferiority O
of O
the O
reduction O
of O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of O
the O
short O
protocol O
versus O
the O
long O
protocol. O
[['Physiological-Clinical']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

This O
is O
a O
post O
hoc O
analysis O
of O
the O
St. O
Carlos O
gestational O
diabetes O
mellitus O
(GDM) O
Prevention O
Study. O
[]

OBJECTIVE: O
To O
pilot O
test O
the O
effectiveness O
of O
"MyNutriCart", O
a O
smartphone O
application O
(app) O
that O
generates O
healthy O
grocery O
lists, O
on O
diet B-outcome ['Life-Impact']
and O
weight B-outcome ['Physiological-Clinical']
. O
METHODS: O
A O
pilot O
randomized O
trial O
was O
conducted O
to O
test O
the O
efficacy O
of O
using O
the O
"MyNutriCart" O
app O
compared O
to O
one O
face-to-face O
counseling O
session O
(Traditional O
group) O
in O
Hispanic O
overweight O
and O
obese O
adults. O
[['Life-Impact'], ['Physiological-Clinical']]

Journal O
ID: O
101160020 O
[]

RESULTS: O
We O
conducted O
three O
sub-studies O
in O
consecutive O
years O
of O
2011, O
2012, O
and O
2013 O
to O
reach O
an O
adequate O
sample O
size. O
[]

The O
general O
clinical O
data O
of O
the O
two O
groups O
including O
gender, O
gestational O
age, O
birth O
weight, O
age, O
5-minute O
neonatal O
asphyxia O
score O
(Apgar O
score), O
score O
for O
neonatal O
acute O
physiology O
perinatal O
extension O
version O
II O
(SNAPPE O
II) O
were O
collected. O
[]

Tai O
Chi O
as O
a O
mild O
to O
moderate O
mind-body O
exercise O
is O
suitable O
for O
older O
individuals O
who O
suffer O
from O
depression. O
[]

Journal O
ID: O
2985248R O
[]

Infant O
colic O
is O
a O
common O
condition O
of O
unknown O
pathogenesis O
that O
brings O
frustration O
to O
families O
seeking O
for O
effective O
management. O
[]

Trial O
registered O
with O
Current O
Controlled O
Trials, O
number O
ISRCTN17975376. O
[]

Funded O
by O
Alnylam O
Pharmaceuticals; O
ClinicalTrials.gov O
number, O
NCT02452372 O
.). O
[]

The O
aims O
of O
our O
study O
were O
to O
analyze O
not O
only O
the O
influence O
of O
daily O
vs. O
monthly O
administration O
of O
vitamin O
D O
on O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
but O
also O
the O
effects O
of O
different O
routes O
of O
administration O
on O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
in O
a O
cohort O
of O
adults O
with O
low O
levels O
of O
25(OH) O
vitamin O
D3 O
at O
baseline. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Scorpion O
envenomation O
and O
its O
consequences O
represented O
a O
serious O
healthcare O
problem O
in O
Upper O
Egypt O
and O
considered O
to O
be O
an O
important O
cause O
of O
life-threatening O
emergency O
particularly O
in O
children. O
[]

METHODS: O
Using O
a O
single-blind, O
counterbalanced, O
crossover O
design, O
we O
compared O
the O
rehydrating B-outcome ['Physiological-Clinical']
efficacy O
of O
MW O
vs. O
maple-flavored O
bottled O
water O
(control) O
in O
26 O
young O
healthy O
(22 O
+/- O
4 O
yrs., O
[['Physiological-Clinical']]

Operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
difficulty B-outcome ['Life-Impact']
of O
finding O
the O
specimen O
was O
significantly O
lower O
in O
the O
modified O
localization O
group O
than O
in O
the O
methylene O
blue O
localization O
group O
(P O
< O
.05). O
[['Life-Impact'], ['Life-Impact']]

METHODS: O
A O
sample O
of O
2262 O
male O
truckers O
registered O
in O
the O
North O
Star O
Alliance O
electronic O
health O
record O
system O
who, O
based O
on O
these O
records, O
were O
not O
testing O
for O
HIV O
regularly O
were O
randomized O
to O
one O
of O
three O
study O
groups O
in O
which O
they O
were O
sent O
text O
messages O
about O
the O
availability O
of O
(1) O
oral O
HIV O
self-test O
kits O
at O
all O
8 O
North O
Star O
Alliance O
Kenya O
clinics O
that O
was O
sent O
three O
times O
(intervention), O
(2) O
HIV O
testing O
in O
general O
(not O
self-testing) O
at O
all O
North O
Star O
Alliance O
clinics O
sent O
three O
times O
(enhanced O
standard O
of O
care O
[SOC]), O
or O
(3) O
HIV O
testing O
in O
general O
(not O
self-testing) O
at O
all O
North O
Star O
Alliance O
clinics O
sent O
one O
time O
(SOC). O
[]

Title: O
Comparison O
of O
fit O
factors O
among O
healthcare O
providers O
working O
in O
the O
Emergency O
Department O
Center O
before O
and O
after O
training O
with O
three O
types O
of O
N95 O
and O
higher O
filter O
respirators. O
[]

METHODS: O
In O
this O
24-week, O
randomized, O
double-blind, O
placebo-controlled O
phase O
3 O
study, O
225 O
patients, O
142 O
of O
which O
were O
East O
Asian O
(63.4%), O
were O
enrolled: O
Japan O
(n O
= O
114), O
South O
Korea O
(n O
= O
20), O
Taiwan O
(n O
= O
8), O
the O
Czech O
Republic O
(n O
= O
42), O
and O
Poland O
(n O
= O
40). O
[]

There O
was O
no O
significant O
difference O
in O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
at O
1 O
year O
between O
intervention O
and O
usual O
care O
groups O
(unadjusted O
cumulative O
incidence, O
10.2% O
vs O
10.6%; O
P O
= O
.65; O
adjusted O
difference, O
0.66% O
[95% O
CI, O
-0.73% O
to O
2.06%]; O
adjusted O
hazard O
ratio, O
1.07 O
[95% O
CI, O
0.93 O
to O
1.25]). O
[['Physiological-Clinical', 'Mortality']]

The O
relationship O
of O
marginal O
bone O
responses O
and O
peri-implant O
mucosal O
stability O
requires O
further O
evaluation. O
[]

Journal O
ID: O
7501160 O
[]

OBJECTIVE: O
To O
test O
the O
efficacy O
of O
Gua O
Sha O
therapy O
in O
patients O
with O
chronic O
low O
back O
pain. O
[]

Patients O
who O
received O
Ahmed O
glaucoma O
valve O
implantation O
surgery O
from O
August O
2015 O
to O
January O
2017 O
at O
the O
Xiamen O
Eye O
Center O
were O
randomly O
divided O
into O
2 O
groups. O
[]

Undoubtedly, O
further O
in O
vitro O
and O
in O
vivo O
studies O
need O
to O
be O
performed O
in O
order O
to O
elucidate O
possible O
mechanisms O
of O
action O
and O
corroborate O
our O
preliminary O
results. O
[]

We O
sought O
to O
determine O
whether O
a O
one-time O
azithromycin O
mass O
treatment O
would O
reduce O
trachomatous B-outcome ['Physiological-Clinical']
inflammation-follicular I-outcome ['Physiological-Clinical']
(TF) I-outcome ['Physiological-Clinical']
levels O
below O
the O
elimination O
threshold O
of O
5% O
in O
communities O
with O
disease O
prevalence O
between O
5 O
and O
9.9%. O
[['Physiological-Clinical']]

Fisher's O
exact O
test O
was O
used O
to O
verify O
the O
differences O
between O
categorical O
variables. O
[]

The O
Mediterranean O
diet O
(MD) O
is O
recognized O
as O
one O
of O
the O
healthiest O
dietary O
patterns O
and O
has O
benefits O
such O
as O
improving O
glycaemic O
control O
among O
patients O
with O
type O
2 O
diabetes O
(T2DM). O
[]

RESULTS: O
At O
all O
time O
points, O
tramadol B-outcome ['Resource-use']
consumption O
of O
the O
OSTAP O
group O
remained O
significantly O
lower O
when O
compared O
with O
Sham O
group. O
[['Resource-use']]

Journal O
ID: O
7511141 O
[]

Moreover, O
the O
change O
in O
ICAM1 O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
correlated O
positively O
with O
the O
intake O
of O
FF O
(P O
< O
0.05) O
and O
negatively O
with O
the O
intake O
of O
LF O
(P O
< O
0.05), O
independently O
of O
study O
group. O
[['Physiological-Clinical']]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT01206062. O
[]

We O
have O
shown O
that O
a O
diet O
intervention O
postpartum O
produced O
a O
2-y O
weight O
loss O
of O
8%. O
[]

RESULTS: O
The O
preoperative O
MDCT O
images O
for O
standard-dose O
protocol O
had O
better O
quality B-outcome ['Life-Impact']
than O
low-dose O
protocol O
(P O
< O
.001, O
q O
= O
4.57). O
[['Life-Impact']]

At O
D58, O
the O
adjusted O
efficacy O
was O
55% O
(95% O
CI O
32-78%) O
in O
the O
monotherapy O
arm, O
and O
88% O
(95% O
CI O
79-98%) O
in O
the O
combination O
arm. O
[]

Journal O
ID: O
2985248R O
[]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

Title: O
Acute O
Effect O
of O
Resistant O
Starch O
on O
Food B-outcome ['Life-Impact']
Intake I-outcome ['Life-Impact']
, O
Appetite B-outcome ['Physiological-Clinical']
and O
Satiety B-outcome ['Physiological-Clinical']
in O
Overweight/Obese O
Males. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Serum, O
peripheral O
blood O
mononuclear O
cells O
(PBMCs) O
and O
kidney O
biopsy O
specimens O
were O
obtained O
from O
participants. O
[]

All O
three O
indicators O
of O
CHW O
functioning O
(as O
measured O
by O
reports O
submitted O
from O
CHWs) O
improved O
more O
in O
the O
intervention O
area O
relative O
to O
the O
comparison O
area, O
with O
2 O
out O
of O
3 O
measures O
of O
improvement O
reaching O
statistical O
significance. O
[]

Title: O
White O
Sweet O
Potato O
as O
Meal O
Replacement O
for O
Overweight O
White-Collar O
Workers: O
A O
Randomized O
Controlled O
Trial. O
[]

Whey O
protein O
isolate O
(WPI) O
is O
high O
in O
vitamin O
B12 O
and O
folate. O
[]

13 O
046 O
women O
(intervention O
n=7067, O
usual O
care O
n=5979) O
with O
data O
based O
on O
the O
national O
Dutch O
perinatal O
registry O
or O
hospital O
records O
were O
included O
in O
the O
analyses. O
[]

In O
the O
conventional O
group, O
the O
treatment O
goal O
was O
clinical B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
. O
Main O
Outcomes O
and O
Measures: O
Co-primary O
outcomes O
were O
proportions O
of O
patients O
achieving O
DAS28-CRP B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
(DAS28-CRP O
<2.6) O
and O
with O
no O
radiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
(no O
increase O
in O
total O
van O
der O
Heijde-modified O
Sharp O
score) O
at O
24 O
months. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/02/19 O
00:00 O
[accepted] O
[]

This O
study O
aimed O
to O
evaluate O
the O
influence O
of O
music O
therapy O
intervention O
on O
the O
autonomic O
control O
of O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
in O
mothers. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

CONCLUSIONS: O
These O
findings O
call O
into O
question O
the O
validity O
of O
the O
self-affirmation O
manipulation, O
which O
is O
purported O
to O
reduce O
defensive B-outcome ['Life-Impact']
reactions I-outcome ['Life-Impact']
to O
threatening O
warnings. O
[['Life-Impact']]

Conclusions: O
No O
dose-response O
relationship O
of O
netupitant O
in O
terms O
of O
overall O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
rate O
was O
observed O
in O
this O
study. O
[['Physiological-Clinical']]

Journal-Name:Marine O
drugs O
[]

One O
patient O
(4%) O
died B-outcome ['Mortality']
from O
sepsis B-outcome ['Physiological-Clinical']
in O
the O
context O
of O
neutropenic B-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
, O
infection B-outcome ['Physiological-Clinical']
, O
and O
haemorrhage B-outcome ['Physiological-Clinical']
in O
the O
5-day O
group, O
and O
in O
the O
10-day O
group O
six O
patients O
(14%) O
died B-outcome ['Mortality']
from O
infection B-outcome ['Physiological-Clinical']
. O
Early O
mortality B-outcome ['Mortality']
was O
similar O
in O
the O
two O
groups. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Mortality']]

The O
poster O
will O
be O
adapted O
into O
a O
sticker O
format O
on O
the O
ABHR O
bottle. O
[]

Moreover, O
a O
significant O
reduction O
in O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
markers O
( O
CK B-outcome ['Physiological-Clinical']
and O
LDH B-outcome ['Physiological-Clinical']
, O
p O
< O
0.001) O
was O
observed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

DISCUSSION: O
The O
evidence O
provided O
will O
inform O
program O
investment O
and O
design, O
and O
contribute O
to O
the O
literature O
on O
the O
effect O
of O
menstrual O
health-based O
interventions O
on O
girls' O
agency B-outcome ['Life-Impact']
, O
safety O
and O
life B-outcome ['Life-Impact']
outcomes. O
[['Life-Impact'], ['Life-Impact']]

Cumulative O
opioid B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
after O
48 O
hours O
were O
similar O
between O
the O
groups. O
[['Resource-use']]

No O
statistically O
significant O
difference O
(P O
> O
0.05) O
among O
the O
groups O
was O
found O
regarding O
degree O
or O
duration O
of O
pain B-outcome ['Physiological-Clinical']
. O
There O
was O
no O
statistically O
significant O
difference O
(P O
> O
0.05) O
among O
the O
4(o)C O
and O
2.5(o)C O
groups. O
[['Physiological-Clinical']]

Title: O
Tafenoquine O
versus O
Primaquine O
to O
Prevent O
Relapse B-outcome ['Physiological-Clinical']
of O
Plasmodium O
vivax O
Malaria. O
[['Physiological-Clinical']]

Background: O
Acne O
vulgaris O
(acne) O
is O
the O
most O
common O
dermatologic O
disease O
seen O
in O
a O
racially, O
geographically, O
politically, O
culturally, O
and O
socioeconomically O
diverse O
Hispanic O
population. O
[]

In O
the O
SSD O
(n O
= O
37) O
and O
NPWT O
(n O
= O
36) O
cohorts, O
the O
superficial O
surgical B-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
(SSI) I-outcome ['Physiological-Clinical']
, O
deep B-outcome ['Physiological-Clinical']
surgical I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
(SSI) I-outcome ['Physiological-Clinical']
, O
seroma B-outcome ['Physiological-Clinical']
, O
and O
dehiscence B-outcome ['Physiological-Clinical']
rates O
were O
16 O
per O
cent O
and O
14 O
per O
cent O
(P O
> O
0.99), O
5 O
per O
cent O
and O
8 O
per O
cent O
(P O
= O
0.67), O
16 O
per O
cent O
and O
11 O
per O
cent O
(P O
= O
0.74), O
and O
5 O
per O
cent O
and O
3 O
per O
cent O
(P O
>/= O
0.99), O
respectively. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE: O
To O
observe O
the O
effect O
of O
Ronghuang O
granule O
on O
serum O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
23 I-outcome ['Physiological-Clinical']
(FGF23) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
(FGFRs) I-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
in O
non-dialysis O
patients O
with O
chronic O
kidney O
disease-mineral O
and O
bone O
disorder O
(CKD-MBD) O
and O
kidney O
deficiency O
and O
damp O
heat O
syndrome. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

There O
were O
significant O
improvements O
in O
household O
purchasing B-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
vegetables I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
whole I-outcome ['Life-Impact', 'Life-Impact']
grains S2-outcome ['Life-Impact', 'Life-Impact']
, O
in O
individual O
intakes B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
refined I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
grains I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
healthy I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
proteins I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
whole-fat I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
dairies I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
legumes I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
100% I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
fruit I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
juices I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
sweets I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
snacks S2-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
; O
and O
in O
the O
individual O
frequency O
of O
intake B-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
fruits I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
cold I-outcome ['Life-Impact', 'Life-Impact']
cuts/cured I-outcome ['Life-Impact', 'Life-Impact']
meats S2-outcome ['Life-Impact', 'Life-Impact']
within O
the O
intervention O
group O
(p O
< O
0.05). O
[['Life-Impact', 'Life-Impact'], ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact'], ['Life-Impact', 'Life-Impact']]

No O
significant O
differences O
were O
noted O
between O
carvedilol O
and O
placebo O
in O
terms O
of O
the O
development O
of O
diastolic B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
, O
clinically B-outcome ['Physiological-Clinical']
overt I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
. O
CONCLUSIONS: O
Carvedilol O
might O
prevent O
deterioration O
in O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
(LVEF) I-outcome ['Physiological-Clinical']
in O
cancer O
patients O
treated O
with O
doxorubicin. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical']]

There O
was O
no O
significant O
difference O
between O
groups O
in O
the O
median O
cumulative O
time O
with O
mean O
arterial O
pressure O
below O
60 O
mm O
Hg O
(7 O
vs O
7 O
minutes; O
difference, O
0.0 O
[95% O
CI, O
-1.7 O
to O
1.7]). O
[]

Depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
were O
collected O
by O
the O
Beck O
Depression O
Inventory-II]. O
Logistic O
regression O
models O
were O
used O
to O
estimate O
the O
association O
between O
seafood O
products O
and O
omega-3 O
PUFA O
consumption O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Multiple O
linear O
regression O
models O
were O
fitted O
to O
assess O
the O
association O
between O
fish O
and O
long-chain O
(LC) O
omega-3 O
PUFA O
intake O
and O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
. O
RESULTS: O
Out O
of O
6587 O
participants, O
there O
were O
1367 O
cases O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Total O
seafood O
consumption O
was O
not O
associated O
with O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
The O
odds O
ratios O
(ORs) O
(95% O
confidence O
intervals O
(CIs)) O
for O
the O
2nd, O
3rd, O
and O
4th O
quintiles O
of O
consumption O
of O
fatty O
fish O
were O
0.77 O
(0.63(-)0.94), O
0.71 O
(0.58(-)0.87), O
and O
0.78 O
(0.64(-)0.96), O
respectively, O
and O
p O
for O
trend O
= O
0.759. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Journal-Name:The O
journal O
of O
headache O
and O
pain O
[]

CONCLUSIONS: O
Adjuvant O
therapy O
with O
a O
modified O
FOLFIRINOX O
regimen O
led O
to O
significantly O
longer O
survival B-outcome ['Mortality']
than O
gemcitabine O
among O
patients O
with O
resected O
pancreatic O
cancer, O
at O
the O
expense O
of O
a O
higher O
incidence O
of O
toxic B-outcome ['Adverse-effects']
effects. O
( O
[['Mortality'], ['Adverse-effects']]

Main O
outcome O
measures O
were O
best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(BCVA) I-outcome ['Physiological-Clinical']
gain O
of O
15 O
or O
more O
ETDRS O
letters O
from O
baseline, O
Snellen O
equivalent O
of O
20/40 O
or O
better O
vision B-outcome ['Physiological-Clinical']
, O
and O
baseline O
factors O
associated O
with O
early O
clinically O
significant O
improvement O
in O
best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(BCVA) I-outcome ['Physiological-Clinical']
. O
RESULTS: O
The O
median O
time B-outcome ['Physiological-Clinical']
for O
patients O
to O
achieve O
a O
best-corrected O
visual O
acuity O
(BCVA) O
of O
20/40 O
or O
better O
was O
59 O
days O
and O
the O
median O
time O
for O
patients O
to O
gain O
15 O
or O
more O
{ O
Early O
Treatment O
Diabetic B-outcome ['Physiological-Clinical']
Retinopathy I-outcome ['Physiological-Clinical']
Study O
(ETDRS)]} O
letters O
was O
63 O
days. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
A O
total O
of O
1548 O
patients O
were O
randomly O
assigned O
to O
undergo O
bilateral O
internal-thoracic-artery O
grafting O
(the O
bilateral-graft O
group) O
and O
1554 O
to O
undergo O
single O
internal-thoracic-artery O
grafting O
(the O
single-graft O
group). O
[]

Title: O
The O
influence O
of O
high-dose O
intraoperative O
remifentanil O
on O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
: O
a O
prospective O
randomized O
study: O
A O
CONSORT O
compliant O
article. O
[['Physiological-Clinical']]

Publication O
date: O
2018/12/14 O
06:00 O
[entrez] O
[]

Other O
potential O
moments O
for O
hand B-outcome ['Life-Impact', 'Life-Impact']
hygiene I-outcome ['Life-Impact', 'Life-Impact']
were O
introduced O
by O
participants, O
such O
as O
after O
tending O
to O
domestic O
animals O
and O
gardening. O
[['Life-Impact', 'Life-Impact']]

Title: O
Comparison O
of O
oncological O
benefits O
of O
deep O
neuromuscular O
block O
in O
obese O
patients O
with O
gastric O
cancer O
(DEBLOQS_GC O
study): O
A O
study O
protocol O
for O
a O
double-blind, O
randomized O
controlled O
trial. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

Method:Sixty O
patients O
with O
nasal O
NK/T O
cell O
lymphoma O
admitted O
to O
our O
hospital O
from O
February O
2012 O
to O
February O
2016 O
were O
selected O
as O
the O
study O
subject. O
[]

TRIAL O
REGISTRATION: O
ISRCTN10894523 O
. O
[]

BACKGROUND: O
Heartburn O
that O
persists O
despite O
proton-pump O
inhibitor O
(PPI) O
treatment O
is O
a O
frequent O
clinical O
problem O
with O
multiple O
potential O
causes. O
[]

The O
efficacy O
of O
PZQ O
will O
be O
evaluated O
in O
stool O
samples O
using O
the O
KK O
technique O
and O
real-time O
PCR O
as O
well O
as O
in O
urine O
using O
the O
point-of-care O
circulating O
cathodic O
antigen O
test O
and O
the O
up-converting O
phosphor, O
lateral O
flow, O
circulating O
anodic O
antigen O
assay. O
[]

Title: O
Iodoform O
Vs O
Calcium O
Hydroxide/Zinc O
Oxide O
based O
pastes: O
12-month O
findings O
of O
a O
Randomized O
Controlled O
Trial. O
[]

Conclusion: O
Berberine O
improves O
diabetic O
kidney O
disease O
by O
reducing O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
and O
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
in O
T2DM O
patients, O
and O
it O
was O
safe. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Vitamin O
D O
and O
probiotic O
co-supplementation O
affects O
mental B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
hormonal B-outcome ['Physiological-Clinical']
, O
inflammatory B-outcome ['Physiological-Clinical']
and O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
parameters O
in O
women O
with O
polycystic O
ovary O
syndrome. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
A O
randomized O
comparative O
study O
between O
intravenous O
and O
intramuscular O
scorpion O
antivenom O
regimens O
in O
children. O
[]

RESULTS: O
There O
were O
positive O
associations O
among O
SPC, O
MSI, O
and O
EBV O
statuses O
among O
586 O
patients. O
[]

Eligible O
infants O
were O
randomly O
assigned O
(1:1) O
to O
receive O
either O
enteral O
bovine O
lactoferrin O
(150 O
mg/kg O
per O
day; O
maximum O
300 O
mg/day; O
lactoferrin O
group) O
or O
sucrose O
(same O
dose; O
control O
group) O
once O
daily O
until O
34 O
weeks' O
postmenstrual O
age. O
[]

Similarly, O
adjusted O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
were O
reduced O
by O
20.4% O
(- O
6.3 O
points, O
p O
= O
0.02). O
[['Physiological-Clinical', 'Life-Impact']]

In O
the O
other O
group, O
each O
had O
a O
different O
color. O
[]

The O
same O
multidisciplinary O
protocol O
for O
detecting O
and O
managing O
fetal O
growth O
restriction O
was O
used O
in O
both O
strategies. O
[]

Journal O
ID: O
0255562 O
[]

At O
the O
test-of-cure O
visit, O
composite O
cure B-outcome ['Physiological-Clinical']
was O
observed O
in O
81.7% O
(156 O
of O
191 O
patients) O
and O
70.1% O
(138 O
of O
197 O
patients), O
respectively O
(difference, O
11.6 O
percentage O
points; O
95% O
CI, O
2.7 O
to O
20.3). O
[['Physiological-Clinical']]

Complication B-outcome ['Adverse-effects']
rates O
in O
all O
strategy O
groups O
were O
significantly O
lower O
than O
in O
the O
control O
group; O
however, O
no O
significant O
difference O
was O
found O
among O
the O
strategy O
groups. O
[['Adverse-effects']]

Recovery B-outcome ['Physiological-Clinical', 'Life-Impact']
conditions I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
postoperative O
agitation B-outcome ['Life-Impact']
were O
also O
recorded. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact']]

24 O
+/- O
4 O
kg/m(2)) O
males O
(n O
= O
13) O
and O
females O
(n O
= O
13) O
after O
exercise-induced O
dehydration O
(~ O
2.0%DeltaBody O
Weight O
[BW]) O
in O
the O
heat O
(30 O
degrees O
C, O
50% O
relative O
humidity O
[RH]). O
[]

Title: O
Standard-dose O
versus O
low-dose O
multidetector O
computed O
tomography O
examinations O
in O
patients O
with O
uncontrolled O
chronic O
rhinosinusitis: O
A O
randomized, O
controlled O
trial. O
[]

Title: O
Phase O
1 O
Trial O
of O
an O
RNA O
Interference O
Therapy O
for O
Acute O
Intermittent O
Porphyria. O
[]

Neither O
coefficient O
of O
variation O
nor O
percentage O
of O
hexagonal O
cells O
changed O
significantly O
from O
baseline O
at O
any O
time O
point. O
[]

METHOD: O
a O
randomized O
controlled O
trial, O
with O
102 O
patients O
in O
the O
preoperative O
period, O
randomized O
in O
a O
control O
group, O
with O
usual O
care, O
and O
an O
experimental O
group, O
which O
received O
menthol O
gum, O
which O
was O
the O
study O
treatment O
variable. O
[]

Journal O
ID: O
101599229 O
[]

The O
treatment O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
without O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
or O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
Thus, O
our O
WSP O
formula O
as O
an O
MR O
can O
facilitate O
individual O
weight B-outcome ['Physiological-Clinical']
loss O
and O
thus O
has O
commercial O
application O
in O
the O
food O
industry. O
[['Life-Impact'], ['Adverse-effects'], ['Adverse-effects'], ['Physiological-Clinical']]

PATIENTS O
AND O
METHODS: O
A O
multicentre, O
prospective, O
randomized, O
double-blind, O
placebo-controlled O
trial O
was O
undertaken O
involving O
229 O
patients O
undergoing O
primary O
cementless O
THA O
using O
a O
posterior O
approach, O
whose O
extended O
rivaroxaban O
thromboprophylaxis O
started O
on O
the O
day O
of O
surgery. O
[]

According O
to O
several O
qualitative O
studies O
in O
Africa, O
such O
pressures O
are O
exacerbated O
by O
girls' O
lack O
of O
knowledge O
of O
their O
bodies, O
their O
rights, O
and O
the O
implications O
of O
their O
decisions, O
and O
by O
their O
inability O
to O
manage O
puberty O
and O
adolescence O
safely O
and O
comfortably O
with O
appropriate O
menstrual O
health O
and O
hygiene O
management O
(MHM) O
products. O
[]

Therefore, O
exercise O
training O
in O
combined O
form O
(aerobic O
and O
resistance) O
may O
be O
incorporated O
in O
the O
management O
programs O
of O
the O
patients O
suffering O
from O
hypertension O
in O
order O
to O
augment O
improvement O
in O
their O
cardiac O
autonomic O
control. O
[]

Funded O
by O
the O
British O
Heath O
Foundation O
and O
others; O
Current O
Controlled O
Trials O
number, O
ISRCTN46552265 O
.). O
[]

Athens O
Insomnia B-outcome ['Physiological-Clinical']
Scale O
(AIS) O
was O
recorded O
at O
18: O
00 O
at O
the O
second O
day O
after O
surgery. O
[['Physiological-Clinical']]

Independent O
research O
on O
the O
experiences O
and O
behavioral O
aspects O
of O
using O
IQOS(TM), O
and O
how O
it O
compares O
to O
e-cigarettes, O
is O
largely O
lacking. O
[]

One O
hundred O
and O
fourteen O
obese O
women O
aged O
from O
18 O
to O
40 O
years O
were O
divided O
into O
insulin O
sensitive O
(IS) O
and O
insulin O
resistant O
(IR) O
groups O
and O
received O
a O
low O
calorie O
diet O
(LC), O
or O
an O
isocaloric O
diet O
and O
500 O
mg O
metformin O
twice O
daily O
(IM), O
or O
isocaloric O
diet O
with O
120 O
mg O
orlistat O
three O
times O
daily O
(IO). O
[]

Hydration B-outcome ['Physiological-Clinical']
indicators O
( O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
(BW) I-outcome ['Physiological-Clinical']
, O
salivary B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
urine B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
osmolality E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
[SOsm/UOsm], O
urine B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
gravity I-outcome ['Physiological-Clinical']
[USG] I-outcome ['Physiological-Clinical']
, O
urine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
[UV] I-outcome ['Physiological-Clinical']
, O
urine B-outcome ['Physiological-Clinical']
color I-outcome ['Physiological-Clinical']
[UC] I-outcome ['Physiological-Clinical']
), O
thirst B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
recovery B-outcome ['Physiological-Clinical']
( O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
[HR) I-outcome ['Physiological-Clinical']
], O
and O
HR B-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
[HRV] I-outcome ['Physiological-Clinical']
) O
were O
taken O
at O
baseline, O
post-exercise, O
0.5, O
1, O
and O
2 O
h O
post-consumption O
of O
1 O
L O
of O
MW O
or O
control. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
0372541 O
[]

A O
total O
of O
82 O
older O
adults O
were O
randomly O
assigned O
to O
3 O
groups: O
a O
HIIT O
group O
(n=28), O
a O
continuous O
intensity O
training O
group O
(MIIT O
group, O
n=27), O
or O
a O
control O
group O
(CG, O
n=27). O
[]

Publication O
Type: O
Multicenter O
Study O
[]

ID: O
ISRCTN13021107]. O
[]

Journal-Name:Zhongguo O
xiu O
fu O
chong O
jian O
wai O
ke O
za O
zhi O
= O
Zhongguo O
xiufu O
chongjian O
waike O
zazhi O
= O
Chinese O
journal O
of O
reparative O
and O
reconstructive O
surgery O
[]

Journal-Name:BMC O
ophthalmology O
[]

Journal O
ID: O
100967802 O
[]

Title: O
Efficacy O
of O
RADPAD O
protection O
drape O
in O
reducing O
radiation B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
in O
the O
catheterization O
laboratory-First O
Indian O
study. O
[['Life-Impact']]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Further O
rigorous O
studies O
are O
needed O
to O
confirm O
and O
extend O
these O
results. O
[]

Both O
LOCF O
and O
BOCF O
showed O
similar O
results O
but O
lower O
effect O
sizes. O
[]

All O
the O
patients O
were O
given O
routine O
treatment O
combined O
with O
traditional O
Chinese O
medicine O
retention O
enema, O
and O
the O
patients O
in O
the O
treatment O
group O
received O
additional O
Ronghuang O
granule O
treatment O
(3 O
times O
a O
day). O
[]

Changes O
in O
QOL O
were O
measured O
using O
the O
36-item O
Short O
Form O
Health B-outcome ['Physiological-Clinical']
Survey O
and O
EQ-5D]. O
The O
analysis O
of O
cost-effectiveness O
was O
a O
cost-utility O
analysis O
with O
a O
health O
care O
perspective O
and O
included O
costs B-outcome ['Resource-use']
of I-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
for O
stakeholder, O
quality-adjusted O
life-years O
(QALYs) O
gained O
and O
savings B-outcome ['Resource-use']
in O
health O
care O
. O
The O
likelihood O
of O
cost-effectiveness O
was O
examined O
using O
the O
net O
monetary O
benefit O
method. O
[['Physiological-Clinical'], ['Resource-use'], ['Resource-use']]

Journal-Name:BMC O
neurology O
[]

METHODS: O
A O
total O
of O
100 O
children O
with O
chronic O
constipation O
were O
included O
in O
this O
randomized O
controlled O
trial. O
[]

Neuromuscular O
monitoring O
is O
usually O
used O
to O
evaluate O
neuromuscular O
recovery O
in O
patients O
undergoing O
general O
anesthesia. O
[]

Before O
crossover, O
the O
objective O
response B-outcome ['Physiological-Clinical']
rate O
was O
33% O
(95% O
CI, O
20 O
to O
48) O
in O
the O
sorafenib O
group O
and O
20% O
(95% O
CI, O
8 O
to O
38) O
in O
the O
placebo O
group. O
[['Physiological-Clinical']]

Overall, O
the O
study O
demonstrated O
the O
acceptability B-outcome ['Life-Impact']
of O
an O
adapted O
version O
of O
the O
WHO O
Moments O
for O
Hand O
Hygiene O
poster O
in O
the O
introduction O
of O
an O
intervention O
in O
the O
community. O
[['Life-Impact']]

Methods: O
A O
total O
of O
52 O
women O
were O
included O
in O
the O
analysis: O
28 O
participants O
were O
allocated O
to O
the O
experimental O
group O
(EG) O
and O
24 O
to O
the O
control O
group O
(CG). O
[]

Journal O
ID: O
101521595 O
[]

The O
2nd O
dose O
was O
administered O
after O
an O
interval O
of O
6 O
months. O
[]

CONCLUSIONS: O
Probing O
combined O
with O
tobramycin/dexamethasone O
eye O
drops O
was O
effective O
and O
easy-to-perform B-outcome ['Life-Impact']
in O
the O
clinic, O
and O
it O
may O
be O
a O
better O
choice O
for O
persistent O
CNLDO. O
[['Life-Impact']]

CONCLUSION: O
Green O
tea O
was O
an O
effective O
adjunct O
to O
trimethoprim-sulfamethoxazole O
to O
treat O
acute O
uncomplicated O
cystitis O
in O
women. O
[]

These O
findings O
will O
inform O
future O
mass O
drug O
administration O
policy O
and O
shed O
light O
on O
position O
of O
novel O
diagnostic O
tools O
to O
evaluate O
schistosomiasis O
control O
strategies. O
[]

The O
effect O
on O
humans O
has O
not O
been O
elucidated, O
therefore, O
we O
investigated O
the O
effects O
of O
beta-Eudesmol O
on O
reducing O
objective O
and O
subjective O
markers O
related O
to O
sympathetic B-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
after O
the O
application O
of O
mental O
stress O
in O
healthy O
participants. O
[['Physiological-Clinical']]

Of O
these, O
95 O
(52%) O
patients O
were O
excluded O
because O
they O
no O
longer O
met O
study O
criteria O
and O
80 O
(43%) O
patients O
entered O
the O
placebo O
lead-in O
phase. O
[]

Prevention O
of O
body O
posture O
abnormalities O
is O
worth O
promoting O
in O
groups O
of O
children, O
also O
with O
various O
diseases O
including O
asthma O
and O
allergies O
symptoms. O
[]

CONCLUSIONS: O
In O
high-risk O
ambulatory O
patients O
with O
cancer, O
treatment O
with O
rivaroxaban O
did O
not O
result O
in O
a O
significantly O
lower O
incidence O
of O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
due I-outcome ['Mortality']
to I-outcome ['Mortality']
venous I-outcome ['Mortality']
thromboembolism I-outcome ['Mortality']
in O
the O
180-day O
trial O
period. O
[['Physiological-Clinical'], ['Mortality']]

DISCUSSION: O
Halitosis O
treatment O
is O
a O
topic O
that O
still O
needs O
attention. O
[]

P O
<.05) O
CONCLUSIONS:: O
A O
single O
bolus O
injection O
of O
oxycodone O
is O
more O
effective O
than O
that O
of O
fentanyl O
in O
the O
acute O
phase O
of O
postoperative O
pain B-outcome ['Physiological-Clinical']
after O
THR. O
[['Physiological-Clinical']]

Title: O
Action O
of O
antimicrobial O
photodynamic O
therapy O
with O
red O
leds O
in O
microorganisms O
related O
to O
halitose: O
Controlled O
and O
randomized O
clinical O
trial. O
[]

There O
was O
no O
significant O
difference O
in O
the O
overall O
remission B-outcome ['Physiological-Clinical']
rate O
between O
the O
2 O
groups O
(3.7% O
vs O
0%, O
P O
= O
.322). O
[['Physiological-Clinical']]

Journal-Name:Nutrients O
[]

At O
4, O
8, O
and O
12 O
weeks O
of O
treatment, O
the O
patients O
in O
the O
treatment O
group O
had O
significantly O
lowered O
scores O
of O
TCM B-outcome ['Physiological-Clinical']
syndromes I-outcome ['Physiological-Clinical']
compared O
with O
the O
score O
before O
treatment O
(P O
&lt; O
0.05 O
or O
0.01), O
while O
in O
the O
control O
group, O
significant O
reduction O
of O
the O
scores O
occurred O
only O
at O
12 O
weeks O
(P O
&lt; O
0.05); O
at O
each O
of O
the O
time O
points, O
the O
treatment O
group O
had O
significantly O
greater O
reductions O
in O
the O
score O
than O
the O
control O
group O
(P O
&lt; O
0.01). O
[['Physiological-Clinical']]

Journal-Name:Zhonghua O
lao O
dong O
wei O
sheng O
zhi O
ye O
bing O
za O
zhi O
= O
Zhonghua O
laodong O
weisheng O
zhiyebing O
zazhi O
= O
Chinese O
journal O
of O
industrial O
hygiene O
and O
occupational O
diseases O
[]

There O
was O
no O
difference O
in O
FPPA O
(knee O
valgus O
angle) O
between O
groups O
(15, O
0.63-377.99). O
[]

There O
were O
no O
significant O
differences O
in O
VAS O
scores O
and O
recognition O
thresholds O
for O
four O
basic O
tastes B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
before O
treatment. O
[['Physiological-Clinical']]

FINDINGS: O
In O
the O
original O
study, O
from O
Dec O
14, O
2006, O
to O
Feb O
2, O
2012, O
161 O
patients O
were O
enrolled O
and O
155 O
were O
randomly O
assigned O
to O
either O
the O
ATLG O
group O
(n=83) O
or O
to O
the O
non-ATLG O
group O
(n=72). O
[]

Clinicaltrials.gov O
NCT01702974. O
[]

CONCLUSIONS: O
Intraoperative O
propofol O
sedation O
can O
alleviate O
the O
patients' O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
improve O
the O
comfort B-outcome ['Life-Impact']
level, O
and O
lessen O
physiological B-outcome ['Physiological-Clinical', 'Life-Impact']
stress I-outcome ['Physiological-Clinical', 'Life-Impact']
during O
surgeries O
under O
epidural O
anesthesia. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Supplementation O
with O
oral O
vitamin O
D O
can O
favor O
the O
state O
of O
iron O
metabolism, O
and O
testosterone O
and O
cortisol O
as O
an O
indicator O
of O
muscle O
recovery O
of O
the O
athlete O
with O
a O
deficiency. O
[]

Objective: O
Netupitant O
is O
a O
novel, O
selective O
neurokinin-1 O
receptor O
antagonist O
used O
for O
prevention O
of O
chemotherapy-induced O
nausea O
and O
vomiting, O
a O
distressing O
side O
effect O
of O
chemotherapy. O
[]

Journal O
ID: O
101090633 O
[]

These O
findings O
may O
caution O
the O
use O
of O
erythromycin O
as O
empirical O
therapy O
in O
these O
patients. O
[]

This O
study O
investigated O
the O
effects O
of O
yoga O
on O
women O
with O
PMS O
suffering O
from O
depression O
during O
menstrual O
cycle. O
[]

Further, O
amongst O
all O
views, O
LAO O
views O
have O
significantly O
higher O
emitted O
radiation O
as O
compared O
to O
Non O
LAO O
views O
and O
need O
more O
radiation O
protection. O
[]

Results O
demonstrated O
both O
subjective O
and O
objective O
functional B-outcome ['Life-Impact']
mobility I-outcome ['Life-Impact']
improvements O
after O
treatment O
in O
participants O
receiving O
hippotherapy O
and O
standard O
outpatient O
PT, O
as O
determined O
by O
the O
Peabody O
Developmental B-outcome ['Life-Impact']
Motor I-outcome ['Life-Impact']
Scales-2], O
the O
Pediatric O
Evaluation O
of O
Disability B-outcome ['Life-Impact']
Inventory], O
and O
the O
Goal B-outcome ['Life-Impact']
Attainment I-outcome ['Life-Impact']
Scaling]. O
STATEMENT O
OF O
CONCLUSION O
AND O
RECOMMENDATIONS O
FOR O
CLINICAL O
PRACTICE:: O
When O
compared O
with O
standard O
outpatient O
PT, O
hippotherapy O
appears O
to O
be O
a O
viable O
treatment O
strategy O
for O
children O
aged O
2 O
to O
5 O
years O
with O
neurological O
impairments O
and O
gross O
motor O
delays, O
but O
additional O
research O
in O
this O
area O
is O
needed O
to O
validate O
findings. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

INTERVENTIONS: O
Patients O
were O
subjected O
to O
low-dose O
preoperative O
protocols O
of O
MDCT O
(n O
= O
144; O
ldMDCT O
group) O
or O
standard-dose O
preoperative O
protocols O
of O
MDCT O
(n O
= O
144; O
sdMDCT O
group). O
[]

Publication O
date: O
2018/12/16 O
00:00 O
[accepted] O
[]

The O
trial O
was O
halted O
after O
an O
interim O
safety O
analysis O
(n=11) O
due O
to O
excess O
grade O
3 O
neutropenia B-outcome ['Physiological-Clinical']
, O
dose B-outcome ['Life-Impact']
reductions I-outcome ['Life-Impact']
and O
treatment B-outcome ['Life-Impact']
delays I-outcome ['Life-Impact']
. O
Grade O
3 O
or O
4 O
neutropenia B-outcome ['Physiological-Clinical']
was O
observed O
in O
64% O
of O
patients. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

All O
children O
returned O
to O
full B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
Similar O
results O
were O
obtained O
in O
patients O
in O
2nd O
group, O
where O
MPFL O
was O
reconstructed O
with O
ipsilateral O
gracilis O
tendon. O
[ O
[['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Radiation O
protection O
dosimetry O
[]

METHODS: O
In O
this O
randomised O
placebo-controlled O
trial, O
we O
recruited O
very O
preterm O
infants O
born O
before O
32 O
weeks' O
gestation O
in O
37 O
UK O
hospitals O
and O
younger O
than O
72 O
h O
at O
randomisation. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrials.gov, O
NCT03112083 O
, O
retrospectively O
registered. O
[]

BACKGROUND: O
Hypoxemia O
is O
the O
most O
common O
complication O
during O
tracheal O
intubation O
of O
critically O
ill O
adults O
and O
may O
increase O
the O
risk O
of O
cardiac O
arrest O
and O
death. O
[]

Participants O
viewed O
promotional O
videos O
and O
news O
stories O
about O
an O
upcoming O
international, O
multi-sport O
event O
(with O
sponsor O
content O
edited O
to O
reflect O
each O
condition), O
completed O
a O
distractor O
task, O
and O
then O
answered O
questions O
assessing O
the O
response O
variables. O
[]

Journal O
ID: O
101281800 O
[]

Participants O
included O
44 O
adults O
with O
serotonin O
reuptake O
inhibitor O
treatment-refractory O
OCD O
and O
they O
received O
a O
stable O
fluvoxamine O
pharmacotherapy O
with O
Yale-Brown O
Obsessive B-outcome ['Physiological-Clinical', 'Life-Impact']
Compulsive I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(Y-BOCS) O
scores O
higher O
than O
20. O
[['Physiological-Clinical', 'Life-Impact']]

CONCLUSION: O
Our O
results O
support O
the O
mechanisms O
occurring O
with O
the O
use O
of O
either O
of O
the O
described O
orthotic O
interventions. O
[]

Several O
studies O
demonstrated O
that O
polyphenols O
are O
able O
to O
inhibit O
the O
growth O
of O
TMA-producing O
bacterial O
strains, O
and O
resveratrol O
(RSV) O
reduced O
TMAO O
levels O
in O
mice. O
[]

CONCLUSIONS: O
This O
double O
blinded, O
randomized, O
and O
placebo-controlled O
trial O
demonstrated O
that O
the O
single O
use O
of O
20 O
mg O
nifedipine O
given O
30 O
minutes O
before O
embryo O
transfer O
did O
not O
improve O
the O
implantation B-outcome ['Physiological-Clinical']
rate O
or O
the O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate O
of O
the O
infertility O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101303164 O
[]

In O
both O
groups, O
the O
efficacy O
of O
the O
trial O
drug O
was O
similar O
for O
methicillin-susceptible O
and O
methicillin-resistant O
Staphylococcus B-outcome ['Physiological-Clinical']
aureus I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
. O
Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
in O
48.3% O
of O
the O
patients O
in O
the O
omadacycline O
group O
and O
in O
45.7% O
of O
those O
in O
the O
linezolid O
group; O
the O
most O
frequent O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
both O
groups O
were O
gastrointestinal B-outcome ['Physiological-Clinical']
(in O
18.0% O
and O
15.8% O
of O
the O
patients O
in O
the O
respective O
groups). O
[['Physiological-Clinical'], ['Adverse-effects'], ['Adverse-effects'], ['Physiological-Clinical']]

All O
patients O
received O
3 O
sessions O
per O
week O
of O
SPT O
for O
8 O
weeks. O
[]

Title: O
Piloting O
a O
participatory, O
community-based O
health O
information O
system O
for O
strengthening O
community-based O
health O
services: O
findings O
of O
a O
cluster-randomized O
controlled O
trial O
in O
the O
slums O
of O
Freetown, O
Sierra O
Leone. O
[]

Patients O
were O
operated O
in O
two O
orthopedic O
centers. O
[]

RESULTS:: O
There O
is O
good O
agreement O
when O
comparing O
radiographer O
contours O
to O
the O
gold-standard O
for O
all O
three O
imaging O
types O
with O
Dice O
similarity O
co-efficient O
0.91-0.94, O
Cohen's O
kappa O
0.85-0.91, O
Hausdorff O
distance O
4.6-7.6 O
mm O
and O
mean O
distance O
between O
contours O
0.9-1.2 O
mm. O
[]

In O
2 O
randomized O
controlled O
trials O
(RCTs) O
of O
stressed O
community O
adults, O
mindfulness O
skills O
were O
dismantled O
into O
2 O
structurally O
equivalent O
interventions: O
(a) O
training O
in O
both O
monitoring O
and O
acceptance O
(Monitor O
+ O
Accept) O
and O
(b) O
training O
in O
monitoring O
only O
(Monitor O
Only) O
without O
acceptance O
training. O
[]

BACKGROUND: O
Belatacept O
(Nulojix; O
Bristol-Myers O
Squibb, O
New O
York, O
NY) O
is O
a O
biological O
immunosuppressive O
drug O
used O
for O
the O
prophylaxis O
of O
acute O
rejection O
after O
renal O
transplantation. O
[]

Journal-Name:BMC O
public O
health O
[]

Secondary O
outcome O
was O
time B-outcome ['Resource-use']
to I-outcome ['Resource-use']
emergency I-outcome ['Resource-use']
medical I-outcome ['Resource-use']
services I-outcome ['Resource-use']
(EMS) I-outcome ['Resource-use']
activation I-outcome ['Resource-use']
. O
We O
analyzed O
data O
via O
Kruskal-Wallis O
rank O
sum O
test. O
[['Resource-use']]

Our O
finding O
that O
highly-severe O
health O
warnings O
increase O
avoidance B-outcome ['Life-Impact']
and O
reactance B-outcome ['Life-Impact']
but O
are O
also O
perceived O
as O
being O
more O
effective O
and O
more O
likely O
to O
motivate B-outcome ['Life-Impact']
people O
to O
drink O
less O
will O
inform O
future O
health O
warning O
design O
and O
have O
implications O
for O
health O
warning O
label O
theory. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Weaknesses O
in O
the O
CHW O
intervention O
severely O
limited O
the O
extent O
to O
which O
the O
PCBHIS O
could O
be O
used O
to O
observe O
trends O
in O
mortality O
and O
morbidity. O
[]

RESULTS: O
Plazomicin O
was O
noninferior O
to O
meropenem O
with O
respect O
to O
the O
primary O
efficacy O
end O
points. O
[]

Vitamin O
D O
and O
probiotic O
co-supplementation O
was O
associated O
with O
a O
significant O
reduction O
in O
total O
testosterone B-outcome ['Physiological-Clinical']
(beta O
- O
0.19 O
ng/mL; O
95% O
CI, O
- O
0.28, O
- O
0.10; O
P O
< O
0.001), O
hirsutism B-outcome ['Physiological-Clinical']
(beta O
- O
0.95; O
95% O
CI, O
- O
1.39, O
- O
0.51; O
P O
< O
0.001), O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(hs-CRP) I-outcome ['Physiological-Clinical']
(beta O
- O
0.67 O
mg/L; O
95% O
CI, O
- O
0.97, O
- O
0.38; O
P O
< O
0.001) O
and O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
levels O
(beta O
- O
0.25 O
mumol/L; O
95% O
CI, O
- O
0.40, O
- O
0.10; O
P O
= O
0.001), O
and O
a O
significant O
increase O
in O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity O
(TAC) O
(beta O
82.81 O
mmol/L; O
95% O
CI, O
42.86, O
122.75; O
P O
< O
0.001) O
and O
total O
glutathione B-outcome ['Physiological-Clinical']
(GSH) I-outcome ['Physiological-Clinical']
levels O
(beta O
40.42 O
mumol/L; O
95% O
CI, O
4.69, O
76.19; O
P O
= O
0.02), O
compared O
with O
the O
placebo. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101215702 O
[]

Clinicians O
may O
find O
these O
helpful O
when O
considering O
the O
likelihood O
of O
achieving O
early O
clinically O
significant O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(VA) I-outcome ['Physiological-Clinical']
improvements O
with O
ranibizumab O
in O
patients O
with O
RVO. O
[['Physiological-Clinical']]

CONCLUSIONS: O
Moderate-intensity O
combined O
aerobic O
and O
resistance O
training O
is O
safe O
in O
physically O
unfit O
patients O
with O
quiescent O
Inflammatory O
Bowel O
Disease O
and O
can O
quickly O
achieve O
favourable O
body B-outcome ['Physiological-Clinical']
compositional I-outcome ['Physiological-Clinical']
changes O
without O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
TRIAL O
REGISTRATION: O
The O
study O
was O
registered O
at O
ClinicalTrials.gov; O
Trial O
number: O
NCT02463916 O
. O
[['Physiological-Clinical'], ['Adverse-effects']]

Baseline O
characteristics O
were O
detectable O
viral O
loads O
(median O
7897 O
copies/mL), O
low O
CD4(+) O
(median O
410 O
cells/microL), O
and O
elevated O
CD8(+) O
(median O
930 O
cells/microL) O
T O
cell O
counts. O
[]

We O
previously O
conducted O
a O
regional O
study O
in O
the O
Quebec's O
Eastern O
Townships O
region, O
the O
PromoVac O
Study, O
to O
test O
a O
new O
educational O
intervention, O
based O
on O
motivational O
interviewing O
techniques, O
aimed O
at O
promoting O
infant B-outcome ['Life-Impact']
vaccination I-outcome ['Life-Impact']
. O
This O
first O
study O
evidenced O
that O
the O
intervention O
led O
to O
a O
marked O
increase O
in O
mothers' O
intention B-outcome ['Life-Impact']
to O
vaccinate, O
and O
vaccine B-outcome ['Life-Impact']
coverage O
in O
their O
infants. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Journal-Name:JAMA O
[]

BACKGROUND: O
Vaccination O
has O
a O
huge O
public O
health O
impact. O
[]

Publication O
date: O
2019/01/15 O
06:00 O
[medline] O
[]

During O
a O
total O
median O
follow-up O
of O
5.11 O
years, O
adjudicated O
probable O
dementia B-outcome ['Physiological-Clinical', 'Life-Impact']
occurred O
in O
149 O
participants O
in O
the O
intensive O
treatment O
group O
vs O
176 O
in O
the O
standard O
treatment O
group O
(7.2 O
vs O
8.6 O
cases O
per O
1000 O
person-years; O
hazard O
ratio O
[HR], O
0.83; O
95% O
CI, O
0.67-1.04). O
[['Physiological-Clinical', 'Life-Impact']]

Journal-Name:Medicine O
[]

Title: O
[Effects O
of O
berberine O
on O
the O
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
levels O
and O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
mellitus]. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Objective: O
To O
evaluate O
the O
effectiveness O
of O
SuperPATH O
approach O
in O
total O
hip O
arthroplasty O
(THA) O
compared O
with O
conventional O
posterolateral O
approach. O
[]

Title: O
Analgesic O
effect O
of O
trigger O
point O
injection O
and O
EMLA O
for O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
total O
laparoscopic O
hysterectomy: O
A O
randomized O
controlled O
study. O
[['Physiological-Clinical']]

Title: O
Process O
evaluation O
of O
a O
pilot O
multi-component O
physical O
activity O
intervention O
- O
active O
schools: O
Skelmersdale. O
[]

Journal-Name:Clinical O
interventions O
in O
aging O
[]

Further O
studies O
are O
required O
to O
demonstrate O
the O
clinical O
benefits O
and O
risks O
of O
nifedipine O
usage O
in O
embryo O
transfer. O
[]

Therefore, O
a O
novel O
system O
for O
patient O
classification O
(category O
14) O
was O
developed O
in O
the O
present O
study O
based O
on O
these O
two O
indices O
to O
assist O
in O
predicting O
the O
prognosis O
and O
therapeutic O
response. O
[]

Efficacy O
assessments O
included O
changes O
in O
baseline O
inflammatory O
and O
noninflammatory O
lesions B-outcome ['Physiological-Clinical']
and O
treatment B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
(at O
least O
2-grade O
reduction O
in O
Evaluator's O
Global O
Severity O
Score O
(EGSS) O
and O
clear/almost O
clear). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
101225531 O
[]

Surveys O
with O
established O
validity O
and O
reliability O
were O
used O
to O
measure O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress, O
emotional O
coping B-outcome ['Life-Impact']
response, O
and O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
for O
stress O
management. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Methods: O
A O
total O
of O
60 O
patients O
with O
silicosis O
complicated O
by O
stable O
COPD O
who O
were O
hospitalized O
in O
Department O
of O
Occupational O
Diseases, O
Laigang O
Hospital O
Affiliated O
to O
Taishan O
Medical O
College, O
from O
August O
2017 O
to O
April O
2018 O
were O
enrolled O
and O
randomly O
divided O
into O
control O
group O
and O
observation O
group, O
with O
30 O
patients O
in O
each O
group. O
[]

CONCLUSIONS: O
Inhalation O
aromatherapy O
using O
lavender O
essential O
oil O
can O
improve O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
of O
postmenopausal O
women O
with O
a O
reduction O
in O
the O
severity O
of O
complications B-outcome ['Adverse-effects']
and O
physical-psychological B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
. O
[['Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical', 'Life-Impact']]

Publication O
date: O
2018/11/19 O
00:00 O
[accepted] O
[]

Journal O
ID: O
9113221 O
[]

Journal-Name:Beijing O
da O
xue O
xue O
bao. O
[]

Title: O
Single O
Patient O
Classifier O
Assay, O
Microsatellite O
Instability, O
and O
Epstein-Barr O
Virus O
Status O
Predict O
Clinical O
Outcomes O
in O
Stage O
II/III O
Gastric O
Cancer: O
Results O
from O
CLASSIC O
Trial. O
[]

Publication O
date: O
2018/03/27 O
00:00 O
[accepted] O
[]

For O
all O
analyses O
a O
level O
of O
significance O
of O
95% O
(P O
< O
.05) O
will O
be O
considered. O
[]

Journal-Name:Anticancer O
research O
[]

The O
therapeutic O
benefits O
of O
LOWFODMAP O
diets O
in O
recreational O
and O
trained O
athletes O
during O
sustained O
training O
periods O
warrants O
further O
investigation. O
[]

At O
4-weeks O
post-baseline O
there O
were O
significant O
increases O
in O
identified B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
, O
integrated B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
, O
intrinsic B-outcome ['Life-Impact']
motivation I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
norms I-outcome ['Life-Impact']
and O
intentions B-outcome ['Life-Impact']
in O
intervention O
compared O
to O
control O
participants. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

We O
report O
unpublished O
data O
on O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QoL) I-outcome ['Life-Impact']
from O
the O
original O
study O
and O
the O
results O
of O
a O
follow-up O
extension. O
[['Life-Impact']]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

A O
diet O
enriched O
in O
CSO, O
a O
rich O
source O
of O
alpha-linolenic O
acid O
(ALA), O
decreased O
PBMC O
IFNG O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
(P O
< O
0.01). O
[['Physiological-Clinical']]

RESULTS: O
A O
2 O
(group) O
x O
2 O
(time) O
repeated O
measures O
ANOVA O
showed O
there O
was O
a O
significant O
main O
effect O
on O
time O
for O
increase O
in O
the O
composite O
strength B-outcome ['Life-Impact']
score O
(p O
= O
.002, O
engp2 O
= O
.18). O
[['Life-Impact']]

RESULTS: O
The O
Numeric O
rating O
scale O
of O
group O
O O
in O
the O
PACU O
was O
significantly O
lower O
(P O
<.05); O
fewer O
patients O
in O
group O
O O
required O
additional O
fentanyl B-outcome ['Resource-use']
boluses I-outcome ['Resource-use']
in O
the O
PACU O
(P O
<.05). O
[['Resource-use']]

Journal-Name:International O
journal O
of O
environmental O
research O
and O
public O
health O
[]

Title: O
[Effects O
of O
propofol O
sedation O
on O
psychological B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
in O
surgical O
patients O
under O
epidural]. O
[['Life-Impact']]

Among O
the O
men O
in O
the O
IG, O
76% O
had O
a O
positive B-outcome ['Life-Impact']
experience I-outcome ['Life-Impact']
of O
the O
counselling, O
and O
77% O
had O
received B-outcome ['Life-Impact']
new I-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
. O
CONCLUSION: O
The O
intervention O
managed O
to O
increase O
different O
aspects O
of O
men's O
fertility B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
. O
In O
the O
future, O
the O
format O
for O
preconception O
care O
for O
men O
needs O
further O
development. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Recently, O
we O
revealed O
that O
beta-Eudesmol O
ingestion O
affected O
autonomic O
nerve O
activity O
in O
an O
animal O
model. O
[]

METHODS: O
We O
used O
data O
from O
the O
Fluid O
Lavage O
of O
Open O
Wounds O
trial O
to O
determine, O
in O
1560 O
open O
fracture O
patients O
undergoing O
surgical O
repair, O
the O
association O
between O
Somatic O
PreOccupation O
and O
Coping O
(captured O
by O
the O
SPOC O
questionnaire) O
and O
recovery O
at O
1 O
yr. O
[]

Journal O
ID: O
2985248R O
[]

Hydrocephalus O
is O
seen O
in O
11.8% O
of O
children O
with O
Myelomeningocele O
(MMC). O
[]

BACKGROUND: O
Truckers O
in O
sub-Saharan O
Africa O
are O
at O
higher O
risk O
of O
contracting O
HIV O
than O
the O
general O
population. O
[]

Journal-Name:Medicine O
[]

We O
assessed O
a O
composite O
primary O
endpoint O
of O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
platelet O
recovery O
(CRp) O
, O
and O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
haematological O
recovery O
(CRi) O
achieved O
at O
any O
time O
and O
assessed O
by O
intention O
to O
treat. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Interventions: O
Patients O
were O
randomly O
allocated O
(1:1) O
to O
an O
MRI-guided O
vs O
a O
conventional O
treat-to-target O
strategy. O
[]

Title: O
The O
effect O
of O
L-theanine O
supplementation O
on O
the O
immune O
system O
of O
athletes O
exposed O
to O
strenuous O
physical O
exercise. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

However, O
knowledge O
about O
their O
effects O
on O
hemodynamics O
and O
cardiac O
efficiency O
remains O
limited O
due O
largely O
to O
the O
lack O
of O
direct O
monitoring O
method. O
[]

Participants O
were O
randomly O
assigned O
in O
a O
1:1 O
ratio O
to O
either O
endometrial O
scratching O
(by O
pipelle O
biopsy O
between O
day O
3 O
of O
the O
cycle O
preceding O
the O
embryo-transfer O
cycle O
and O
day O
3 O
of O
the O
embryo-transfer O
cycle) O
or O
no O
intervention. O
[]

Journal-Name:Medicine O
[]

OBJECTIVE: O
In O
view O
of O
the O
high O
incidence O
of O
polycystic O
ovary O
syndrome O
(PCOS) O
and O
the O
unsatisfactory O
therapeutic O
effects O
of O
dimethyldiguanide O
or O
clomifene O
citrate O
alone, O
our O
study O
aimed O
to O
investigate O
the O
therapeutic O
effects O
of O
dimethyldiguanide O
combined O
with O
clomifene O
citrate O
in O
the O
treatment O
of O
PCOS. O
[]

Title: O
Impact O
of O
pharmacotherapeutic O
education O
on O
medication O
adherence B-outcome ['Life-Impact']
and O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
in O
patients O
with O
type O
2 O
diabetes O
mellitus: O
a O
prospective, O
randomized O
study. O
[['Life-Impact'], ['Adverse-effects']]

TRIAL O
REGISTRATION O
NUMBER: O
UMIN-CTR O
Study O
Design: O
trial O
number: O
UMIN000022032. O
[]

Title: O
Comparison O
of O
analgesic B-outcome ['Resource-use']
efficacy O
of O
oxycodone O
and O
fentanyl O
after O
total O
hip O
replacement O
surgery: O
A O
randomized O
controlled O
trial. O
[['Resource-use']]

Both O
intervention O
groups O
aimed O
for O
equivalent O
weight O
loss O
(6-7%) O
following O
a O
calorie-restricted O
diet O
(diet O
group) O
or O
a O
partly O
supervised O
intensive O
exercise O
programme O
(4 O
h O
per O
week) O
combined O
with O
a O
small O
caloric O
restriction O
(exercise O
plus O
diet O
group). O
[]

The O
primary O
safety O
end O
point O
was O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
RESULTS: O
Of O
1080 O
enrolled O
patients, O
49 O
(4.5%) O
had O
thrombosis O
at O
screening O
and O
did O
not O
undergo O
randomization. O
[['Physiological-Clinical']]

The O
deadline O
for O
follow-up O
was O
June O
2017 O
and O
the O
incidence O
of O
thromboembolism B-outcome ['Physiological-Clinical']
events O
within O
6 O
months O
after O
operation O
was O
counted. O
[['Physiological-Clinical']]

Dual O
trigger O
may O
be O
preferable O
to O
reduce O
the O
risk O
of O
OHSS. O
[]

Title: O
The O
efficacy O
of O
cervical O
spine O
phantoms O
for O
improving O
resident O
proficiency B-outcome ['Life-Impact']
in O
performing O
ultrasound-guided O
cervical O
medial O
branch O
block: O
A O
prospective, O
randomized, O
comparative O
study. O
[['Life-Impact']]

INTERPRETATION: O
Compared O
with O
ICSI, O
PICSI O
does O
not O
significantly O
improve O
term O
livebirth B-outcome ['Mortality']
rates. O
[['Mortality']]

Of O
the O
841 O
patients O
who O
underwent O
randomization, O
the O
primary O
end O
point O
occurred O
in O
25 O
of O
420 O
patients O
(6.0%) O
in O
the O
rivaroxaban O
group O
and O
in O
37 O
of O
421 O
(8.8%) O
in O
the O
placebo O
group O
(hazard O
ratio, O
0.66; O
95% O
confidence O
interval O
[CI], O
0.40 O
to O
1.09; O
P O
= O
0.10) O
in O
the O
period O
up O
to O
day O
180. O
[]

All O
canals O
were O
cleaned O
and O
shaped O
with O
Reciproc O
instruments, O
and O
were O
used O
with O
a O
micro O
motor O
(VDW, O
Munich O
Germany). O
[]

The O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
length B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
incision I-outcome ['Life-Impact']
, O
and O
perioperative O
complications B-outcome ['Adverse-effects']
related O
to O
operation O
were O
recorded. O
[['Life-Impact'], ['Resource-use'], ['Life-Impact'], ['Adverse-effects']]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

Journal O
ID: O
7807333 O
[]

These O
findings O
were O
potentially O
explained O
by O
within-group O
significance O
for O
the O
same O
variables O
for O
the O
first O
10 O
min O
split O
(P O
</= O
0.01), O
and O
for O
distance O
covered O
(P O
= O
0.01) O
in O
the O
second O
10-min O
split. O
[]

Consequently, O
the O
overall B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
decreased O
in O
EMLA O
group O
and O
TPI O
group O
(P O
= O
.023). O
[['Physiological-Clinical']]

The O
results O
showed O
that O
there O
was O
a O
significant O
difference O
between O
the O
mean O
scores O
of O
pre-test O
(before O
MBI) O
and O
post-test O
(after O
MBI) O
in O
the O
experimental O
group O
compared O
to O
the O
control O
group, O
and O
MBCT O
had O
a O
significant O
effect O
on O
the O
perception B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the O
disease O
and O
the O
psychological B-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
in O
the O
experimental O
group O
compared O
to O
the O
control O
group. O
[['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

Title: O
Intermittent O
exercise-heat O
exposures O
and O
intense O
physical O
activity O
sustain O
heat B-outcome ['Physiological-Clinical']
acclimation I-outcome ['Physiological-Clinical']
adaptations. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/23 O
06:00 O
[entrez] O
[]

All O
the O
clinical O
and O
biochemical O
parameters O
were O
routinely O
evaluated O
before O
and O
after O
treatment. O
[]

Journal O
ID: O
101238455 O
[]

The O
efficacy O
of O
short- O
and O
long-TXA O
protocols O
in O
the O
reduction O
of O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL) O
was O
compared O
with O
a O
placebo O
group. O
[['Physiological-Clinical']]

RESULTS: O
Between O
September O
2014 O
and O
October O
2015, O
we O
recruited O
and O
randomly O
assigned O
37 O
clusters O
(from O
nine O
organisations; O
mean O
clusters O
per O
organisation O
= O
four) O
and O
853 O
participants O
to O
the O
intervention O
(n O
= O
19 O
with O
457 O
participants) O
or O
control O
group O
(n O
= O
18 O
with O
396 O
participants). O
[]

Publication O
Type: O
Journal O
Article O
[]

CONCLUSIONS: O
Systematic O
pelvic O
and O
paraaortic O
lymphadenectomy O
in O
patients O
with O
advanced O
ovarian O
cancer O
who O
had O
undergone O
intraabdominal O
macroscopically O
complete O
resection O
and O
had O
normal O
lymph O
nodes O
both O
before O
and O
during O
surgery O
was O
not O
associated O
with O
longer O
overall B-outcome ['Mortality', 'Physiological-Clinical']
or Seperator ['Mortality', 'Physiological-Clinical']
progression-free B-outcome ['Mortality', 'Physiological-Clinical']
survival E1-outcome ['Mortality', 'Physiological-Clinical']
than O
no O
lymphadenectomy O
and O
was O
associated O
with O
a O
higher O
incidence O
of O
postoperative O
complications B-outcome ['Adverse-effects']
. O
(Funded O
by O
Deutsche O
Forschungsgemeinschaft O
and O
the O
Austrian O
Science O
Fund; O
LION O
ClinicalTrials.gov O
number, O
NCT00712218.). O
[['Mortality', 'Physiological-Clinical'], ['Adverse-effects']]

The O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
at O
3 O
years O
was O
63.4% O
in O
the O
modified-FOLFIRINOX O
group O
and O
48.6% O
in O
the O
gemcitabine O
group. O
[['Mortality']]

Journal O
ID: O
101212761 O
[]

Journal O
ID: O
100968555 O
[]

At O
day O
5, O
composite O
cure B-outcome ['Physiological-Clinical']
was O
observed O
in O
88.0% O
of O
the O
patients O
(168 O
of O
191 O
patients) O
in O
the O
plazomicin O
group O
and O
in O
91.4% O
(180 O
of O
197 O
patients) O
in O
the O
meropenem O
group O
(difference, O
-3.4 O
percentage O
points; O
95% O
confidence O
interval O
[CI], O
-10.0 O
to O
3.1). O
[['Physiological-Clinical']]

RESULTS: O
The O
daily O
administration O
of O
250 O
mg O
of O
elemental O
Mg O
indicated O
a O
significant O
improvement O
in O
HbA1C B-outcome ['Physiological-Clinical']
(8.32 O
to O
7.96%, O
p O
< O
0.001), O
insulin B-outcome ['Physiological-Clinical']
levels O
(IL) O
(15.56 O
to O
12.18 O
muIU/mL, O
p O
< O
0.001), O
C-peptide B-outcome ['Physiological-Clinical']
(2.28 O
to O
1.90 O
ng/mL, O
p O
= O
0.001), O
HOMA.IR B-outcome ['Physiological-Clinical']
(6.16 O
to O
4.44, O
p O
< O
0.001) O
and O
HOMA.beta B-outcome ['Physiological-Clinical']
% O
(59.99 O
to O
52.37, O
p O
= O
0.036) O
of O
the O
intervention O
group O
when O
compared O
with O
the O
control O
group O
after O
three O
months O
of O
intervention. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

There O
were O
5 O
cases O
of O
"shell" B-outcome ['Physiological-Clinical']
phenomenon I-outcome ['Physiological-Clinical']
in O
the O
treatment O
group O
and O
4 O
cases O
of O
nonunion B-outcome ['Physiological-Clinical']
at O
last O
follow-up, O
23 O
cases O
of O
"shell" B-outcome ['Physiological-Clinical']
phenomenon I-outcome ['Physiological-Clinical']
in O
the O
control O
group O
and O
19 O
cases O
of O
nonunion B-outcome ['Physiological-Clinical']
at O
last O
follow-up; O
there O
was O
a O
significant O
difference O
between O
the O
two O
groups O
( O
P<0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
A O
single-blind O
randomized O
controlled O
trial O
was O
performed. O
[]

Of O
10 O
key O
secondary O
end O
points, O
8 O
were O
null O
and O
2 O
showed O
statistically O
significant O
benefit O
for O
the O
MRI O
treat-to-target O
group. O
[]

No O
robotic O
rehabilitation O
session O
had O
to O
be O
replaced B-outcome ['Life-Impact']
by O
conventional O
rehabilitation. O
[['Life-Impact']]

BACKGROUND: O
Persistent O
post-surgical O
pain O
and O
associated O
disability O
are O
common O
after O
a O
traumatic O
fracture O
repair. O
[]

After O
a O
10-min O
rest, O
they O
exercised O
to O
a O
Trec O
of O
39.5 O
degrees O
C. O
Subsequently, O
they O
underwent O
CWI O
(9.99 O
+/- O
0.03 O
degrees O
C) O
until O
Trec O
reached O
38 O
degrees O
C. O
On O
control O
(CON) O
days, O
the O
same O
procedures O
occurred O
without O
the O
15-min O
PC O
intervention. O
[]

PURPOSE: O
The O
purpose O
of O
this O
study O
is O
to O
translate O
laboratory-based O
research O
on O
beverage-based O
supplements O
to O
a O
naturalistic, O
field O
setting O
in O
adolescent O
athletes. O
[]

Journal-Name:Ophthalmic O
epidemiology O
[]

Journal O
ID: O
0372541 O
[]

Ixazomib O
is O
ideally O
suited O
for O
maintenance O
therapy O
given O
its O
convenient O
once-weekly O
oral O
dosing O
and O
low O
toxicity O
profile. O
[]

Journal O
ID: O
101627676 O
[]

METHODS: O
This O
prospective, O
interventional, O
randomized O
clinical O
study O
was O
done O
at O
Alpha O
Vision O
Center, O
Zagazig, O
Egypt. O
[]

SETTING: O
Athletic O
training O
rooms. O
[]

Title: O
EYE O
LENS O
RADIATION O
EXPOSURE O
OF O
WORKERS O
DURING O
MEDICAL O
INTERVENTIONAL O
PROCEDURES O
AND O
SURGERY. O
[]

RESULTS: O
Better O
scores O
were O
observed O
with O
the O
forearm O
band, O
as O
compared O
with O
no O
orthosis, O
for O
multiple O
outcomes O
including O
joint B-outcome ['Physiological-Clinical']
position I-outcome ['Physiological-Clinical']
reproduction I-outcome ['Physiological-Clinical']
score O
at O
70 O
degrees O
of O
elbow O
flexion O
(P O
= O
.006), O
pain B-outcome ['Physiological-Clinical']
(P O
< O
.001), O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
(P O
= O
.01), O
and O
dexterity B-outcome ['Physiological-Clinical']
(P O
< O
.001). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Secondary O
analyses O
included O
the O
progression B-outcome ['Physiological-Clinical']
of O
symptoms, O
as O
measured O
by O
the O
UPDRS O
score, O
between O
weeks O
4 O
and O
40 O
and O
the O
noninferiority O
of O
early O
initiation O
of O
treatment O
to O
delayed O
initiation O
between O
weeks O
44 O
and O
80, O
with O
a O
noninferiority O
margin O
of O
0.055 O
points O
per O
week. O
[['Physiological-Clinical']]

Captured O
drug O
was O
quantified O
using O
Eu-labeled O
protein O
A O
and O
time-resolved O
fluorescence. O
[]

Results: O
Among O
559 O
randomized O
participants O
(mean O
age, O
67 O
years; O
277 O
[50%] O
women), O
556 O
(99.5%) O
completed O
the O
trial O
and O
were O
included O
in O
the O
analysis. O
[]

Title: O
Partial O
thickness O
cornea O
tissue O
from O
small O
incision O
lenticule O
extraction: O
A O
novel O
patch O
graft O
in O
glaucoma O
drainage O
implant O
surgery. O
[]

During O
each O
session, O
participants O
used O
one O
of O
three O
products O
(cigarette, O
e-cigarette, O
or O
IQOS(TM)) O
for O
five O
minutes. O
[]

Between-group O
differences O
were O
not O
significant. O
[]

Journal O
ID: O
101234168 O
[]

METHODS: O
We O
randomly O
assigned O
adults O
attending O
U.K. O
National O
Health O
Service O
stop-smoking O
services O
to O
either O
nicotine-replacement O
products O
of O
their O
choice, O
including O
product O
combinations, O
provided O
for O
up O
to O
3 O
months, O
or O
an O
e-cigarette O
starter O
pack O
(a O
second-generation O
refillable O
e-cigarette O
with O
one O
bottle O
of O
nicotine O
e-liquid O
[18 O
mg O
per O
milliliter]), O
with O
a O
recommendation O
to O
purchase O
further O
e-liquids O
of O
the O
flavor O
and O
strength O
of O
their O
choice. O
[]

CONCLUSIONS: O
The O
TFP O
(25 O
mug/h) O
affixed O
14 O
h O
before O
surgery O
reached O
a O
higher O
constant B-outcome ['Life-Impact']
concentration I-outcome ['Life-Impact']
than O
the O
same O
dose O
setting O
of O
a O
constant O
IV O
infusion O
of O
fentanyl O
after O
surgery. O
[['Life-Impact']]

The O
data O
sources O
were O
pooled O
to O
produce O
the O
themes O
presented O
in O
the O
results O
section. O
[]

In O
this O
single-blind O
randomized O
crossover O
study, O
overweight/obese O
healthy O
males O
consumed O
a O
test O
breakfast O
and O
lunch O
containing O
either O
48 O
g O
RS O
or O
a O
placebo. O
[]

Publication O
Type: O
Journal O
Article, O
Multicenter O
Study, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
Non-U.S. O
Gov't, O
[]

BACKGROUND: O
Many O
men O
have O
limited O
knowledge O
about O
reproductive O
health O
and O
fertility. O
[]

The O
CD8+ O
T O
cells O
were O
isolated O
from O
the O
peripheral O
blood O
and O
their O
phenotype O
was O
analyzed O
by O
flow O
cytometry. O
[]

CONCLUSIONS: O
Postdischarge O
MRSA O
decolonization O
with O
chlorhexidine O
and O
mupirocin O
led O
to O
a O
30% O
lower O
risk O
of O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
than O
education O
alone. O
( O
[['Physiological-Clinical']]

This O
study O
was O
conducted O
on O
240 O
patients O
of O
dyslipidemia O
(as O
per O
ACC/AHA O
2013 O
lipid O
guidelines) O
attending O
the O
OPD/wards/CCU O
of O
department O
of O
cardiology, O
Sir O
Ganga O
Ram O
Hospital. O
[]

Publication O
Type: O
Journal O
Article O
[]

Title: O
Treatment B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
indacaterol/glycopyrronium O
versus O
salmeterol/fluticasone O
in O
exacerbating O
COPD O
patients O
by O
gender: O
a O
post-hoc O
analysis O
in O
the O
FLAME O
study. O
[['Physiological-Clinical']]

The O
rates O
of O
dyskinesia B-outcome ['Physiological-Clinical']
and O
levodopa-related O
fluctuations O
in O
motor B-outcome ['Physiological-Clinical', 'Life-Impact']
response I-outcome ['Physiological-Clinical', 'Life-Impact']
did O
not O
differ O
significantly O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact']]

Secondary O
outcomes O
include O
any O
maternal O
or O
fetal O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
miscarriage B-outcome ['Mortality']
, O
pregnancy B-outcome ['Physiological-Clinical']
, O
live B-outcome ['Mortality']
births I-outcome ['Mortality']
, O
and O
neonatal B-outcome ['Physiological-Clinical']
outcomes. O
[['Adverse-effects'], ['Mortality'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical']]

Journal-Name:The O
western O
journal O
of O
emergency O
medicine O
[]

In O
the O
dry O
needling O
group, O
all O
the O
effect O
sizes O
for O
headache O
variables O
were O
large. O
[]

Subpopulations O
of O
T B-outcome ['Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
(Tregs) I-outcome ['Physiological-Clinical']
( O
CD4+ B-outcome ['Physiological-Clinical']
/ O
CD25+ B-outcome ['Physiological-Clinical']
/ O
CD127- B-outcome ['Physiological-Clinical']
), O
cytotoxic B-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
(CTLs) I-outcome ['Physiological-Clinical']
( O
CD8+ B-outcome ['Physiological-Clinical']
/ O
TCRalphabeta+ B-outcome ['Physiological-Clinical']
), O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
(NK) I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( O
CD3- B-outcome ['Physiological-Clinical']
/ O
CD16+ B-outcome ['Physiological-Clinical']
/ O
CD56+ B-outcome ['Physiological-Clinical']
) O
and O
TCRdeltagamma-positive B-outcome ['Physiological-Clinical']
(Tdeltagamma) I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
determined O
by O
means O
of O
flow O
cytometry. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Devices O
that O
promote O
interaction O
with O
tasks O
on O
computers O
can O
enhance O
performance O
and O
lead O
to O
greater O
independence O
and O
utilization O
of O
technology. O
[]

A O
prenatal O
diet O
affects O
materno-foetal O
outcomes. O
[]

Journal O
ID: O
2985213R O
[]

Measures O
included O
a O
composite O
strength B-outcome ['Life-Impact']
score O
(bench O
press O
+ O
squat). O
[['Life-Impact']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Journal O
ID: O
0404312 O
[]

BACKGROUND: O
Registered O
healthcare O
workers O
worldwide O
have O
a O
high O
prevalence O
of O
work-related O
musculoskeletal O
disorders, O
particularly O
of O
the O
back. O
[]

RESULTS: O
Endometrial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
increased O
significantly O
to O
8.67 O
+/- O
0.64 O
in O
PRP O
group O
than O
in O
controls O
(p O
= O
0.001). O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

Title: O
Fracture O
Prevention O
with O
Zoledronate O
in O
Older O
Women O
with O
Osteopenia. O
[]

METHODS: O
We O
conducted O
a O
pragmatic, O
multicenter, O
open-label, O
randomized, O
controlled O
trial. O
[]

Title: O
Hybrid O
Minimally O
Invasive O
Esophagectomy O
for O
Esophageal O
Cancer. O
[]

Conclusion: O
The O
treatment O
of O
thoracolumbar O
fracture O
with O
short-segment O
fixation O
combined O
with O
injured O
vertebral O
reconstruction O
can O
effectively O
prevent O
the O
"shell" B-outcome ['Physiological-Clinical']
phenomenon I-outcome ['Physiological-Clinical']
, O
which O
is O
conducive O
to O
maintaining O
the O
height O
of O
injured O
vertebral O
and O
improving O
the O
long-term O
function. O
[['Physiological-Clinical']]

This O
study O
aimed O
to O
describe O
the O
playfulness B-outcome ['Life-Impact']
in O
children O
with O
HIV O
and O
PHE O
on O
HAART O
living O
in O
challenging O
socioeconomic O
areas O
in O
South O
Africa O
aged O
6 O
months O
to O
8 O
years O
and O
to O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
and O
preliminary O
effectiveness O
of O
a O
play-informed, O
caregiver-implemented, O
home-based O
intervention O
(PICIHBI) O
for O
improving O
play. O
[['Life-Impact'], ['Life-Impact']]

Funded O
by O
R&D O
Unicancer O
and O
others; O
ClinicalTrials.gov O
number, O
NCT01526135 O
; O
EudraCT O
number, O
2011-002026-52 O
.). O
[]

Before O
program O
implementation, O
the O
schools O
were O
stratified O
by O
sub-county O
and O
randomized O
to O
one O
of O
four O
study O
arms O
(35 O
schools O
per O
arm): O
1) O
control, O
2) O
disposable O
sanitary O
pads O
distribution, O
2) O
reproductive O
health O
education, O
and O
4) O
sanitary O
pad O
distribution O
and O
reproductive O
health O
education. O
[]

Results: O
19 O
patients O
were O
randomly O
distributed O
in O
57.89% O
in O
the O
G2 O
and O
42.11% O
in O
the O
G1. O
[]

Title: O
To O
study O
the O
effect O
of O
high O
dose O
Atorvastatin O
40mg O
versus O
80mg O
in O
patients O
with O
dyslipidemia. O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

OBJECTIVE: O
To O
compare O
the O
hemostatic B-outcome ['Physiological-Clinical']
effect O
of O
hematostatic O
agent O
Surgiflo O
and O
absorbable O
gelatin O
sponge O
(AGS) O
in O
posterior O
lumbar O
surgery. O
[['Physiological-Clinical']]

Objective: O
To O
explore O
the O
surgical O
treatment O
strategy O
of O
the O
vertebral O
"shell" O
after O
thoracolumbar O
fracture, O
and O
provide O
clinical O
reference O
for O
the O
intervention O
and O
treatment O
of O
"shell". O
[]

Journal-Name:Terapevticheskii O
arkhiv O
[]

No O
significant O
effects O
were O
found O
for O
sprint B-outcome ['Physiological-Clinical']
variables O
(P O
> O
0.05) O
with O
comparable O
values O
at O
T3 O
for O
mean O
distance B-outcome ['Physiological-Clinical']
(betaA1: O
163.9 O
+/- O
3.8 O
m; O
betaA2: O
161.2 O
+/- O
3.5 O
m; O
PL: O
162.7 O
+/- O
3.6 O
m), O
average O
power B-outcome ['Physiological-Clinical']
(betaA1: O
352.7 O
+/- O
14.5 O
W; O
betaA2: O
342.2 O
+/- O
13.5 O
W; O
PL: O
348.2 O
+/- O
13.9 O
W) O
and O
lactate B-outcome ['Physiological-Clinical']
(betaA1: O
10.0 O
+/- O
0.9 O
mmol. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE: O
The O
assessment O
of O
pelvis O
reposition O
exercise O
efficacy O
in O
the O
treatment O
of O
pelvic O
floor O
muscles O
(PFM) O
asymmetry. O
[]

Chlorhexidine O
is O
most O
widely O
used O
antiseptic O
which O
is O
thought O
to O
be O
helpful O
to O
prevent O
alveolar O
osteitis. O
[]

Injection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
reported O
by O
11 O
of O
28 O
(39%) O
in O
the O
Group O
N O
and O
in O
2 O
of O
28 O
(7%) O
in O
the O
Group O
R O
(difference O
in O
proportion: O
32%, O
95% O
CI: O
10-51%, O
P O
= O
.01). O
[['Physiological-Clinical']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

There O
were O
98 O
male O
and O
131 O
female O
patients, O
with O
a O
mean O
age O
of O
65.5 O
years O
(32 O
to O
91). O
[]

Methods: O
A O
total O
of O
114 O
T2DM O
inpatients O
or O
outpatients, O
including O
46 O
males O
and O
68 O
females O
aged O
(55+/-14) O
years O
between O
January O
2015 O
and O
January O
2016 O
were O
randomly O
divided O
into O
two O
groups: O
the O
control O
group O
(n=57) O
only O
with O
hypoglycemic O
agents, O
and O
the O
intervention O
group O
(n=57) O
with O
berberine O
(0.4 O
g, O
3 O
times O
a O
day) O
on O
the O
basis O
of O
treatment O
from O
the O
control O
group. O
[]

Conclusion O
We O
demonstrated O
the O
feasibility B-outcome ['Life-Impact']
and O
acceptability B-outcome ['Life-Impact']
of O
the O
use O
of O
a O
robotic O
walking O
aid O
from O
the O
perspective O
of O
both O
older O
individuals O
and O
physiotherapists. O
[['Life-Impact'], ['Life-Impact']]

METHODS: O
We O
evaluated O
40 O
patients O
aged O
>/=18 O
years O
who O
underwent O
elective O
muscle O
sparing O
thoracotomies. O
[]

METHODS: O
A O
total O
of O
82 O
patients O
with O
UIAS O
were O
randomly O
assigned O
to O
2 O
groups O
that O
received O
NMES O
therapy O
(NMES O
group) O
or O
sham O
NMES O
(sham O
group) O
for O
10 O
weeks. O
[]

Electromyography O
was O
used O
to O
objectively O
evaluate O
eyestrain B-outcome ['Physiological-Clinical']
. O
Linear O
mixed O
models O
were O
used O
to O
assess O
differences O
between O
toric O
and O
spherical O
contact O
lenses. O
[['Physiological-Clinical']]

Title: O
Does O
all O
single O
infarction O
have O
lower O
risk O
of O
stroke B-outcome ['Physiological-Clinical']
recurrence O
than O
multiple O
infarctions O
in O
minor O
stroke? O
[['Physiological-Clinical']]

Journal O
ID: O
0373125 O
[]

This O
study O
was O
aimed O
to O
compare O
the O
prophylactic O
effects O
of O
paracetamol O
and O
dexmedetomidine O
for O
controlling O
hemodynamics B-outcome ['Physiological-Clinical']
during O
surgery O
and O
postoperative O
pain B-outcome ['Physiological-Clinical']
. O
METHODS: O
The O
study O
population O
consisted O
of O
132 O
patients O
aged O
18 O
to O
70 O
years O
and O
from O
both O
genders, O
who O
were O
candidates O
for O
emergency O
cholecystectomy O
or O
elective O
surgery. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Objective: O
To O
investigate O
the O
clinical O
effect O
of O
nursing O
intervention O
for O
respiratory O
function O
exercise O
in O
patients O
with O
silicosis O
complicated O
by O
stable O
chronic O
obstructive O
pulmonary O
disease O
(COPD) O
. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

Clinical O
and O
radiographic O
assessments O
of O
abutments B-outcome ['Physiological-Clinical']
and O
crowns B-outcome ['Physiological-Clinical']
, O
peri-implant B-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
, O
and O
marginal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
levels O
were O
recorded. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BTX-A O
is O
thus O
a O
potential O
treatment O
option O
for O
patients O
with O
intractable O
DED. O
[]

Interventions: O
Hospitals O
randomized O
to O
the O
intervention O
(n O
= O
131 O
[6436 O
patients]) O
provided O
patients O
with O
co-payment O
vouchers O
for O
clopidogrel O
or O
ticagrelor O
for O
1 O
year O
(median O
voucher O
value O
for O
a O
30-day O
supply, O
$137 O
[25th-75th O
percentile, O
$20-$339]). O
[]

The O
EIFEL O
score O
and O
the O
Dallas O
Pain B-outcome ['Physiological-Clinical']
Questionnaire O
score O
had O
a O
similar O
evolution O
over O
time O
between O
groups O
(P O
= O
.18 O
and O
P O
= O
.50 O
respectively). O
[['Physiological-Clinical']]

PURPOSE: O
This O
report O
assesses O
functional B-outcome ['Life-Impact']
mobility I-outcome ['Life-Impact']
in O
children O
with O
neurological O
impairments O
and O
documented O
gross O
motor O
delays, O
before O
and O
after O
receiving O
either O
hippotherapy O
or O
standard O
outpatient O
physical O
therapy O
(PT). O
[['Life-Impact']]

Plasma O
vitamins B-outcome ['Physiological-Clinical']
and O
phytonutrients B-outcome ['Physiological-Clinical']
were O
significantly O
correlated O
with O
ROS O
scavenging O
and O
DNA O
damage. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Respiratory O
research O
[]

Total O
distance B-outcome ['Physiological-Clinical']
(m), O
average O
power B-outcome ['Physiological-Clinical']
(W), O
relative O
average O
power B-outcome ['Physiological-Clinical']
(W.kg(- O
1)), O
cardio-respiratory B-outcome ['Physiological-Clinical']
measures O
and O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
were O
assessed O
for O
each O
10-min O
split. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Within O
groups, O
there O
were O
also O
significant O
differences O
at O
different O
times O
(P O
< O
.05).The O
rESWT O
combined O
with O
rehabilitation O
can O
quickly O
and O
effectively O
relieve O
paralysis B-outcome ['Physiological-Clinical', 'Life-Impact']
of O
lower O
extremities, O
reduce O
the O
tension B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
hamstrings I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
calf I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
muscles S2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
relieve O
muscle B-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
, O
and O
rapidly O
improve O
limb B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
children O
with O
spastic O
cerebral O
palsy. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

RESULTS: O
A O
total O
of O
445 O
patients O
were O
randomly O
assigned: O
222 O
to O
the O
early-start O
group O
and O
223 O
to O
the O
delayed-start O
group. O
[]

PMID: O
31618328 O
[]

The O
implantation B-outcome ['Physiological-Clinical']
rate O
and O
per-cycle O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate O
were O
significantly O
higher O
in O
PRP O
group O
(p O
= O
0.002 O
and O
0.044, O
respectively O
(p O
= O
0.002). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/19 O
06:00 O
[entrez] O
[]

Publication O
date: O
2019/01/31 O
06:00 O
[entrez] O
[]

METHODS: O
One O
hundred O
twenty-four O
eligible O
patients O
with O
AGC O
were O
included O
in O
this O
randomized O
controlled O
trial. O
[]

CONCLUSIONS: O
In O
this O
study O
on O
patients O
with O
chronic O
low O
back O
pain O
and O
Modic O
changes O
at O
the O
level O
of O
a O
previous O
disc O
herniation, O
three O
months O
of O
treatment O
with O
amoxicillin O
did O
not O
provide O
a O
clinically O
important O
benefit O
compared O
with O
placebo. O
[]

Title: O
Mothers O
In O
Motion O
intervention O
effect O
on O
psychosocial B-outcome ['Life-Impact', 'Life-Impact']
health I-outcome ['Life-Impact', 'Life-Impact']
in O
young, O
low-income O
women O
with O
overweight O
or O
obesity. O
[['Life-Impact', 'Life-Impact']]

BACKGROUND: O
Magnesium O
(Mg) O
supplementation O
may O
help O
control O
glycemic O
response O
among O
type O
2 O
diabetes O
(T2D) O
patients. O
[]

Interventions: O
Patients O
were O
randomized O
to O
1 O
of O
4 O
groups O
receiving O
postoperative O
analgesia O
with O
IV O
acetaminophen O
or O
placebo O
every O
6 O
hours O
for O
48 O
hours O
and O
postoperative O
sedation O
with O
dexmedetomidine O
or O
propofol O
starting O
at O
chest O
closure O
and O
continued O
for O
up O
to O
6 O
hours O
(acetaminophen O
and O
dexmedetomidine: O
n O
= O
29; O
placebo O
and O
dexmedetomidine: O
n O
= O
30; O
acetaminophen O
and O
propofol: O
n O
= O
31; O
placebo O
and O
propofol: O
n O
= O
30). O
[]

Journal O
ID: O
7511141 O
[]

Undesirable B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
occurred O
in O
137 O
patients O
(22.3%) O
in O
the O
guided O
and O
95 O
(15.4%) O
in O
the O
usual O
care O
group. O
[['Physiological-Clinical']]

All O
groups O
perceived O
the O
instruction O
as O
effective. O
[]

Patients O
with O
coexisting O
cataract O
and O
glaucoma O
were O
randomized O
to O
receive O
either O
phaco-viscocanalostomy O
(Phacovisco O
group) O
(39 O
eyes) O
or O
phaco-viscocanalostomy O
with O
Ologen(R) O
implant O
(OloPhacovisco O
group) O
(40 O
eyes). O
[]

Before O
treatment, O
the O
average O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
in O
Novafen O
and O
Ginger O
users O
were O
7.12 O
+/- O
2.32 O
and O
7.60 O
+/- O
1.84, O
respectively O
and O
after O
treatment O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
decreased O
to O
3.10 O
+/- O
2.69 O
and O
2.97 O
+/- O
2.69, O
respectively. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

We O
used O
minimally O
invasive O
technique O
pressure O
recording O
analytical O
method O
(PRAM) O
to O
directly O
monitor O
hemodynamics B-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
efficiency O
and O
compared O
the O
effects O
of O
the O
two O
anesthetic O
regimens O
in O
children O
undergoing O
ventricular O
septal O
defect O
repair. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Multicenter O
Study O
[]

Journal O
ID: O
100940562 O
[]

AIM: O
To O
evaluate O
the O
impact O
of O
pharmacotherapeutic O
education O
on O
30-day O
post-discharge O
medication O
adherence B-outcome ['Life-Impact']
and O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM). O
[['Life-Impact'], ['Adverse-effects']]

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
influence O
of O
5-minute O
SMV O
application O
along O
with O
supervised O
physical O
therapy O
(SPT) O
on O
improving O
activities B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
and O
motor B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
on O
the O
hemiparetic O
upper O
extremity O
in O
patients O
with O
stroke. O
[['Life-Impact'], ['Physiological-Clinical']]

Title: O
The O
effect O
of O
progressive O
muscle O
relaxation O
on O
cancer O
patients' O
self-efficacy B-outcome ['Life-Impact']
. O
[['Life-Impact']]

Primary O
endpoint O
was O
the O
ratio B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
operator I-outcome ['Life-Impact']
received I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
in O
mrem O
to O
total O
radiation O
in O
Gyat O
the O
end O
of O
the O
procedure O
which O
was O
designated O
''Relative O
operator O
exposure'', O
with O
or O
without O
RADPAD. O
[['Life-Impact']]

Journal O
ID: O
2985248R O
[]

METHODS: O
This O
study O
was O
designed O
as O
a O
randomized, O
double-blind, O
sham O
control O
trial. O
[]

Aim: O
To O
clinically O
assess O
the O
efficacy O
of O
resin O
infiltration O
versus O
fluoride O
varnish O
for O
arresting O
white B-outcome ['Physiological-Clinical']
spot I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
(WSLs) I-outcome ['Physiological-Clinical']
on O
permanent O
teeth O
in O
children. O
[['Physiological-Clinical']]

More O
focus O
could O
be O
put O
into O
an O
education O
tool O
for O
other O
caregivers O
who O
wish O
to O
hold O
the O
baby. O
[]

L(- O
1)) O
was O
monitored O
pre-post O
time-trial O
and O
following O
maximal O
sprint O
efforts. O
[]

Title: O
Comparison O
the O
cost-efficacy O
of O
furazolidone-based O
versus O
clarithromycin-based O
quadruple O
therapy O
in O
initial O
treatment O
of O
Helicobacter O
pylori O
infection O
in O
a O
variable O
clarithromycin O
drug-resistant O
region, O
a O
single-center, O
prospective, O
randomized, O
open-label O
study. O
[]

Transcutaneous O
electrical O
acupoint O
stimulation O
(TEAS) O
is O
a O
emerging O
treatment O
which O
combines O
transcutaneous O
electrical O
nerve O
stimulation O
with O
traditional O
acupoint O
therapy. O
[]

Journal-Name:Medicine O
[]

This O
could O
fill O
the O
gap O
between O
devices O
that O
fully O
compensate O
for O
walking O
and O
those O
which O
allow O
patients O
to O
maintain O
residual O
mobility. O
[]

CONCLUSION: O
Music O
therapy O
had O
a O
significant O
and O
positive O
impact O
on O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
acting O
on O
prevention O
of O
cardiovascular O
diseases, O
major O
threats O
to O
modern O
society. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Publication O
date: O
2019/01/01 O
06:00 O
[medline] O
[]

There O
were O
no O
significantly O
difference O
of O
the O
numbers O
of O
bucking B-outcome ['Physiological-Clinical']
or O
body B-outcome ['Physiological-Clinical']
moving I-outcome ['Physiological-Clinical']
, O
the O
satisfaction B-outcome ['Life-Impact']
of O
operators O
and O
patients, O
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
(all O
P>0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Adverse-effects']]

Therefore, O
treatment O
with O
natural O
herbal O
medicine, O
non-synthetic O
drug, O
to O
reduce O
primary B-outcome ['Physiological-Clinical']
dysmenorrhea I-outcome ['Physiological-Clinical']
is O
recommended. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/05 O
06:00 O
[medline] O
[]

Baltimore O
Community-based O
Organizations O
Neighborhood O
Network: O
Enhancing O
Capacity O
Together O
(CONNECT) O
was O
a O
randomized, O
controlled O
trial O
based O
on O
the O
core O
tenets O
of O
the O
World O
Health O
Organization's O
(WHO) O
African O
Partnerships O
for O
Patient O
Safety O
Community O
Engagement O
(ACE) O
approach. O
[]

PURPOSE: O
To O
determine O
the O
effects O
of O
botulinum O
toxin O
type O
A O
(BTX-A) O
injection O
on O
dry B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
eye I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
signs I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, Seperator ['Physiological-Clinical', 'Physiological-Clinical']
symptoms S2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
and O
tear O
cytokine B-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
intractable O
dry O
eye O
disease O
(DED). O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/02/26 O
06:00 O
[entrez] O
[]

Improvement O
in O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
was O
achieved O
by O
the O
intervention O
group O
(n O
= O
13) O
with O
a O
median O
decrease O
of O
2.1% O
body O
fat O
compared O
with O
a O
non-exercising O
group O
(n O
= O
7) O
(0.1% O
increase; O
p O
= O
0.022). O
[['Physiological-Clinical']]

No O
protocol-related O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
confirmed. O
[['Adverse-effects']]

ClinicalTrials.gov:NCT01485562. O
[]

RESULTS: O
The O
fentanyl O
level O
peaked O
1 O
h O
after O
operation O
in O
the O
TFP O
group O
(3.27 O
+/- O
0.34 O
ng/mL) O
and O
24 O
h O
postoperatively O
in O
the O
IV O
group O
(2.9 O
+/- O
0.42 O
ng/mL). O
[]

Publication O
date: O
2019/01/07 O
00:00 O
[accepted] O
[]

One-quarter O
were O
African O
American O
or O
Black. O
[]

Journal-Name:Journal O
of O
clinical O
psychopharmacology O
[]

After O
the O
exacerbation, O
mean O
FEV1 B-outcome ['Physiological-Clinical']
improved O
but O
did O
not O
return O
to O
pre-exacerbation O
levels O
(mean O
Days O
36-56 O
after O
the O
exacerbation, O
0.875 O
L). O
[['Physiological-Clinical']]

Journal O
ID: O
2985213R O
[]

INTERVENTIONS: O
60 O
midwifery O
practices O
offered O
usual O
care O
(serial O
fundal O
height O
measurements O
with O
clinically O
indicated O
ultrasonography). O
[]

An O
equivalent O
volume O
of O
normal O
saline O
was O
administered O
in O
patients O
in O
the O
control O
group. O
[]

The O
study O
also O
examines O
the O
cost O
effectiveness O
of O
this O
therapy O
in O
this O
setting O
through O
examination O
of O
health O
care O
service O
utilisation O
across O
groups O
during O
the O
first O
3 O
months. O
[]

All O
patients O
were O
treated O
with O
combined O
chemotherapy O
and O
IMRTintensity O
modulated O
conformal O
radiotherapy. O
[]

The O
term O
livebirth B-outcome ['Mortality']
rate O
did O
not O
differ O
significantly O
between O
PICSI O
(27.4% O
[379/1381]) O
and O
ICSI O
(25.2% O
[346/1371]) O
groups O
(odds O
ratio O
1.12, O
95% O
CI O
0.95-1.34; O
p=0.18). O
[['Mortality']]

Journal O
ID: O
101521595 O
[]

DESIGN: O
Randomized, O
double-blind O
(patients O
and O
evaluators O
blind), O
controlled, O
trial. O
[]

These O
findings O
do O
not O
support O
the O
use O
of O
this O
psychological O
intervention. O
[]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

The O
percentage O
of O
patients O
with O
a O
composite O
outcome O
event O
was O
74% O
lower O
with O
caplacizumab O
than O
with O
placebo O
(12% O
vs. O
49%, O
P<0.001). O
[]

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

The O
intervention O
arm O
received O
a O
single O
mass O
drug O
administration O
of O
azithromycin. O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

It O
may O
be O
a O
more O
acceptable O
and O
viable O
option O
for O
the O
common O
man. O
[]

Data O
was O
analyzed O
by O
repeated O
measures O
analysis O
of O
variance O
(rANOVA) O
and O
chi-squared O
test O
(chi O
test). O
[]

BACKGROUND: O
In O
acquired O
thrombotic O
thrombocytopenic O
purpura O
(TTP), O
an O
immune-mediated O
deficiency O
of O
the O
von O
Willebrand O
factor-cleaving O
protease O
ADAMTS13 O
allows O
unrestrained O
adhesion O
of O
von O
Willebrand O
factor O
multimers O
to O
platelets O
and O
microthrombosis, O
which O
result O
in O
thrombocytopenia, O
hemolytic O
anemia, O
and O
tissue O
ischemia. O
[]

Journal O
ID: O
0255562 O
[]

Title: O
Resin-modified O
glass O
ionomer O
cement O
vs O
composite O
for O
orthodontic O
bonding: O
A O
multicenter, O
single-blind, O
randomized O
controlled O
trial. O
[]

Results: O
After O
the O
treatment, O
the O
improvement O
of O
glycosylated B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
(HbA1c) I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
urea I-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
(BUN) I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(SP), O
high B-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(hs-CRP) I-outcome ['Physiological-Clinical']
, O
erythrocyte B-outcome ['Physiological-Clinical']
sedimentation I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(ESR) I-outcome ['Physiological-Clinical']
, O
estimated B-outcome ['Physiological-Clinical']
glomerular I-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(eGFR) I-outcome ['Physiological-Clinical']
in O
the O
intervention O
group O
were O
significantly O
better O
than O
those O
in O
the O
control O
group O
(all O
P<0.05), O
as O
well O
as O
the O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
[47(26, O
120) O
mg/g O
vs O
103(42, O
267) O
mg/g, O
P<0.001]and O
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
[(0.83+/-0.30) O
mg/L O
vs O
(0.98+/-0.25) O
mg/L, O
P=0.031]. O
However, O
there O
was O
no O
statistically O
significant O
difference O
of O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
and O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
between O
before O
and O
after O
treatment O
in O
the O
control O
group O
(all O
P>0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Baltimore O
CONNECT: O
A O
Randomized O
Trial O
to O
Build O
Partnership O
Between O
Community O
Organizations O
and O
a O
Local O
Health O
System. O
[]

The O
pain B-outcome ['Physiological-Clinical']
scores O
of O
both O
groups O
were O
significantly O
reduced O
after O
treatment, O
and O
the O
difference O
was O
significant O
between O
group O
A O
and O
group O
B O
[(1.1+/-0.4) O
vs O
(3.2+/- O
0.6) O
(P<0.05). O
[['Physiological-Clinical']]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

After O
administration O
of O
2 O
doses, O
the O
seropositivity O
rates O
in O
the O
Avaxim, O
Epaxal, O
and O
Havrix O
groups O
were O
all O
100% O
(95% O
confidence O
intervals O
[CIs]: O
99.0-100, O
98.9-100, O
and O
99.0-100, O
respectively; O
P O
< O
.001). O
[]

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Post-hoc O
tests O
demonstrated O
statistically O
significant O
differences O
in O
time B-outcome ['Physiological-Clinical']
under O
tension O
(TUT) O
when O
comparing O
the O
group O
supplemented O
with O
caffeine O
(13.689 O
s O
GCAF) O
to O
the O
one O
ingesting O
a O
placebo O
(15.332 O
s O
GCON) O
at O
p O
= O
0.002. O
[['Physiological-Clinical']]

To O
evaluate O
whether O
all O
SAI O
had O
lower O
risk O
of O
stroke B-outcome ['Physiological-Clinical']
recurrence O
than O
MAIs O
in O
minor O
stroke. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

RESULTS: O
CART O
group O
demonstrated O
an O
increase O
in O
HFnu B-outcome ['Physiological-Clinical']
, O
TP B-outcome ['Physiological-Clinical']
, O
SDNN B-outcome ['Physiological-Clinical']
, O
and O
RMSSD B-outcome ['Physiological-Clinical']
, O
(p<0.05) O
along O
with O
a O
significant O
decrease O
in O
LFnu B-outcome ['Physiological-Clinical']
, O
LF/HF B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(p<0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
subjects O
were O
divided O
into O
two O
groups O
of O
control O
and O
intervention. O
[]

['2018/12/21 O
06:00' O
[]

CONCLUSIONS: O
This O
study's O
findings O
showed O
that O
an O
educational O
video O
can O
be O
as O
beneficial O
as O
expert O
proctoring, O
which O
implies O
that O
the O
development O
of O
a O
standardized O
educational O
video O
would O
be O
worthwhile. O
[]

Retrospectively O
registered O
12 O
March O
2018. O
[]

Journal O
ID: O
101521595 O
[]

lacrimal O
duct O
probing O
is O
the O
major O
treatment. O
[]

CONCLUSION: O
Muscle O
relaxation O
can O
enhance O
self-efficacy B-outcome ['Life-Impact']
of O
cancer O
patients. O
[['Life-Impact']]

Journal-Name:Medicine O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

OUTCOME O
MEASURES: O
Image O
analysis O
was O
performed O
by O
the O
workstation. O
[ O
[]

Title: O
Radical O
Prostatectomy O
or O
Watchful O
Waiting O
in O
Prostate O
Cancer O
- O
29-Year O
Follow-up. O
[]

The O
160 O
patients O
fulfilled O
the O
study O
requirements. O
[]

Thermal B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
significantly O
differed O
between O
conditions O
only O
at O
pre-exercise O
(PC O
= O
3 O
+/- O
1, O
CON O
= O
5 O
+/- O
0.5).DISCUSSION: O
PC O
delayed O
severe B-outcome ['Physiological-Clinical']
hyperthermia I-outcome ['Physiological-Clinical']
and O
mitigated O
dehydration B-outcome ['Physiological-Clinical']
without O
affecting O
thermal B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
or O
cooling B-outcome ['Physiological-Clinical']
rates O
posthyperthermia. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Additional O
arterial O
or O
vein O
grafts O
were O
used O
as O
indicated. O
[]

A O
2015 O
review. O
[]

Participants O
were O
randomized O
in O
a O
1:1 O
ratio O
to O
receive O
either O
800 O
mug O
of O
misoprostol O
or O
placebo O
sublingually O
if O
PPH O
was O
diagnosed, O
having O
previously O
received O
a O
prophylactic O
oral O
dose O
of O
600 O
mug O
misoprostol. O
[]

Title: O
Multivitamin O
and O
Mineral O
Supplementation O
Containing O
Phytonutrients O
Scavenges O
Reactive O
Oxygen O
Species O
in O
Healthy O
Subjects: O
A O
Randomized, O
Double-Blinded, O
Placebo-Controlled O
Trial. O
[]

Patients O
were O
randomly O
allocated O
to O
the O
Surgiflo O
Haemostatic O
Matrix O
(SHM) O
group O
or O
the O
AGS O
group O
(AGS) O
by O
computer-generated O
randomization O
codes. O
[]

Thus, O
reasons O
for O
engaging O
in O
weight O
loss O
interventions O
needs O
exploring, O
in O
order O
to O
engage O
more O
workplaces O
in O
weight O
loss O
interventions. O
[]

BACKGROUND: O
The O
management O
of O
acute O
esophageal O
variceal O
bleeding O
remains O
a O
clinical O
challenge. O
[]

Publication O
date: O
2019/01/05 O
06:00 O
[entrez] O
[]

CONCLUSIONS: O
Exercise O
once O
a O
week O
for O
6 O
months O
combined O
with O
five O
sessions O
of O
back O
care O
counseling O
after O
working O
hours O
in O
real-life O
settings O
effectively O
reduced O
the O
intensity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
work B-outcome ['Life-Impact']
interference I-outcome ['Life-Impact']
due O
to O
LBP, O
and O
fear B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
pain I-outcome ['Life-Impact']
, O
but O
was O
not O
cost-effective. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

On O
the O
other O
hand, O
plasma O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
and O
lactate B-outcome ['Physiological-Clinical']
dehydrogenase I-outcome ['Physiological-Clinical']
remained O
unchanged. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Of O
the O
560 O
total O
metabolites B-outcome ['Physiological-Clinical']
identified O
from O
the O
cooked O
navy O
beans, O
there O
were O
237 O
possible O
navy B-outcome ['Physiological-Clinical']
bean-derived I-outcome ['Physiological-Clinical']
metabolites I-outcome ['Physiological-Clinical']
that O
were O
identified O
in O
the O
stool O
of O
participants O
consuming O
navy O
beans, O
such O
as O
N-methylpipecolate B-outcome ['Physiological-Clinical']
, O
2-aminoadipate B-outcome ['Physiological-Clinical']
, O
piperidine B-outcome ['Physiological-Clinical']
, O
and O
vanillate B-outcome ['Physiological-Clinical']
. O
The O
microbial O
metabolism B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
amino I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
acids I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
acids S2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
were O
also O
identified O
in O
stool O
after O
4 O
weeks O
of O
navy O
bean O
intake O
including O
cadaverine B-outcome ['Physiological-Clinical']
, O
hydantoin-5 B-outcome ['Physiological-Clinical']
propionic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
4-hydroxyphenylacetate B-outcome ['Physiological-Clinical']
, O
and O
caprylate B-outcome ['Physiological-Clinical']
. O
The O
stool O
relative O
abundance O
of O
ophthalmate B-outcome ['Physiological-Clinical']
increased O
5.25-fold O
for O
navy O
bean O
consumers O
that O
can O
indicate O
glutathione O
regulation, O
and O
involving O
cancer O
control O
mechanisms O
such O
as O
detoxification O
of O
xenobiotics, O
antioxidant O
defense, O
proliferation, O
and O
apoptosis. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

The O
effects O
were O
analyzed O
by O
the O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
end I-outcome ['Life-Impact']
the O
task O
after O
overcoming O
the O
learning O
curve O
which O
is O
determined O
by O
several O
performance B-outcome ['Life-Impact']
parameters. O
[['Life-Impact'], ['Life-Impact']]

At O
3 O
years, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
67% O
(95% O
CI, O
57 O
to O
75) O
in O
the O
hybrid-procedure O
group, O
as O
compared O
with O
55% O
(95% O
CI, O
45 O
to O
64) O
in O
the O
open-procedure O
group; O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
Survival I-outcome ['Physiological-Clinical', 'Mortality']
was O
57% O
(95% O
CI, O
47 O
to O
66) O
and O
48% O
(95% O
CI, O
38 O
to O
57), O
respectively. O
[['Mortality'], ['Physiological-Clinical', 'Mortality']]

The O
primary O
outcomes O
were O
safety O
and O
the O
absolute O
change O
in O
hepatic B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
after O
16 O
weeks O
of O
treatment. O
[['Physiological-Clinical']]

BACKGROUND: O
Guidelines O
recommend O
macrolides O
and O
fluoroquinolones O
in O
patients O
hospitalized O
with O
community-acquired O
pneumonia O
(CAP), O
but O
their O
use O
has O
been O
associated O
with O
cardiac O
events. O
[]

Journal O
ID: O
2985248R O
[]

The O
primary O
outcome O
was O
the O
recovery B-outcome ['Physiological-Clinical']
perceived O
by O
the O
patient. O
[['Physiological-Clinical']]

RESULTS: O
Comparison O
of O
baseline O
and O
12-month O
follow-up O
showed O
no O
significant O
difference O
in O
the O
overall O
TF1-9 B-outcome ['Physiological-Clinical']
prevalence O
by O
balozi O
between O
control O
and O
treatment O
arms. O
[['Physiological-Clinical']]

Registered O
5 O
October O
2015. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Importance: O
Multimodal O
postoperative O
analgesia O
is O
widely O
used O
but O
lacks O
evidence O
of O
benefit. O
[]

The O
mean O
number O
of O
accurate O
lifestyle B-outcome ['Life-Impact', 'Life-Impact']
factors I-outcome ['Life-Impact', 'Life-Impact']
(that O
could O
affect O
fertility) O
mentioned O
increased O
from O
3.6 O
to O
4.4 O
(P O
< O
0.001) O
in O
the O
IG. O
[['Life-Impact', 'Life-Impact']]

Participants O
were O
critically O
ill O
patients O
who O
regained O
mental O
capacity O
following O
receipt O
of O
level O
3 O
(intensive) O
care. O
[]

A O
randomized O
clinical O
trial. O
[]

Journal-Name: O
JAMA O
[]

CONCLUSIONS: O
This O
study O
demonstrates O
the O
safety O
of O
BT-11 O
in O
the O
adolescent O
by O
showing O
no O
apparent O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
related O
to O
it. O
[['Adverse-effects']]

As O
compared O
to O
inhalational O
sevoflurane, O
intravenous O
sufentanil-midazolam O
exerts O
more O
favorable O
effects O
on O
systemic B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
efficiency O
during O
anesthetic O
induction O
in O
this O
group O
of O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Complications B-outcome ['Adverse-effects']
were O
comparable O
between O
treatment O
groups. O
[['Adverse-effects']]

Cost O
is O
frequently O
cited O
as O
an O
explanation O
for O
both O
of O
these O
observations. O
[]

Aortic O
enhancement B-outcome ['Life-Impact']
during O
the O
hepatic O
arterial O
phase O
and O
hepatic O
enhancement O
during O
the O
portal O
venous O
phase O
was O
compared. O
[['Life-Impact']]

TRIAL O
REGISTRATION: O
Brazilian O
Registry O
of O
Clinical O
Trials O
(no. O
[]

RESULTS: O
There O
were O
no O
significant O
differences O
with O
respect O
to O
the O
best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
(BCVA) I-outcome ['Physiological-Clinical']
between O
the O
groups O
at O
any O
time O
point. O
[['Physiological-Clinical']]

Journal O
ID: O
0255562 O
[]

Journal O
ID: O
0210174 O
[]

The O
population O
studied O
had O
a O
mean O
age O
of O
60.6 O
years. O
[]

Journal-Name:Zhong O
nan O
da O
xue O
xue O
bao. O
[]

Journal O
ID: O
101521595 O
[]

We O
used O
descriptive O
analyses O
due O
to O
the O
small O
sample O
size. O
[]

Study O
1 O
tested O
8-week O
group-based O
Monitor O
+ O
Accept O
and O
Monitor O
Only O
interventions O
compared O
with O
a O
no O
treatment O
control O
group. O
[]

The O
sham O
dry O
needling O
procedure O
was O
applied O
into O
the O
adipose O
tissue O
located O
at O
any O
area O
where O
an O
active O
trigger O
point O
was O
absent. O
[]

Statistically O
significant O
root B-outcome ['Physiological-Clinical']
coverage I-outcome ['Physiological-Clinical']
percentage O
was O
observed O
at O
one O
year O
post-treatment O
for O
both O
groups O
(p O
< O
0.05). O
[['Physiological-Clinical']]

Thus, O
krill O
powder O
has O
a O
lot O
of O
potential O
in O
improving O
lipid O
and O
metabolic O
profile O
and O
reinforcing O
the O
activity O
of O
the O
antioxidant O
system. O
[]

Publication O
date: O
2019/02/27 O
06:00 O
[medline] O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Significant O
differences O
were O
not O
observed O
in O
the O
remaining O
Makoto O
tests. O
[]

Patients O
received O
IV O
plus O
IA O
TXA O
has O
decreased O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(TBL), O
hidden B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(HBL) I-outcome ['Physiological-Clinical']
, O
and O
maximum O
hemoglobin B-outcome ['Physiological-Clinical']
(Hb) I-outcome ['Physiological-Clinical']
drop O
than O
those O
received O
IV O
TXA-alone O
and O
IA O
TXA-alone, O
with O
reductions O
in O
FDP B-outcome ['Physiological-Clinical']
and O
D-dimer B-outcome ['Physiological-Clinical']
, O
indicating O
that O
IV O
plus O
IA O
TXA O
injection O
is O
superior O
to O
prevent O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
hyperfibrinolysis B-outcome ['Physiological-Clinical']
during O
TKA. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/27 O
00:00 O
[accepted] O
[]

There O
were O
four O
serious B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
(SAEs) I-outcome ['Adverse-effects']
reported O
(two O
each O
group) O
unrelated O
to O
treatment. O
[['Adverse-effects']]

BACKGROUND: O
This O
study O
aimed O
to O
evaluate O
the O
effectiveness O
of O
neuromuscular O
electrical O
stimulation O
(NMES) O
therapy O
in O
patients O
with O
urinary O
incontinence O
after O
stroke O
(UIAS). O
[]

Clinical O
changes O
were O
defined O
as O
improvements O
on O
the O
Fugl-Meyer O
motor B-outcome ['Physiological-Clinical', 'Life-Impact']
assessment O
(FMA) O
and O
Wolf O
motor B-outcome ['Physiological-Clinical', 'Life-Impact']
function I-outcome ['Physiological-Clinical', 'Life-Impact']
test O
(WMFT)]. O
Results: O
All O
participants O
adhered O
to O
FT/ST O
without O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
and O
comparable O
Borg O
rating O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
ratings O
were O
noted O
between O
groups O
throughout O
the O
training O
(P>/=0.42). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical']]

Non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
and O
triglyceride B-outcome ['Physiological-Clinical']
were O
evaluated O
following O
breakfast O
and O
lunch. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

There O
was O
no O
significant O
difference O
in O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
between O
2 O
groups O
( O
t=0.474, O
P=0.640). O
[['Resource-use']]

Journal-Name:Lancet O
(London, O
England) O
[]

Journal-Name:Medicine O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
Patients' O
main B-outcome ['Physiological-Clinical']
curve I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
after O
surgical O
procedure O
regardless O
type O
of O
rod O
was O
48.95+/-11.04 O
(13-75) O
degree. O
[['Physiological-Clinical']]

RESULTS: O
Truckers O
in O
the O
intervention O
group O
were O
significantly O
more O
likely O
to O
test B-outcome ['Life-Impact']
for O
HIV O
compared O
to O
those O
in O
the O
enhanced O
SOC O
(OR O
= O
2.7, O
p O
= O
0.009). O
[['Life-Impact']]

The O
primary O
end O
point O
was O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
. O
Secondary O
end O
points O
included O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
safety. O
[['Physiological-Clinical', 'Mortality'], ['Mortality']]

Publication O
date: O
2018/06/14 O
00:00 O
[accepted] O
[]

Journal O
ID: O
2985248R O
[]

TRIAL O
REGISTRATION: O
Clinical O
Trials O
NCT01839708 O
; O
registered O
February O
28, O
2013. O
[]

CONCLUSION: O
These O
data O
suggest O
that O
a O
single O
round O
of O
MDA O
may O
not O
be O
sufficient O
to O
decrease O
trachomatous B-outcome ['Physiological-Clinical']
inflammation-follicular I-outcome ['Physiological-Clinical']
levels O
below O
5% O
when O
TF1-9 O
is O
between O
5 O
and O
9.9% O
at O
baseline. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/16 O
06:00 O
[entrez] O
[]

There O
was O
no O
significant O
difference O
in O
Pittsburgh O
Sleep B-outcome ['Physiological-Clinical']
Quality I-outcome ['Physiological-Clinical']
Index O
(PSQI) O
score O
and O
Treatment O
Emergent O
Symptom O
Scale O
(TESS) O
score O
between O
the O
two O
groups. O
[['Physiological-Clinical']]

Journal-Name:BMC O
infectious O
diseases O
[]

However, O
this O
needs O
reconfirmation O
in O
a O
larger O
study. O
[]

Complications B-outcome ['Adverse-effects']
, O
for O
both O
groups O
were O
similar O
with O
30% O
in O
proposed O
drainage O
and O
25% O
in O
traditional O
approach O
(p=0.723). O
[['Adverse-effects']]

METHODS: O
In O
this O
prospective, O
controlled O
study, O
60 O
age-related O
cataract O
patients O
with O
mild O
Meibomian O
gland O
dysfunction O
(MGD) O
were O
randomized O
to O
treatment O
with O
an O
ocular O
bandage O
contact O
lens O
(BCL) O
(n O
= O
30) O
or O
to O
an O
untreated O
control O
group O
(n O
= O
30) O
after O
phacoemulsification O
and O
intraocular O
lens O
implantation. O
[]

Dental B-outcome ['Physiological-Clinical']
, O
skeletal B-outcome ['Physiological-Clinical']
, O
and O
soft B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
measurements O
were O
performed O
on O
lateral O
cephalograms O
taken O
just O
before O
and O
at O
the O
end O
of O
the O
Herbst O
appliance O
therapy. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
[Efficacy O
of O
fluvoxamine O
combined O
with O
extended-release O
methylphenidate O
on O
treatment-refractory O
obsessive-compulsive O
disorder]. O
[]

Increases O
in O
serum O
creatinine B-outcome ['Physiological-Clinical']
levels O
of O
0.5 O
mg O
or O
more O
per O
deciliter O
(>/=40 O
mumol O
per O
liter) O
above O
baseline O
occurred O
in O
7.0% O
of O
patients O
in O
the O
plazomicin O
group O
and O
in O
4.0% O
in O
the O
meropenem O
group. O
[['Physiological-Clinical']]

Band O
ligation O
is O
the O
main O
therapeutic O
option, O
but O
it O
may O
be O
technically O
difficult O
to O
perform O
in O
active O
bleeders. O
[]

Navy O
bean O
consumption O
was O
previously O
shown O
to O
modulate O
host O
and O
microbiome O
metabolism, O
and O
this O
investigation O
was O
performed O
to O
assess O
the O
impact O
on O
the O
human O
stool B-outcome ['Physiological-Clinical']
metabolome I-outcome ['Physiological-Clinical']
, O
which O
includes O
the O
presence O
of O
navy B-outcome ['Physiological-Clinical']
bean I-outcome ['Physiological-Clinical']
metabolites I-outcome ['Physiological-Clinical']
. O
This O
4-week, O
randomized-controlled O
trial O
with O
overweight O
and O
obese O
CRC O
survivors O
involved O
consumption O
of O
1 O
meal O
and O
1 O
snack O
daily. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

All O
included O
patients O
were O
randomly O
allocated O
to O
a O
treatment O
group O
(n O
= O
43) O
or O
a O
sham O
group O
(n O
= O
43). O
[]

Journal O
ID: O
0014171 O
[]

METHODS: O
We O
randomly O
divided O
529 O
patients O
(279 O
men, O
250 O
women; O
median O
age, O
66 O
years) O
scheduled O
for O
hepatic O
dynamic O
computed O
tomography O
into O
2 O
groups. O
[]

Therefore, O
our O
results O
do O
not O
support O
the O
use O
of O
antibiotic O
treatment O
for O
chronic O
low O
back O
pain O
and O
Modic O
changes. O
[]

30582753_PD.tx O
[]

Complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
platelet O
recovery O
(CRp) O
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
haematological O
recovery O
(CRi) O
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
did O
not O
differ O
between O
groups O
when O
stratified O
by O
cytogenetics, O
de-novo O
versus O
secondary O
or O
therapy-related O
acute O
myeloid O
leukaemia, O
or O
TP53(mut) O
status. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

h(-1)), O
but O
did O
not O
affect O
ratings O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
or O
CWI O
cooling B-outcome ['Physiological-Clinical']
rates O
(PC O
= O
0.18 O
+/- O
0.14 O
degrees O
C O
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
In O
the O
study, O
60 O
children O
of O
American O
Society O
of O
Anesthesiology O
classification O
(ASA O
I-II), O
aged O
2-9 O
years, O
were O
randomly O
assigned O
to O
one O
of O
two O
equal O
groups. O
[]

INTRODUCTION: O
The O
purpose O
of O
this O
research O
was O
to O
compare O
the O
effects O
of O
Herbst O
appliance O
therapy O
using O
incremental O
vs O
maximum O
advancement O
in O
late O
adolescent O
and O
young O
adult O
patients O
with O
Class O
II O
skeletal O
malocclusion. O
[]

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O
[]

Journal O
ID: O
0374675 O
[]

There O
were O
formed O
two O
groups O
or O
patients: O
the O
first O
group O
involved O
45 O
patients O
- O
were O
treated O
with O
nicorandil O
(Cordinic, O
PIQ-FHARMA O
LLC) O
(the O
main O
group) O
the O
other O
group O
included O
43 O
patients O
who O
were O
treated O
by O
the O
standard O
therapy O
(the O
comparison O
group). O
[]

The O
experimental O
sets O
were O
performed O
to O
momentary O
muscular O
failure. O
[]

BACKGROUND: O
Maintenance O
therapy O
following O
autologous O
stem O
cell O
transplantation O
(ASCT) O
can O
delay O
disease O
progression O
and O
prolong O
survival O
in O
patients O
with O
multiple O
myeloma. O
[]

Secondary O
outcomes O
included O
participant-reported O
treatment B-outcome ['Life-Impact']
usage I-outcome ['Life-Impact']
and O
respiratory B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
RESULTS: O
A O
total O
of O
886 O
participants O
underwent O
randomization. O
[['Life-Impact'], ['Physiological-Clinical']]

The O
red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
haematocrit B-outcome ['Physiological-Clinical']
of O
the O
AGS O
group O
before O
operation O
were O
lower O
than O
those O
in O
the O
control O
group O
(P O
= O
.039, O
P O
= O
.029), O
but O
there O
was O
no O
difference O
after O
operation O
(P O
>.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Journal O
of O
strength O
and O
conditioning O
research O
[]

Journal O
ID: O
101521595 O
[]

GnRH-agonist O
trigger O
and O
adjuvant O
low O
dose O
hCG O
has O
been O
proposed O
to O
improve O
birth O
rates, O
but O
timing O
of O
this O
hCG O
support O
to O
corpus O
luteum O
function O
has O
never O
been O
fully O
described. O
[]

A O
representative O
from O
the O
municipality, O
the O
manager O
at O
a O
home-care O
centre, O
the O
project O
manager O
of O
the O
weight O
loss O
intervention O
and O
six O
health-care O
workers O
were O
interviewed O
at O
the O
end O
of O
a O
one-year O
weight O
loss O
intervention O
at O
the O
workplace. O
[]

Children O
were O
filmed O
playing O
pre-, O
mid-, O
and O
postintervention, O
using O
the O
Test O
of O
Playfulness B-outcome ['Life-Impact']
(ToP) O
to O
assess O
playfulness B-outcome ['Life-Impact']
. O
The O
PICIHBI O
comprised O
of O
10 O
monthly O
sessions O
facilitated O
by O
an O
occupational O
therapist, O
involving O
group O
discussions O
with O
caregivers O
and O
periods O
of O
experiential O
play. O
[['Life-Impact'], ['Life-Impact']]

Title: O
Effect O
of O
Low-Dose O
Intracoronary O
Alteplase O
During O
Primary O
Percutaneous O
Coronary O
Intervention O
on O
Microvascular B-outcome ['Physiological-Clinical']
Obstruction I-outcome ['Physiological-Clinical']
in O
Patients O
With O
Acute O
Myocardial O
Infarction: O
A O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical']]

BACKGROUND: O
Shoulder O
pain O
syndrome O
(SPS) O
is O
frequent O
and O
management O
in O
primary O
care O
is O
precarious, O
with O
a O
high O
rate O
of O
referral O
without O
adequate O
treatment, O
overloading O
rehabilitation O
and O
orthopedic O
services. O
[]

Patients O
in O
the O
intervention O
group O
found O
that O
the O
rehabilitation O
sessions O
were O
easier B-outcome ['Life-Impact']
(p O
= O
0.048). O
[['Life-Impact']]

Serum O
cortisol B-outcome ['Physiological-Clinical']
level O
was O
measured O
before O
anesthesia O
and O
at O
the O
end O
of O
operation O
to O
calculate O
the O
changes O
in O
cortisol O
level. O
[['Physiological-Clinical']]

Compared O
to O
the O
control O
group, O
the O
patients O
in O
the O
intervention O
group O
had O
lesser O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
[47(26, O
120) O
mg/g O
vs O
68(28, O
158) O
mg/g, O
P=0.039], O
and O
lower O
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
[(0.83+/-0.30) O
mg/L O
vs O
(0.96+/-0.30)mg/L, O
P=0.041]. O
Berberine O
had O
no O
obvious O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
Multiple O
linear O
regression O
analysis O
revealed O
that O
the O
berberine O
administration O
was O
independently O
associated O
with O
the O
reduction O
of O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
(beta=-0.051, O
P=0.041) O
and O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
(beta=-0.068, O
P=0.033) O
in O
T2DM O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusion: O
Peer O
support O
for O
education O
intervention O
seemed O
beneficial O
for O
diabetic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
The O
combination O
of O
education O
and O
effect O
evaluation O
was O
important O
in O
the O
evaluation O
of O
diabetes B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
prevention I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
control S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
Peer O
support O
education O
also O
benefited O
the O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
general O
population. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Both O
MRI O
sequences O
scored O
significantly O
higher O
compared O
to O
CT O
for O
image O
quality O
and O
confidence O
in O
contouring, O
particularly O
T2*W. O
This O
was O
also O
reflected O
in O
the O
shorter O
time O
for O
contouring, O
measuring O
15.4, O
9.6 O
and O
9.8 O
min O
for O
CT, O
T2W O
and O
T2*W O
MRI O
respectively. O
[]

Journal O
ID: O
101224380 O
[]

Journal-Name:Indian O
heart O
journal O
[]

Publication O
date: O
2019/03/01 O
06:00 O
[medline] O
[]

Title: O
Role O
of O
Lactobacillus O
rhamnosus O
(FloraActive) O
19070-2 O
and O
Lactobacillus O
reuteri O
(FloraActive) O
12246 O
in O
Infant O
Colic: O
A O
Randomized O
Dietary O
Study. O
[]

After O
4 O
weeks, O
the O
levels O
of O
Trimethylamine B-outcome ['Physiological-Clinical']
N-oxide I-outcome ['Physiological-Clinical']
(TMAO) I-outcome ['Physiological-Clinical']
were O
significantly O
decreased O
in O
the O
treatment O
group O
compared O
to O
placebo O
(63.6% O
vs. O
0.54%, O
respectively, O
P O
< O
0.0001). O
[['Physiological-Clinical']]

Compared O
with O
group O
C, O
the O
number O
of O
patients O
with O
postoperative O
pain B-outcome ['Physiological-Clinical']
(VAS O
score>/=4) O
in O
group O
D O
was O
obviously O
less O
at O
T(6), O
T(7), O
T(8)(10 O
vs O
20, O
4 O
vs O
12, O
3 O
vs O
10; O
chi(2)=4.762, O
4.762, O
4.332, O
respectively; O
all O
P<0.05). O
[['Physiological-Clinical']]

METHODS: O
This O
pilot O
randomized O
controlled O
trial O
compared O
BZSF O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
with O
ceftriaxone O
alone O
for O
Chinese O
female O
patients O
with O
uncomplicated O
gonorrhea. O
[]

Further O
studies O
are O
needed O
to O
validate O
the O
current O
observations. O
[]

The O
risk O
ratio O
adjusted O
for O
minimisation O
factors O
was O
0.95 O
(95% O
CI O
0.86-1.04; O
p=0.233). O
[]

Journal O
ID: O
2985248R O
[]

This O
tendency O
of O
the O
improvement O
was O
maintained, O
in O
favour O
of O
the O
IG, O
at O
the O
12-month O
follow-up O
visit. O
[]

BACKGROUND: O
We O
aimed O
to O
investigate O
how O
high-dose O
ecabet O
sodium O
affects O
low-dose O
aspirin-induced O
small O
intestinal O
mucosal O
injury O
in O
healthy O
volunteers. O
[]

Three O
patients O
died B-outcome ['Mortality']
in O
group O
A O
and O
11 O
patients O
died B-outcome ['Mortality']
in O
group O
B O
during O
the O
3-year O
follow-up. O
[['Mortality'], ['Mortality']]

BACKGROUND: O
Health O
promotion O
programs O
can O
only O
lead O
to O
improvements O
in O
health O
outcomes O
if O
they O
are O
effectively O
implemented. O
[]

No O
clinically O
significant O
alterations O
in O
the O
alpha- B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
beta- B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
diversity I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
gut I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
microbiota E4-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and O
associated O
metabolic O
pathways O
were O
evident. O
[['Physiological-Clinical', 'Physiological-Clinical']]

The O
postoperative O
mean B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(MAP) I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
and O
pulse B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
(SpO(2)) I-outcome ['Physiological-Clinical']
in O
the O
ward O
were O
recorded O
with O
a O
multi-function O
monitor O
on O
first O
night O
after O
surgery. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusions O
and O
Relevance: O
Among O
ambulatory O
adults O
with O
hypertension, O
treating O
to O
a O
systolic O
blood O
pressure O
goal O
of O
less O
than O
120 O
mm O
Hg O
compared O
with O
a O
goal O
of O
less O
than O
140 O
mm O
Hg O
did O
not O
result O
in O
a O
significant O
reduction O
in O
the O
risk O
of O
probable O
dementia B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Because O
of O
early O
study O
termination O
and O
fewer O
than O
expected O
cases O
of O
dementia, O
the O
study O
may O
have O
been O
underpowered O
for O
this O
end O
point. O
[['Physiological-Clinical', 'Life-Impact']]

Our O
results O
support O
the O
efficacy O
of O
vitamin O
D3 O
given O
monthly O
both O
for O
correcting O
hypovitaminosis B-outcome ['Physiological-Clinical']
and O
for O
maintaining O
vitamin O
D O
levels. O
[['Physiological-Clinical']]

The O
primary O
outcome O
was O
the O
Kaplan-Meier O
estimated O
percentage O
of O
patients O
who O
were O
free O
from O
recurrence B-outcome ['Physiological-Clinical']
at O
6 O
months, O
defined O
as O
P. O
vivax O
clearance O
without O
recurrent O
parasitemia. O
[['Physiological-Clinical']]

CONCLUSION: O
Our O
study O
indicates O
that O
mitochondrial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
could O
be O
the O
hallmark O
of O
tubular O
injury O
in O
DKD O
patients, O
and O
this O
would O
provide O
a O
novel O
and O
attractive O
therapeutic O
target O
to O
improve O
this O
disease. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Pain B-outcome ['Physiological-Clinical']
scores O
and O
the O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
rescue I-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
were O
not O
significantly O
different O
between O
2 O
groups. O
[['Physiological-Clinical'], ['Resource-use']]

Title: O
A O
Randomized O
Trial O
of O
E-Cigarettes O
versus O
Nicotine-Replacement O
Therapy. O
[]

During O
operations, O
the O
ETView O
tubes O
provided O
continuous B-outcome ['Life-Impact']
airway I-outcome ['Life-Impact']
visualization I-outcome ['Life-Impact']
in O
all O
patients; O
a O
good O
view B-outcome ['Life-Impact']
was O
obtained O
in O
24/25 O
patients O
in O
VDT/VST, O
moderate O
in O
4/12 O
patients O
in O
VDT/VST, O
and O
poor O
in O
1/1 O
patients O
in O
VDT/VST. O
[['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Traditional O
chest O
drainage O
versus O
drainage O
by O
thoracotomy: O
a O
prospective O
randomized O
study. O
[]

Regression O
models O
that O
show O
the O
collaborative O
relationship O
between O
mother O
and O
child, O
and O
their O
reciprocity O
in O
the O
process O
of O
adaptation O
were O
proposed. O
[]

Title: O
The O
effect O
of O
probiotics O
on O
glycemic O
index. O
[]

Journal-Name:Journal O
of O
foot O
and O
ankle O
research O
[]

The O
eye-lens O
dosemeters O
were O
placed O
near O
the O
eye O
closest O
to O
the O
radiation O
source O
(Carinou, O
E., O
Ferrari, O
P., O
Bjelac, O
O. O
C., O
Gingaume, O
M., O
Merce, O
M. O
S. O
and O
O'Connor, O
U. O
Eye O
lens O
monitoring O
for O
interventional O
radiology O
personnel: O
dosemeters, O
calibration O
and O
practical O
aspects O
of O
H O
p O
(3) O
monitoring. O
[]

TRIAL O
REGISTRATION O
NUMBER: O
ClinicalTrials.gov O
(NCT03196791), O
date O
of O
registration: O
October O
10, O
2017. O
[]

TPI O
group O
received O
TPIs O
with O
2 O
mL O
of O
0.2% O
ropivacaine, O
and O
EMLA O
group O
received O
an O
occlusive O
dressing O
with O
EMLA O
cream O
2 O
g O
on O
both O
shoulders. O
[]

Journal-Name:Oxidative O
medicine O
and O
cellular O
longevity O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT02571361. O
[]

Journal-Name:Nutrients O
[]

The O
primary O
endpoint O
is O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
; O
secondary O
endpoints O
include O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
resection B-outcome ['Life-Impact']
rate, O
recurrence-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
, O
residual B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
nodal B-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
and O
tumor B-outcome ['Physiological-Clinical']
marker I-outcome ['Physiological-Clinical']
kinetics I-outcome ['Physiological-Clinical']
. O
The O
target O
sample O
size O
was O
required O
to O
be O
at O
least O
163 O
(alpha-error O
0.05; O
power O
0.8) O
in O
both O
arms. O
[['Mortality'], ['Adverse-effects'], ['Life-Impact'], ['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

The O
primary O
endpoint O
was O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(PFS) I-outcome ['Physiological-Clinical', 'Mortality']
by O
intention-to-treat O
analysis. O
[['Physiological-Clinical', 'Mortality']]

Materials O
and O
Methods: O
A O
total O
of O
240 O
(129 O
females O
and O
111 O
male) O
aged O
18 O
- O
65 O
years O
were O
referred O
and O
integrated O
in O
this O
clinical O
trial, O
All O
patients O
presented O
with O
a O
vital O
maxillary O
or O
mandibular O
molar, O
premolar O
or O
front O
teeth O
designated O
for O
conventional O
root O
canal O
treatment O
for O
prosthetic O
reasons O
detected O
with O
only O
vital O
pulps. O
[]

The O
primary O
outcome O
included O
symptoms B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
appetite B-outcome ['Physiological-Clinical']
. O
The O
secondary O
outcomes O
included O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
as O
measured O
by O
the O
MD O
Anderson O
Symptom O
Inventory O
(MDASI) O
score, O
and O
functional B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
as O
evaluated O
by O
the O
Karnofsky O
score. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Journal O
ID: O
101479826 O
[]

METHODS: O
This O
randomized O
crossover O
study O
evaluated O
23 O
healthcare O
providers. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Heart O
Rate O
Variability O
following O
Combined O
Aerobic O
and O
Resistance O
Training O
in O
Sedentary O
Hypertensive O
Women: O
A O
Randomised O
Control O
Trial. O
[]

Patients O
who O
enrolled O
in O
SHORE O
fulfilled O
eligibility O
criteria O
per O
protocol O
(N O
= O
202). O
[]

Methods: O
By O
theoretically O
analyzing O
the O
influential O
factors O
for O
children's O
unintentional O
injury O
risk O
behaviors, O
children's O
cognitive O
development O
characteristics O
and O
the O
social O
learning O
theory, O
an O
intervention O
protocol O
was O
established O
on O
the O
basis O
of O
changing O
the O
unintentional O
injury O
attribution O
and O
negative O
information O
transmission O
of O
risk O
behavior O
consequences. O
[]

The O
secondary O
efficacy O
endpoints O
were O
assessed O
by O
the O
Tinnitus B-outcome ['Physiological-Clinical']
Handicap I-outcome ['Physiological-Clinical']
Inventory O
(THI)], O
12-Item O
Short O
Form O
Health B-outcome ['Physiological-Clinical']
Survey O
(SF-12) O
questionnaire], O
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
All O
outcome O
efficacy O
endpoints O
were O
measured O
at O
baseline O
and O
after O
4 O
weeks O
of O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Satisfactory O
compliance B-outcome ['Life-Impact']
with O
mask O
application O
was O
40% O
in O
control O
group O
vs. O
73.3% O
in O
DEX O
group O
(P<0.05). O
[['Life-Impact']]

SETTING: O
University O
hospital O
between O
2010 O
and O
2014. O
[]

BACKGROUND: O
Primary O
care O
physicians O
(PCPs) O
working O
in O
mental O
health O
care O
in O
Tunisia O
often O
lack O
knowledge O
and O
skills O
needed O
to O
adequately O
address O
mental O
health-related O
issues. O
[]

Muscular B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
was O
significantly O
different O
between O
limbs O
in O
the O
RT O
group O
at O
the O
end O
of O
the O
intervention O
(p O
= O
0.01). O
[['Life-Impact']]

In O
addition, O
for O
the O
upper O
50th O
percentile O
group, O
the O
adjusted O
mean O
post-supplementation O
baseline O
hydroxyproline B-outcome ['Physiological-Clinical']
(HYP) I-outcome ['Physiological-Clinical']
for O
the O
high O
dose O
group O
(1.5 O
+/- O
0.3 O
mug.mL(- O
1)) O
was O
significantly O
less O
than O
both O
the O
low O
dose O
(2.4 O
+/- O
0.3 O
mug.mL(- O
1); O
p O
= O
0.034) O
and O
placebo O
(2.4 O
+/- O
0.3 O
mug.mL(- O
1), O
p O
= O
0.024) O
groups. O
[['Physiological-Clinical']]

The O
efficacy O
of O
tafenoquine O
was O
not O
shown O
to O
be O
noninferior O
to O
that O
of O
primaquine O
(odds O
ratio O
for O
recurrence, O
1.81; O
95% O
CI, O
0.82 O
to O
3.96). O
[]

No O
venous B-outcome ['Physiological-Clinical']
or O
arterial O
thromboembolic O
complications O
were O
reported. O
[['Physiological-Clinical']]

Title: O
"We O
have O
to O
clean O
ourselves O
to O
ensure O
that O
our O
children O
are O
healthy O
and O
beautiful": O
findings O
from O
a O
qualitative O
assessment O
of O
a O
hand O
hygiene O
poster O
in O
rural O
Uganda. O
[]

Title: O
Effect O
of O
Medication O
Co-payment O
Vouchers O
on O
P2Y12 B-outcome ['Physiological-Clinical']
Inhibitor I-outcome ['Physiological-Clinical']
Use I-outcome ['Physiological-Clinical']
and O
Major B-outcome ['Physiological-Clinical', 'Mortality']
Adverse I-outcome ['Physiological-Clinical', 'Mortality']
Cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
Events I-outcome ['Physiological-Clinical', 'Mortality']
Among O
Patients O
With O
Myocardial O
Infarction: O
The O
ARTEMIS O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality']]

We O
aimed O
to O
examine O
the O
correlation O
between O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
train-of-four O
ratio O
(TOFr) O
to O
examine O
whether O
assessing O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
can O
be O
used O
clinically O
to O
monitor O
residual B-outcome ['Physiological-Clinical']
neuromuscular I-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
. O
METHODS: O
One O
hundred O
twenty O
patients O
with O
ASA O
I O
or O
II O
scheduled O
for O
laparoscopic O
cholecystectomy O
under O
general O
anesthesia O
were O
enrolled O
in O
this O
study. O
[['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

BACKGROUND: O
Recently, O
a O
novel O
approach O
with O
delaying O
the O
start O
of O
controlled O
ovarian O
stimulation O
along O
with O
gonadotropin-releasing O
hormone O
(GnRH) O
antagonist O
pretreatment O
for O
7 O
days O
after O
estrogen O
priming O
for O
further O
suppression O
of O
endogenous O
follicle O
stimulating O
hormone O
(FSH) O
during O
the O
early O
follicular O
phase, O
resulting O
in O
more O
FSH-responsive O
follicles O
and O
thus O
improving O
synchronous O
follicular O
development O
was O
introduced. O
[]

METHODS: O
Participants O
were O
randomly O
assigned O
to O
either O
the O
CART O
group O
that O
performed O
combined O
aerobic O
and O
resistance O
exercise O
of O
moderate O
intensity O
[aerobic O
exercise O
50-80% O
of O
HRmax O
(maximum O
heart O
rate) O
and O
resistance O
exercises O
at O
50-80% O
of O
1 O
Repetition O
Maximum O
(RM)], O
5 O
times/week O
for O
4 O
weeks, O
or O
to O
the O
control O
group O
that O
followed O
conventional O
treatment O
without O
any O
supervised O
exercise O
intervention. O
[]

Adult O
patients O
with O
CT-scan O
diagnosed O
uncomplicated O
acute O
appendicitis O
will O
be O
enrolled O
in O
nine O
Finnish O
hospitals. O
[]

CONCLUSIONS: O
Overall, O
the O
co-administration O
of O
vitamin O
D O
and O
probiotic O
for O
12 O
weeks O
to O
women O
with O
PCOS O
had O
beneficial O
effects O
on O
mental B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
parameters, O
serum O
total O
testosterone B-outcome ['Physiological-Clinical']
, O
hirsutism B-outcome ['Physiological-Clinical']
, O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(hs-CRP) I-outcome ['Physiological-Clinical']
, O
plasma O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity O
(TAC), O
glutathione B-outcome ['Physiological-Clinical']
(GSH) I-outcome ['Physiological-Clinical']
and O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
levels. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

Journal O
ID: O
2985248R O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
Shilajit O
is O
a O
safe, O
fluvic O
mineral O
complex O
exudate O
that O
is O
common O
to O
Ayurvedic O
medicine O
and O
is O
composed O
of O
fulvic O
acids, O
dibenzo-alpha-pyrones, O
proteins, O
and O
minerals. O
[]

Journal-Name:Medicine O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
of O
green O
tea O
as O
an O
adjunctive O
therapy O
to O
standard O
antimicrobial O
treatment O
in O
women O
with O
acute O
uncomplicated O
cystitis. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
The O
effects O
of O
position O
on O
gastric B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
premature O
infants O
in O
NICU. O
[['Physiological-Clinical']]

METHODS: O
From O
September O
2014 O
to O
September O
2015, O
60 O
patients O
diagnosed O
with O
NSCLC O
were O
included O
to O
the O
study. O
[]

All O
centers O
had O
to O
qualify O
with O
regard O
to O
surgical O
skills O
before O
participation O
in O
the O
trial. O
[]

Journal-Name:Zhong O
nan O
da O
xue O
xue O
bao. O
[]

CONCLUSION: O
BTX-A O
injection O
into O
the O
medial O
part O
of O
eyelid O
improves O
dry B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
eye I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
signs I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
symptoms S2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and O
reduces O
tear O
cytokine B-outcome ['Physiological-Clinical']
levels. O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/09/21 O
00:00 O
[accepted] O
[]

The O
control O
group O
received O
the O
placebo O
(distilled O
water) O
in O
the O
same O
manner O
as O
the O
intervention O
group. O
[]

Whether O
hybrid O
minimally O
invasive O
esophagectomy O
results O
in O
lower O
morbidity O
than O
open O
esophagectomy O
is O
unclear. O
[]

Publication O
date: O
2018/12/19 O
06:00 O
[entrez] O
[]

Importance: O
Abnormal O
peripheral O
perfusion O
after O
septic O
shock O
resuscitation O
has O
been O
associated O
with O
organ O
dysfunction O
and O
mortality. O
[]

We O
evaluated O
the O
effects O
on O
ADHD B-outcome ['Life-Impact', 'Life-Impact']
symptoms I-outcome ['Life-Impact', 'Life-Impact']
, O
self-report O
on O
the O
Behavior O
Rating O
Inventory O
of O
Executive B-outcome ['Life-Impact']
Function I-outcome ['Life-Impact']
of O
executive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
methylphenidate B-outcome ['Life-Impact']
dosing I-outcome ['Life-Impact']
, O
neuropsychological B-outcome ['Life-Impact', 'Life-Impact']
test O
measures, O
the O
Adult O
ADHD B-outcome ['Life-Impact', 'Life-Impact']
Self-report O
scale], O
emotional B-outcome ['Life-Impact']
dysregulation I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
adjustment I-outcome ['Life-Impact']
, O
and O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
, O
as O
well O
as O
moderating O
effects O
of O
body O
mass O
index, O
autoantibodies O
to O
folate O
receptors, O
and O
select O
genetic O
polymorphisms. O
[['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Journal O
ID: O
8912748 O
[]

The O
subjects, O
who O
had O
inclusion O
criteria, O
were O
selected O
through O
convenience O
sampling O
based O
on O
inclusion O
criteria O
and O
randomly O
allocated O
into O
three O
groups. O
[]

In O
one O
group, O
all O
four O
eye O
drops O
were O
transparent. O
[]

Maintenance O
of O
effect O
during O
the O
double-blind O
phase O
was O
evaluated O
based O
on O
a O
comparison O
of O
the O
percentages O
of O
galcanezumab- O
and O
placebo-treated O
patients O
with O
maintenance O
of O
30, O
50, O
75, O
and O
100% O
response B-outcome ['Physiological-Clinical']
(defined O
as O
>/=30, O
>/=50, O
>/=75, O
and O
100% O
reduction O
from O
baseline O
in O
monthly O
migraine O
headache O
days O
[MHD]) O
at O
an O
individual O
patient O
level. O
[['Physiological-Clinical']]

Journal-Name: O
Revista O
latino-americana O
de O
enfermagem O
[]

RESULTS: O
In O
the O
dry O
needling O
group, O
intensity B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of, I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
frequency X ['Physiological-Clinical', 'Physiological-Clinical']
and X ['Physiological-Clinical', 'Physiological-Clinical']
duration B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
headache E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
and O
the O
scores O
of O
Short O
Form-36 O
subscales O
were O
significantly O
improved O
after O
treatment O
(P O
< O
.05). O
[['Physiological-Clinical', 'Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

It O
has O
been O
reported O
that O
the O
intensity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
from O
dysmenorrhea O
decreased O
in O
the O
Novafen O
and O
Ginger O
groups. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

DISCUSSION: O
This O
trial O
is O
designed O
to O
confirm O
the O
effectiveness O
of O
Simvastatin O
to O
protect O
healthy O
and O
steatotic O
livers O
undergoing O
cold O
storage O
and O
warm O
reperfusion O
before O
transplantation O
and O
to O
evaluate O
if O
the O
addition O
of O
Simvastatin O
translates O
into O
improved O
graft B-outcome ['Physiological-Clinical']
outcomes. O
[['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
ISRCTN17975376 O
(Registered O
19/09/2014). O
[]

Both O
groups O
completed O
+25d O
in O
the O
hot O
condition. O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Tafenoquine O
was O
associated O
with O
asymptomatic O
declines O
in O
hemoglobin O
levels, O
which O
resolved O
without O
intervention. O
[]

MATERIALS O
AND O
METHODS: O
This O
is O
a O
double-blind, O
randomized O
controlled O
multicenter O
prospective O
trial. O
[]

Publication O
date: O
2019/03/06 O
06:00 O
[medline] O
[]

INTERPRETATION: O
Enteral O
supplementation O
with O
bovine O
lactoferrin O
does O
not O
reduce O
the O
risk O
of O
late-onset O
infection B-outcome ['Physiological-Clinical']
in O
very O
preterm O
infants. O
[['Physiological-Clinical']]

BACKGROUND: O
Residual O
postoperative O
neuromuscular O
blockade O
is O
an O
important O
clinical O
issue. O
[]

This O
was O
an O
educational O
tool O
which O
aimed O
to O
remind O
mothers O
in O
rural O
Uganda O
to O
clean O
their O
hands O
to O
prevent O
neonatal O
infection. O
[]

Patient-reported O
persistence B-outcome ['Life-Impact']
with O
P2Y12 O
inhibitors O
at O
1 O
year O
was O
higher O
in O
the O
intervention O
group O
than O
in O
the O
control O
group O
(unadjusted O
rates, O
5340/6135 O
[87.0%] O
vs O
3324/3967 O
[83.8%], O
respectively; O
P O
< O
.001; O
adjusted O
difference, O
2.3% O
[95% O
CI, O
0.4% O
to O
4.1%]; O
adjusted O
odds O
ratio, O
1.19 O
[95% O
CI, O
1.02 O
to O
1.40]). O
[['Life-Impact']]

Mean O
central B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
(CCT) I-outcome ['Physiological-Clinical']
was O
similar O
at O
baseline O
(550 O
+/- O
35 O
mum) O
and O
at O
12 O
months O
(551 O
+/- O
37 O
mum) O
and O
24 O
months O
(555 O
+/- O
35 O
mum). O
[['Physiological-Clinical']]

The O
same O
tools O
were O
used O
at O
two, O
six O
and O
at O
twelve O
weeks O
post O
injection O
to O
evaluate O
the O
functional B-outcome ['Life-Impact']
outcome O
and O
pain B-outcome ['Physiological-Clinical']
. O
Result O
One O
hundred O
and O
seventeen O
patients O
were O
available O
for O
analysis O
among O
which, O
55(48.7%) O
patients O
received O
Triamcinolone O
and O
58(51.3%) O
received O
placebo. O
[['Life-Impact'], ['Physiological-Clinical']]

The O
median O
opioid B-outcome ['Resource-use']
use I-outcome ['Resource-use']
in O
24 O
hours O
after O
operation O
in O
the O
paracetamol O
group O
was O
lower O
when O
compared O
with O
that O
in O
the O
dexmedetomidine O
group, O
and O
the O
mean O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
in O
the O
paracetamol O
group O
was O
higher O
when O
comparing O
with O
dexmedetomidine O
group. O
[['Resource-use'], ['Resource-use']]

Compared O
with O
those O
in O
the O
rhodiola O
treatment O
group, O
Self-rating O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(SDS) O
and O
self-rating O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
SAS O
scores O
of O
patients O
in O
the O
rhodiola+non-invasive O
breathing O
group O
decreased O
after O
treatment O
P<0.05. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Journal-Name:Taiwanese O
journal O
of O
obstetrics O
& O
gynecology O
[]

Obesity O
prevention O
campaign O
sponsorship O
promoted O
higher O
campaign O
awareness B-outcome ['Life-Impact']
and O
perceived B-outcome ['Life-Impact']
event-sponsor I-outcome ['Life-Impact']
fit I-outcome ['Life-Impact']
, O
but O
did O
not O
impact O
food O
attitudes B-outcome ['Life-Impact']
or O
preference B-outcome ['Life-Impact']
for O
unhealthy O
versus O
healthier O
foods. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

The O
patients O
in O
the O
sedation O
group O
received O
a O
loading O
dose O
of O
propofol O
of O
0.6 O
mg.kg(- O
1). O
[]

The O
Physical O
Activity O
Loyalty O
Scheme O
(PAL) O
intervention O
was O
based O
on O
high-street O
loyalty O
cards O
where O
participants O
earned O
points O
for O
minutes O
of O
activity B-outcome ['Life-Impact']
that O
could O
be O
redeemed O
for O
rewards, O
complemented O
by O
evidence-based O
behaviour O
change O
techniques. O
[['Life-Impact']]

BACKGROUND: O
Research O
has O
demonstrated O
that O
low O
fermentable O
oligiosaccharide, O
disaccharide, O
monosaccharide O
and O
polyol O
(FODMAP) O
diets O
improve O
gastrointestinal O
(GI) O
symptoms O
in O
irritable O
bowel O
syndrome O
sufferers. O
[]

Journal-Name:Panminerva O
medica O
[]

Retrospectively O
registered O
on O
November O
17, O
2017. O
[]

As O
well O
as O
receiving O
usual O
care, O
women O
in O
the O
intervention O
strategy O
were O
offered O
two O
routine O
biometry O
scans O
at O
28-30 O
and O
34-36 O
weeks' O
gestation. O
[]

However, O
the O
underlying O
mechanisms O
and O
effective O
therapeutic O
targets O
are O
still O
unclear. O
[]

Main O
parameters O
setting O
of O
respirator: O
VCV O
group O
was O
given O
450, O
550, O
650 O
mL O
preset O
VT, O
and O
PCV O
group O
was O
given O
12, O
16, O
20 O
cmH2O O
(1 O
cmH2O O
= O
0.098 O
kPa) O
preset O
suction O
pressure. O
[]

Age, O
sex, O
type O
of O
femoral O
prosthesis, O
and O
the O
injection O
method O
of O
TXA O
were O
risk O
factors O
for O
HBL O
of O
patients O
after O
receiving O
TKA. O
[]

Primary O
outcome O
data O
were O
available O
for O
249 O
(54.4%) O
intervention O
and O
236 O
(59.6%) O
control O
participants. O
[]

RESULTS: O
A O
total O
of O
213 O
patients O
(95.1%) O
completed O
the O
study. O
[]

BACKGROUND: O
Total O
hip O
replacement O
(THR) O
is O
often O
accompanied O
by O
severe O
postoperative O
pain. O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

BACKGROUND: O
To O
compare O
the O
superiority O
of O
teaching O
methods O
for O
acquiring O
a O
proficient O
level O
of O
surgical O
skill B-outcome ['Life-Impact']
in O
a O
robotic O
surgery-naive O
individual O
using O
a O
robotic O
virtual O
reality O
simulator. O
[['Life-Impact']]

TRIAL O
REGISTRATION: O
Clinicaltrials.gov O
, O
NCT03236961, O
retrospectively O
registered O
on O
the O
2nd O
of O
August O
2017. O
[]

Journal O
ID: O
101474849 O
[]

CONCLUSIONS: O
Among O
patients O
who O
were O
scheduled O
for O
CABG O
and O
had O
been O
randomly O
assigned O
to O
undergo O
bilateral O
or O
single O
internal-thoracic-artery O
grafting, O
there O
was O
no O
significant O
between-group O
difference O
in O
the O
rate O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
at O
10 O
years O
in O
the O
intention-to-treat O
analysis. O
[['Mortality']]

Objective: O
To O
investigate O
the O
effects O
of O
berberine O
on O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
(UACR) I-outcome ['Physiological-Clinical']
and O
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
(Cys I-outcome ['Physiological-Clinical']
C) I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O
[]

Results: O
HP/TAZ O
lotion O
demonstrated O
statistically O
significant O
superiority O
at O
week O
8 O
(versus O
TAZ O
and O
vehicle) O
and O
week O
12 O
(versus O
HP, O
TAZ, O
and O
vehicle). O
[]

We O
looked O
at O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
over O
a O
2-month O
study O
period O
following O
the O
first O
text. O
[['Life-Impact']]

BACKGROUND: O
Dyslipidemia O
is O
one O
of O
the O
most O
frequently O
implicated O
risk O
factors O
for O
development O
of O
atherosclerosis. O
[]

Primary O
endpoint O
is O
the O
success B-outcome ['Physiological-Clinical']
of O
the O
randomised O
treatment, O
defined O
as O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
appendicitis I-outcome ['Physiological-Clinical']
resulting O
in O
discharge B-outcome ['Resource-use']
from I-outcome ['Resource-use']
the O
hospital O
without O
the O
need O
for O
surgical B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
and O
no O
recurrent B-outcome ['Physiological-Clinical']
appendicitis I-outcome ['Physiological-Clinical']
during O
one-year O
follow-up. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Physiological-Clinical']]

RESULTS: O
All O
the O
patients O
were O
followed O
up O
for O
at O
least O
1 O
month. O
[]

Journal O
ID: O
101150032 O
[]

Publication O
date: O
2018/05/26 O
00:00 O
[accepted] O
[]

Overall, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
abdominal, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
shoulder B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
pains E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
were O
evaluated O
at O
rest O
and O
in O
motion O
on O
postoperative O
day O
3. O
[['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']]

We O
measured O
the O
correct O
index O
in O
the O
identification B-outcome ['Life-Impact']
of O
the O
eye O
drops O
of O
the O
two O
groups. O
[['Life-Impact']]

Importance: O
There O
are O
currently O
no O
proven O
treatments O
to O
reduce O
the O
risk O
of O
mild O
cognitive O
impairment O
and O
dementia. O
[]

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O
[]

Results O
The O
TC O
had O
produced O
significant O
positive O
chances O
in O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
some O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
parameters O
(mean O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
RMSSD B-outcome ['Physiological-Clinical']
, O
HF B-outcome ['Physiological-Clinical']
, O
LFnorm B-outcome ['Physiological-Clinical']
, O
and O
HFnorm B-outcome ['Physiological-Clinical']
) O
(p O
< O
0.05), O
whereas O
these O
positive O
results O
were O
not O
observed O
in O
the O
control O
group. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
, O
antioxidant B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
were O
assessed O
at O
baseline O
and O
after O
30 O
days O
of O
chocolate O
intake. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
participants O
performed O
a O
2000-m O
test O
on O
a O
rowing O
ergometer O
at O
the O
beginning O
(1st O
examination) O
and O
at O
the O
end O
of O
the O
supplementation O
period O
(2nd O
examination). O
[]

At O
enrolment, O
90 O
women O
will O
be O
randomly O
assigned O
into O
each O
intervention O
arm O
to O
receive O
either O
a O
daily O
tablet O
of O
200 O
mug O
elemental O
selenium O
or O
placebo. O
[]

The O
secondary O
aim O
was O
to O
examine O
if O
serum O
25(OH)D B-outcome ['Physiological-Clinical']
is O
a O
predictor O
of O
testosterone B-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
levels. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

It O
aims O
to O
evaluate O
the O
effect O
of O
a O
late O
first-trimester O
(>12 O
gestational O
weeks) O
degree O
of O
adherence O
to O
a O
MedDiet O
pattern-based O
on O
six O
food O
targets-on O
a O
composite O
of O
materno-foetal O
outcomes O
(CMFCs). O
[]

The O
primary O
endpoint, O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
according O
to O
blinded O
independent O
central O
review, O
was O
analysed O
by O
intent-to-treat. O
[['Physiological-Clinical', 'Mortality']]

AIM: O
The O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
efficacy O
of O
curcumin O
gel O
as O
local O
drug O
delivery O
post-scaling O
and O
root O
planing O
and O
its O
effect O
on O
clinical O
parameters O
like O
plaque B-outcome ['Physiological-Clinical']
, O
gingival B-outcome ['Physiological-Clinical']
scores, O
pocket B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
level I-outcome ['Physiological-Clinical']
(CAL) I-outcome ['Physiological-Clinical']
. O
MATERIALS O
AND O
METHODS: O
Ten O
patients O
with O
two O
sites O
in O
the O
contralateral O
quadrants O
having O
probing O
pocket O
depths O
(PPDs) O
of O
>/=5 O
mm O
were O
selected. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

This O
double-blind, O
randomized, O
Phase O
II O
study O
investigated O
the O
dose-response O
of O
oral O
netupitant O
in O
Japanese O
patients O
receiving O
highly O
emetogenic O
chemotherapy. O
[]

METHODS: O
Sixty-nine O
patients O
receiving O
VATS O
lobectomy O
in O
Department O
of O
Thoracic O
Surgery, O
West O
China O
Hospital, O
Sichuan O
University O
from O
September O
15, O
2017 O
to O
January O
15, O
2018 O
were O
randomly O
divided O
into O
the O
acapella O
group O
(AG) O
or O
the O
control O
group O
(CG). O
[]

Journal O
ID: O
101088661 O
[]

BACKGROUND: O
Alveolar O
osteitis O
is O
a O
frequent O
postoperative O
complication O
of O
third O
molar O
surgery. O
[]

BACKGROUND: O
Head O
to O
head O
trials O
of O
clinical O
outcomes O
of O
sirolimus O
eluting O
polymer O
free O
vs. O
biodegradable O
polymer O
stents O
are O
lacking. O
[]

Plasma O
Nitrotyrosine B-outcome ['Physiological-Clinical']
(NT) I-outcome ['Physiological-Clinical']
concentrations O
versus O
patient O
satisfaction O
following O
surgery O
are O
significantly O
correlated O
in O
benign O
disease O
and O
cancer. O
[['Physiological-Clinical']]

Publication O
Type: O
Multicenter O
Study O
[]

Median O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
was O
48.2 O
months O
(95% O
CI O
35.2-not O
evaluable) O
in O
the O
A+CHP O
group O
and O
20.8 O
months O
(12.7-47.6) O
in O
the O
CHOP O
group O
(hazard O
ratio O
0.71 O
[95% O
CI O
0.54-0.93], O
p=0.0110). O
[['Physiological-Clinical', 'Mortality']]

Journal-Name:BMC O
public O
health O
[]

In O
the O
current O
clinical O
trial, O
we O
examined O
the O
antioxidant B-outcome ['Physiological-Clinical']
and O
DNA B-outcome ['Physiological-Clinical']
protection I-outcome ['Physiological-Clinical']
capacity O
of O
a O
plant-based, O
multi-vitamin/mineral, O
and O
phytonutrient O
(PMP) O
supplementation O
in O
healthy O
adults O
who O
were O
habitually O
low O
in O
the O
consumption O
of O
fruits O
and O
vegetables. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
primary O
end O
point O
was O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
occurrence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
a O
nonvertebral O
or O
vertebral O
fragility O
fracture O
. O
RESULTS: O
At O
baseline, O
the O
mean O
(+/-SD) O
age O
was O
71+/-5 O
years, O
the O
T O
score O
at O
the O
femoral O
neck O
was O
-1.6+/-0.5, O
and O
the O
median O
10-year O
risk O
of O
hip O
fracture O
was O
2.3%. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/05 O
06:00 O
[medline] O
[]

Publication O
date: O
2018/05/09 O
00:00 O
[accepted] O
[]

Pain B-outcome ['Physiological-Clinical']
is O
an O
important O
factor O
that O
inversely O
correlates O
with O
the O
improvements O
in O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
[['Physiological-Clinical'], ['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

Anti-HA B-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
(HAV) I-outcome ['Physiological-Clinical']
immunoglobulin I-outcome ['Physiological-Clinical']
(Ig) I-outcome ['Physiological-Clinical']
G I-outcome ['Physiological-Clinical']
was O
measured O
to O
assess O
geometric O
mean O
concentrations O
(GMCs) O
and O
seropositvity O
rates O
(>/=20 O
mIU/mL O
anti-HAV O
IgG). O
[['Physiological-Clinical']]

Journal-Name:BMC O
public O
health O
[]

A O
fragility B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
occurred O
in O
190 O
women O
in O
the O
placebo O
group O
and O
in O
122 O
women O
in O
the O
zoledronate O
group O
(hazard O
ratio O
with O
zoledronate, O
0.63; O
95% O
confidence O
interval, O
0.50 O
to O
0.79; O
P<0.001). O
[['Physiological-Clinical']]

Main O
outcome O
measures O
The O
primary O
outcome O
was O
the O
feasibility B-outcome ['Life-Impact']
and O
acceptability B-outcome ['Life-Impact']
of O
rehabilitation O
sessions O
at O
five O
and O
ten O
days O
based O
on O
(i) O
questionnaires O
completed O
by O
patient O
and O
physiotherapist, O
(ii) O
the O
number O
of O
steps B-outcome ['Life-Impact']
performed O
during O
sessions, O
(iii) O
replacement B-outcome ['Life-Impact']
of O
a O
robotic O
session O
by O
a O
conventional O
one. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

The O
investigated O
program O
can O
be O
improved O
by O
considering O
the O
following O
suggestions: O
The O
quality O
of O
the O
implementation O
process O
should O
be O
monitored O
during O
the O
implementation O
phase, O
and O
regular O
feedback O
loops O
and O
learning O
opportunities O
for O
teachers O
should O
accompany O
a O
program. O
[]

The O
subjects O
were O
randomly O
allocated O
into O
2 O
groups O
according O
to O
activation O
type: O
incremental O
advancement O
(IA) O
and O
maximum O
advancement O
(MA). O
[]

Journal O
ID: O
0255562 O
[]

Similarly, O
time-to-first B-outcome ['Physiological-Clinical']
moderate/severe I-outcome ['Physiological-Clinical']
exacerbation I-outcome ['Physiological-Clinical']
was O
also O
delayed O
(hazard O
ratio O
[95% O
CI]: O
0.79 O
[0.70-0.89] O
and O
0.76 O
[0.63-0.91] O
in O
men O
and O
women, O
respectively). O
[['Physiological-Clinical']]

Journal-Name:Nutrients O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Approval O
from O
ethical O
committee O
was O
obtained. O
[]

Helicobacter O
pylori O
(Hp) O
drug O
resistant O
rate O
to O
clarithromycin O
(CLA) O
has O
increased O
to O
20% O
to O
50%, O
which O
cause O
concerns O
regarding O
its O
effectiveness O
in O
eradicating O
Hp, O
we O
aim O
to O
evaluate O
the O
cost-effectiveness O
of O
CLA-based O
versus O
furazolidone O
(FZD)-based O
quadruple O
therapy, O
and O
assess O
factors O
that O
affect O
anti-Hp O
efficacy. O
[]

In O
the O
group O
of O
participants O
diagnosed O
with O
asthma, O
percentage O
differences O
of O
participants O
with O
good O
body O
posture O
(without O
postural O
defects) O
were O
statistically O
significant. O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

The O
scores O
of O
unintentional O
injury O
risk B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
before O
intervention, O
3 O
months O
and O
6 O
months O
after O
intervention, O
and O
the O
frequency O
before O
intervention O
and O
6 O
months O
after O
intervention, O
were O
collected O
and O
compared. O
[['Life-Impact']]

Small B-outcome ['Physiological-Clinical']
for O
gestational O
age O
at O
birth O
was O
significantly O
more O
often O
detected O
in O
the O
intervention O
group O
than O
in O
the O
usual O
care O
group O
(179 O
of O
556 O
(32%) O
v O
78 O
of O
407 O
(19%), O
P<0.001). O
[['Physiological-Clinical']]

Further O
controlled O
prospective O
studies O
are O
needed O
to O
confirm O
these O
results. O
[]

The O
ETView O
single O
lumen O
endotracheal O
tube O
had O
fewer O
associated O
complications B-outcome ['Adverse-effects']
and O
is O
superior O
to O
the O
2 O
double-lumen O
tubes. O
[['Adverse-effects']]

Results: O
The O
improvement O
in O
the O
Yale-Brown O
Obsessive B-outcome ['Physiological-Clinical', 'Life-Impact']
Compulsive I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(Y-BOCS) O
total O
score, O
Yale-Brown O
Obsessive B-outcome ['Physiological-Clinical', 'Life-Impact']
Compulsive I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(Y-BOCS) O
obsession B-outcome ['Physiological-Clinical', 'Life-Impact']
subscale O
score O
and O
Hamilton O
Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(HAMA) O
score O
were O
more O
prominent O
in O
the O
study O
group O
than O
those O
in O
the O
control O
group O
(P<0.001). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Future O
research O
will O
benefit O
from O
longer O
study O
durations O
with O
larger O
numbers O
of O
participants. O
[]

The O
composite O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
stroke B-outcome ['Physiological-Clinical']
was O
a O
secondary O
outcome. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Nutrients O
[]

For O
normal O
breathing, O
the O
adequate O
protection B-outcome ['Life-Impact']
rates O
before O
and O
after O
training O
were O
62 O
(0-100) O
vs O
100 O
(90-100) O
for O
cup-type, O
100 O
(0-100) O
vs O
100 O
(100-100) O
for O
fold-type, O
and O
19 O
(0-100) O
vs O
100 O
(44-100) O
for O
valve-type O
(all O
P O
< O
.05). O
[['Life-Impact']]

Interventions: O
Patients O
were O
randomized O
to O
a O
step-by-step O
resuscitation O
protocol O
aimed O
at O
either O
normalizing O
capillary O
refill O
time O
(n O
= O
212) O
or O
normalizing O
or O
decreasing O
lactate O
levels O
at O
rates O
greater O
than O
20% O
per O
2 O
hours O
(n O
= O
212), O
during O
an O
8-hour O
intervention O
period. O
[]

The O
primary O
endpoint O
was O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
(FEV1) O
and O
ratio B-outcome ['Physiological-Clinical']
between O
FEV1 O
and O
forced O
vital O
capacity O
(FEV1/FVC) O
. O
The O
secondary O
endpoints O
included O
the O
symptom B-outcome ['Physiological-Clinical']
improvements, O
as O
measured O
by O
clinical B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
score, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QoL) I-outcome ['Life-Impact']
, O
as O
assessed O
with O
Paediatric O
Allergic B-outcome ['Life-Impact']
Disease I-outcome ['Life-Impact']
Quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
Questionnaire O
(PADQLQ) O
scores. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Main B-outcome ['Physiological-Clinical']
curve I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
success O
rate O
was O
in O
association O
with O
patients' O
age O
and O
type O
of O
rod O
(P-value=0.054, O
r=-1.863 O
and O
P-value=0.001, O
r=8.865 O
respectively). O
[['Physiological-Clinical']]

Journal-Name:International O
journal O
of O
sports O
medicine O
[]

The O
intervention O
strategy O
showed O
a O
higher O
incidence O
of O
induction B-outcome ['Resource-use']
of I-outcome ['Resource-use']
labour I-outcome ['Resource-use']
(1.16, O
1.04 O
to O
1.30) O
and O
a O
lower O
incidence O
of O
augmentation B-outcome ['Resource-use']
of I-outcome ['Resource-use']
labour I-outcome ['Resource-use']
(0.78, O
0.71 O
to O
0.85). O
[['Resource-use'], ['Resource-use']]

Treatments O
for O
PPI-refractory O
heartburn O
are O
of O
unproven O
efficacy O
and O
focus O
on O
controlling O
gastroesophageal O
reflux O
with O
reflux-reducing O
medication O
(e.g., O
baclofen) O
or O
antireflux O
surgery O
or O
on O
dampening O
visceral O
hypersensitivity O
with O
neuromodulators O
(e.g., O
desipramine). O
[]

There O
were O
no O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
CONCLUSIONS: O
There O
is O
no O
evidence O
that O
the O
use O
of O
resin O
modified O
glass O
ionomer O
cement O
over O
light-cured O
composite O
for O
bonding O
brackets O
reduces O
the O
incidence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
or O
bond B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
. O
There O
might O
be O
other O
reasons O
for O
using O
resin O
modified O
glass O
ionomer O
cement. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
scores O
of O
unintentional O
injury O
risk B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
for O
children O
in O
the O
intervention O
group O
at O
3 O
and O
6 O
months O
after O
intervention O
were O
14.42+/-5.67 O
and O
14.14+/-8.95, O
respectively, O
lower O
than O
those O
before O
the O
intervention O
(16.85+/-8.48) O
and O
in O
the O
control O
group O
(P=0.001). O
[['Life-Impact']]

Cry B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
fuss B-outcome ['Life-Impact', 'Life-Impact']
time E1-outcome ['Life-Impact', 'Life-Impact']
were O
measured O
with O
validated O
Baby's O
Day O
Diary O
on O
days O
0 O
and O
28. O
[['Life-Impact', 'Life-Impact']]

In O
addition, O
all O
subjects O
were O
required O
to O
undergo O
indwelling O
urinary O
catheter O
throughout O
the O
study O
period. O
[]

The O
study O
compares O
the O
efficacy O
of O
MCP O
using O
the O
AIMhi O
Stay O
Strong O
App O
with O
two O
control O
groups O
(control O
app O
intervention O
and O
treatment O
as O
usual) O
on O
participant-reported O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
(the O
primary O
outcome) O
using O
the O
Kessler O
Distress O
Scale O
(K10)]; O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
using O
the O
adapted O
Patient O
Health B-outcome ['Physiological-Clinical']
Questionnaire O
(PHQ-9)]; O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
using O
the O
EuroQoL O
instrument O
( O
EQ5D]) O
and O
adherence B-outcome ['Life-Impact']
to O
dialysis O
treatment O
planning O
through O
file O
audit. O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

To O
evaluates O
the O
eye-lens O
radiation O
exposure O
of O
workers O
during O
medical O
interventional O
procedures O
and O
surgery O
in O
a O
military O
hospital O
as O
well O
as O
of O
the O
equine O
veterinarians. O
[]

Conclusion: O
The O
results O
suggest O
that O
it O
is O
feasible O
to O
use O
the O
Borg O
rating O
of O
perceived B-outcome ['Physiological-Clinical', 'Life-Impact']
exertion I-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
to O
adjust O
FT O
intensity. O
[['Physiological-Clinical', 'Life-Impact']]

+25d O
post-exercise O
epinephrine B-outcome ['Physiological-Clinical']
was O
higher O
in O
CON O
vs. O
IHE O
(p=0.04). O
[['Physiological-Clinical']]

The O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(MBP), O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
SpO2 B-outcome ['Physiological-Clinical']
, O
Observer's O
Assessment O
of O
Alertness B-outcome ['Physiological-Clinical']
/ O
Sedation B-outcome ['Physiological-Clinical']
(OAA/S)], O
and O
the O
indicators O
of O
psychological B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
of O
brain O
functional O
state O
of O
the O
patients O
(including O
the O
wavelet B-outcome ['Physiological-Clinical']
index O
[WLi], O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
index O
[ANXi], O
comfortable B-outcome ['Life-Impact']
index O
[CFi] O
and O
pain B-outcome ['Physiological-Clinical']
index O
[Pi]) O
were O
recorded O
at O
5 O
min O
after O
entering O
the O
operating O
room O
(T0), O
at O
the O
time O
of O
lumbar O
puncture O
(T1) O
and O
change O
to O
supine O
position O
after O
the O
puncture O
(T2), O
at O
20 O
s O
(T3), O
40 O
s O
(T4), O
and O
60 O
s O
(T5) O
after O
intravenous O
administration, O
and O
at O
2 O
min O
(T6), O
4 O
min O
(T5), O
6 O
min O
(T8), O
8 O
min O
(T9), O
10 O
min O
(T10) O
and O
40 O
min O
(T11) O
after O
skin O
incision. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

Among O
these, O
glasses B-outcome ['Life-Impact']
ownership I-outcome ['Life-Impact']
at O
the O
end O
of O
the O
school O
year O
was O
68.6% O
among O
1252 O
treatment O
group O
students O
(82 O
schools), O
and O
26.4% O
(p O
< O
0.01) O
among O
1461 O
controls O
(82 O
schools). O
[['Life-Impact']]

Our O
primary O
aim O
was O
to O
examine O
in O
a O
randomized O
controlled O
setting O
whether O
diets O
enriched O
in O
fatty O
fish O
(FF), O
lean O
fish O
(LF) O
or O
ALA-rich O
camelina O
sativa O
oil O
(CSO) O
differ O
in O
their O
effects O
on O
the O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
response O
of O
selected O
inflammation-related O
genes O
in O
peripheral O
blood O
mononuclear O
cells O
(PBMCs) O
and O
subcutaneous O
adipose O
tissue O
(SAT) O
in O
subjects O
with O
impaired O
fasting O
glucose. O
[['Physiological-Clinical']]

The O
use O
of O
cadaver O
allograft O
spares O
the O
hamstring B-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
and O
reduces O
the O
time B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
surgery I-outcome ['Life-Impact']
. O
Therefore, O
such O
study O
appears O
to O
be O
useful O
because O
it O
provides O
valuable O
information O
that O
would O
help O
to O
guide O
treatment O
of O
this O
condition O
in O
children. O
[['Physiological-Clinical'], ['Life-Impact']]

Journal O
ID: O
0255562 O
[]

As O
compared O
with O
the O
placebo O
group, O
women O
who O
received O
zoledronate O
had O
a O
lower O
risk O
of O
nonvertebral B-outcome ['Physiological-Clinical']
fragility I-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
(hazard O
ratio, O
0.66; O
P=0.001), O
symptomatic B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
(hazard O
ratio, O
0.73; O
P=0.003), O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
(odds O
ratio, O
0.45; O
P=0.002), O
and O
height B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(P<0.001). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

At O
late O
follow-up O
(24 O
to O
32 O
days O
after O
initiation O
of O
therapy), O
fewer O
patients O
in O
the O
plazomicin O
group O
than O
in O
the O
meropenem O
group O
had O
microbiologic B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
(3.7% O
vs. O
8.1%) O
or O
clinical B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
(1.6% O
vs. O
7.1%). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Objective:To O
investigate O
the O
efficacy O
and O
safety O
of O
LOPasparaginase O
+ O
vincristine O
+ O
dexamethasone O
chemotherapy O
combined O
with O
radiotherapy O
in O
patients O
with O
nasal O
NK/T O
cell O
lymphoma. O
[]

BACKGROUND: O
Based O
on O
the O
encouraging O
activity O
and O
manageable O
safety O
profile O
observed O
in O
a O
phase O
1 O
study, O
the O
ECHELON-2 O
trial O
was O
initiated O
to O
compare O
the O
efficacy O
and O
safety O
of O
brentuximab O
vedotin, O
cyclophosphamide, O
doxorubicin, O
and O
prednisone O
(A+CHP) O
versus O
cyclophosphamide, O
doxorubicin, O
vincristine, O
and O
prednisone O
(CHOP) O
for O
the O
treatment O
of O
CD30-positive O
peripheral O
T-cell O
lymphomas. O
[]

Following O
baseline O
measures, O
two O
study O
intervals O
occurred O
with O
the O
intervention O
group O
receiving O
live O
music O
for O
the O
first O
interval O
followed O
by O
no O
music O
during O
the O
second O
interval; O
the O
control O
group O
received O
no O
music O
during O
both O
intervals. O
[]

METHODS: O
Utilizing O
a O
randomized, O
double-blind, O
placebo-controlled, O
parallel O
design, O
healthy, O
recreationally-active O
men O
and O
women O
(n O
= O
142) O
received O
900 O
mg O
of O
PSE O
or O
placebo O
(PLA) O
daily O
for O
90 O
days. O
[]

Comparing O
the O
groups, O
the O
slow B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(p=0.0027) O
and O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(p=0.0028) O
showed O
a O
significant O
difference O
between O
the O
treatments, O
while O
the O
PAR-G O
showed O
smaller O
declines O
in O
these O
capacities. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusion:Compared O
with O
CHOP+IMRT O
regimen, O
the O
LOP+IMRT O
regimen O
for O
nasal O
NK/T-cell O
lymphoma O
patients O
resulted O
in O
higher O
overall O
remission B-outcome ['Physiological-Clinical']
rate, O
survival B-outcome ['Mortality']
rate O
and O
lower O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
so O
it O
is O
worth O
in O
clinical O
promotion. O
[['Physiological-Clinical'], ['Mortality'], ['Adverse-effects']]

There O
was O
significant O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
the O
group O
receiving O
Triamcinolone O
at O
two O
and O
six O
week O
but O
not O
in O
twelve O
weeks. O
[['Physiological-Clinical']]

Facilitators: O
peer O
influence, O
teacher O
influence, O
staggered O
implementation, O
incentives, O
rewards, O
challenges O
and O
competition, O
flexibility O
and O
adaptability, O
child O
ownership, O
routine. O
[]

Depression B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
were O
measured O
using O
the O
GDS O
and O
digital O
electrocardiogram O
at O
baseline O
and O
after O
the O
24-week O
intervention. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

All O
secondary O
endpoints O
were O
met. O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

Publication O
Type: O
Journal O
Article O
[]

While O
the O
mhGAP-IG O
has O
been O
used O
extensively O
in O
low- O
and O
middle-income O
countries O
(LMICs) O
to O
help O
build O
non-specialists' O
mental O
health O
capacity, O
little O
research O
has O
focused O
on O
how O
contextual O
factors O
interact O
with O
the O
implemented O
training O
program O
to O
influence O
its O
expected O
outcomes. O
[]

Journal O
ID: O
101643584 O
[]

Children O
with O
spastic O
cerebral O
palsy O
6 O
weeks O
after O
multistage O
surgery O
were O
randomly O
divided O
into O
treatment O
group O
(received O
rESWT O
and O
conventional O
rehabilitation O
therapy) O
and O
control O
group O
(received O
conventional O
rehabilitation O
only). O
[]

The O
proportion O
of O
patients O
with O
SAEs B-outcome ['Adverse-effects']
in O
groups O
receiving O
IBU O
was O
15%, O
and O
in O
the O
PCM-alone O
group, O
was O
11%. O
[['Adverse-effects']]

Publication O
date: O
2019/01/12 O
06:00 O
[entrez] O
[]

Los O
Angeles O
Biomedical O
Research O
Institute, O
Los O
Angeles, O
CA O
dr.mckinnell@gmail.com. O
[]

Conclusions O
and O
Relevance: O
Among O
patients O
with O
septic O
shock, O
a O
resuscitation O
strategy O
targeting O
normalization O
of O
capillary O
refill O
time, O
compared O
with O
a O
strategy O
targeting O
serum O
lactate O
levels, O
did O
not O
reduce O
all-cause O
28-day O
mortality B-outcome ['Mortality']
. O
Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT03078712. O
[['Mortality']]

Follow O
up O
of O
the O
participants' O
outcomes O
was O
conducted O
via O
electronic O
medical O
records. O
[]

Whey O
protein O
is O
rich O
in O
the O
branched-chain O
amino O
acids, O
L-leucine, O
L-isoleucine O
and O
L-valine. O
[]

Gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
flatulence B-outcome ['Physiological-Clinical']
, O
( O
heartburn B-outcome ['Physiological-Clinical']
and O
diarrhea B-outcome ['Physiological-Clinical']
) O
were O
the O
most O
commonly O
reported O
among O
those O
probably O
related O
to O
the O
test O
products. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

A O
community-based O
randomized O
controlled O
trial O
was O
conducted O
on O
the O
selected O
students O
once O
a O
week O
for O
5 O
consecutive O
weeks. O
[]

Major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiac I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
( O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
nonfatal B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
, O
unplanned B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
for O
heart O
failure O
) O
occurred O
in O
15 O
patients O
(10.1%) O
in O
the O
placebo O
group, O
18 O
(12.9%) O
in O
the O
10-mg O
alteplase O
group, O
and O
12 O
(8.2%) O
in O
the O
20-mg O
alteplase O
group. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Physiological-Clinical'], ['Resource-use']]

Medical O
sciences O
[]

The O
outcome O
parameters O
were O
recession B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
depth I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
/ X ['Physiological-Clinical', 'Physiological-Clinical']
width S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
root B-outcome ['Physiological-Clinical']
coverage I-outcome ['Physiological-Clinical']
percentage, O
and O
root B-outcome ['Physiological-Clinical']
coverage I-outcome ['Physiological-Clinical']
aesthetic I-outcome ['Physiological-Clinical']
score O
(RES). O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
secondary O
endpoints O
are O
surgeon's O
surgical B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
score, O
patient's O
sedation B-outcome ['Physiological-Clinical']
score, O
and O
surgical O
outcomes O
including O
peak B-outcome ['Physiological-Clinical']
inspiratory I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
postoperative O
pain B-outcome ['Physiological-Clinical']
, O
and O
morbidity B-outcome ['Physiological-Clinical']
. O
DISCUSSION: O
This O
is O
the O
first O
study O
that O
compares O
deep O
NMB O
with O
moderate O
NMB O
during O
laparoscopic O
gastrectomy O
in O
obese O
patients O
with O
gastric O
cancer. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Statistical O
analyses O
will O
be O
carried O
out O
using O
SPSS O
version O
23.0 O
for O
Windows. O
[]

Seventeen O
patients O
(17%) O
in O
the O
MRI-guided O
treat-to-target O
group O
and O
6 O
patients O
(6%) O
in O
the O
conventional O
treat-to-target O
group O
experienced O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
Conclusions O
and O
Relevance: O
Among O
patients O
with O
RA O
in O
clinical O
remission, O
an O
MRI-guided O
treat-to-target O
strategy O
compared O
with O
a O
conventional O
treat-to-target O
strategy O
did O
not O
result O
in O
improved O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
rates O
or O
reduce O
radiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
These O
findings O
do O
not O
support O
the O
use O
of O
an O
MRI-guided O
strategy O
for O
treating O
patients O
with O
RA. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Pulpectomy O
was O
performed O
on O
27 O
primary O
teeth O
with O
necrosis O
or O
irreversible O
pulpitis, O
caused O
by O
dental O
caries O
or O
trauma, O
in O
23 O
children O
(2-7 O
years O
old). O
[]

Title: O
[Effects O
of O
aerosol O
inhalation O
on O
respiratory B-outcome ['Physiological-Clinical']
mechanical I-outcome ['Physiological-Clinical']
parameters O
under O
different O
ventilation O
patterns O
and O
ventilator O
parameters]. O
[['Physiological-Clinical']]

Journal O
ID: O
9435674 O
[]

Publication O
date: O
2018/12/24 O
06:00 O
[pubmed] O
[]

The O
study O
included O
204 O
subjects O
between O
25(-)70 O
years O
with O
T2DM. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

We O
conducted O
a O
double-blinded, O
randomized, O
and O
placebo-controlled O
trial O
in O
Addis O
Ababa, O
Ethiopia, O
to O
investigate O
if O
daily O
nutritional O
supplementation O
with O
vitD(3) O
(5000 O
IU) O
and O
phenylbutyrate O
(PBA, O
2 O
x O
500 O
mg) O
could O
mediate O
beneficial O
effects O
in O
treatment-naive O
HIV O
patients. O
[]

The O
prevalence O
of O
halitosis O
in O
the O
population O
is O
approximately O
30%, O
of O
which O
80 O
to O
90% O
of O
the O
cases O
originate O
in O
the O
oral O
cavity O
resulting O
from O
proteolytic O
degradation O
by O
gram O
negative O
anaerobic O
bacteria. O
[]

The O
findings O
do O
not O
support O
routine O
ultrasonography O
in O
the O
third O
trimester O
for O
low O
risk O
pregnancies. O
[]

The O
endpoints O
were O
radiation-induced O
esophagitis B-outcome ['Physiological-Clinical']
, O
mucositis B-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
loss, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
. O
RESULTS: O
The O
60 O
patients O
with O
NSCLC O
included O
42 O
men O
and O
18 O
women O
with O
a O
mean O
age O
+/- O
standard O
deviation O
of O
60.3 O
years O
+/- O
18.2 O
(range, O
44-78 O
years).At O
a O
median O
follow-up O
of O
26.4 O
months O
(range O
10.4-32.2), O
all O
patients O
tolerated B-outcome ['Life-Impact']
GLN O
well. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical', 'Mortality'], ['Life-Impact']]

After O
surgery, O
the O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
reduced O
significantly O
in O
both O
groups O
(P O
< O
.05). O
[['Physiological-Clinical']]

Conclusions O
The O
results O
of O
this O
study O
indicated O
that O
TC O
may O
alleviate O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
of O
the O
elderly O
through O
modulating O
autonomous O
nervous O
system O
or O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
parameters. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O
[]

Additional O
analyses O
showed O
that O
changes O
in O
active B-outcome ['Physiological-Clinical']
B12 I-outcome ['Physiological-Clinical']
, O
HcY B-outcome ['Physiological-Clinical']
and O
folate B-outcome ['Physiological-Clinical']
measures O
during O
WPI O
treatment O
correlated O
with O
improvements O
in O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
(all O
p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Parents O
were O
taught O
the O
same O
3 O
infant-handling O
techniques O
after O
random O
assignment O
to O
the O
(1) O
direct, O
(2) O
video, O
or O
(3) O
written-pictorial O
instructional O
groups. O
[]

Journal-Name:Journal O
of O
drugs O
in O
dermatology O
: O
JDD O
[]

CONCLUSIONS: O
A O
short-term O
LOWFODMAP O
diet O
under O
free-living O
conditions O
reduced O
exercise-related O
GI B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
improved O
the O
perceived O
ability B-outcome ['Life-Impact']
to O
exercise O
in O
otherwise O
healthy, O
recreational O
runners. O
[['Physiological-Clinical'], ['Life-Impact']]

CONCLUSIONS: O
HP O
had O
superior O
rates O
of O
hemostasis B-outcome ['Physiological-Clinical']
, O
shorter O
preparation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
a O
similar O
safety O
profile O
compared O
to O
G O
+ O
T O
in O
this O
prospective, O
randomized O
trial O
using O
quantitative O
bleeding B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
criteria. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/18 O
06:00 O
[medline] O
[]

Journal O
ID: O
101238455 O
[]

Primary O
endpoint: O
the O
change O
in O
plasma O
HIV-1 B-outcome ['Physiological-Clinical']
comparing O
week O
0 O
to O
16 O
using O
modified O
intention-to-treat O
(mITT, O
n O
= O
197) O
and O
per-protocol O
(n O
= O
173) O
analyses. O
[['Physiological-Clinical']]

0.05). O
[]

Fifty-three O
patients O
undergoing O
spine O
surgery O
were O
randomly O
divided O
into O
2 O
groups: O
control O
group O
(group O
C, O
n O
= O
26) O
and O
transcutaneous O
electrical O
acupoint O
stimulation O
group O
(group O
TEAS, O
n O
= O
27). O
[]

The O
levels O
of O
interleukin B-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
(IL-2) I-outcome ['Physiological-Clinical']
, O
interleukin B-outcome ['Physiological-Clinical']
4 I-outcome ['Physiological-Clinical']
(IL-4) I-outcome ['Physiological-Clinical']
, O
interleukin B-outcome ['Physiological-Clinical']
10 I-outcome ['Physiological-Clinical']
(IL-10) I-outcome ['Physiological-Clinical']
, O
interferon B-outcome ['Physiological-Clinical']
gamma I-outcome ['Physiological-Clinical']
(INF-) I-outcome ['Physiological-Clinical']
and O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity O
(TAC) O
were O
determined O
with O
commercially O
available O
diagnostic O
kits. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Self-reported O
responses B-outcome ['Life-Impact']
to O
the O
pictorial O
health O
warning O
labels O
were O
then O
measured, O
including O
avoidance B-outcome ['Life-Impact']
, O
reactance B-outcome ['Life-Impact']
, O
effectiveness, O
susceptibility B-outcome ['Life-Impact']
and O
motivation B-outcome ['Life-Impact']
to O
drink O
less. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O
[]

Journal O
ID: O
101521595 O
[]

Journal-Name:Reproductive O
biology O
and O
endocrinology O
: O
RB&E O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

They O
were O
randomly O
assigned O
to O
either O
neoadjuvant O
chemotherapy O
or O
upfront O
surgery. O
[]

In O
conclusion, O
the O
multifactorial O
intervention O
performed O
could O
improve O
adherence B-outcome ['Life-Impact']
to O
the O
MD O
and O
diet B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
among O
patients O
with O
T2DM. O
[['Life-Impact'], ['Life-Impact']]

Publication O
date: O
2019/02/26 O
06:00 O
[medline] O
[]

Title: O
Effect O
of O
nerve O
electrical O
stimulation O
for O
treating O
chemotherapy-induced O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
patients O
with O
advanced O
gastric O
cancer: O
A O
randomized O
controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
clinical O
examination O
included O
hematology B-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
tests, O
urinalysis B-outcome ['Physiological-Clinical']
, O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
and O
electrocardiogram B-outcome ['Physiological-Clinical']
(ECG) I-outcome ['Physiological-Clinical']
. O
RESULTS: O
Eleven O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
observed O
in O
ten O
subjects O
receiving O
BT-11 O
while O
seven O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
in O
six O
subjects O
receiving O
placebo. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Adverse-effects']]

The O
primary O
outcome O
was O
the O
reduction O
in O
the O
incidence O
of O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
(CIN) I-outcome ['Physiological-Clinical']
. O
The O
secondary O
outcomes O
were O
the O
maximum O
improvement O
in O
eGFR B-outcome ['Physiological-Clinical']
, O
maximum O
reduction O
in O
serum O
creatinine B-outcome ['Physiological-Clinical']
and O
composite O
of O
requirement O
of O
hemodialysis B-outcome ['Resource-use']
, O
death B-outcome ['Mortality']
and O
rehospitalization B-outcome ['Resource-use']
for O
heart O
failure O
up O
to O
6 O
weeks O
after O
PCI. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Mortality'], ['Resource-use']]

Journal O
ID: O
101225531 O
[]

Superoxide B-outcome ['Physiological-Clinical']
dismutase I-outcome ['Physiological-Clinical']
activity O
was O
significantly O
elevated O
after O
exercise O
(p O
= O
0.002) O
in O
placebo O
but O
not O
AA. O
[['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
http://www.clinicaltrials.gov O
Unique O
identifier: O
NCT00979589 O
. O
[]

Phytonutrients O
and O
vitamin O
and O
mineral O
supplementation O
have O
been O
reported O
to O
provide O
increased O
antioxidant O
capacity O
in O
humans; O
however, O
there O
is O
still O
controversy. O
[]

Patients O
receiving O
dexmedetomidine O
vs O
propofol O
had O
no O
significant O
difference O
in O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
(17% O
vs O
21%; O
difference, O
-4% O
[95% O
CI, O
-18% O
to O
10%]; O
P O
= O
.54; O
HR, O
0.8 O
[95% O
CI, O
0.4-1.9]). O
[['Physiological-Clinical', 'Life-Impact']]

Time B-outcome ['Resource-use']
to I-outcome ['Resource-use']
emergency I-outcome ['Resource-use']
medical I-outcome ['Resource-use']
services I-outcome ['Resource-use']
(EMS) I-outcome ['Resource-use']
activation I-outcome ['Resource-use']
was O
24.7 O
seconds O
(s) O
(95% O
CI O
[15.7-40.8]) O
for O
SIM O
group O
and O
79.5 O
s O
(95% O
CI O
[44.8-119.6]) O
for O
STD O
group, O
p=0.007. O
[['Resource-use']]

PURPOSE: O
While O
some O
micro-organisms, O
such O
as O
Staphylococcus O
aureus, O
are O
clearly O
implicated O
in O
causing O
tissue O
damage O
in O
diabetic O
foot O
ulcers O
(DFUs), O
our O
knowledge O
of O
the O
contribution O
of O
the O
entire O
microbiome O
to O
clinical O
outcomes O
is O
limited. O
[]

White O
sweet O
potato O
(WSP; O
Ipomoea O
batatas O
L.), O
used O
in O
traditional O
medicine O
in O
Brazil, O
Japan, O
and O
Taiwan, O
is O
a O
healthy O
carbohydrate O
source. O
[]

There O
was O
no O
significant O
difference O
in O
intraoperative O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
hemoglobin B-outcome ['Physiological-Clinical']
and O
hematocrit B-outcome ['Physiological-Clinical']
before O
operation O
and O
at O
1 O
and O
3 O
days O
after O
operation, O
and O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
and O
erythrocyte B-outcome ['Physiological-Clinical']
sedimentation I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
before O
operation O
and O
at O
1, O
3, O
and O
14 O
days O
between O
2 O
groups O
( O
P>0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/31 O
06:00 O
[medline] O
[]

Journal O
ID: O
8900488 O
[]

The O
efficacy O
was O
evaluated O
by O
Pittsburgh O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
index O
(PSQI)], O
Beck O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
index O
(BDI) O
, O
Beck O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
inventory O
(BAI) O
and O
sleep B-outcome ['Physiological-Clinical']
diary O
variables O
at O
baseline, O
middle O
and O
end O
of O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

During O
the O
study O
period O
(0-12 O
months) O
mean O
total O
costs B-outcome ['Resource-use']
were O
lowest O
in O
the O
Combined-arm O
(euro476 O
vs. O
euro1062-euro1992, O
p O
< O
0.001) O
as O
were O
the O
mean O
number O
of O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
days O
(0.15 O
vs. O
2.29-4.17, O
p O
= O
0.025). O
[['Resource-use'], ['Life-Impact']]

Journal-Name: O
Lin O
chuang O
er O
bi O
yan O
hou O
tou O
jing O
wai O
ke O
za O
zhi O
= O
Journal O
of O
clinical O
otorhinolaryngology, O
head, O
and O
neck O
surgery O
[]

Low O
DHA O
intakes O
might O
explain O
subtle O
neurological B-outcome ['Physiological-Clinical']
deficits I-outcome ['Physiological-Clinical']
in O
PKU. O
[['Physiological-Clinical']]

Title: O
Effects O
of O
Grape O
Pomace O
Polyphenolic O
Extract O
(Taurisolo((R))) O
in O
Reducing O
Trimethylamine B-outcome ['Physiological-Clinical']
N-oxide I-outcome ['Physiological-Clinical']
(TMAO) I-outcome ['Physiological-Clinical']
Serum O
Levels O
in O
Humans: O
Preliminary O
Results O
from O
a O
Randomized, O
Placebo-Controlled, O
Cross-Over O
Study. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Effectiveness O
and O
cost-effectiveness O
of O
a O
loyalty O
scheme O
for O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
behaviour O
change O
maintenance: O
results O
from O
a O
cluster O
randomised O
controlled O
trial. O
[['Life-Impact']]

METHODS: O
A O
total O
of O
79 O
patients O
with O
POCS O
and O
35 O
healthy O
females O
were O
included, O
and O
endometrial O
biopsies O
were O
obtained. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

While O
30% O
report O
working O
full O
or O
part O
time, O
45% O
were O
retired O
due O
to O
disability. O
[]

METHODS: O
We O
randomly O
assigned O
695 O
men O
with O
localized O
prostate O
cancer O
to O
watchful O
waiting O
or O
radical O
prostatectomy O
from O
October O
1989 O
through O
February O
1999 O
and O
collected O
follow-up O
data O
through O
2017. O
[]

Self-reported O
pain B-outcome ['Physiological-Clinical']
measures, O
observed O
pain B-outcome ['Physiological-Clinical']
measures, O
and O
observed O
measures O
of O
pedaling O
adherence B-outcome ['Life-Impact']
were O
collected O
for O
each O
participant. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Journal-Name:Medicine O
[]

Methods: O
Between O
June O
2016 O
and O
September O
2017, O
60 O
patients O
who O
underwent O
curettage O
for O
retained O
placental O
tissue O
after O
medically O
induced O
or O
spontaneous O
pregnancy O
loss O
in O
the O
second O
trimester O
were O
enrolled O
in O
the O
study. O
[]

The O
participants O
were O
randomly O
allocated O
to O
two O
groups O
receiving O
the O
drugs O
Novafen O
and O
Ginger. O
[]

Journal-Name: O
Revista O
da O
Associacao O
Medica O
Brasileira O
(1992) O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
Medical O
researchers O
have O
been O
reluctant O
to O
use O
neuromuscular O
blocking O
drugs O
(NMBD) O
during O
the O
use O
of O
intraoperative O
motor O
evoked O
potential O
(MEP) O
monitoring O
despite O
the O
possibility O
of O
patient O
movement. O
[]

AIMS: O
The O
aims O
of O
this O
study O
were O
to O
compare O
the O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
resources I-outcome ['Resource-use']
, O
costs B-outcome ['Resource-use']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
outcomes O
associated O
with O
subacromial O
decompression, O
arthroscopy O
only O
(placebo O
surgery), O
and O
no O
treatment O
for O
subacromial O
pain O
in O
the O
United O
Kingdom O
National O
Health O
Service O
(NHS), O
and O
to O
estimate O
their O
cost-effectiveness. O
[['Resource-use'], ['Resource-use'], ['Life-Impact']]

CONCLUSION: O
RADPAD O
significantly O
reduces O
radiation B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
to O
the O
primary O
operator O
during O
prolonged O
complex O
PCI O
procedures. O
[['Life-Impact']]

Title: O
Daily O
Nutritional O
Supplementation O
with O
Vitamin O
D(3) O
and O
Phenylbutyrate O
to O
Treatment-Naive O
HIV O
Patients O
Tested O
in O
a O
Randomized O
Placebo-Controlled O
Trial. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
Delayed-release O
dimethyl O
fumarate O
(DMF) O
has O
demonstrated O
efficacy O
and O
a O
favorable O
benefit-risk O
profile O
in O
phase O
2 O
and O
3 O
studies O
that O
enrolled O
predominantly O
white O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
(RRMS). O
[]

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India. O
[]

Journal-Name:Italian O
journal O
of O
pediatrics O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Electronic O
randomization O
was O
undertaken, O
with O
group O
allocation O
concealed O
using O
opaque, O
sealed O
envelopes. O
[]

Were O
used O
highly B-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
(HF-Tr) I-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
phosphokinase-MB I-outcome ['Physiological-Clinical']
as O
an O
irreversible O
myocardial O
damage O
biomarkers. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Two O
groups O
of O
patients O
were O
randomly O
categorized O
according O
to O
the O
route O
of O
administration O
of O
scorpion O
antivenom; O
intramuscular O
and O
intravenous O
with O
50 O
patients O
in O
each O
group. O
[]

Title: O
Effect O
of O
Intensive O
vs O
Standard O
Blood O
Pressure O
Control O
on O
Probable O
Dementia B-outcome ['Physiological-Clinical', 'Life-Impact']
: O
A O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical', 'Life-Impact']]

The O
rate O
of O
stroke B-outcome ['Physiological-Clinical']
recurrence O
was O
7.6%, O
15.1% O
and O
15.3% O
in O
lacunar O
infarction O
of O
SAI, O
non-lacunar O
infarction O
of O
SAI O
and O
MAIs O
at O
one O
year, O
respectively. O
[['Physiological-Clinical']]

antibiotic O
therapy O
followed O
by O
p.o. O
[]

The O
intervention O
contained O
35 O
g O
of O
cooked O
navy O
bean O
or O
macronutrient O
matched O
meals O
and O
snacks O
with O
0 O
g O
of O
navy O
beans O
for O
the O
control O
group O
(n O
= O
18). O
[]

AIMS: O
Adductor O
canal O
block O
(ACB) O
has O
emerged O
as O
an O
alternative O
to O
femoral O
nerve O
block O
(FNB) O
for O
analgesia O
after O
total O
knee O
arthroplasty O
(TKA). O
[]

BACKGROUND: O
We O
evaluated O
the O
effectiveness O
and O
cost-effectiveness O
of O
a O
loyalty O
scheme O
based O
intervention O
involving O
rewards O
for O
increasing O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
in O
public O
sector O
employees. O
[['Life-Impact']]

Publication O
Type: O
Comparative O
Study O
[]

Interventions: O
Participants O
were O
randomized O
to O
a O
systolic O
blood O
pressure O
goal O
of O
either O
less O
than O
120 O
mm O
Hg O
(intensive O
treatment O
group; O
n O
= O
4678) O
or O
less O
than O
140 O
mm O
Hg O
(standard O
treatment O
group; O
n O
= O
4683). O
[]

The O
primary O
outcome, O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL), O
was O
evaluated O
at O
72 O
hours O
postoperatively. O
[['Physiological-Clinical']]

Study O
design: O
Controlled O
laboratory O
study; O
cross-sectional O
design. O
[]

Primary O
endpoint O
was O
comparison O
of O
mean O
change O
in O
serum O
hydroxymethylglutaryl-CoA B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
(HMGCR) I-outcome ['Physiological-Clinical']
levels O
and O
lipid O
indices O
of O
both O
groups O
and O
their O
correlation O
with O
each O
other. O
[['Physiological-Clinical']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Incremental O
cost-effectiveness O
ratios O
were O
calculated, O
with O
uncertainty O
around O
the O
values O
estimated O
using O
bootstrapping. O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Publication O
date: O
2018/12/14 O
06:00 O
[pubmed] O
[]

The O
primary O
endpoint O
is O
the O
number O
of O
harvested B-outcome ['Physiological-Clinical']
lymph I-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
, O
which O
is O
a O
critical O
index O
of O
the O
quality O
of O
surgery O
in O
gastric O
cancer O
treatment. O
[['Physiological-Clinical']]

Additionally, O
no O
significant O
differences O
regarding O
all O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
detected O
between O
2 O
groups. O
[['Adverse-effects']]

CONCLUSIONS: O
In O
summary, O
the O
findings O
of O
this O
study O
showed O
that O
NMES O
therapy O
may O
not O
benefit O
patients O
with O
CUR O
following O
TBI. O
[]

A O
follow-up O
extension O
was O
then O
done, O
with O
the O
primary O
endpoint O
cumulative O
incidence O
of O
chronic B-outcome ['Physiological-Clinical']
graft-versus-host I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(cGVHD) I-outcome ['Physiological-Clinical']
. O
Enrolment O
has O
been O
completed O
for O
both O
studies. O
[['Physiological-Clinical']]

In O
group O
B, O
although O
the O
median O
number O
[range] O
of O
lesions B-outcome ['Physiological-Clinical']
in O
the O
first O
tertile O
of O
the O
small O
intestine O
did O
not O
increase O
two O
weeks O
after O
low-dose O
aspirin O
administration O
(baseline: O
0 O
[0-4], O
after: O
1.5 O
[0-8]; O
p O
= O
0.2969), O
the O
number O
of O
lesions B-outcome ['Physiological-Clinical']
in O
the O
second O
and O
third O
tertiles O
of O
the O
small O
intestine O
increased O
significantly O
(baseline: O
0 O
[0-5], O
after: O
2 O
[0-15]; O
p O
= O
0.0469). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Upsala O
journal O
of O
medical O
sciences O
[]

Title: O
Menthol O
chewing O
gum O
on O
preoperative O
thirst B-outcome ['Physiological-Clinical']
management: O
randomized O
clinical O
trial. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Medicine O
[]

Title: O
A O
Randomized O
Trial O
of O
Endometrial O
Scratching O
before O
In O
Vitro O
Fertilization. O
[]

Extracorporeal O
magnetic O
innervation O
(ExMI) O
is O
a O
relatively O
new O
conservative O
treatment O
method O
for O
UI. O
[]

Segmental O
muscle O
vibration O
(SMV) O
is O
one O
of O
the O
interventions O
that O
incorporate O
sensory O
stimulation O
to O
improve O
motor O
cortical O
excitability. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:The O
bone O
& O
joint O
journal O
[]

RESULTS: O
From O
October O
2009 O
through O
April O
2012, O
we O
randomly O
assigned O
103 O
patients O
to O
the O
hybrid-procedure O
group O
and O
104 O
to O
the O
open-procedure O
group. O
[]

The O
95% O
confidence O
interval O
for O
the O
difference O
in O
aortic O
and O
hepatic O
enhancement B-outcome ['Life-Impact']
between O
the O
2 O
protocols O
was O
within O
the O
range O
of O
the O
predetermined O
equivalence O
margins O
in O
all O
BMI O
subgroups. O
[['Life-Impact']]

Eligible O
women O
(aged O
18-43 O
years) O
had O
a O
body-mass O
index O
of O
19-35 O
kg/m(2) O
and O
a O
follicle-stimulating O
hormone O
(FSH) O
concentration O
of O
3.0-20.0 O
mIU/mL O
or, O
if O
no O
FSH O
measurement O
was O
available, O
an O
anti-mullerian O
hormone O
concentration O
of O
at O
least O
1.5 O
pmol/L. O
Eligible O
men O
(aged O
18-55 O
years) O
had O
not O
had O
a O
vasovasostomy O
or O
been O
treated O
for O
cancer O
in O
the O
24 O
months O
before O
recruitment O
and O
were O
able, O
after O
at O
least O
3 O
days O
of O
sexual O
abstinence, O
to O
produce O
freshly O
ejaculated O
sperm O
for O
the O
treatment O
cycle. O
[]

Comparison O
of O
the O
mean O
differences O
at O
the O
beginning O
and O
two O
months O
after O
the O
study O
in O
the O
two O
groups O
showed O
that O
the O
scores O
related O
to O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
dimensions O
in O
the O
experimental O
group O
were O
significantly O
greater O
than O
the O
control O
group O
(p</=0.05). O
[['Life-Impact']]

More O
interestingly, O
preoperative O
analgesia O
group O
patients O
consumed O
less O
patient-controlled O
analgesia B-outcome ['Resource-use']
compared O
to O
postoperative O
analgesia O
group O
patients O
at O
72 O
hours O
post O
operation. O
[['Resource-use']]

Proton O
pump O
inhibitor O
(PPI) O
is O
a O
useful O
drug O
in O
the O
treatment O
of O
LPR, O
but O
its O
effect O
on O
hypogeusia O
is O
not O
known. O
[]

Subjects O
practiced O
yoga O
over O
two O
months O
in O
three O
sessions, O
the O
duration O
of O
each O
session O
was O
60min. O
[]

METHODS: O
This O
was O
a O
prospective O
single O
blind O
randomized O
sham O
controlled O
trial O
where O
patients O
undergoing O
coronary O
angioplasty O
with O
stage O
III O
chronic O
kidney O
disease O
were O
randomized O
into O
sham O
preconditioning O
and O
remote O
ischemic O
preconditioning. O
[]

Palo O
Alto, O
CA, O
USA. O
[]

Functional B-outcome ['Life-Impact']
outcomes O
were O
not O
associated O
with O
DHA O
status O
before O
and O
after O
intervention O
and O
remained O
unchanged O
by O
supplementation. O
[['Life-Impact']]

T O
Numeric O
rating O
scale O
(NRS) O
was O
used O
to O
assess O
pain B-outcome ['Physiological-Clinical']
in O
the O
post-anesthesia O
care O
unit O
(PACU). O
[['Physiological-Clinical']]

Title: O
Does O
nifedipine O
improve O
outcomes O
of O
embryo O
transfer?: O
[]

The O
trial O
was O
conducted O
at O
seven O
hospitals O
or O
clinics O
in O
Peru, O
Brazil, O
Colombia, O
Vietnam, O
and O
Thailand O
and O
involved O
patients O
with O
normal O
glucose-6-phosphate O
dehydrogenase O
(G6PD) O
enzyme O
activity O
and O
female O
patients O
with O
moderate O
G6PD O
enzyme O
deficiency; O
all O
patients O
had O
confirmed O
P. O
vivax O
parasitemia. O
[]

Journal O
ID: O
101238455 O
[]

Interventions: O
Participants O
were O
randomized O
to O
an O
intervention O
group O
that O
encouraged O
an O
energy-reduced O
Mediterranean O
diet, O
promoted O
physical O
activity, O
and O
provided O
behavioral O
support O
(n O
= O
3406) O
or O
to O
a O
control O
group O
that O
encouraged O
an O
energy-unrestricted O
Mediterranean O
diet O
(n O
= O
3468). O
[]

CONCLUSION: O
The O
application O
of O
preoperative O
localization O
of O
small O
nodules O
by O
placing O
wire O
and O
intrapleural O
fibrin O
glue O
improves O
the O
success O
[rate] O
of O
resection B-outcome ['Life-Impact']
, O
reduces O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
the O
risk O
of O
the O
operation B-outcome ['Life-Impact']
, O
and O
lowers O
the O
difficulty B-outcome ['Life-Impact']
of O
finding O
pathological O
specimens O
after O
the O
operation. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Funded O
by O
the O
French O
National O
Cancer O
Institute; O
ClinicalTrials.gov O
number, O
NCT00937456 O
.). O
[]

Journal-Name: O
The O
journal O
of O
contemporary O
dental O
practice O
[]

The O
original O
trial O
(number, O
NCT00678275) O
and O
follow-up O
extension O
(number, O
NCT03042676) O
are O
registered O
at O
ClinicalTrials.gov. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Results: O
Overall, O
402 O
patients O
(30 O
mg: O
134; O
100 O
mg: O
135; O
300 O
mg: O
133) O
were O
treated O
and O
evaluable O
for O
efficacy O
and O
safety. O
[]

Title: O
Effect O
of O
segmental O
muscle O
vibration O
on O
upper B-outcome ['Life-Impact']
extremity I-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
poststroke: O
A O
randomized O
controlled O
trial. O
[['Life-Impact']]

Little O
is O
known O
about O
the O
impact O
of O
bracing O
on O
sensory O
function. O
[]

Importance: O
Postoperative O
delirium O
is O
common O
following O
cardiac O
surgery O
and O
may O
be O
affected O
by O
choice O
of O
analgesic O
and O
sedative. O
[]

Publication O
date: O
2018/12/20 O
06:00 O
[entrez] O
[]

Resting O
blood O
samples O
were O
collected O
prior O
to O
and O
on O
completion O
of O
each O
diet O
to O
determine O
plasma O
intestinal B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(I-FABP) I-outcome ['Physiological-Clinical']
as O
a O
marker O
of O
acute B-outcome ['Physiological-Clinical']
GI I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
. O
RESULTS: O
Overall O
Irritable B-outcome ['Physiological-Clinical']
Bowel I-outcome ['Physiological-Clinical']
Syndrome-Severity I-outcome ['Physiological-Clinical']
Scoring O
System O
(IBS-SSS) O
score O
significantly O
reduced O
in O
the O
LOWFODMAP O
condition O
from O
81.1 O
+/- O
16.4 O
to O
31.3 O
+/- O
9.2 O
(arbitrary O
units; O
P O
= O
0.004). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Compared O
with O
noninvasive O
breathing O
unit O
after O
treatment, O
rhodiola+noninvasive O
breathing O
unit O
after O
treatment O
in O
patients O
with O
elevated O
levels O
of O
serum O
SOD B-outcome ['Physiological-Clinical']
, O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
level O
decreased O
P<0.05, O
and O
for O
the O
treatment O
group O
after O
treatment O
in O
patients O
with O
serum O
SOD B-outcome ['Physiological-Clinical']
levels O
drop, O
the O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
levels O
P<0.05, O
and O
the O
after O
rhodiola O
rosea O
treatment O
group O
compared, O
rhodiola+noninvasive O
breathing O
unit O
after O
treatment O
in O
patients O
with O
elevated O
levels O
of O
serum O
SOD B-outcome ['Physiological-Clinical']
, O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
level O
decreased O
P<0.05. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

So O
we O
tried O
tobramycin/dexamethasone O
eye O
drops O
as O
a O
replacement. O
[]

Journal-Name:Toxicon O
: O
official O
journal O
of O
the O
International O
Society O
on O
Toxinology O
[]

The O
IV O
group O
(n O
= O
30) O
received O
a O
placebo O
patch. O
[]

Publication O
Type: O
Journal O
Article O
[]

Systolic B-outcome ['Physiological-Clinical']
(SBP) I-outcome ['Physiological-Clinical']
and O
mean O
(MBP) O
blood O
pressure O
, O
and O
cardiac B-outcome ['Physiological-Clinical']
index O
(CI) O
were O
related O
to O
time O
after O
polynomial O
transformation, O
and O
showed O
an O
increase O
after O
intubation O
in O
Group O
SM O
but O
a O
decrease O
in O
Group O
S O
(Ptime2*group<0.0001). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/02/08 O
06:00 O
[entrez] O
[]

In O
conclusion, O
intraduodenal O
infusion O
of O
L-valine, O
at O
loads O
that O
are O
moderately O
(3.3 O
g) O
or O
substantially O
(9.9 O
g) O
above O
World O
Health O
Organization O
valine O
requirement O
recommendations, O
does O
not O
appear O
to O
have O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
- O
or O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
-lowering O
effects. O
[['Life-Impact'], ['Physiological-Clinical']]

METHODS: O
A O
total O
of O
320 O
treatment-naive O
HBeAg-positive O
CHB O
patients O
who O
received O
randomly O
a O
single O
regimen O
of O
either O
entecavir O
capsule O
(ETV) O
(n O
= O
160) O
or O
tenofovir O
disoproxil O
fumarate O
capsule O
(TDF) O
(n O
= O
160) O
for O
144 O
weeks O
were O
consecutively O
enrolled O
from O
14 O
tertiary O
hospitals O
or O
university O
hospitals O
in O
China O
between O
January O
2012 O
and O
December O
2014. O
[]

We O
aimed O
to O
study O
the O
radiation B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
reduction O
to O
operators O
with O
the O
use O
of O
RADPAD O
and O
also O
measureradiation O
doses O
in O
different O
angiographic O
projections. O
[['Life-Impact']]

There O
was O
significant O
difference O
in O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during O
hemostatic O
process O
between O
the O
2 O
groups O
(P O
<.001). O
[['Physiological-Clinical']]

The O
between-group O
difference O
in O
the O
incidence O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
not O
significant O
(146 O
of O
527 O
participants O
[27.7%] O
in O
the O
intravenous O
group O
and O
138 O
of O
527 O
[26.2%] O
in O
the O
oral O
group; O
P=0.58). O
[['Adverse-effects']]

At O
the O
3-month O
follow-up O
visit, O
there O
were O
improvements O
in O
adherence B-outcome ['Life-Impact']
to O
the O
MD O
and O
diet B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of O
2.2 O
and O
2.5 O
points, O
compared O
to O
the O
baseline O
visit, O
respectively, O
in O
favour O
of O
the O
IG. O
[['Life-Impact'], ['Life-Impact']]

In O
contrast, O
all O
active O
interventions O
in O
Studies O
1 O
and O
2 O
decreased O
negative B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
. O
These O
studies O
provide O
the O
first O
experimental O
evidence O
that O
developing O
an O
orientation O
of O
acceptance O
toward O
present-moment O
experiences O
is O
a O
central O
mechanism O
of O
mindfulness O
interventions O
for O
boosting O
positive B-outcome ['Life-Impact']
emotions I-outcome ['Life-Impact']
in O
daily O
life. O
( O
[['Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

Subjects O
exercised O
significantly O
longer O
(PC O
= O
66.7 O
+/- O
16.3 O
min, O
CON O
= O
45.7 O
+/- O
9.5 O
min) O
and O
at O
lower O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
(approximately O
0.5 O
+/- O
0.5 O
degrees O
C) O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(approximately O
10 O
+/- O
7 O
bpm) O
following O
PC. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
ISRCTN27083228 O
[]

Publication O
Type: O
Journal O
Article O
[]

In O
the O
current O
exploratory O
analysis, O
these O
ardms O
were O
categorized O
into O
the O
moderate O
hypofractionated O
(MHF) O
group O
(52 O
patients O
in O
Arms O
1-3) O
and O
the O
extreme O
hypofractionated O
(EHF) O
group O
(30 O
patients O
in O
Arms O
4-5). O
[]

a O
randomized O
clinical O
trial. O
[]

After O
6 O
months, O
RA B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
RV B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
area E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
RV B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
tricuspid I-outcome ['Physiological-Clinical']
regurgitation I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
showed O
a O
significant O
reduction. O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Objective: O
To O
determine O
whether O
removing O
co-payment O
barriers O
increases O
P2Y12 B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
persistence I-outcome ['Physiological-Clinical']
and O
lowers O
risk O
of O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
. O
Design, O
Setting, O
and O
Participants: O
Cluster O
randomized O
clinical O
trial O
among O
301 O
hospitals O
enrolling O
adult O
patients O
with O
acute O
MI O
(June O
5, O
2015, O
through O
September O
30, O
2016); O
patients O
were O
followed O
up O
for O
1 O
year O
after O
discharge O
(final O
date O
of O
follow-up O
was O
October O
23, O
2017), O
with O
blinded O
adjudication O
of O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
; O
choice O
of O
P2Y12 O
inhibitor O
was O
per O
clinician O
discretion. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical', 'Mortality']]

Journal O
ID: O
8200894 O
[]

Compared O
with O
clomifene O
citrate O
alone, O
the O
combined O
treatment O
improved O
cervical B-outcome ['Physiological-Clinical']
mucus I-outcome ['Physiological-Clinical']
score, O
follicle B-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
rate, O
single B-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
ovulation I-outcome ['Physiological-Clinical']
rate, O
endometrial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
positive O
rate O
of O
three B-outcome ['Physiological-Clinical']
lines I-outcome ['Physiological-Clinical']
sign I-outcome ['Physiological-Clinical']
, O
and O
follicle-stimulating B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
level. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O
[]

Wohlfert O
TM, O
Miller O
KC. O
[]

CONCLUSIONS: O
A O
BCL O
can O
improve O
tear B-outcome ['Physiological-Clinical']
film I-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
and O
lessen O
dry B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
immediately O
after O
phacoemulsification. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

In O
23 O
research O
centers O
in O
Spain, O
6874 O
men O
and O
women O
aged O
55 O
to O
75 O
years O
with O
metabolic O
syndrome O
and O
no O
cardiovascular O
disease O
were O
enrolled O
in O
the O
trial O
between O
September O
2013 O
and O
December O
2016, O
with O
final O
data O
collection O
in O
March O
2019. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
101521595 O
[]

METHODS: O
This O
study O
employed O
a O
prospective, O
randomized O
study O
design O
to O
assess O
student's O
learning B-outcome ['Life-Impact']
curve. O
[['Life-Impact']]

Journal O
ID: O
101307187 O
[]

There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
when O
baseline O
( O
DIAGNOdent O
pen O
(DD) O
values O
were O
compared O
(P O
> O
0.05). O
[]

Results: O
All O
patients O
were O
followed O
up O
12-18 O
months O
with O
an O
average O
of O
14.4 O
months. O
[]

Journal O
ID: O
0370522 O
[]

Publication O
Type: O
Journal O
Article O
[]

Publication O
date: O
2019/02/13 O
06:00 O
[medline] O
[]

Publication O
Type: O
Comparative O
Study, O
Journal O
Article, O
Multicenter O
Study, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
Non-U.S. O
Gov't, O
[]

The O
paired O
sample O
t-test O
or O
Wilcoxon O
test O
were O
employed O
to O
calculate O
the O
differences O
between O
variables O
before O
and O
after O
music O
therapy O
intervention. O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
7, O
9, O
11, O
13 O
or O
15 O
mg O
intrathecal O
hyperbaric O
ropivacaine O
respectively. O
[]

Journal O
ID: O
8303003 O
[]

OBJECTIVE: O
To O
investigate O
the O
use O
of O
Bilevel O
Positive O
Airway O
Pressure O
(BiPAP) O
in O
morbidly O
obese O
individuals O
in O
two O
moments O
following O
bariatric O
surgery O
(Roux-en-Y O
gastric O
bypass): O
post-anesthetic O
recovery O
(PAR) O
and O
first O
postoperative O
day O
(1PO). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Key O
exclusion O
criteria O
included O
diagnosis O
of O
neuromyelitis O
optica O
spectrum O
disorder. O
[]

Publication O
date: O
2019/02/13 O
06:00 O
[medline] O
[]

The O
two O
groups O
were O
compared O
in O
terms O
of O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
parameters, O
and O
six-minute O
walk B-outcome ['Physiological-Clinical']
distance I-outcome ['Physiological-Clinical']
before O
intervention O
and O
after O
2 O
months O
of O
intervention. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:BMC O
public O
health O
[]

Echocardiography O
was O
analysed O
off-line O
at O
baseline, O
after O
3, O
6 O
and O
12 O
months O
by O
investigators O
who O
were O
blinded O
to O
clinical O
data. O
[]

The O
study O
consisted O
of O
a O
pre-screening, O
screening, O
day O
0 O
baseline O
(randomization O
visit) O
and O
three O
follow-up O
visits O
on O
days O
14, O
28 O
and O
56. O
[]

Journal O
ID: O
101476450 O
[]

Design, O
Setting, O
and O
Participants: O
A O
multicenter, O
parallel-group, O
cluster-randomized O
clinical O
trial O
with O
integrated O
economic O
and O
process O
evaluations O
conducted O
in O
24 O
ICUs O
in O
the O
United O
Kingdom. O
[]

RESULTS: O
Cumulative O
mean O
QALYs/mean O
costs B-outcome ['Resource-use']
of I-outcome ['Resource-use']
health I-outcome ['Resource-use']
care I-outcome ['Resource-use']
service I-outcome ['Resource-use']
use I-outcome ['Resource-use']
and O
surgery O
per O
patient O
from O
baseline O
to O
12 O
months O
were O
estimated O
as O
0.640 O
(standard O
error O
(se) O
0.024)/ O
pound3147 O
(se O
166) O
in O
the O
decompression O
arm, O
0.656 O
(se O
0.020)/ O
pound2830 O
(se O
183) O
in O
the O
arthroscopy O
only O
arm O
and O
0.522 O
(se O
0.029)/ O
pound1451 O
(se O
151) O
in O
the O
no O
treatment O
arm. O
[['Resource-use']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Journal O
of O
cancer O
research O
and O
therapeutics O
[]

Crossover O
to O
the O
sorafenib O
group O
was O
permitted O
for O
patients O
in O
the O
placebo O
group O
who O
had O
disease O
progression. O
[]

Title: O
Clinical O
Outcome O
following O
Intra-articular O
Triamcinolone O
Injection O
in O
Osteoarthritic O
Knee O
at O
the O
Community: O
A O
Randomized O
Double O
Blind O
Placebo O
Controlled O
Trial. O
[]

Results: O
Recruitment O
stopped O
on O
December O
21, O
2017, O
because O
conditional O
power O
for O
the O
primary O
outcome O
based O
on O
a O
prespecified O
analysis O
of O
the O
first O
267 O
randomized O
participants O
was O
less O
than O
30% O
in O
both O
treatment O
groups O
(futility O
criterion). O
[]

Trimethylamine O
N-oxide O
(TMAO) O
is O
considered O
a O
novel O
risk O
factor O
for O
cardiovascular O
diseases. O
[]

Journal-Name:BMC O
infectious O
diseases O
[]

Those O
in O
the O
training O
group O
received O
a O
further O
individual O
3-hour O
training O
session, O
and O
were O
tested O
again O
after O
1 O
week O
(test-2). O
[]

Publication O
date: O
2019/01/04 O
06:00 O
[entrez] O
[]

During O
the O
follow-up O
period, O
2 O
children O
of O
SBH O
treatment O
group O
and O
2 O
children O
of O
routine O
treatment O
group O
were O
lost O
or O
the O
outcome O
was O
unknown. O
[]

The O
effective O
concentration B-outcome ['Life-Impact']
values O
for O
remifentanil O
TCI O
were O
determined O
using O
sequential O
method O
and O
probit O
analysis. O
[['Life-Impact']]

When O
comparing O
survey O
responses O
between O
individuals O
who O
met O
online O
and O
in O
person, O
we O
did O
not O
detect O
a O
difference O
in O
demographics O
with O
the O
exception O
of O
preferred O
meeting O
method O
(p=0.0225). O
[]

PURPOSE: O
The O
primary O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effectiveness O
of O
3 O
different O
methods O
for O
delivering O
instruction O
on O
infant O
handling O
to O
parents O
in O
the O
neonatal O
intensive O
care O
unit O
(NICU). O
[]

Both O
T2W O
and O
T2*W O
MRI O
show O
reduced O
interobserver O
variability O
and O
improved O
accuracy O
compared O
to O
CT, O
this O
was O
statistically O
significant O
for O
T2*W O
imaging O
compared O
to O
CT O
across O
all O
four O
comparison O
metrics. O
[]

Publication O
date: O
2018/07/01 O
00:00 O
[accepted] O
[]

Publication O
date: O
2018/12/03 O
00:00 O
[accepted] O
[]

Publication O
date: O
['2019/10/18 O
06:00' O
[]

The O
patients O
inhaled O
hydrogen O
gas O
for O
3 O
h/day O
at O
their O
own O
homes O
and O
received O
chemotherapy O
at O
the O
Tamana O
Regional O
Health O
Medical O
Center O
(Tamana, O
Kumamoto, O
Japan). O
[]

The O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
groups O
were O
compared O
as O
primary O
endpoint O
and O
haematological B-outcome ['Physiological-Clinical']
safety O
parameters O
and O
changes O
in O
systolic B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
diastolic B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
pressure E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and O
blood O
total O
and O
lipoprotein B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
lipids E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
were O
measured O
as O
secondary O
end O
points. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical']]

RESULTS: O
No O
statistical O
differences O
in O
the O
implantation B-outcome ['Physiological-Clinical']
rate O
(42.6% O
vs O
39.1%, O
P O
= O
.737, O
rate O
ratio O
0.868, O
95% O
confidence O
interval O
[CI]: O
0.379-1.986) O
and O
the O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate O
(23.4% O
vs O
26.1%, O
P O
= O
.764, O
rate O
ratio O
1.155, O
95% O
CI: O
0.450-2.966) O
were O
detected O
between O
the O
placebo O
and O
the O
treatment O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Although O
there O
are O
studies O
confirming O
ergogenic O
effects O
of O
caffeine O
(CAF) O
on O
different O
physical O
and O
mental O
abilities, O
much O
controversy O
remains O
about O
its O
influence O
on O
power. O
[]

RESULTS: O
More O
than O
one O
third O
of O
girls O
(35.1%) O
reported O
having O
no O
hope O
for O
the O
future. O
[]

Title: O
Omadacycline O
for O
Acute O
Bacterial O
Skin O
and O
Skin-Structure O
Infections. O
[]

RESULTS: O
In O
1st O
group O
of O
children O
operated O
with O
cadaver O
allografts, O
the O
Kujala O
score O
significantly O
improved O
from O
73.91 O
points O
preoperatively O
to O
94.50 O
points O
postoperatively O
(P O
< O
.001). O
[]

TRIAL O
REGISTRATION: O
ClinicalTrials.gov, O
NCT01465698 O
November O
7, O
2011 O
(prospective). O
[]

This O
indicates O
that O
changing O
lifestyle B-outcome ['Life-Impact', 'Life-Impact']
is O
an O
important O
first O
step, O
but O
maintaining O
this O
change O
is O
needed O
for O
improving O
cardiometabolic B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
in O
the O
long-term. O
[['Life-Impact', 'Life-Impact'], ['Physiological-Clinical']]

The O
incidences O
of O
postoperative O
pulmonary B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
(PPCs) I-outcome ['Physiological-Clinical']
and O
atelectasis O
(2.9%, O
0.0%) O
in O
the O
AG O
were O
significantly O
lower O
than O
that O
in O
the O
CG O
(20.6%, O
14.7%)(P=0.03, O
P=0.03). O
[['Physiological-Clinical']]

Mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(MBP) I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
and O
SpO2 B-outcome ['Physiological-Clinical']
at O
the O
time O
points O
from O
T6 O
to O
T10 O
and O
Observer's O
Assessment O
of O
Alertness B-outcome ['Physiological-Clinical']
/ O
Sedation B-outcome ['Physiological-Clinical']
(OAA/S)], O
wavelet B-outcome ['Physiological-Clinical']
index O
[WLi], O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
index O
[ANXi], O
comfortable B-outcome ['Life-Impact']
index O
[CFi], O
and O
pain B-outcome ['Physiological-Clinical']
index O
[Pi] O
at O
the O
time O
points O
from O
T6 O
to O
T11 O
were O
significantly O
lower O
in O
the O
sedation O
group O
(all O
P O
&lt; O
0.05), O
and O
these O
parameters O
were O
not O
significantly O
different O
between O
the O
two O
groups O
at O
the O
other O
time O
points O
(all O
P&gt;0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
Clinicaltrials.gov O
Identifier: O
NCT03173339. O
[]

Publication O
date: O
2019/02/14 O
06:00 O
[entrez] O
[]

Journal-Name:Nutrients O
[]

Anti-CT694 B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
increased O
in O
both O
study O
arms O
(p O
= O
0.009 O
for O
control O
arm O
and O
p O
= O
0.04 O
for O
treatment O
arm). O
[['Physiological-Clinical']]

Publication O
date: O
2018/11/26 O
00:00 O
[accepted] O
[]

Title: O
Effect O
of O
Kinesio O
taping O
on O
electromyographic O
activity O
of O
leg O
muscles O
during O
gait O
in O
children O
with O
developmental O
coordination O
disorder: O
A O
randomized O
controlled O
trial. O
[]

CONCLUSION: O
RIPC O
does O
not O
result O
in O
significant O
reduction O
of O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
. O
However O
RIPC O
helps O
in O
the O
prevention O
of O
post O
procedural O
worsening O
in O
eGFR B-outcome ['Physiological-Clinical']
and O
serum O
creatinine B-outcome ['Physiological-Clinical']
even O
up O
to O
6 O
weeks. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/10/25 O
00:00 O
[accepted] O
[]

All O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
6-week O
treatment O
and O
2-week O
follow-up O
after O
the O
treatment. O
[]

Journal-Name:BMC O
infectious O
diseases O
[]

The O
evaluation O
of O
the O
Nia O
Project O
is O
one O
of O
the O
first O
to O
analyze O
the O
individual O
and O
combined O
contributions O
of O
sanitary O
pads O
and O
provision O
of O
comprehensive O
reproductive O
health O
education O
on O
girls' O
education B-outcome ['Life-Impact']
and O
reproductive B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
outcomes. O
[['Life-Impact'], ['Physiological-Clinical']]

The O
comparison O
between O
two O
doses O
revealed O
a O
non-significant O
difference O
(p=.118 O
& O
p=.149 O
respectively). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Objective: O
The O
aim O
of O
this O
clinical O
trial O
was O
to O
assess O
whether O
controlled O
irrigation O
with O
three O
different O
irrigation O
regimens O
with O
different O
temperature O
would O
result O
in O
reduction O
of O
post-endodontic O
pain B-outcome ['Physiological-Clinical']
after O
one-visit O
root O
canal O
treatment O
(RCT). O
[['Physiological-Clinical']]

CONCLUSIONS: O
Mean O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
starts O
to O
decline O
prior O
to O
the O
first O
reported O
symptoms O
of O
an O
exacerbation, O
and O
does O
not O
recover O
to O
pre-exacerbation O
levels O
8 O
weeks O
after O
the O
event. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O
[]

BACKGROUND: O
Pharmacologic O
angiotensin O
axis O
blockade O
(AAB) O
has O
been O
associated O
with O
profound O
hypotension O
following O
anesthetic O
induction O
with O
propofol. O
[]

The O
appearance B-outcome ['Life-Impact']
, O
graft B-outcome ['Physiological-Clinical']
, O
conjunctiva B-outcome ['Physiological-Clinical']
melting I-outcome ['Physiological-Clinical']
, O
and O
tube B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
were O
the O
primary O
observation O
points. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Hippotherapy O
in O
Rehabilitation O
Care O
for O
Children O
With O
Neurological O
Impairments O
and O
Developmental O
Delays: O
A O
Case O
Series. O
[]

BACKGROUND: O
Micronutrient O
deficiencies O
are O
common O
during O
pregnancy, O
especially O
in O
pregnant O
women O
from O
economically O
disadvantaged O
settings O
where O
diets O
with O
low O
content O
of O
minerals O
and O
vitamins O
are O
consumed. O
[]

BACKGROUND: O
E-cigarettes O
are O
commonly O
used O
in O
attempts O
to O
stop O
smoking, O
but O
evidence O
is O
limited O
regarding O
their O
effectiveness O
as O
compared O
with O
that O
of O
nicotine O
products O
approved O
as O
smoking-cessation O
treatments. O
[]

There O
was O
no O
significant O
difference O
in O
gender, O
age, O
injury O
cause, O
Denis O
classification, O
fracture O
segment, O
the O
degree O
of O
injured O
vertebra O
compression, O
bone O
mineral O
density, O
and O
American O
Spinal O
Cord O
Injury O
Association O
(ASIA) O
classification O
between O
the O
two O
groups O
( O
P>0.05). O
[]

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

Publication O
Type: O
Multicenter O
Study O
[]

In O
conclusion, O
our O
data O
show O
that O
Taurisolo((R)) O
may O
represent O
a O
novel O
and O
useful O
natural O
remedy O
to O
reduce O
prognostic O
markers O
for O
incident O
cardiovascular O
events. O
[]

Patients O
were O
tested O
4 O
weeks O
post-treatment O
to O
confirm O
eradication. O
[]

Publication O
Type: O
Journal O
Article O
[]

They O
were O
equally O
and O
randomly O
allocated O
to O
a O
treatment O
group O
(n O
= O
50) O
and O
a O
placebo O
group O
(n O
= O
50). O
[]

RESULTS: O
Fifty-two O
residents O
participated O
in O
the O
study O
(Group O
C: O
n O
= O
27, O
Group O
3D: O
n O
= O
25). O
[]

There O
were O
no O
differences O
in O
the O
live B-outcome ['Mortality']
birth I-outcome ['Mortality']
rates O
between O
Group O
1 O
and O
Group O
2 O
by O
intention-to-treat O
(14/34, O
41.2% O
versus O
21/37, O
56.8%, O
p O
= O
0.19) O
or O
per-protocol O
(14/26, O
53.8% O
versus O
19/31, O
61.3%, O
p O
= O
0.57) O
analyses. O
[['Mortality']]

Electromyographic O
analysis O
of O
the O
pectoralis O
major O
and O
triceps O
brachii O
were O
monitored O
during O
3 O
maximal O
isometric O
contractions O
and O
a O
fatiguing O
endurance O
task. O
[]

Publication O
date: O
2019/02/08 O
06:00 O
[entrez] O
[]

The O
selection O
of O
proper O
respirators O
and O
training O
would O
be O
beneficial O
to O
the O
safety O
of O
healthcare O
providers. O
[]

Publication O
date: O
2018/10/29 O
00:00 O
[accepted] O
[]

One O
participant O
was O
lost B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
follow-up I-outcome ['Life-Impact']
. O
Outcome B-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
rates O
ranged O
from O
89 O
to O
97%. O
[['Life-Impact'], ['Life-Impact']]

We O
found O
that O
the O
two O
regimens O
were O
equivalent; O
36 O
out O
of O
44 O
patients O
reached O
the O
normal O
range O
of O
vitamin O
D O
after O
six O
months O
of O
treatment. O
[]

Results O
indicate O
that O
WPI O
itself O
did O
not O
result O
in O
improved O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
but O
some O
evidence O
of O
benefit O
of O
SPI O
for O
females O
was O
found. O
[['Life-Impact']]

We O
used O
fuzzy-set O
qualitative O
comparative O
analysis O
(fsQCA) O
to O
identify O
combinations O
of O
conditions O
that O
were O
associated O
with O
either O
an O
increase O
or O
no O
increase O
in O
the O
outcome O
emotional B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
and O
social O
school O
experience O
(SCE) O
in O
comparison O
to O
the O
control O
group O
at O
20 O
months O
post O
intervention. O
[['Life-Impact', 'Life-Impact', 'Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
clinical O
value O
of O
OPEP O
has O
been O
widely O
discussed O
in O
chronic O
obstructive O
pulmonary O
disease, O
bronchiectasis O
as O
well O
as O
pulmonary O
cyst. O
[]

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
degree O
of O
injured O
vertebra B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
, O
VAS O
score, O
and O
Oswestry O
disability B-outcome ['Life-Impact']
index O
(ODI) O
score O
were O
significantly O
improved O
in O
both O
groups O
at O
immediate O
after O
operation O
and O
last O
follow-up O
( O
P<0.05). O
[['Physiological-Clinical'], ['Life-Impact']]

Journal O
ID: O
100968562 O
[]

The O
aim O
of O
this O
split-mouth, O
randomized O
controlled O
clinical O
trial O
was O
to O
evaluate O
the O
efficacy O
of O
low-level O
laser O
therapy O
(LLLT) O
and O
photodynamic O
therapy O
(PDT) O
as O
an O
adjunct O
to O
scaling O
and O
root O
planing O
(SRP) O
in O
treatment O
of O
chronic O
periodontitis. O
[]

METHODS: O
WISDOM O
was O
a O
multinational, O
randomized, O
double-blind, O
active-controlled, O
52-week O
study O
in O
patients O
with O
severe-to-very O
severe O
COPD. O
[]

Title: O
Bilateral O
versus O
Single O
Internal-Thoracic-Artery O
Grafts O
at O
10 O
Years. O
[]

RESULTS: O
A O
significant O
difference O
was O
found O
in O
the O
median O
number O
[range] O
of O
small B-outcome ['Physiological-Clinical']
intestinal I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
between O
baseline O
and O
two O
weeks O
after O
low-dose O
aspirin O
administration O
in O
group O
A O
(baseline: O
1 O
[0-5], O
after: O
5 O
[1-11]; O
p O
= O
0.0059) O
but O
not O
in O
group O
B O
(baseline: O
0.5 O
[0-9], O
after: O
3 O
[0-23]; O
p O
= O
0.0586). O
[['Physiological-Clinical']]

The O
primary O
outcome O
was O
live B-outcome ['Mortality']
birth I-outcome ['Mortality']
. O
RESULTS: O
A O
total O
of O
1364 O
women O
underwent O
randomization. O
[['Mortality']]

The O
secondary O
outcome O
was O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
For O
the O
safety O
assessment, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
recorded O
during O
the O
study O
period. O
[['Physiological-Clinical'], ['Adverse-effects']]

The O
success O
rates O
of O
hemostasis B-outcome ['Physiological-Clinical']
for O
3 O
minutes O
and O
5 O
minutes, O
the O
time B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
, O
the O
amount O
of O
intraoperative O
bleeding B-outcome ['Physiological-Clinical']
, O
the O
volume O
of O
autogenously O
blood B-outcome ['Resource-use']
transfusion I-outcome ['Resource-use']
, O
the O
amount O
of O
blood B-outcome ['Physiological-Clinical']
during O
hemostasis, O
the O
amount O
of O
blood B-outcome ['Resource-use']
transfusion I-outcome ['Resource-use']
, O
and O
BP B-outcome ['Physiological-Clinical']
, O
red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
(RBC) I-outcome ['Physiological-Clinical']
, O
haematocrit B-outcome ['Physiological-Clinical']
(HCT) I-outcome ['Physiological-Clinical']
, O
haemoglobin B-outcome ['Physiological-Clinical']
(HB) I-outcome ['Physiological-Clinical']
of O
preoperative, O
2 O
to O
3 O
days, O
and O
5 O
to O
7 O
days O
following O
operation O
were O
recorded O
to O
compare. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

In O
the O
experimental O
group, O
the O
patients O
performed O
relaxation O
techniques O
once O
a O
day O
for O
30min O
over O
two O
months. O
[]

OBJECTIVE: O
To O
observe O
the O
preoperative O
sedation B-outcome ['Physiological-Clinical']
, O
the O
status B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
separation I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
parents I-outcome ['Life-Impact']
, O
compliance B-outcome ['Life-Impact']
with O
the O
mask, O
hemodynamic B-outcome ['Physiological-Clinical']
parameters O
and O
postoperative O
agitation B-outcome ['Life-Impact']
of O
intranasal O
dexmedetomidine O
(DEX) O
premedication O
on O
children O
undergoing O
dental O
rehabilitation O
under O
general O
anesthesia. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact']]

There O
were O
also O
major O
re-structuring O
of O
several O
organisations O
which O
presented O
significant O
implementation O
challenges, O
and O
technical O
limitations. O
[]

SAI O
were O
classified O
as O
lacunar O
infarction O
and O
non-lacunar O
infarction. O
[]

Introduction: O
Peri- O
and O
postmenopausal O
women O
frequently O
suffer O
from O
urinary O
incontinence O
(UI). O
[]

RESULTS: O
TXA O
significantly O
reduced O
perioperative O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
(p O
< O
0.001); O
the O
mean O
differences O
were O
525.3 O
ml O
(short-TXA O
vs O
placebo) O
and O
550.1 O
ml O
(long-TXA O
vs O
placebo). O
[['Physiological-Clinical']]

Parents O
and O
caregivers O
of O
children O
6 O
to O
40 O
months O
age O
group O
in O
intervention O
villages O
received O
intensive O
education O
on O
hand O
hygiene. O
[]

Title: O
The O
influence O
of O
pelvis O
reposition O
exercises O
on O
pelvic B-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
asymmetry I-outcome ['Physiological-Clinical']
: O
A O
randomized O
prospective O
study. O
[['Physiological-Clinical']]

Cholesterol B-outcome ['Physiological-Clinical']
reduction O
is O
achieved O
without O
concomitant O
reduction O
of O
Coenzyme B-outcome ['Physiological-Clinical']
Q10 I-outcome ['Physiological-Clinical']
(CoQ10) I-outcome ['Physiological-Clinical']
, O
in O
contrast O
to O
what O
is O
observed O
with O
statins. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

AIM: O
To O
assess O
the O
effectiveness O
of O
a O
self-administered O
rehabilitation O
program O
in O
adults O
with O
shoulder O
pain O
syndrome O
in O
primary O
care. O
[]

METHODS: O
Forty-four O
adults O
with O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders, O
Fifth O
Edition O
diagnosis O
of O
ADHD O
participated O
in O
a O
randomized, O
double-blind, O
placebo-controlled, O
12-week O
trial O
of O
15 O
mg O
of O
L-methylfolate O
in O
combination O
with O
osmotic-release O
oral O
system O
methylphenidate. O
[]

RESULTS: O
The O
ED95 O
and O
95% O
confidence O
intervals O
(95% O
CI) O
of O
spinal O
hyperbaric O
bupivacaine O
in O
group O
D O
and O
group O
C O
were O
7.4 O
mg O
(95% O
CI, O
5.6-12.4 O
mg) O
and O
11.0 O
mg O
(95% O
CI, O
4.4-56.8 O
mg), O
respectively. O
[]

Givosiran O
is O
an O
investigational O
RNA O
interference O
therapeutic O
agent O
that O
inhibits O
hepatic O
ALAS1 O
synthesis. O
[]

METHODS: O
FLAME O
was O
a O
52-week O
randomized O
controlled O
trial O
in O
patients O
with O
severe-to-very-severe O
COPD O
and O
a O
history O
of O
exacerbations. O
[]

BACKGROUND: O
Maintenance O
of O
effect O
following O
treatment O
with O
galcanezumab O
compared O
to O
placebo O
in O
adult O
patients O
with O
episodic O
or O
chronic O
migraine O
was O
evaluated. O
[]

Better O
baseline O
BCVA O
(> O
50 O
ETDRS O
letters/Snellen O
equivalent O
>/= O
20/100), O
greater O
baseline O
total O
macular O
volume O
(> O
9.99 O
mm(3)), O
and O
presence O
of O
subretinal O
fluid O
at O
baseline O
were O
all O
associated O
with O
early O
improvement O
to O
20/40 O
or O
better O
vision B-outcome ['Physiological-Clinical']
( O
Early O
Treatment O
Diabetic B-outcome ['Physiological-Clinical']
Retinopathy I-outcome ['Physiological-Clinical']
Study O
(ETDRS) O
equivalent O
>/= O
69 O
letters; O
P O
< O
.0001, O
P O
= O
.02, O
and O
P O
= O
.03, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Lipids O
in O
health O
and O
disease O
[]

The O
secondary O
outcome O
composite O
of O
requirement O
of O
hemodialysis B-outcome ['Resource-use']
, O
death B-outcome ['Mortality']
and O
rehospitalization B-outcome ['Resource-use']
for O
heart O
failure O
was O
not O
statistically O
significant O
(p: O
0.646). O
[['Resource-use'], ['Mortality'], ['Resource-use']]

Constant O
score O
for O
function B-outcome ['Life-Impact']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
using O
SF-36], O
simple O
shoulder O
test O
(SST) O
and O
the O
Disabilities B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
the Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
Arm I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
Shoulder I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
Hand S3-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
(DASH) O
score O
were O
also O
calculated O
at O
six, O
12 O
and O
24 O
weeks O
of O
follow-up. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact', 'Life-Impact', 'Life-Impact']]

Significance O
testing O
for O
the O
primary O
outcome O
was O
based O
on O
1-sided O
testing. O
[]

Bispectral O
index(BIS) O
was O
used O
to O
monitor O
the O
depth O
of O
anesthesia O
and O
maintained O
between O
45-60 O
during O
operation. O
[]

The O
primary O
outcome O
of O
the O
study O
will O
be O
the O
difference O
in O
cure B-outcome ['Physiological-Clinical']
rate O
of O
intense O
versus O
standard O
treatment O
with O
PZQ O
on O
individuals O
with O
a O
confirmed O
S.mansoni O
infection O
measured O
by O
KK. O
[['Physiological-Clinical']]

CONCLUSIONS: O
Among O
patients O
referred O
to O
VA O
gastroenterology O
clinics O
for O
PPI-refractory O
heartburn, O
systematic O
workup O
revealed O
truly O
PPI-refractory O
and O
reflux-related O
heartburn O
in O
a O
minority O
of O
patients. O
[]

The O
population O
pharmacokinetic O
model O
visualized O
both O
measured O
and O
predicted O
concentrations. O
[]

RESULTS: O
After O
6 O
weeks O
treatment, O
lactulose O
showed O
better O
outcomes O
in O
daily O
stool B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
(P O
< O
.01), O
and O
stool B-outcome ['Physiological-Clinical']
consistency I-outcome ['Physiological-Clinical']
(P O
< O
.01), O
except O
the O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
(P O
= O
.24), O
and O
flatulence B-outcome ['Physiological-Clinical']
(P O
= O
.44), O
compared O
with O
the O
placebo. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Wound B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
in O
the O
first O
30 O
days O
and O
incisional B-outcome ['Physiological-Clinical']
hernia I-outcome ['Physiological-Clinical']
rates O
were O
assessed. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Hence, O
we O
aimed O
to O
identify O
which O
combinations O
of O
teacher O
and O
implementation O
process O
characteristics O
affected O
the O
emotional B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
and O
social O
school O
experience O
(SCE) O
of O
pupils O
participating O
in O
a O
school-based O
health O
promotion O
program. O
[['Life-Impact', 'Life-Impact', 'Life-Impact']]

Methods: O
Post O
hoc O
analysis O
of O
two O
multicenter, O
randomized, O
double-blind, O
vehicle-controlled O
Phase O
3 O
studies O
in O
moderate O
or O
severe O
acne. O
[]

Publication O
date: O
2019/03/12 O
06:00 O
[medline] O
[]

Journal-Name:The O
bone O
& O
joint O
journal O
[]

Subjects O
were O
fed O
a O
fully O
controlled O
base O
diet O
for O
4 O
weeks O
with O
either O
no O
additions O
or O
with O
the O
addition O
of O
42 O
g/day O
(1.5 O
servings) O
of O
cashew O
nuts, O
with O
the O
final O
treatment O
diets O
being O
isocaloric. O
[]

Secondary O
endpoints O
include O
post-intervention O
complications B-outcome ['Adverse-effects']
, O
late O
recurrence B-outcome ['Physiological-Clinical']
of O
acute O
appendicitis O
after O
one O
year, O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
pain B-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
and O
treatment B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
Primary O
endpoint O
will O
be O
evaluated O
in O
two O
stages: O
point O
estimates O
with O
95% O
confidence O
interval O
(CI) O
will O
be O
calculated O
for O
both O
groups O
and O
proportion O
difference O
between O
groups O
with O
95% O
CI O
will O
be O
calculated O
and O
evaluated O
based O
on O
6 O
percentage O
point O
non-inferiority O
margin. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Resource-use']]

Publication O
date: O
2019/02/18 O
06:00 O
[entrez] O
[]

Title: O
Contrast O
Material O
Injection O
Protocol O
With O
the O
Dose O
Determined O
According O
to O
Lean O
Body O
Weight O
at O
Hepatic O
Dynamic O
Computed O
Tomography: O
Comparison O
Among O
Patients O
With O
Different O
Body O
Mass O
Indices. O
[]

Poor O
ovarian O
response O
was O
defined O
according O
to O
the O
Bologna O
criteria. O
[]

OBJECTIVES: O
To O
compare O
the O
effect O
of O
toric O
versus O
spherical O
soft O
contact O
lenses O
on O
objective O
measures O
of O
visual B-outcome ['Physiological-Clinical']
performance O
using O
visual O
acuity O
and O
electromyography O
of O
the O
orbicularis O
oculi O
muscle. O
[['Physiological-Clinical']]

Patients O
were O
enrolled O
after O
the O
diagnosis O
of O
resectable O
or O
borderline O
resectable O
by O
portal O
vein O
involvement O
pancreatic O
cancer O
with O
histological O
confirmation. O
[]

In O
conclusion, O
cashews O
provide O
fewer O
calories O
than O
the O
values O
predicted O
by O
the O
Atwater O
factors, O
as O
found O
on O
current O
food O
labels. O
[]

Music O
therapy O
sessions O
lasting O
30-45 O
min O
were O
individually O
delivered O
weekly O
using O
receptive O
techniques. O
[]

In O
conclusion, O
PPI O
could O
ameliorate O
hypogeusia B-outcome ['Physiological-Clinical']
by O
improving O
bitter, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
salty, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
sour B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
tastes E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
among O
patients O
with O
LPR. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']]

The O
admission O
of O
prolonged O
form O
of O
nitrates O
before O
the O
PCI O
was O
allowed O
in O
the O
second O
group. O
[]

RESULTS: O
The O
repeated O
measures O
ANOVA O
between O
the O
GCAF O
and O
GCON O
groups O
revealed O
statistically O
significant O
differences O
in O
2 O
variables. O
[]

Title: O
The O
Mitochondria-Targeted O
Metabolic O
Tubular O
Injury O
in O
Diabetic O
Kidney O
Disease. O
[]

RESULTS: O
In O
the O
experimental O
group O
both O
the O
Ober O
and O
Thomas O
tests O
were O
positive O
at O
baseline O
in O
most O
subjects. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Effects O
of O
ascorbic O
acid O
supplementation O
on O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
markers O
in O
healthy O
women O
following O
a O
single O
bout O
of O
exercise. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Mean O
wear B-outcome ['Life-Impact']
durations I-outcome ['Life-Impact']
were O
8.78 O
hours O
a O
day O
in O
the O
PT O
group O
and O
12.38 O
hours O
in O
the O
FT O
group. O
[['Life-Impact']]

BACKGROUND: O
Myelomeningocele O
is O
a O
congenital O
anomaly O
of O
Central O
Nervous O
System O
(CNS) O
leading O
to O
serious O
sequels O
related O
to O
various O
systems O
and O
organs O
of O
the O
affected O
patient. O
[]

The O
amount O
of O
postoperative O
pain B-outcome ['Physiological-Clinical']
was O
measured O
on O
the O
basis O
of O
visual O
analog O
scale, O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
at O
recovery O
and O
4, O
12, O
and O
24 O
hours O
after O
surgery. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Conclusion O
Intra-articular O
injection O
of O
Triamcinolone O
acetenoid O
is O
effective O
in O
symptoms B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
improving O
functional B-outcome ['Life-Impact']
outcome O
in O
clinically O
diagnosed O
osteoarthritis O
of O
knees O
in O
community O
set O
up O
during O
health O
camps. O
[['Physiological-Clinical'], ['Life-Impact']]

Publication O
date: O
2019/02/08 O
06:00 O
[medline] O
[]

BACKGROUND: O
Upper O
extremity O
functional O
impairments O
are O
common O
consequences O
of O
stroke. O
[]

Pair-matched O
participants O
were O
randomized O
into O
a O
control O
group O
(CON; O
n=7) O
that O
exercised O
in O
a O
temperate O
environment O
(24 O
degrees O
C, O
21%RH) O
or O
IHE O
group O
(n=9) O
that O
exercised O
in O
a O
hot O
environment O
(40 O
degrees O
C, O
40%RH) O
every O
fifth O
day O
for O
25 O
days O
following O
HA O
(+25d) O
with O
out-of-laboratory O
exercise B-outcome ['Life-Impact', 'Life-Impact']
intensity I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
duration S1-outcome ['Life-Impact', 'Life-Impact']
recorded. O
[['Life-Impact', 'Life-Impact']]

Publication O
date: O
2019/03/07 O
06:00 O
[medline] O
[]

Publication O
date: O
2018/11/08 O
00:00 O
[accepted] O
[]

Journal O
ID: O
101090633 O
[]

CONCLUSION: O
The O
results O
of O
this O
study O
demonstrated O
that O
NES O
may O
help O
to O
relieve O
CINV O
in O
patients O
with O
AGC. O
[]

Title: O
Oral O
glutamine O
supplements O
reduce O
concurrent O
chemoradiotherapy-induced O
esophagitis O
in O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer. O
[]

Mean O
+/- O
SD O
central O
ECD O
at O
baseline O
was O
2453 O
+/- O
359 O
cells/mm, O
decreasing O
by O
10% O
+/- O
14% O
to O
2195 O
+/- O
517 O
cells/mm O
at O
3 O
months O
(P O
< O
0.001) O
but O
stabilizing O
thereafter O
with O
mean O
endothelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
loss O
(ECL) O
from O
baseline O
to O
24 O
months O
of O
9% O
+/- O
13% O
(P O
< O
0.001). O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CrCo-Ti O
rods O
provide O
significant O
and O
stable O
spinal B-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
, O
especially O
in O
correction B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
main I-outcome ['Physiological-Clinical']
curve I-outcome ['Physiological-Clinical']
. O
This O
rate O
was O
associated O
with O
patients' O
age O
and O
type O
of O
rod O
administered O
but O
not O
gender. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Patients O
aged O
11 O
years O
or O
older, O
in O
the O
permanent O
dentition, O
and O
about O
to O
start O
fixed O
orthodontic O
treatment O
in O
these O
6 O
centers O
were O
randomly O
allocated O
to O
have O
either O
resin-modified O
glass O
ionomer O
cement O
or O
light-cured O
composite O
for O
bonding O
brackets, O
forward O
of O
the O
first O
molars. O
[]

MATERIALS O
AND O
METHODS: O
Participants O
requiring O
replacement O
of O
single O
maxillary O
anterior O
and O
first O
premolar O
teeth O
were O
recruited O
and O
treated O
under O
an O
institutional O
review O
board O
(IRB)-approved O
protocol. O
[]

Journal-Name:Journal O
of O
vector O
borne O
diseases O
[]

Among O
healthy O
children, O
percentages O
of O
the O
participants O
were O
higher O
in O
active O
children O
than O
in O
inactive O
children. O
[]

Safety, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
(AEs), O
and O
cutaneous O
tolerability B-outcome ['Life-Impact']
were O
evaluated O
throughout O
using O
a O
4-point O
scale O
where O
0=none O
and O
3=severe. O
[['Adverse-effects'], ['Life-Impact']]

In O
this O
phase O
2a O
study, O
we O
aimed O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
pegbelfermin O
in O
patients O
with O
non-alcoholic O
steatohepatitis. O
[]

Journal-Name:National O
Bureau O
of O
Economic O
Research O
bulletin O
on O
aging O
and O
health O
[]

The O
mean O
age O
of O
the O
patients O
was O
14.9 O
years O
and O
the O
mean O
follow-up O
was O
24 O
months. O
[]

Group O
A O
consisted O
of O
66 O
patients O
who O
received O
dexmedetomidine, O
and O
Group O
B O
included O
66 O
patients O
with O
paracetamol O
administration. O
[]

Trial O
Registration: O
ISRCTN53448131. O
[]

Journal O
ID: O
2985248R O
[]

Journal O
ID: O
101230586 O
[]

Journal O
ID: O
0374675 O
[]

SHM O
is O
a O
safe O
and O
effective O
hemostatic B-outcome ['Physiological-Clinical']
agent O
in O
lumbar O
posterior O
surgery. O
[['Physiological-Clinical']]

Repeated-measures O
ANOVA O
with O
group O
factor O
(GC O
and O
GVD3) O
were O
used O
to O
examine O
if O
the O
interaction O
of O
the O
different O
values O
was O
the O
same O
or O
different O
between O
the O
groups O
throughout O
the O
study O
(time O
x O
group) O
after O
vitamin O
D3 O
treatment. O
[]

Potential O
for O
skin O
irritation O
and O
dryness, O
as O
well O
as O
pigmentary O
changes O
are O
key O
concerns. O
[]

Following O
8 O
weeks O
of O
supplementation, O
the O
subjects O
repeated O
the O
pre-supplementation O
testing O
procedures. O
[]

Journal O
ID: O
2985248R O
[]

In O
comparison O
to O
moderately-severe O
health O
warnings, O
highly-severe O
health O
warnings O
increased O
avoidance B-outcome ['Life-Impact']
and O
reactance B-outcome ['Life-Impact']
and O
were O
perceived O
as O
more O
effective O
and O
increased O
motivation B-outcome ['Life-Impact']
to O
drink O
less. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

HR's O
for O
erythromycin, O
compared O
to O
beta-lactam O
monotherapy, O
on O
any O
cardiac B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
1.60 O
(95% O
CI O
1.09;2.36) O
and O
1.89 O
(95% O
CI O
1.22;2.91), O
respectively. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

BACKGROUND: O
Systematic O
pelvic O
and O
paraaortic O
lymphadenectomy O
has O
been O
widely O
used O
in O
the O
surgical O
treatment O
of O
patients O
with O
advanced O
ovarian O
cancer, O
although O
supporting O
evidence O
from O
randomized O
clinical O
trials O
has O
been O
limited. O
[]

Secondary O
outcomes O
included O
health B-outcome ['Physiological-Clinical']
, O
mental B-outcome ['Life-Impact']
wellbeing I-outcome ['Life-Impact']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
work B-outcome ['Life-Impact', 'Life-Impact']
absenteeism I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
presenteeism S1-outcome ['Life-Impact', 'Life-Impact']
, O
and O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
healthcare I-outcome ['Resource-use']
resources I-outcome ['Resource-use']
. O
Cost-effectiveness, O
cost-benefit O
and O
mediation O
analyses O
were O
conducted. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Resource-use']]

Journal O
ID: O
0255562 O
[]

Overweight O
and O
obesity O
are O
a O
global O
concern. O
[]

316 O
(29%) O
of O
1093 O
infants O
in O
the O
intervention O
group O
acquired O
a O
late-onset O
infection B-outcome ['Physiological-Clinical']
versus O
334 O
(31%) O
of O
1089 O
in O
the O
control O
group. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/31 O
00:00 O
[accepted] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Comparison O
the O
efficacy O
of O
hemorrhage O
control O
of O
Surgiflo O
Haemostatic O
Matrix O
and O
absorbable O
gelatin O
sponge O
in O
posterior O
lumbar O
surgery: O
A O
randomized O
controlled O
study. O
[]

Zero" O
marginal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
level O
(MBL) O
loss O
or O
gain O
was O
measured O
over O
the O
3-year O
period O
at O
72.1% O
CI, O
3.0% O
FI, O
and O
16.6% O
PS O
implants. O
[['Physiological-Clinical']]

The O
primary O
outcome O
measurement O
was O
the O
headache B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
. O
Secondary O
outcomes O
were O
frequency O
and O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
assessed O
by O
the O
Short O
Form-36. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Publication O
date: O
2018/11/06 O
00:00 O
[accepted] O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

The O
trial O
is O
registered O
with O
the O
International O
Standard O
Randomised O
Controlled O
Trial O
Number O
88261002. O
[]

Journal O
ID: O
0255562 O
[]

Journal-Name:Oxidative O
medicine O
and O
cellular O
longevity O
[]

Title: O
Corneal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Endothelial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Cell I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Density I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
Morphology S3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
After O
Phacoemulsification O
in O
Patients O
With O
Primary O
Open-Angle O
Glaucoma O
and O
Cataracts: O
2-Year O
Results O
of O
a O
Randomized O
Multicenter O
Trial. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Methods O
Forty-Four O
children O
(2.3+/-0.9 O
years) O
were O
randomly O
divided O
into O
two O
groups O
to O
receive O
either O
intravenous O
sufentanil O
(1 O
mug/kg) O
and O
midazolam O
(0.2 O
mg/kg) O
(Group O
SM) O
or O
2.0 O
minimal O
alveolar O
concentration O
(MAC) O
sevoflurane O
(Group O
S) O
to O
complete O
induction O
after O
sedation O
was O
obtained O
with O
2.0 O
MAC O
sevoflurane. O
[]

Journal-Name:Medicine O
[]

Funded O
by O
GlaxoSmithKline O
and O
Medicines O
for O
Malaria O
Venture; O
DETECTIVE O
ClinicalTrials.gov O
number, O
NCT01376167 O
.). O
[]

BACKGROUND: O
Ovarian O
hyperstimulation O
syndrome O
remains O
a O
serious O
complication O
during O
in O
vitro O
fertilization O
cycles O
if O
high O
dose O
human O
chorionic O
gonadotropin O
(hCG) O
is O
used O
to O
trigger O
ovulation O
in O
high O
responder O
patients. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

PURPOSE: O
To O
investigate O
the O
rehydrating B-outcome ['Physiological-Clinical']
efficacy O
of O
MW O
after O
exercise-induced O
dehydration. O
[['Physiological-Clinical']]

RESULTS: O
A O
total O
of O
366 O
patients O
(mean O
age, O
48.5 O
years; O
280 O
men) O
were O
enrolled. O
[]

MATERIALS O
AND O
METHODS: O
A O
randomized, O
controlled, O
clinical O
trial O
was O
conducted O
on O
62 O
postmenopausal O
women O
referred O
to O
health O
centers O
of O
Isfahan, O
Iran. O
[]

Title: O
[Clinical O
observation O
of O
LOP O
chemotherapy O
combined O
with O
radiotherapy O
in O
the O
treatment O
of O
early O
nasal O
NK/T O
cell O
lymphoma]. O
[]

Journal O
ID: O
2985248R O
[]

PROTOCOL: O
The O
protocol O
is O
available O
from O
the O
corresponding O
author O
on O
request. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSION: O
In O
patients O
undergoing O
primary O
cementless O
THA, O
using O
a O
posterior O
approach, O
who O
are O
treated O
with O
rivaroxaban O
for O
thromboembolic O
prophylaxis, O
short- O
and O
long-TXA O
IV O
protocols O
are O
significantly O
more O
effective O
than O
placebo O
in O
reducing O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL), O
without O
any O
thromboembolic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
Non-inferiority O
of O
a O
short- O
versus O
a O
long-TXA O
protocol O
in O
reducing O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL) O
was O
supported O
in O
a O
secondary O
analysis. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Ascorbic O
acid O
is O
a O
water-soluble O
chain O
breaking O
antioxidant. O
[]

RESULTS: O
Overall, O
834 O
patients O
with O
minor O
stroke O
were O
included O
in O
this O
subgroup, O
553 O
SAI O
(381 O
lacunar O
infarction, O
172 O
non-lacunar O
infarction) O
and O
281 O
MAIs. O
[]

There O
is O
a O
paucity O
of O
evidence O
on O
interventions O
that O
might O
provide O
cardio-protection. O
[]

Title: O
Rectus O
Sheath O
Block O
(RSB) O
Analgesia O
Could O
Enhance O
Significantly O
the O
Patient O
Satisfaction B-outcome ['Life-Impact']
Following O
Midline O
Laparotomy O
in O
Benign O
Disease O
and O
in O
Cancer: O
A O
Prospective O
Study O
With O
Special O
Reference O
to O
Nitrosative O
Stress O
Marker O
Nitrotyrosine B-outcome ['Physiological-Clinical']
(NT) I-outcome ['Physiological-Clinical']
Plasma O
Concentrations. O
[['Life-Impact'], ['Physiological-Clinical']]

CONCLUSION: O
The O
local O
application O
of O
curcumin O
gel O
when O
used O
in O
conjunction O
with O
SRP O
showed O
a O
significant O
improvement O
in O
periodontal O
parameters O
and O
has O
a O
beneficial O
effect O
in O
patients O
with O
chronic O
periodontitis. O
[]

METHODOLOGY/PRINCIPAL O
FINDINGS: O
An O
open-label, O
non-comparative O
randomized O
trial O
of O
AmBisome O
(30 O
mg/kg) O
with O
miltefosine O
(100 O
mg/day O
for O
28 O
days), O
and O
AmBisome O
monotherapy O
(40 O
mg/kg) O
was O
conducted O
in O
Ethiopian O
VL O
patients O
co-infected O
with O
HIV O
(NCT02011958). O
[]

CONCLUSION: O
This O
is O
the O
first O
randomised O
controlled O
trial O
to O
compare O
a O
structured O
multidisciplinary, O
multisite O
intervention O
with O
standard O
care O
in O
symptomatic O
childhood O
hypermobility. O
[]

At O
the O
beginning O
of O
pain, O
in O
the O
two O
groups O
200 O
mg O
capsule O
was O
given O
every O
6 O
h O
for O
two O
serial O
cycles. O
[]

Eradication B-outcome ['Physiological-Clinical']
failures O
were O
not O
associated O
with O
factors O
including O
gender, O
age, O
body O
mass O
index, O
smoking, O
alcohol O
consumption, O
educational O
level, O
and O
urban-rural O
distribution O
in O
this O
observation O
(P O
> O
.05).Despite O
increasing O
drug B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
to O
CLA, O
Hp B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
rates O
in O
FZD O
and O
CLA O
groups O
have O
no O
significant O
difference O
at O
present; O
as O
FZD-based O
quadruple O
therapy O
is O
more O
cost-effective, O
we O
recommend O
this O
regimen O
be O
a O
first-line O
choice O
for O
Hp O
eradication. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Serum O
cytokines O
were O
quantified, O
and O
microbiota O
assessed O
using O
metagenomic O
sequencing. O
[]

METHODS: O
In O
this O
prospective O
study, O
patients O
with O
intractable O
DED O
were O
randomized O
to O
a O
BTX-A O
(group O
A) O
or O
control O
group O
(group O
B). O
[]

Rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
thermal B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
, O
and O
ratings O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
were O
measured O
at O
various O
times O
before, O
during, O
and O
after O
exercise. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Journal O
of O
personality O
and O
social O
psychology O
[]

Result:The O
clinical O
manifestations O
of O
60 O
patients O
mainly O
included O
nasal B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
81.67%, O
accompanied O
by O
fever B-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
nosebleed B-outcome ['Physiological-Clinical']
and O
runny B-outcome ['Physiological-Clinical']
nose I-outcome ['Physiological-Clinical']
. O
Forty-one O
patients68.33% O
had O
only O
one O
site O
of O
lesion B-outcome ['Physiological-Clinical']
, O
and O
21 O
patients35.00% O
had O
multiple O
sites O
of O
lesions B-outcome ['Physiological-Clinical']
. O
In O
terms O
of O
total O
remission B-outcome ['Physiological-Clinical']
rate, O
it O
was O
significantly O
higher O
in O
group O
A O
than O
that O
in O
group O
B93.33% O
vs. O
66.67%, O
P<0.05. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Villages O
will O
be O
grouped O
into O
blocks, O
with O
blocks O
transitioned O
monthly O
from O
control O
(no O
repellent) O
to O
intervention O
states O
(to O
receive O
repellent) O
across O
14 O
monthly O
intervals O
in O
random O
order). O
[]

Participants O
who O
underwent O
SCTG+CAF+EMD O
application O
were O
identified O
as O
the O
test O
group O
(n O
= O
19) O
and O
those O
who O
underwent O
SCTG+CAF O
as O
control O
group O
(n O
= O
19). O
[]

BACKGROUND: O
We O
performed O
a O
prospective O
phase O
II O
study O
to O
compare O
acute O
toxicity B-outcome ['Adverse-effects']
among O
five O
different O
hypofractionated O
schedules O
using O
proton O
therapy. O
[['Adverse-effects']]

Title: O
The O
impact O
of O
unhealthy O
food O
sponsorship O
vs. O
pro-health O
sponsorship O
models O
on O
young O
adults' O
food B-outcome ['Life-Impact']
preferences I-outcome ['Life-Impact']
: O
a O
randomised O
controlled O
trial. O
[['Life-Impact']]

Journal-Name:Japanese O
journal O
of O
clinical O
oncology O
[]

Containing O
dominantly O
EPA, O
it O
is O
considered O
to O
be O
effective O
in O
lowering O
lipids, O
foremost O
serum O
triglycerides O
and O
LDL O
cholesterol. O
[]

Title: O
Pegbelfermin O
(BMS-986036), O
a O
PEGylated O
fibroblast O
growth O
factor O
21 O
analogue, O
in O
patients O
with O
non-alcoholic O
steatohepatitis: O
a O
randomised, O
double-blind, O
placebo-controlled, O
phase O
2a O
trial. O
[]

Among O
patients O
who O
received O
sorafenib, O
the O
most O
frequently O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
grade O
1 O
or O
2 O
events O
of O
rash B-outcome ['Physiological-Clinical']
(73%), O
fatigue B-outcome ['Physiological-Clinical']
(67%), O
hypertension B-outcome ['Physiological-Clinical']
(55%), O
and O
diarrhea B-outcome ['Physiological-Clinical']
(51%). O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

After O
adjustment O
for O
confounders, O
the O
difference O
between O
the O
groups O
was O
not O
significant O
(odds O
ratio O
0.88, O
95% O
confidence O
interval O
0.70 O
to O
1.20). O
[]

RESULTS: O
Participants O
in O
MTG O
had O
an O
average O
of O
seven O
sessions O
of O
music O
therapy, O
and O
showed O
improvement O
in O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scores O
and O
autonomic B-outcome ['Physiological-Clinical']
indexes O
of O
the O
time O
domain O
(p O
< O
0.05). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

CONCLUSION: O
Compared O
with O
AGS, O
SHM O
could O
decrease O
the O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during O
hemostatic O
process O
and O
the O
postoperative O
drainage B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
posterior O
operation O
of O
lumbar O
degenerative O
disease. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

However, O
the O
combination O
did O
not O
result O
in O
a O
clinically O
important O
improvement O
over O
ibuprofen O
alone, O
suggesting O
that O
ibuprofen O
alone O
may O
be O
a O
reasonable O
option O
for O
early O
postoperative O
oral O
analgesia. O
[]

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
related O
to O
test O
beverage O
ingestion O
were O
observed. O
[['Adverse-effects']]

After O
adjusting O
for O
pancreatic O
fistula O
and O
delayed O
gastric O
emptying, O
no O
statistically O
significant O
differences O
in O
the O
primary O
outcomes O
were O
observed. O
[]

Title: O
[Effect O
of O
dexmedetomidine O
on O
perioperative O
stress B-outcome ['Physiological-Clinical']
and O
postoperative O
pain B-outcome ['Physiological-Clinical']
in O
patients O
with O
radical O
resection O
of O
esophageal O
cancer O
under O
combined O
thoracoscope O
and O
laparoscope]. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
elbow O
sleeve O
yielded O
better O
scores O
than O
no O
orthosis O
for O
the O
following O
outcomes: O
joint B-outcome ['Physiological-Clinical']
position I-outcome ['Physiological-Clinical']
reproduction I-outcome ['Physiological-Clinical']
score O
at O
110 O
degrees O
(P O
< O
.001), O
pain B-outcome ['Physiological-Clinical']
(P O
< O
.001), O
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
(P O
= O
.012). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
allocation O
sequence O
was O
concealed O
by O
using O
a O
computer O
generated O
number O
on O
the O
prescription. O
[]

There O
was O
no O
significant O
difference O
in O
the O
age, O
MAS O
score, O
and O
GMFM O
score O
between O
the O
2 O
groups O
before O
treatment. O
[]

No O
differences O
in O
the O
evolution O
of O
the O
other O
scores O
assessed O
were O
observed O
between O
groups. O
[]

Therefore, O
we O
investigated O
the O
induction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
of O
anesthesia O
based O
on O
type O
of O
remifentanil O
administration O
in O
target-controlled O
anesthesia. O
[['Life-Impact']]

In O
the O
primary O
analysis, O
the O
mean O
microvascular B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
did O
not O
differ O
between O
the O
20-mg O
alteplase O
and O
placebo O
groups O
(3.5% O
vs O
2.3%; O
estimated O
difference, O
1.16%; O
95% O
CI, O
-0.08% O
to O
2.41%; O
P O
= O
.32) O
nor O
in O
the O
analysis O
of O
10-mg O
alteplase O
vs O
placebo O
groups O
(2.6% O
vs O
2.3%; O
estimated O
difference, O
0.29%; O
95% O
CI, O
-0.76% O
to O
1.35%; O
P O
= O
.74). O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Acute O
consumption O
of O
RS O
at O
breakfast/lunch O
significantly O
reduced O
the O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
at O
the O
ad O
libitum O
dinner O
(p O
= O
0.017). O
[['Life-Impact']]

Difference O
in O
detection O
rate O
between O
intervention O
arm O
and O
control O
arm O
was O
compared O
using O
Z O
test. O
[]

GLN O
supplementation O
appeared O
to O
significantly O
delay O
acute O
radiation-induced O
esophagitis B-outcome ['Physiological-Clinical']
(ARIE) O
onset O
for O
5.8 O
days O
(18.2 O
days O
vs O
12.4 O
days; O
P O
= O
.027) O
and O
reduced O
incidence O
of O
weight B-outcome ['Physiological-Clinical']
loss O
(20% O
vs O
73.3%; O
P O
= O
.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

white B-outcome ['Physiological-Clinical']
spot I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
assessed O
using O
a O
laser O
fluorescence O
device O
( O
DIAGNOdent O
pen], O
Kavo, O
Germany) O
and O
were O
characterized O
at O
baseline, O
immediately O
following O
resin O
infiltration O
application O
and O
at O
a O
6-month O
follow-up. O
[['Physiological-Clinical']]

Most O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
mild; O
the O
most O
common O
events O
were O
diarrhoea B-outcome ['Physiological-Clinical']
in O
eight O
(16%) O
of O
49 O
patients O
treated O
with O
pegbelfermin O
and O
two O
(8%) O
of O
26 O
patients O
treated O
with O
placebo O
and O
nausea B-outcome ['Physiological-Clinical']
in O
seven O
(14%) O
patients O
treated O
with O
pegbelfermin O
and O
two O
(8%) O
patients O
treated O
with O
placebo. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
wider O
use O
of O
PICSI, O
therefore, O
is O
not O
recommended O
at O
present. O
[]

Conclusion: O
The O
protocol O
for O
changing O
the O
attribution O
to O
unintentional O
injury O
and O
negative O
information O
transmission O
for O
risk O
behavior O
consequences O
was O
proved O
to O
effectively O
reduce O
children's O
unintentional O
injury O
risk B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
relevant O
events. O
[['Life-Impact']]

The O
objective O
of O
this O
study O
was O
to O
explore O
the O
effects O
of O
music O
therapy/physical O
therapy O
co-treatment O
using O
live O
music-supported O
exercise O
on O
pain B-outcome ['Physiological-Clinical']
and O
exercise O
adherence B-outcome ['Life-Impact']
during O
a O
lower O
extremity O
pedaling O
exercise O
to O
facilitate O
range B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
(ROM) I-outcome ['Physiological-Clinical']
. O
The O
researcher O
randomized O
32 O
TKA O
inpatient O
rehabilitation O
participants O
to O
an O
intervention O
or O
control O
group. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

CONCLUSION: O
These O
results O
suggest O
that O
toric O
contact O
lenses O
provided O
improved O
objective O
measures O
of O
vision B-outcome ['Physiological-Clinical']
in O
a O
low-to-moderate O
astigmatic O
population. O
[['Physiological-Clinical']]

RESULTS: O
After O
treatment, O
patients O
in O
the O
Gua O
Sha O
group O
reported O
lower O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
(p<0.001) O
and O
better O
overall O
health B-outcome ['Physiological-Clinical']
status O
(p=0.002) O
compared O
to O
the O
waitlist O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Blood B-outcome ['Physiological-Clinical']
lactate I-outcome ['Physiological-Clinical']
([La-]b O
mmol. O
[['Physiological-Clinical']]

L(- O
1); O
betaA2: O
9.2 O
+/- O
1.1 O
mmol. O
[]

RESULTS: O
A O
repeated O
measures O
ANOVA O
revealed O
significant O
time-dependent O
increases O
in O
plasma O
epinephrine B-outcome ['Physiological-Clinical']
(E) I-outcome ['Physiological-Clinical']
and O
norepinephrine B-outcome ['Physiological-Clinical']
(NE) I-outcome ['Physiological-Clinical']
at O
I2 O
only O
in O
the O
CA O
+ O
C O
trial O
(p O
< O
0.05), O
and O
a O
significant O
decrease O
in O
blood O
glucose B-outcome ['Physiological-Clinical']
at O
I2 O
in O
the O
PLA O
trial O
(p O
< O
0.05); O
however, O
no O
meaningful O
changes O
in O
glucose B-outcome ['Physiological-Clinical']
was O
observed O
following O
CA O
+ O
C O
ingestion. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/02/15 O
06:00 O
[medline] O
[]

Additional O
implications O
and O
limitations O
are O
discussed. O
[]

Journal-Name:Journal O
of O
cancer O
research O
and O
therapeutics O
[]

OBJECTIVE: O
This O
study O
means O
to O
determine O
whether O
Mg O
supplementation O
improves O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
indicators O
in O
patients O
with O
T2D. O
METHODS: O
After O
one O
week O
of O
the O
dietary O
stabilization O
phase, O
42 O
T2D O
patients O
were O
stratified O
according O
to O
sex, O
age, O
fasting O
blood O
sugar O
(FBS) O
and O
Mg O
levels O
and O
then O
randomly O
allocated O
into O
two O
groups. O
[['Physiological-Clinical']]

Journal O
ID: O
101225531 O
[]

Withdrawal B-outcome ['Physiological-Clinical', 'Life-Impact', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact', 'Life-Impact']
declined O
immediately O
after O
smoking O
or O
using O
IQOS(TM), O
and O
with O
some O
delay O
after O
vaping. O
[['Physiological-Clinical', 'Life-Impact', 'Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
outcomes O
were O
evaluated O
clinically O
and O
radiographically O
according O
to O
specific O
criteria. O
[]

METHODS: O
This O
randomized, O
double-blinded, O
placebo-controlled O
clinical O
trial O
was O
carried O
out O
on O
60 O
subjects, O
aged O
18-40 O
years O
old. O
[]

Dietary O
fibre O
from O
resistant O
starch O
(RS) O
has O
been O
shown O
to O
have O
an O
impact O
on O
food O
intake O
in O
normal O
weight O
individuals, O
but O
its O
role O
in O
obesity O
is O
unknown. O
[]

Journal O
ID: O
0255562 O
[]

Survival B-outcome ['Mortality']
without O
moderate O
or O
severe O
neurodevelopmental B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
at O
24 O
months O
occurred O
in O
802 O
of O
1224 O
infants O
(65.5%) O
assigned O
to O
the O
faster O
increment O
and O
848 O
of O
1246 O
(68.1%) O
assigned O
to O
the O
slower O
increment O
(adjusted O
risk O
ratio, O
0.96; O
95% O
confidence O
interval O
[CI], O
0.92 O
to O
1.01; O
P O
= O
0.16). O
[['Mortality'], ['Life-Impact']]

We O
deductively O
selected O
five O
conditions O
based O
on O
the O
Consolidated O
Framework O
for O
Implementation O
Research: O
teachers' O
perceived O
self-efficacy B-outcome ['Life-Impact']
, O
teachers' O
expectations B-outcome ['Life-Impact']
of O
the O
benefits O
of O
the O
intervention, O
teachers' O
previous O
knowledge B-outcome ['Life-Impact']
about O
the O
intervention, O
dosage B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
breaks I-outcome ['Life-Impact']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the O
implementation O
. O
RESULTS: O
We O
identified O
five O
different O
pathways O
that O
led O
to O
no O
increase O
in O
the O
pupils' O
outcome O
(parameters O
of O
fit: O
consistency O
94%, O
coverage O
66%). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

PROTOCOL: O
The O
protocol O
was O
not O
published O
before O
trial O
commencement. O
[]

All O
students O
managed O
a O
simulated O
cardiac O
arrest O
scenario O
with O
primary O
outcome O
based O
on O
the O
AHA O
guidelines O
definition O
of O
high-quality O
CPR O
(specifies O
metrics O
for O
compression B-outcome ['Physiological-Clinical']
rate, O
depth O
, O
recoil B-outcome ['Physiological-Clinical']
, O
and O
compression B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Nutrients O
[]

Title: O
The O
Effects O
of O
Adiponectin O
and O
Adiponectin O
Receptor O
1 O
Levels O
on O
Macrovascular O
Complications O
Among O
Patients O
with O
Type O
2 O
Diabetes O
Mellitus. O
[]

Few O
patients O
maintained O
>/=75% O
response B-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
Treatment O
with O
galcanezumab O
120 O
mg O
or O
240 O
mg O
demonstrated O
statistically O
significant O
and O
clinically O
meaningful O
persistence O
of O
effect O
in O
patients O
with O
episodic O
migraine O
(>/=3 O
and O
6 O
consecutive O
months) O
and O
in O
patients O
with O
chronic O
migraine O
(for O
3 O
months). O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
101521595 O
[]

After O
3 O
days O
of O
treatment, O
the O
serum O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
and O
S100 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
in O
both O
groups O
were O
significantly O
decreased O
as O
compared O
with O
those O
before O
treatment O
[NSE O
(mug/L): O
30.15+/-15.18 O
vs. O
31.32+/-14.75, O
S100 O
(ng/L): O
387.5 O
(273.3, O
573.0) O
vs. O
890.0 O
(590.5, O
1 O
162.5) O
in O
routine O
treatment O
group; O
NSE O
(mug/L): O
29.09+/-16.22 O
vs. O
32.25+/-15.43, O
S100 O
(ng/L): O
402.5 O
(302.2, O
580.5) O
vs. O
842.0 O
(462.3, O
1 O
200.5) O
in O
SBH O
treatment O
group, O
all O
P O
< O
0.05]. O
There O
was O
no O
significant O
difference O
in O
serum O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
or O
S100 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
level O
between O
the O
two O
groups O
(all O
P O
> O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2018/12/06 O
00:00 O
[accepted] O
[]

TRIAL O
REGISTRATION: O
researchregistry4264 O
dated O
1 O
March O
2016 O
(www.researchregistry.com). O
[]

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
recorded O
in O
both O
groups. O
[['Adverse-effects']]

Journal O
ID: O
101521595 O
[]

Title: O
Spirometric B-outcome ['Physiological-Clinical']
changes O
during O
exacerbations O
of O
COPD: O
a O
post O
hoc O
analysis O
of O
the O
WISDOM O
trial. O
[['Physiological-Clinical']]

To O
test O
this O
hypothesis, O
a O
randomized O
double-blind O
placebo-controlled O
study O
was O
performed. O
[]

FUNDING: O
Bristol-Myers O
Squibb. O
[]

Result/Key O
findings. O
[]

Moreover, O
further O
studies O
should O
allow O
assessments O
of O
the O
safety O
and O
effectiveness O
of O
pegbelfermin O
in O
a O
larger O
number O
of O
patients. O
[]

CONCLUSION: O
This O
study O
demonstrated O
the O
potential O
benefits O
and O
high O
clinical O
relevance O
of O
exercise O
programs O
to O
improve O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
older O
breast O
cancer O
survivors O
undergoing O
aromatase O
inhibitor O
therapy. O
[['Life-Impact']]

CONCLUSION: O
This O
study O
presents O
novel O
and O
important O
findings O
when O
selecting O
interaction O
devices O
for O
individuals O
with O
ALS O
to O
access O
technology O
by O
demonstrating O
immediate O
performance B-outcome ['Life-Impact']
benefits O
of O
using O
a O
touchscreen O
device, O
such O
as O
improvement O
of O
motor B-outcome ['Physiological-Clinical', 'Life-Impact']
skills I-outcome ['Physiological-Clinical', 'Life-Impact']
. O
There O
were O
possible O
transferable O
skills O
obtained O
when O
using O
virtual O
systems O
which O
may O
allow O
flexibility O
and O
enable O
individuals O
to O
maintain O
performance O
overtime. O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Publication O
date: O
2019/01/31 O
06:00 O
[entrez] O
[]

Publication O
date: O
2019/01/20 O
06:00 O
[entrez] O
[]

Amnestic O
mild O
cognitive O
impairment O
(aMCI), O
an O
Alzheimer's O
disease O
prodrome, O
is O
characterized O
by O
cognitive O
and O
psychological O
symptoms, O
the O
latter O
aggravating O
prognosis. O
[]

Title: O
Using O
physical O
education O
to O
promote O
out-of O
school O
physical O
activity O
in O
lower O
secondary O
school O
students O
- O
a O
randomized O
controlled O
trial O
protocol. O
[]

Publication O
date: O
2018/12/15 O
06:00 O
[entrez] O
[]

Most O
fractures O
in O
postmenopausal O
women O
occur O
in O
those O
with O
osteopenia, O
so O
therapies O
that O
are O
effective O
in O
women O
with O
osteopenia O
are O
needed. O
[]

Yoga O
decreased O
the O
state O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
diastolic B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
the O
subjects O
with O
PMS O
complaining O
from O
depression. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/02/17 O
06:00 O
[entrez] O
[]

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India O
- O
rajesh.venkyresearch01@gmail.com. O
[]

METHODS: O
Healthy O
volunteers O
were O
enrolled O
randomly O
into O
one O
of O
two O
groups O
with O
the O
following O
drug O
regimens O
for O
2 O
weeks: O
group O
A, O
low-dose O
aspirin O
once O
per O
day O
and O
group O
B, O
low-dose O
aspirin O
and O
4.0 O
g O
of O
ecabet O
sodium. O
[]

We O
studied O
whether O
a O
DHA O
supply O
modified O
plasma O
docosahexaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
(DHA) I-outcome ['Physiological-Clinical']
and O
neurological B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
intellectual B-outcome ['Life-Impact', 'Life-Impact']
functioning E1-outcome ['Life-Impact', 'Life-Impact']
in O
PKU. O
[['Physiological-Clinical'], ['Life-Impact', 'Life-Impact']]

IQOS(TM) O
scored O
higher O
in O
terms O
of O
subjective O
reward/satisfaction B-outcome ['Life-Impact']
and O
was O
slightly O
preferred O
to O
the O
e-cigarette. O
[['Life-Impact']]

Patient O
satisfaction B-outcome ['Life-Impact']
at O
24 O
h O
postoperatively O
was O
filed O
on O
a O
11-point O
numeric O
rating O
scale O
(SFS24; O
0=fully O
unsatisfied; O
10=fully O
satisfied). O
[['Life-Impact']]

Physical B-outcome ['Life-Impact', 'Life-Impact']
activity-related I-outcome ['Life-Impact', 'Life-Impact']
fear I-outcome ['Life-Impact', 'Life-Impact']
was O
reduced O
only O
in O
the O
Exercise-arm O
(p O
= O
0.008). O
[['Life-Impact', 'Life-Impact']]

ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Polygala O
tenuifolia O
Willdenow O
root O
extract O
(BT-11) O
has O
beneficial O
effects O
on O
central O
nervous O
system O
disorders O
in O
human. O
[]

This O
study O
aimed O
to O
determine O
whether O
two O
intravenous O
(IV) O
TXA O
regimens O
(a O
three-hour O
two-dose O
(short-TXA) O
and O
11-hour O
four-dose O
(long-TXA)) O
were O
more O
effective O
than O
placebo O
in O
reducing O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL, O
between O
baseline O
and O
day O
3 O
postoperatively) O
in O
patients O
undergoing O
THA O
who O
receive O
rivaroxaban O
as O
thromboprophylaxis. O
[['Physiological-Clinical']]

PMID: O
31615781 O
[]

The O
median O
difference O
in O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
between O
the O
PCM O
+ O
IBU O
group O
vs O
PCM O
alone O
was O
16 O
mg O
(99.6% O
CI, O
6.5 O
to O
24; O
P O
< O
.001); O
for O
the O
PCM-alone O
group O
vs O
HS-PCM O
+ O
IBU, O
8 O
mg O
(99.6% O
CI, O
-1 O
to O
14; O
P O
= O
.001); O
and O
for O
the O
PCM O
+ O
IBU O
group O
vs O
IBU O
alone, O
6 O
mg O
(99.6% O
CI, O
-2 O
to O
16; O
P O
= O
.002). O
[['Resource-use']]

The O
prophylactic O
phenylephrine O
infusion O
(50 O
mug/min) O
was O
initiated O
immediately O
at O
the O
same O
time O
of O
spinal O
injection. O
[]

Publication O
date: O
2018/12/14 O
06:00 O
[entrez] O
[]

METHODS: O
This O
randomized O
clinical O
trial O
was O
conducted O
at O
infertility O
department O
of O
Royan O
Institute O
from O
January O
2017 O
to O
June O
2018. O
[]

Journal-Name:Zhonghua O
yi O
xue O
za O
zhi O
[]

Additionally O
mean O
radiation B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
per O
shoot O
of O
recorded O
Left O
anterior O
oblique O
(LAO) O
oriented O
projections O
was O
34.4+/-15.7mGyvs O
24.9+/-12.9 O
mGy O
for O
a O
non O
LAO O
oriented O
projection. O
( O
[['Life-Impact']]

There O
was O
also O
a O
significant O
-decrease O
in O
creatine B-outcome ['Physiological-Clinical']
phosphokinase-MB I-outcome ['Physiological-Clinical']
after O
24 O
hours O
in O
the O
nicorandil O
group O
(2.7 O
ng/L) O
compared O
to O
the O
control O
group O
(2.0 O
ng/L), O
p O
= O
0.008. O
[['Physiological-Clinical']]

Journal-Name:Indian O
heart O
journal O
[]

However, O
anesthesia O
induction O
time O
by O
timing O
remifentanil O
administration O
was O
not O
identified. O
[]

TRIAL O
REGISTRATION O
NUMBER: O
NCT03386149 O
(clinicaltrials.gov) O
and O
KCT0002848 O
(Clinical O
Research O
Information O
Service O
of O
the O
Republic O
of O
Korea). O
[]

Title: O
Effect O
of O
Ginger O
and O
Novafen O
on O
menstrual B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
: O
A O
cross-over O
trial. O
[['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

CONCLUSIONS: O
The O
Amla O
extract O
has O
shown O
significant O
potential O
in O
reducing O
total O
cholesterol B-outcome ['Physiological-Clinical']
(TC) O
and O
triglyceride B-outcome ['Physiological-Clinical']
(TG) I-outcome ['Physiological-Clinical']
levels O
as O
well O
as O
lipid B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
, O
atherogenic B-outcome ['Physiological-Clinical']
index O
of O
the O
plasma O
(AIP) O
and O
apoB/apo B-outcome ['Physiological-Clinical']
A-I I-outcome ['Physiological-Clinical']
in O
dyslipidemic O
persons O
and O
thus O
has O
scope O
to O
treat O
general O
as O
well O
as O
diabetic O
dyslipidemia. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

They O
were O
randomly O
divided O
into O
volume O
controlled O
ventilation O
(VCV) O
group O
and O
pressure O
controlled O
ventilation O
(PCV) O
group O
according O
to O
random O
number O
table. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

During O
pre-supplementation O
testing, O
the O
subjects O
performed O
2 O
pretest O
MVICs, O
2 O
sets O
of O
50 O
maximal, O
bilateral, O
concentric O
isokinetic O
leg O
extensions O
at O
180 O
degrees O
.s(- O
1) O
separated O
by O
2-min O
of O
rest, O
and O
2 O
posttest O
MVICs. O
[]

Serum O
levels O
of O
AdipoR1 O
were O
positively O
correlated O
with O
APN O
(r O
= O
0.726, O
P<0.01), O
and O
negatively O
correlated O
with O
BMI, O
SBP, O
DBP, O
FBG, O
TC O
and O
LDL-C O
(r O
= O
-0.440, O
-0.446, O
-0.374, O
-0.444, O
-0.344, O
-0.709, O
respectively; O
all O
P<0.01). O
[]

The O
last O
date O
of O
follow-up O
was O
June O
12, O
2018. O
[]

BACKGROUND: O
Pegbelfermin O
(BMS-986036), O
a O
PEGylated O
human O
fibroblast O
growth O
factor O
21 O
(FGF21) O
analogue, O
has O
previously O
been O
shown O
to O
improve O
markers O
of O
metabolism O
and O
liver O
fibrosis O
in O
obese O
patients O
with O
type O
2 O
diabetes. O
[]

Journal-Name: O
Lin O
chuang O
er O
bi O
yan O
hou O
tou O
jing O
wai O
ke O
za O
zhi O
= O
Journal O
of O
clinical O
otorhinolaryngology, O
head, O
and O
neck O
surgery O
[]

Title: O
Enteral O
lactoferrin O
supplementation O
for O
very O
preterm O
infants: O
a O
randomised O
placebo-controlled O
trial. O
[]

Results: O
The O
self-assessment O
scores O
of O
WDCs' O
capacity O
to O
fulfil O
their O
roles O
improved O
more O
in O
the O
intervention O
than O
in O
the O
comparison O
area O
for O
all O
six O
components, O
but O
for O
only O
1 O
of O
the O
6 O
was O
the O
improvement O
statistically O
significant O
(monthly O
and O
quarterly O
meetings O
in O
which O
Peer O
Supervisor O
and/or O
CHW O
supervision O
was O
an O
agenda O
item). O
[]

There O
were O
no O
significant O
differences O
in O
the O
other O
6 O
secondary O
outcomes. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

Results O
suggest O
there O
is O
value O
in O
further O
methodologically O
rigorous O
investigations O
into O
improving O
community-based O
health O
system O
functioning O
through O
a O
similar O
approach O
to O
community O
engagement. O
[]

Journal O
ID: O
2985248R O
[]

Study O
participants O
were O
admitted O
30 O
minutes O
prior O
to O
ET O
and O
given O
either O
tablet O
after O
their O
baseline O
vital O
signs O
were O
recorded. O
[]

Age O
was O
significantly O
associated O
with O
endothelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
loss O
(ECL) O
after O
cataract O
surgery O
(P O
= O
0.02), O
but O
baseline O
intraocular O
pressure, O
number O
of O
glaucoma B-outcome ['Resource-use']
medications I-outcome ['Resource-use']
, O
and O
central B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
(CCT) I-outcome ['Physiological-Clinical']
were O
not. O
[['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical']]

Patients O
were O
assigned O
to O
receive O
20 O
mg/m(2) O
decitabine O
intravenously O
for O
5 O
or O
10 O
consecutive O
days O
as O
induction O
therapy, O
every O
4-8 O
weeks O
for O
up O
to O
three O
cycles. O
[]

The O
primary O
efficacy O
endpoint O
was O
non-inferiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
success O
at O
achieving O
hemostasis B-outcome ['Physiological-Clinical']
within O
6 O
minutes. O
[['Physiological-Clinical']]

Title: O
Bilevel O
positive O
airway O
pressure O
in O
two O
moments O
after O
bariatric O
surgery. O
[]

The O
aim O
of O
the O
study O
was O
to O
evaluate O
if O
Reproductive O
Life O
Plan O
(RLP)-based O
counselling O
during O
a O
sexual O
health O
visit O
could O
increase O
men's O
fertility B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
. O
MATERIAL O
AND O
METHODS: O
The O
study O
was O
a O
randomized O
controlled O
trial O
including O
201 O
men O
aged O
18-50 O
who O
visited O
either O
of O
two O
participating O
sexual O
health O
clinics O
in O
Sweden O
for O
sexually O
transmitted O
infection O
testing O
during O
2014-2016. O
[['Life-Impact']]

For O
the O
representative O
of O
the O
municipality O
the O
possible O
economical O
gain O
of O
the O
project O
was O
in O
focus. O
[]

Publication O
date: O
2018/12/28 O
06:00 O
[entrez] O
[]

The O
aim O
of O
this O
study O
was O
therefore O
to O
explore O
reasons O
for O
employee O
engagement O
in O
weight O
loss O
projects O
at O
the O
workplace O
and O
the O
incentives O
a O
municipality, O
a O
manager O
at O
a O
home-care O
centre, O
and O
a O
project O
manager O
have O
to O
launch O
such O
project. O
[]

MATERIALS O
AND O
METHODS: O
The O
120 O
elderly O
housebound O
were O
randomly O
divided O
into O
3 O
intervention O
groups: O
Baduanjin O
training, O
Baduanjin O
training O
combined O
with O
CBT, O
and O
CBT. O
[]

Results: O
The O
age, O
sex O
ratio, O
body O
mass O
index O
(BMI) O
and O
ASA O
grading O
ratio O
in O
two O
groups O
were O
not O
significantly O
different(all O
P>0.05). O
[]

The O
visual O
analogue O
scale O
(VAS) O
of O
taste B-outcome ['Physiological-Clinical']
disturbance I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
the O
gustatory B-outcome ['Physiological-Clinical']
tests O
were O
assessed O
before O
and O
8 O
weeks O
after O
treatment O
with O
esomeprazole, O
a O
PPI O
(20 O
patients, O
aged O
50.0 O
+/- O
1.7 O
years) O
or O
famotidine, O
a O
H2 O
blocker O
(20 O
patients, O
aged O
47.1 O
+/- O
1.8 O
years). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
A O
randomized O
controlled O
trial O
of O
ultrasound-guided O
pulsed O
radiofrequency O
for O
patients O
with O
frozen O
shoulder. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RS O
may O
indeed O
have O
short-term O
beneficial O
effects O
in O
obese O
individuals. O
[]

To O
assess O
safety, O
local B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
(AEs) I-outcome ['Adverse-effects']
, O
systemic B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
unsolicited B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
and O
serious B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
(SAEs) I-outcome ['Adverse-effects']
were O
graded. O
[['Adverse-effects'], ['Adverse-effects'], ['Adverse-effects'], ['Adverse-effects']]

Title: O
A O
Randomized O
Trial O
to O
Evaluate O
the O
Effect O
of O
Toric O
Versus O
Spherical O
Contact O
Lenses O
on O
Vision B-outcome ['Physiological-Clinical']
and O
Eyestrain B-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

These O
parameters O
were O
also O
examined O
in O
20 O
healthy O
volunteers. O
[]

Generally, O
UI O
becomes O
more O
severe O
with O
age. O
[]

Journal-Name:Medicine O
[]

The O
primary O
efficacy O
end O
point O
was O
a O
composite O
of O
objectively O
confirmed O
proximal B-outcome ['Physiological-Clinical']
deep-vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
in O
a O
lower O
limb O
, O
pulmonary B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
, O
symptomatic B-outcome ['Physiological-Clinical']
deep-vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
in O
an O
upper O
limb O
or O
distal B-outcome ['Physiological-Clinical']
deep-vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
in O
a O
lower O
limb O
, O
and O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
venous I-outcome ['Mortality']
thromboembolism I-outcome ['Mortality']
and O
was O
assessed O
up O
to O
day O
180. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality']]

Methods: O
From O
March O
2017 O
to O
June O
2018, O
third-year O
medical O
students O
rotating O
through O
the O
mandatory, O
four-week O
emergency O
medicine O
(EM) O
clerkship O
at O
a O
single O
medical O
school O
were O
randomly O
assigned O
either O
to O
a O
web-based O
videoconference O
meeting O
via O
Google O
Hangouts, O
or O
to O
a O
traditional O
in-person O
meeting O
for O
their O
MCF O
session. O
[]

Meanwhile, O
the O
correlation O
analysis O
and O
multiple O
stepwise O
regression O
analysis O
were O
used O
to O
analyze O
the O
association O
of O
APN O
and O
AdipoR1 O
with O
clinical O
factors. O
[]

Effectiveness O
of O
a O
national O
quality O
improvement O
programme O
to O
improve O
survival O
after O
emergency O
abdominal O
surgery O
(EPOCH): O
a O
stepped-wedge O
cluster-randomised O
trial. O
[]

BACKGROUND: O
Bisphosphonates O
prevent O
fractures O
in O
patients O
with O
osteoporosis, O
but O
their O
efficacy O
in O
women O
with O
osteopenia O
is O
unknown. O
[]

METHODS: O
A O
cervical O
spine O
phantom O
was O
prepared O
using O
a O
cervical O
spine O
model O
immersed O
in O
a O
mixture O
of O
gelatin O
and O
psyllium O
husk. O
[]

AIM: O
The O
purpose O
of O
the O
study O
is O
to O
prove O
the O
effectiveness O
of O
pharmacological O
preconditioning O
caused O
by O
nicorandil O
in O
patients O
with O
stable O
coronary O
heart O
disease O
(CHD) O
during O
the O
elective O
percutaneous O
coronary O
intervention O
(PCI). O
[]

The O
patient O
satisfaction B-outcome ['Life-Impact']
scores O
were O
significantly O
higher O
in O
the O
sedation O
group O
(Z=2.07, O
P O
&lt; O
0.05). O
[['Life-Impact']]

The O
Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
Short O
Form O
(KDQOL-SF) O
questionnaire O
was O
completed O
by O
all O
participants O
at O
the O
beginning O
of O
the O
trial O
and O
two O
months O
after O
completion O
of O
the O
intervention. O
[['Life-Impact']]

Title: O
Determinants O
of O
Plasma O
Docosahexaenoic O
Acid O
Levels O
and O
Their O
Relationship O
to O
Neurological B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
Cognitive B-outcome ['Life-Impact', 'Life-Impact']
Functions E1-outcome ['Life-Impact', 'Life-Impact']
in O
PKU O
Patients: O
A O
Double O
Blind O
Randomized O
Supplementation O
Study. O
[['Life-Impact', 'Life-Impact']]

PMID: O
31596415 O
[]

Journal O
ID: O
9420934 O
[]

TRIAL O
REGISTRATION: O
The O
study O
is O
registered O
at O
EudraCT O
(2016-003017-10, O
date O
of O
registration: O
22 O
July O
2016) O
and O
( O
NCT02868385 O
, O
date O
of O
registration: O
16 O
August O
2016). O
[]

Results: O
Patients O
in O
both O
groups O
were O
followed O
up O
1 O
year. O
[]

At O
baseline O
and O
endline, O
knowledge, O
practice O
and O
coverage O
(KPC) O
surveys O
measured O
household O
health-related O
behaviors O
and O
care-seeking O
behaviors. O
[]

Necrotizing B-outcome ['Physiological-Clinical']
enterocolitis I-outcome ['Physiological-Clinical']
occurred O
in O
70 O
of O
1394 O
infants O
(5.0%) O
in O
the O
faster-increment O
group O
and O
78 O
of O
1399 O
(5.6%) O
in O
the O
slower-increment O
group O
(adjusted O
risk O
ratio, O
0.88; O
95% O
CI, O
0.68 O
to O
1.16). O
[['Physiological-Clinical']]

Peri-implant O
mucosal O
stability O
was O
generally O
observed. O
[]

Journal O
ID: O
2985248R O
[]

CONCLUSION: O
In O
conclusion, O
higher O
noggin B-outcome ['Physiological-Clinical']
levels O
reflected O
more O
BMP O
inhibition, O
since O
our O
assay O
detects O
free O
bioactive O
noggin B-outcome ['Physiological-Clinical']
, O
which O
in O
turn O
impaired O
bone O
formation O
in O
placebo O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
The O
central B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
endothelium I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
serial O
specular O
microscopy O
at O
0 O
to O
24 O
months. O
[['Physiological-Clinical']]

Journal-Name:Indian O
heart O
journal O
[]

RESULTS: O
There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
in O
patient O
characteristics, O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
extubation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
recovery B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
Compared O
with O
the O
children O
in O
control O
group, O
those O
in O
DEX O
group O
were O
significantly O
more O
sedated B-outcome ['Physiological-Clinical']
when O
they O
were O
separated O
from O
their O
parents O
(56.7% O
vs. O
26.7%, O
P<0.05). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
pilates O
exercises O
on O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
of O
CKD O
patients. O
[['Life-Impact']]

Title: O
[Nursing O
intervention O
for O
respiratory O
function O
exercise O
in O
patients O
with O
silicosis O
complicated O
by O
stable O
chronic O
obstructive O
pulmonary O
disease]. O
[]

Title: O
A O
randomized O
controlled O
trial O
comparing O
methohexital O
and O
propofol O
for O
induction O
in O
patients O
receiving O
angiotensin O
axis O
blockade. O
[]

Conclusions O
and O
Relevance: O
Among O
patients O
with O
acute O
STEMI O
presenting O
within O
6 O
hours O
of O
symptoms, O
adjunctive O
low-dose O
intracoronary O
alteplase O
given O
during O
the O
primary O
percutaneous O
intervention O
did O
not O
reduce O
microvascular B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
. O
The O
study O
findings O
do O
not O
support O
this O
treatment. O
[['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

Following O
a O
review O
of O
the O
information, O
attendees O
proposed O
actions O
to O
strengthen O
community-based O
health O
services O
in O
their O
community. O
[]

METHODS: O
We O
randomly O
assigned O
493 O
patients O
with O
resected O
pancreatic O
ductal O
adenocarcinoma O
to O
receive O
a O
modified O
FOLFIRINOX O
regimen O
(oxaliplatin O
[85 O
mg O
per O
square O
meter O
of O
body-surface O
area], O
irinotecan O
[180 O
mg O
per O
square O
meter, O
reduced O
to O
150 O
mg O
per O
square O
meter O
after O
a O
protocol-specified O
safety O
analysis], O
leucovorin O
[400 O
mg O
per O
square O
meter], O
and O
fluorouracil O
[2400 O
mg O
per O
square O
meter O
every O
2 O
weeks) O
or O
gemcitabine O
(1000 O
mg O
per O
square O
meter O
on O
days O
1, O
8, O
and O
15 O
every O
4 O
weeks) O
for O
24 O
weeks. O
[]

Journal-Name:Pediatric O
physical O
therapy O
: O
the O
official O
publication O
of O
the O
Section O
on O
Pediatrics O
of O
the O
American O
Physical O
Therapy O
Association O
[]

Whether O
L-valine O
affects O
energy O
intake, O
and O
the O
gastrointestinal O
functions O
involved O
in O
the O
regulation O
of O
energy O
intake, O
as O
well O
as O
blood O
glucose, O
in O
humans, O
is O
currently O
unknown. O
[]

PATIENTS: O
A O
total O
of O
288 O
patients O
with O
clinically O
confirmed O
uncontrolled O
chronic O
rhinosinusitis O
were O
subjected O
to O
randomization O
(1:1 O
ratio). O
[]

RESULTS: O
The O
combination O
of O
data O
sources O
revealed O
four O
themes O
and O
16 O
sub-themes. O
[]

We O
observed O
a O
significant O
decrease O
in O
absolute O
hepatic B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
in O
the O
group O
receiving O
10 O
mg O
pegbelfermin O
daily O
(-6.8% O
vs O
-1.3%; O
p=0.0004) O
and O
in O
the O
group O
receiving O
20 O
mg O
pegbelfermin O
weekly O
(-5.2% O
vs O
-1.3%; O
p=0.008) O
compared O
with O
the O
placebo O
group. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/29 O
06:00 O
[medline] O
[]

Journal-Name:Hematology O
(Amsterdam, O
Netherlands) O
[]

Demographic O
characteristics O
and O
hormonal O
profiles O
of O
the O
patients O
did O
not O
differ O
between O
groups. O
[]

The O
mechanism O
behind O
this O
second-meal O
phenomenon O
of O
CRHP O
diet O
on O
important O
risk O
factors O
for O
aggravating O
T2DM O
and O
cardiovascular O
disease O
awaits O
further O
investigation. O
[]

Participants O
who O
were O
not O
already O
taking O
vitamin O
D O
supplements O
received O
cholecalciferol O
before O
the O
trial O
began O
(a O
single O
dose O
of O
2.5 O
mg) O
and O
during O
the O
trial O
(1.25 O
mg O
per O
month). O
[]

After O
interventions, O
the O
exercise O
group O
had O
lower O
percentage O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
(%BF) O
and O
cardiometabolic B-outcome ['Physiological-Clinical']
risk O
markers, O
and O
higher O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
(LM) I-outcome ['Physiological-Clinical']
and O
leg B-outcome ['Life-Impact']
muscle I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
compared O
to O
the O
usual O
care O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Patients O
of O
ldMDCT O
group O
with O
large O
growth O
of O
nasal O
polyps O
(P O
= O
.03, O
q O
= O
5.35) O
and O
complete O
opacification O
of O
sinuses O
(P O
= O
.03, O
q O
= O
7.94) O
had O
complications B-outcome ['Adverse-effects']
after O
sinus O
surgeries. O
[['Adverse-effects']]

BACKGROUOND: O
The O
purpose O
of O
this O
study O
was O
to O
examine O
resting O
the O
metabolic O
response O
to O
the O
ingestion B-outcome ['Physiological-Clinical']
of O
a O
complex O
containing O
Citrus O
Aurantium O
+ O
Caffeine O
(CA O
+ O
C) O
and O
if O
its O
consumption O
influences O
metabolic B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
following O
a O
high-intensity O
anaerobic O
exercise O
bout O
in O
habitual O
caffeine O
users. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
[Randomized O
controlled O
trial O
of O
comparison O
between O
the O
SuperPATH O
and O
posterolateral O
approaches O
in O
total O
hip O
arthroplasty]. O
[]

These O
effects O
were O
absent O
in O
AA O
cohort. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Our O
results O
suggest O
that O
a O
HIIT O
training O
program O
with O
TRX O
have O
benefits O
in O
BMI B-outcome ['Physiological-Clinical']
, O
handgrip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
gait B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
older O
adults. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Title: O
A O
comparative O
study O
on O
the O
prophylactic O
effects O
of O
paracetamol O
and O
dexmedetomidine O
for O
controlling O
hemodynamics B-outcome ['Physiological-Clinical']
during O
surgery O
and O
postoperative O
pain B-outcome ['Physiological-Clinical']
in O
patients O
with O
laparoscopic O
cholecystectomy. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Outcome O
measures O
used O
were O
Barthel O
index O
(BI)], O
modified O
Ashworth O
scale], O
manual O
muscle O
testing, O
and O
goniometry O
for O
range B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
(ROM) I-outcome ['Physiological-Clinical']
assessment. O
[['Physiological-Clinical']]

The O
primary O
outcome O
of O
this O
trial O
is O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate. O
[['Physiological-Clinical']]

BACKGROUND: O
The O
burden O
of O
chronic O
obstructive O
lung O
disease O
(COPD) O
is O
increasing O
in O
women, O
with O
recent O
evidence O
suggesting O
gender O
differences O
in O
disease O
characteristics O
and O
potentially O
in O
treatment O
outcomes. O
[]

The O
primary O
end O
point O
was O
early O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
defined O
as O
survival B-outcome ['Mortality']
with O
improvement O
in O
at O
least O
two O
of O
four O
symptoms B-outcome ['Physiological-Clinical']
( O
cough B-outcome ['Physiological-Clinical']
, O
sputum B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
, O
pleuritic B-outcome ['Physiological-Clinical']
chest I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
dyspnea B-outcome ['Physiological-Clinical']
) O
and O
no O
worsening O
of O
symptoms B-outcome ['Physiological-Clinical']
at O
72 O
to O
120 O
hours, O
without O
receipt O
of O
rescue B-outcome ['Resource-use']
antibacterial I-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
. O
A O
secondary O
end O
point O
was O
investigator-assessed O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
a O
post-treatment O
evaluation O
5 O
to O
10 O
days O
after O
the O
last O
dose, O
with O
clinical O
response O
defined O
as O
resolution O
or O
improvement O
in O
signs B-outcome ['Physiological-Clinical']
or O
symptoms B-outcome ['Physiological-Clinical']
to O
the O
extent O
that O
further O
antibacterial O
therapy O
was O
unnecessary. O
[['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Total O
follow-up O
was O
38.2 O
months, O
during O
which O
the O
median O
duration O
of O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
5.5 O
months O
(IQR O
2.1-11.7) O
in O
the O
5-day O
group O
and O
6.0 O
months O
(1.9-11.7) O
in O
the O
10-day O
group. O
[['Mortality']]

Only O
3 O
(4.4%) O
Veterans O
declined O
participation O
due O
to O
lack O
of O
interest. O
[]

Of O
these, O
64 O
(85%) O
vs O
83 O
(88%), O
respectively, O
reached O
the O
primary O
clinical O
end O
point O
(risk O
difference, O
-4.8% O
[1-sided O
95% O
CI, O
-13.6% O
to O
+ O
infinity; O
1-sided O
P O
= O
.19]) O
and O
49 O
(66%) O
vs O
58 O
(62%), O
respectively, O
reached O
the O
primary O
radiographic O
end O
point O
(risk O
difference, O
4.7% O
[1-sided O
95% O
CI, O
-7.0% O
to O
+ O
infinity; O
1-sided O
P O
= O
.25). O
[]

The O
primary O
end O
points O
were O
composite O
cure B-outcome ['Physiological-Clinical']
( O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
and O
microbiologic O
eradication O
) O
at O
day O
5 O
and O
at O
the O
test-of-cure O
visit O
(15 O
to O
19 O
days O
after O
initiation O
of O
therapy) O
in O
the O
microbiologic O
modified O
intention-to-treat O
population. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Multicenter O
Study O
[]

Journal O
ID: O
9433361 O
[]

Journal-Name:Clinical O
interventions O
in O
aging O
[]

Title: O
[Comparison O
of O
effects O
of O
two O
anesthesia O
methods O
on O
the O
first O
night O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
in O
middle-aged O
and O
elderly O
patients O
undergoing O
surgery O
for O
lower O
extremity O
varicose O
vein]. O
[['Physiological-Clinical']]

Funded O
by O
the O
Department O
of O
Veterans O
Affairs O
Cooperative O
Studies O
Program; O
ClinicalTrials.gov O
number, O
NCT01265550.). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

STUDY O
IDENTIFICATION O
AND O
TRIAL O
REGISTRATION: O
Study O
Identification: O
EVOLVE-1 O
(I5Q-MC-CGAG); O
EVOLVE-2 O
(I5Q-MC-CGAH); O
REGAIN O
(I5Q-MC-CGAI) O
TRIAL O
REGISTRATION: O
ClinicalTrials.gov O
; O
NCT02614183 O
(EVOLVE-1); O
NCT02614196 O
(EVOLVE-2); O
NCT02614261 O
(REGAIN). O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

The O
primary O
outcome O
included O
bacteriological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
. O
It O
was O
assessed O
by O
the O
eradication O
of O
urogenital O
gonorrhea O
at O
any O
site O
cultured O
after O
taken O
the O
study O
medications. O
[['Physiological-Clinical']]

CONCLUSION: O
Serum O
levels O
of O
APN O
and O
AdipoR1 O
are O
significantly O
lower O
in O
T2DM O
group O
and O
T2DM O
+ O
MVC O
group, O
showing O
lowest O
value O
in O
T2DM O
+ O
MVC O
group. O
[]

These O
data O
do O
not O
support O
its O
routine O
use O
to O
prevent O
late-onset O
infection O
and O
associated O
morbidity O
or O
mortality O
in O
very O
preterm O
infants. O
[]

Statistical O
analyses O
will O
be O
conducted O
under O
the O
intention-to-treat O
principle. O
[]

The O
incidence O
of O
severe B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
in O
the O
SBH O
treatment O
group O
was O
significantly O
lower O
than O
that O
in O
the O
routine O
treatment O
group O
[5.6% O
(1/18) O
vs. O
44.4% O
(8/18), O
P O
< O
0.05]. O
There O
was O
1 O
child O
death B-outcome ['Mortality']
in O
the O
routine O
treatment O
group O
and O
no O
death O
in O
the O
SBH O
treatment O
group. O
[['Life-Impact'], ['Mortality']]

The O
PICIHBI O
group O
demonstrated O
a O
significant O
increase O
in O
one O
Test O
of O
Playfulness B-outcome ['Life-Impact']
(ToP) O
item O
score O
at O
midassessment. O
[['Life-Impact']]

Eligible O
participants O
are O
HIV-infected O
pregnant O
women O
aged O
15 O
to O
49 O
years O
and O
have O
a O
singleton O
gestation O
at O
14 O
to O
27 O
weeks' O
gestation. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHOD/DESIGN: O
This O
is O
a O
multicenter, O
open-label, O
randomized, O
controlled, O
and O
equivalence O
trial O
with O
2 O
parallel O
arms. O
[]

Data O
were O
analysed O
using O
Systematic O
Text O
Condensation. O
[]

However, O
this O
is O
the O
first O
report O
about O
the O
effects O
on O
indicators O
of O
endothelial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
More O
research O
in O
this O
field O
is O
necessary O
to O
gain O
an O
insight O
into O
the O
effects O
of O
Spirulina O
on O
these O
indicators. O
[['Physiological-Clinical']]

This O
may O
necessitate O
an O
alternative O
therapy O
for O
this O
group O
of O
patients. O
[]

Importance: O
High-quality O
dietary O
patterns O
may O
help O
prevent O
chronic O
disease, O
but O
limited O
data O
exist O
from O
randomized O
trials O
about O
the O
effects O
of O
nutritional O
and O
behavioral O
interventions O
on O
dietary O
changes. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Participants O
were O
recruited O
from O
the O
Institute O
of O
Dentistry, O
Barts O
and O
the O
London O
School O
of O
Medicine O
and O
Dentistry, O
London, O
United O
Kingdom, O
and O
recalled O
at O
6- O
to O
8-week O
intervals. O
[]

Publication O
date: O
2018/12/29 O
06:00 O
[entrez] O
[]

INTERVENTION: O
KT O
group O
received O
KT O
application O
to O
the O
quadriceps O
and O
gastrocnemius O
muscles O
whereas O
the O
control O
group O
received O
no O
intervention. O
[]

CONCLUSION: O
The O
therapeutic O
effect O
of O
combined O
treatment O
is O
better O
than O
clomifene O
citrate O
alone O
in O
the O
treatment O
of O
PCOS. O
[]

Registered O
19.7.2018. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Multidisciplinary O
interventions O
among O
these O
workers O
have O
improved O
fear O
avoidance O
beliefs B-outcome ['Life-Impact']
, O
but O
not O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
(LBP) I-outcome ['Physiological-Clinical']
and O
related O
sickness B-outcome ['Life-Impact']
absences I-outcome ['Life-Impact']
, O
cost-effectiveness O
studies O
are O
scarce. O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact']]

PATIENTS O
AND O
METHODS: O
We O
examined O
baseline O
characteristics O
associated O
with O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(DFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
among O
757 O
patients O
with O
resected, O
histologically O
proven, O
MAGE-A3-positive O
Stage O
IB-IIIA O
NSCLC O
assigned O
to O
placebo O
in O
the O
MAGRIT O
study O
(NCT00480025). O
[['Physiological-Clinical', 'Mortality'], ['Mortality']]

Title: O
A O
Randomized O
Trial O
of O
Lymphadenectomy O
in O
Patients O
with O
Advanced O
Ovarian O
Neoplasms. O
[]

In O
part O
B, O
patients O
without O
recent O
attacks O
were O
randomly O
assigned O
to O
receive O
once-monthly O
injections O
of O
one O
of O
two O
doses O
of O
givosiran O
(0.35 O
or O
1.0 O
mg O
per O
kilogram) O
or O
placebo O
(total O
of O
two O
injections O
28 O
days O
apart). O
[]

OBJECTIVE: O
To O
evaluate O
the O
effect O
of O
lacrimal O
duct O
probing O
combined O
with O
tobramycin/dexamethasone O
eye O
drops O
or O
ointment O
on O
persistent O
CNLDO O
in O
children O
older O
than O
1-year-old. O
[]

As O
the O
method O
of O
blind O
randomization O
envelope O
method O
was O
used. O
[]

RESULTS: O
The O
levels O
of O
APN O
and O
AdipoR1 O
were O
significantly O
decreased O
in O
T2DM O
group O
and O
T2DM O
+ O
MVC O
group O
compared O
with O
NC O
group, O
with O
the O
lowest O
value O
in O
T2DM O
+ O
MVC O
group O
(all O
P<0.01). O
[]

CONCLUSION: O
PRP O
may O
be O
effective O
in O
improving O
the O
endometrial B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
, O
and O
possibly O
pregnancy B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
in O
women O
with O
a O
thin O
endometrium. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:JAMA O
[]

Journal O
ID: O
8410840 O
[]

There O
were O
statistically O
significant O
differences O
between O
the O
2 O
groups O
at O
2 O
weeks O
and O
4 O
weeks O
after O
treatment, O
including O
the O
modified O
Ashworth O
Scale O
(MAS) O
score, O
Gross B-outcome ['Life-Impact']
Motor I-outcome ['Life-Impact']
Function I-outcome ['Life-Impact']
Measure O
(GMFM) O
score, O
plantar B-outcome ['Physiological-Clinical']
area I-outcome ['Physiological-Clinical']
and O
plantar B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(P O
< O
.05). O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Therefore, O
denosumab O
possibly O
regulates O
noggin B-outcome ['Physiological-Clinical']
and O
favours O
bone O
turnover O
in O
TDT O
patients O
with O
osteoporosis O
through O
a O
novel O
mechanism O
of O
action. O
[['Physiological-Clinical']]

Title: O
Gua O
Sha O
therapy O
for O
chronic O
low O
back O
pain: O
A O
randomized O
controlled O
trial. O
[]

METHODS: O
In O
a O
crossover O
design O
with O
a O
1 O
wk. O
[]

(1) O
Background: O
Spirulina O
(Arthrospira) O
maxima O
has O
shown O
beneficial O
effects O
such O
as O
being O
anti-dyslipidemic, O
antiviral, O
antioxidant O
and O
antihypertensive. O
[]

Journal-Name:Nutrients O
[]

Title: O
A O
High O
Adherence O
to O
Six O
Food O
Targets O
of O
the O
Mediterranean O
Diet O
in O
the O
Late O
First O
Trimester O
is O
Associated O
with O
a O
Reduction O
in O
the O
Risk O
of O
Materno-Foetal O
Outcomes: O
The O
St. O
Carlos O
Gestational O
Diabetes O
Mellitus O
Prevention O
Study. O
[]

To O
compare O
students' O
MCF O
experiences O
we O
sent O
out O
an O
electronic O
survey O
afterward O
to O
assess O
the O
following O
using O
a O
0-100 O
sliding O
scale: O
overall O
satisfaction B-outcome ['Life-Impact']
with O
the O
meeting; O
the O
effectiveness O
of O
communication B-outcome ['Life-Impact']
; O
the O
helpfulness O
of O
the O
meeting; O
their O
stress B-outcome ['Life-Impact']
levels, O
and O
the O
convenience B-outcome ['Life-Impact']
of O
their O
meeting O
location. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Significant O
improvements O
in O
serum O
Ca B-outcome ['Physiological-Clinical']
, O
P B-outcome ['Physiological-Clinical']
and O
iPTH B-outcome ['Physiological-Clinical']
levels O
were O
observed O
at O
4, O
8, O
and O
12 O
weeks O
in O
the O
treatment O
group O
(P O
&lt; O
0.05) O
but O
only O
at O
12 O
weeks O
in O
the O
control O
group O
(P O
&lt; O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Among O
2806 O
eligible O
children O
with O
visiual O
impairment O
(visual O
acuity O
</= O
6/12 O
in O
either O
eye), O
93 O
(3.31%) O
were O
lost O
to O
follow-up, O
leaving O
2713 O
students O
(45.0% O
boys). O
[]

The O
sterol B-outcome ['Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical']
element-binding I-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
(SREBP1) I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
in O
endometrial O
tissues O
was O
detected O
by O
qRT-PCR. O
[['Physiological-Clinical']]

The O
remifentanil O
effective O
concentration B-outcome ['Life-Impact']
(EC50) O
of O
that O
suppressed O
responses O
to O
extubation O
during O
anesthetic O
emergence O
was O
1.20 O
ng/mL O
in O
group O
TEAS, O
a O
value O
that O
was O
significantly O
lower O
than O
the O
1.64 O
ng/mL O
needed O
by O
patients O
in O
group O
C.The O
TEAS O
can O
enhance O
the O
efficacy O
of O
remifentanil O
on O
suppressing O
responses B-outcome ['Physiological-Clinical']
to O
tracheal O
extubation O
in O
elderly O
patients, O
the O
effective O
concentration B-outcome ['Life-Impact']
(EC50) O
of O
remifentanil O
can O
reduce O
approximately O
27% O
compared O
with O
group O
C. O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact']]

A O
common O
approach O
to O
deliver O
malaria O
services O
is O
to O
assign O
Village O
Health O
Volunteers O
(VHVs) O
to O
villages, O
particularly O
where O
limited O
or O
no O
services O
exist. O
[]

Treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
occurred O
in O
74 O
of O
506 O
participants O
(14.6%) O
in O
the O
intravenous O
group O
and O
67 O
of O
509 O
participants O
(13.2%) O
in O
the O
oral O
group. O
[['Physiological-Clinical']]

However, O
significant O
differences O
between O
the O
groups O
were O
not O
observed O
in O
terms O
of O
total O
RES O
and O
complete O
root B-outcome ['Physiological-Clinical']
coverage I-outcome ['Physiological-Clinical']
rate O
(p O
> O
0.05). O
[['Physiological-Clinical']]

Randomisation O
was O
stratified O
by O
induction O
regimen, O
pre-induction O
disease O
stage, O
and O
response O
post-transplantation. O
[]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

Title: O
beta-Eudesmol, O
an O
Oxygenized O
Sesquiterpene, O
Reduces O
the O
Increase O
in O
Saliva O
3-Methoxy-4-Hydroxyphenylglycol B-outcome ['Physiological-Clinical']
After O
the O
"Trier O
Social O
Stress O
Test" O
in O
Healthy O
Humans: O
A O
Randomized, O
Double-Blind, O
Placebo-Controlled O
Cross-Over O
Study. O
[['Physiological-Clinical']]

Conclusion: O
Our O
results O
suggest O
that O
LCME-required O
MCF O
sessions O
can O
be O
successfully O
conducted O
via O
web-based O
programs O
such O
as O
Google O
Hangouts O
without O
jeopardizing O
overall O
meeting O
experience B-outcome ['Life-Impact']
. O
While O
the O
convenience B-outcome ['Life-Impact']
of O
the O
meetings O
was O
improved, O
it O
is O
also O
important O
for O
clerkship O
directors O
to O
note O
the O
perceived O
deficit O
in O
the O
effectiveness O
of O
communication B-outcome ['Life-Impact']
with O
videoconferencing. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

There O
is O
a O
need O
of O
future O
studies O
to O
demonstrate O
the O
effectiveness O
of O
the O
proposed O
intervention O
in O
endemic O
regions O
of O
the O
state. O
[]

Also, O
compared O
to O
the O
control O
group, O
LF O
decreased O
ICAM1 O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
(P O
< O
0.05). O
[['Physiological-Clinical']]

AIM O
OF O
THE O
STUDY: O
To O
evaluate O
the O
safety O
of O
BT-11 O
in O
human O
aged O
from O
9 O
to O
19 O
years O
old. O
[]

J O
Drugs O
Dermatol. O
[]

Compared O
with O
MAIs, O
lacunar O
infarction O
of O
SAI O
had O
lower O
risk O
of O
stroke B-outcome ['Physiological-Clinical']
recurrence O
(hazard O
ratio O
[HR] O
0.41, O
95% O
confidence O
interval O
[CI] O
0.21-0.80, O
P O
= O
0.009), O
but O
not O
in O
non-lacunar O
infarction O
of O
SAI O
(HR O
1.01, O
95% O
CI O
0.60-1.69, O
P O
= O
0.98). O
[['Physiological-Clinical']]

Mean O
steps/day B-outcome ['Life-Impact']
were O
significantly O
lower O
in O
the O
intervention O
vs O
control O
group O
(adjusted O
mean O
difference O
= O
- O
336, O
95% O
CI: O
-612 O
to O
- O
60, O
p O
= O
0.02) O
at O
6 O
months. O
[['Life-Impact']]

PE O
teachers O
(n O
= O
29) O
from O
eleven O
schools O
will O
apply O
the O
intervention O
program O
to O
students O
(n O
= O
502) O
in O
PE O
classes O
for O
one O
month. O
[]

We O
also O
examined O
how O
health O
warning O
severity O
influences O
these O
reactions B-outcome ['Life-Impact']
and O
whether O
there O
is O
an O
interaction O
between O
self-affirmation O
and O
severity. O
[['Life-Impact']]

The O
corneal B-outcome ['Physiological-Clinical']
fluorescein I-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
grades O
in O
group O
A O
were O
significantly O
lower O
until O
4 O
months. O
[['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
Trial O
registered O
at O
ClinicalTrials.gov O
with O
protocol O
number O
Medical O
College O
of O
Wisconsin O
PRO00019269 O
on O
11/29/2018 O
(Retrospectively O
registered). O
[]

During O
the O
trial O
treatment O
period, O
three O
patients O
in O
the O
placebo O
group O
died B-outcome ['Mortality']
. O
One O
patient O
in O
the O
caplacizumab O
group O
died B-outcome ['Mortality']
from O
cerebral O
ischemia O
after O
the O
end O
of O
the O
treatment O
period. O
[['Mortality'], ['Mortality']]

METHODS: O
The O
study O
included O
20 O
men O
(20-31 O
yrs., O
[]

Before O
treatment, O
2 O
weeks O
and O
1 O
month O
after O
treatment, O
the O
Gross B-outcome ['Life-Impact']
Motor I-outcome ['Life-Impact']
Function I-outcome ['Life-Impact']
Measure O
(GMFM)], O
modified O
Ashworth O
Scale O
(MAS)] O
of O
the O
hamstrings O
and O
triceps O
, O
plantar B-outcome ['Physiological-Clinical']
area I-outcome ['Physiological-Clinical']
and O
plantar B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
examined O
for O
efficacy O
assessment. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

FGDs O
were O
audio-recorded, O
transcribed O
then O
translated O
into O
English. O
[]

RESULTS: O
There O
were O
in O
total O
80 O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
during O
the O
follow-up; O
50 O
in O
placebo O
and O
30 O
in O
krill O
powder O
group. O
[['Adverse-effects']]

This O
study O
will O
assess O
the O
effect O
of O
selenium O
supplementation O
on O
major O
pregnancy B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
and O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
among O
HIV-infected O
pregnant O
women O
in O
Lagos, O
Nigeria. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Multicenter O
Study O
[]

However, O
this O
procedure O
is O
inconvenient O
and O
not O
widely O
adopted. O
[]

Only O
PPI O
therapy O
significantly O
decreased O
the O
VAS O
scores, O
suggesting O
the O
improvement O
of O
taste B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
. O
Moreover, O
PPI O
therapy O
significantly O
decreased O
recognition O
thresholds O
for O
bitter B-outcome ['Physiological-Clinical']
taste I-outcome ['Physiological-Clinical']
in O
the O
anterior O
tongue O
(chorda O
tympani O
nerve O
area) O
and O
the O
thresholds O
in O
the O
posterior O
tongue O
(glossopharyngeal O
nerve O
area) O
for O
salty, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
sour, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
bitter B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
tastes E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
. O
By O
contrast, O
H2-blocker O
therapy O
caused O
no O
significant O
changes O
of O
thresholds O
in O
the O
anterior O
tongue, O
but O
improved O
the O
threshold O
{only} O
for O
bitter B-outcome ['Physiological-Clinical']
in O
the O
posterior O
tongue, O
the O
value O
of O
which O
was O
however O
significantly O
higher O
than O
that O
in O
PPI O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Although O
the O
intervention O
successfully O
altered O
several O
hypothesised O
mediating O
constructs O
it O
did O
not O
translate O
into O
long-term O
behaviour O
change. O
[]

After O
3, O
7, O
and O
10 O
months, O
a O
third O
of O
the O
practices O
were O
randomised O
to O
the O
intervention O
strategy. O
[]

BACKGROUND: O
Dexmedetomidine O
(Dex), O
as O
an O
adjuvant, O
has O
been O
reported O
to O
prolong O
the O
duration O
of O
spinal O
analgesia O
when O
adding O
to O
local O
anesthetic. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

and O
1 O
y, O
with O
pronounced O
differences O
for O
the O
dimensions O
general B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
and O
mental B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
the O
mental B-outcome ['Life-Impact']
component O
summary O
score O
(all O
p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact']]

Jitter O
plots O
of O
the O
individual O
SFS24 O
values O
versus O
plasma O
NT O
concentrations O
were O
significantly O
correlated O
in O
benign O
and O
cancer O
patients O
(r=-0.284, O
p=0.028). O
[]

Journal O
ID: O
8102988 O
[]

Krill-derived O
protein O
hydrolysates/peptides O
may O
have O
positive O
effect O
on O
blood O
pressure O
and O
astaxanthin O
has O
anti-oxidative O
and O
anti-inflammatory O
properties. O
[]

CONCLUSIONS: O
Rather O
than O
being O
a O
time O
of O
optimism, O
a O
third O
of O
low O
caste O
girls O
in O
rural O
north, O
Karnataka O
have O
limited O
hope O
for O
the O
future, O
with O
some O
contemplating O
suicide. O
[]

CONCLUSIONS: O
The O
application O
of O
KT O
on O
children O
with O
DCD O
had O
an O
increased O
gastrocnemius B-outcome ['Physiological-Clinical']
medialis I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
during O
stance O
phase. O
[['Physiological-Clinical']]

Cite O
this O
article: O
Bone O
Joint O
J O
2019;101-B:340-347 O
[]

179.8 O
+/- O
6.3 O
cm; O
83.1 O
+/- O
12.7 O
kg) O
volunteered O
to O
participate O
in O
this O
study. O
[]

Journal O
ID: O
0255562 O
[]

The O
cumulative O
opioid B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
was O
significantly O
less O
in O
group O
O O
at O
6, O
12, O
24, O
and O
48 O
hours O
after O
surgery. O
( O
[['Resource-use']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND/AIM: O
Our O
hypothesis O
was O
that O
rectus O
sheath O
block O
(RSB) O
analgesia O
could O
enhance O
satisfaction B-outcome ['Life-Impact']
following O
midline O
laparotomy O
in O
patients O
with O
benign O
disease O
and O
cancer O
patients. O
[['Life-Impact']]

A O
total O
of O
45 O
menopausal O
participants O
were O
recruited O
in O
this O
study. O
[]

Title: O
Oral O
versus O
Intravenous O
Antibiotics O
for O
Bone O
and O
Joint O
Infection. O
[]

CONCLUSION: O
The O
findings O
of O
this O
study O
suggested O
that O
normal O
recommended O
dosages O
of O
100 O
mg O
CA O
+ O
100 O
mg O
C O
is O
sufficient O
to O
promote O
glucose B-outcome ['Physiological-Clinical']
sparing O
at O
rest, O
with O
modest O
increases O
in O
SNS B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
; O
however, O
the O
individual O
role O
of O
CA O
or O
C O
in O
this O
response O
can O
not O
be O
determined. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
The O
obtained O
data O
shows O
the O
significant O
differences O
of O
an O
increase O
in O
highly B-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
(HS-Tp) I-outcome ['Physiological-Clinical']
in O
24 O
hours O
after O
PCI O
in O
patients O
with O
no O
admission O
of O
nicorandil O
(117 O
ng/l) O
as O
compared O
with O
the O
nicorandil O
group O
(73 O
ng/l), O
p O
= O
0.04. O
[['Physiological-Clinical']]

We O
aimed O
to O
study O
whether O
oxycodone O
can O
be O
an O
effective O
alternative O
for O
fentanyl O
in O
the O
management O
of O
early O
postoperative O
pain B-outcome ['Physiological-Clinical']
after O
total O
hip O
replacement. O
[['Physiological-Clinical']]

Main O
Outcomes O
and O
Measures: O
The O
primary O
outcome O
was O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
at O
28 O
days. O
[['Mortality']]

The O
aim O
of O
this O
study O
was O
to O
investigate O
how O
body O
posture O
is O
shaped O
in O
children O
diagnosed O
with O
asthma O
symptoms O
and O
whether O
body O
posture O
is O
associated O
with O
PA. O
[]

There O
was O
no O
difference O
in O
the O
amount O
of O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
autologous O
blood B-outcome ['Resource-use']
transfusion I-outcome ['Resource-use']
between O
the O
2 O
groups, O
and O
there O
was O
no O
difference O
in O
the O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
between O
the O
2 O
groups. O
[['Physiological-Clinical'], ['Resource-use'], ['Life-Impact']]

The O
prevalence O
of O
low B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
(LBW) I-outcome ['Physiological-Clinical']
was O
also O
lower O
in O
three-dose O
(3.5%) O
than O
in O
two-dose O
(12.2%) O
group O
(aOR, O
0.15; O
95% O
CI, O
0.04-0.63); O
however, O
the O
prevalence O
of O
maternal B-outcome ['Physiological-Clinical']
anaemia I-outcome ['Physiological-Clinical']
, O
pre-term B-outcome ['Physiological-Clinical']
births I-outcome ['Physiological-Clinical']
, O
clinical B-outcome ['Physiological-Clinical']
malaria I-outcome ['Physiological-Clinical']
and O
SP O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
similar O
between O
the O
two O
arms O
of O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

However, O
there O
were O
no O
significant O
differences O
in O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
for O
stress O
management O
and O
negative B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
between O
these O
two O
groups. O
[['Life-Impact'], ['Life-Impact']]

ED95 O
of O
spinal O
bupivacaine O
was O
calculated O
using O
logistic O
regression O
model. O
[]

Publication O
date: O
2018/10/17 O
00:00 O
[accepted] O
[]

Journal O
ID: O
8008349 O
[]

Title: O
Prognostic O
Factors O
in O
Early-stage O
NSCLC: O
Analysis O
of O
the O
Placebo O
Group O
in O
the O
MAGRIT O
Study. O
[]

METHODS: O
Sixty-seven O
stable O
COPD O
patients O
were O
enrolled O
and O
assigned O
to O
the O
experiment O
group O
(n O
= O
36) O
and O
the O
control O
group O
(n O
= O
31). O
[]

Journal-Name:Journal O
of O
drugs O
in O
dermatology O
: O
JDD O
[]

A O
25% O
and O
50% O
improvement O
in O
IGAxBSA O
was O
achieved O
within O
1.9 O
and O
4.6 O
weeks, O
respectively, O
and O
47.5% O
of O
patients O
achieved O
IGAxBSA-75 O
by O
week O
8. O
[]

J. O
Radiol. O
[]

The O
results O
is O
surprising, O
so O
we O
hope O
to O
do O
some O
further O
research O
in O
order O
to O
prove O
it O
is O
worth O
to O
clinical O
application. O
[]

BACKGROUND: O
Acute O
bacterial O
skin O
and O
skin-structure O
infections O
are O
associated O
with O
substantial O
morbidity O
and O
health O
care O
costs. O
[]

Journal O
ID: O
100968567 O
[]

The O
incidence O
of O
radiation-induced O
complications B-outcome ['Adverse-effects']
was O
similar O
in O
these O
two O
groups. O
[['Adverse-effects']]

Title: O
Effect O
of O
preintravenous O
injection O
of O
parecoxib, O
combined O
with O
transversus O
abdominis O
plane O
block O
in O
strategy O
of O
enhanced O
recovery B-outcome ['Physiological-Clinical']
after O
radical O
resection O
of O
colorectal O
cancer. O
[['Physiological-Clinical']]

RESULTS: O
The O
scapular B-outcome ['Physiological-Clinical']
dyskinesis I-outcome ['Physiological-Clinical']
percentage O
( O
P O
< O
.05) O
decreased O
and O
the O
pectoralis B-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
index O
( O
P O
< O
.001) O
increased O
immediately O
and O
at O
60 O
to O
72 O
hours O
after O
taping O
in O
the O
rigid-taping O
and O
Kinesio-taping O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND: O
Visceral O
leishmaniasis O
(VL) O
in O
human O
immunodeficiency O
virus O
(HIV) O
co-infected O
patients O
requires O
special O
case O
management. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O
[]

In O
third O
postoperative O
day, O
mean O
was O
3.18 O
for O
the O
first O
group O
and O
3.11 O
for O
the O
traditional O
group O
(p=0.937). O
[]

The O
authors O
did O
not O
find O
any O
statistically O
significant O
differences O
between O
all O
measured O
variables O
for O
the O
CG O
at O
the O
initial O
and O
final O
assessments. O
[]

Journal-Name:Croatian O
medical O
journal O
[]

Publication O
Type: O
Journal O
Article O
[]

T O
Self-rating O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(SDS) O
and O
self-rating O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
SAS O
scores O
of O
patients O
in O
the O
rhodiola O
treatment O
group O
increased O
after O
treatment O
P<0.05. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Both O
groups O
showed O
significant O
gains O
at O
the O
Fugl-Meyer O
motor B-outcome ['Physiological-Clinical', 'Life-Impact']
assessment I-outcome ['Physiological-Clinical', 'Life-Impact']
(FMA) O
(ST: O
5+/-4 O
points/FT: O
6+/-4 O
points; O
P=0.04) O
and O
Wolf O
motor B-outcome ['Physiological-Clinical', 'Life-Impact']
function I-outcome ['Physiological-Clinical', 'Life-Impact']
test O
(ST: O
0.4+/-0.3 O
points/FT: O
0.6+/-0.4 O
points; O
P=0.05), O
which O
were O
comparable O
between O
groups O
(P>/=0.47). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Journal-Name:Medicine O
[]

Publication O
date: O
2018/02/01 O
00:00 O
[accepted] O
[]

The O
TBW O
group O
(n O
= O
251) O
was O
injected O
with O
600 O
mg O
iodine/kg O
TBW. O
[]

Journal-Name:Anticancer O
research O
[]

Interventions: O
Patients O
were O
randomized O
1:1 O
(stratified O
by O
cardiac O
vs O
noncardiac O
surgery O
and O
positive O
vs O
negative O
recent O
fall O
history) O
to O
receive O
EEG-guided O
anesthetic O
administration O
(n O
= O
614) O
or O
usual O
anesthetic O
care O
(n O
= O
618). O
[]

Journal-Name:Medicine O
[]

Results: O
The O
PFOA O
group O
had O
less O
ankle O
dorsiflexion O
(odds O
ratio O
6.7, O
95% O
confidence O
interval O
2.46-18.2), O
greater O
midfoot O
height O
mobility O
(5.2, O
1.78-15.14) O
and O
width O
mobility O
(4.3, O
1.33-14.39, O
and O
greater O
foot O
mobility O
magnitude O
(8.4, O
2.32-30.69) O
than O
controls. O
[]

Among O
participants O
with O
1-year O
abstinence, O
those O
in O
the O
e-cigarette O
group O
were O
more O
likely O
than O
those O
in O
the O
nicotine-replacement O
group O
to O
use B-outcome ['Life-Impact']
their O
assigned O
product O
at O
52 O
weeks O
(80% O
[63 O
of O
79 O
participants O
vs. O
9% O
[4 O
of O
44 O
participants]). O
[['Life-Impact']]

At O
T3, O
the O
intervention O
group O
still O
reported O
significantly O
higher O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress O
(d O
= O
0.32) O
and O
better O
emotional O
coping B-outcome ['Life-Impact']
response O
(d O
= O
0.34) O
than O
the O
comparison O
group O
but O
did O
not O
report O
significantly O
higher O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
for O
stress O
management, O
stress B-outcome ['Life-Impact']
, O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
positive B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
negative B-outcome ['Life-Impact', 'Life-Impact']
affect E1-outcome ['Life-Impact', 'Life-Impact']
. O
CONCLUSIONS: O
To O
help O
young, O
low-income O
women O
with O
overweight O
or O
obesity O
manage O
stress, O
researchers O
and O
program O
planners O
may O
consider O
focusing O
on O
building O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact']]

Journal-Name:The O
American O
surgeon O
[]

CONCLUSIONS: O
Among O
patients O
with O
early O
Parkinson's O
disease O
who O
were O
evaluated O
over O
the O
course O
of O
80 O
weeks, O
treatment O
with O
levodopa O
in O
combination O
with O
carbidopa O
had O
no O
disease-modifying O
effect. O
( O
[]

DISCUSSION: O
This O
study O
will O
provide O
data O
on O
the O
efficacy O
of O
repeated O
PZQ O
treatment O
on O
the O
clearance O
of O
S.mansoni O
as O
measured O
by O
several O
diagnostic O
techniques. O
[]

TRIAL O
REGISTRATION: O
Australian O
New O
Zealand O
Clinical O
Trial O
Registry; O
ACTRN12617000249358 O
; O
Date O
registered: O
17/02/2017. O
[]

Exhaled B-outcome ['Physiological-Clinical']
CO I-outcome ['Physiological-Clinical']
(eCO) I-outcome ['Physiological-Clinical']
measurements O
and O
questionnaires O
were O
repeatedly O
administered O
throughout O
the O
session. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
101150032 O
[]

SETTING: O
People's O
Hospital O
of O
Guanghan, O
China. O
[]

Title: O
Why O
people O
engage O
in O
a O
weight O
loss O
intervention O
at O
their O
workplace O
- O
a O
stratified O
case O
study. O
[]

The O
aim O
of O
the O
study O
was O
to O
compare O
the O
influence O
of O
orlistat O
(IO), O
metformin O
(IM), O
or O
calorie-restricted O
diet O
(LC) O
on O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
, O
with O
special O
respect O
to O
insulin-resistance O
status. O
[['Physiological-Clinical']]

Title: O
Plazomicin O
for O
Infections O
Caused O
by O
Carbapenem-Resistant O
Enterobacteriaceae. O
[]

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
metabolizable O
energy O
in O
cashew O
nuts. O
[]

This O
paper O
presents O
the O
MIM's O
intervention O
effect O
on O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress, O
emotional O
coping B-outcome ['Life-Impact']
response, O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
for O
stress O
management, O
stress B-outcome ['Life-Impact']
, O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
positive B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
negative B-outcome ['Life-Impact', 'Life-Impact']
affect E1-outcome ['Life-Impact', 'Life-Impact']
. O
METHODS: O
Participants O
(N O
= O
612) O
were O
recruited O
from O
the O
Special O
Supplemental O
Nutrition O
Program O
for O
Women, O
Infants, O
and O
Children O
in O
Michigan. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact', 'Life-Impact']]

Some O
of O
the O
earlier O
studies O
have O
reported O
several, O
non-serious O
adverse O
events, O
mostly O
related O
to O
gastrointestinal O
tract, O
but O
systematic O
sufficiently O
powered O
study O
on O
safety O
is O
lacking. O
[]

Journal-Name:Medicine O
[]

Hispanic O
subjects O
(aged O
11 O
to O
50 O
years, O
N=766) O
were O
randomized O
(1:1) O
to O
receive O
tretinoin O
0.05% O
lotion O
or O
vehicle, O
once-daily O
for O
12 O
weeks. O
[]

Publication O
date: O
2019/02/08 O
06:00 O
[entrez] O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

RESULTS: O
In O
the O
methylene O
blue O
localization O
group, O
3 O
patients O
had O
localization B-outcome ['Life-Impact']
failure O
due O
to O
the O
intrathoracic O
diffusion O
of O
methylene O
blue, O
and O
the O
success B-outcome ['Life-Impact']
rate O
was O
93.61%. O
[['Life-Impact'], ['Life-Impact']]

Meal O
replacements O
(MRs) O
are O
portion- O
and O
calorie-controlled O
meals, O
which O
make O
the O
food O
environment O
part O
of O
an O
individual's O
weight O
loss O
regimen. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Publication O
date: O
2019/03/07 O
06:00 O
[medline] O
[]

Title: O
When O
color O
helps. O
[]

The O
chi O
independent O
test O
or O
2-tailed O
paired O
t O
test O
were O
performed O
for O
statistical O
analysis. O
[]

Main O
Outcomes O
and O
Measures: O
The O
primary O
clinical O
outcome O
was O
posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
stress I-outcome ['Physiological-Clinical', 'Life-Impact']
disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
severity I-outcome ['Physiological-Clinical', 'Life-Impact']
among O
survivors O
at O
6 O
months O
measured O
using O
the O
posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
stress I-outcome ['Physiological-Clinical', 'Life-Impact']
disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
severity I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale-Self-Report O
questionnaire O
(score O
range, O
0-51, O
with O
higher O
scores O
indicating O
greater O
symptom O
severity; O
the O
minimal O
clinically O
important O
difference O
was O
considered O
to O
be O
4.2 O
points). O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Journal-Name:Nutrients O
[]

DISCUSSION: O
The O
study O
will O
make O
a O
unique O
contribution O
to O
the O
literature O
by O
testing O
a O
theory-based O
intervention O
delivered O
by O
PE O
teachers O
to O
promote O
school O
students' O
participation B-outcome ['Life-Impact']
in O
out-of-school O
physical O
activity. O
[['Life-Impact']]

AIMS O
OF O
THE O
STUDY: O
The O
safety O
and O
efficacy O
of O
a O
hemostatic O
powder O
(HP) O
versus O
a O
control O
agent, O
absorbable O
gelatin O
sponge O
and O
thrombin O
(G O
+ O
T), O
were O
assessed, O
using O
a O
validated, O
quantitative O
bleeding B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
scale. O
[['Physiological-Clinical']]

Publication O
date: O
2018/11/13 O
00:00 O
[accepted] O
[]

Publication O
date: O
2019/02/13 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Journal O
Article O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Participants O
are O
randomised O
to O
receive O
MCP O
either O
at O
baseline O
(early O
treatment) O
or O
after O
3 O
months O
(delayed O
treatment). O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

RESULTS: O
Thirty-four O
subjects O
high-responder O
patients O
were O
randomized O
to O
receive O
low-dose O
hCG O
at O
the O
time O
of O
GnRH-agonist O
trigger O
(Group O
1) O
and O
37 O
received O
low-dose O
hCG O
at O
the O
time O
of O
oocyte O
retrieval O
(Group O
2). O
[]

This O
study O
was O
an O
exploratory O
analysis O
to O
investigate O
the O
secondary O
end-point O
of O
biochemical B-outcome ['Physiological-Clinical', 'Mortality']
failure-free I-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(BCFFS) I-outcome ['Physiological-Clinical', 'Mortality']
of O
patients O
with O
long-term O
follow-up. O
[['Physiological-Clinical', 'Mortality']]

Patients O
with O
clinically O
diagnosed O
osteoarthritis O
of O
knee O
were O
injected O
either O
Triamcinolone O
or O
Placebo O
after O
recording O
the O
baseline O
scores O
of O
the O
knee O
by O
Knee O
injury O
and O
Osteoarthritis O
Outcome O
Score O
(KOOS) O
- O
Physical O
Function O
Short O
form O
(KOOS-PS), O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
(WOMAC) O
and O
Visual O
Analogue O
Scale O
(VAS). O
[]

Journal O
ID: O
101090552 O
[]

Journal O
ID: O
2985248R O
[]

Conclusion: O
The O
approach O
in O
both O
selecting O
the O
patients O
participating O
in O
the O
study O
and O
analyzing O
the O
data O
in O
this O
randomized O
clinical O
trial O
allows O
us O
to O
conclude O
that O
cryotherapy O
is O
an O
aid O
of O
clinical O
procedures O
to O
clean O
and O
shape O
the O
canals O
to O
reduce O
the O
occurrence O
of O
postendodontic O
pain B-outcome ['Physiological-Clinical']
and O
the O
need B-outcome ['Resource-use']
for O
medication O
in O
patients O
presenting O
with O
a O
diagnosis O
of O
vital O
pulp. O
[['Physiological-Clinical'], ['Resource-use']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Nutrients O
[]

Title: O
Is O
the O
transdermal O
fentanyl O
patch O
an O
efficient O
way O
to O
achieve O
acute O
postoperative O
pain B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
?: O
[['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
clinicaltrials.gov, O
NCT02518165 O
. O
[]

METHODS: O
In O
this O
double-blind O
trial, O
we O
randomly O
assigned O
adults O
with O
acute O
bacterial O
skin O
and O
skin-structure O
infections O
(in O
a O
1:1 O
ratio) O
to O
receive O
omadacycline O
(100 O
mg O
given O
intravenously O
every O
12 O
hours O
for O
two O
doses, O
then O
100 O
mg O
given O
intravenously O
every O
24 O
hours) O
or O
linezolid O
(600 O
mg O
given O
intravenously O
every O
12 O
hours). O
[]

In O
this O
study O
62 O
subjects O
were O
randomly O
selected O
for O
the O
yoga O
group O
and O
control O
groups. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Methods: O
A O
feasibility O
randomized O
control O
trial O
allowed O
for O
comparison O
of O
PICIHBI O
and O
conventional O
one-on-one O
occupational O
therapy O
interventions. O
[]

The O
rate O
of O
wearing B-outcome ['Life-Impact']
glasses I-outcome ['Life-Impact']
was O
55.2% O
in O
the O
treatment O
group O
and O
23.4% O
(p O
< O
0.01) O
among O
the O
control O
group. O
[['Life-Impact']]

Patients O
in O
the O
routine O
chemotherapy O
group O
(n O
= O
30, O
RC O
group) O
received O
cisplatin O
infusion O
within O
1 O
h O
and O
5-FU O
infusion O
for O
about O
24 O
h. O
The O
dose O
in O
the O
RC O
group O
was O
the O
same O
as O
that O
in O
the O
CC O
group. O
[]

Conclusions: O
CBT-i O
for O
chronic O
insomnia O
is O
effective O
in O
both O
CBT-i O
alone O
and O
combination O
with O
tapered O
hypnotic O
agents. O
[]

Simulation O
has O
been O
shown O
in O
similar O
settings O
to O
enhance O
performance O
and O
knowledge. O
[]

Before O
and O
after O
supplementation, O
we O
determined O
plasma O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
concentrations, O
latencies O
of O
visually B-outcome ['Physiological-Clinical']
evoked I-outcome ['Physiological-Clinical']
potentials I-outcome ['Physiological-Clinical']
, O
fine B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
gross B-outcome ['Life-Impact', 'Life-Impact']
motor I-outcome ['Life-Impact', 'Life-Impact']
behaviour E2-outcome ['Life-Impact', 'Life-Impact']
, O
and O
IQ B-outcome ['Life-Impact']
. O
Fatty O
acid O
desaturase O
genotypes O
were O
also O
determined. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact', 'Life-Impact'], ['Life-Impact']]

Publication O
Type: O
Journal O
Article O
[]

Journal-Name:BMC O
psychology O
[]

Energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
from O
a O
buffet-meal O
immediately O
after O
the O
infusions O
was O
quantified. O
[['Life-Impact']]

Based O
on O
the O
benefit O
of O
polyphenolic O
compounds O
on O
osteoporosis, O
we O
hypothesized O
that O
the O
polyphenol-rich O
herbal O
congee O
containing O
the O
combined O
extract O
of O
Morus O
alba O
and O
Polygonum O
odoratum O
leaves O
should O
improve O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
markers O
in O
menopausal O
women. O
[['Physiological-Clinical']]

CONCLUSIONS: O
Among O
patients O
with O
progressive, O
refractory, O
or O
symptomatic O
desmoid O
tumors, O
sorafenib O
significantly O
prolonged O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
and O
induced O
durable O
responses. O
( O
[['Physiological-Clinical', 'Mortality']]

Patients O
with O
clinical O
stage O
I-II O
gastric O
cancer O
with O
a O
body O
mass O
index O
of O
25 O
and O
over, O
who O
undergo O
laparoscopic O
subtotal O
gastrectomy O
will O
be O
eligible O
for O
trial O
inclusion. O
[]

Reports O
of O
CHW O
household O
contact O
and O
assessments O
of O
CHW O
quality O
were O
obtained O
in O
the O
endline O
KPC O
household O
survey, O
and O
household O
contacts O
measured O
in O
monthly O
submitted O
reports O
were O
also O
tabulated. O
[]

At O
the O
end O
of O
4-week O
follow-up, O
there O
were O
also O
no O
significant O
differences O
regarding O
the O
post-voiding B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(PV-VRU) I-outcome ['Physiological-Clinical']
(P O
= O
.42), O
voided B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(P O
= O
.71), O
maximum B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
(Qmax) O
(P O
= O
.24), O
and O
Barthel O
Index O
(BI) O
scores O
(P O
= O
.75) O
between O
2 O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

PMID: O
31609293 O
[]

Journal-Name:British O
journal O
of O
anaesthesia O
[]

Similar O
results O
were O
observed O
in O
patients O
who O
underwent O
CyPass O
micro-stent O
implantation O
accompanying O
phacoemulsification. O
[]

METHODS: O
A O
cluster O
randomised O
wait-list O
controlled O
trial O
in O
public O
sector O
organisations O
in O
Northern O
Ireland. O
[]

Journal O
ID: O
8109496 O
[]

RESULTS: O
In O
PBMCs, O
LF O
decreased O
ICAM1 O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
(P O
< O
0.05), O
which O
was O
different O
(P O
= O
0.06, O
Bonferroni O
correction) O
from O
the O
observed O
increase O
in O
the O
FF O
group O
(P O
< O
0.05). O
[['Physiological-Clinical']]

In O
part O
A O
of O
the O
trial, O
patients O
without O
recent O
porphyria O
attacks O
(i.e., O
no O
attacks O
in O
the O
6 O
months O
before O
baseline) O
were O
randomly O
assigned O
to O
receive O
a O
single O
subcutaneous O
injection O
of O
one O
of O
five O
ascending O
doses O
of O
givosiran O
(0.035, O
0.10, O
0.35, O
1.0, O
or O
2.5 O
mg O
per O
kilogram O
of O
body O
weight) O
or O
placebo. O
[]

Secondary O
outcomes O
include O
the O
difference O
in O
cure B-outcome ['Physiological-Clinical']
rate O
and O
intensity B-outcome ['Physiological-Clinical']
reduction O
rate O
between O
the O
intense O
and O
standard O
treatment O
groups O
as O
measured O
by O
the O
other O
diagnostic O
tests, O
as O
well O
as O
the O
accuracy O
of O
the O
different O
diagnostic O
tests, O
and O
the O
safety O
of O
PZQ. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSIONS: O
Similar O
skeletal B-outcome ['Physiological-Clinical']
, O
dental B-outcome ['Physiological-Clinical']
, O
and O
soft B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
changes O
were O
obtained O
in O
both O
groups O
after O
Herbst O
therapy. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

During O
the O
follow-up, O
no O
loosening B-outcome ['Physiological-Clinical']
or O
migration B-outcome ['Physiological-Clinical']
was O
observed. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
most O
common O
grade O
3-4 O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
neutropenic B-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
(seven O
patients O
[25%] O
in O
the O
5-day O
group O
and O
14 O
[33%] O
in O
the O
10-day O
group) O
and O
infection B-outcome ['Physiological-Clinical']
(five O
[18%] O
and O
16 O
[37%], O
respectively). O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Participants, O
the O
study O
team O
administering O
treatment, O
and O
investigators O
analysing O
outcomes O
(who O
were O
independent O
of O
the O
study O
team O
and O
had O
no O
further O
involvement) O
were O
masked O
to O
treatment O
groups. O
[]

Journal-Name:BMC O
neurology O
[]

Electromyographic B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
median X ['Physiological-Clinical', 'Physiological-Clinical']
frequency S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
did O
not O
differ O
between O
limbs O
at O
the O
start O
of O
the O
intervention. O
[['Physiological-Clinical', 'Physiological-Clinical']]

The O
1st O
group O
contained O
22 O
patients O
and O
surgery O
was O
performed O
using O
a O
fascia O
lata O
allograft. O
[]

Journal-Name:Zhonghua O
yi O
xue O
za O
zhi O
[]

There O
is O
no O
standard O
of O
care. O
[]

Objective: O
To O
determine O
if O
a O
peripheral O
perfusion-targeted O
resuscitation O
during O
early O
septic O
shock O
in O
adults O
is O
more O
effective O
than O
a O
lactate O
level-targeted O
resuscitation O
for O
reducing O
mortality B-outcome ['Mortality']
. O
Design, O
Setting, O
and O
Participants: O
Multicenter, O
randomized O
trial O
conducted O
at O
28 O
intensive O
care O
units O
in O
5 O
countries. O
[['Mortality']]

Five O
minutes O
before O
taking O
the O
Trier O
Social O
Stress O
Test O
(TSST) O
as O
a O
mental O
stressor, O
participants O
in O
each O
group O
ingested O
a O
beverage O
containing O
beta-Eudesmol, O
the O
active O
beverage, O
or O
a O
placebo O
beverage O
that O
did O
not O
contain O
beta-Eudesmol. O
[]

The O
primary O
outcome O
was O
survival B-outcome ['Mortality']
without O
moderate O
or O
severe O
neurodevelopmental B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
at O
24 O
months. O
[['Mortality'], ['Life-Impact']]

Visual O
impairment O
is O
common O
among O
rural O
Chinese O
children, O
but O
fewer O
than O
a O
quarter O
of O
children O
who O
need O
glasses O
actually O
own O
and O
use O
them. O
[]

Journal O
ID: O
101126433 O
[]

A O
total O
of O
312 O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
recorded O
in O
110 O
patients. O
[['Adverse-effects']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
Improved O
physical B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
was O
demonstrated O
in O
the O
exercise O
group O
by O
increases O
in O
median O
estimated O
VO2max O
(Baseline: O
43.41mls/kg/min; O
post-intervention: O
46.01mls/kg/min; O
p O
= O
0.03). O
[['Physiological-Clinical']]

Among O
the O
108 O
participants O
enrolled, O
37, O
34, O
and O
37 O
received O
Avaxim, O
Epaxal, O
and O
Havrix, O
respectively. O
[]

Publication O
date: O
2019/01/04 O
00:00 O
[accepted] O
[]

Reduction O
in O
radiation O
dose O
may O
lead O
to O
a O
compromise O
in O
quality O
of O
MDCT O
images O
and O
have O
chances O
of O
postoperative O
complications. O
[]

Compared O
with O
the O
control O
group, O
the O
combination O
therapy O
in O
the O
experiment O
group O
could O
significantly O
improve O
the O
6MWT O
(P O
= O
.0094), O
CAT O
(P O
= O
.0071) O
and O
BODE O
index O
(P O
= O
.0064) O
as O
well O
as O
the O
changes O
of O
6MWT O
(P O
< O
.01), O
CAT O
(P O
< O
.01), O
and O
BODE O
index O
(P O
< O
.01) O
before O
and O
after O
treatment. O
[]

However, O
limited O
studies O
to O
investigate O
the O
association O
of O
health O
education O
via O
Wechat O
platform O
on O
increased O
the O
basic O
self-care O
skills O
and O
glycemic O
control O
rate O
in O
patients O
with O
type O
2 O
diabetes. O
[]

After O
further O
exclusions, O
75 O
(94%) O
patients O
were O
randomly O
assigned O
to O
groups, O
received O
at O
least O
one O
dose O
of O
treatment O
(25 O
patients O
to O
receive O
10 O
mg O
pegbelfermin O
once O
a O
day; O
24 O
patients O
to O
receive O
20 O
mg O
pegbelfermin O
once O
a O
week, O
and O
26 O
patients O
to O
receive O
placebo), O
and O
were O
included O
in O
the O
primary O
analysis. O
[]

CONCLUSIONS: O
Both O
LASIK O
and O
SMILE O
resulted O
in O
significant O
epithelial B-outcome ['Physiological-Clinical']
thickening I-outcome ['Physiological-Clinical']
. O
This O
response O
seemed O
to O
be O
surprisingly O
quite O
similar O
between O
the O
2 O
different O
techniques. O
[['Physiological-Clinical']]

CONCLUSION: O
The O
results O
of O
this O
study O
revealed O
that O
oral O
Mg O
supplementation O
reduces O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and O
improves O
the O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
indicators O
among O
T2D O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
Clinical O
trials, O
NCT01949558 O
, O
2013-09-24. O
[]

This O
trial O
is O
designed O
to O
evaluate O
the O
impact O
of O
muscle O
relaxation O
during O
laparoscopic O
subtotal O
gastrectomy O
on O
the O
oncological O
benefits, O
particularly O
in O
obese O
patients O
with O
gastric O
cancer. O
[]

In O
patients O
with O
episodic O
migraine, O
>/=50% O
response O
was O
maintained O
in O
41.5 O
and O
41.1% O
of O
galcanezumab-treated O
patients O
(120 O
mg O
and O
240 O
mg, O
respectively) O
for O
>/=3 O
consecutive O
months O
(until O
patient's O
endpoint) O
and O
19.0 O
and O
20.5%, O
respectively, O
for O
6 O
consecutive O
months O
and O
was O
significantly O
greater O
than O
the O
21.4 O
and O
8.0% O
of O
placebo-treated O
patients O
at O
>/=3 O
and O
6 O
months O
consecutively O
(P O
< O
0.001). O
[]

Results: O
Students O
in O
the O
SIM O
group O
performed O
CPR O
that O
more O
closely O
adhered B-outcome ['Life-Impact']
to O
the O
AHA O
guidelines O
of O
compression B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
and O
compression B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
. O
Mean O
compression B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
was O
4.57 O
centimeters O
(cm) O
(95% O
confidence O
interval O
[CI] O
[4.30-4.82]) O
for O
SIM O
and O
3.89 O
cm O
(95% O
CI O
[3.50-4.27]) O
for O
STD, O
p=0.02. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Journal O
of O
shoulder O
and O
elbow O
surgery O
[]

Journal O
ID: O
101627676 O
[]

Background/aim: O
In O
South O
Africa, O
contextual O
factors O
have O
been O
identified O
as O
barriers O
to O
outdoor, O
unstructured O
play. O
[]

Journal O
ID: O
2985248R O
[]

Publication O
date: O
2019/03/08 O
06:00 O
[medline] O
[]

METHODS: O
Ninety-six O
parents O
in O
the O
NICU O
received O
instruction. O
[]

There O
were O
no O
statistical O
differences O
between O
the O
two O
groups O
on O
the O
other O
outcome O
measures. O
[]

PMP O
supplementation O
for O
eight O
weeks O
reduced O
reactive B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
species I-outcome ['Physiological-Clinical']
(ROS) I-outcome ['Physiological-Clinical']
and O
prevented O
DNA B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
without O
altering O
endogenous O
antioxidant O
system. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

After O
30 O
days O
of O
dark O
chocolate O
intake, O
an O
increased O
antioxidant B-outcome ['Physiological-Clinical']
power I-outcome ['Physiological-Clinical']
was O
found O
in O
elite O
athletes O
assuming O
dark O
chocolate. O
[['Physiological-Clinical']]

Exercise-related O
GI O
issues O
are O
a O
common O
cause O
of O
underperformance, O
with O
current O
evidence O
focusing O
on O
the O
use O
of O
FODMAP O
approaches O
with O
recreationally O
competitive O
or O
highly O
trained O
athletes. O
[]

OBJECTIVE: O
to O
evaluate O
the O
effectiveness O
of O
menthol O
chewing O
gum, O
in O
the O
relief O
of O
the O
intensity B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
discomfort B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
the X ['Physiological-Clinical', 'Physiological-Clinical']
surgical X ['Physiological-Clinical', 'Physiological-Clinical']
patient's X ['Physiological-Clinical', 'Physiological-Clinical']
thirst E2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
in O
the O
preoperative O
period. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Publication O
Type: O
Multicenter O
Study O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
analgesic B-outcome ['Resource-use']
benefits O
and O
physiotherapy B-outcome ['Physiological-Clinical']
(PT) I-outcome ['Physiological-Clinical']
outcomes O
of O
single-shot O
ACB O
to O
two O
different O
regimens O
of O
infusion O
of O
the O
continuous O
ACB, O
24-hour O
and O
48-hour O
infusion. O
[['Resource-use'], ['Physiological-Clinical']]

No O
changes O
were O
detected O
in O
weight B-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
"MyNutriCart" O
app O
use O
led O
to O
significant O
improvements O
in O
food-related B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
compared O
to O
baseline, O
with O
no O
significant O
differences O
when O
compared O
to O
the O
Traditional O
group. O
[['Physiological-Clinical'], ['Life-Impact']]

Journal O
ID: O
9425194 O
[]

Topical O
repellents O
are O
an O
intervention O
that O
can O
be O
used O
to O
target O
residual O
malaria O
transmission O
not O
covered O
by O
long O
lasting O
insecticide O
nets O
and O
indoor O
residual O
spraying. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Catheter O
complications B-outcome ['Adverse-effects']
, O
analyzed O
as O
a O
secondary O
end O
point, O
were O
more O
common O
in O
the O
intravenous O
group O
(9.4% O
vs. O
1.0%). O
[['Adverse-effects']]

PMID: O
31597637 O
[]

L(- O
1); O
PL: O
8.7 O
+/- O
0.9 O
mmol. O
[]

Recent O
studies O
have O
demonstrated O
that O
the O
energy O
provided O
by O
several O
tree O
nuts O
is O
less O
than O
that O
predicted O
by O
the O
Atwater O
factors, O
though O
energy O
available O
from O
cashews O
has O
never O
been O
assessed. O
[]

Journal O
ID: O
0255562 O
[]

Does O
the O
timing O
of O
hCG O
support O
make O
a O
difference? O
[]

Journal-Name:Pediatric O
rheumatology O
online O
journal O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
including O
incidence O
and O
severity B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
febrile B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
neutropenia E2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(41 O
[18%] O
patients O
in O
the O
A+CHP O
group O
and O
33 O
[15%] O
in O
the O
CHOP O
group) O
and O
peripheral B-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
(117 O
[52%] O
in O
the O
A+CHP O
group O
and O
124 O
[55%] O
in O
the O
CHOP O
group), O
were O
similar O
between O
groups. O
[['Adverse-effects'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE: O
Compare O
the O
outcome O
of O
spinal B-outcome ['Physiological-Clinical']
deformity I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
between O
Ti-Ti O
and O
CrCo-Ti O
rods O
for O
the O
treatment O
of O
spinal O
Adolescent O
Idiopathic O
Scoliosis O
(AIS) O
using O
rods O
mentioned O
with O
all O
pedicle O
screws O
and O
translation O
technique. O
[['Physiological-Clinical']]

The O
frequency O
of O
live B-outcome ['Mortality']
birth I-outcome ['Mortality']
was O
180 O
of O
690 O
women O
(26.1%) O
in O
the O
endometrial-scratch O
group O
and O
176 O
of O
674 O
women O
(26.1%) O
in O
the O
control O
group O
(adjusted O
odds O
ratio, O
1.00; O
95% O
confidence O
interval, O
0.78 O
to O
1.27). O
[['Mortality']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
101654770 O
[]

Postmenopausal O
overweight O
women O
were O
randomized O
to O
a O
diet O
(n O
= O
97), O
exercise O
plus O
diet O
(n O
= O
98) O
or O
control O
group O
(n O
= O
48). O
[]

LESSONS O
LEARNED: O
It O
is O
feasible O
to O
engage O
and O
maintain O
a O
network O
of O
CBOs O
linked O
with O
a O
local O
health O
system. O
[]

Statistical O
significance O
was O
set O
at O
P O
</= O
0.05. O
[]

When O
the O
intensity O
of O
pain B-outcome ['Physiological-Clinical']
was O
taken O
into O
consideration O
in O
the O
analysis O
of O
the O
EG, O
there O
was O
a O
significantly O
greater O
increment O
in O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
specific O
for O
CD O
after O
treatment O
in O
people O
without O
pain B-outcome ['Physiological-Clinical']
than O
in O
those O
with O
pain B-outcome ['Physiological-Clinical']
(P O
= O
.02) O
The O
improvements O
in O
global B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(GQoL) I-outcome ['Life-Impact']
were O
independent O
from O
the O
disease O
status O
(P O
= O
.16). O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

CONCLUSION: O
Drainage O
by O
the O
same O
thoracotomy O
intercostal O
space O
was O
feasible O
and O
results O
30 O
days O
after O
surgery O
were O
not O
inferior O
to O
those O
of O
the O
traditional O
chest O
drainage O
approach. O
[]

Digestibility O
of O
energy, O
fat, O
protein, O
and O
carbohydrate O
was O
lower O
for O
the O
cashew-containing O
diet O
compared O
to O
the O
control O
diet O
(92.9% O
vs. O
94.9%, O
p O
< O
0.0001 O
for O
energy; O
96.1% O
vs. O
97.8%, O
p O
= O
0.0009 O
for O
fat; O
90.1% O
vs. O
91.2%, O
p O
= O
0.0012 O
for O
protein; O
92.9% O
vs. O
94.9%, O
p O
< O
0.0001 O
for O
carbohydrate; O
for O
the O
cashew-containing O
diet O
vs. O
the O
control O
diet, O
respectively). O
[]

Title: O
Effectiveness O
and O
cost-effectiveness O
of O
neuromuscular O
exercise O
and O
back O
care O
counseling O
in O
female O
healthcare O
workers O
with O
recurrent O
non-specific O
low O
back O
pain: O
a O
blinded O
four-arm O
randomized O
controlled O
trial. O
[]

Journal O
ID: O
2985248R O
[]

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
prevalence O
and O
correlates O
of O
different O
indicators O
of O
psychological O
distress O
among O
13-14 O
year O
old O
low O
caste O
girls O
in O
rural, O
south O
India. O
[]

Publication O
date: O
2019/01/11 O
00:00 O
[accepted] O
[]

Moreover, O
the O
WSP-MR O
group O
demonstrated O
a O
5% O
decrease O
in O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
and O
mid-arm B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
and O
a O
3.5% O
decrease O
in O
glycated B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
levels O
(p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSIONS: O
The O
traditional O
respiratory O
training O
combined O
with O
device-guided O
pulmonary O
rehabilitation O
can O
improve O
the O
respiratory B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
athletic B-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
in O
stable O
COPD O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSION: O
The O
findings O
indicated O
the O
pilates O
exercises O
can O
be O
valuable O
for O
improvement O
of O
CKD O
patients' O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
. O
[['Life-Impact']]

Systemic O
hemodynamic B-outcome ['Physiological-Clinical']
data O
recorded O
by O
PRAM O
included O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
(SBP) I-outcome ['Physiological-Clinical']
and O
mean O
(MBP) O
blood O
pressure O
, O
stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
index O
(SVI), O
cardiac B-outcome ['Physiological-Clinical']
index O
(CI), O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
index O
(SVRI), O
the O
maximal O
slope O
of O
systolic B-outcome ['Physiological-Clinical']
upstroke I-outcome ['Physiological-Clinical']
(dp/dtmax) O
and O
cardiac B-outcome ['Physiological-Clinical']
cycle I-outcome ['Physiological-Clinical']
efficiency O
(CCE) O
after O
sedation O
obtained, O
1, O
2, O
5 O
min O
after O
induction O
achieved, O
1, O
2, O
5 O
and O
10 O
min O
after O
intubation. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O
[]

Of O
these, O
105 O
completed O
follow O
up O
at O
12 O
months. O
[]

Efficacy O
assessments O
using O
the O
validated O
IGAxBSA O
composite O
tool. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

The O
remaining O
78 O
patients O
underwent O
randomization. O
[]

Most O
studies O
assessing O
PZQ O
efficacy O
have O
used O
relatively O
insensitive O
parasitological O
diagnostics, O
such O
as O
the O
Kato-Katz O
(KK) O
and O
urine-filtration O
methods, O
thereby O
overestimating O
cure O
rates O
(CRs). O
[]

DESIGN: O
A O
parallel-group O
randomized O
controlled O
trial. O
[]

Objective: O
The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
preintravenous O
injection O
of O
parecoxib, O
combined O
with O
transversus O
abdominis O
plane O
(TAP) O
block O
and O
postoperative O
patient-controlled O
intravenous O
analgesia O
(PCIA) O
pump, O
in O
strategy O
of O
enhanced O
recovery B-outcome ['Physiological-Clinical']
after O
surgery O
for O
patients O
with O
radical O
resection O
of O
colorectal O
cancer. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS: O
We O
performed O
a O
multicenter, O
open-label, O
randomized, O
controlled O
trial O
involving O
patients O
18 O
to O
75 O
years O
of O
age O
with O
resectable O
cancer O
of O
the O
middle O
or O
lower O
third O
of O
the O
esophagus. O
[]

No O
patients O
experienced O
a O
deterioration O
in O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
scores O
during O
the O
exercise O
intervention. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND/AIMS: O
Diabetic O
kidney O
disease O
(DKD) O
is O
a O
leading O
cause O
of O
end-stage O
renal O
disease O
(ESRD) O
worldwide, O
and O
the O
importance O
of O
tubular O
injury O
has O
been O
highlighted O
in O
recent O
years. O
[]

Design, O
Setting, O
and O
Participants: O
Randomized, O
placebo-controlled, O
factorial O
clinical O
trial O
among O
120 O
patients O
aged O
60 O
years O
or O
older O
undergoing O
on-pump O
coronary O
artery O
bypass O
graft O
(CABG) O
surgery O
or O
combined O
CABG/valve O
surgeries O
at O
a O
US O
center. O
[]

PATIENTS O
AND O
METHODS: O
This O
was O
a O
prospective, O
randomized, O
unblinded O
study. O
[]

Exercise B-outcome ['Life-Impact']
intensity I-outcome ['Life-Impact']
during O
out-of-lab O
exercise O
and O
+25d O
post-exercise O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
correlated O
(r=-0.89, O
p=0.02) O
in O
IHE. O
[['Life-Impact'], ['Physiological-Clinical']]

It O
correlates O
well O
with O
the O
Psoriasis O
Area O
and O
Severity O
Index O
(PASI) O
and O
demonstrates O
sensitivity O
to O
changes O
from O
baseline O
in O
patients O
with O
both O
mild O
and O
moderately O
severe O
disease. O
[]

RESULTS: O
In O
the O
modified O
intention-to-treat O
population, O
omadacycline O
(316 O
patients) O
was O
noninferior O
to O
linezolid O
(311 O
patients) O
with O
respect O
to O
early O
clinical O
response O
(rate O
of O
response, O
84.8% O
and O
85.5%, O
respectively; O
difference, O
-0.7 O
percentage O
points; O
95% O
confidence O
interval O
[CI], O
-6.3 O
to O
4.9). O
[]

RESULTS: O
Most O
mothers O
reported O
that O
they O
understood B-outcome ['Life-Impact']
the O
message O
in O
the O
poster O
("The O
picture O
shows O
me O
you O
must O
use O
these O
drugs O
to O
keep O
your O
baby O
healthy") O
and O
that O
they O
could O
adhere B-outcome ['Life-Impact']
to O
the O
moments O
from O
the O
poster. O
[['Life-Impact'], ['Life-Impact']]

RESULTS: O
The O
independent O
t-test O
showed O
a O
significant O
difference O
in O
the O
mean O
total O
score O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
and O
its O
various O
dimensions O
( O
vasomotor B-outcome ['Physiological-Clinical']
, O
psychosocial B-outcome ['Life-Impact', 'Life-Impact']
, O
physical B-outcome ['Physiological-Clinical']
, O
and O
sexual B-outcome ['Physiological-Clinical']
dimensions) O
after O
the O
intervention O
between O
the O
aromatherapy O
and O
placebo O
groups O
(P<0.001). O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/15 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

To O
compare O
the O
means O
the O
student O
t O
test O
and O
analysis O
of O
variance O
(ANOVA) O
will O
be O
used O
and O
to O
analyse O
the O
correlation O
between O
the O
continuous O
variables O
the O
correlation O
test O
by O
Pearson O
will O
be O
applied. O
[]

No O
other O
complications B-outcome ['Adverse-effects']
, O
such O
as O
infection B-outcome ['Physiological-Clinical']
or O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
occurred O
in O
both O
groups. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/19 O
06:00 O
[entrez] O
[]

Introduction: O
Videoconferencing O
has O
been O
employed O
in O
numerous O
medical O
education O
settings O
ranging O
from O
remote O
supervision O
of O
medical O
trainees O
to O
conducting O
residency O
interviews. O
[]

The O
final O
follow-up O
visit O
was O
April O
2017. O
[]

CONCLUSIONS: O
A O
diet O
intervention O
that O
produced O
clinically O
relevant O
postpartum O
weight O
loss O
also O
resulted O
in O
increased O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
and O
was O
cost-effective. O
[['Life-Impact']]

Maintaining O
vaccine O
coverage O
is O
key O
to O
avoid O
the O
devastating O
consequences O
of O
resurgence. O
[]

To O
ensure O
adequate O
input O
and O
secure O
implementation, O
study O
design O
and O
results O
will O
be O
reviewed O
with O
relevant O
stakeholders, O
including O
the O
children's O
families, O
and O
provincial O
and O
regional O
decision-makers. O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Missing O
end-point O
data O
(39 O
participants, O
3.7%) O
were O
imputed. O
[]

METHODS: O
We O
conducted O
a O
case O
study O
with O
a O
purposeful O
sample O
of O
18 O
trained O
PCPs. O
[]

In O
this O
post-hoc O
analysis, O
gender-based O
baseline O
differences O
and O
treatment O
outcomes O
between O
indacaterol/glycopyrronium O
110/50 O
mug O
once O
daily O
(IND/GLY) O
and O
salmeterol/fluticasone O
50/500 O
twice O
daily O
(SFC) O
were O
assessed O
in O
terms O
of O
rate O
of O
exacerbations B-outcome ['Physiological-Clinical']
, O
time-to-first B-outcome ['Physiological-Clinical']
exacerbation I-outcome ['Physiological-Clinical']
, O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
health B-outcome ['Physiological-Clinical']
status, O
and O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
use I-outcome ['Resource-use']
. O
RESULTS: O
This O
post-hoc O
analysis O
included O
2557 O
men O
and O
805 O
women. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

However, O
blood O
loss O
and O
fibrinolytic O
activity, O
accounting O
for O
a O
poor O
prognosis O
following O
TKA O
operation, O
were O
relieved O
by O
fibrinolytic O
inhibitor O
tranexamic O
acid O
(TXA). O
[]

To O
combat O
this O
problem, O
investigators O
have O
attempted O
to O
withhold O
angiotensin-converting O
enzyme O
inhibitors O
(ACEi) O
and O
angiotensin O
receptor O
blockers O
(ARB) O
preoperatively, O
or O
evaluated O
the O
effects O
of O
different O
induction O
agents O
in O
conferring O
greater O
hemodynamic O
stability. O
[]

Prerandomization O
procedures O
excluded O
288 O
patients: O
42 O
had O
relief O
of O
their O
heartburn O
during O
the O
2-week O
omeprazole O
trial, O
70 O
did O
not O
complete O
trial O
procedures, O
54 O
were O
excluded O
for O
other O
reasons, O
23 O
had O
non-GERD O
esophageal O
disorders, O
and O
99 O
had O
functional O
heartburn O
(not O
due O
to O
GERD O
or O
other O
histopathologic, O
motility, O
or O
structural O
abnormality). O
[]

We O
assessed O
the O
associations O
between O
infarction O
patterns O
and O
stroke B-outcome ['Physiological-Clinical']
recurrence O
using O
multivariable O
Cox O
regression O
models. O
[['Physiological-Clinical']]

Publication O
date: O
2018/12/19 O
00:00 O
[accepted] O
[]

Other O
parameters O
evaluated O
were O
apolipoprotein B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
(Apo I-outcome ['Physiological-Clinical']
B) I-outcome ['Physiological-Clinical']
, O
apolipoprotein B-outcome ['Physiological-Clinical']
A1 I-outcome ['Physiological-Clinical']
(Apo I-outcome ['Physiological-Clinical']
A1) I-outcome ['Physiological-Clinical']
, O
Coenzyme B-outcome ['Physiological-Clinical']
Q10 I-outcome ['Physiological-Clinical']
(CoQ10) I-outcome ['Physiological-Clinical']
, O
high-sensitive B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(hsCRP) I-outcome ['Physiological-Clinical']
, O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
(FBS) I-outcome ['Physiological-Clinical']
, O
homocysteine B-outcome ['Physiological-Clinical']
and O
thyroid B-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
(TSH) I-outcome ['Physiological-Clinical']
. O
RESULTS: O
In O
12 O
weeks, O
the O
major O
lipids B-outcome ['Physiological-Clinical']
such O
as O
total O
cholesterol B-outcome ['Physiological-Clinical']
(TC) O
(p O
= O
0.0003), O
triglyceride B-outcome ['Physiological-Clinical']
(TG) I-outcome ['Physiological-Clinical']
(p O
= O
0.0003), O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
(LDL-C) I-outcome ['Physiological-Clinical']
(p O
= O
0.0064) O
and O
very B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
(VLDL-C) I-outcome ['Physiological-Clinical']
(p O
= O
0.0001) O
were O
significantly O
lower O
in O
amla O
group O
as O
compared O
to O
placebo O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
positive O
percent O
of O
coli-form B-outcome ['Physiological-Clinical']
on O
the O
hand O
swabs O
in O
intervention O
group O
(2.00%) O
were O
significantly O
lower O
than O
that O
in O
control O
group O
(9.45%) O
at O
the O
end O
of O
year O
2.The O
intervention O
of O
intensive O
education O
on O
hand O
hygiene O
effectively O
improved O
the O
personal B-outcome ['Life-Impact']
hygiene I-outcome ['Life-Impact']
both O
of O
children O
and O
parents, O
as O
well O
as O
reduced O
the O
incidence O
of O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
We O
suggested O
expanding O
the O
intervention O
measures O
in O
community O
to O
prevent O
HFMD. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

There O
were O
no O
Significant O
differences O
in O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
liquid B-outcome ['Physiological-Clinical']
input I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
between O
group O
C O
and O
group O
D(all O
P>0.05). O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Randomized O
study O
of O
the O
impact O
of O
a O
therapeutic O
education O
program O
on O
patients O
suffering O
from O
chronic O
low-back O
pain O
who O
are O
treated O
with O
transcutaneous O
electrical O
nerve O
stimulation. O
[]

Interestingly, O
the O
increase O
was O
higher O
in O
the O
placebo O
group. O
[]

Journal-Name:Cellular O
physiology O
and O
biochemistry O
: O
international O
journal O
of O
experimental O
cellular O
physiology, O
biochemistry, O
and O
pharmacology O
[]

Publication O
Type: O
Multicenter O
Study O
[]

PsycINFO O
Database O
Record O
(c) O
2018 O
APA, O
all O
rights O
reserved). O
[]

The O
Perceived O
Stress B-outcome ['Life-Impact']
Scale], O
Center O
for O
Epidemiologic O
Studies O
Depression B-outcome ['Physiological-Clinical', 'Life-Impact']
Scale], O
and O
Positive B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
Negative B-outcome ['Life-Impact', 'Life-Impact']
Affect E1-outcome ['Life-Impact', 'Life-Impact']
Scale O
were O
used O
to O
measure O
stress B-outcome ['Life-Impact']
, O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
positive B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
negative B-outcome ['Life-Impact', 'Life-Impact']
affect E1-outcome ['Life-Impact', 'Life-Impact']
, O
respectively. O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact', 'Life-Impact']]

We O
aimed O
to O
investigate O
the O
efficacy O
of O
PICSI O
versus O
standard O
ICSI O
for O
improving O
livebirth B-outcome ['Mortality']
rates O
among O
couples O
undergoing O
fertility O
treatment. O
[['Mortality']]

The O
participants O
were O
randomly O
assigned O
to O
either O
the O
resin O
infiltration O
group O
or O
the O
fluoride O
varnish O
group. O
[]

Journal-Name:JAMA O
[]

Journal-Name:Nutrients O
[]

Methods: O
Fifty-one O
participants O
with O
PFOA O
(66% O
women, O
mean O
+/- O
SD O
age O
57 O
+/- O
10 O
years, O
body O
mass O
index O
(BMI) O
27 O
+/- O
6 O
kg/m(2)), O
and O
23 O
controls O
(56% O
women, O
age O
56 O
+/- O
9 O
years, O
BMI O
24 O
+/- O
4 O
kg/m(2)) O
had O
ankle O
dorsiflexion O
measured O
using O
the O
knee-to-wall O
test, O
foot O
mobility, O
calculated O
as O
the O
difference O
in O
midfoot O
height O
or O
width O
between O
non-weightbearing O
and O
weightbearing, O
and O
static O
foot O
posture O
characterized O
utilizing O
the O
Foot O
Posture O
Index. O
[]

Publication O
Type: O
Journal O
Article O
[]

BACKGROUND: O
Pregnancy O
has O
been O
identified O
as O
a O
contributor O
to O
obesity. O
[]

A O
mixed O
analysis O
of O
variance O
(ANOVA) O
with O
repeated O
measures O
showed O
no O
significant O
effects O
for O
self-reported O
pain B-outcome ['Physiological-Clinical']
perception. O
[['Physiological-Clinical']]

Journal O
ID: O
7903310 O
[]

Furthermore, O
glycolysis B-outcome ['Physiological-Clinical']
and O
tricarboxylic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
(TCA) I-outcome ['Physiological-Clinical']
cycle I-outcome ['Physiological-Clinical']
was O
perturbed, O
and O
increased O
dihydroxyacetone B-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
(DHAP) I-outcome ['Physiological-Clinical']
and O
decreased O
succinyl-CoA B-outcome ['Physiological-Clinical']
synthetase I-outcome ['Physiological-Clinical']
(SCS) I-outcome ['Physiological-Clinical']
respectively O
in O
these O
two O
metabolic O
pathways O
were O
identified O
as O
potential O
biomarkers O
for O
tubular O
injury O
in O
DKD. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS: O
In O
well-controlled O
T2DM O
a O
modest O
reduction O
of O
dietary O
carbohydrate O
with O
a O
corresponding O
increase O
in O
protein O
and O
fat O
acutely O
reduced O
postprandial O
serum O
non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
suppression O
and O
increased O
serum O
triglyceride B-outcome ['Physiological-Clinical']
(TG) I-outcome ['Physiological-Clinical']
responses O
after O
a O
breakfast O
meal O
but O
had O
the O
opposite O
effect O
after O
a O
lunch O
meal. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/03/09 O
06:00 O
[medline] O
[]

The O
secondary O
objective O
was O
to O
investigate O
the O
postinduction O
levels O
of O
serum O
neurohormones B-outcome ['Physiological-Clinical']
in O
an O
attempt O
to O
explain O
the O
mechanisms O
involved. O
[['Physiological-Clinical']]

With O
a O
median O
follow-up O
of O
31 O
months O
(IQR O
27.3-35.7), O
we O
observed O
a O
28% O
reduction O
in O
the O
risk O
of O
progression B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Physiological-Clinical']
with O
ixazomib O
versus O
placebo O
(median O
PFS O
26.5 O
months O
[95% O
CI O
23.7-33.8 O
vs O
21.3 O
months O
[18.0-24.7]; O
hazard O
ratio O
0.72, O
95% O
CI O
0.58-0.89; O
p=0.0023). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Cost O
and O
resource O
savings O
of O
using O
the O
app O
compared O
to O
face-to-face O
counseling O
may O
make O
it O
a O
good O
option O
for O
interventionists. O
[]

Journal O
ID: O
2985213R O
[]

Title: O
Rivaroxaban O
for O
Thromboprophylaxis O
in O
High-Risk O
Ambulatory O
Patients O
with O
Cancer. O
[]

Title: O
Effects O
of O
Instruction O
on O
Parent O
Competency B-outcome ['Life-Impact']
During O
Infant O
Handling O
in O
a O
Neonatal O
Intensive O
Care O
Unit. O
[['Life-Impact']]

The O
intervention O
group O
inhaled O
2% O
lavender O
essential O
oil O
every O
night O
before O
bedtime O
for O
20 O
minutes O
during O
one O
month. O
[]

Findings O
reveal O
that O
respondents O
(N O
= O
205) O
are O
not O
averse B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
bitter I-outcome ['Life-Impact']
taste I-outcome ['Life-Impact']
; O
while, O
socio-demographic O
traits O
influence O
bitter B-outcome ['Life-Impact']
acceptance I-outcome ['Life-Impact']
, O
as O
higher O
education O
level O
and O
gender O
(female) O
positively O
affect O
preferences B-outcome ['Life-Impact']
, O
together O
with O
specific O
individual O
characteristics O
as O
high O
compensatory O
health O
beliefs. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Patients O
were O
divided O
into O
two O
groups O
of O
20 O
patients. O
[]

A O
masked O
evaluator O
assessed O
parent O
performance B-outcome ['Life-Impact']
, O
and O
parents O
rated O
instructional B-outcome ['Life-Impact']
effectiveness. O
[['Life-Impact'], ['Life-Impact']]

The O
incidence O
of O
postoperative O
nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
drowsiness B-outcome ['Physiological-Clinical']
, O
and O
headache B-outcome ['Physiological-Clinical']
was O
similar O
between O
the O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Study O
design O
20 O
participants O
with O
psychomotor O
disadaptation O
admitted O
to O
an O
academic O
rehabilitation O
ward O
were O
randomised O
to O
receive O
physiotherapist O
care O
supported O
by O
the O
SafeWalker(R) O
robotic O
walking O
aid O
or O
standard O
care O
only, O
for O
ten O
days. O
[]

The O
study O
involves O
140 O
public O
primary O
schools O
in O
three O
rural O
sub-counties O
(Magarini, O
Kaloleni O
and O
Ganze) O
of O
Kilifi O
County O
in O
the O
Coastal O
area O
of O
Kenya. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

OBJECTIVE: O
To O
investigate O
the O
effect O
of O
combined O
aerobic O
and O
resistance O
training O
(CART) O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
in O
sedentary, O
hypertensive O
women. O
[['Physiological-Clinical']]

Respiratory O
mechanical O
indices O
[ O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(Ppeak) I-outcome ['Physiological-Clinical']
, O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(VTi) I-outcome ['Physiological-Clinical']
, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(VTe) I-outcome ['Physiological-Clinical']
were O
recorded O
before O
atomization O
(atomized O
oxygen O
flow O
was O
0) O
and O
10 O
minutes O
after O
the O
beginning O
of O
atomization O
under O
the O
condition O
of O
7 O
L/min O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow O
respectively. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101234168 O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

METHODS: O
Ninety O
patients O
with O
ASA O
I O
or O
II, O
who O
underwent O
cesarean O
section, O
were O
randomized O
into O
2 O
groups: O
group O
D O
(bupivacaine O
+ O
5 O
mug O
Dex) O
and O
group O
C O
(bupivacaine O
+ O
the O
same O
volume O
of O
saline). O
[]

The O
mean O
(+/-SD) O
Unified O
Parkinson's B-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Rating O
Scale O
(UPDRS) O
score O
at O
baseline O
was O
28.1+/-11.4 O
points O
in O
the O
early-start O
group O
and O
29.3+/-12.1 O
points O
in O
the O
delayed-start O
group. O
[['Physiological-Clinical']]

Journal-Name:Therapeutic O
drug O
monitoring O
[]

A O
total O
of O
40 O
eligible O
patients O
were O
randomly O
allocated O
to O
a O
treatment O
group O
(received O
BZSF O
and O
ceftriaxone) O
or O
a O
control O
group O
(received O
ceftriaxone O
alone). O
[]

The O
eligible O
women O
were O
randomly O
allocated O
into O
an O
experimental O
and O
control O
groups. O
[]

At O
these O
time O
points: O
T(0)(the O
day O
before O
operation), O
T(1)(immediate O
before O
anesthesia O
induction), O
T(2)(1 O
h O
after O
emergence), O
T(3)(24 O
h O
after O
operation), O
T(4)(3 O
d O
after O
operation), O
T(5)(7 O
d O
after O
operation), O
T(6)(one O
month O
after O
operation), O
T(7)(3 O
months O
after O
operation) O
and O
T(8)(6 O
month O
after O
operation) O
, O
venous O
blood O
samples O
of O
patients O
were O
collected O
for O
detection O
of O
epinephrine B-outcome ['Physiological-Clinical']
, O
norepinephrine B-outcome ['Physiological-Clinical']
and O
corticosterone B-outcome ['Physiological-Clinical']
. O
The O
pain B-outcome ['Physiological-Clinical']
visual O
analogue O
scale(VSA) O
was O
used O
to O
assess O
pain B-outcome ['Physiological-Clinical']
levels O
in O
patients O
at O
T(2), O
T(3), O
T(4), O
T(5), O
T(6), O
T(7), O
T(8). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

In O
the O
analysis O
of O
the O
risk O
of O
the O
primary O
end O
point, O
the O
noninferiority O
margin O
was O
7.5 O
percentage O
points. O
[]

Title: O
Yoga O
positively O
affected O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
women O
with O
premenstrual O
syndrome O
in O
a O
randomized O
controlled O
clinical O
trial. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

Publication O
date: O
2018/10/28 O
00:00 O
[accepted] O
[]

Plazomicin O
is O
an O
aminoglycoside O
with O
bactericidal O
activity O
against O
multidrug-resistant O
(including O
carbapenem-resistant) O
Enterobacteriaceae. O
[]

Perceived O
exercise B-outcome ['Physiological-Clinical']
frequency O
(z O
= O
2.309, O
P O
= O
0.02) O
and O
intensity O
(z O
= O
2.687, O
P O
= O
0.007) O
was O
significantly O
improved O
following O
a O
short-term O
LOWFODMAP O
approach O
compared O
to O
HIGHFODMAP. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/05 O
06:00 O
[medline] O
[]

Title: O
The O
effect O
of O
two O
beta-alanine O
dosing O
strategies O
on O
30-minute O
rowing B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
: O
a O
randomized, O
controlled O
trial. O
[['Physiological-Clinical']]

CONSLUSIONS: O
Kangfuxin O
liquid O
combined O
with O
Garlicin O
Capsules O
can O
improve O
the O
therapeutic O
effect O
of O
ROU O
and O
repair B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
damaged I-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
in O
children, O
increasing O
the O
immune O
function O
of O
children. O
[['Physiological-Clinical']]

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O
[]

Additional O
studies O
that O
use O
liver O
biopsies O
would O
allow O
for O
the O
assessment O
of O
pegbelfermin's O
effects O
on O
liver O
histology. O
[]

Objective:The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
rhodiola O
rosea O
on O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
, O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
in O
patients O
with O
OSA. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

As O
shown O
by O
subjective O
symptoms B-outcome ['Physiological-Clinical']
, O
the O
results O
in O
95% O
of O
patients O
were O
rated O
as O
good O
or O
very O
good. O
[['Physiological-Clinical']]

This O
study O
explored O
the O
efficacy O
of O
WPI O
for O
improving O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
via O
delivery O
of O
vitamin O
B12. O
[['Life-Impact']]

In O
addition, O
no O
statistical O
significance O
between O
the O
placebo O
and O
the O
treatment O
groups O
for O
any O
secondary O
outcomes O
were O
detected. O
[]

These O
reductions O
were O
associated O
with O
a O
79% O
lower O
mean O
annualized O
attack B-outcome ['Physiological-Clinical']
rate O
than O
that O
observed O
with O
placebo O
(exploratory O
efficacy O
end O
point). O
[['Physiological-Clinical']]

The O
outcome O
assessor O
was O
blinded; O
however, O
it O
was O
not O
feasible O
to O
blind O
either O
operator O
or O
patients. O
[]

Highly B-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
(HS-Tp) I-outcome ['Physiological-Clinical']
as O
a O
biomarker O
of O
irreversible O
damage O
to O
the O
myocardium O
was O
evaluated O
before O
PCI O
and O
after O
PCI O
in O
24 O
hours. O
[['Physiological-Clinical']]

The O
rowers O
were O
subjected O
to O
blood O
tests O
at O
the O
beginning O
of O
the O
study O
(T1) O
and O
after O
eight O
weeks O
of O
treatment O
(T2), O
for O
the O
analysis O
of O
haematological B-outcome ['Physiological-Clinical']
and O
hormonal B-outcome ['Physiological-Clinical']
values. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Funded O
by O
GlaxoSmithKline O
and O
Medicines O
for O
Malaria O
Venture; O
GATHER O
ClinicalTrials.gov O
number, O
NCT02216123 O
.). O
[]

Conclusions: O
Our O
study O
demonstrates O
that O
NCH O
gel O
appears O
to O
be O
able O
to O
reduce O
the O
formation O
of O
intrauterine B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
in O
women O
who O
undergo O
curettage O
in O
the O
second O
trimester, O
although O
larger O
controlled, O
randomized, O
multicenter O
studies O
are O
needed O
to O
confirm O
these O
results. O
[['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

Title: O
Using O
misoprostol O
to O
treat O
postpartum O
hemorrhage O
in O
home O
deliveries O
attended O
by O
traditional O
birth O
attendants. O
[]

Journal O
ID: O
101627676 O
[]

TRIAL O
REGISTRATION: O
Netherlands O
Trial O
Register O
NTR4367. O
[]

Functional B-outcome ['Life-Impact']
outcome O
was O
significantly O
improved O
compared O
to O
baseline O
in O
both O
the O
groups O
until O
six O
weeks O
however, O
in O
the O
triamcinolone O
group, O
it O
was O
significant O
until O
twelve O
weeks. O
[['Life-Impact']]

At O
+25d, O
post-exercise O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(p=0.01) O
and O
physiological B-outcome ['Physiological-Clinical']
strain I-outcome ['Physiological-Clinical']
index O
(p<0.05) O
but O
neither O
Tre B-outcome ['Physiological-Clinical']
(p=0.18) O
nor O
sweat B-outcome ['Physiological-Clinical']
rate O
(p=0.44) O
were O
lower O
in O
IHE O
vs. O
CON. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Asthma O
among O
children O
and O
adolescents, O
its O
relations O
with O
physical O
activity O
(PA) O
and O
PA O
relations O
with O
body O
posture O
were O
and O
are O
still O
being O
investigated. O
[]

A O
transition O
to O
oral O
omadacycline O
(300 O
mg O
every O
24 O
hours) O
or O
moxifloxacin O
(400 O
mg O
every O
24 O
hours), O
respectively, O
was O
allowed O
after O
3 O
days; O
the O
total O
treatment O
duration O
was O
7 O
to O
14 O
days. O
[]

Main O
Outcomes O
and O
Measures: O
The O
primary O
outcome O
was O
the O
amount O
of O
microvascular B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
(% O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
) O
demonstrated O
by O
contrast-enhanced O
cardiac O
magnetic O
resonance O
imaging O
(MRI) O
conducted O
from O
days O
2 O
through O
7 O
after O
enrollment. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

They O
then O
underwent O
ET O
and O
were O
observed O
for O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
for O
another O
30 O
minutes O
post-ET. O
[['Adverse-effects']]

BACKGROUND: O
Single O
acute O
infarction O
(SAI) O
usually O
had O
lower O
risk O
of O
stroke O
recurrence O
than O
multiple O
acute O
infarctions O
(MAIs) O
in O
minor O
stroke. O
[]

Journal-Name:International O
journal O
of O
environmental O
research O
and O
public O
health O
[]

At O
2 O
years O
follow-up, O
the O
mean O
intraocular B-outcome ['Physiological-Clinical']
pressure(IOP) I-outcome ['Physiological-Clinical']
level O
was O
statistically O
significantly O
decreased O
in O
the O
OloPhacovisco O
group O
(p O
= O
0.02) O
and O
complete O
success B-outcome ['Physiological-Clinical']
occurred O
in O
23 O
eyes O
(59.0%) O
in O
the O
Phacovisco O
group O
and O
in O
32 O
eyes O
(80.0%) O
in O
the O
OloPhacovisco O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101249598 O
[]

Use O
of O
hyaluronan-based O
sperm O
selection O
for O
ICSI O
(so-called O
physiological O
ICSI O
[PICSI]) O
is O
reported O
to O
reduce O
the O
proportion O
of O
pregnancies O
that O
end O
in O
miscarriage. O
[]

Clinical O
trial O
registration: O
JapicCTI-142 O
483. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

FINDINGS: O
We O
recruited O
2203 O
participants O
between O
May O
7, O
2014, O
and O
Sept O
28, O
2017, O
of O
whom O
1099 O
were O
assigned O
to O
the O
lactoferrin O
group O
and O
1104 O
to O
the O
control O
group. O
[]

Journal O
ID: O
9812598 O
[]

Publication O
Type: O
Journal O
Article O
[]

However, O
in O
patients O
with O
a O
low O
BMI, O
the O
LBW O
protocol O
delivered O
a O
significantly O
higher O
dose B-outcome ['Life-Impact']
than O
the O
TBW O
protocol O
(620.7 O
vs O
600.0 O
mg O
iodine/kg, O
P O
< O
0.001). O
[['Life-Impact']]

To O
address O
the O
growing O
interest O
in O
connecting O
mental O
and O
physical O
performance, O
the O
present O
study O
examined O
whether O
the O
nootropic O
effects O
of O
PSE O
translate O
into O
changes O
in O
reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
following O
daily O
supplementation O
with O
PSE. O
[['Life-Impact']]

Journal-Name:Lipids O
in O
health O
and O
disease O
[]

IRCT. O
[]

Serum O
APN O
levels O
were O
positively O
correlated O
with O
FINS O
and O
TG O
(r O
= O
0.412, O
0.316, O
respectively; O
both O
P<0.05), O
and O
negatively O
correlated O
with O
SBP, O
DBP O
and O
LDL-C O
(r O
= O
-0.292, O
-0.383, O
-0.334, O
respectively; O
all O
P<0.05). O
[]

METHODS: O
In O
this O
multicentre, O
randomised, O
double-blind, O
placebo-controlled, O
parallel-group, O
phase O
2a O
study, O
we O
recruited O
adults O
(aged O
21-75 O
years) O
with O
a O
body-mass O
index O
of O
at O
least O
25 O
kg/m(2), O
biopsy-confirmed O
non-alcoholic O
steatohepatitis O
(fibrosis O
stage O
1-3), O
and O
a O
hepatic O
fat O
fraction O
of O
at O
least O
10% O
when O
assessed O
by O
magnetic O
resonance O
imaging-proton O
density O
fat O
fraction. O
[]

This O
trial O
is O
registered O
with O
ClinicalTrials.gov, O
number O
NCT02181413, O
and O
follow-up O
is O
ongoing. O
[]

Conclusions: O
HP/TAZ O
lotion O
was O
associated O
with O
significant O
and O
rapid O
reductions O
in O
disease B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
as O
assessed O
by O
the O
IGAxBSA O
composite O
tool. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

Muscular B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
was O
significantly O
different O
between O
limbs O
at O
the O
start O
of O
the O
intervention O
(p O
= O
0.02). O
[['Life-Impact']]

Journal-Name:Nutrients O
[]

Results: O
During O
the O
study O
period, O
133 O
third-year O
medical O
students O
responded O
to O
the O
survey. O
[]

METHODS: O
50 O
patients O
with O
chronic O
low O
back O
pain O
(78% O
female, O
49.7+/-10.0 O
years) O
were O
randomized O
to O
two O
Gua O
Sha O
treatments O
(n=25) O
or O
waitlist O
control O
(n=25). O
[]

Greater O
proclination B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
more X ['Physiological-Clinical', 'Physiological-Clinical']
protrusion B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
incisors E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
were O
found O
in O
the O
IA O
group. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
A O
high-fidelity O
task O
simulator O
for O
cricothyroidotomy O
was O
created O
using O
data O
from O
a O
3-dimensional O
(3D) O
computed O
tomography O
scan O
using O
a O
3D O
printer. O
[]

As O
we O
now O
know O
that O
antibiotic O
therapy O
for O
uncomplicated O
acute O
appendicitis O
is O
feasible O
and O
safe, O
further O
studies O
evaluating O
optimisation O
of O
the O
antibiotic O
treatment O
regarding O
both O
antibiotic O
spectrum O
and O
shorter O
hospital O
stay O
are O
needed O
to O
evaluate O
antibiotics O
as O
the O
first-line O
treatment O
for O
uncomplicated O
acute O
appendicitis. O
[]

Title: O
Effectiveness O
of O
Adjunctive O
Use O
of O
Low-Level O
Laser O
Therapy O
and O
Photodynamic O
Therapy O
After O
Scaling O
and O
Root O
Planing O
in O
Patients O
with O
Chronic O
Periodontitis. O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

CONCLUSION: O
Premedication O
with O
intranasal O
DEX O
2 O
mug/kg O
for O
children O
undergoing O
dental O
rehabilitation O
under O
general O
anesthesia O
produces O
good O
preoperative O
sedation B-outcome ['Physiological-Clinical']
. O
The O
levels O
of O
sedation B-outcome ['Physiological-Clinical']
, O
scores O
of O
parental B-outcome ['Life-Impact']
separation I-outcome ['Life-Impact']
and O
compliance B-outcome ['Life-Impact']
with O
the O
mask O
were O
satisfied. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

The O
primary O
outcome, O
hemoglobin B-outcome ['Physiological-Clinical']
decrease O
of O
20 O
g/L O
or O
greater O
from O
pre- O
to O
post-delivery O
assessment, O
was O
compared O
on O
a O
modified O
intention-to-treat O
basis. O
[['Physiological-Clinical']]

CONCLUSIONS: O
In O
summary, O
we O
demonstrated O
that O
10 O
weeks O
of O
NMES O
therapy O
was O
efficacious O
in O
patients O
with O
UIAS. O
[]

PARTICIPANTS: O
A O
total O
of O
twenty-eight O
hypertensive O
(Stage O
1 O
and O
2) O
sedentary O
women O
(Age O
40.54+/-4.2 O
yrs; O
Height O
155.14+/-5.4cm; O
Weight O
70.96+/-10.2kg; O
BMI O
29.6+/-4.4; O
Duration O
of O
HTN: O
6.43+/-2.5 O
yrs) O
were O
recruited O
for O
the O
study. O
[]

Interpretation O
& O
conclusion: O
: O
Addition O
of O
a O
third O
SP O
dose O
to O
the O
standard O
two-dose O
SP O
for O
IPTp O
led O
to O
improved O
reductions O
in O
the O
risk O
of O
some O
adverse B-outcome ['Adverse-effects']
pregnancy I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
. O
[['Adverse-effects']]

RESULTS: O
The O
general O
score O
of O
the O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
after O
yoga O
intervention O
was O
statistically O
significant O
compared O
to O
the O
control O
group O
(P<0.036) O
and O
yoga O
group O
before O
intervention O
(P<0.001). O
[['Physiological-Clinical', 'Life-Impact']]

No O
significant O
difference O
of O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
2-hour B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentrations O
were O
found O
between O
intervention O
and O
control O
groups O
at O
6 O
months O
and O
12 O
months O
(P O
>.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
95% O
effective O
dose B-outcome ['Life-Impact']
was O
calculated O
with O
Probit O
analysis. O
[['Life-Impact']]

Funded O
by O
the O
Netherlands O
Organization O
for O
Health O
Research O
and O
Development O
and O
others; O
LEAP O
Current O
Controlled O
Trials O
number, O
ISRCTN30518857 O
.). O
[]

Publication O
date: O
2019/01/01 O
06:00 O
[medline] O
[]

Title: O
Effect O
of O
Combination O
of O
Paracetamol O
(Acetaminophen) O
and O
Ibuprofen O
vs O
Either O
Alone O
on O
Patient-Controlled O
Morphine B-outcome ['Resource-use']
Consumption I-outcome ['Resource-use']
in O
the O
First O
24 O
Hours O
After O
Total O
Hip O
Arthroplasty: O
The O
PANSAID O
Randomized O
Clinical O
Trial. O
[['Resource-use']]

Group O
A O
consisted O
patients O
who O
received O
Atorvastatin O
40mg O
daily O
and O
Group O
B O
Atorvastatin O
80mg O
daily. O
[]

The O
primary O
efficacy O
endpoints O
were O
measured O
by O
urodynamic B-outcome ['Physiological-Clinical']
values, O
and O
Overactive B-outcome ['Physiological-Clinical']
Bladder I-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
(OABSS)]. O
The O
secondary O
efficacy O
endpoints O
were O
assessed O
by O
International O
Consultation O
on O
Incontinence B-outcome ['Physiological-Clinical']
Questionnaire-Short O
Form O
(ICIQ-SF) O
score, O
Barthel O
Index O
(BI) O
scale, O
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
All O
outcomes O
were O
evaluated O
at O
baseline O
and O
at O
the O
end O
of O
10 O
weeks O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

It O
can O
improve O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
has O
no O
adverse B-outcome ['Adverse-effects']
effect I-outcome ['Adverse-effects']
on O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical', 'Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical']]

RESULTS: O
Statistically O
significant O
and O
different O
increases O
were O
observed O
in O
the O
group-by-time O
interaction O
of O
25(OH)D O
in O
VD3G O
in O
respect O
to O
CG O
during O
the O
study O
(p O
< O
0.001; O
VD3G O
(T1: O
26.24 O
+/- O
8.18 O
ng/mL O
vs. O
T2: O
48.12 O
+/- O
10.88 O
ng/mL) O
vs O
CG O
(T1: O
30.76 O
+/- O
6.95 O
ng/mL O
vs. O
T2: O
35.14 O
+/- O
7.96 O
ng/mL). O
[]

Title: O
Effect O
of O
a O
short-term O
low O
fermentable O
oligiosaccharide, O
disaccharide, O
monosaccharide O
and O
polyol O
(FODMAP) O
diet O
on O
exercise-related O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

The O
exercise O
protocol O
consisted O
of O
performing O
the O
bench O
press O
movement O
with O
a O
load O
equal O
to O
70%1RM O
with O
maximal O
possible O
velocity O
(X/0/X/0). O
[]

Results: O
A O
total O
of O
194 O
children O
were O
included O
in O
the O
study: O
98 O
in O
the O
intervention O
group; O
96 O
in O
the O
control O
group; O
96 O
(49.5%) O
boys O
and O
98 O
(50.5%) O
girls O
between O
7 O
and O
8 O
years O
old. O
[]

Methods O
Sixty O
older O
individuals O
with O
depression O
score O
of O
10 O
or O
above O
(the O
Geriatric O
Depression O
Scale, O
GDS]) O
were O
randomly O
assigned O
into O
two O
groups: O
TC O
(n O
= O
30) O
and O
control O
group O
(n O
= O
30). O
[]

Journal-Name:International O
journal O
of O
gynaecology O
and O
obstetrics: O
the O
official O
organ O
of O
the O
International O
Federation O
of O
Gynaecology O
and O
Obstetrics O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

In O
the O
2nd O
group O
of O
patients O
which O
also O
contained O
22 O
children O
and O
autologous O
gracilis O
graft O
was O
used. O
[]

In O
SAT, O
when O
compared O
with O
the O
control O
group, O
the O
effect O
of O
FF O
on O
decreasing O
IL1RN O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
significant O
(P O
< O
0.03). O
[['Physiological-Clinical']]

The O
most O
preferred B-outcome ['Life-Impact']
respirator O
type O
was O
the O
valve-type O
(10 O
persons, O
45.5%). O
[['Life-Impact']]

All O
patients O
were O
randomly O
selected O
to O
receive O
standard O
anesthesia O
induction O
with O
either O
0.6 O
mg.kg O
rocuronium O
or O
0.2 O
mg.kg O
cisatracurium. O
[]

The O
patients O
in O
the O
treatment O
group O
received O
UGPRF, O
while O
the O
subjects O
in O
the O
sham O
group O
underwent O
sham O
UGPRF. O
[]

PURPOSE: O
Clinical O
implications O
of O
single O
patient O
classifier O
(SPC) O
and O
microsatellite O
instability O
(MSI) O
in O
stage O
II/III O
gastric O
cancer O
have O
been O
reported. O
[]

Publication O
Type: O
Journal O
Article O
[]

As O
well O
as O
having O
important O
development O
benefits, O
interventions O
that O
address O
the O
upstream O
structural O
and O
gender-norms O
based O
determinants O
of O
poor O
mental O
health, O
and O
provide O
adolescent O
services O
for O
girls O
who O
require O
treatment O
and O
support, O
should O
have O
important O
benefits O
for O
girls' O
psychological O
wellbeing. O
[]

The O
minimal O
clinically O
important O
between O
group O
difference O
in O
mean O
Roland-Morris O
Disability B-outcome ['Life-Impact']
Questionnaire O
(RMDQ) O
score O
was O
predefined O
as O
4. O
[['Life-Impact']]

Publication O
date: O
2019/01/15 O
06:00 O
[medline] O
[]

We O
performed O
a O
subset O
analysis O
of O
73 O
patients O
who O
underwent O
pancreatectomy. O
[]

The O
objective O
responses B-outcome ['Physiological-Clinical']
are O
ongoing. O
[['Physiological-Clinical']]

And O
the O
safety O
of O
berberine O
was O
assessed. O
[]

Title: O
Resin O
infiltration O
technique O
and O
fluoride O
varnish O
on O
white O
spot O
lesions O
in O
children: O
Preliminary O
findings O
of O
a O
randomized O
clinical O
trial. O
[]

Safety O
was O
assessed O
in O
all O
patients O
who O
received O
at O
least O
one O
dose O
of O
ixazomib O
or O
placebo, O
according O
to O
treatment O
actually O
received. O
[]

Secondary O
outcomes O
were O
clinical O
and O
MRI O
measures O
of O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
Results: O
Of O
200 O
patients O
randomized O
(133 O
women O
[67%]; O
mean O
[SD] O
age, O
61.6 O
[10.5] O
years; O
median O
baseline O
DAS28-CRP, O
1.9 O
[interquartile O
range, O
1.7-2.2]; O
van O
der O
Heijde-modified O
Sharp O
score, O
18.0 O
[interquartile O
range, O
7.0-42.5]), O
76 O
patients O
(76%) O
in O
the O
MRI-guided O
group O
and O
95 O
(95%) O
in O
the O
conventional O
group O
completed O
the O
study. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Trial O
Registration O
Date: O
August O
22, O
2017. O
[]

Regression O
multivariate O
analysis O
showed O
that O
cortisol B-outcome ['Physiological-Clinical']
and O
testosterone B-outcome ['Physiological-Clinical']
levels O
were O
associated O
with O
25(OH)D B-outcome ['Physiological-Clinical']
levels O
(p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
addition O
of O
SPOC O
scores O
to O
an O
adjusted O
regression O
model O
to O
predict O
persistent B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
improved O
the O
concordance O
statistic O
from O
0.66 O
to O
0.74, O
and O
found O
the O
greatest O
risk O
was O
associated O
with O
high O
(>/=74) O
SPOC O
scores O
[odds O
ratio: O
5.63; O
99% O
confidence O
interval O
(CI): O
3.59-8.84; O
absolute O
risk O
increase O
40.6%; O
99% O
CI: O
30.8%, O
48.6%]. O
Thirty-eight O
per O
cent O
(484 O
of O
1277) O
reported O
moderate O
to O
extreme O
pain B-outcome ['Physiological-Clinical']
interference I-outcome ['Physiological-Clinical']
at O
1 O
yr. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
A O
stratified O
case O
study O
was O
conducted. O
[]

RESULTS: O
Sixty-five O
patients O
completed O
the O
study, O
including O
33 O
in O
the O
control O
group O
and O
32 O
in O
the O
treatment O
group. O
[]

The O
mean O
time B-outcome ['Life-Impact']
for O
completing O
the O
task O
during O
the O
stabilization O
period O
was O
significantly O
different O
between O
group O
I O
and O
group O
III O
and O
group O
II O
and O
group O
III, O
which O
means O
that O
the O
independent O
training O
method O
was O
inferior O
to O
the O
other O
methods O
(group O
I O
vs. O
group O
II O
vs. O
group O
III: O
187.38 O
vs. O
187.07 O
vs. O
253.47 O
seconds, O
P O
< O
.001). O
[['Life-Impact']]

BACKGROUND: O
Hospitalized O
patients O
who O
are O
colonized O
with O
methicillin-resistant O
Staphylococcus O
aureus O
(MRSA) O
are O
at O
high O
risk O
for O
infection O
after O
discharge. O
[]

Journal-Name:Medicine O
[]

Funded O
by O
the O
Health O
Research O
Council O
of O
New O
Zealand; O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
number, O
ACTRN12609000593235 O
.). O
[]

Journal O
ID: O
7909660 O
[]

wash-out O
period, O
19 O
healthy O
women O
performed O
30 O
min O
moderate-intensity O
cycling O
after O
ingesting O
1000 O
mg O
of O
ascorbic O
acid O
(AA) O
or O
placebo. O
[]

Evaluation O
of O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
can O
be O
used O
as O
an O
additional O
strategy O
to O
evaluate O
postoperative O
residual B-outcome ['Physiological-Clinical']
neuromuscular I-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
. O
[['Life-Impact'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Title: O
Proton O
Pump O
Inhibitor O
Ameliorates O
Taste B-outcome ['Physiological-Clinical']
Disturbance I-outcome ['Physiological-Clinical']
among O
Patients O
with O
Laryngopharyngeal O
Reflux: O
A O
Randomized O
Controlled O
Study. O
[['Physiological-Clinical']]

RESULTS: O
A O
protocol-defined O
decrease O
in O
the O
hemoglobin B-outcome ['Physiological-Clinical']
level O
occurred O
in O
4 O
of O
166 O
patients O
(2.4%; O
95% O
confidence O
interval O
[CI], O
0.9 O
to O
6.0) O
in O
the O
tafenoquine O
group O
and O
in O
1 O
of O
85 O
patients O
(1.2%; O
95% O
CI, O
0.2 O
to O
6.4) O
in O
the O
primaquine O
group, O
for O
a O
between-group O
difference O
of O
1.2 O
percentage O
points O
(95% O
CI, O
-4.2 O
to O
5.0). O
[['Physiological-Clinical']]

The O
number O
needed O
to O
treat O
to O
avert O
one O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
was O
8.4. O
[['Mortality']]

During O
the O
trial O
there O
were O
16 O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
for O
infants O
in O
the O
lactoferrin O
group O
and O
10 O
for O
infants O
in O
the O
control O
group. O
[['Adverse-effects']]

BACKGROUND: O
Although O
conventional O
60 O
mg O
of O
prasugrel O
allows O
for O
rapid O
and O
potent O
platelet O
inhibition O
within O
30 O
min O
after O
loading O
dose, O
the O
efficacy O
and O
safety O
of O
lower O
doses O
of O
prasugrel O
in O
Indian O
patients O
has O
not O
yet O
been O
investigated. O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

RESULTS: O
Among O
the O
401 O
patients O
enrolled, O
the O
median O
lowest O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
was O
96% O
(interquartile O
range, O
87 O
to O
99) O
in O
the O
bag-mask O
ventilation O
group O
and O
93% O
(interquartile O
range, O
81 O
to O
99) O
in O
the O
no-ventilation O
group O
(P O
= O
0.01). O
[['Physiological-Clinical']]

MAIN O
OUTCOME O
MEASURES: O
Resting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
measured O
and O
standard O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
(HRV) I-outcome ['Physiological-Clinical']
indices O
were O
calculated O
using O
time O
domain O
( O
SDNN B-outcome ['Physiological-Clinical']
, O
pNN50 B-outcome ['Physiological-Clinical']
, O
RMSSD B-outcome ['Physiological-Clinical']
) O
and O
frequency O
domain O
( O
LFnu B-outcome ['Physiological-Clinical']
, O
HFnu B-outcome ['Physiological-Clinical']
, O
LF/HF B-outcome ['Physiological-Clinical']
and O
TP B-outcome ['Physiological-Clinical']
) O
analysis. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Use O
of O
a O
robotic O
walking O
aid O
in O
rehabilitation O
to O
reduce O
fear B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
falling I-outcome ['Life-Impact']
is O
feasible B-outcome ['Life-Impact']
and O
acceptable B-outcome ['Life-Impact']
from O
the O
end O
user's O
perspective: O
A O
randomised O
comparative O
study. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

RESULTS: O
A O
total O
of O
23 O
patients O
in O
parts O
A O
and O
B O
and O
17 O
patients O
in O
part O
C O
underwent O
randomization. O
[]

Publication O
Type: O
Journal O
Article O
[]

Blood O
samples O
were O
taken O
immediately O
before, O
immediately O
after O
and O
30 O
min O
post-exercise O
to O
determine O
plasma O
albumin B-outcome ['Physiological-Clinical']
, O
total O
protein B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
markers. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Less O
onerous O
PT O
wear O
regimens O
may O
therefore O
be O
a O
viable O
alternative O
to O
FT O
wear O
of O
removable O
functional O
appliances. O
[]

The O
study O
involved O
192 O
children. O
[]

Title: O
Taping O
to O
Improve O
Scapular B-outcome ['Physiological-Clinical']
Dyskinesis I-outcome ['Physiological-Clinical']
, O
Scapular B-outcome ['Physiological-Clinical']
Upward I-outcome ['Physiological-Clinical']
Rotation I-outcome ['Physiological-Clinical']
, O
and O
Pectoralis B-outcome ['Physiological-Clinical']
Minor I-outcome ['Physiological-Clinical']
Length I-outcome ['Physiological-Clinical']
in O
Overhead O
Athletes. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

FUNDING: O
Millennium O
Pharmaceuticals, O
a O
wholly O
owned O
subsidiary O
of O
Takeda O
Pharmaceutical O
Company. O
[]

Publication O
date: O
2018/03/20 O
00:00 O
[accepted] O
[]

Sporting O
organisations O
should O
be O
encouraged O
to O
seek O
sponsorship O
from O
companies O
who O
produce O
healthier O
food O
brands O
and O
government-funded O
social O
marketing O
campaigns. O
[]

OBJECTIVE: O
This O
study O
aims O
to O
investigate O
the O
accuracy O
of O
the O
preoperative O
localization B-outcome ['Life-Impact']
of O
small O
nodules O
by O
computerized O
tomography O
(CT)-guided O
placing O
wire O
and O
intrapleural O
fibrin O
glue O
near O
the O
nodules O
at O
3 O
days O
before O
the O
operation. O
[['Life-Impact']]

Therefore, O
continuous O
investigation O
of O
effective O
interventions O
for O
upper O
extremity O
functions O
after O
stroke O
is O
a O
necessity. O
[]

Journal-Name:BMC O
surgery O
[]

Additionally, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
documented O
during O
the O
period O
of O
the O
treatment. O
[['Adverse-effects']]

A O
administration O
of O
GLN O
was O
associated O
with O
a O
decrease O
in O
the O
incidence O
of O
grade O
2 O
or O
3 O
acute O
radiation-induced O
esophagitis B-outcome ['Physiological-Clinical']
(ARIE) O
(6.7% O
vs O
53.4% O
for O
Gln+ O
vs O
Gln-; O
P O
= O
.004). O
[['Physiological-Clinical']]

END O
POINTS: O
Primary O
end O
point O
was O
MACE B-outcome ['Physiological-Clinical', 'Mortality']
at O
1 O
year O
and O
secondary O
end O
points O
at O
the O
end O
of O
1 O
year O
were O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
urgent O
target O
lesion B-outcome ['Resource-use']
revascularization I-outcome ['Resource-use']
, O
acute B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
and O
in-stent B-outcome ['Physiological-Clinical']
re-stenosis I-outcome ['Physiological-Clinical']
. O
RESULTS: O
204 O
patients O
were O
enrolled O
between O
January O
2013 O
to O
July O
2014, O
91 O
in O
the O
polymer-free O
group O
and O
113 O
in O
the O
biodegradable O
polymer O
group. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Medicine O
[]

Conclusion: O
Children O
with O
HIV O
were O
found O
to O
have O
the O
most O
difficulty O
on O
Test O
of O
Playfulness B-outcome ['Life-Impact']
(ToP) O
items O
relating O
to O
the O
play B-outcome ['Life-Impact']
elements O
of O
internal B-outcome ['Life-Impact']
control I-outcome ['Life-Impact']
and O
freedom B-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
constraints I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
reality I-outcome ['Life-Impact']
. O
The O
PICIHBI O
did O
not O
significantly O
improve O
children's O
play B-outcome ['Life-Impact']
and O
was O
not O
more O
effective O
than O
the O
conventional O
intervention. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

CONCLUSIONS: O
The O
risk O
of O
nonvertebral B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
or Seperator ['Physiological-Clinical', 'Physiological-Clinical']
vertebral B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
fragility I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
fractures E2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
was O
significantly O
lower O
in O
women O
with O
osteopenia O
who O
received O
zoledronate O
than O
in O
women O
who O
received O
placebo. O
( O
[['Physiological-Clinical', 'Physiological-Clinical']]

FINDINGS: O
Between O
Feb O
1, O
2014, O
and O
Aug O
31, O
2016, O
2772 O
couples O
were O
randomly O
assigned O
to O
receive O
PICSI O
(n=1387) O
or O
ICSI O
(n=1385), O
of O
whom O
2752 O
(1381 O
in O
the O
PICSI O
group O
and O
1371 O
in O
the O
ICSI O
group) O
were O
included O
in O
the O
primary O
analysis. O
[]

The O
intercostal O
drainage O
group O
had O
mean O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
(p=0.527) O
and O
drainage O
(p=0.547) O
of O
4 O
days, O
and O
the O
traditional O
chest O
drainage O
group O
and O
2 O
and O
5.5 O
days, O
respectively. O
[['Resource-use']]

Publication O
date: O
2019/02/14 O
06:00 O
[entrez] O
[]

Title: O
Endoscopic O
injection O
sclerotherapy O
versus O
N-Butyl-2 O
Cyanoacrylate O
injection O
in O
the O
management O
of O
actively O
bleeding O
esophageal O
varices: O
a O
randomized O
controlled O
trial. O
[]

Statistically O
significant O
differences O
in O
cumulative O
QALYs O
and O
costs B-outcome ['Resource-use']
were O
found O
at O
six O
and O
12 O
months O
for O
the O
decompression O
versus O
no O
treatment O
comparison O
only. O
[['Resource-use']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSION: O
The O
SPT O
intervention O
can O
improve O
functional O
outcomes O
of O
upper O
extremity O
in O
people O
after O
stroke. O
[]

RESULTS: O
Supplementation O
with O
L-theanine O
contributed O
to O
a O
significant O
post-exercise O
decrease O
in O
IL-10 B-outcome ['Physiological-Clinical']
concentration, O
which O
was O
reflected O
by O
higher O
values O
of O
IL-2 B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
to I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
IL-10 I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
IFN-gamma B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
to I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
IL-10 I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
ratios E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
Moreover, O
a O
significant O
post-recovery O
decrease O
in O
cytotoxic B-outcome ['Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical']
(CTL) I-outcome ['Physiological-Clinical']
count, O
T B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(Treg) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
to I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
natural I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
killer I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(NK) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
T B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(Treg) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
to I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
cytotoxic I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(CTL) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
ratios E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
was O
observed O
in O
the O
supplemented O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical']]

However, O
using O
SMV O
may O
have O
superior O
effect O
on O
improving O
muscle B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
after O
stroke. O
[['Physiological-Clinical']]

Anticoagulants O
are O
effective O
as O
venous O
thromboprophylaxis, O
but O
with O
an O
increased O
risk O
of O
bleeding. O
[]

Journal O
ID: O
101160941 O
[]

Publication O
date: O
2019/01/22 O
06:00 O
[entrez] O
[]

It O
is O
currently O
unknown O
whether O
these O
unilateral O
deficits O
can O
be O
corrected O
by O
a O
standard O
bilateral O
strength O
training O
intervention. O
[]

Title: O
Green O
tea O
as O
an O
adjunctive O
therapy O
for O
treatment O
of O
acute O
uncomplicated O
cystitis O
in O
women: O
A O
randomized O
clinical O
trial. O
[]

Journal O
ID: O
101599229 O
[]

2019; O
90(1):12-17. O
[]

Conclusions O
and O
Relevance: O
In O
this O
preliminary O
analysis O
of O
an O
ongoing O
trial, O
an O
intervention O
that O
encouraged O
an O
energy-reduced O
Mediterranean O
diet O
and O
physical O
activity, O
compared O
with O
advice O
to O
follow O
an O
energy-unrestricted O
Mediterranean O
diet, O
resulted O
in O
a O
significantly O
greater O
increase O
in O
diet O
adherence B-outcome ['Life-Impact']
after O
12 O
months. O
[['Life-Impact']]

RESULTS: O
At O
T2, O
the O
intervention O
group O
reported O
significantly O
higher O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress O
(effect O
size O
[Cohen's O
d O
= O
0.53), O
better O
emotional O
coping B-outcome ['Life-Impact']
response O
(d O
= O
0.38), O
less O
stress B-outcome ['Life-Impact']
(d O
= O
0.34), O
fewer O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
(d O
= O
- O
0.27), O
and O
more O
positive B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
(d O
= O
0.31) O
than O
the O
comparison O
group. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact']]

The O
studyPeden O
CJ, O
Stephens O
T, O
Martin O
G O
et O
al. O
[]

Spirometry, O
SF-36 O
health O
survey O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
and O
Lawton O
and O
Brody O
Instrumental O
Activities B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Daily I-outcome ['Life-Impact']
Living I-outcome ['Life-Impact']
Scale O
(IADL) O
were O
used O
to O
collect O
physical B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
data, O
and O
self-evaluation O
of O
overall B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status, O
self-evaluation O
of O
loneliness B-outcome ['Life-Impact']
, O
and O
short-form O
geriatric O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(GDS-15) O
were O
used O
to O
collect O
mental B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
data O
at O
baseline, O
3 O
months, O
and O
6 O
months O
after O
intervention. O
[['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Future O
randomized O
trials O
with O
longer-term O
outcomes O
that O
include O
sensorimotor O
mechanisms O
might O
enhance O
our O
understanding O
of O
the O
comparative O
effectiveness. O
[]

Journal O
ID: O
101224380 O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
primary O
outcomes O
were O
success B-outcome ['Life-Impact']
rate O
and O
procedure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
The O
secondary O
outcome O
was O
a O
subjective O
measure O
of O
the O
similarity O
of O
the O
simulator O
to O
the O
porcine O
larynx. O
[['Life-Impact'], ['Life-Impact']]

RESULTS: O
The O
volunteers O
had O
a O
level O
of O
education O
from O
incomplete O
junior O
school O
to O
complete O
graduate O
course, O
with O
16 O
males O
(48%) O
and O
18 O
females O
(52%), O
age O
range O
of O
21 O
to O
87 O
years. O
[]

After O
consumption, O
participants O
were O
monitored O
throughout O
a O
45-min O
ingestion O
period, O
then O
completed O
a O
repeated O
Wingate O
protocol, O
and O
were O
then O
monitored O
throughout O
a O
45-min O
recovery O
period. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
100968562 O
[]

Journal O
ID: O
101599229 O
[]

Journal-Name:Nutrition O
& O
diabetes O
[]

Other O
outcomes O
include O
gonadotrophin B-outcome ['Physiological-Clinical']
(Gn) I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
, O
the O
total O
dose B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
follicle-stimulating I-outcome ['Life-Impact']
hormone I-outcome ['Life-Impact']
(FSH) I-outcome ['Life-Impact']
used, O
number O
of O
oocytes B-outcome ['Physiological-Clinical']
retrieved I-outcome ['Physiological-Clinical']
, O
number O
of O
embryos B-outcome ['Physiological-Clinical']
available I-outcome ['Physiological-Clinical']
for O
transfer O
, O
implantation B-outcome ['Physiological-Clinical']
rate, O
the O
abortion B-outcome ['Physiological-Clinical']
rate, O
live B-outcome ['Mortality']
birth I-outcome ['Mortality']
rate, O
and O
incidence O
of O
moderate-to-severe O
ovarian B-outcome ['Physiological-Clinical']
hyperstimulation I-outcome ['Physiological-Clinical']
. O
The O
sample O
size O
of O
this O
trial O
is O
estimated O
to O
be O
421 O
participants O
for O
each O
of O
the O
two O
arms. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical']]

Journal-Name: O
The O
International O
journal O
of O
periodontics O
& O
restorative O
dentistry O
[]

Mindfulness O
meditation O
interventions-which O
train O
skills O
in O
monitoring O
present-moment O
experiences O
with O
a O
lens O
of O
acceptance-have O
shown O
promise O
for O
increasing O
positive O
emotions. O
[]

Significant O
treatment O
x O
time O
effects O
were O
found O
for O
postprandial O
glucose B-outcome ['Physiological-Clinical']
(p O
= O
0.004) O
for O
RS O
compared O
to O
placebo, O
with O
a O
trend O
for O
higher O
C-peptide B-outcome ['Physiological-Clinical']
concentrations O
following O
RS. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
9308586 O
[]

On O
the O
basis O
of O
traditional O
treatment, O
the O
children O
in O
the O
SBH O
treatment O
group O
were O
given O
SBH O
treatment O
within O
6 O
hours O
after O
birth. O
[]

RESULTS: O
Twenty-two O
patients O
(44%) O
were O
still O
assessable O
at O
the O
end-of-study O
visit, O
whereas O
33 O
(70%) O
were O
assessable O
at O
the O
same O
time O
point O
in O
the O
TENS-TEP O
group O
(P O
= O
.013). O
[]

Each O
group O
was O
subdivided O
into O
the O
3 O
classes O
based O
on O
the O
body O
mass O
index O
(BMI; O
low, O
normal, O
high). O
[]

BACKGROUND: O
This O
study O
aimed O
to O
investigate O
the O
efficacy O
and O
safety O
of O
lactulose O
for O
the O
treatment O
of O
Chinese O
children O
with O
chronic O
constipation. O
[]

In O
conclusion, O
reductions O
in O
snack B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
were O
associated O
with O
reduced O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
3(-)8 O
years O
later, O
but O
adjustment O
for O
current O
lifestyle B-outcome ['Life-Impact', 'Life-Impact']
reduced O
these O
associations. O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact', 'Life-Impact']]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

INTRODUCTION: O
The O
aim O
of O
this O
2-arm O
parallel O
study O
was O
to O
compare O
the O
dentoalveolar B-outcome ['Physiological-Clinical']
and O
skeletal B-outcome ['Physiological-Clinical']
changes O
achieved O
with O
Twin-block O
appliance O
therapy O
prescribed O
on O
either O
a O
part- O
or O
full-time O
basis O
for O
12 O
months. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Thus, O
the O
aim O
of O
this O
study O
is O
to O
explore O
the O
impact O
of O
the O
application O
of O
OPEP O
device O
(acapella) O
in O
lung O
cancer O
patients O
undergoing O
video-assisted O
thorascopic O
surgery O
(VATS). O
[]

In O
multivariate O
analysis O
of O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
, O
SPC-prognosis O
[hazard O
ratio O
(HR): O
1.879 O
(1.101-3.205), O
2.399 O
(1.415-4.067), O
p=0.003 O
and O
MSI O
status O
(HR: O
0.363, O
95% O
confidence O
interval: O
0.161-0.820, O
p=0.015) O
were O
independent O
prognostic O
factors O
along O
with O
age, O
Lauren O
classification, O
TNM O
stage, O
and O
chemotherapy. O
[['Physiological-Clinical', 'Mortality']]

Conjunctiva B-outcome ['Physiological-Clinical']
melted I-outcome ['Physiological-Clinical']
and O
drainage B-outcome ['Physiological-Clinical']
tube I-outcome ['Physiological-Clinical']
exposed I-outcome ['Physiological-Clinical']
in O
0 O
eyes O
(0%) O
in O
the O
corneal O
graft O
group O
and O
2 O
eyes O
(1.6%) O
in O
the O
scleral O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

PMID: O
31618539 O
[]

Few O
galcanezumab-treated O
patients O
maintained O
100% O
response B-outcome ['Physiological-Clinical']
. O
In O
patients O
with O
chronic O
migraine, O
29% O
of O
galcanezumab-treated O
patients O
maintained O
>/=30% O
response B-outcome ['Physiological-Clinical']
all O
3 O
months O
compared O
to O
16% O
of O
placebo O
patients O
while O
>/=50% O
response B-outcome ['Physiological-Clinical']
was O
maintained O
in O
16.8 O
and O
14.6% O
of O
galcanezumab-treated O
patients O
(120 O
mg O
and O
240 O
mg) O
and O
was O
greater O
than O
placebo O
(6.3%; O
p O
< O
0.001). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
patients O
in O
the O
control O
group O
were O
given O
routine O
treatment O
and O
respiratory O
function O
exercise, O
and O
those O
in O
the O
observation O
group O
were O
given O
nursing O
intervention O
in O
addition O
to O
the O
treatment O
in O
the O
control O
group. O
[]

The O
effect O
of O
the O
combined O
intervention O
exceeded O
that O
of O
CBT O
or O
Baduanjin O
alone. O
[]

Participants O
were O
randomly-assigned O
to O
receive O
either O
CM O
or O
CHO O
immediately O
post-exercise. O
[]

Journal O
ID: O
9308586 O
[]

Journal O
ID: O
0374675 O
[]

Journal-Name:Medicine O
[]

The O
return O
of O
symmetrical B-outcome ['Physiological-Clinical']
pelvic I-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
(PFM) I-outcome ['Physiological-Clinical']
work O
after O
pelvis O
reposition O
exercise O
was O
observed O
in O
the O
experimental O
group. O
[['Physiological-Clinical']]

Pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
evaluated O
too. O
[['Physiological-Clinical'], ['Adverse-effects']]

Secondary O
outcomes O
included O
components O
of O
the O
primary O
outcome, O
confirmed O
or O
suspected O
late-onset O
sepsis B-outcome ['Physiological-Clinical']
, O
necrotizing B-outcome ['Physiological-Clinical']
enterocolitis I-outcome ['Physiological-Clinical']
, O
and O
cerebral B-outcome ['Physiological-Clinical']
palsy I-outcome ['Physiological-Clinical']
. O
RESULTS: O
Among O
2804 O
infants O
who O
underwent O
randomization, O
the O
primary O
outcome O
could O
be O
assessed O
in O
1224 O
(87.4%) O
assigned O
to O
the O
faster O
increment O
and O
1246 O
(88.7%) O
assigned O
to O
the O
slower O
increment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

METHOD: O
59 O
patients O
operated O
for O
spinal O
deformity O
(Lenke O
1 O
or O
2) O
AIS. O
[]

Title: O
Effectiveness O
of O
routine O
third O
trimester O
ultrasonography O
to O
reduce O
adverse B-outcome ['Adverse-effects']
perinatal I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
in O
low O
risk O
pregnancy O
(the O
IRIS O
study): O
nationwide, O
pragmatic, O
multicentre, O
stepped O
wedge O
cluster O
randomised O
trial. O
[['Adverse-effects']]

Complete O
diet O
collections O
were O
analyzed O
for O
nitrogen O
(for O
protein), O
fat, O
energy, O
and O
carbohydrate O
by O
difference. O
[]

Title: O
Effectiveness O
of O
Bazhengsan O
formula O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
for O
female O
patients O
with O
uncomplicated O
gonorrhea: O
A O
pilot O
study. O
[]

Mean O
change O
in O
cry B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
fuss B-outcome ['Life-Impact', 'Life-Impact']
time E1-outcome ['Life-Impact', 'Life-Impact']
from O
day O
0 O
through O
day O
28 O
was O
-163 O
(99) O
minutes O
in O
the O
probiotic O
and O
-116 O
(94) O
minutes O
in O
the O
control O
group O
(p O
= O
0.019). O
[['Life-Impact', 'Life-Impact']]

Mitochondrial B-outcome ['Physiological-Clinical']
fragmentation I-outcome ['Physiological-Clinical']
was O
specifically O
presented O
in O
tubules, O
but O
not O
in O
podocytes O
of O
DKD O
patients. O
[['Physiological-Clinical']]

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O
[]

All O
other O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
observed O
during O
the O
test O
period O
were O
resolved O
completely O
without O
special O
treatment. O
[['Adverse-effects']]

RESULTS: O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
(LVEF) I-outcome ['Physiological-Clinical']
decreased O
from O
62+/-5% O
at O
baseline O
to O
58+/-7% O
at O
6-months O
(p=0.002) O
in O
patients O
assigned O
to O
placebo O
but O
no O
statistically O
significant O
changes O
were O
observed O
in O
any O
of O
the O
3 O
carvedilol O
groups. O
[['Physiological-Clinical']]

However, O
there O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
for O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
(5.0 O
vs. O
4.0 O
months; O
HR O
= O
1.03; O
95% O
CI, O
0.56-1.90; O
P O
= O
.914). O
[['Mortality']]

Endothelial B-outcome ['Physiological-Clinical']
Cell I-outcome ['Physiological-Clinical']
Density I-outcome ['Physiological-Clinical']
(ECD) I-outcome ['Physiological-Clinical']
, O
coefficient O
of O
variation, O
and O
percentage O
of O
hexagonal B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
evaluated O
by O
a O
central O
image O
analysis O
reading O
center O
and O
central B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
(CCT) I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
ultrasound O
pachymetry. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/27 O
06:00 O
[medline] O
[]

CONCLUSIONS: O
The O
application O
of O
OPEP O
device O
during O
the O
perioperative O
period O
was O
valuable O
in O
decreasing O
pulmonary B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
and O
enhancing O
recovery B-outcome ['Physiological-Clinical']
for O
lung O
cancer O
patients O
receiving O
VATS O
lobectomy. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
['2019/10/17 O
06:00' O
[]

This O
anatomically O
high-fidelity O
simulator O
did O
not O
have O
any O
advantages O
compared O
with O
conventional O
dry O
simulators. O
[]

Tafenoquine O
is O
a O
single-dose O
8-aminoquinoline O
that O
has O
recently O
been O
registered O
for O
the O
radical O
cure O
of O
P. O
vivax. O
[]

BACKGROUND: O
This O
study O
assessed O
the O
effectiveness O
and O
safety O
of O
ultrasound-guided O
pulsed O
radiofrequency O
(UGPRF) O
for O
patients O
with O
frozen O
shoulder O
(FS). O
[]

Funded O
by O
the O
National O
Cancer O
Institute O
and O
others; O
ClinicalTrials.gov O
number, O
NCT02066181 O
.). O
[]

Title: O
Preventive O
effect O
of O
ecabet O
sodium O
on O
low-dose O
aspirin-induced O
small B-outcome ['Physiological-Clinical']
intestinal I-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
: O
a O
randomized, O
double-blind, O
pilot O
study. O
[['Physiological-Clinical']]

As O
a O
result O
of O
better O
wound O
healing B-outcome ['Physiological-Clinical']
, O
the O
EMD-added O
group O
exhibited O
better O
results O
in O
terms O
of O
the O
harmony B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the O
mucogingival O
junction O
between O
adjacent O
teeth O
. O
This O
paper O
is O
the O
first O
split-mouth O
study O
in O
which O
SCTG+CAF O
and O
SCTG+CAF+EMD O
were O
compared O
using O
RES O
in O
bilateral O
canines. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Nutrients O
[]

PMID: O
31619437 O
[]

None O
of O
the O
findings O
that O
favored O
the O
comparison O
area O
were O
statistically O
significant. O
[]

Secondary O
outcomes O
were O
from O
start O
of O
the O
propofol O
infusion O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
(LOC) I-outcome ['Physiological-Clinical']
, O
rocuronium B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Bispectral I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BIS) I-outcome ['Physiological-Clinical']
60 I-outcome ['Physiological-Clinical']
, O
and O
hemodynamic B-outcome ['Physiological-Clinical']
variables. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Journal O
ID: O
100968562 O
[]

CONCLUSIONS: O
Lacunar O
infarction O
of O
SAI O
have O
lower O
risk O
of O
stroke B-outcome ['Physiological-Clinical']
recurrence O
than O
MAIs, O
while O
non-lacunar O
infarction O
of O
SAI O
might O
have O
similar O
risk O
as O
MAIs. O
[['Physiological-Clinical']]

For O
observed O
pain B-outcome ['Physiological-Clinical']
, O
ANOVA O
results O
did O
show O
a O
significant O
interaction O
(p O
< O
.05) O
between O
group O
and O
study O
interval. O
[['Physiological-Clinical']]

Journal O
ID: O
0255562 O
[]

Title: O
Novel O
Tretinoin O
0.05% O
Lotion O
for O
Once-Daily O
Treatment O
of O
Moderate-to-Severe O
Acne O
Vulgaris O
in O
a O
Hispanic O
Population O
[]

Balozis O
were O
randomly O
assigned O
to O
the O
intervention O
and O
control O
arms. O
[]

In O
this O
randomized, O
prospective O
trial, O
we O
explore O
differences O
in O
live B-outcome ['Mortality']
birth I-outcome ['Mortality']
rates O
and O
incidence O
of O
ovarian B-outcome ['Physiological-Clinical']
hyperstimulation I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
(OHSS) I-outcome ['Physiological-Clinical']
in O
high-responder O
patients O
undergoing O
in O
vitro O
fertilization O
(IVF) O
receiving O
low O
dose O
hCG O
at O
the O
time O
of O
GnRH-agonist O
(dual O
trigger) O
or O
hCG O
adjuvant O
at O
the O
time O
of O
oocyte O
retrieval. O
[['Mortality'], ['Physiological-Clinical']]

Common O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
included O
nasopharyngitis B-outcome ['Physiological-Clinical']
, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
diarrhea B-outcome ['Physiological-Clinical']
. O
Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
6 O
patients O
who O
received O
givosiran O
in O
parts O
A O
through O
C O
combined. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Journal O
ID: O
0417355 O
[]

Objective: O
To O
investigate O
effects O
of O
two O
anesthesia O
methods O
on O
the O
first O
night O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
in O
middle-aged O
and O
elderly O
patients O
after O
surgery. O
[['Physiological-Clinical']]

CONCLUSIONS: O
Phacoemulsification O
in O
eyes O
with O
mild-to-moderate O
primary O
open-angle O
glaucoma O
results O
in O
early O
endothelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
loss O
(ECL), O
with O
Endothelial B-outcome ['Physiological-Clinical']
Cell I-outcome ['Physiological-Clinical']
Density I-outcome ['Physiological-Clinical']
(ECD) I-outcome ['Physiological-Clinical']
stabilizing O
after O
3 O
months O
and O
no O
effect O
on O
other O
endothelial B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
markers O
up O
to O
2 O
years O
postoperatively. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/22 O
06:00 O
[medline] O
[]

Publication O
date: O
2018/08/29 O
00:00 O
[accepted] O
[]

Publication O
Type: O
Journal O
Article O
[]

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
such O
as O
acute B-outcome ['Physiological-Clinical']
appendicitis I-outcome ['Physiological-Clinical']
and O
acute B-outcome ['Physiological-Clinical']
viral I-outcome ['Physiological-Clinical']
gastroenteritis I-outcome ['Physiological-Clinical']
were O
observed O
in O
the O
BT-11 O
group4 O
and O
the O
placebo O
group, O
respectively. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Safety, O
pharmacokinetic, O
pharmacodynamic, O
and O
exploratory O
efficacy O
outcomes O
were O
evaluated. O
[]

MATERIAL O
AND O
METHODS: O
The O
safety O
was O
evaluated O
in O
randomly O
assigned O
subjects O
who O
received O
the O
test O
products O
(61 O
subjects O
in O
BT-11 O
300mg O
daily O
or O
60 O
subjects O
in O
matching O
placebo) O
for O
12 O
weeks. O
[]

METHODS: O
In O
this O
double-blind, O
randomized O
trial O
involving O
high-risk O
ambulatory O
patients O
with O
cancer O
(Khorana O
score O
of O
>/=2, O
on O
a O
scale O
from O
0 O
to O
6, O
with O
higher O
scores O
indicating O
a O
higher O
risk O
of O
venous O
thromboembolism), O
we O
randomly O
assigned O
patients O
without O
deep-vein O
thrombosis O
at O
screening O
to O
receive O
rivaroxaban O
(at O
a O
dose O
of O
10 O
mg) O
or O
placebo O
daily O
for O
up O
to O
180 O
days, O
with O
screening O
every O
8 O
weeks. O
[]

Secondary O
outcomes O
included O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
duration I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
cognitive B-outcome ['Life-Impact']
decline I-outcome ['Life-Impact']
, O
breakthrough O
analgesia B-outcome ['Resource-use']
within O
the O
first O
48 O
hours, O
and O
ICU B-outcome ['Resource-use']
and O
hospital O
length O
of O
stay O
. O
Results: O
Among O
121 O
patients O
randomized O
(median O
age, O
69 O
years; O
19 O
women O
[15.8%]), O
120 O
completed O
the O
trial. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Resource-use'], ['Resource-use']]

Title: O
A O
randomized-controlled O
trial O
pilot O
study O
examining O
the O
effect O
of O
extracorporeal O
magnetic O
innervation O
in O
the O
treatment O
of O
stress O
urinary O
incontinence O
in O
women. O
[]

Journal O
ID: O
0255562 O
[]

Journal-Name:The O
Lancet. O
[]

Journal O
ID: O
2985248R O
[]

Group O
A O
(n O
= O
53) O
was O
the O
single-shot O
group O
(16 O
female O
patients O
and O
37 O
male O
patients O
with O
a O
mean O
age O
of O
63.9 O
years O
(sd O
9.6)), O
group O
B O
(n O
= O
51) O
was O
the O
24-hour O
infusion O
group O
(22 O
female O
patients O
and O
29 O
male O
patients O
with O
a O
mean O
age O
of O
66.5 O
years O
(sd O
8.5)), O
and O
group O
C O
(n O
= O
52) O
was O
the O
48-hour O
infusion O
group O
(18 O
female O
patients O
and O
34 O
male O
patients O
with O
a O
mean O
age O
of O
62.2 O
years O
(sd O
8.7)). O
[]

Omadacycline O
was O
noninferior O
to O
moxifloxacin O
for O
early O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
(81.1% O
and O
82.7%, O
respectively; O
difference, O
-1.6 O
percentage O
points; O
95% O
confidence O
interval O
[CI], O
-7.1 O
to O
3.8), O
and O
the O
rates O
of O
investigator-assessed O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
the O
post-treatment O
evaluation O
were O
87.6% O
and O
85.1%, O
respectively O
(difference, O
2.5 O
percentage O
points; O
95% O
CI, O
-2.4 O
to O
7.4). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

OBJECTIVE: O
To O
evaluate O
performance B-outcome ['Life-Impact']
on O
a O
computer O
task O
in O
individuals O
with O
ALS O
using O
three O
different O
commonly O
used O
non-immersive O
devices. O
[['Life-Impact']]

Knee B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
was O
assessed O
using O
HSS, O
KSS, O
NASS, O
and O
ROM. O
[['Life-Impact']]

Journal-Name:Nan O
fang O
yi O
ke O
da O
xue O
xue O
bao O
= O
Journal O
of O
Southern O
Medical O
University O
[]

Title: O
Announcing O
the O
availability O
of O
oral O
HIV O
self-test O
kits O
via O
text O
message O
to O
increase O
HIV O
testing O
among O
hard-to-reach O
truckers O
in O
Kenya: O
a O
randomized O
controlled O
trial. O
[]

PMID: O
31613945 O
[]

Publication O
date: O
2019/01/29 O
06:00 O
[entrez] O
[]

Further O
studies O
are O
needed O
to O
determine O
whether O
multiple O
arterial O
grafts O
provide O
better O
outcomes O
than O
a O
single O
internal-thoracic-artery O
graft. O
( O
[]

Conclusions: O
Tretinoin O
0.05% O
lotion O
was O
significantly O
more O
effective O
than O
its O
vehicle O
in O
achieving O
treatment B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
and O
reducing O
inflammatory O
and O
noninflammatory O
acne O
lesions B-outcome ['Physiological-Clinical']
in O
a O
Hispanic O
population. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Child O
engagement: O
enjoyment O
and O
positive O
behaviour. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrials.gov O
NCT02323412. O
[]

Title: O
Prophylactic O
use O
of O
carvedilol O
to O
prevent O
ventricular B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
in O
patients O
with O
cancer O
treated O
with O
doxorubicin. O
[['Physiological-Clinical']]

In O
the O
prespecified O
intervention-period O
analysis, O
the O
primary O
end O
point O
occurred O
in O
11 O
patients O
(2.6%) O
in O
the O
rivaroxaban O
group O
and O
in O
27 O
(6.4%) O
in O
the O
placebo O
group O
(hazard O
ratio, O
0.40; O
95% O
CI, O
0.20 O
to O
0.80). O
[]

Journal-Name: O
Journal O
of O
computer O
assisted O
tomography O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
Myocarditis B-outcome ['Physiological-Clinical']
, O
encephalopathy B-outcome ['Physiological-Clinical']
, O
cardiogenic B-outcome ['Physiological-Clinical']
shock I-outcome ['Physiological-Clinical']
, O
ICU B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
, O
need B-outcome ['Resource-use']
for O
mechanical O
ventilation O
, O
mean O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
mortality B-outcome ['Mortality']
were O
significantly O
lower O
in O
those O
received O
intravenous O
antivenom O
compared O
with O
those O
received O
intramuscular O
one. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Resource-use'], ['Mortality']]

CONCLUSION: O
The O
use O
of O
colorings O
in O
eye O
drops O
can O
help O
distinguishing O
the O
vials O
and O
preventing O
misidentification B-outcome ['Life-Impact']
. O
[['Life-Impact']]

5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
relapse-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
, O
and O
non-relapse B-outcome ['Physiological-Clinical', 'Mortality']
mortality I-outcome ['Physiological-Clinical', 'Mortality']
did O
not O
differ O
significantly O
between O
groups. O
[['Mortality'], ['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical', 'Mortality']]

Publication O
date: O
2018/12/14 O
06:00 O
[pubmed] O
[]

CONCLUSIONS: O
Ologen(R) O
implant O
improved O
the O
success B-outcome ['Physiological-Clinical']
rate O
of O
phaco-viscocanalostomy. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

Web-based O
randomisation O
minimised O
for O
recruitment O
site, O
gestation O
(completed O
weeks), O
sex, O
and O
single O
versus O
multifetal O
pregnancy. O
[]

METHODS: O
This O
2-arm O
randomized O
controlled O
trial O
(RCT) O
enrolled O
86 O
eligible O
patients O
with O
CUR O
following O
TBI. O
[]

Journal O
ID: O
2985248R O
[]

All O
patients O
received O
sufentanil O
(0.3 O
mug/kg) O
30 O
min O
before O
the O
end O
of O
the O
operation O
and O
then O
received O
intravenous O
analgesia O
pump O
for O
postoperative O
patient O
controlled O
analgesia(PCA). O
[]

TRIAL O
REGISTRATION: O
WISDOM O
(ClinicalTrials.gov O
number, O
NCT00975195 O
). O
[]

Title: O
A O
Double-Blind O
Placebo-Controlled O
Randomized O
Trial O
Evaluating O
the O
Effect O
of O
Polyphenol-Rich O
Herbal O
Congee O
on O
Bone B-outcome ['Physiological-Clinical']
Turnover I-outcome ['Physiological-Clinical']
Markers O
of O
the O
Perimenopausal O
and O
Menopausal O
Women. O
[['Physiological-Clinical']]

Journal-Name:Progress O
in O
community O
health O
partnerships O
: O
research, O
education, O
and O
action O
[]

The O
first B-outcome ['Life-Impact']
out-of-bed I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
first B-outcome ['Physiological-Clinical']
anus I-outcome ['Physiological-Clinical']
exhaust I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
time I-outcome ['Resource-use']
of O
the O
parecoxib O
+ O
TAP O
group O
were O
significantly O
shorter O
than O
those O
of O
the O
other O
groups, O
while O
the O
control O
group O
was O
all O
significantly O
higher O
than O
the O
other O
groups. O
[['Life-Impact'], ['Physiological-Clinical'], ['Resource-use']]

A O
total O
of O
37 O
patients O
(36%) O
in O
the O
hybrid-procedure O
group O
had O
a O
major O
intraoperative O
or O
postoperative O
complication B-outcome ['Adverse-effects']
, O
as O
compared O
with O
67 O
(64%) O
in O
the O
open-procedure O
group O
(odds O
ratio, O
0.31; O
95% O
confidence O
interval O
[CI], O
0.18 O
to O
0.55; O
P<0.001). O
[['Adverse-effects']]

The O
subjects O
in O
D1 O
and O
D2 O
groups O
must O
consume O
the O
congee O
containing O
the O
combined O
extract O
of O
M. O
alba O
and O
P. O
odoratum O
leaves O
at O
doses O
of O
50 O
and O
1500 O
mg/day, O
respectively. O
[]

Two O
operative O
procedures O
were O
evaluated; O
a O
fascia O
lata O
allograft O
and O
an O
autologous O
gracilis O
graft. O
[]

Publication O
date: O
2018/09/01 O
00:00 O
[accepted] O
[]

No O
further O
group O
differences O
were O
found. O
[]

MATERIALS O
AND O
METHODS: O
We O
included O
88 O
patients O
with O
a O
stable O
form O
of O
CHD, O
who O
were O
going O
to O
pass O
the O
elective O
PCI, O
in O
the O
study. O
[]

This O
study O
therefore O
aimed O
to O
assess O
whether O
a O
short-term O
LOWFODMAP O
diet O
improved O
exercise-related O
GI B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
the O
perceived O
ability B-outcome ['Life-Impact']
to O
exercise O
in O
recreational O
runners. O
[['Physiological-Clinical'], ['Life-Impact']]

Participants O
were O
divided O
into O
groups O
that O
received O
16 O
weeks O
of O
either O
usual O
care O
or O
exercise O
intervention. O
[]

Implants, O
titanium O
abutments, O
and O
provisional O
crowns O
were O
placed O
in O
healed O
ridges O
5 O
months O
following O
preservation O
after O
tooth O
extraction O
with O
recombinant O
human O
bone O
morphogenetic O
protein-2 O
(rhBMP-2). O
[]

Overall, O
throat B-outcome ['Physiological-Clinical']
or O
mouth O
irritation O
was O
reported O
more O
frequently O
in O
the O
e-cigarette O
group O
(65.3%, O
vs. O
51.2% O
in O
the O
nicotine-replacement O
group) O
and O
nausea B-outcome ['Physiological-Clinical']
more O
frequently O
in O
the O
nicotine-replacement O
group O
(37.9%, O
vs. O
31.3% O
in O
the O
e-cigarette O
group). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Five O
of O
7 O
household O
behaviors O
judged O
to O
be O
amenable O
to O
promotion O
by O
CHWs O
improved O
more O
in O
the O
intervention O
area O
than O
in O
the O
comparison O
area, O
and O
2 O
out O
of O
the O
5 O
were O
statistically O
significant O
(feeding O
colostrum O
and O
appropriate O
infant O
and O
young O
child O
feeding). O
[]

One O
patient O
in O
the O
gemcitabine O
group O
died B-outcome ['Mortality']
from O
toxic B-outcome ['Adverse-effects']
effects O
( O
interstitial B-outcome ['Physiological-Clinical']
pneumonitis I-outcome ['Physiological-Clinical']
). O
[['Mortality'], ['Adverse-effects'], ['Physiological-Clinical']]

Funded O
by O
Achaogen O
and O
the O
Biomedical O
Advanced O
Research O
and O
Development O
Authority; O
EPIC O
ClinicalTrials.gov O
number, O
NCT02486627.). O
[]

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
efficacy O
and O
safety O
of O
apatinib O
in O
patients O
with O
advanced O
colorectal O
cancer O
for O
whom O
at O
least O
two O
lines O
of O
prior O
chemotherapy O
had O
failed. O
[]

Publication O
Type: O
Journal O
Article O
[]

Title: O
A O
randomized O
trial O
of O
trigger O
point O
dry O
needling O
versus O
sham O
needling O
for O
chronic O
tension-type O
headache. O
[]

The O
mean O
value O
of O
all O
measured O
hematology B-outcome ['Physiological-Clinical']
variables O
remained O
within O
the O
reference O
values O
in O
all O
study O
subject O
and O
no O
significant O
changes O
were O
observed O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
lipid B-outcome ['Physiological-Clinical']
values. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Hydrocephalus O
is O
a O
common O
condition O
associated O
with O
myelomeningocele. O
[]

Publication O
date: O
2019/02/27 O
06:00 O
[medline] O
[]

MBCT O
as O
an O
evidence-based O
psychotherapeutic O
intervention O
and O
Mindfulness-Based O
Intervention O
(MBI), O
is O
an O
8-week O
course O
developed O
for O
patients O
with O
relapsing O
depression O
that O
integrates O
mindfulness O
meditation O
practices O
and O
cognitive O
therapy. O
[]

Journal O
ID: O
7501160 O
[]

There O
was O
no O
significant O
difference O
in O
the O
degree O
of O
injured O
vertebra B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
at O
immediate O
after O
operation O
( O
P>0.05), O
but O
which O
was O
significantly O
higher O
in O
the O
control O
group O
than O
that O
in O
the O
treatment O
group O
at O
last O
follow-up O
( O
P<0.05). O
[['Physiological-Clinical']]

Journal-Name:Nutrients O
[]

This O
study O
evaluated O
the O
effectiveness O
of O
two-dose O
versus O
three-dose O
of O
SP O
for O
IPTp-SP O
in O
the O
prevention O
of O
low B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
(LBW) I-outcome ['Physiological-Clinical']
and O
malaria B-outcome ['Physiological-Clinical']
parasitaemia I-outcome ['Physiological-Clinical']
. O
Methods: O
: O
An O
open, O
randomized, O
controlled, O
longitudinal O
trial O
was O
conducted O
in O
a O
secondary O
level O
hospital O
in O
Nsukka O
region O
of O
Enugu O
State, O
Nigeria. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS: O
An O
overall O
treatment O
effect O
(p O
= O
0.019) O
was O
evident O
for O
increased O
hits B-outcome ['Life-Impact']
with O
PSE O
on O
the O
stationary O
test O
with O
footplates, O
with O
between O
group O
differences O
at O
Day O
30 O
(PSE O
vs. O
PLA: O
28.96 O
+/- O
2.08 O
vs. O
28.09 O
+/- O
1.92 O
hits; O
p O
= O
0.040) O
and O
Day O
90 O
(PSE O
vs. O
PLA: O
28.42 O
+/- O
2.54 O
vs. O
27.02 O
+/- O
3.55 O
hits; O
p O
= O
0.002). O
[['Life-Impact']]

Fatal B-outcome ['Mortality', 'Adverse-effects']
adverse I-outcome ['Mortality', 'Adverse-effects']
events I-outcome ['Mortality', 'Adverse-effects']
occurred O
in O
seven O
(3%) O
patients O
in O
the O
A+CHP O
group O
and O
nine O
(4%) O
in O
the O
CHOP O
group. O
[['Mortality', 'Adverse-effects']]

Publication O
date: O
2019/01/09 O
06:00 O
[entrez] O
[]

Publication O
date: O
2019/02/26 O
06:00 O
[medline] O
[]

Journal-Name:Reproductive O
health O
[]

Secondary O
outcomes O
included O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
determined O
on O
the O
basis O
of O
clinical O
judgment, O
infection O
from O
any O
cause, O
and O
infection-related O
hospitalization. O
[['Physiological-Clinical']]

RESULTS: O
The O
expression O
level O
of O
sterol B-outcome ['Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical']
element-binding I-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
was O
higher O
in O
PCOS O
patients O
than O
that O
in O
the O
healthy O
control. O
[['Physiological-Clinical']]

In O
part O
C, O
all O
6 O
patients O
who O
were O
assigned O
to O
receive O
once-monthly O
injections O
of O
givosiran O
had O
sustained O
reductions O
in O
ALAS1 B-outcome ['Physiological-Clinical']
messenger I-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
(mRNA) I-outcome ['Physiological-Clinical']
, O
delta B-outcome ['Physiological-Clinical']
aminolevulinic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
and O
porphobilinogen B-outcome ['Physiological-Clinical']
levels O
to O
near O
normal. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

No O
significant O
ToP O
item O
changes O
were O
found O
in O
the O
conventional O
group. O
[]

Journal O
ID: O
101225531 O
[]

CONCLUSION: O
This O
study O
does O
not O
support O
the O
use O
of O
TENS O
in O
the O
treatment O
of O
patients O
with O
chronic O
LBP O
even O
though O
patients O
benefited O
from O
a O
therapeutic O
education O
program O
by O
a O
pain O
resource O
nurse. O
[]

Vaccination O
coverage O
will O
be O
assessed O
at O
3-years O
of O
age, O
thus O
the O
trial O
is O
expected O
to O
be O
completed O
in O
March O
2019. O
[]

Pilot O
study. O
[]

Furthermore, O
trends O
for O
sex O
differences O
were O
discovered O
in O
urinary, O
but O
not O
salivary, O
hydration B-outcome ['Physiological-Clinical']
markers, O
with O
discrepancies O
in O
kinetics O
between O
fluid O
compartments O
both O
warranting O
further O
study. O
[['Physiological-Clinical']]

Publication O
Type: O
Observational O
Study O
[]

Journal-Name:Nutrients O
[]

Intravenous O
boluses O
of O
50 O
mug O
were O
administered O
for O
breakthrough O
pain. O
[]

Journal-Name:BMC O
public O
health O
[]

Reduction O
in O
serum O
hydroxymethylglutaryl-CoA B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
(HMGCR) I-outcome ['Physiological-Clinical']
levels O
was O
comparable O
in O
both O
the O
groups O
(31.17% O
vs O
28.19%). O
[['Physiological-Clinical']]

The O
increase O
in O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
was O
parallel O
to O
the O
improvement O
of O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
parameters. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Results O
will O
be O
adapted O
and O
shared O
with O
all O
stakeholders. O
[]

The O
task O
used O
in O
this O
study O
was O
the O
Tube O
2 O
and O
it O
imitates O
a O
vesicourethral O
anastomosis O
in O
robotic O
prostatectomy. O
[]

APN O
and O
AdipoR1 O
levels O
may O
influence O
glucose O
and O
lipid O
metabolism O
in O
T2DM O
patients. O
[]

METHODOLOGY: O
In O
total, O
237 O
samples O
were O
analysed O
from O
28 O
DFUs, O
collected O
at O
fortnightly O
intervals O
for O
6 O
months O
or O
until O
healing. O
[]

The O
primary O
end O
point O
was O
an O
early O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
48 O
to O
72 O
hours, O
defined O
as O
survival B-outcome ['Mortality']
with O
a O
reduction O
in O
lesion B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
of O
at O
least O
20% O
without O
rescue B-outcome ['Resource-use']
antibacterial I-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
. O
A O
secondary O
end O
point O
was O
an O
investigator-assessed O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
the O
post-treatment O
evaluation O
7 O
to O
14 O
days O
after O
the O
last O
dose, O
with O
clinical O
response O
defined O
as O
survival B-outcome ['Mortality']
with O
resolution O
or O
improvement O
in O
signs B-outcome ['Physiological-Clinical']
or O
symptoms O
of O
infection O
to O
the O
extent O
that O
further O
antibacterial O
therapy O
was O
unnecessary. O
[['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical']]

Journal-Name:Einstein O
(Sao O
Paulo, O
Brazil) O
[]

Interventions: O
Participants O
were O
randomly O
assigned O
to O
treatment O
with O
placebo O
(n O
= O
151), O
alteplase O
10 O
mg O
(n O
= O
144), O
or O
alteplase O
20 O
mg O
(n O
= O
145) O
by O
manual O
infusion O
over O
5 O
to O
10 O
minutes. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
2985248R O
[]

Qualitative O
data O
was O
analyzed O
using O
thematic O
analysis. O
[]

Publication O
date: O
2019/02/13 O
06:00 O
[entrez] O
[]

BACKGROUND: O
This O
study O
investigated O
the O
effectiveness O
and O
safety O
of O
exercise O
training O
(ET) O
as O
an O
adjunctive O
therapy O
to O
montelukast O
for O
children O
with O
mild O
asthma O
(MA). O
[]

Publication O
date: O
['2019/10/16 O
06:00' O
[]

This O
was O
a O
post O
hoc O
investigation O
of O
serum O
noggin B-outcome ['Physiological-Clinical']
levels O
among O
TDT O
patients O
with O
osteoporosis O
who O
participated O
in O
a O
randomized, O
placebo-control, O
phase O
2b O
study. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Blood O
samples O
were O
obtained O
from O
the O
antecubital O
vein O
before O
each O
exercise O
test, O
1 O
min O
after O
completing O
the O
test, O
and O
after O
a O
24-h O
recovery. O
[]

In O
IHE O
only, O
post-exercise O
Tre B-outcome ['Physiological-Clinical']
and O
perceptual B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
at O
Post O
HA O
and O
+25d O
were O
lower O
than O
Pre O
HA O
(p</=0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
['2019/10/10 O
06:00' O
[]

However, O
higher O
frequencies O
of O
all O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
were O
consistently O
observed O
in O
the O
control O
group. O
[['Adverse-effects']]

BACKGROUND: O
Multiple O
arterial O
grafts O
may O
result O
in O
longer O
survival O
than O
single O
arterial O
grafts O
after O
coronary-artery O
bypass O
grafting O
(CABG) O
surgery. O
[]

Before O
clinicians O
can O
advocate O
PC O
as O
an O
EHS O
prevention O
strategy, O
it O
must O
effectively O
mitigate O
factors O
associated O
with O
EHS O
development O
while O
not O
lessening O
the O
effectiveness O
of O
EHS O
treatment. O
[]

Journal-Name:Zhonghua O
liu O
xing O
bing O
xue O
za O
zhi O
= O
Zhonghua O
liuxingbingxue O
zazhi O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Effects O
of O
selenium O
supplementation O
on O
pregnancy B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
and O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
HIV-infected O
pregnant O
women O
in O
Lagos, O
Nigeria: O
Study O
protocol O
for O
a O
randomised, O
double-blind, O
placebo-controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
capacity O
of O
HMCs O
and O
WDCs O
to O
engage O
with O
the O
local O
health O
system O
was O
also O
measured O
at O
baseline O
and O
endline. O
[]

Cumulative O
incidence O
and O
relative O
risks O
with O
95% O
confidence O
intervals O
for O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
, O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
, O
and O
metastasis B-outcome ['Physiological-Clinical']
were O
estimated O
in O
intention-to-treat O
and O
per-protocol O
analyses, O
and O
numbers O
of O
years O
of O
life O
gained O
were O
estimated. O
[['Mortality'], ['Mortality'], ['Physiological-Clinical']]

BACKGROUND: O
We O
aimed O
to O
assess O
whether O
an O
ultrasound O
(US)-guided O
oblique O
subcostal O
transversus O
abdominis O
plane O
(OSTAP) O
block O
would O
improve O
the O
postoperative O
pain B-outcome ['Physiological-Clinical']
scores O
and O
decrease O
the O
tramadol B-outcome ['Resource-use']
consumption O
after O
a O
laparoscopic O
hysterectomy. O
[['Physiological-Clinical'], ['Resource-use']]

PURPOSE: O
Trachoma, O
caused O
by O
repeated O
ocular O
infection O
with O
Chlamydia O
trachomatis, O
is O
the O
leading O
infectious O
cause O
of O
blindness O
worldwide O
and O
is O
targeted O
for O
elimination O
as O
a O
public O
health O
problem. O
[]

This O
effect O
may O
not O
be O
dose O
related O
within O
the O
studied O
range. O
[]

The O
primary O
outcome O
was O
total O
induction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
based O
on O
the O
order O
of O
remifentanil O
administration. O
[['Life-Impact']]

Publication O
date: O
2019/02/15 O
06:00 O
[medline] O
[]

Publication O
date: O
2018/11/21 O
00:00 O
[accepted] O
[]

Patients O
in O
the O
chronomodulated O
chemotherapy O
group O
(n O
= O
30, O
CC O
group) O
received O
cisplatin O
at O
80 O
mg/m(2) O
through O
intravenous O
infusion O
from O
10:00 O
to O
22:00 O
and O
5-fluorouracil O
(5-FU) O
at O
1000 O
mg/m(2) O
plus O
citrovorum O
factor O
at O
200 O
mg/m(2) O
from O
22:00 O
to O
10:00 O
each O
day O
for O
3 O
days. O
[]

These O
metabolites B-outcome ['Physiological-Clinical']
and O
metabolic B-outcome ['Physiological-Clinical']
pathways O
represent O
an O
acute O
response O
to O
increased O
navy O
bean O
intake, O
which O
merit O
further O
investigation O
for O
improving O
colonic O
health O
after O
long-term O
consumption. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

It O
builds O
on O
an O
existing O
program O
of O
mental O
health O
research O
with O
demonstrated O
efficacy O
- O
the O
Aboriginal O
and O
Islander O
Mental O
Health O
Initiative O
(AIMhi) O
- O
to O
test O
the O
newly O
developed O
electronic O
motivational O
care O
planning O
(MCP) O
therapy O
- O
the O
AIMhi O
Stay O
Strong O
App. O
[]

Journal O
ID: O
2985213R O
[]

Emphasis O
has O
been O
placed O
on O
TKA O
pain O
management O
for O
postoperative O
care O
and O
during O
rehabilitation. O
[]

SAEs B-outcome ['Adverse-effects']
after O
the O
1st O
and O
2nd O
doses O
were O
reported O
in O
2 O
participants O
and O
1 O
participant, O
respectively, O
but O
none O
was O
assessed O
as O
being O
related O
to O
vaccination. O
[['Adverse-effects']]

OBJECTIVE: O
The O
aim O
of O
the O
present O
study O
was O
to O
observe O
the O
feasibility B-outcome ['Life-Impact']
and O
effect O
of O
cornea O
slice O
acquired O
from O
femtosecond O
laser O
surgery, O
small O
incision O
lenticule O
extraction O
(SMILE) O
as O
patch O
graft O
for O
the O
prevention O
of O
drainage B-outcome ['Physiological-Clinical']
tube I-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
and O
to O
compare O
with O
the O
sclera. O
[['Life-Impact'], ['Physiological-Clinical']]

RESULTS: O
The O
D-group O
increased O
their O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
more O
than O
the O
C-group O
at O
12 O
wk. O
[['Life-Impact']]

Title: O
The O
impact O
of O
an O
exercise O
program O
on O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
older O
breast O
cancer O
survivors O
undergoing O
aromatase O
inhibitor O
therapy: O
a O
randomized O
controlled O
trial. O
[['Life-Impact']]

h(- O
1) O
given O
after O
the O
Observer's O
Assessment O
of O
Alertness B-outcome ['Physiological-Clinical']
/ O
Sedation B-outcome ['Physiological-Clinical']
(OAA/S) O
score O
reached O
2-3. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
research O
sample O
includes O
3489 O
girls, O
with O
about O
25 O
girls O
per O
school O
on O
average. O
[]

Our O
incentive O
level O
may O
have O
been O
too O
low O
to O
incentivise O
change, O
despite O
being O
designed O
a O
priori O
by O
a O
Contingent O
Valuation O
Survey. O
[]

We O
followed O
a O
standard O
general O
anesthetic O
technique, O
with O
endotracheal O
intubation. O
[]

Title: O
The O
acute O
effects O
of O
dietary O
carbohydrate O
reduction O
on O
postprandial O
responses O
of O
non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
: O
a O
randomized O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Journal O
of O
ovarian O
research O
[]

Results: O
Among O
1458 O
enrolled O
patients O
(mean O
[SD] O
age, O
58 O
[16] O
years; O
599 O
women O
[41%]), O
1353 O
(93%) O
completed O
the O
study O
and O
were O
included O
in O
the O
final O
analysis. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/01/05 O
06:00 O
[entrez] O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

In O
addition, O
the O
groups O
were O
dichotomized O
at O
the O
50th O
percentile O
based O
on O
pre-supplementation O
MVIC O
and O
baseline O
HYP. O
[]

Journal O
ID: O
101125284 O
[]

The O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
54.4 O
months O
in O
the O
modified-FOLFIRINOX O
group O
and O
35.0 O
months O
in O
the O
gemcitabine O
group O
(stratified O
hazard O
ratio O
for O
death B-outcome ['Mortality']
, O
0.64; O
95% O
CI, O
0.48 O
to O
0.86; O
P=0.003). O
[['Mortality'], ['Mortality']]

These O
patients O
were O
randomly O
divided O
into O
2 O
groups: O
methylene O
blue O
localization O
group O
(n O
= O
47), O
and O
modified O
localization O
group O
(n O
= O
32), O
where O
the O
patients O
received O
preoperative O
localization O
of O
the O
small O
nodules O
by O
CT-guided O
placing O
wire O
and O
intrapleural O
fibrin O
glue O
near O
the O
nodule O
at O
3 O
days O
before O
the O
operation. O
[]

For O
the O
secondary O
endpoint, O
from O
baseline O
to O
week O
24, O
the O
total O
number O
of O
new O
gadolinium-enhancing B-outcome ['Physiological-Clinical']
(Gd(+)) I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
was O
reduced O
by O
75% O
and O
the O
mean O
number O
of O
new/newly O
enlarging O
T2 B-outcome ['Physiological-Clinical']
hyperintense I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
was O
reduced O
by O
63% O
(both O
p O
< O
0.0001). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

INTERVENTIONS: O
Routine O
care O
(TENS O
group) O
or O
routine O
care O
plus O
a O
therapeutic O
education O
program O
(TENS-TEP O
group) O
based O
on O
consultation O
support O
by O
a O
pain O
resource O
nurse. O
[]

CONCLUSIONS: O
Omadacycline O
was O
noninferior O
to O
linezolid O
for O
the O
treatment O
of O
acute O
bacterial O
skin O
and O
skin-structure O
infections O
and O
had O
a O
similar O
safety O
profile. O
( O
[]

Journal-Name:JSLS O
: O
Journal O
of O
the O
Society O
of O
Laparoendoscopic O
Surgeons O
[]

No O
increase O
in O
second B-outcome ['Physiological-Clinical']
malignancies I-outcome ['Physiological-Clinical']
was O
noted O
with O
ixazomib O
therapy O
(12 O
[3%] O
patients) O
compared O
with O
placebo O
(eight O
[3%] O
patients) O
at O
the O
time O
of O
this O
analysis. O
[['Physiological-Clinical']]

County O
hospital-based O
vision O
centers O
appear O
effective O
in O
delivering O
childrens' O
glasses O
in O
rural O
China. O
[]

Respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
was O
not O
happened O
in O
both O
groups. O
[['Physiological-Clinical']]

The O
primary O
outcome O
was O
sustained O
abstinence B-outcome ['Physiological-Clinical']
for O
1 O
year, O
which O
was O
validated O
biochemically O
at O
the O
final O
visit. O
[['Physiological-Clinical']]

Title: O
The O
effects O
of O
Shilajit O
supplementation O
on O
fatigue-induced O
decreases O
in O
muscular B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
serum O
hydroxyproline B-outcome ['Physiological-Clinical']
levels. O
[['Life-Impact'], ['Physiological-Clinical']]

Compared O
with O
MIIT O
and O
control O
groups, O
HIIT O
showed O
improvements O
in O
the O
SF-36 O
domains: O
general B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
(p<.001 O
for O
both) O
health B-outcome ['Physiological-Clinical']
changes O
(p<.001 O
for O
both), O
vitality B-outcome ['Physiological-Clinical']
(p=.002 O
and O
p=.001 O
respectively) O
and O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
(p=.036 O
and O
p<.001 O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

BACKGROUND: O
The O
management O
of O
complex O
orthopedic O
infections O
usually O
includes O
a O
prolonged O
course O
of O
intravenous O
antibiotic O
agents. O
[]

Overall, O
the O
group O
(n O
= O
24) O
had O
a O
median O
score O
of O
0 O
(lowest O
item O
score) O
on O
nine O
of O
24 O
Test O
of O
Playfulness B-outcome ['Life-Impact']
(ToP) O
items O
and O
only O
had O
a O
median O
score O
of O
3 O
(highest O
score) O
on O
two O
items. O
[['Life-Impact']]

Treatment B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
was O
achieved O
by O
19.6% O
of O
subjects O
by O
week O
12, O
compared O
with O
12.7% O
on O
vehicle O
(P=0.015). O
[['Physiological-Clinical']]

The O
human O
immunodeficiency O
virus O
(HIV) O
and O
resulting O
progressive O
HIV O
encephalopathy O
(PHE) O
is O
a O
pandemic O
in O
this O
area, O
associated O
with O
development O
delays O
that O
are O
not O
addressed O
by O
highly O
active O
antiretroviral O
treatment O
(HAART). O
[]

Journal-Name:BMC O
public O
health O
[]

METHODS: O
We O
randomly O
assigned O
very O
preterm O
or O
very-low-birth-weight O
infants O
to O
daily O
milk O
increments O
of O
30 O
ml O
per O
kilogram O
of O
body O
weight O
(faster O
increment) O
or O
18 O
ml O
per O
kilogram O
(slower O
increment) O
until O
reaching O
full O
feeding O
volumes. O
[]

Journal-Name:Zhonghua O
wei O
zhong O
bing O
ji O
jiu O
yi O
xue O
[]

RESULTS: O
In O
the O
primary O
analysis O
of O
the O
total O
cohort O
at O
one O
year, O
the O
difference O
in O
the O
mean O
Roland-Morris O
Disability B-outcome ['Life-Impact']
Questionnaire O
(RMDQ) O
score O
between O
the O
amoxicillin O
group O
and O
the O
placebo O
group O
was O
-1.6 O
(95% O
confidence O
interval O
-3.1 O
to O
0.0, O
P=0.04). O
[['Life-Impact']]

This O
study O
adds O
to O
a O
growing O
body O
of O
research O
showing O
that O
TC O
may O
be O
effective O
in O
treating O
depression O
of O
the O
elderly. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

MATERIALS O
AND O
METHODS: O
Young O
adults O
in O
the O
age O
group O
between O
18 O
and O
25 O
years O
with O
diagnosis O
of O
halitosis O
will O
be O
included O
in O
this O
research. O
[]

Results: O
The O
authors O
compared O
the O
EG O
results O
at O
the O
initial O
and O
final O
assessments O
and O
found O
a O
statistically O
significant O
improvement O
in O
severity O
of O
urinary B-outcome ['Physiological-Clinical']
incontinence I-outcome ['Physiological-Clinical']
(P=0.001) O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
severity O
(P=0.006), O
and O
a O
decrease O
in O
myostatin B-outcome ['Physiological-Clinical']
concentration O
(P</=0.001). O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

This O
study O
aims O
to O
determine O
the O
efficacy O
of O
repeated O
PZQ O
treatments O
against O
Schistosoma B-outcome ['Physiological-Clinical']
mansoni I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
school-aged O
children O
in O
Cote O
d'Ivoire O
using O
the O
traditional O
KK O
technique, O
as O
well O
as O
more O
sensitive O
antigen- O
and O
DNA-detection O
methods. O
[['Physiological-Clinical']]

Patients O
were O
randomly O
assigned O
to O
3 O
groups, O
based O
on O
the O
tube O
ETView O
double-lumen O
tube O
(VDT), O
ETView O
single-lumen O
tube O
(VST), O
or O
traditional O
double O
lumen O
tube O
(DT).All O
83 O
patients' O
intubations O
were O
successful O
to O
achieve B-outcome ['Life-Impact']
1-lung I-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
: O
74 O
patients O
at O
the O
first O
attempt O
(22/26 O
in O
VDT, O
26/28 O
in O
VST, O
26/29 O
in O
DT O
group) O
and O
9 O
patients O
at O
the O
second O
attempt. O
[['Life-Impact']]

After O
an O
anesthetic O
induction, O
bolus O
of O
rocuronium O
0.1 O
mg/kg O
was O
injected O
when O
it O
was O
needed O
(for O
patient O
involuntary B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
or O
at O
the O
request O
of O
the O
surgeon) O
in O
group O
B, O
and O
5 O
mcg/kg/min O
of O
rocuronium O
were O
infused O
in O
group O
I O
study O
participants. O
[['Physiological-Clinical']]

Journal O
ID: O
101566341 O
[]

Gains O
in O
motor B-outcome ['Physiological-Clinical', 'Life-Impact']
function I-outcome ['Physiological-Clinical', 'Life-Impact']
in O
both O
groups O
suggest O
that O
undergoing O
therapy, O
regardless O
of O
its O
type, O
might O
be O
a O
sufficient O
stimulus O
to O
produce O
gains O
when O
intensity O
is O
adequately O
adjusted. O
[['Physiological-Clinical', 'Life-Impact']]

Title: O
Foot O
and O
ankle O
characteristics O
and O
dynamic O
knee O
valgus O
in O
individuals O
with O
patellofemoral O
osteoarthritis. O
[]

The O
primary O
outcome O
was O
objectively O
measured O
mean O
steps/day B-outcome ['Life-Impact']
at O
6 O
months O
using O
a O
validated O
pedometer O
(Yamax O
Digi-Walker O
CW-701) O
over O
7 O
days, O
assessed O
with O
intention O
to O
treat O
analysis. O
[['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSION: O
Both O
drugs O
reduced O
menstrual B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
Ginger O
as O
well O
as O
Novafen O
is O
effective O
in O
relieving O
pain B-outcome ['Physiological-Clinical']
in O
girls O
with O
primary O
dysmenorrhea O
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Similarly, O
no O
clinical O
or O
statistical O
differences O
were O
noted O
for O
skeletal B-outcome ['Physiological-Clinical']
changes: O
ANB B-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
(PT, O
-1.51 O
degrees O
; O
FT, O
-1.25 O
degrees O
; O
P O
= O
0.828; O
95% O
CI, O
-0.68, O
0.849), O
pogonion-sella B-outcome ['Physiological-Clinical']
vertical I-outcome ['Physiological-Clinical']
(PT, O
3.25 O
mm; O
FT, O
3.35 O
mm) O
or O
A-sella B-outcome ['Physiological-Clinical']
vertical I-outcome ['Physiological-Clinical']
(PT, O
1.28 O
mm; O
FT, O
1.06 O
mm). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Conditioning O
regimens O
were O
cyclophosphamide O
120 O
mg/kg O
with O
either O
total O
body O
irradiation O
(12 O
Gy) O
or O
busulfan O
(12.8 O
mg/kg O
intravenously O
or O
16 O
mg/kg O
orally), O
with O
or O
without O
etoposide O
(30-60 O
mg/kg). O
[]

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

Eligible O
participants O
were O
adults O
with O
a O
confirmed O
diagnosis O
of O
symptomatic O
multiple O
myeloma O
according O
to O
International O
Myeloma O
Working O
Group O
criteria O
who O
had O
achieved O
at O
least O
a O
partial O
response O
after O
undergoing O
standard-of-care O
induction O
therapy O
followed O
by O
high-dose O
melphalan O
(200 O
mg/m(2)) O
conditioning O
and O
single O
ASCT O
within O
12 O
months O
of O
diagnosis. O
[]

The O
subjects O
were O
randomly O
assigned O
to O
the O
supplemented O
group O
(n O
= O
10), O
receiving O
150 O
mg O
of O
L-theanine O
extract O
for O
6 O
weeks, O
or O
to O
the O
placebo O
group O
(n O
= O
10). O
[]

Journal O
ID: O
0255562 O
[]

Publication O
date: O
2018/11/14 O
00:00 O
[accepted] O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
therapeutic O
benefits O
of O
soft O
non-manipulative O
osteopathic O
techniques O
in O
patients O
with O
CD. O
[]

Journal O
ID: O
8900488 O
[]

Subgroup O
analysis O
revealed O
that O
there O
were O
no O
differences O
in O
mean O
maximum O
grip O
value O
recovery O
between O
patients O
treated O
with O
rocuronium O
and O
those O
treated O
with O
cisatracurium O
when O
TOFr O
was O
0.7, O
0.8, O
and O
0.9 O
or O
when O
the O
TOFr O
was O
0.25 O
after O
60 O
minutes O
(all O
P O
>.05). O
[]

RESULTS: O
A O
majority O
(71%) O
of O
men O
wanted B-outcome ['Life-Impact']
children I-outcome ['Life-Impact']
in O
the O
future. O
[['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Hyperpigmentation B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
reduced O
progressively O
with O
treatment. O
[['Physiological-Clinical']]

kg(-1).h(-1) O
for O
patients O
in O
group O
D. O
The O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
liquid B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
input I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
output S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
during O
operation, O
the O
number O
of O
patient O
controlled O
analgesia B-outcome ['Resource-use']
(PCA) O
pressings O
after O
operation O
were O
recorded. O
[['Life-Impact'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Resource-use']]

For O
both O
end O
points, O
the O
noninferiority O
margin O
was O
10 O
percentage O
points. O
[]

CONCLUSIONS: O
There O
was O
no O
significant O
difference O
in O
survival B-outcome ['Mortality']
without O
moderate O
or O
severe O
neurodevelopmental B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
at O
24 O
months O
in O
very O
preterm O
or O
very-low-birth-weight O
infants O
with O
a O
strategy O
of O
advancing O
milk O
feeding O
volumes O
in O
daily O
increments O
of O
30 O
ml O
per O
kilogram O
as O
compared O
with O
18 O
ml O
per O
kilogram. O
( O
[['Mortality'], ['Life-Impact']]

Subepithelial O
connective O
tissue O
grafts O
(SCTGs) O
with O
a O
coronally O
advanced O
flap O
(CAF) O
are O
accepted O
as O
the O
gold O
standard O
for O
covering O
denuded O
root O
surfaces. O
[]

At O
6 O
months O
of O
follow O
up, O
few O
patients O
reported O
myalgia B-outcome ['Physiological-Clinical']
(2 O
in O
group O
A O
and O
7 O
in O
Group O
B). O
[['Physiological-Clinical']]

Journal O
ID: O
101521595 O
[]

In O
the O
bilateral-graft O
group, O
13.9% O
of O
the O
patients O
received O
only O
a O
single O
internal-thoracic-artery O
graft, O
and O
in O
the O
single-graft O
group, O
21.8% O
of O
the O
patients O
also O
received O
a O
radial-artery O
graft. O
[]

Title: O
Pathways O
leading O
to O
success O
and O
non-success: O
a O
process O
evaluation O
of O
a O
cluster O
randomized O
physical O
activity O
health O
promotion O
program O
applying O
fuzzy-set O
qualitative O
comparative O
analysis. O
[]

The O
pancreaticoduodectomy B-outcome ['Physiological-Clinical']
rate O
was O
68 O
per O
cent, O
whereas O
27 O
per O
cent O
of O
patients O
underwent O
distal B-outcome ['Physiological-Clinical']
or O
subtotal O
pancreatectomy O
, O
and O
4 O
per O
cent O
total O
pancreatectomy B-outcome ['Physiological-Clinical']
. O
Incisional B-outcome ['Physiological-Clinical']
hernia I-outcome ['Physiological-Clinical']
rates O
were O
32 O
per O
cent O
and O
14 O
per O
cent O
between O
the O
SSD O
and O
NPWT O
groups, O
respectively O
(P O
= O
0.067). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
primary O
efficacy O
endpoint O
was O
measured O
by O
the O
Tinnitus B-outcome ['Physiological-Clinical']
Severity I-outcome ['Physiological-Clinical']
Scale O
(TSS) O
and O
Tinnitus B-outcome ['Physiological-Clinical']
Questionnaire O
(TQ) O
sum O
score. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Effect O
of O
a O
Resuscitation O
Strategy O
Targeting O
Peripheral O
Perfusion O
Status O
vs O
Serum O
Lactate O
Levels O
on O
28-Day O
Mortality B-outcome ['Mortality']
Among O
Patients O
With O
Septic O
Shock: O
The O
ANDROMEDA-SHOCK O
Randomized O
Clinical O
Trial. O
[['Mortality']]

Journal-Name:Pediatric O
physical O
therapy O
: O
the O
official O
publication O
of O
the O
Section O
on O
Pediatrics O
of O
the O
American O
Physical O
Therapy O
Association O
[]

Journal-Name:Indian O
heart O
journal O
[]

Successful B-outcome ['Life-Impact']
spinal I-outcome ['Life-Impact']
anesthesia I-outcome ['Life-Impact']
was O
defined O
as O
a O
T5 O
sensory O
level O
achieved O
within O
10 O
min O
after O
intrathecal O
drug O
administration O
and O
no O
epidural O
supplement O
was O
required O
during O
the O
surgery. O
[['Life-Impact']]

Journal-Name:Revista O
medica O
de O
Chile O
[]

Title: O
The O
Effect O
of O
a O
Multidisciplinary O
Lifestyle O
Intervention O
on O
Obesity B-outcome ['Physiological-Clinical']
Status, O
Body B-outcome ['Physiological-Clinical']
Composition I-outcome ['Physiological-Clinical']
, O
Physical B-outcome ['Physiological-Clinical']
Fitness I-outcome ['Physiological-Clinical']
, O
and O
Cardiometabolic B-outcome ['Physiological-Clinical']
Risk O
Markers O
in O
Children O
and O
Adolescents O
with O
Obesity. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Advanced O
colorectal O
cancer O
patients O
with O
2 O
or O
fewer O
metastatic O
sites O
experienced O
longer O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
than O
those O
with O
more O
than O
2 O
sites. O
[['Physiological-Clinical', 'Mortality']]

The O
contribution O
of O
MAT O
components O
and O
of O
ruminations' O
reduction O
to O
intervention O
efficacy O
were O
examined. O
[]

The O
objective O
of O
this O
study O
was O
to O
evaluate O
a O
mixture O
of O
two O
Lactobacillus O
strains O
in O
decreasing O
infant B-outcome ['Life-Impact', 'Life-Impact']
cry I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
fuss S1-outcome ['Life-Impact', 'Life-Impact']
in O
this O
population. O
[['Life-Impact', 'Life-Impact']]

Follow-up O
period O
was O
2 O
years. O
[]

The O
decrease O
in O
albuminemia B-outcome ['Physiological-Clinical']
had O
a O
direct O
correlation O
with O
CRP O
levels, O
which O
were O
higher O
in O
the O
G1. O
[['Physiological-Clinical']]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

METHODS: O
One O
hundred O
patients O
presented O
to O
the O
emergency O
department O
of O
Assiut O
University O
Children O
Hospital O
with O
a O
history O
of O
scorpion O
sting O
aged O
less O
than O
18 O
years O
were O
included O
in O
our O
randomized O
comparative O
trial O
during O
2016. O
[]

Exploratory O
analyses O
suggested O
that O
variation O
in O
a O
guanosine O
triphosphate O
cyclohydrolase O
gene O
predicted O
association O
with O
higher O
doses B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
methylphenidate I-outcome ['Life-Impact']
(P O
< O
0.001). O
[['Life-Impact']]

These O
occurred O
in O
11 O
of O
207 O
(5.3%), O
18 O
of O
250 O
(7.2%), O
and O
31 O
of O
277 O
(11.2%) O
patients O
exposed O
to O
azithromycin, O
clarithromycin, O
and O
erythromycin O
for O
at O
least O
one O
day, O
and O
in O
9 O
of O
234 O
(3.8%), O
5 O
of O
194 O
(2.6%), O
and O
23 O
of O
566 O
(4.1%) O
exposed O
to O
ciprofloxacin, O
levofloxacin, O
and O
moxifloxacin, O
respectively. O
[]

Journal O
ID: O
8610224 O
[]

The O
LOP O
regimen O
was O
used O
in O
group O
A O
and O
the O
CHOPcyclophosphamide O
+ O
pirarubicin O
+ O
vincristine O
+ O
dexamethasone O
regimen O
was O
used O
in O
group O
B. O
The O
short-term O
efficacy, O
long-term O
efficacy O
and O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
of O
the O
two O
groups O
were O
compared. O
[['Adverse-effects']]

Before O
and O
after O
the O
intervention O
anthropometric B-outcome ['Physiological-Clinical']
parameters, O
serum O
lipid B-outcome ['Physiological-Clinical']
profile, O
serum O
concentrations O
of O
alanine B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
, O
aspartate B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
, O
HOMA-IR B-outcome ['Physiological-Clinical']
(homeostatic O
model O
assessment), O
and O
visceral B-outcome ['Physiological-Clinical']
adiposity I-outcome ['Physiological-Clinical']
index O
(VAI), O
and O
their O
changes O
were O
registered. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

These O
results O
indicate O
that O
polyphenol-rich O
nutrient O
supplementation O
by O
means O
of O
dark O
chocolate O
positively O
modulates O
redox B-outcome ['Physiological-Clinical']
status O
and O
reduced O
exercise-induced O
muscular B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
biomarkers O
in O
elite O
football O
athletes. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Three O
models O
of O
eye-lens O
dosemeters O
(Dosilab, O
Landauer O
and O
IRSN) O
were O
assessed O
in O
term O
of O
ergonomics B-outcome ['Life-Impact']
. O
The O
annual O
estimation O
of O
eye-lens B-outcome ['Physiological-Clinical']
doses I-outcome ['Physiological-Clinical']
did O
not O
reach O
the O
annual O
dose O
limit O
of O
20 O
mSv O
revised O
by O
the O
ICRP, O
ranged O
from O
0.00 O
to O
18.12 O
mSv O
with O
a O
mean O
of O
0.96 O
+/- O
2.28 O
mSv. O
[['Life-Impact'], ['Physiological-Clinical']]

No O
trial-dependent O
differences O
were O
observed O
in O
the O
Recovery O
period. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS:: O
Five O
therapeutic O
radiographers O
contoured O
the O
prostate O
individually O
on O
CT, O
T2 O
weighted O
(T2W) O
and O
T2* O
weighted O
(T2*W) O
imaging O
for O
10 O
patients. O
[]

CONCLUSIONS: O
Rigid O
or O
Kinesio O
taping O
of O
the O
shoulder O
and O
scapular O
region O
improved O
scapular B-outcome ['Physiological-Clinical']
dyskinesis I-outcome ['Physiological-Clinical']
and O
pectoralis B-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
but O
did O
not O
alter O
scapular B-outcome ['Physiological-Clinical']
upward I-outcome ['Physiological-Clinical']
rotation I-outcome ['Physiological-Clinical']
. O
Short-term O
rigid O
and O
Kinesio O
taping O
may O
help O
improve O
scapular B-outcome ['Physiological-Clinical']
dyskinesis I-outcome ['Physiological-Clinical']
and O
pectoralis B-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
in O
overhead O
athletes. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Registered O
August O
7, O
2015 O
- O
retrospectively O
registered. O
[]

Publication O
date: O
2018/08/13 O
00:00 O
[accepted] O
[]

This O
study O
was O
conducted O
to O
evaluate O
the O
Effectiveness O
of O
Mindfulness-Based O
Cognitive O
Therapy O
(MBCT) O
on O
the O
Illness B-outcome ['Life-Impact']
Perception I-outcome ['Life-Impact']
(IP) I-outcome ['Life-Impact']
and O
Psychological B-outcome ['Life-Impact']
Symptoms I-outcome ['Life-Impact']
(PS) I-outcome ['Life-Impact']
for O
Patients O
in O
primary O
care O
with O
an O
active O
symptom O
of O
Rheumatoid O
Arthritis O
(RA). O
[['Life-Impact'], ['Life-Impact']]

BACKGROUND: O
Levodopa O
is O
the O
main O
treatment O
for O
symptoms O
of O
Parkinson's O
disease. O
[]

Participants O
redeemed O
only O
39% O
(SD O
43%) O
of O
their O
earned O
points. O
[]

Journal-Name:BMC O
complementary O
and O
alternative O
medicine O
[]

BACKGROUND: O
Endometrial O
scratching O
(with O
the O
use O
of O
a O
pipelle O
biopsy) O
is O
a O
technique O
proposed O
to O
facilitate O
embryo B-outcome ['Physiological-Clinical']
implantation I-outcome ['Physiological-Clinical']
and O
increase O
the O
probability O
of O
pregnancy B-outcome ['Physiological-Clinical']
in O
women O
undergoing O
in O
vitro O
fertilization O
(IVF). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
patients O
in O
the O
treatment O
group O
showed O
significantly O
better O
treatment B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
than O
those O
in O
the O
control O
group O
(P O
&lt; O
0.05 O
or O
0.01). O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

Three O
group O
patients O
were O
no O
significant O
difference O
in O
serum O
SOD B-outcome ['Physiological-Clinical']
and O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
before O
treatment O
P>0.05. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
A O
randomized, O
double-blind, O
placebo-controlled O
trial O
on O
the O
efficacy O
of O
tranexamic O
acid O
combined O
with O
rivaroxaban O
thromboprophylaxis O
in O
reducing O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
after O
primary O
cementless O
total O
hip O
arthroplasty. O
[['Physiological-Clinical']]

Background: O
A O
unique O
fixed O
combination O
halobetasol O
propionate O
0.01% O
and O
tazarotene O
0.045% O
(HP/TAZ) O
lotion O
has O
been O
shown O
to O
be O
effective O
in O
psoriasis O
using O
Investigator O
Global O
Assessment O
(IGA) O
tools O
to O
assess O
erythema, O
plaque O
elevation, O
and O
scaling. O
[]

C-group O
received O
a O
brochure. O
[]

From O
January O
2015 O
to O
June O
2017, O
42 O
children O
with O
moderate O
to O
severe O
HIE O
in O
the O
neonatal O
intensive O
care O
unit O
(NICU) O
of O
the O
First O
Affiliated O
Hospital O
of O
Bengbu O
Medical O
College O
were O
enrolled, O
and O
they O
were O
randomly O
divided O
into O
SBH O
treatment O
group O
and O
routine O
treatment O
group O
after O
obtaining O
the O
consent O
of O
the O
guardian O
of O
the O
children. O
[]

METHODS: O
A O
between-subjects O
web-based O
experiment O
was O
conducted, O
consisting O
of O
four O
sponsorship O
conditions O
(A O
through O
D) O
featuring O
three O
product O
categories O
within O
each O
condition. O
[]

The O
primary O
outcome O
was O
treatment B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
, O
defined O
as O
a O
decrease O
of O
50% O
or O
more O
in O
the O
Gastroesophageal O
Reflux O
Disease O
(GERD)-Health O
Related O
Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
score O
(range, O
0 O
to O
50, O
with O
higher O
scores O
indicating O
worse O
symptoms) O
at O
1 O
year. O
[['Physiological-Clinical'], ['Life-Impact']]

The O
number O
of O
minor O
unintentional O
injuries B-outcome ['Physiological-Clinical']
in O
the O
intervention O
group O
decreased O
from O
119 O
to O
56, O
and O
the O
number O
of O
children O
suffering O
2 O
or O
more O
injuries O
dropped O
from O
34 O
to O
10 O
(P<0.001) O
at O
6 O
months O
after O
the O
intervention, O
while O
both O
of O
them O
were O
lower O
than O
that O
in O
the O
control O
group O
(P=0.011). O
[['Physiological-Clinical']]

Pre- O
to O
postintervention O
overall O
Test O
of O
Playfulness B-outcome ['Life-Impact']
(ToP) O
scores O
improved O
marginally O
for O
the O
PICIHBI O
group O
(n O
= O
12) O
and O
the O
conventional O
group O
(n O
= O
12). O
[['Life-Impact']]

We O
describe O
the O
first O
randomised O
controlled O
trial O
to O
address O
both O
chronic O
disease O
and O
mental O
health O
in O
Indigenous O
people O
with O
ESKD, O
which O
is O
the O
first O
to O
test O
the O
effectiveness O
of O
a O
culturally O
adapted O
e-mental O
health O
intervention O
in O
this O
population. O
[]

Localization B-outcome ['Life-Impact']
accuracy, O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
difficulty B-outcome ['Life-Impact']
in O
postoperative O
seeking O
for O
pathological O
specimens O
were O
compared O
between O
these O
2 O
groups. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Publication O
date: O
2019/02/26 O
06:00 O
[medline] O
[]

Body O
posture O
is O
directly O
related O
to O
PA O
and O
the O
lack O
of O
activity O
affects O
disturbances O
within O
posturometric O
parameters. O
[]

No O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred. O
[['Adverse-effects']]

CONCLUSION: O
In O
Indian O
patients, O
30 O
mg O
of O
prasugrel O
loading O
is O
as O
effective O
as O
60 O
mg O
of O
prasugrel O
with O
significantly O
less O
minor B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

This O
study O
evaluated O
the O
efficacy O
of O
amla O
(Emblica O
officinalis) O
extract O
(composed O
of O
polyphenols, O
triterpenoids, O
oils O
etc. O
[]

The O
primary O
outcome O
was O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
at O
10 O
years. O
[['Mortality']]

Noggin B-outcome ['Physiological-Clinical']
was O
measured, O
for O
the O
first O
time O
in O
thalassemia O
patients, O
at O
baseline O
and O
at O
12 O
months, O
using O
a O
recently O
developed O
high O
sensitivity O
fluorescent O
immunoassay. O
[['Physiological-Clinical']]

Fourteen O
performed O
a O
16-week O
resistance O
training O
(RT) O
intervention, O
9 O
were O
assigned O
to O
a O
usual O
care O
waitlist O
control O
group. O
[]

Journal O
ID: O
0255562 O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

Publication O
date: O
2019/02/09 O
06:00 O
[entrez] O
[]

RESULTS: O
By O
December O
31, O
2017, O
a O
total O
of O
261 O
of O
the O
347 O
men O
in O
the O
radical-prostatectomy O
group O
and O
292 O
of O
the O
348 O
men O
in O
the O
watchful-waiting O
group O
had O
died B-outcome ['Mortality']
; O
71 O
deaths B-outcome ['Mortality']
in O
the O
radical-prostatectomy O
group O
and O
110 O
in O
the O
watchful-waiting O
group O
were O
due O
to O
prostate O
cancer O
(relative O
risk, O
0.55; O
95% O
confidence O
interval O
[CI], O
0.41 O
to O
0.74; O
P<0.001; O
absolute O
difference O
in O
risk, O
11.7 O
percentage O
points; O
95% O
CI, O
5.2 O
to O
18.2). O
[['Mortality'], ['Mortality']]

Title: O
Rehydrating B-outcome ['Physiological-Clinical']
efficacy O
of O
maple O
water O
after O
exercise-induced O
dehydration. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSION: O
CrCo-Ti O
rods O
have O
the O
ability O
to O
produce O
higher O
correction B-outcome ['Physiological-Clinical']
rates O
in O
AIS O
compared O
to O
Ti-Ti O
rod O
of O
the O
same O
diameter. O
[['Physiological-Clinical']]

Decreases O
in O
savory B-outcome ['Life-Impact']
and O
sweet O
snack O
intake O
were O
associated O
with O
lower O
HOMA-IR B-outcome ['Physiological-Clinical']
3(-)8 O
years O
later, O
but O
these O
associations O
disappeared O
after O
adjustment O
for O
current O
lifestyle. O
[['Life-Impact'], ['Physiological-Clinical']]

Results O
were O
extrapolated O
to O
two O
years O
after O
randomization. O
[]

In B-outcome ['Physiological-Clinical']
vitro I-outcome ['Physiological-Clinical']
fertilization I-outcome ['Physiological-Clinical']
(IVF) I-outcome ['Physiological-Clinical']
/ O
intracytoplasmic B-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
(ICSI) I-outcome ['Physiological-Clinical']
outcomes O
were O
compared O
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Pain B-outcome ['Physiological-Clinical']
scores, O
opioid B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
PT O
test O
results, O
and O
patient-reported O
outcome O
instruments O
were O
compared O
between O
the O
three O
groups. O
[['Physiological-Clinical'], ['Resource-use']]

Hence, O
the O
present O
study O
aims O
to O
establish O
the O
clinical O
evidence O
regarding O
the O
efficacy O
and O
safety O
of O
Bosinji O
in O
improving O
pain B-outcome ['Physiological-Clinical']
, O
function B-outcome ['Life-Impact']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
LHIVD O
patients. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

EBV-encoded O
small O
RNA O
in O
situ O
hybridization O
was O
performed O
to O
define O
EBV O
status. O
[]

The O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
benefits O
of O
treating O
the O
donor O
liver O
with O
Simvastatin O
compared O
with O
the O
standard O
transplant O
procedure. O
[]

DESIGN: O
Randomized O
controlled O
trial. O
[]

We O
profiled O
the O
microbiome O
of O
a O
longitudinal O
sample O
series O
of O
28 O
people O
with O
diabetes O
and O
DFUs O
of O
the O
heel O
in O
an O
attempt O
to O
better O
characterize O
the O
relationship O
between O
healing, O
infection O
and O
the O
microbiome. O
[]

Journal O
ID: O
16210490R O
[]

This O
clinical O
trial O
aimed O
to O
determine O
whether O
a O
structured O
multidisciplinary, O
multisite O
intervention O
resulted O
in O
improved O
clinical O
outcomes O
compared O
with O
standard O
care. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal O
ID: O
7511141 O
[]

Journal O
ID: O
100968567 O
[]

Publication O
date: O
2019/02/15 O
06:00 O
[medline] O
[]

A O
number O
was O
assigned O
to O
each O
eye O
drop, O
and O
the O
volunteer O
was O
asked O
to O
identify O
it O
by O
color. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS: O
Among O
critically O
ill O
adults O
undergoing O
tracheal O
intubation, O
patients O
receiving O
bag-mask O
ventilation O
had O
higher O
oxygen B-outcome ['Physiological-Clinical']
saturations I-outcome ['Physiological-Clinical']
and O
a O
lower O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
hypoxemia I-outcome ['Physiological-Clinical']
than O
those O
receiving O
no O
ventilation. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Nutrients O
[]

Journal O
ID: O
8216186 O
[]

In O
the O
control O
group, O
19 O
cases O
were O
successfully O
hemostatic B-outcome ['Physiological-Clinical']
in O
3 O
minutes, O
4 O
cases O
were O
successful O
in O
5 O
minutes, O
and O
7 O
cases O
were O
combined O
with O
hemostasis. O
[['Physiological-Clinical']]

Statistical O
analyses O
included O
t O
tests, O
a O
Poisson O
regression O
model, O
and O
analysis O
of O
covariance O
(ANCOVA) O
using O
STATA. O
[]

METHODS: O
A O
total O
number O
of O
120 O
type O
2 O
diabetes O
patients O
were O
randomized O
into O
intervention O
(health O
education O
by O
Wechat O
platform O
plus O
usual O
care) O
and O
the O
control O
group O
(usual O
care). O
[]

However, O
no O
studies O
have O
yet O
documented O
the O
utility O
of O
and O
student O
response O
to O
videoconference O
meetings O
for O
mid-clerkship O
feedback O
(MCF) O
sessions O
required O
by O
the O
Liaison O
Committee O
on O
Medical O
Education O
(LCME). O
[]

Data O
analysis O
was O
conducted O
using O
Chi-square, O
independent O
t-test, O
and O
paired O
t-test. O
[]

Publication O
date: O
2019/01/09 O
06:00 O
[medline] O
[]

The O
1-year O
abstinence B-outcome ['Physiological-Clinical']
rate O
was O
18.0% O
in O
the O
e-cigarette O
group, O
as O
compared O
with O
9.9% O
in O
the O
nicotine-replacement O
group O
(relative O
risk, O
1.83; O
95% O
confidence O
interval O
[CI], O
1.30 O
to O
2.58; O
P<0.001). O
[['Physiological-Clinical']]

The O
inflammatory O
response O
indicators O
( O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
erythrocyte B-outcome ['Physiological-Clinical']
sedimentation I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
) O
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
index O
( O
creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
) O
were O
recorded O
in O
both O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/05 O
06:00 O
[pubmed] O
[]

Journal O
ID: O
2985213R O
[]

METHODS: O
Cross-sectional O
analyses O
of O
the O
PREDIMED-Plus O
trial. O
[]

Journal-Name:BMC O
public O
health O
[]

Journal-Name:BMC O
public O
health O
[]

Topics O
of O
discussion O
in O
CHDRs O
focused O
primarily O
on O
CHW O
functionality. O
[]

There O
were O
significant O
differences O
in O
the O
24 O
hours O
increment O
in O
highly B-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
(HS-Tp) I-outcome ['Physiological-Clinical']
in O
the O
control O
group, O
it O
was O
higher O
(112 O
ng/l) O
than O
in O
the O
nicorandil O
group O
(67 O
ng/l), O
p O
= O
0.03. O
[['Physiological-Clinical']]

The O
degree O
to O
which O
individuals O
change O
their O
lifestyle B-outcome ['Life-Impact', 'Life-Impact']
in O
response O
to O
interventions O
differs O
and O
this O
variation O
could O
affect O
cardiometabolic B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
. O
We O
examined O
if O
changes O
in O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
weight B-outcome ['Physiological-Clinical']
of O
obese O
infertile O
women O
during O
the O
first O
six O
months O
of O
the O
LIFEstyle O
trial O
were O
associated O
with O
cardiometabolic B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
3(-)8 O
years O
later O
(N O
= O
50(-)78). O
[['Life-Impact', 'Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

In O
addition, O
there O
is O
good O
concordance O
between O
radiographers O
across O
all O
imaging O
modalities. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Title: O
Pilates O
exercises O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
of O
patients O
with O
chronic O
kidney O
disease. O
[['Life-Impact']]

Title: O
Comparing O
the O
effect O
between O
continuous O
infusion O
and O
intermittent O
bolus O
of O
rocuronium O
for O
intraoperative O
neurophysiologic O
monitoring O
of O
neurointervention O
under O
general O
anesthesia. O
[]

The O
white O
sclera O
slice O
could O
be O
seen O
under O
the O
conjunctiva, O
thereby O
affecting O
the O
cosmetic B-outcome ['Life-Impact']
appearance I-outcome ['Life-Impact']
. O
CONCLUSION: O
The O
cornea O
slice O
acquired O
from O
SMILE O
surgery O
can O
effectively O
prevent O
drainage B-outcome ['Physiological-Clinical']
tube I-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
. O
Moreover, O
it O
is O
easy B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
acquire I-outcome ['Life-Impact']
, O
safe, O
and O
cheaper B-outcome ['Resource-use']
, O
giving O
the O
patient O
a O
better O
cosmetic B-outcome ['Life-Impact']
appearance I-outcome ['Life-Impact']
. O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Resource-use'], ['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Exacerbation O
onset O
was O
the O
first O
day O
of O
a O
reported O
symptom O
of O
exacerbation. O
[]

Journal-Name:JAMA O
[]

J O
Drugs O
Dermatol. O
[]

Likewise, O
significant O
differences O
between O
groups O
were O
observed O
throughout O
the O
study O
in O
the O
group-by-time O
interaction O
and O
changes O
of O
haemoglobin B-outcome ['Physiological-Clinical']
(GC: O
-2.89 O
+/- O
2.29% O
vs. O
VD3G: O
0.71 O
+/- O
1.91%; O
p O
= O
0.009), O
hematocrit B-outcome ['Physiological-Clinical']
(CG: O
-1.57 O
+/- O
2.49% O
vs. O
VD3G: O
1.16 O
+/- O
1.81%; O
p O
= O
0.019) O
and O
transferrin B-outcome ['Physiological-Clinical']
(CG: O
0.67 O
+/- O
4.88% O
vs. O
VD3G: O
6.51 O
+/- O
4.36%; O
p O
= O
0.007). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Extended O
follow-up O
(median O
5.9 O
years O
[IQR O
1.7-7.9]) O
confirmed O
a O
lower O
5-year O
chronic B-outcome ['Physiological-Clinical']
graft-versus-host I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(cGVHD) I-outcome ['Physiological-Clinical']
incidence O
(30.0% O
[95% O
CI O
21.4-41.9 O
vs O
69.1% O
[59.1-80.1]; O
analysis O
for O
entire O
follow-up, O
p<0.001), O
no O
increase O
in O
relapses B-outcome ['Physiological-Clinical']
(35.4% O
[26.4-47.5] O
vs O
22.5% O
[14.6-34.7]; O
p=0.09), O
improved O
cGVHD-free B-outcome ['Physiological-Clinical', 'Mortality']
and O
relapse-free O
survival O
(cGRFS) O
(34.3% O
[24.2-44.5] O
vs O
13.9% O
[7.1-22.9]; O
p=0.005), O
and O
fewer O
patients O
still O
in O
immunosuppression B-outcome ['Physiological-Clinical']
(9.6% O
vs O
28.3%; O
p=0.017) O
in O
the O
ATLG O
group O
compared O
with O
the O
non-ATLG O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical']]

For O
the O
first O
3 O
groups, O
we O
applied O
tape O
to O
the O
shoulder O
and O
scapular O
region. O
[]

Patients O
in O
both O
groups O
were O
treated O
for O
a O
total O
of O
12 O
weeks. O
[]

intrauterine B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
were O
observed O
in O
6 O
patients O
in O
group O
2, O
while O
no O
intrauterine B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
was O
observed O
in O
group O
1 O
(P O
= O
.007). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Participants O
(55% O
female) O
consumed O
50 O
g O
whey O
(WPI; O
active) O
or O
soy O
protein O
isolate O
(SPI; O
control) O
for O
eight O
weeks. O
[]

Freedom O
from O
recurrence B-outcome ['Physiological-Clinical']
of O
P. O
vivax O
parasitemia O
at O
6 O
months O
was O
the O
primary O
efficacy O
outcome O
in O
a O
planned O
patient-level O
meta-analysis O
of O
the O
current O
trial O
and O
another O
phase O
3 O
trial O
of O
tafenoquine O
and O
primaquine O
(per-protocol O
populations), O
and O
an O
odds O
ratio O
for O
recurrence B-outcome ['Physiological-Clinical']
of O
1.45 O
(tafenoquine O
vs. O
primaquine) O
was O
used O
as O
a O
noninferiority O
margin. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
percentage O
of O
patients O
who O
had O
a O
recurrence B-outcome ['Physiological-Clinical']
of O
TTP O
at O
any O
time O
during O
the O
trial O
was O
67% O
lower O
with O
caplacizumab O
than O
with O
placebo O
(12% O
vs. O
38%, O
P<0.001). O
[['Physiological-Clinical']]

There O
were O
no O
differences O
in O
these O
results O
based O
on O
demographic O
variables. O
[]

The O
patients O
in O
the O
AG O
had O
better O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
the O
first O
second O
and O
peak B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
[(1.50+/-0.32) O
L,(252.06+/-75.27) O
L/min O
compared O
with O
the O
CG O
[(1.34+/-0.19) O
L, O
(216.94+/-49.72) O
L/min O
(P=0.03, O
P=0.03) O
at O
discharge. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

BACKGROUND: O
Chronic O
obstructive O
pulmonary O
disease O
(COPD) O
is O
a O
serious O
lung O
disease O
for O
individuals O
in O
middle O
age O
and O
especially O
in O
old O
people. O
[]

Serum O
epinephrine B-outcome ['Physiological-Clinical']
in O
group O
D O
were O
significantly O
lower O
than O
them O
in O
group O
C O
at O
T(2), O
T(3), O
T(4), O
T(5) O
(t=6.153, O
8.774, O
9.127, O
8.409, O
respectively; O
all O
P<0.05), O
but O
there O
were O
no O
difference O
between O
these O
two O
groups O
at O
T(0), O
T(1), O
T(6), O
T(7), O
T(8)(all O
P>0.05). O
[['Physiological-Clinical']]

Pain B-outcome ['Physiological-Clinical']
score O
in O
the O
paracetamol O
group O
was O
significantly O
lower O
than O
that O
in O
the O
dexmedetomidine O
group O
(P O
= O
.04); O
nevertheless, O
there O
were O
no O
group O
differences O
in O
the O
mean O
scores O
of O
pain B-outcome ['Physiological-Clinical']
during O
these O
hours O
(P O
> O
.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

A O
sequential O
design O
was O
used O
with O
a O
triangular O
continuation O
region. O
[]

Journal-Name:BMC O
gastroenterology O
[]

Importance: O
Whether O
using O
magnetic O
resonance O
imaging O
(MRI) O
to O
guide O
treatment O
in O
patients O
with O
rheumatoid O
arthritis O
(RA) O
improves O
disease O
activity O
and O
slows O
joint O
damage O
progression O
is O
unknown. O
[]

Conclusion: O
The O
combination O
of O
parecoxib, O
TAP, O
and O
PCIA O
pump O
could O
significantly O
reduce O
patient O
postoperative O
pain B-outcome ['Physiological-Clinical']
and O
enhance O
recovery B-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Cornea O
[]

However, O
there O
is O
a O
paucity O
of O
research O
exploring O
the O
potential O
benefit O
of O
FODMAP O
strategies O
to O
support O
healthy, O
recreational O
athletes O
who O
experience O
GI O
issues O
during O
training. O
[]

RESULTS: O
At O
3 O
and O
6 O
month O
follow O
up, O
Atorvastatin O
40mg O
leads O
to O
mean O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
reduction O
of O
47.18+/-20.81 O
& O
50.03+/-18.06 O
respectively. O
[['Physiological-Clinical']]

Publication O
date: O
['2019/10/18 O
06:00' O
[]

Eighty-three O
patients O
with O
pulmonary O
bullae O
(American O
Society O
of O
Anesthesiologists O
(ASA) O
I-III) O
undergoing O
lobectomy, O
with O
general O
anaesthesia, O
were O
included. O
[]

Journal-Name:BMC O
public O
health O
[]

Suicidal O
ideation O
was O
independently O
associated O
with O
sexual O
abuse O
(AOR O
11.9 O
(3.0-47.0)) O
and O
a O
lack O
of O
parental O
emotional O
support O
(AOR O
0.2 O
(0.1-0.5)). O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

Journal O
ID: O
0374675 O
[]

Publication O
date: O
2019/01/23 O
06:00 O
[entrez] O
[]

It O
was O
also O
registered O
after O
completion O
at O
ClinicalTrials.gov O
( O
ClinicalTrials.gov O
Identifier: O
NCT03662165): O
https://clinicaltrials.gov/ct2/show/NCT03662165?term=NCT03662165&type=Intr&cond=H O
IV&rank=1 O
[]

RESULTS: O
All O
mandibular B-outcome ['Physiological-Clinical']
skeletal I-outcome ['Physiological-Clinical']
dimensions O
increased, O
and O
improvements O
of O
the O
sagittal B-outcome ['Physiological-Clinical']
maxillomandibular I-outcome ['Physiological-Clinical']
parameters O
were O
found O
in O
both O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Twenty-three O
survivors O
of O
BC O
were O
included O
in O
this O
analysis. O
[]

Title: O
The O
Effects O
of O
Oral O
Magnesium O
Supplementation O
on O
Glycemic B-outcome ['Physiological-Clinical']
Response I-outcome ['Physiological-Clinical']
among O
Type O
2 O
Diabetes O
Patients. O
[['Physiological-Clinical']]

Children O
with O
phenylketonuria O
(PKU) O
follow O
a O
protein O
restricted O
diet O
with O
negligible O
amounts O
of O
docosahexaenoic O
acid O
(DHA). O
[]

Journal O
ID: O
7511141 O
[]

It O
is O
recommended O
its O
teaching O
to O
mothers O
and O
its O
application O
in O
the O
home O
environment. O
[]

The O
BRPE O
could O
be O
a O
valuable O
tool O
for O
clinicians O
to O
dose O
FT O
intensity O
after O
a O
stroke, O
but O
this O
remains O
to O
be O
tested. O
[]

Publication O
date: O
2019/02/27 O
06:00 O
[medline] O
[]

Either O
low-dose O
or O
standard-dose O
MDCT O
protocol O
was O
performed, O
the O
experience O
of O
otolaryngologist O
had O
decreased O
complication B-outcome ['Adverse-effects']
after O
surgeries. O
[['Adverse-effects']]

A O
general O
linear O
mixed O
model O
was O
applied O
to O
test O
the O
intervention O
effect O
at O
the O
end O
of O
the O
16-week O
intervention O
(T2, O
n O
= O
338) O
and O
at O
three-month O
follow-up O
(T3, O
n O
= O
311). O
[]

All O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
2-week, O
and O
1-month O
follow-up O
period. O
[]

Secondary O
endpoints O
in O
rank O
order O
included: O
superiority O
of O
HP O
relative O
to O
G O
+ O
T O
in O
mean O
preparation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
; O
non-inferiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
achieving O
hemostasis B-outcome ['Physiological-Clinical']
within O
3 O
min; O
superiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
achieving O
hemostasis B-outcome ['Physiological-Clinical']
within O
6 O
min; O
and O
superiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
success O
for O
achieving O
hemostasis B-outcome ['Physiological-Clinical']
within O
3 O
min. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Of O
the O
185 O
enrolled O
patients, O
180 O
completed O
the O
study. O
[]

However, O
data O
on O
the O
optimal O
route O
of O
administration O
are O
not O
consistent. O
[]

The O
results O
of O
this O
trial O
could O
support O
decision-making O
by O
clinicians O
regarding O
aPDT O
using O
aPDT O
for O
treating O
halitosis. O
[]

The O
primary O
objective O
was O
to O
show O
the O
noninferiority O
of O
plazomicin O
to O
meropenem O
in O
the O
treatment O
of O
complicated O
UTIs, O
including O
acute O
pyelonephritis, O
with O
a O
noninferiority O
margin O
of O
15 O
percentage O
points. O
[]

Compared O
with O
the O
general O
anesthesia O
group, O
the O
first O
night O
of O
total B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
the O
spinal O
anesthesia O
group O
was O
significantly O
shorter[(357.2+/-83.4)min O
vs O
(275.1+/-64.8)min, O
t=-9.635, O
P<0.05], O
while O
the O
rate O
of O
wakefulness B-outcome ['Physiological-Clinical']
, O
total B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
overall B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
daytime B-outcome ['Life-Impact']
mood I-outcome ['Life-Impact']
and O
daytime B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
were O
significantly O
higher[(25.9%, O
22.2%, O
25.9%, O
18.5%18.5%) O
vs O
(51.7%, O
51.7%, O
55.2%, O
48.3%44.8%), O
chi(2)=3.901, O
5.192, O
4.941, O
5.523 O
and O
4.437, O
all O
P<0.05], O
and O
the O
cases O
of O
postoperative O
urinary B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
and O
lower B-outcome ['Physiological-Clinical']
limb I-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
were O
significantly O
higher[(8 O
and O
6) O
vs O
(1 O
and O
0), O
all O
P<0.05]. O
Conclusion: O
Both O
anesthesia O
methods O
can O
be O
safely O
and O
effectively O
applied O
to O
middle-aged O
and O
elderly O
patients O
with O
lower O
extremity O
varicose O
veins O
surgery, O
but O
patients O
with O
general O
anesthesia O
show O
fewer O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
on O
the O
first O
night O
after O
surgery O
and O
have O
better O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical']]

In O
the O
SMILE O
eyes, O
it O
increased O
from O
52.52 O
+/- O
3.01 O
mum O
to O
57.15 O
+/- O
4.57 O
mum O
and O
also O
remained O
stable O
for O
up O
to O
24 O
months. O
[]

PURPOSE: O
To O
evaluate O
corneal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
cell I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
density I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(ECD) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
morphology S3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
2 O
years O
after O
phacoemulsification O
in O
subjects O
from O
the O
COMPASS O
trial O
(ClinicalTrials.gov, O
NCT01085357) O
who O
had O
mild-to-moderate O
primary O
open-angle O
glaucoma O
and O
visually O
significant O
cataracts. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Publication O
Type: O
Multicenter O
Study O
[]

Results O
were O
similar O
for O
all O
(mild/moderate/severe) O
exacerbations B-outcome ['Physiological-Clinical']
. O
Improvements O
in O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
health B-outcome ['Physiological-Clinical']
status O
and O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
use I-outcome ['Resource-use']
with O
IND/GLY O
vs O
SFC O
were O
comparable O
between O
men O
and O
women. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

METHOD: O
an O
experimental O
and O
blind O
study O
composed O
of O
120 O
dyads O
of O
first-time O
mothers O
and O
full-term O
newborns, O
who O
practiced O
breastfeeding. O
[]

METHODS: O
This O
multicenter, O
double-blind, O
double-dummy, O
parallel O
group, O
randomized, O
placebo-controlled O
trial O
was O
conducted O
in O
Ethiopia, O
Peru, O
Brazil, O
Cambodia, O
Thailand, O
and O
the O
Philippines. O
[]

BACKGROUND: O
We O
examined O
whether O
enhancing O
self-affirmation O
among O
a O
population O
of O
drinkers, O
prior O
to O
viewing O
threatening O
alcohol O
pictorial O
health O
warning O
labels, O
would O
reduce O
defensive B-outcome ['Life-Impact']
reactions I-outcome ['Life-Impact']
and O
promote O
reactions B-outcome ['Life-Impact']
related O
to O
behaviour O
change. O
[['Life-Impact'], ['Life-Impact']]

BACKGROUND: O
This O
study O
assessed O
the O
feasibility B-outcome ['Life-Impact']
and O
acceptability B-outcome ['Life-Impact']
of O
two O
common O
types O
of O
exercise O
training-high-intensity O
interval O
training O
(HIIT) O
and O
moderate-intensity O
continuous O
training O
(MICT)-in O
adults O
with O
Crohn's O
disease O
(CD). O
[['Life-Impact'], ['Life-Impact']]

METHODS: O
This O
was O
a O
post-hoc O
analysis O
of O
a O
cluster-randomized O
trial O
as O
a O
cohort O
study; O
including O
patients O
with O
a O
working O
diagnosis O
of O
CAP O
admitted O
to O
non-ICU O
wards O
without O
a O
cardiac O
event O
on O
admission. O
[]

Data O
elicited O
from O
18 O
participating O
children O
via O
a O
write O
draw, O
show O
and O
tell O
task O
included, O
frequency O
counts O
of O
most O
enjoyable O
intervention O
components, O
drawings, O
and O
verbatim O
data. O
[]

Title: O
Open-labeled O
randomized O
controlled O
trial O
to O
evaluate O
the O
1-year O
clinical O
outcomes O
of O
polymer-free O
sirolimus-eluting O
coronary O
stents O
as O
compared O
with O
biodegradable O
polymer-based O
sirolimus-eluting O
coronary O
stents. O
[]

The O
primary O
outcome O
was O
full-term B-outcome ['Mortality']
(>/=37 O
weeks' O
gestational O
age) O
livebirth O
, O
which O
was O
assessed O
in O
all O
eligible O
couples O
who O
completed O
follow-up. O
[['Mortality']]

However, O
these O
results O
can O
not O
be O
representative O
of O
a O
heavy O
workload O
or O
incident O
situations O
for O
which O
radiation O
exposure O
to O
the O
eye-lens O
could O
exceed O
this O
limit. O
[]

Metabolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
measured O
through O
blood O
glucose B-outcome ['Physiological-Clinical']
, O
plasma O
insulin B-outcome ['Physiological-Clinical']
, O
plasma O
triglycerides B-outcome ['Physiological-Clinical']
, O
and O
plasma O
catecholamines B-outcome ['Physiological-Clinical']
: O
epinephrine B-outcome ['Physiological-Clinical']
(E) I-outcome ['Physiological-Clinical']
and O
norepinephrine B-outcome ['Physiological-Clinical']
(NE) I-outcome ['Physiological-Clinical']
. O
Biomarkers O
were O
taken O
at O
four O
different O
time O
points; O
Ingestion O
period: O
baseline O
(I1), O
post-ingestion O
period O
(I2); O
Recovery O
period: O
immediately O
post-exercise O
(R1), O
post-recovery O
period O
(R2). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Peak O
FPPA O
was O
determined O
from O
video O
recordings O
while O
participants O
performed O
5 O
single-leg O
squats. O
[]

Journal O
ID: O
100968562 O
[]

METHODS: O
In O
a O
double-blind O
trial, O
we O
randomly O
assigned O
(in O
a O
1:1 O
ratio) O
adults O
with O
community-acquired O
bacterial O
pneumonia O
(Pneumonia O
Severity O
Index O
risk O
class O
II, O
III, O
or O
IV) O
to O
receive O
omadacycline O
(100 O
mg O
intravenously O
every O
12 O
hours O
for O
two O
doses, O
then O
100 O
mg O
intravenously O
every O
24 O
hours), O
or O
moxifloxacin O
(400 O
mg O
intravenously O
every O
24 O
hours). O
[]

Journal O
ID: O
1307333 O
[]

Journal-Name:Journal O
of O
Ayub O
Medical O
College, O
Abbottabad O
: O
JAMC O
[]

Total O
treatment B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
9.7 O
+/- O
1.1 O
months O
for O
the O
IA O
group O
and O
9.5 O
+/- O
1.1 O
months O
for O
the O
MA O
group. O
[['Life-Impact']]

No O
significant O
changes O
in O
HIV B-outcome ['Physiological-Clinical']
viral I-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
, O
CD4(+) B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
or Seperator ['Physiological-Clinical', 'Physiological-Clinical']
CD8(+) B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
T I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
cell I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
counts E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BMI) I-outcome ['Physiological-Clinical']
or O
middle-upper-arm B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
(MUAC) I-outcome ['Physiological-Clinical']
could O
be O
detected. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2018/12/06 O
00:00 O
[accepted] O
[]

Further O
studies O
with O
larger O
sample O
sizes O
are O
needed O
to O
confirm O
these O
findings. O
[]

The O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
measured O
at O
baseline O
and O
12 O
weeks O
by O
TaqMan(R) O
Low O
Density O
Array. O
[['Physiological-Clinical']]

However, O
based O
on O
the O
study O
protocols O
to O
ensure O
patient O
safety, O
these O
randomised O
studies O
used O
mainly O
broad-spectrum O
intravenous O
antibiotics O
requiring O
additional O
hospital O
resources O
and O
prolonged O
hospital O
stay. O
[]

The O
aim O
of O
this O
split-mouth O
and O
randomized O
controlled O
study O
was O
to O
assess O
the O
clinical O
and O
aesthetical O
impacts O
of O
EMD O
application O
in O
combination O
with O
SCTG+CAF O
in O
patients O
with O
Miller's O
Class O
I O
and O
II O
gingival O
recessions O
in O
contralateral O
canines O
of O
the O
maxilla. O
[]

0.05). O
[]

Stratified O
by O
country, O
patients O
were O
randomized O
1:1 O
to O
receive O
DMF O
240 O
mg O
twice O
daily O
or O
placebo. O
[]

Publication O
date: O
2019/02/09 O
06:00 O
[medline] O
[]

We O
compared O
the O
efficacy O
and O
safety O
of O
a O
modified O
FOLFIRINOX O
regimen O
with O
gemcitabine O
as O
adjuvant O
therapy O
in O
patients O
with O
resected O
pancreatic O
cancer. O
[]

Bivariate O
and O
multivariate O
logistic O
regression O
analysis O
assessed O
correlates O
of O
different O
indicators O
of O
psychological O
distress. O
[]

Day O
1) O
and O
dexamethasone O
(9.9 O
mg O
i.v. O
[]

At O
10 O
minutes O
after O
the O
beginning O
of O
atomization, O
the O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
in O
different O
preset O
suction O
pressure O
groups O
was O
significantly O
lower O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
917.33+/-4.51 O
vs. O
1 O
103.33+/-5.77 O
at O
20 O
cmH2O O
of O
preset O
suction O
pressure O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05), O
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
1 O
433.33+/-4.73 O
vs. O
1 O
103.33+/-5.77 O
at O
20 O
cmH2O O
of O
preset O
suction O
pressure O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

CONCLUSIONS: O
Gua O
Sha O
appears O
to O
be O
an O
acceptable B-outcome ['Life-Impact']
, O
safe, O
and O
effective O
treatment O
for O
patients O
with O
chronic O
low O
back O
pain. O
[['Life-Impact']]

The O
new O
lotion O
formulation O
was O
well- B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
, O
and O
all O
treatment-related B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
were O
both O
mild O
and O
transient O
in O
nature. O
[['Life-Impact'], ['Adverse-effects']]

Journal O
ID: O
100884618 O
[]

The O
KT O
group O
demonstrated O
26.87%MVIC O
(95% O
CI O
= O
26.87, O
7.11) O
higher O
gastrocnemius O
medialis O
muscle O
peak O
activation O
during O
mid O
stance O
phase O
at O
post-test O
when O
compared O
with O
the O
control O
group. O
[]

Publication O
date: O
2018/12/28 O
06:00 O
[medline] O
[]

The O
combination O
of O
an O
unsatisfying O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
implementing I-outcome ['Life-Impact']
the O
intervention O
and O
a O
low O
previous O
knowledge B-outcome ['Life-Impact']
about O
the O
intervention O
showed O
the O
highest O
empirical O
relevance. O
[['Life-Impact'], ['Life-Impact']]

BACKGROUND: O
Nutrition O
cares O
are O
of O
the O
main O
measures O
to O
save O
premature O
infants. O
[]

2) O
Simulated O
scuba O
test O
in O
vitro: O
the O
ventilator O
was O
connected O
to O
the O
simulated O
scuba, O
and O
an O
external O
mechanical O
ventilation O
model O
was O
constructed. O
[]

Journal-Name:Indian O
heart O
journal O
[]

Journal-Name:Nutrients O
[]

Methods: O
Seventy-five O
patients O
were O
randomized O
into O
either O
CBT-i O
group O
(n=37) O
or O
combination O
group O
(n=38). O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

It O
may O
be O
used O
as O
an O
alternative O
drug O
for O
fentanyl O
in O
pain O
control O
after O
orthopedic O
surgery. O
[]

METHODS: O
In O
this O
crossover, O
randomized O
controlled O
trial, O
elbow B-outcome ['Physiological-Clinical']
proprioception I-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
, O
pain-free B-outcome ['Life-Impact']
grip I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
and O
finger B-outcome ['Life-Impact']
dexterity I-outcome ['Life-Impact']
were O
measured O
in O
50 O
participants O
with O
a O
diagnosis O
of O
lateral O
elbow O
tendinopathy. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Only O
4 O
children O
in O
each O
arm O
were O
found O
to O
have O
heart B-outcome ['Physiological-Clinical']
diseases I-outcome ['Physiological-Clinical']
, O
with O
prevalence O
of O
(0.17/1000 O
and O
0.16/1000), O
respectively, O
after O
clinical O
and O
echocardiography O
evaluation. O
[['Physiological-Clinical']]

Eligible O
patients O
were O
stratified O
by O
type O
2 O
diabetes O
status O
and O
they O
were O
randomly O
assigned O
(1:1:1) O
by O
a O
computer-based O
system O
to O
receive O
subcutaneous O
injections O
of O
placebo O
once O
a O
day, O
10 O
mg O
pegbelfermin O
once O
a O
day, O
or O
20 O
mg O
pegbelfermin O
once O
a O
week, O
all O
for O
16 O
weeks. O
[]

Publication O
date: O
2018/08/02 O
00:00 O
[accepted] O
[]

BACKGROUND: O
Health O
education O
has O
been O
considered O
as O
the O
effectiveness O
method O
to O
increase O
the O
self-care O
skills O
of O
diabetes O
patients. O
[]

Publication O
date: O
2018/12/17 O
00:00 O
[accepted] O
[]

Journal O
ID: O
2985248R O
[]

There O
were O
no O
significant O
between-group O
differences O
in O
the O
rates O
of O
ongoing B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
multiple B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
ectopic B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
or O
miscarriage B-outcome ['Mortality']
. O
The O
median O
score O
for O
pain B-outcome ['Physiological-Clinical']
from O
endometrial O
scratching O
(on O
a O
scale O
of O
0 O
to O
10, O
with O
higher O
scores O
indicating O
worse O
pain) O
was O
3.5 O
(interquartile O
range, O
1.9 O
to O
6.0). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Larger O
studies O
with O
longer O
follow-up O
periods O
may O
be O
required O
to O
confirm O
these O
findings. O
[]

Title: O
Cardiac O
events O
after O
macrolides O
or O
fluoroquinolones O
in O
patients O
hospitalized O
for O
community-acquired O
pneumonia: O
post-hoc O
analysis O
of O
a O
cluster-randomized O
trial. O
[]

METHODS: O
This O
pragmatic, O
randomized, O
controlled, O
parallel-group O
clinical O
trial O
will O
compare O
the O
effectiveness O
of O
the O
motivational O
interviewing O
to O
an O
educational O
intervention, O
including O
the O
distribution O
of O
an O
information O
flyer O
as O
standard O
of O
care O
on O
vaccination O
coverage O
in O
four O
maternity O
wards O
across O
the O
Province O
of O
Quebec O
(PromovaQ). O
[]

Teacher O
verbatim O
data O
was O
collected O
from O
3 O
interviews, O
and O
18 O
researcher O
observations O
were O
recorded O
using O
field O
notes. O
[]

h(-1), O
CON O
= O
1.22 O
+/- O
0.39 O
L O
. O
[]

RESULTS: O
Both O
groups O
heat B-outcome ['Physiological-Clinical']
acclimated I-outcome ['Physiological-Clinical']
similarly O
(p>0.05) O
evidenced O
by O
lower O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
thermoregulatory, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
physiological, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
perceptual B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
responses E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
( O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
thermal B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
) O
Pre O
HA O
vs. O
Post O
HA O
(p</=0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
Patients O
received O
either O
60 O
mg O
denosumab O
(n O
= O
32) O
or O
placebo O
(n O
= O
31) O
every O
6 O
months O
for O
12 O
months. O
[]

Journal O
ID: O
8102988 O
[]

At O
D29, O
intention-to-treat O
efficacy O
in O
the O
AmBisome O
arm O
was O
70% O
(95% O
CI O
45-87%) O
in O
the O
unadjusted O
analysis, O
and O
50% O
(95% O
CI O
27-73%) O
in O
the O
adjusted O
analysis, O
while O
in O
the O
combination O
arm, O
it O
was O
81% O
(95% O
CI O
67-90%) O
and O
67% O
(95% O
CI O
48-82%) O
respectively. O
[]

Schools O
were O
randomly O
assigned O
to O
either O
the O
treatment O
group O
to O
receive O
free O
vision O
care O
and O
eyeglasses, O
if O
needed, O
or O
control O
group, O
who O
received O
glasses O
only O
at O
the O
end O
of O
the O
study. O
[]

CONCLUSION: O
There O
was O
a O
strong O
correlation O
between O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
TOFr O
during O
recovery O
from O
general O
anesthesia. O
[['Life-Impact']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Eighteen O
healthy O
adults O
were O
enrolled O
in O
a O
randomized, O
crossover O
study O
with O
two O
treatment O
periods. O
[]

Title: O
Single-Dose O
Tafenoquine O
to O
Prevent O
Relapse B-outcome ['Physiological-Clinical']
of O
Plasmodium O
vivax O
Malaria. O
[['Physiological-Clinical']]

Dietary O
carbohydrate O
reduction O
has O
been O
suggested O
as O
non-pharmacological O
therapy O
for O
T2DM, O
but O
the O
acute O
effects O
on O
non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
(NEFA) I-outcome ['Physiological-Clinical']
and O
triglyceride B-outcome ['Physiological-Clinical']
(TG) I-outcome ['Physiological-Clinical']
during O
subsequent O
meals O
remain O
to O
be O
investigated. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
subjects O
in O
the O
treatment O
group O
received O
ET O
plus O
montelukast, O
while O
the O
participants O
in O
the O
control O
group O
received O
montelukast O
alone. O
[]

Title: O
Comparison O
of O
prostate O
delineation O
on O
multimodality O
imaging O
for O
MR-guided O
radiotherapy. O
[]

The O
outcome O
was O
stroke B-outcome ['Physiological-Clinical']
recurrence O
within O
one-year O
follow-up. O
[['Physiological-Clinical']]

CONCLUSIONS: O
Men O
with O
clinically O
detected, O
localized O
prostate O
cancer O
and O
a O
long O
life O
expectancy O
benefited O
from O
radical O
prostatectomy, O
with O
a O
mean O
of O
2.9 O
years O
of O
life O
gained. O
[]

We O
therefore O
assessed O
the O
effects O
of O
PPI O
or O
a O
histamine O
H2 O
receptor O
antagonist O
(H2 O
blocker) O
on O
hypogeusia B-outcome ['Physiological-Clinical']
among O
patients O
with O
LPR. O
[['Physiological-Clinical']]

During O
the O
16-week O
intervention, O
intervention O
participants O
watched O
ten O
video O
lessons O
at O
home O
and O
joined O
ten O
peer O
support O
group O
teleconferences. O
[]

Main O
Outcomes O
and O
Measures: O
The O
primary O
cognitive O
outcome O
was O
occurrence O
of O
adjudicated O
probable O
dementia B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Secondary O
cognitive O
outcomes O
included O
adjudicated O
mild O
cognitive B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
and O
a O
composite O
outcome O
of O
mild O
cognitive B-outcome ['Physiological-Clinical', 'Life-Impact']
impairment I-outcome ['Physiological-Clinical', 'Life-Impact']
or O
probable O
dementia O
. O
Results: O
Among O
9361 O
randomized O
participants O
(mean O
age, O
67.9 O
years; O
3332 O
women O
[35.6%]), O
8563 O
(91.5%) O
completed O
at O
least O
1 O
follow-up O
cognitive O
assessment. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Journal O
ID: O
101521595 O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

Title: O
A O
prospective O
randomized O
open-label O
study O
of O
single O
injection O
versus O
continuous O
adductor O
canal O
block O
for O
postoperative O
analgesia O
after O
total O
knee O
arthroplasty. O
[]

Most O
participants O
were O
women O
(>88%), O
with O
a O
mean O
age O
of O
35.3 O
years, O
more O
than O
a O
high O
school O
education O
(>80%), O
a O
family O
composition O
of O
at O
least O
three O
members, O
and O
a O
mean O
baseline O
body O
mass O
index O
(BMI) O
of O
34.5 O
kg/m(2). O
[]

Further O
evaluation O
of O
long-term O
cardiovascular O
effects O
is O
needed. O
[]

TRIAL O
REGISTRATION: O
This O
study O
is O
registered O
at O
ClinicalTrials.gov, O
no. O
[]

Periprosthetic B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
occurred O
in O
1 O
case O
of O
the O
SuperPATH O
group. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

The O
primary O
endpoint O
is O
defined O
as O
the O
number O
of O
individuals O
positive O
for O
Plasmodium B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
falciparum I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
Plasmodium B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
vivax I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
infections E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
diagnosed O
by O
a O
rapid O
diagnostic O
test. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Journal-Name:The O
Lancet. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND: O
Infections O
acquired O
in O
hospital O
are O
an O
important O
cause O
of O
morbidity O
and O
mortality O
in O
very O
preterm O
infants. O
[]

DESIGN: O
A O
parallel O
group O
trial O
with O
follow-up O
METHODS:: O
Thirty O
young O
women O
were O
divided O
into O
2 O
groups: O
experimental O
(n O
= O
15) O
and O
control O
(n O
= O
15). O
[]

TRIAL O
REGISTRATION: O
current O
controlled O
trials O
PHRC/HC/32/15. O
[]

Twelve O
weeks O
later, O
permanent O
crowns O
were O
placed O
on O
patient-specific O
abutments O
and O
evaluated O
at O
6, O
12, O
and O
36 O
months O
following O
implant O
placement. O
[]

A O
definitive O
trial O
is O
warranted. O
[]

Changes O
in O
unilateral O
upper B-outcome ['Life-Impact']
limb I-outcome ['Life-Impact']
muscular I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
Electromyographic B-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
after O
a O
16-week O
strength O
training O
intervention O
in O
survivors O
of O
breast O
cancer. O
[['Life-Impact'], ['Physiological-Clinical']]

By O
day O
28, O
74 O
patients O
(34.9%) O
in O
the O
peripheral O
perfusion O
group O
and O
92 O
patients O
(43.4%) O
in O
the O
lactate O
group O
had O
died B-outcome ['Mortality']
(hazard O
ratio, O
0.75 O
[95% O
CI, O
0.55 O
to O
1.02]; O
P O
= O
.06; O
risk O
difference, O
-8.5% O
[95% O
CI, O
-18.2% O
to O
1.2%]). O
[['Mortality']]

BACKGROUND: O
This O
pilot O
study O
aimed O
to O
investigate O
the O
feasible O
effectiveness O
and O
safety O
of O
Bazhengsan O
formula O
(BZSF) O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
for O
female O
patients O
with O
uncomplicated O
gonorrhea. O
[]

Title: O
Grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
can O
be O
used O
to O
evaluate O
postoperative O
residual B-outcome ['Physiological-Clinical']
neuromuscular I-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
general O
anesthesia. O
[['Life-Impact'], ['Physiological-Clinical']]

Antropyloroduodenal B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
, O
plasma O
cholecystokinin B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
appetite B-outcome ['Physiological-Clinical']
perceptions I-outcome ['Physiological-Clinical']
and O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
measured O
during O
90-min O
intraduodenal O
infusions O
of O
L-valine O
at O
0.15 O
kcal/min O
(total: O
3.3 O
g) O
or O
0.45 O
kcal/min O
(total: O
9.9 O
g), O
or O
0.9% O
saline O
(control). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
101265111 O
[]

Publication O
Type: O
Equivalence O
Trial O
[]

The O
APPAC O
II O
trial O
aims O
to O
add O
clinical O
evidence O
on O
the O
debated O
role O
of O
antibiotics O
as O
the O
first-line O
treatment O
for O
a O
CT-confirmed O
uncomplicated O
acute O
appendicitis O
as O
well O
as O
to O
optimise O
the O
non-operative O
treatment O
for O
uncomplicated O
acute O
appendicitis. O
[]

No O
significant O
differences O
between O
sclerotherapy O
and O
cyanoacrylate O
groups O
regarding O
rebleeding B-outcome ['Physiological-Clinical']
(26.79, O
19.30% O
respectively, O
P O
= O
0.344), O
complications B-outcome ['Adverse-effects']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
or O
mortality B-outcome ['Mortality']
rate O
were O
observed. O
[['Physiological-Clinical'], ['Adverse-effects'], ['Resource-use'], ['Mortality']]

CONCLUSION: O
Electrolyte-containing O
MW, O
was O
similar O
in O
effectiveness O
to O
water, O
but O
has O
antioxidant B-outcome ['Physiological-Clinical']
properties. O
[['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Journal-Name:Journal O
of O
physiology O
and O
pharmacology O
: O
an O
official O
journal O
of O
the O
Polish O
Physiological O
Society O
[]

Findings O
remained O
consistent O
after O
adjustment O
for O
confounders O
and/or O
in O
a O
sensitivity O
analysis O
of O
radiologically O
confirmed O
CAP O
(n O
= O
1604, O
76.1%). O
[]

Title: O
Effect O
of O
Intravenous O
Acetaminophen O
vs O
Placebo O
Combined O
With O
Propofol O
or O
Dexmedetomidine O
on O
Postoperative O
Delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
Among O
Older O
Patients O
Following O
Cardiac O
Surgery: O
The O
DEXACET O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical', 'Life-Impact']]

Publication O
date: O
2018/11/20 O
00:00 O
[accepted] O
[]

All O
patients O
received O
tramadol O
patient-controlled O
analgesia O
for O
the O
first O
24th O
hour. O
[]

CONCLUSIONS: O
The O
findings O
of O
the O
current O
study O
demonstrate O
that O
consumption O
of O
900 O
mg O
of O
PSE O
improved O
specific O
measures O
of O
reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
in O
a O
young, O
active O
population. O
[['Life-Impact']]

Publication O
date: O
2019/01/22 O
06:00 O
[medline] O
[]

Title: O
Hydrogen O
gas O
restores O
exhausted O
CD8+ B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in O
patients O
with O
advanced O
colorectal O
cancer O
to O
improve O
prognosis. O
[['Physiological-Clinical']]

Saliva O
3-methoxy-4-hydroxyphenylglycol B-outcome ['Physiological-Clinical']
(MHPG) I-outcome ['Physiological-Clinical']
, O
a O
major O
product O
of O
noradrenaline O
breakdown O
and O
a O
representative O
marker O
of O
sympathetic B-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
was O
significantly O
lower O
just O
after O
the O
TSST O
in O
the O
active O
group O
compared O
with O
the O
placebo O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Up O
to O
50% O
of O
reproductive-age O
women O
suffer O
from O
pelvic O
pain. O
[]

Significant O
differences O
were O
also O
observed O
in O
mean O
velocity O
during O
the O
eccentric O
phase O
of O
movement O
(0.690 O
m/s O
in O
the O
GCAF O
to O
0.609 O
in O
GCON O
with O
p O
= O
0.002). O
[]

Publication O
Type: O
Journal O
Article O
[]

Randomisation O
was O
stratified O
according O
to O
centre O
and O
disease O
risk. O
[]

Title: O
A O
Pilot O
Randomized O
Controlled O
Trial O
of O
Transcutaneous O
Electrical O
Nerve O
Stimulation O
for O
Patients O
With O
Acute O
Tinnitus. O
[]

Hence O
this O
operative O
procedure O
is O
worthy O
of O
popularization. O
[]

Publication O
date: O
2018/10/28 O
00:00 O
[accepted] O
[]

The O
test O
group O
had O
significantly O
better O
results O
than O
the O
control O
according O
to O
the O
soft B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
texture I-outcome ['Physiological-Clinical']
and O
mucogingival B-outcome ['Physiological-Clinical']
junction I-outcome ['Physiological-Clinical']
alignment I-outcome ['Physiological-Clinical']
results O
(p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

These O
meetings O
were O
held O
over O
a O
period O
of O
20 O
months O
from O
July O
2015 O
to O
March O
2017. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Netupitant O
was O
well O
tolerated B-outcome ['Life-Impact']
at O
all O
doses O
without O
clinically O
harmful O
safety O
signals O
observed. O
[['Life-Impact']]

RESULTS: O
Ulcer B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
(3.5+/-0.6) O
d, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
(3.1+/-0.3)d O
in O
group O
A O
were O
shorter O
than O
in O
group O
B O
(P<0.05); O
treatment O
efficiency O
was O
96.08% O
in O
group O
A, O
88.24% O
in O
group O
B( O
chi(2)=6.264, O
P<0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/22 O
06:00 O
[medline] O
[]

The O
safety O
profile O
of O
netupitant O
was O
comparable O
in O
the O
three O
arms. O
[]

Household B-outcome ['Life-Impact']
food I-outcome ['Life-Impact']
purchasing I-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
three O
24-h O
food B-outcome ['Life-Impact']
recalls, O
Tucker's O
semi-quantitative O
food B-outcome ['Life-Impact']
frequency I-outcome ['Life-Impact']
questionnaire O
(FFQ)], O
and O
weight B-outcome ['Physiological-Clinical']
were O
assessed O
at O
baseline O
and O
after O
8 O
weeks. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

METHODS: O
In O
this O
randomized, O
single-blinded, O
and O
controlled O
study, O
total O
75 O
patients O
were O
randomly O
allocated O
to O
TPI O
group O
(n O
= O
25), O
EMLA O
group O
(n O
= O
25), O
and O
control O
group O
(n O
= O
25). O
[]

Title: O
Comparison O
of O
effective O
teaching O
methods O
to O
achieve O
skill B-outcome ['Life-Impact']
acquisition O
using O
a O
robotic O
virtual O
reality O
simulator: O
Expert O
proctoring O
versus O
an O
educational O
video O
versus O
independent O
training. O
[['Life-Impact']]

Journal O
ID: O
0332203 O
[]

The O
most O
common O
adverse B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
was O
mucocutaneous B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
which O
was O
reported O
in O
65% O
of O
the O
patients O
in O
the O
caplacizumab O
group O
and O
in O
48% O
in O
the O
placebo O
group. O
[['Adverse-effects'], ['Physiological-Clinical']]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

The O
patients O
in O
the O
AG O
received O
oscillating O
positive O
expiratory O
pressure O
training O
and O
the O
CG O
underwent O
standard O
perioperative O
treatment. O
[]

BACKGROUND: O
To O
investigate O
the O
effectiveness O
of O
Baduanjin O
qigong O
combined O
with O
cognitive-behavior O
therapy O
(CBT) O
on O
the O
physical B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
and O
psychological B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
of O
elderly O
housebound. O
[['Physiological-Clinical'], ['Life-Impact']]

PURPOSE: O
Many O
studies O
have O
demonstrated O
the O
advantage O
of O
maintaining O
intraoperative O
deep O
neuromuscular O
block O
(NMB) O
with O
sugammadex. O
[]

Colorectal O
cancer O
(CRC) O
is O
the O
third O
leading O
cause O
of O
cancer-related O
death O
in O
the O
United O
States O
and O
emerging O
evidence O
supports O
that O
increased O
consumption O
of O
legumes, O
such O
as O
navy O
beans, O
can O
reduce O
risk. O
[]

PATIENTS O
AND O
METHODS: O
Initially, O
56 O
patients O
were O
randomized O
into O
four O
groups; O
control O
group O
(n=12), O
single-dose O
(n=16), O
repeated-dose O
(n=12) O
and O
continuous O
infusion O
(n=16) O
RSB O
analgesia O
groups. O
[]

Title: O
Combined O
intravenous O
and O
intra-articular O
tranexamic O
acid O
administration O
in O
total O
knee O
arthroplasty O
for O
preventing O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
hyperfibrinolysis B-outcome ['Physiological-Clinical']
: O
A O
randomized O
controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS: O
ECHELON-2 O
is O
a O
double-blind, O
double-dummy, O
randomised, O
placebo-controlled, O
active-comparator O
phase O
3 O
study. O
[]

RESULTS: O
The O
assay O
range O
was O
0.9-30 O
mg/L O
with O
accuracy O
within O
91%-99% O
and O
coefficients O
of O
variation O
ranging O
from O
1.2% O
to O
3.6%. O
[]

Secondary O
analyses O
and O
sensitivity O
analyses O
supported O
this O
finding. O
[]

Journal O
ID: O
101521595 O
[]

The O
response O
was O
independent O
of O
the O
degree O
of O
hypermobility. O
[]

The O
Harris O
and O
VAS O
scores O
of O
SuperPATH O
group O
at O
1 O
and O
3 O
days O
after O
operation O
were O
better O
than O
those O
of O
control O
group O
( O
P<0.05). O
[]

Journal O
ID: O
7501160 O
[]

BACKGROUND: O
Neonatal O
sepsis O
is O
a O
major O
cause O
of O
mortality O
worldwide, O
with O
most O
deaths O
occurring O
in O
low-income O
countries. O
[]

Publication O
date: O
2019/01/05 O
00:00 O
[accepted] O
[]

AmBisome O
monotherapy O
at O
40 O
mg/kg O
is O
recommended O
by O
the O
World O
Health O
Organization. O
[]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

Journal-Name:BMC O
public O
health O
[]

BACKGROUND: O
The O
ability O
to O
generate O
high O
levels O
of O
power O
is O
one O
of O
the O
key O
factors O
determining O
success O
in O
many O
sport O
disciplines. O
[]

In O
addition, O
post-training, O
participants O
still O
felt O
uncomfortable O
with O
certain O
aspects O
of O
treatment O
and O
the O
management O
of O
some O
mental O
health O
conditions. O
[]

Journal O
ID: O
101225531 O
[]

RESULTS: O
Compared O
to O
the O
control O
condition, O
unhealthy O
food O
sponsorship O
promoted O
higher O
awareness B-outcome ['Life-Impact']
of, O
and O
more O
favourable O
attitudes B-outcome ['Life-Impact']
towards, O
unhealthy O
food O
sponsor O
brands. O
[['Life-Impact'], ['Life-Impact']]

Incidence O
of O
treatment-related B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
with O
tretinoin O
0.05% O
lotion O
was O
lower O
than O
in O
the O
overall O
study O
population; O
the O
most O
frequently O
were O
application O
site O
pain B-outcome ['Physiological-Clinical']
(2.0%), O
dryness B-outcome ['Physiological-Clinical']
(1.4%), O
and O
erythema B-outcome ['Physiological-Clinical']
(1.2%). O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Objective: O
To O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
and O
safety O
of O
supraglottic O
tracheal O
tube O
ventilation O
by O
comparing O
with O
modified O
laryngeal O
mask O
airway O
ventilation O
during O
painless O
fiberbronchoscopy. O
[['Life-Impact']]

